DDrare: Database of Drug Development for Rare Diseases

46. 悪性関節リウマチ　［臨床試験数：1,999，薬物数：1,752（DrugBank：321），標的遺伝子数：172，標的パスウェイ数：213］

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = (+) erythromefloquine; (+)erythromefloquine; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile,; (cdp6038; 0109-0012a 100 mg/ml; 0109-0012a 25 mg/ml; 0109-0012a 50 mg/ml; 0114-0006b; 0881; 1 ml 0.9 % nacl; 1,5-anhydro-2,3-dideoxy-3-[[(1r,3s)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5h)-yl]c; 100 mg lx3305 qd; 13-valent pneumococcal conjugate vaccine; 15-o labeled water; 150 mg lx3305 qd; 18f-fdg; 18f-ge-180; 1h-pyrazol; 2 million hmsc/kg; 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1h-benz[e]-indolium hydroxide,inner salt; 200 mg lx3305 qd; 23-valent pneumococcal polysaccharide vaccine; 250 mg lx3305 bid; 250 mg lx3305 qd; 2593; 300 mg lx3305 qd; 331731-18-1; 4 million hmsc/kg; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl] benzenesulfonamide; 40 mg msb11022; 400 mg lx3305 qd; 42942019; 5-chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin; 50 mg ap1189; 50 mg etanercept; 50 mg lx3305 qd; 500 mg lx3305 qd; 6 million hmsc/kg; 6-(nitrooxy)hexyl(2z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate; 68ga-bnota-prgd2; 7-valent pneumococcal conjugate vaccine; 70930.00.00; 89zr-dfo-czp; 9512; 99mtc-3prgd2; 99mtc-rhannexin v-128; 99mtc-s-hynic certolizumab pegol; A natural remedy for rheumatoid arthritis vs. common drugs; Ab1010; Aba, open-label (ol); Abatacept; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept, rituximab or tocilizumab; Abbv-105; Abbv-105, a-1519938.0; Abbv-257; Abbv-3373; Abp 501; Abp 710; Abp 710 - biosimilar to infliximab; Abp 798; Abp 798 - biosimilar to rituximab; Abt 494; Abt 494 12mg; Abt 494 3mg; Abt-122; Abt-494; Abt-humira; Abx464; Abx464 100mg; Abx464 50mg; Ac430; Acalabrutinib; Aceclofenac; Acellbia; Acetaminophen; Acetaminophen tablets; Acetate; Acetylsalicylic acid; Acetylsalicylzuur cardio pch disp tablet 80mg; Actemra; Actemra(eu-licensed); Acthar; Acthar gel; Acthar injectable product; Active comparator; Acycloguanosine; Acz885; Acz885 (investigational); Acz885 drug substance; Ad 452; Ad 452 18 mg tablet; Ad 452 4.5 mg tablet; Ad 452 9 mg tablet; Adalimumab; Adalimumab (ada); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab pfs and pen; Adalimumab with methotrexate; Adalimumab-eu; Adalimumab-pfizer; Adalimummab; Adefovir; Adenin; Adl5859; Administration of cimzia®; Agm 719; Agrippal s1 (influenza vaccination); Ain457; Ak106-001616; Ald518; Ald518 monoclonal antibody (anti il-6 mab); Alemtuzumab; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alendronat teva; Alendronate; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Alendronic acid; Alfacalcidol; Alkaline phosphatase; Allogeneic mesenchymal precursor cells; Allopurinol; Aluminium; Aluminium phosphate; Alx-0061; Alx-0061 nanobody; Amg 108; Amg 162; Amg 357; Amg 570; Amg 592; Amg 714; Amg 719; Amg 827; Amg 827 140 mg; Amg 827 210 mg; Amg 827 70 mg; Amg592; Aminopterin; Amoxapine; Amoxapine & dipyridamole; Amoxicilina; Amoxicillin; Amp-110; Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra and peg stnf-r1; Andecaliximab; Angiotensin; Angiotensin receptor blockers; Anifrolumab; Anifrolumab (medi-546); Anti human granulocyte-macrophage colony-stimulating factor (gm-csf) monoclonal antibody; Anti il-1beta antibody; Anti il-1beta antibody, subclass igg4; Anti il-1ß antibody; Anti il-1ß antibody, subclass igg4; Anti lp40 antibody, subclass igg4 la294; Anti tnf + meth; Anti-c5ar; Anti-cd20 small modular immunopharmaceutical, wye-400087; Anti-gm-csf receptor alpha; Anti-il-20; Anti-il-20 (109-0012); Anti-il-6 mab; Anti-inflammatory drugs; Anti-pandemic h1n1 influenza vaccine; Anti-thymocyte globulin; Anti-tnf; Anti-tnf biologics; Anti-tnf biologics therapy; Anti-tnf humanized antibody fab fragment - peg conjugate; Anti-tnf suspended perioperatively; Anti-tnf therapy; Anti-tnf therapy (etanercept or adalimumab); Anti-tnfa continued perioperatively; Anti-tumor necrosing factor (tnf) therapy; Antihistamine; Ap1189; Apl a12; Apremilast; Apremilast 20 mg; Apremilast 30 mg; Ara290; Arava; Arava 20 mg filmdrasjerte tabletter; Arava 20 mg tablets (aventis pharmaceutical, inc.); Arava®; Arcoxia; Arry-371797, p38 inhibitor; Arry-438162; Arry-438162, mek inhibitor; Art621; Arthroscopy & saline irrigation alone; Ascal(r) / carbasalate calcium; Asendis 50 mg; Ask8007; Asp1707; Asp2408; Asp2409; Asp5094; Aspirin; Aspirin 81mg tablet; Aspirin tablets; Atacicept; Atn-103; Atn-103 10 mg q4wks; Atn-103 10 mg q8wks; Atn-103 30 mg q4wks; Atn-103 80 mg q4wks; Atn-103 80 mg q8wks; Atorvastatin; Atorvastatin tablet 20 mg; Auto injector; Autologous apoptotic cells injection; Autologous mesenchymal stem cells; Autologous stromal vascular fraction cells; Ave9897; Avelox- moxifloxacin; Avelox®; Azathioprin; Azathioprine; Azd5672; Azd9056; Azd9056 hydrochloride; Azd9567; Azd9567 10 mg; Azd9567 125 mg; Azd9567 155 mg; Azd9567 20 mg; Azd9567 40 mg; Azd9567 80 mg; Azd9567 monohydrat; Azd9567 monohydrate; Baminercept; Baminercept alfa; Baminercept alfa (bg9924); Baricitinib; Baricitinib, olumiant®; Bat1806; Bat1806 injection; Bay1834845; Bcd-055; Bcd-089, 162 mg, s/c, q2w; Bcd-089, 162 mg, s/c, qw; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Belatacept; Belimumab; Belimumab 1 mg/kg; Belimumab 10 mg/kg; Belimumab 4 mg/kg; Benepali; Benzimidazole; Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 h-benzimidazole; Betamethasone; Betamethasone acibutate; Bg00012; Bg9924; Bgx-0214; Bi 655064; Bi 695500; Bi 695501; Bi 695501 autoinjector; Bi 695501 prefilled syringe; Biap; Bibr 796 bs; Bicain spinal; Biib023; Biib057; Biil 284 bs high dose; Biil 284 bs low dose; Biil 284 bs medium dose; Bimekizumab; Binyrebarkhormon; Binyrebsrkhormon; Biodmards; Biologic agents; Biologic dmard; Biologic tnfi; Biological agents; Biologics; Biosimilar; Biosimilar infliximab; Biosimilar product to adalimumab; Birb 796 bs, high dose; Birb 796 bs, low dose; Blood; Blood sample; Blood samples; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Bms-188667; Bms-582949; Bms-582949 and methotrexate; Bms-817399; Bms-945429; Bms-986104; Bms-986142; Bms-986142 200mg; Bms-986142 350mg; Bms-986195; Bms-986251; Borage seed oil; Bortezomib; Bovine intesastinal alkaline phosphatase (biap); Bow015; Br9001; Br900a; Bredinin; Bredinin tablet 150mg; Bredinin tablet 50mg; Brl-049653; Bt061; Bt061 (cd4 monoclonal antibody); Bt971; Btt-1023; Bucillamine; Bupivacaine; Bupivacaine hydrochloride; Buprenorphine; Buprenorphine transdermal patch; C. albicans; C10aa05; Caffeine; Calcitriol; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium citrate; Cam-3001; Canakinumab; Canakinumab (investigational); Canakinumab (proposed); Cannabidiol; Cannabidiol tablet 10 mg; Capture; Carbasalate calcium; Carbon; Carbonate; Cc-292; Cci-779; Ccx 354; Ccx 354-c; Ccx354; Ccx354-c; Cdmard; Cdp6038; Cdp870; Cdp870 100mg; Cdp870 200mg; Cdp870 400mg; Cdp870 fab'-peg; Ce 224,535; Ce-224,535; Celbesta®; Celebrex; Celebrex 200 mg; Celebrex 200 mg capsule, hard; Celebrex®; Celecoxib; Celecoxib 200mg capsule; Ceramic on polyethylene articulation; Certolizumab; Certolizumab pegol; Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol + methotrexate (mtx); Cetrorelix; Cf101; Cf101 1 mg; Cf101 2 mg; Cfz533; Ch-1504; Ch-4051; Chicken; Chicken type ii collagen; Chimeric human-murine igg1 <monocolonal antibody; Chimeric human/mouse anti-cd-20 monoclonal antibody; Chlor; Chloride; Chloroquine; Cholecalciferol; Chong kun dang tofacitinib tablet; Chromium; Chs-0214; Ciclosporin; Cimzia; Cimzia 200 mg injeksjonsvæske, oppløsning; Cimzia 200 mg solution for injection; Cimzia®; Citalopram; Citrate; Ckd-374 5mg tab.; Classic dmards treatment group; Clazakizumab; Clindamycin; Clofarabine; Cmab008; Cnto 136 100 mg; Cnto 136 25 mg; Cnto 136 50 mg; Cnto 148; Cnto 1959; Cnto 1959 igg; Cnto1275; Cnto148; Cnto6785; Co-medication: synthetic dmards; Cobalt; Cobiprostone; Cod liver oil; Coenzyme q10; Colecalciferol; Collect of 10 ml of peripheric blood for dna extraction; Combination; Combination fish oil and borage seed oil; Combination of minocycline and mtx or mtx alone; Combination steroid; Commercial formulation etanercept; Comparator: diclofenac; Comparator: diclofenac sodium; Comparator: naproxen tablet 500 mg; Control; Control group; Control intervention (no dexamethasone); Conventional dmard combination; Conventional dmards; Corn; Corn oil capsules; Corticosteroid and non-biological agents.; Corticosteroid or nsaid; Corticosteroids; Corticotrophin; Corticotrophin 80 units; Corticotropin; Cp 690,550; Cp-195,543; Cp-690,55-10; Cp-690,550; Cp-690,550 (tasocitinib); Cp-690,550 (tofacitinib); Cp-690,550 + methotrexate; Cp-690,550-10; Cp-690-550; Cp690,550; Cr 1; Cr 2; Cr 3; Cr6086; Cr6086z; Creatine; Creatinine; Crx-102; Crx-102 (2.7/180); Crx-102 (2.7/360); Crx-139; Crx-150; Csdmards; Ct- p10; Ct-p13; Ct-p17; Ct-p17 sc; Ctla4ig; Cura-100; Curcumin; Curcumin (longvida™); Cyclophosphamide; Cyclosporine; Cyklokapron®; D569 tab.; Dacortin; Dacortin ®; Dalacin c phosphate; Decortin; Decortin 5mg tablets; Decortin®; Decrease tocilizumab, abatacept; Dekavil; Deltacortene forte*10cpr 25mg; Deltacortril enteric; Denosumab; Depalgos*20+325mg 28cpr rp; Depo medrol; Depo-medrone; Dexamethason; Dexamethasone; Dextromethorphan; Dextromethorphan hydrobromide; Diacerein; Diazepam; Diazepam, melatonin; Dibase*im os 2f 1ml 300000ui/m; Diclofenac; Diclofenac + omeprazole; Diclofenac natrium pch retard tablet mga 75mg; Diclofenac sodium; Dietary supplement omega3 fatty acids aand vitamins; Digoxin; Dimeythl fumarate; Dipotassium salt; Diprofos depot; Dipyridamole; Disease modified antirheumatic drugs or biological agents; Disease-modifying antirheumatic drug; Disease-modifying antirheumatic drugs (dmards); Dmard; Dmard cessation; Dmard maintenance; Dmard therapy; Dmards; Dmards (disease-modifying antirheumatic drugs); Dmards or biologics; Dnaj peptide; Donepezil; Dose level 1; Dose level 2; Dose level 3; Dose level 4; Double-blind abatacept; Double-blind adalimumab; Doxycycline; Drl_ri; Dronabinol; Dronabinol capsule 2.5. mg; Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom; Dwp422 25mg; E-device; E6011; Ebetrexat; Ec 3.1.3.1; Edoxaban; Efalizumab; Efexor; Efexor xl 75 mg; Efexor xl 75 mg (venlafaxine); Eldecalcitol; Emea/h/c000262; Enalapril; Enalapril maleate; Enbrel; Enbrel (etanercept); Enbrel 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.; Enbrel 25 mg powder and solvent for solution for injection; Enbrel 25mg pfs; Enbrel 25mg pfs inj.; Enbrel 50 mg powder and solvent for solution for injection; Enbrel 50 mg solution for injection in pre-filled syringe; Enbrel 50mg pfs; Enbrel 50mg pre-filled pen; Enbrel 50mg pre-filled syringe; Enbrel auto injector; Enbrel liquid; Enbrel pre-filled pen; Enbrel pre-filled syringe; Enbrel®; Enbrel® 50 mg solution for injection in pre-filled syringe; Engineered humanized monoclonal anti-human cd19 antibody. lot numbers: 1-fin-1588 (9.6mg/ml); Enia11; Enoxaparin; Entecavir; Epax 6000 ee 1000mg (0.6 gr dha+epa); Epaxal; Epinephrine; Epoetin alfa; Erb-041; Erbium citrate; Ergocalciferol; Ermm-1; Esomeprazole; Esomeprazole 20 mg; Estradiol; Eszopiclone; Etanercept; Etanercept (enbrel); Etanercept (enbreltm); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50mg; Etanercept biosimilar; Etanercept liquid; Etanercept or adalimumab; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Ethinyl estradiol; Etn alone; Etn+mtx; Etodolac; Etoricoxib; Eu-humira; Eu/1/99/126/017; Eu/1/99/126/020; Evobrutinib; F8il10; Famotidine; Fang yi qing feng shi granule; Fang(30); Fb704a; Fendrix; Fendrix suspension for injection; Fendrix suspension for injection hepatitis b (rdna) vaccine (adjuvanted, adsorbed).; Fentanyl; Fentanyl transdermal patch; Ferrograd; Ferrograd folic tablets; Filgotinib; Filgrastim; Fish oil; Fish oil supplement; Fish oil, gamma-linolenic acid; Fkb327; Fkb327 ai; Fkb327 pfs; Fludarabine; Fluorine f 18; Flurbiprofen; Focetria; Focetria (monovalent mf59-adjuvanted vaccine); Folate; Folatescan (technetium tc 99mec20); Folic (or folinic) acid; Folic acid; Folic acid or folate; Folinic acid; Fontolizumab; Fosd; Fostamatinib; Fostamatinib 50 mg blue film-coated tablet; Fostamatinib disodium; Fostamatinib disodium (r935788); Fpa008; Fr104; Fsme-immun; Furestem-ra inj; Furestem-ra inj.; Fx125l; Gadobutrol; Gadolinium; Gamma-linolenic acid; Gck 100 mg; Gck 200 mg; Gck 300 mg; Gdc 0853; Gdc-0853; Gdc-0853 ro7010939; Gerilimzumab; Gfi 38518168-aek-b-007; Ginger; Ginseng; Ginsenoside; Glpg0259; Glpg0634; Glucocorticoid; Glucocorticoid agent; Glucocorticoids (permitted,not necessary); Glucophage (metformin); Glucosamine; Gm-csf; Gold; Golimumab; Golimumab 100 mg; Golimumab 100 mg injections; Golimumab 2 mg/kg iv; Golimumab 50 mg; Golimumab 50 mg injections; Golimumab final vialed product (fvp); Golimumab intravenous; Golimumab intravenous (iv); Golimumab liquid in prefilled pen; Golimumab liquid in prefilled syringe; Golimumab liquid in vial; Golimumab pre-filled syringe; Gp2013; Gp2013 - a proposed biosimilar rituximab; Gp2015; Gp2017; Grapefruit; Grc 4039; Green tea; Green tea group; Group 1 or orencia treated group; Growth hormone; Gs-4059; Gs-5745; Gs-6034; Gs-9876; Gsk1827771; Gsk1841157; Gsk2982772; Gsk2982772 60 mg; Gsk2982772a, where a denotes the free base; Gsk3117391; Gsk3152314a; Gsk315234; Gsk315234 injection 100mg/ml; Gsk3196165; Gsk3196165 dose 1; Gsk3196165 dose 2; Gsk3196165 dose 3; Gsk706769; Gum arabic; Guna-anti interleukin 1; Guna-antiinterleukin 1 alfa; Guna-antiinterleukin 1 beta; Guna-interleukin 10; Guna-interleukin 4; Gw274150; Gw274150 tablets; Gw406381; Gw406381x; Gw856553; H.p. acthar gel; Ha20 (immu-106); Hb-admsc; Hbvaxpro; Hbvaxpro 5 micrograms/0.5 ml; Hbvaxpro 5 micrograms/0.5 ml suspension for injection hepatitis b vaccine (rdna); Hbvaxpro® 40 micrograms; Hd-tiv; He3286; Hematopoietic stem cell transplantation; Hepatitis a vaccine; Hepatitis a vaccine and tetanus vaccine; Hepatitis b vaccine (rdna); Hepatitis b virus surface antigen recombinant (s protein); Herpes zoster vaccine; High dose of biil 284 bs tablets; Hl237; Hlx01; Hm71224 food effect; Hm71224 multiple ascending dose; Hm71224 single ascending dose; Hmpl-523; Hril-2 active; Huang qi gui zhi wu wu granule; Huc-msc + dmards; Huc-msc suspension; Human anti tnf-alpha monoclonal antibody; Human anti-tnf igg1 monoclonal antibody; Human anti-tnf-alpha monoclonal antibody; Human anti-tnfalfa; Human monoclonal antibody directed against cd20 on b-cells; Human recombinant igg1, lambda; Humanised anti-cd 20 antibody; Humanised anti-cd4 igg1 monoclonal; Humanized immunoglobulin gamma 1 (igg1) kappa monoclonal antibody; Humanized tnfa monoclonal antibody; Humax-cd20; Humax-cd4; Humira; Humira (adalimumab); Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte; Humira 40 mg solution for injection in pre-filled syringe; Humira 40 mg/0.8 ml solution for injection; Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira 40mg/0.8ml solution for injection in pre-filled syringe; Humira sc; Humira*sc 2sir+f 40mg 0,8ml+2t; Humira, 40 mg solution for injection in pre-filled syringe; Humira®; Humira® (adalimumab); Humira® 40 mg solution for injection in pre-filled syringe; Hyaluronic acid; Hydroxide; Hydroxychloroquine; Hydroxychloroquine sulfate; Hydroxycholoquine; Hydroxycloroquina; Hylase; Hzt-501; Ib-meca; Ibandronate; Ibuprofen; Ibuprofen pch tablet 600mg; Icg-pulsion; Icp-022; Idec-c2b8 (rituximab); Iguratimod; Iguratimod (careram); Il-2; Il-6 receptor inhibitor, recombinant humanized monoclonal antibody; Ilv-094; Imatinib; Immune ablation and hematopoietic stem cell transplant; Immunoscintigraphy with radiolabeled cimzia®.; Immunosporin; Impact; Incb018424; Incb028050; Incb028050 phosphate; Incb028050 phosphate salt; Incb047986; Indocyanine green; Indocyanine green(icg); Infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab [infliximab biosimilar 3]; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Influenza vaccine; Influvac; Infusion without ald518`; Inn - filgotinib; Inn not available; Innovator infliximab; Insulin; Integrative medicine; Interleukin 10; Interleukin 2; Interleukin 4; Intra-articular compound betamethasone; Intra-articular tocilizumab; Intraarticular betamethasone; Intraarticular dexamethasone; Intraarticular injection; Intraarticular morphine; Intravenous (iv) abatacept; Intravenous dexamethasone 1 mg; Iodine; Ipi 145; Ipi-145; Isis 104838; Isis crp rx; Itacitinib; Iv abatacept; Iv golimumab; Jak1 / jak2 inhibtor; Jhl1101; Jnj-16240159-aac; Jnj-38518168; Jnj-38518168 (10 mg); Jnj-38518168 (3 mg); Jnj-38518168 (30 mg); Jnj-38518168 / mtx; Jnj-38518168 50-mg over encapsulated tablet; Jnj-39758979; Jnj-39758979 / mtx; Jnj-39758979-aac - enteric coated tablet - 10 mg; Jnj-39758979-aac - enteric coated tablet - 100 mg; Jnj-39758979-aac - enteric coated tablet - 30 mg; Jnj-40346527; Jnj-40346527-aac - capsule - 50 mg; Jte-051; Juanbi pill; K-832; Kb003; Kc706; Kenalog; Ketoprofen; Keyhole limpet hemocyanin; Kineret*sc 7sir 100mg 0,67ml; Kineret®; Kineret® (anakinra); Kolbet; Kr002524; Kunxian capsule; L-000124467; L-000124467 (freebase); L-000124467-009j (succinat; L-000883191; L-001069957; L01xc02; L04041); L04aa24; L04ab01; L04ab04; L04ab05; L04ab06; L04ac07; Lacosamide; Lamivudine; Lantarel; Large protein molecule; Lbal; Lbec0101; Ld-aminopterin; Ledertrexate; Leflunomide; Leflunomide (permitted, not necessary); Leflunomide 20 mg tablets (geneva pharmaceutical); Leflunomide 20mg tab; Leflunomide-sulfasalazine-hydroxychloroquine; Leucovorin; Levobupivacaine; Lidocaine; Lingzhi and sen miao san; Linolenic acid; Lipitor®; Lisinopril; Lnp1955; Lodotra®; Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Long-chain n-3 pufa; Long-circulating liposomal prednisolone; Loratadine; Losartan; Losec; Lovastatin; Low dose of biil 284 bs tablets; Loxoprofen; Lts 0.25mg; Lts 0.5mg; Lts 1.0mg; Lumiracoxib; Lx3305; Lx3305 dihydrate; Lx3305 high dose; Lx3305 low dose; Lx3305 mid dose; Ly2127399; Ly2127399 (tabalumab); Ly2189102; Ly2439821; Ly3009104; Ly3090106 - iv; Ly3090106 - sq; Ly3337641; M2951; M923; Mabioncd20; Mabthera; Mabthera (rituximab); Mabthera 500 mg; Mabthera 500 mg (10mg/ml); Mabthera 500 mg concentrado para solución para perfusión; Mabthera 500 mg concentrate for solution for infusion; Mabthera 500 mg konzentrat zur herstellung einer infusionslösung; Mabthera 500mg; Mabthera infusions; Mabthera*ev 1fl 50ml 500mg; Mabthera/rituxan; Mabthera®; Mabthera® (rituximab); Mabthera®, 100 mg concentrate for solution for infusion; Magnesium; Manufacturerd by cambridge therapeutic antibody centre, burroughs wellcome, glaxo wellcome); Maraviroc; Masitinib; Masitinib (ab1010); Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate; Mavrilimumab; Mavrilimumab 100 mg; Mavrilimumab 150 mg; Mavrilimumab 30 mg; Mbs2320; Mdx-1100; Mdx-1342; Medi-522; Medi4920; Medi5117; Medrol 4 mg tablets; Medrol a 16 mg tablets; Melatonin; Meloxicam; Meloxicam 0.125 mg/kg; Meloxicam 0.25 mg/kg; Meloxicam ampoule; Meloxicam cf tablet 7,5mg; Meloxicam oral suspension; Meloxicam tablet; Meriva; Mesalazine; Mesenchymal cell transplantation; Metex 10 mg/ml injektionslösung, fertigspritze; Metex 10mg tabletten; Metex 2,5mg; Metex 2,5mg tabletten; Metex 50 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte; Metex 7,5mg tabletten; Metex®; Metex® 50 mg/ml injektionslösung, fertigspritze; Metformin; Metformin/cp-690,550; Methorexate; Methotrexat; Methotrexat hexal® 2,5 mg tabletten; Methotrexat lederle 2.5mg tablets; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Methotrextate; Methoxsalen; Methyl 1-[n6-(3-iodobenzyl)-adenin-9-yl]-beta-dribofuronamide; Methyl 1-[n6-(3-iodobenzyl)-adenin-9-yl]-ß-dribofuronamide; Methylaminopterin; Methylprednisolone; Methylprednisolone sodium succinate; Methylprednisone; Metoject; Metotrexato; Metotrexato sodio; Metronidazol; Metronidazole; Mextrex; Micellar paclitaxel for injection; Microgynon® 30 (oral contraceptive); Midazolam; Milnacipran; Minocycline; Minodronate; Minodronic acid; Misoprostol; Mizoribin; Mk-0663; Mk-0873; Mk-8457; Mk-8457 100 mg; Mk-8808; Mk0359; Mk0663, etoricoxib; Mk0812; Mk0812 / duration of treatment: 12 weeks; Mk0966; Mln3897; Mlta3698a; Mm-093; Monitor; Montelukast; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Mor103; Morab-022; Morphine; Morphine hexal; Morphine sulfate; Morphinsulfat; Moxifloxacin; Mp-435(dose1) + methotrexate; Mra (tocilizumab); Mra(tocilizumab); Mra-sc; Mrc375; Mrc375 150mg; Msb11022; Mt203; Mtrx1011a; Mtx plus anti-tnf; Mtx start; Mtx therapy; Multigrain powder (s); Mushroom extract; Mussel oil capsules; N-3 lc-pufa; N.a.; Namilumab; Namilumab (mt203); Nanocort; Naprosyn 500 mg; Naproxen; Naproxen (ec-narosyn) delayed release tables, 375 (syntex (usa), inc.); Naproxen 10 mg/kg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Naproxen delayed release tables, 375 (gevena pharmaceuticals, inc.); Naproxen oral suspension; Naproxen pch tablet 500mg; Naproxen sodium 550mg tablet; Natalizumab; Natriumklorid 9mg/ml; Nc-503 (anti-amyloidotic (aa) agent); Nerve block; New formulation adalimumab; New formulation etanercept; Ni-0101; Ni-071; Niclosamide; Nimesulide; Nitric oxide; Nitroglycerine; Niubangzi pill; Nivolumab; Nnc 0109-0000-0012; Nnc 0141-0000-0100; Nnc 0142-0000-0002; Nnc 0151-0000-0000; Nnc 142-0002; Nnc0109-0012; Nnc0114-0000-0005; Nnc0114-0006; Nnc0142-0002; Nnc0151-0000-0000; Nnc0215-0384; Nnc151-0000; Non-anti-tnf biologics; Non-biologic anti-rheumatic drugs; Non-biologic disease modifying anti-rheumatic drug (dmard); Non-biological dmard's; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Non-steroidal anti-inflammatory drug (nsaid); Nonbiologic dmards of investigator's choice; None; None as of yet; Norethindrone; Normal saline; Nsaids; Nsaids (permitted,not necessary); Null; Nulojix; Ocrelizumab; Ocrelizumab / rhumab 2h7; Ocrelizumab 500mg; Ocrelizumabu 200mg; Ocrelizumabu 50mg; Ofatumumab; Olikizumab; Olokizumab; Olokizumab 120 mg; Olokizumab 240 mg; Olokizumab 60 mg; Olokizumab 64 mg sc q2w; Olokizumab 64 mg sc q4w; Olokizumab 64mg q2w; Olokizumab 64mg q4w; Olokizumab q2w; Olokizumab q4w; Olumiant; Omega-3; Omega-3 and vitamin e supplementation; Omega-3 fatty acid; Omega3; Omega3 fatty acids; Omegaven (10% fish-oil emulsion; Omeprazole; Oncoxin + viusid; Open-label abatacept; Open-label adalimumab; Open-labeladalimumabrescue; Oral bovine type ii collagen; Oral methotrexate; Oral scio-469 capsule; Orencia; Orencia (abatacept); Orencia 125 mg; Orencia 125 mg solution for injection; Orencia 125 mg, solution injectable en seringue préremplie; Orencia 250mg powder for concentrate for solution for infusion; Orencia abatacept; Orencia subcutaneous injection; Originator; Originator (legacy) drug; Originator rituximab - rituxan ® or mabthera ®; Ortho-novum® 1/35; Otelixizumab; Other biological agent; Other biologics; Other dmards; Other non steroidal anti-inflammatory drugs (nsaids) except etodolac; Otl38; Overencapsulated prednisolone tablets; Oxicodone dc.it; Oxycodone; Oxycodone by patient-controlled analgesia (pca); Oxygen; Ozoralizumab; P38 (4) map kinase inhibitor; P38 inhibitor (4); P38 inhibitor (4) 150mg; P38 inhibitor (4) 25mg; P38 inhibitor (4) 300mg; P38 inhibitor (4) 50mg; P38 inhibitor (4) 75mg; P38(4) map kinase inhibitor; Paclitaxel; Panax quinquefolius; Pandemrix,; Paracetamol; Paracetamol (acetaminophen); Paracetamolo dc.it fu; Parecoxib; Paroxetine; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Part a; Part b; Patient current care; Patient treated with dmard; Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses; Pd 0360324; Pda001; Peficitinib; Pegsunercept; Pegsunercept (peg stnf-ri); Pelubiprofen; Pelubiprofen 30 mg; Peri-neural dexamethasone 1 mg; Permitted dmards; Persantin 100 mg and; Pertussis vaccine; Pf-04171327; Pf-04171327 10 mg; Pf-04171327 25 mg; Pf-05280586; Pf-06410293; Pf-06438179; Pf-06650833; Pf-06651600; Pf-06835375; Pg-760564; Ph-797804; Phase 1: conventiaonal dmard; Phase 1: etanercept; Phase 1: methotrexate; Phase 2: optional etn, ssz, hcq, mtx; Phosphate; Pig whipworm eggs; Pioglitazone; Pirfenidone; Pl 00095/5079r; Pla + mtx switched to aba+ mtx, db; Pla-695; Placebo; Plaebo; Plaquenil; Plaquenil 200 mg filmdrasjerte tabletter; Plasma analysis for bacterial translocation; Platelet rich plasma; Plx3397; Plx5622; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Pneumo23 / pneumovax; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) conjugated to crm197 carrier protein and adsorbed on aluminium phosphate; Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19a, 19f, 20, 22f, 23f and 33f; Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f; Pneumococcal polysaccharide vaccine; Pneumococcal polysaccharide vaccine (23 valent); Pneumovax; Pneumovax 23; Potassium; Potassium supplement; Pr-06410293; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab); Pravastatin; Prd4862257; Pre-filled syringe; Pred; Pred + meth; Prednihexal; Prednihexal® 10mg tabletten; Prednihexal® 20mg tabletten; Prednihexal® 5mg tabletten; Prednihexal® 5mg tabletten, prednihexal® 10mg tabletten; Prednihexal® 5mg tabletten, prednihexal® 20mg tabletten; Predniso; Prednisolon; Prednisolone; Prednisolone & dipyridamole; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednison; Prednisone; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 5 mg; Pregabalin; Prevenar 13; Prevenar vaccination; Prevenar vaccine; Previously known as r935788; Primus; Pro283698; Probiotic capsules containing lactobacillus rhamnosus gr-1 and l. reuteri rc-14; Progressive spacing of tnf-blocker injections; Propofol; Propolipid; Proposed inn - filgotinib; Propsoed inn - filgotinib; Protein; Prtx-100 at 1.5 mcg/kg; Prtx-100 at 12.0 mcg/kg; Prtx-100 at 240 mcg; Prtx-100 at 3.0 mcg/kg; Prtx-100 at 420 mcg; Prtx-100 at 6.0 mcg/kg; Puerarin; Puerarin injection 400 mg; Puerarin tablet 50 mg; Qal964; Qingkailing injection 40 ml; Quensyl; R788; R788 sodium hexahydrate, rig2-01, rig-g; R788 sodium, r788 na, r788; R935788; Radiofrequency; Raloxifene; Raloxifene hydrochloride; Ramelteon; Ramipril; Rapamycin; Raptiva 100 mg/ml powder and solvent for solution for injection; Rayos (delayed-release prednisone); Rc18 160 mg plus mtx; Rebamipide; Recombinant factor fc fusion protein; Recombinant human anti il-22 monoclonal antibody igg1; Recombinant human mab of igg4 subtype; Recombinant human monoclonal antibody; Recombinant human monoclonal antibody to inerleukin-1beta of the igg1-k-class; Recombinant humanised anti-human monoclonal antibody directed against the il-6r; Recombinant humanized anti-human monoclonal antibody directed against the il-6r; Recombinant tnf-a receptor: igg fc fusion protein; Reference1505; Regn88; Remicade; Remicade (infliximab); Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning.; Remicade*ev f 100mg+f 2ml; Remicade®; Remicade® (infliximab); Remsima; Remsima (infliximab); Remsima - 100 mg polvere per concentrato per soluzione per infusione - uso endovenoso - flanconcino (vetro) - 1 flaconcino; Repository corticotropin injection; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Reumatocept (etanercept); Revamilast; Rgb-03; Rheumatoid arthritis with disease-modifying drugs (dmards); Rhumab 2h7; Rhumab to il-17a (igg1-k-class); Rhustoxicodendron 30; Rhutnfr; Rhutnfr:fc; Ribazen; Riboflavin; Rifampicin; Rimacalib; Risedronate; Ritumax®; Rituxan; Rituxan (inn: rituximab), brand name in the united states; Rituxan/sait101; Rituxan®; Rituxan® (rituximab); Rituximab; Rituximab - mabthera; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rivaroxaban; Ro 001-9265/f02-01; Ro 002-9893/f02; Ro 45-2294; Ro 487-7533; Ro 487-7533/f01; Ro 487-7533/f10; Ro 487-7533/f10-02; Ro 487-7533/f10-04; Ro 496-4913; Ro 496-4913/f03; Ro 551-6922; Ro actemra; Ro-actemra; Ro001-9265/f04; Ro0029893; Ro045-2294; Ro04877533; Ro0506997; Ro4402257; Ro487-7533; Ro487-7533/f01-f05; Ro487-7533/f10-04; Ro4877533; Ro4877533 (tcz); Ro7010939; Ro7123520; Ro7123520/f03-01; Roactemra; Roactemra 162 mg; Roactemra 162 mg solution injectable en seringue préremplie; Roactemra 20 mg/ml concentrado para solución para perfusión; Roactemra 20 mg/ml concentrate for solution for infusion; Roactemra 20 mg/ml concentrate for solution for infusion.; Roactemra 20 mg/ml, concentrado para solución para perfusión; Roactemra®; Roactemra®ev product code: prd82321; Roactmera; Rob 803; Rob 803 (9-chloro-2,3-dimethyl-6-(n,n-dimethylaminoethylamino-2-oxoethyl)-6h-indolo[2,3-b] quinoxali; Rob 803 12.5mg capsule; Rob 803 15mg capsule; Rob 803 25mg capsule; Rob 803 6.25mg capsule; Ropivacaine; Rosiglitazone; Rosiglitazone extended release tablets; Rosiglitazone maleate; Rosiglitazone xr; Rosuvastatin; Roxithromycin; Rtnv148b igg; Rupatadine; Rwj-445380 100 mg; Rwj-445380 200 mg; Rwj-445380 300 mg; Rwj-445380 capsule 100 mg; Rwj-445380 capsules 150 mg; Rwj-445380 capsules 50 mg; Rwj-445380-002; S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2h)-yl]-n,4-dimethylbenzamide; Sait101; Sait101 (proposed rituximab biosimilar); Salazopyrin en 500 mg enterotabletter; Salazopyrin en-tabs; Salazopyrine; Salazosulfapyridine; Same; San-300; Sar153191; Sar153191 (regn88); Sarilumab; Sarilumab sar153191 (regn88); Sb-681323; Sb-681323 oral tablets; Sb-681323 tablets; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Sb5 (proposed biosimilar to adalimumab); Sbi-087; Sc golimumab; Sc12267; Sc12267 (4sc-101); Sch 900259; Scio-469; Sd-qiv; Seasonal influenza vaccine; Secukinumab; Secukinumab (ain457); See d.3.9.3 'other descriptive name' below; Sham; Shingrix; Shr0302; Sildenafil; Simponi; Simponi 50 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.; Simponi®; Simvastatin; Sirolimus; Sirukuma; Sirukumab; Sirukumab 100 mg; Sirukumab 50 mg; Ski-o-703; Ski-o-703 capsule; Smp-114; Sodium aurothiomalate; Sodium aurothiomalate (intramuscular gold); Sodium chloride; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Solu-medrone 125mg; Solu-medrone 2 gram; Solu-medrone 2mg; Somatropin; Somatropin [rdna origin] for injection; Ssr150106xb; Sta 5326 mesylate; Stable weekly dose of methotrexate; Statins; Stem cell transplantation; Steroids; Stnf-r1; Stool analysis; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous tocilizumab; Subcutaneous(sc) abatacept; Subcutanious administration; Sublingual nitroglycerine; Sulfasalazine; Sulfate; Sulphasalazine; Sulphasalazine + hydroxychloroquine or prednisolone; Sunflower oil; Sunpharma1505 1; Sunpharma1505 2; Suspension ir; Synovial biopsy; Synthetic dmard(s); Systemic non-biological treatments; T-614; T0001; Ta-650 (infliximab); Ta-650 10 mg/kg; Ta-650 3 mg/kg; Ta-650 6 mg/kg; Tab08; Tabalumab; Tabalumab auto-injector; Tabalumab prefilled syringe; Taci-fc5; Tacrolimus; Tacrolimus (prograf®); Tacrolimus with methotrexate; Tak-715; Tak-783; Tas5315 high dose; Tas5315 low dose; Tasocitinib; Tasocitinib plus methotrexate; Tc 99m tilmanocept; Tc99m-tilmanocept; Tdmards; Teriparatide; Tetanus + pnemococcal vaccines alone; Tetanus toxoid adsorbed booster vaccine; Tetanus toxoid adsorbed vaccine; Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed); Tetraccycline; Tetraccycline-hydrochloride; Tetracycline; The effectiveness of xeljanz in rheumatoid arthritis patients; Therapy with disease-modifying anti rheumatic drugs (dmard); Ticagrelor; Tick-borne encephalitis virus (inactivated); Tilmanocept; Titan; Tl011; Tl011, anti cd20, for the treatment of rheumatoid arthritis; Tmi-005; Tmi-005 (way-177005); Tnf alpha blockers; Tnf alpha inhibitors; Tnf antagonist; Tnf antagonist (enbrel, humire, remicade, cimzia, symponi); Tnf blockers (infliximab, adalimumab, etanercept); Tnf blockers monotherapy; Tnf inhibitor; Tnf inhibitor/tcz; Tnf inhibitors; Tnf start; Tnf-a antagonists, non-tnfs, dmard non-biologics; Tnf-alpha antagonist and other biotherapy; Tnf-alpha antagonists; Tnf-alpha inhibitor; Tnf-blockers suspension in patients with rheumatoid arthritis; Tnf-k; Tnf-kinoid; Tnfr:fc; Tnr-001; To be confirmed; Tocilizumab; Tocilizumab (actemra®); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab prefilled syringe; Tocilizumab sc; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; Tofacitinib; Tofacitinib (xeljanz); Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5mg po bid; Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate cp-690550; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib; Toldc; Tolerogenic dendritic cells; Tolicizumab; Topical compound tripterygium; Topical tripterygium gel; Tramadol; Tramadol hydrochloride + acetaminophen; Tranexamic acid; Tranilast; Treatment a; Treatment b; Treatment c; Treatment of mtx; Treatment of mtx and hcq; Treatment of mtx and twhf; Treatment of tcm; Treatment of twhf; Tregalizumab; Trexan; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Triam 40 mg lichtenstein; Triamcinolonacetonid; Triamcinolonacetonid ep; Triamcinolone; Triamcinolone acetonide; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan); Trichuris suis ova; Tripterygium; Tripterygium wilfordii; Tripterygium wilfordii hook f; Tripterygium wilfordii hook f (twhf); Trivalent inactivated influenza vaccine; Tru-015; Ts-152; Tuberculin ppd; Tuberculin ppd rt 23 ssi for mantoux testing; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Twhf; Uc-msc+dmards; Uc-mscs; Ucb4940; Uk-427,857; Umbilical cord mesenchymal stem cells; Umbilical cord-derived mesenchymal stem cells (uc-mscs); Upadacitinib; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Ustekinumab; Uvadex; Uvedose; Valdecoxib; Vancomycin; Varicella zoster vaccine; Vay736; Velcade®; Veltuzumab; Veltuzumab solution 75mg/ml; Venlafaxine; Venlafaxine hydrochloride; Venous blood sample; Vitamin d; Vitamin d in arm b; Vitamin d3; Vitamin e; Vitamin k; Voltrarol sr; Vx-509; Vx-702; Warfarin; Water; Way-177005; Whale blubber oil; Whey protein&prebiotic supplement; Xeljanz; Xeljanz 5mg tablet; Xenp5871; Xinfeng capsule; Xmab5871_0.3mg; Xmab5871_1.0mg; Xmab5871_10.0mg; Xmab5871_3.0mg; Xmab®5871; Xoma 052; Yellow fever vaccine; Yellow fever vaccine (17d); Yisaipu; Ylb113; Yra-1909 high dose; Yra-1909 low dose; Yra-1909 mid dose; Z102; Z102 (prednisolone and dipyridamole).; Zd 4522; Zoledronate; Zoledronic acid; Zostavax (varicella zoster virus) vaccine; Zostavax vaccine; [18f]peg-folate

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02903212	March 2020	27 May 2019	Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis	Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Autologous apoptotic cells injection	Centre Hospitalier Universitaire de Besancon		Not recruiting	18 Years	80 Years	All	22	Phase 1/Phase 2
2	NCT04086745	January 2, 2020	11 November 2019	A Study of Baricitinib in Participants With Rheumatoid Arthritis	A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Baricitinib;Drug: TNF Inhibitor	Eli Lilly and Company	Incyte Corporation	Not recruiting	18 Years	N/A	All	1300	Phase 4
3	NCT04115423	January 1, 2020	14 October 2019	A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab	A Retrospective Cohort Study to Examine the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared With Tumor Necrosis Factor Inhibitors Using the National Health Insurance Database	Infection;Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)	Sungkyunkwan University	Ministry of Food and Drug Safety, Korea	Not recruiting	18 Years	N/A	All	4540	Phase 4
4	NCT04117165	January 1, 2020	14 October 2019	Assessment of the Clinical and Medico-economic Impact of SinnoTest® in Patients With Rheumatoid Arthritis	Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid;Biological Therapy	Diagnostic Test: Biotherapy Prescription with SinnoTest® software;Drug: Patient Current Care	University Hospital, Grenoble		Not recruiting	18 Years	70 Years	All	180	N/A	France
5	NCT04115397	January 2020	22 October 2019	Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints	Towards Efficient Prediction and Prevention of Rheumatoid Arthritis	Seropositive Muskuloskeletal Complaints	Drug: Zoledronic Acid;Drug: Placebo	Karolinska Institutet		Not recruiting	18 Years	N/A	All	80	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT04078191	December 2019	16 September 2019	Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue of Subjects With Rheumatoid Arthritis (RA)	A Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue From Subjects Clinically Diagnosed With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tc 99m tilmanocept	Navidea Biopharmaceuticals		Not recruiting	18 Years	N/A	All	24	Phase 2	United Kingdom
7	JPRN-jRCTs071190030	01/11/2019	5 November 2019	Non-inferiority trial of efficacy after switching from Remicade to infliximab BS[CTH] in rheumatoid arthritis patients	Non-inferiority trial of clinical non-relapse rate after switching from Remicade to infliximab BS[CTH] in rheumatoid arthritis patients with clinical remission, a multicenter prospective trial - IFX-SIRIUS STUDY I	Rheumatoid arthritis	Rheumatoid arthritis patients who have been treated with Remicade over 24 weeks and persisted with clinical remission are switched to infliximab BS [CTH] from Remicade. The dose and infusion intervals of infliximab BS[CTH] are kept unchanged from those of Remicade.	Atsushi Kawakami		Recruiting	>= 20age old	Not applicable	Both	80	Phase 4	none
8	NCT04134728	November 1, 2019	4 November 2019	Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors	A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors	Arthritis, Rheumatoid	Biological: GSK3196165;Biological: Sarilumab;Drug: Placebo to GSK3196165/ Sarilumab;Drug: csDMARDs	GlaxoSmithKline	Iqvia Pty Ltd	Not recruiting	18 Years	N/A	All	525	Phase 3	United States
9	NCT04130178	October 25, 2019	28 October 2019	Nerve Block of the Proximal Interphalangeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study	Nerve Block of the Proximal Interphalyngeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study	Rheumatoid Arthritis	Drug: Nerve block	Sohag University		Recruiting	18 Years	N/A	All	42	N/A	Egypt
10	NCT04120831	October 7, 2019	22 October 2019	TOLERA: Tolerance Enhancement in RA	Sequential B Cell/T Cell Therapy to Re-induce Humoral Immune TOLErance in ACPA- Positive Rheumatoid Arthritis A Prospective, Randomized Controlled Open Label Single-centre Clinical Trial in Adult Subjects With Active ACPA-positive Rheumatoid Arthritis Failing Methotrexate	Rheumatoid Arthritis	Drug: Abatacept Injection	University of Erlangen-Nürnberg Medical School		Recruiting	18 Years	N/A	All	20	Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	JPRN-JapicCTI-194932	01/10/2019	5 November 2019	An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis	An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : ozoralizumab INN of the intervention : ozoralizumab Dosage And administration of the intervention : Subcutaneous injection of TS-152 30mg or TS-152 80mg every 4 weeks Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Taisho Pharmaceutical Co.Ltd		Recruiting	20		BOTH	505	Phase 3	Japan
12	NCT04077567	October 1, 2019	22 October 2019	An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis	An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TS-152	Taisho Pharmaceutical Co., Ltd.		Recruiting	20 Years	N/A	All	505	Phase 3	Japan
13	NCT03828344	October 2019	11 February 2019	Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis	A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Tolerability of a Single Intravenous Infusion of BX-U001, a Human Umbilical Cord Tissue Derived Mesenchymal Stem Cell Product, for Refractory Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: hUC-MSC suspension;Biological: Placebo	Baylx Inc.		Not recruiting	18 Years	70 Years	All	16	Phase 1
14	NCT04136262	October 2019	4 November 2019	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis: a Randomized Controlled Trial	Rheumatoid Arthritis	Drug: Tripterygium wilfordii Hook F (TwHF);Drug: Methotrexate;Other: Dummy Tripterygium wilfordii Hook F (TwHF)	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	N/A	N/A	Female	300	Phase 2/Phase 3
15	ChiCTR1900026257	2019-09-28	30 September 2019	A Randomized, Double-Blind Clinical Trial for Effect of Wisconsin Ginseng (Panax quinquefolius) in Improvement of Rheumatoid Arthritis Associated Fatigue	Efficacy, dose comparison, and safety of Wisconsin Ginseng (Panax quinquefolius) in patients with rheumatoid arthritis associated fatigue: Three-arm parallel, multicenter, randomized, double-blind, placebo-controlled, phase 2 trial	Rheumatoid arthritis (RA)	High-dose experimental group :6000mg Wisconsin ginseng (Panax quinquefolius) herb intervention: 3000mg, orally, twice daily (bid) Capsule (6 capsules / 500mg) ;Low-dose experimental group:3000mg Wisconsin ginseng (Panax quinquefolius) herb intervention: 1500mg, orally, twice daily (bid) Capsule (3 capsules / 500mg); 3000mg Placebo: 1500mg, orally, twice daily (bid) Capsule (3 capsules / 500mg) ;Control group :6000mg Placebo: 3000mg, orally, twice daily (bid) Capsule (6 capsules / 500mg) ;	Zhejiang Provincal Hospital of TCM		Not Recruiting	18	70	Both	High-dose experimental group :30;Low-dose experimental group:30;Control group :30;	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT03971253	September 2, 2019	28 October 2019	Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis	Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Drug: Peficitinib	Astellas Pharma Inc		Recruiting	N/A	N/A	All	3000	Phase 4	Japan
17	NCT03895879	September 2019	30 September 2019	Use of Tocilizumab Drug Levels to Optimize Treatment in RA	Concentration-guided Dose Reduction Versus Standard Dosing in Tocilizumab-treated Rheumatoid Arthritis Patients: a Randomised, Multicenter, Non-inferiority Trial (TODORA)	Rheumatoid Arthritis	Drug: Tocilizumab	Reade Rheumatology Research Institute	ZonMw: The Netherlands Organisation for Health Research and Development	Recruiting	18 Years	N/A	All	98	Phase 4	Netherlands
18	NCT03938701	September 2019	26 August 2019	Fluorescence Imaging of Disease Activity in IBD and Rheumatoid Arthritis Using OTL38	Fluorescence Imaging for the Evaluation of Disease Activity in IBD and Rheumatoid Arthritis Using the Fluorescent Tracer OTL38 Targeting the Folate ß Receptor: a Single-center Pilot Study	IBD;Rheumatoid Arthritis	Drug: OTL38;Device: Fluorescence Imaging	University Medical Center Groningen	GlaxoSmithKline;On Target Laboratories, LLC;VU University Medical Center	Not recruiting	18 Years	N/A	All	30	Phase 1	Netherlands
19	NCT03976245	September 2019	22 July 2019	Advanced Therapeutics in Rheumatoid Arthritis (RA)	Advanced Therapeutics in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept;Drug: tofacitinib	Lawson Health Research Institute	Academic Medical Organization of Southwestern Ontario	Not recruiting	18 Years	N/A	All	144	Phase 4	Canada
20	JPRN-JapicCTI-194928	26/8/2019	10 September 2019	-An assessor-blinded, subject-blinded, double-dummy, active-controlled, randomised trial to compare the safety and efficacy of subcutaneous methotrexate (MJK101) with oral methotrexate in methotrexate-naive subjects with active rheumatoid arthritis followed by an open-label, single-arm extension to assess the long-term safety of MJK101	An assessor-blinded, subject-blinded, double-dummy, active-controlled, randomised trial to compare the safety and efficacy of subcutaneous methotrexate (MJK101) with oral methotrexate in methotrexate-naive subjects with active rheumatoid arthritis followed by an open-label, single-arm extension to assess the long-term safety of MJK101	Rheumatoid Arthritis	Intervention name : methotrexate INN of the intervention : methotrexate Dosage And administration of the intervention : Part 1: 7.5 mg MJK101 (SC) or dummy MJK101 (SC) will be administered once a week over a period of 12 weeks. Part 2: All subjects will receive once-weekly MJK101 (SC) for 12 months. At Trial Week 12, the once-weekly dose of MJK101 (SC) will be determined according to the disease activity status of the subject and an assessment of safety. If the subject has not met a low disease activity status at the visits every 4 weeks and has been well tolerated, then the once-weekly MJK101 (SC) dose will be increased by 2.5 mg to a maximum dose of 15 mg. Control intervention name : methotrexate INN of the control intervention : methotrexate Dosage And administration of the control intervention : Part 1: 8 mg MTX (oral) or placebo MTX (oral) will be administered once a week over a period of 12 weeks. The oral administration of MTX or placebo MTX will be divided into 2 doses to be administered approximately within a 12-hour interval.	medac GmbH		Recruiting	20	75	BOTH	100	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT04004429	August 26, 2019	11 November 2019	A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease	A Double-blind, Multicenter, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients With Active Joint Disease	Rheumatoid Arthritis	Drug: 50 mg AP1189;Drug: AP1189;Drug: Placebo	SynAct Pharma Aps		Recruiting	18 Years	85 Years	All	90	Phase 2	Denmark
22	ChiCTR1900025013	2019-08-08	27 August 2019	Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis after total knee arthroplasty	Effects of multiple dose use of tranexamic acid on blood loss and inflammatory factors after total knee arthroplasty in patients with rheumatoid arthritis	Total knee arthroplasty	group 1:Intravenous infusion of 1g of tranexamic acid + 100 ml 3 hours after surgery, intravenous infusion of 100 ml of normal saline 6 and 12 hours after surgery.;group 2:Intravenous infusion of 1g of tranexamic acid + 100 ml of normal saline at 3, 6, and 12 hours after surgery;	Guanghua Hospital, Shanghai University of Traditional Chinese Medicine		Recruiting	50	75	Both	group 1:38;group 2:38;	Phase 4	China
23	ChiCTR1900024902	2019-08-01	27 August 2019	A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis	A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis	Rheumatoid Arthritis	Experimental group:Traditional Chinese medicine (Yi-Shen Tong-Bi Tang);Positive control group:Methotrexate;	The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine		Not Recruiting	18	65	Both	Experimental group:50;Positive control group:50;	N/A	China
24	NCT02418273	August 1, 2019	16 December 2017	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study	Osteoporosis;Juvenile Rheumatoid Arthritis;Dermatomyositis;Polyarthritis;Systemic Lupus Erythematosis;Vasculitis;Glucocorticoid-induced Osteoporosis	Drug: denosumab	Indiana University		Not recruiting	4 Years	16 Years	All	24	Phase 1/Phase 2	United States
25	NCT04068246	August 1, 2019	2 September 2019	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.	Rheumatoid Arthritis	Drug: Metformin	Sadat City University		Recruiting	18 Years	N/A	All	100	Early Phase 1	Egypt
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	ChiCTR1900025021	2019-07-25	27 August 2019	Safety, Tolerance and Pharmacokinetics of Single Administration of Meloxicam Suspension Injection in Healthy Chinese Subjects	Safety, Tolerance and Pharmacokinetics of Single Administration of Meloxicam Suspension Injection in Healthy Chinese Subjects	Osteoarthritis, rheumatoid arthritis	A:TR group: phase I: Meloxicam Suspension Injection (T) 7.5 mg, phase II: Mobi (R) 7.5 mg; RT group: phase I: R, phase II: T.;B:Meloxicam Suspension Injection 15 mg;C:Meloxicam Suspension Injection 30 mg;D:Meloxicam Suspension Injection 60 mg;	Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University		Recruiting			Both	A:12;B:12;C:12;D:12;	Phase 1	China
27	ChiCTR1900024261	2019-07-15	15 July 2019	Efficacy and safety of sirolimus in new-onset rheumatoid arthritis: a prospective, double-blinded, randomized, placebo-controlled, monocentric study in China	Efficacy and safety of sirolimus in new-onset rheumatoid arthritis: a prospective, double-blinded, randomized, placebo-controlled, monocentric study in China	rheumatoid arthritis	A:methotrexate (7.5~15 mg/week)+ placbo (1 mg/d);B:sirolimus (1 mg/d) + methotrexate (7.5~15 mg/week);	The Second Hospital of Shanxi Medical University		Not Recruiting	18	65	Both	A:30;B:30;	Phase 4	China
28	NCT04018599	July 15, 2019	30 September 2019	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects	Rheumatoid Arthritis;Polyarticular Juvenile Idiopathic Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis;Crohn Disease;Ulcerative Colitis;Plaque Psoriasis;Pediatric Plaque Psoriasis;Pediatric Crohns Disease;Hidradenitis Suppurativa;Non-infectious Uveitis	Drug: 40 mg MSB11022	Fresenius Kabi SwissBioSim GmbH	PRA Health Sciences	Recruiting	18 Years	55 Years	All	216	Phase 1	United States
29	NCT03813199	July 4, 2019	29 July 2019	Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis	Phase IIa Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to an Anti- Tumor Necrosis Factor Alpha (Tnfa) Therapy, or Intolerance to Anti-Tnfa Therapy	Rheumatoid Arthritis	Drug: ABX464 50mg;Drug: Matching Placebo;Drug: ABX464 100mg;Drug: Methotrexate	Abivax S.A.		Recruiting	18 Years	75 Years	All	60	Phase 2	France
30	NCT03656627	June 27, 2019	22 October 2019	Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Autoimmune Diseases;Non-small Cell Lung Cancer;Rheumatoid Arthritis;Psoriasis;Giant Cell Arteritis;Polymyalgia Rheumatica;Systemic Lupus Erythematosus;Crohn Disease;Multiple Sclerosis;Ulcerative Colitis	Drug: Nivolumab	Alliance Foundation Trials, LLC.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	72	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	NCT03912428	June 14, 2019	1 July 2019	Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis	Evaluation of Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis	Myositis	Drug: Celecoxib	National Institute of Mental Health (NIMH)		Recruiting	18 Years	99 Years	All	47	Phase 1	United States
32	NCT03970837	June 5, 2019	22 October 2019	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)	A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs	Arthritis, Rheumatoid	Biological: GSK3196165;Drug: Tofacitinib;Drug: Placebo to GSK3196165;Drug: Placebo to Tofacitinib;Drug: csDMARDs	GlaxoSmithKline	Iqvia Pty Ltd	Recruiting	18 Years	N/A	All	1500	Phase 3	United States;Colombia
33	NCT03886038	June 1, 2019	1 April 2019	Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)	The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER)	Rheumatoid Arthritis;Healthy Controls	Biological: Shingrix	Region Skane		Not recruiting	18 Years	N/A	All	150	Phase 4	Sweden
34	NCT03619876	June 2019	27 May 2019	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis	Rheumatoid Arthritis;Myocardial Inflammation	Drug: Abatacept;Drug: Adalimumab	Columbia University	Bristol-Myers Squibb	Not recruiting	18 Years	N/A	All	20	Phase 4	United States
35	NCT04033809	May 30, 2019	29 July 2019	Effectiveness of Multigrain Supplementation Among the Rheumatoid Arthritis Patients	Effectiveness of High Fiber Multigrain Supplementation Among the Rheumatoid Arthritis Patients: A Randomized, Open Label Trial	Rheumatoid Arthritis	Dietary Supplement: Multigrain powder (S)	University of Science Malaysia		Not recruiting	21 Years	N/A	All	50	N/A	Malaysia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	NCT03980483	May 16, 2019	22 October 2019	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	Arthritis, Rheumatoid	Biological: GSK3196165;Drug: Tofacitinib 5 mg;Drug: Placebo to GSK3196165;Drug: Placebo to tofacitinib;Drug: Methotrexate;Drug: Folic (or folinic) acid	GlaxoSmithKline	Iqvia Pty Ltd	Recruiting	18 Years	N/A	All	1500	Phase 3	United States
37	NCT03823378	May 13, 2019	3 June 2019	A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.	A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial With ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599)	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: Upadacitinib placebo;Drug: ABBV-105 placebo;Drug: ABBV-105	AbbVie		Recruiting	18 Years	N/A	All	50	Phase 2	Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom
38	NCT03882008	April 25, 2019	29 April 2019	A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis	Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept	University of Washington	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	25	Phase 4	United States
39	NCT03915964	April 25, 2019	11 November 2019	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis	A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Baricitinib;Drug: TNF Inhibitor	Eli Lilly and Company	Incyte Corporation	Recruiting	18 Years	N/A	All	2600	Phase 4	United States;Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom
40	EUCTR2018-003933-14-EE	09/04/2019	30 April 2019	A study evaluating the effect of filgotinib on sperm parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis.	A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis.	Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: LLT Classification code 10076297 Term: Non-radiographic axial spondyloarthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Filgotinib Product Code: GLPG0634 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Galapagos NV		Authorised			Female: no Male: yes	250	Phase 2	Estonia;Spain;Ukraine;Russian Federation;India;Czech Republic;Belgium;Poland;Romania;Bulgaria;Germany;Latvia;Moldova, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	NCT03938636	April 8, 2019	22 October 2019	Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging	Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging	Rheumatoid Arthritis	Drug: TC99m-tilmanocept	Navidea Biopharmaceuticals		Recruiting	18 Years	N/A	All	105	Phase 2	United States
42	NCT03816345	April 4, 2019	11 November 2019	Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer	A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	Advanced Malignant Neoplasm;Autoimmune Disease;Crohn Disease;Dermatomyositis;Inflammatory Bowel Disease;Metastatic Malignant Neoplasm;Multiple Sclerosis;Rheumatoid Arthritis;Sjogren Syndrome;Systemic Lupus Erythematosus;Systemic Scleroderma;Ulcerative Colitis;Unresectable Malignant Neoplasm	Biological: Nivolumab	National Cancer Institute (NCI)		Recruiting	18 Years	N/A	All	264	Phase 1	United States
43	NCT03669367	April 1, 2019	21 January 2019	EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)	EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA)	Palindromic Rheumatism, Wrist	Drug: Abatacept Injection;Drug: hydroxycloroquina	Fundacion Clinic per a la Recerca Biomédica		Not recruiting	18 Years	N/A	All	98	Phase 4
44	NCT03700021	April 2019	4 February 2019	Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis	Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Abatacept + csDMARD	New York University School of Medicine		Not recruiting	18 Years	N/A	All	25	Phase 4	United States
45	NCT03823391	March 27, 2019	9 September 2019	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Drug: ABBV-3373;Drug: Placebo for ABBV-3373;Drug: Adalimumab;Drug: Placebo for adalimumab	AbbVie		Recruiting	18 Years	75 Years	All	45	Phase 1	United States;Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	NCT03885037	March 20, 2019	4 November 2019	Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Rheumatoid Arthritis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer		Recruiting	N/A	N/A	All	300	Phase 3	Japan
47	NCT04057118	March 20, 2019	4 November 2019	A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies	Rheumatoid Arthritis	Drug: SKI-O-703;Drug: Placebo	Oscotec Inc.		Recruiting	18 Years	N/A	All	148	Phase 2	United States;Czechia;Poland;Russian Federation;Ukraine
48	NCT03890302	March 14, 2019	8 April 2019	A Placebo-controlled Study to Evaluate the Safety, Movement Through, and Reaction of the Body to Single and Multiple Increasing Doses of FB704A	A Phase 1, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Single and Multiple Ascending Doses of FB704A	Rheumatoid Arthritis	Drug: FB704A;Drug: Placebo	Fountain Biopharma Inc.		Recruiting	18 Years	55 Years	All	41	Phase 1	United States
49	ChiCTR1900021808	2019-03-08	18 March 2019	A Phase 1, Randomized, Double-Blind and Paralle, Controlled Single-dose Clinical Trial of Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of QX003S and Tocilizumab in Chinese Health Male Subjects	A Phase 1, Randomized, Double-Blind and Paralle, Controlled Single-dose Clinical Trial of Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of QX003S and Tocilizumab in Chinese Health Male Subjects	Active rheumatoid arthritis	1:8 mg/kg QX003S ;2:Tocilizumab, 8 mg/kg;	JiangSu Qyuns Therapeutics Co., Ltd		Recruiting	18	50	Male	1:43;2:43;	Phase 1	China
50	NCT03813771	March 2019	4 February 2019	Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification	Targeted Treatment Early With Etanercept Plus Methotrexate Versus T2T Care for DMARD-naïve Early RA Patients. A Prospective, Longitudinal Cohort Study With Embedded Pilot Randomised Controlled Trial to Assess Treatment Rationalisation Based on naïve T-cell Stratification.	Rheumatoid Arthritis	Drug: Benepali;Drug: Sulfasalazine;Drug: Methotrexate;Drug: Hydroxychloroquine	University of Leeds	Samsung Bioepis Co., Ltd.	Not recruiting	18 Years	N/A	All	106	Phase 4	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	NCT03858725	February 26, 2019	18 March 2019	Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers	A Randomized, Open-label, Fasted, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteer	Rheumatoid Arthritis	Drug: D569 Tab.;Drug: CKD-374 5mg Tab.	Chong Kun Dang Pharmaceutical		Recruiting	19 Years	54 Years	All	36	Phase 1	Korea, Republic of
52	NCT03852355	February 25, 2019	1 April 2019	the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis	the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis; a Randomized Controlled Trial	Rheumatoid Arthritis;Headache	Drug: Radiofrequency;Drug: Steroids	Assiut University		Recruiting	18 Years	60 Years	All	60	N/A	Egypt
53	NCT03868072	February 22, 2019	18 March 2019	Study to Evaluate the Bioequivalence of Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical Chong Kun Dang Tofacitinib Tablet and Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	Rheumatoid Arthritis	Drug: XELJANZ 5Mg Tablet;Drug: Chong Kun Dang Tofacitinib Tablet	Chong Kun Dang Pharmaceutical		Recruiting	19 Years	N/A	All	40	Phase 1	Korea, Republic of
54	NCT03737708	February 13, 2019	18 March 2019	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)	Compare Efficacy and Safety Between Biologics + Methotrexate (MTX) vs Biologics + Tacrolimus (TAC) (Switched From Biologics + Methotrexate (MTX)) in the Patients With Rheumatoid Arthritis (RA): Randomized, Interventional, Open, Active Controlled, Parallel Group, Multicenter-designed, Phase 4 Clinical Trial	Rheumatoid Arthritis (RA)	Drug: tacrolimus;Drug: methotrexate;Biological: adalimumab;Biological: tocilizumab;Biological: abatacept	Astellas Pharma Korea, Inc.		Recruiting	19 Years	75 Years	All	148	Phase 4	Korea, Republic of
55	NCT03729349	January 15, 2019	22 October 2019	Golimumab for Adherence in Rheumatoid Arthritis	Golimumab for Adherence in Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Golimumab	Janssen Inc.		Recruiting	18 Years	85 Years	All	300	Early Phase 1	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	NCT03863405	January 9, 2019	3 June 2019	Metformin Use in Rheumatoid Arthritis	The Effect of Metformin on the Clinical Outcome of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo Oral Tablet;Drug: Conventional DMARDs;Drug: Metformin	Ain Shams University	Future University in Egypt	Recruiting	18 Years	N/A	All	60	Phase 2	Egypt
57	NCT03981900	January 4, 2019	22 July 2019	IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis	IDentification of Predictive Factors of Continuation of Treatment With Tofacitinib in Patients With Rheumatoid Arthritis in Common Practice and the Impact of the Patient's Behavioural Strategies on Clinical Parameters: The DeFacTo Study.	Arthritis, Rheumatoid	Drug: Tofacitinib	Pfizer		Recruiting	18 Years	N/A	All	500	Phase 1	France
58	EUCTR2018-000666-10-HU	03/01/2019	28 February 2019	A Phase 2 study to investigate the safety and efficacy of ABBV-105 given alone or in combination with ABT-494 (Upadacitinib) in patients with active rheumatoid arthritis who have failed prior treatment with biologic therapy	A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subjects with Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs	Rheumatoid Arthritis MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Code: ABBV-105 Pharmaceutical Form: Capsule CAS Number: 1643570-24-4 Current Sponsor code: ABBV-105 Other descriptive name: ABBV-105, A-1519938.0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Code: ABBV-105 Pharmaceutical Form: Capsule CAS Number: 1643570-24-4 Current Sponsor code: ABBV-105 Other descriptive name: ABBV-105, A-1519938.0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Other descriptive name: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	240	Phase 2	United States;Czech Republic;Hungary;Puerto Rico;Canada;Poland;Belgium;Spain;Germany;United Kingdom
59	NCT03896594	December 24, 2018	15 April 2019	A Multiple Dose of HL237 in Healthy Male Subject	A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Oral Dose of HL237 in Healthy Male Subject	Rheumatoid Arthritis	Drug: HL237;Drug: Placebo Oral Tablet	Hanlim Pharm. Co., Ltd.		Recruiting	20 Years	45 Years	Male	36	Phase 1	Korea, Republic of
60	NCT03652961	December 21, 2018	14 January 2019	Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA)	Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA)	Rheumatoid Arthritis	Drug: Abatacept	Dartmouth-Hitchcock Medical Center	New York University School of Medicine	Recruiting	18 Years	N/A	All	25	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	NCT03574545	December 19, 2018	4 November 2019	Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis	A Randomized, Open Label, Multiple Dose, Parallel Group Study to Assess the Safety and Pharmacokinetic Comparability of Two VAY736 Drug Products in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: VAY736	Novartis Pharmaceuticals		Recruiting	18 Years	65 Years	All	50	Phase 1	Germany;Jordan
62	NCT03830203	December 19, 2018	25 February 2019	Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	A Randomized, Double-Blind, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: BAT1806;Drug: Actemra(EU-licensed)	Bio-Thera Solutions		Recruiting	18 Years	N/A	All	612	Phase 3	China
63	EUCTR2018-001690-25-PL	11/12/2018	7 January 2019	Evaluating efficacy and safety between CT-P17 and Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	Moderate to Severe Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CT-P17 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: CT-P17 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	Celltrion, Inc		Authorised			Female: yes Male: yes	564	Phase 3	Hungary;Poland;Ukraine;Lithuania;Peru;Russian Federation;Bulgaria;Bosnia and Herzegovina
64	NCT03729674	November 26, 2018	3 December 2018	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Rheumatoid Arthritis;Ankylosing Spondylitis;Ulcerative Colitis;Crohn's Disease	Drug: Biosimilar;Drug: Originator (legacy) drug	McGill University Health Center	Université de Sherbrooke;Institut de rhumatologie de Montréal;Hospital for Special Surgery, New York;University of Manitoba;University of Toronto;University of Alberta;University of British Columbia;Alberta Health Services;McMaster University;The Arthritis Program Research Group	Not recruiting	18 Years	N/A	All	800	Phase 3
65	NCT03789292	November 26, 2018	8 April 2019	A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis	A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 With Humira When Co-administered With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: CT-P17 SC;Biological: Humira SC	Celltrion		Not recruiting	18 Years	75 Years	All	564	Phase 3	Bulgaria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	NCT03755466	November 21, 2018	10 December 2018	Examination of Efficacy and Safety of Baricitinib in RA Patients	Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib	Rheumatoid Arthritis	Drug: Baricitinib, olumiant®;Drug: Biologics;Drug: Tofacitinib 5 MG [Xeljanz]	Shinshu University		Recruiting	20 Years	N/A	All	90	Phase 2	Japan
67	NCT03980639	November 20, 2018	24 June 2019	Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase	Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase	Rheumatoid Arthritis	Drug: patient treated with DMARD	University Hospital, Toulouse		Recruiting	18 Years	N/A	All	594226	N/A	France
68	NCT03852888	November 14, 2018	11 March 2019	Kinetics of Elimination of Methotrexate and Its Major Metabolite 7-OH-methotrexate for Observant Patients	Kinetics of Elimination of Methotrexate and Its Major Metabolite 7-OH-methotrexate for Observant Patients	Rheumatoid Arthritis	Biological: Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level	CHU de Reims		Recruiting	18 Years	N/A	All	60	N/A	France
69	EUCTR2018-001690-25-HU	13/11/2018	19 November 2018	Evaluating efficacy and safety between CT-P17 and Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	Moderate to Severe Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CT-P17 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: CT-P17 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	Celltrion, Inc		Authorised			Female: yes Male: yes	564	Phase 3	Hungary;Poland;Ukraine;Lithuania;Peru;Russian Federation;Bulgaria;Bosnia and Herzegovina
70	NCT03707535	November 12, 2018	29 April 2019	To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis	A Randomized, Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: CT-P13;Biological: Remicade	Celltrion		Recruiting	18 Years	75 Years	All	270	Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	ChiCTR1800019277	2018-11-01	5 November 2018	The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients	The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients	Rheumatoid Arthritis	Control group:MTX;Treatment group 1:Zoledronate Acid(ZA);Treatment group 2:MTX+Zoledronate Acid;	Shanghai Traditional Medicine University Affiliated Guanghua Hospital		Recruiting	18	65	Both	Control group:22;Treatment group 1:22;Treatment group 2:22;	Other	China
72	EUCTR2017-004226-15-DK	26/10/2018	26 November 2018	Can-Art Effect and safety of using Canabis derivatives for the treatment of pain in patients with inflammatory Arthritis, such as reumatoid arthritis and ankylosing spondylitis, the latter being a type of arthritis that causes a long term inflammation of the joints of the spine. A randomized, double blinded, placebo controlled trial, i.e. in this drug trial, a control group is given a placebo while another group is given the Cannabis derivative being studied.	CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A randomized, double blinded, placebo controlled trial - Can-Art	Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Cannabidiol tablet 10 mg Pharmaceutical Form: Tablet CAS Number: 13956-29-1 Other descriptive name: CANNABIDIOL Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Dronabinol capsule 2.5. mg Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3	King Christian 10th Hospital for Rheumatology		Authorised			Female: yes Male: yes	180	Phase 2	Denmark
73	ChiCTR1900026079	2018-10-25	30 September 2019	Wangbi capsule combined methotrexate tablets for treatment of Rheumatoid Arthritis: A Randomized,Double-blind,Single analog,Positive Drug Parallel-group controlled clinical study	Wangbi capsule combined methotrexate tablets for treatment of Rheumatoid Arthritis: A Randomized,Double-blind,Single analog,Positive Drug Parallel-group controlled clinical study	Rheumatoid Arthritis	Experimental group:Wangbi capsule combined methotrexate tablets;Control group:Simulation of Wangbi capsule combined methotrexate tablets;	Longhua Hospital Shanghai University of Traditional Chinese Medicine		Recruiting	18	70	Both	Experimental group:60;Control group:60;	Phase 4	China
74	NCT03718611	October 22, 2018	22 July 2019	To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects	A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects	Rheumatoid Arthritis	Drug: BR9001;Drug: BR900A	Boryung Pharmaceutical Co., Ltd		Not recruiting	19 Years	50 Years	All	36	Phase 1	Korea, Republic of
75	NCT03682705	October 8, 2018	14 October 2019	A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.	A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: ABBV-105;Drug: Upadacitinib placebo;Drug: ABBV-105 placebo	AbbVie		Recruiting	18 Years	N/A	All	240	Phase 2	United States;Belgium;Canada;Czechia;Hungary;Poland;Puerto Rico;Spain;United Kingdom;Germany;Ireland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	JPRN-JapicCTI-184031	02/10/2018	7 October 2019	A Phase III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Without Methotrexate (MTX) Therapy	A Phase III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Without Methotrexate (MTX) Therapy	Rheumatoid Arthritis (RA)	Intervention name : TS-152 INN of the intervention : ozoralizumab Dosage And administration of the intervention : Subcutaneous injection every 4 weeks Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Taisho Pharmaceutical co., LTD		Not Recruiting	20		BOTH	135	Phase 3	Japan
77	NCT03511625	October 2, 2018	7 October 2019	The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis	The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study	Rheumatoid Arthritis	Drug: Acthar Injectable Product;Drug: Depo medrol	Attune Health Research, Inc.	Mallinckrodt	Recruiting	18 Years	N/A	All	6	Phase 3	United States
78	NCT03546335	October 1, 2018	22 October 2018	Zr-89 Cimzia PET Imaging Rheumatoid Arthritis	Zirconium-89 Certolizumab PET Imaging in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 89Zr-DFO-CZP	University of California, San Francisco		Recruiting	18 Years	N/A	All	10	Phase 1	United States
79	NCT03593837	October 1, 2018	20 August 2018	Efficacy and Safety of HQGZWWT Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Huang Qi GuiZhi Wu Wu Tang Granulesin Patients With Rheumatoid Arthritis	Huang Qi Gui Zhi Wu Wu Granule;Rheumatoid Arthritis	Drug: Huang qi gui zhi wu wu granule;Drug: Huang qi gui zhi wu wu granule placebo	Cui xuejun		Not recruiting	18 Years	80 Years	All	100	Phase 2/Phase 3
80	NCT03770702	October 1, 2018	18 December 2018	Statins and ARBs on Rheumatoid Activity	Investigational and Comparative Study Between the Anti-inflammatory Effectof Both Angiotensin Reeptor Blockers and Statins on Rheumatoid Arthritis Disease Activity on Egyptian Patients	Rheumatoid Arthritis	Drug: Angiotensin receptor blockers;Drug: Statins	Sherief Abd-Elsalam		Recruiting	18 Years	65 Years	All	45	Phase 3	Egypt
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	NCT03770923	October 1, 2018	18 December 2018	Effect of Some Drugs on Rheumatoid Arithritis Activity	Clinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid Arithritis	Rheumatoid Arthritis	Drug: Rupatadine;Drug: Montelukast	Sherief Abd-Elsalam		Recruiting	18 Years	N/A	All	75	Phase 3	Egypt
82	NCT03660059	September 27, 2018	16 September 2019	A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)	A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX	Rheumatoid Arthritis (RA)	Drug: Peficitinib;Drug: Plaebo;Drug: Disease-modifying antirheumatic drugs (DMARDs)	Astellas Pharma China, Inc.		Recruiting	18 Years	N/A	All	375	Phase 3	China;Korea, Republic of;Taiwan
83	ChiCTR1800018637	2018-09-26	10 October 2018	Correlation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritis	Correlation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritis	rheumatoid arthritis	Gold Standard:Clinical outcome, meet the 2010 ACR/EULAR rheumatoid arthritis classification criteria.;Index test:Human epididymis protein 4,anti-cyclic citrullinated peptide, creatinine, rheumatoid factor;	Affiliated Hospital of North Sichuan Medical College		Recruiting			Both	Target condition:150;Difficult condition:100	Diagnostic New Technique Clincal Study	China
84	NCT03691909	September 25, 2018	2 September 2019	A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis	A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: HB-adMSC	Hope Biosciences		Not recruiting	18 Years	65 Years	All	15	Phase 1/Phase 2	United States
85	NCT03699293	September 22, 2018	15 October 2018	NSAIDs vs. Coxibs in the Presence of Aspirin	NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease	Rheumatoid Arthritis;Cardiovascular Diseases	Drug: celecoxib 200mg capsule;Drug: naproxen sodium 550mg tablet;Drug: Aspirin 81mg tablet	Inova Health Care Services		Recruiting	18 Years	75 Years	All	30	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
86	EUCTR2018-001114-15-NL	18/09/2018	28 February 2019	Predicting the risk for rheumatoid arthritis with the help of a PET scan.	Positron emission tomography with macrophage targeting to select individuals at risk for rheumatoid arthritis. - Early diagnostics in RA	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: [18F]PEG-Folate Pharmaceutical Form: Solution for injection	VU Medical Center, department of Rheumatology		Authorised			Female: yes Male: yes	60	Phase 4	Netherlands
87	JPRN-JapicCTI-184229	12/9/2018	16 July 2019	Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for the First Time With Pralia Subcutaneous Injection 60 mg Syringe -Medical Information Database Network-based Cohort Study-	Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for the First Time With Pralia Subcutaneous Injection 60 mg Syringe -Medical Information Database Network-based Cohort Study-	Rheumatoid Arthritis	Intervention name : PRALIA 60mg Subcutaneous Injection Syringe(denosumab) Dosage And administration of the intervention : For adults under normal conditions, 60 mg of denosumab (genetic recombination) is injected subcutaneously every six months. If bone erosion progression occurs when denosumab is injected once every 6 months, denosumab can be injected subcutaneously once every 3 months.	DAIICHISANKYO Co., Ltd.		Not Recruiting			BOTH	2000	NA
88	NCT03701789	September 11, 2018	22 October 2019	Effect of Baricitinib Treatment on Peripheral Bone in RA	Evaluation of Bone Quality in Patients With Rheumatoid Arthritis Treated With Baricitinib: Single Centre, Mode of Action Study (BARE BONE)	Rheumatoid Arthritis;Bone Density;Finger Joints	Drug: Baricitinib	University of Erlangen-Nürnberg Medical School		Recruiting	18 Years	74 Years	All	15	Phase 3	Germany
89	JPRN-JapicCTI-184029	04/9/2018	7 October 2019	A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) Therapy	A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) Therapy	Rheumatoid Arthritis (RA)	Intervention name : TS-152 INN of the intervention : ozoralizumab Dosage And administration of the intervention : Subcutaneous injection every 4 weeks Control intervention name : Placebo INN of the control intervention : Placebo Dosage And administration of the control intervention : Usage: Subcutaneous injection every 4 weeks, Dosage: No active ingredients contain	Taisho Pharmaceutical co., LTD		Not Recruiting	20	75	BOTH	370	Phase 2-3	Japan
90	NCT04079374	September 3, 2018	22 October 2019	Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel	Open, Randomized, Comparative, Multicenter Study in Parallel Groups of the Efficacy, Safety, Immunogenicity of Etanercept and Enbrel, Lyophilisates for Solution for Subcutaneous Injection, in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Enbrel	Joint Stock Company Farmak	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Recruiting	18 Years	75 Years	All	160	Phase 3	Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
91	EUCTR2015-004386-91-PL	26/08/2018	7 January 2019	Study to explore and compare the effects of a new drug in combination with methotrexate therapy in people with early and established rheumatoid arthritis.	A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination with Methotrexate Therapy in Subjects with Active Rheumatoid Arthritis Despite Treatment with DMARDs	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: GSK3196165 Pharmaceutical Form: Solution for injection INN or Proposed INN: INN not available CAS Number: 1638332-55-4 Current Sponsor code: GSK3196165 Other descriptive name: Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	40	Phase 2	United States;Poland;Germany
92	NCT03636984	August 24, 2018	27 August 2018	Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World	Efficacy and Safety Study of Anbainuo in Chinese Patients With Rheumatoid Arthritis/ Ankylosing Spondylitis in the Real World: a Prospective, Open-label, Multi-center Observational Study	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: recombinant TNF-a receptor: IgG Fc fusion protein	Zhejiang Hisun Pharmaceutical Co. Ltd.		Not recruiting	18 Years	N/A	All	1000	Phase 2/Phase 3
93	NCT03535519	August 7, 2018	26 August 2019	Rheumatoid Arthritis Response to Methotrexate	Rheumatoid Arthritis Ultrasound Response to Methotrexate	Rheumatoid Arthritis	Drug: Methotrexate	Juan Carlos Nieto	Nordic Pharma SAS	Recruiting	18 Years	N/A	All	50	Phase 4	Spain
94	NCT04066803	August 1, 2018	2 September 2019	Optimal MTX Dose With Folic Acid Randomized Case-control Trial	Safety and Efficacy of Optimal Methotrexate With Folic Acid in Patients With Rheumatoid Arthritis in Meizhou, Guangdong: a Randomized Case-control Study	Rheumatoid Arthritis	Drug: DMARDs;Drug: Folic Acid;Drug: MTX	Sun Yat-sen University	Shanghai Pharmaceuticals Holding Co., Ltd	Recruiting	18 Years	70 Years	All	160	Phase 4	China
95	EUCTR2018-002368-18-ES	25/07/2018	20 August 2018	Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with increased antigenic load	Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with increased antigenic load	1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab. 2. breast and lung cancer undertreated by chemotherapy 3. HIV 4. Haematopoietic progenitor cell transplantation (TCPH). MedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 MedDRA version: 20.0 Level: PT Classification code 10058467 Term: Lung neoplasm malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestations MedDRA version: 20.0 Level: PT Classification code 10063581 Term: Stem cell transplant System Organ Class: 10042613 - Surgical and medical procedures ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Fendrix suspension for injection Product Code: Fendrix Pharmaceutical Form: Suspension for injection INN or Proposed INN: Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). Other descriptive name: HEPATITIS B VACCINE (RDNA) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 20- Trade Name: HBVAXPRO 5 micrograms/0.5 ml Product Code: HBVAXPRO® 40 micrograms Pharmaceutical Form: Suspension for injection INN or Proposed INN: HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) Other descriptive name: HEPATITIS B VIRUS SURFACE ANTIGEN RECOMBINANT (S PROTEIN) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 5-	FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)		Authorised			Female: yes Male: yes	740	Phase 4	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
96	NCT03618784	July 11, 2018	26 August 2019	Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: FURESTEM-RA Inj;Other: sterile saline	Kang Stem Biotech Co., Ltd.		Not recruiting	19 Years	80 Years	All	33	Phase 1/Phase 2	Korea, Republic of
97	EUCTR2017-004079-30-ES	10/07/2018	23 July 2018	Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology	Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab. - STRAP-EU	Rhuematoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Other descriptive name: Rituximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: RoActmera Product Name: RoActmera Pharmaceutical Form: Solution for injection Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled pen	Joint Research & Development Office (QMUL)		Authorised			Female: yes Male: yes	207	Phase 3	Portugal;Belgium;Spain;Italy
98	NCT03445871	July 2, 2018	29 July 2019	Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate	Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate	Rheumatoid Arthritis	Biological: Blood sample;Diagnostic Test: CRQ	Centre Hospitalier Universitaire de Saint Etienne		Recruiting	18 Years	N/A	All	60	Phase 4	France
99	NCT03605251	July 1, 2018	11 February 2019	Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.	An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: TAS5315 low dose;Drug: TAS5315 high dose;Drug: Placebos	Taiho Pharmaceutical Co., Ltd.		Recruiting	20 Years	64 Years	All	90	Phase 2	Japan
100	NCT02885597	July 2018	23 July 2018	Juanbi Pill for Rheumatoid Arthritis	Juanbi Pill Combined With Methotrexate for Rheumatoid Arthritis: Multi-center Random Controlled Clinical Trials	Juanbi Pill;Rheumatoid Arthritis	Drug: Juanbi pill;Drug: Juanbi pill placebo;Drug: Methotrexate	Cui xuejun	Shanghai Yueyang Integrated Medicine Hospital;Longhua Hospital;Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine	Recruiting	18 Years	80 Years	All	120	Phase 2/Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
101	NCT03173040	July 2018	23 July 2018	The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis	The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis: a Study Protocol for a Multicenter, Randomized, Controlled Clinical Trial	Niu Bang Zi Pill;Rheumatoid Arthritis	Drug: NiuBangZi pill or NiuBangZi pill placebo	Cui xuejun	Shanghai Yueyang Integrated Medicine Hospital;Longhua Hospital;Shanghai Seventh People's Hospital	Recruiting	18 Years	80 Years	All	100	Phase 2/Phase 3	China
102	NCT03589833	July 2018	20 August 2018	Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA	Effectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Tripterygium Wilfordii;Drug: Methotrexate;Drug: Yisaipu	Peking Union Medical College Hospital		Recruiting	18 Years	65 Years	All	504	Phase 2	China
103	NCT03084419	June 26, 2018	29 July 2019	APRIL (AbatacePt in Rheumatoid Arthritis-ILD)	Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Feasibility Trial	Rheumatoid Arthritis;Interstitial Lung Disease	Drug: Abatacept	Cambridge University Hospitals NHS Foundation Trust	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	30	Phase 2	United Kingdom
104	JPRN-UMIN000033059	2018/06/20	23 April 2019	The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial	The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial - The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial	Osteoarthritis of the hip, rheumatoid arthritis, avascular necrosis of the femoral head, femoral neck fracture	A periarticular injection including methylprednisolone, ropivacaine, morphine, bosmin, and ketoprofen for pain after total hip arthroplasty A periarticular injection including ropivacaine, morphine, bosmin, and ketoprofen for pain after total hip arthroplasty	Hokusuikai Kinen Hospital		Not Recruiting	18years-old	Not applicable	Male and Female	120	Not selected	Japan
105	NCT03550833	June 13, 2018	30 September 2019	Impact of Life Events and Psychological Stress in Rheumatoid Arthritis Set-up : Case-control Study Within a Multifactorial and Integrative Psychological Model	Impact of Life Events and Psychological Stress in Rheumatoid Arthritis Set-up : Case-control Study Within a Multifactorial and Integrative Psychological Model	Arthritis, Rheumatoid;Stress Disorder	Behavioral: Questionnaire;Biological: blood sample	University Hospital, Bordeaux		Not recruiting	18 Years	N/A	All	152	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
106	NCT03606876	June 13, 2018	28 January 2019	Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects	A Randomized, Double-blinded, Single-dose, 3-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT1806 Injection vs Actemra® in Healthy Chinese Male Subjects	Rheumatoid Arthritis	Drug: BAT1806 injection	Bio-Thera Solutions		Not recruiting	18 Years	55 Years	Male	138	Phase 1	China
107	NCT03535402	June 1, 2018	15 July 2019	Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics	Measurement of the Structural Efficacy in Active Rheumatoid Arthritis (RA) Patients Treated With Sarilumab in Combination With Methotrexate (MTX) and Naive to Biologics as Measured by Low-field MRI Using a Modified OMERACT-RAMRIS Score.	Rheumatoid Arthritis	Drug: Sarilumab	Gaylis, Norman B., M.D.		Recruiting	18 Years	N/A	All	20	Phase 3	United States
108	NCT03559686	May 30, 2018	15 July 2019	Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)	Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Arthritis (RA) Who Participated in Open Label Studies C87015, C87028 and C87051	Rheumatoid Arthritis	Drug: Certolizumab Pegol	UCB Biopharma S.P.R.L.		Not recruiting	18 Years	N/A	All		Phase 3
109	NCT03522415	May 28, 2018	23 July 2018	Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HLX01 (Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection) Combined With MTX Therapy in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Moderately to Severely Active Rheumatoid Arthritis	Drug: HLX01;Drug: Methotrexate(MTX)	Shanghai Henlius Biotech		Recruiting	18 Years	75 Years	All	267	Phase 3	China
110	NCT03410056	May 22, 2018	4 November 2019	Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy	Rheumatoid Arthritis RA	Drug: AMG 592;Drug: Placebo	Amgen		Not recruiting	18 Years	70 Years	All	153	Phase 1/Phase 2	United States;Bulgaria;Germany;Poland;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
111	EUCTR2017-001944-36-ES	21/05/2018	18 June 2018	Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy	Rheumatoid Arthritis MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: AMG592 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG 592 Current Sponsor code: AMG 592 Other descriptive name: RECOMBINANT FACTOR FC FUSION PROTEIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Authorised			Female: yes Male: yes	137	Phase 1;Phase 2	United States;Czech Republic;Mexico;Poland;Spain;Romania;Australia;Bulgaria;Germany;New Zealand;United Kingdom
112	NCT03378219	May 18, 2018	26 August 2019	An Observational Study on Sarilumab-exposed Pregnancies	Kevzara® (Sarilumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study	Rheumatoid Arthritis -Exposure During Pregnancy	Drug: Sarilumab SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Recruiting	N/A	N/A	Female	300	N/A	United States;Canada
113	NCT03508713	May 13, 2018	11 June 2018	Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)	Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND): a Multicenter Prospective Observational Study in Southern China	Rheumatoid Arthritis	Drug: disease modified antirheumatic drugs or biological agents	Nanfang Hospital of Southern Medical University	Southern Medical University, China	Not recruiting	18 Years	N/A	All	200	Phase 3
114	EUCTR2017-004054-41-BE	07/05/2018	3 September 2018	COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA	CareRA2020: Effectiveness of a combination of Methotrexate and a step down glucocorticoid regimen (COBRA-Slim) for remission induction in patients with early Rheumatoid Arthritis (RA), with or without fast access to 24 weeks of Tumor Necrosis Factor (TNF) blockade in insufficient responders, a randomized, multicenter, pragmatic trial. - CareRA2020	early active Rheumatoid Arthritis, previously untreated with DMARDs MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: etanercept Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical Form: Coated tablet INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706-12-6 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 10-20	University Hospitals Leuven		Authorised			Female: yes Male: yes	440	Phase 4	Belgium
115	EUCTR2016-002569-68-GB	04/05/2018	28 May 2018	Safety of abatacept in Rheumatoid Arthritis associated Interstitial Lung Disease	Safety of abatacept in Rheumatoid Arthritis associated Interstitial Lung Disease: A feasibility study - APRIL	Rheumatoid-associated Interstitial Lung Disease (RA-ILD) MedDRA version: 20.0 Level: PT Classification code 10022611 Term: Interstitial lung disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Orencia Product Name: Orencia Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 3 332348-12 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: up to Concentration number: 10-	Cambridge University Hospitals NHS Foundation Trust		Authorised			Female: yes Male: yes	30	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
116	NCT03492658	May 2018	11 June 2018	Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)	Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA).	Rheumatoid Arthritis;Rheumatic Diseases	Drug: Abatacept;Drug: Methotrexate	Leiden University Medical Center		Not recruiting	18 Years	N/A	All	46	Phase 4
117	NCT03435601	April 18, 2018	11 June 2018	A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)	A Randomised, Double-blind, Placebo-controlled Phase II Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)	Rheumatoid Arthritis	Drug: Anifrolumab;Drug: Placebos	Josef Smolen, Univ. Prof. Dr.		Recruiting	18 Years	70 Years	All	24	Phase 2	Austria
118	NCT03493269	April 16, 2018	22 October 2019	A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis	A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1834845 in Healthy Male Subjects and in Female and Male Patients With Rheumatoid Arthritis or Psoriasis Over an Extended Treatment Duration	Healthy Volunteers	Drug: BAY1834845;Other: Matching Placebo;Drug: Midazolam	Bayer		Recruiting	18 Years	65 Years	All	88	Phase 1	Germany
119	JPRN-UMIN000030575	2018/03/31	22 July 2019	Comparative study of the inhibitory effect on bone erosion progression with Denosumab treatment and conventional treatment in rheumatoid arthritis patients. An open label randomized controlled trial by HR-pQCT.	Comparative study of the inhibitory effect on bone erosion progression with Denosumab treatment and conventional treatment in rheumatoid arthritis patients. An open label randomized controlled trial by HR-pQCT. - Comparative study of the inhibitory effect on bone erosion progression with Denosumab treatment and conventional treatment in rheumatoid arthritis patients. An open label randomized controlled trial by HR-pQCT.	Rheumatoid arthritis	Patients of the group that starts treatment of Denosumab will be treated with Denosumab at the time of visit on Month 0 and Month 6. Patients of the group that continues conventional treatment will be not treated with Denosumab as a rule.	Daiichi Sankyo Company, Limited		Recruiting	20years-old	Not applicable	Male and Female	44	Not applicable	Japan
120	NCT03478111	March 30, 2018	30 September 2019	CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis	A Randomized, Double-blind, Methotrexate (MTX) Based, Parallel-group, Multicenter Phase III Study to Evaluate Efficacy and Safety of CMAB008 in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis, Compared to Remicade	Rheumatoid Arthritis	Drug: CMAB008;Drug: MTX;Drug: Remicade	Shanghai Biomabs Pharmaceutical Co., Ltd.		Not recruiting	18 Years	N/A	All	390	Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
121	JPRN-UMIN000031890	2018/03/21	2 April 2019	Triple-masked randomized comparison of 5mL or 20nL levobupivacaine to femoral triangle block for total knee arthroplasty		knee osteoarthritis or knee rheumatoid arthritis	Group LV(Low volume): preoperative femoral triangle block with 0.5% levobupivacaine 5mL Group HV(High volume): preoperative femoral triangle block with 0.125% levobupivacaine 20mL	Daiyukai General Hospital		Recruiting	20years-old	100years-old	Male and Female	120	Phase 3	Japan
122	NCT03449758	March 9, 2018	9 September 2019	Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis	Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors	Rheumatoid Arthritis	Drug: SARILUMAB;Drug: Azathioprine;Drug: Chloroquine;Drug: Hydroxychloroquine;Drug: Leflunomide;Drug: Methotrexate;Drug: Sulfasalazine	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	84	Phase 4	France
123	ChiCTR1800014584	2018-03-01	29 January 2018	Clinical efficacy of small dose aspirin in the prevention of deep venous thrombosis and pulmonary embolism after total knee arthroplasty.	Clinical efficacy of small dose aspirin in the prevention of deep venous thrombosis and pulmonary embolism after total knee arthroplasty.	Knee osteoartritis;Rheumatoid arthritis	Experimental group:Asprin;Controlled group:Rivaroxaban;	Department of Orthopaedics, West China Hospital, Sichuan University		Not Recruiting	70	100	Both	Experimental group:90;Controlled group:30;	Other	China
124	ChiCTR1800014872	2018-03-01	19 February 2018	Role of parecoxib sodium in the multimodal analgesia after total knee arthroplasty	Safety and efficacy of parecoxib sodium in the multimodal analgesia after total knee arthroplasty: a prospective randomized controlled trial	osteoarthritis or rheumatoid arthritis	Experimental group:Preoperative intravenous injection of parecoxib sodium and postoperative intravenous patient-controlled analgesia;Control group:Preoperative normal saline injection and postoperative intravenous patient-controlled analgesia;	Peking Union Medical College Hospital		Not Recruiting			Both	Experimental group:50;Control group:50;	Post-market	China
125	JPRN-UMIN000031692	2018/03/01	7 October 2019	Efficacy and Safety of repeated administration of intravenous acetaminophen injection for pain management after total knee arthroplasty	Efficacy and Safety of repeated administration of intravenous acetaminophen injection for pain management after total knee arthroplasty - Efficacy of intravenous acetaminophen injection for pain management after TKA	knee osteoarthritis rheumatoid arthritis	Study group:Fentanyl sustained intravenous administration given after operation end. And use the Intravenous acetaminophen 4 times per 6 hour.Dosage is 15 mg/kg for the patient less than 50 kg in weight and 1000 mg for the patient more than 50 kg in weight. Control group:Fentanyl sustained intravenous administration given after operation end.	Yamaguchi University		Recruiting	20years-old	Not applicable	Male and Female	60	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
126	NCT03100253	March 1, 2018	30 September 2019	Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation	Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Etanercept;Drug: Infliximab;Drug: Adalimumab;Drug: Golimumab;Drug: Certolizumab Pegol	Mario Negri Institute for Pharmacological Research		Recruiting	18 Years	N/A	All	400	Phase 4	Italy
127	NCT03470688	March 1, 2018	11 June 2018	Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents	An Observational Study Designed to Investigate the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents in Australian Rheumatology	Rheumatoid Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis	Biological: Originator;Biological: Biosimilar	Opal Rheumatology Ltd.	Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	All	5000	Phase 4	Australia
128	NCT03480529	March 1, 2018	16 September 2019	Monitoring the IMmUological TOXicity of Drugs	Monitoring the IMmUological TOXicity of Drugs	Arthritis;Systemic Lupus Erythematosus;Rheumatoid Arthritis;Capillary Leak Syndrome;Hepatitis	Drug: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom	Groupe Hospitalier Pitie-Salpetriere	Institut National de la Santé Et de la Recherche Médicale, France	Not recruiting	18 Years	N/A	All	662	Early Phase 1	France
129	EUCTR2017-004079-30-BE	19/02/2018	30 April 2019	Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology	Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab. - STRAP-EU	Rheumatoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion Trade Name: RoActmera Product Name: RoActmera Pharmaceutical Form: Solution for injection Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled pen	Joint Research & Development Office (QMUL)		Authorised			Female: yes Male: yes	219	Phase 3	Portugal;Spain;Belgium;Italy
130	EUCTR2017-002878-38-NL	07/02/2018	5 March 2018	Abatacept to Silence anti-Citrullinated protein Antibody-expressing B cells in Rheumatoid Arthritis	Abatacept to Silence anti-Citrullinated protein Antibody-expressing B cells in Rheumatoid Arthritis - ASCARA	Patients with early, methotrexate-naïve, ACPA-positive rheumatoid arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000018818 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Orencia 125 mg Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125-	Leiden University Medical Center		Authorised			Female: yes Male: yes	46	Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
131	NCT03455842	February 1, 2018	11 February 2019	The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis	International Multicenter Comparative Randomized Double-blind Placebo-controlled Clinical Study of Efficacy and Safety of BCD-089 in Different Dosing Regimens in Patients With Active Rheumatoid Arthritis	Seropositive RA	Drug: placebo;Biological: BCD-089, 162 mg, s/c, q2w;Biological: BCD-089, 162 mg, s/c, qw	Biocad		Not recruiting	18 Years	80 Years	All	105	Phase 2	Belarus;Russian Federation
132	NCT04022525	February 1, 2018	29 July 2019	Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches	Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches	Rheumatoid Arthritis	Drug: Leflunomide 20Mg Tab	Assiut University		Not recruiting	18 Years	N/A	All	80	Phase 1/Phase 2	Egypt
133	NCT01694693	January 31, 2018	16 December 2017	Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study	Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study	Rheumatoid Arthritis	Drug: Orencia	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	0	N/A
134	NCT03430388	January 31, 2018	6 May 2019	Yellow Fever Vaccine in Patients With Rheumatic Diseases	Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area	Systemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile Dermatomyositis	Biological: Yellow Fever vaccine (17D)	University of Sao Paulo General Hospital		Not recruiting	2 Years	60 Years	All	600	N/A	Brazil
135	EUCTR2017-002753-11-FI	25/01/2018	30 April 2019	The effect of the new anti-rheumatic drug tofacitinib on cytokine-induced inflammatory pathways in patients with rheumatoid arthritis	The effect of tofacitinib on the activity of JAK-STAT pathways in patients with rheumatoid arthritis (RA) - TofaSTAT17	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Xeljanz Product Name: Xeljanz Product Code: PRD4862257 Pharmaceutical Form: Tablet CAS Number: 540737-29-9 Other descriptive name: TOFACITINIB CITRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Tofacitinib Product Code: PRD4862257	Tampere University Hospital		Authorised			Female: yes Male: yes	24	Phase 4	Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
136	NCT03227419	January 22, 2018	3 September 2018	Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders	Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial	Arthritis, Rheumatoid	Drug: Tocilizumab Prefilled Syringe;Drug: Abatacept Prefilled Syringe	Lille Catholic University		Recruiting	18 Years	N/A	All	224	Phase 4	France
137	NCT03368235	January 18, 2018	4 November 2019	Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis	A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 Compared to Prednisolone 20 mg in Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: AZD9567;Drug: Prednisolone	AstraZeneca		Recruiting	18 Years	80 Years	All	40	Phase 2	Denmark;Netherlands;Sweden
138	JPRN-UMIN000030828	2018/01/15	2 April 2019	The preventive effect for new vertebral fractures of zoledronic acid and denosumab combined with vitamin D in patients with rheumatoid arthritis.		Rheumatoid Arthritis Osteoporosis	zoledronic acid denosumab	Osaka City University Graduate School of Medicine		Recruiting	20years-old	Not applicable	Male and Female	500	Not selected	Japan
139	EUCTR2017-003259-40-ES	04/01/2018	8 January 2018	Periodontitis treatment in patients with reumatoid arthritis and high clinical activity in the. Randomized clinical trial.	Periodontitis treatment in patients with reumatoid arthritis and high clinical activity in the. Randomized clinical trial.	Patients with rheumatoid arthritis with high clinical activity and chronical peirodontitis moderate-severe. MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: amoxicilina Pharmaceutical Form: Buccal tablet INN or Proposed INN: AMOXICILLIN CAS Number: 26787-78-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Product Name: metronidazol Pharmaceutical Form: Buccal tablet INN or Proposed INN: METRONIDAZOLE Other descriptive name: metronidazol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-	Dra Beatriz Lozano-Hospital Universitario de Canarias		Authorised			Female: yes Male: yes	120	Phase 4	Spain
140	NCT02955212	January 3, 2018	30 September 2019	A Study With Upatacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: Placebo	AbbVie		Not recruiting	18 Years	N/A	All	338	Phase 3	Brazil;China;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
141	JPRN-UMIN000030237	2018/01/01	2 April 2019	Additional postoperative intravenous tranexamic acid administration versus placebo administration for patients treated with intraoperative combined intravenous and intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind, placebo-controlled trial		Osteoarthritis of the knee, rheumatoid arthritis, avascular necrosis	Additional postoperative intravenous tranexamic acid group: Patients received 1000 mg of tranexamic acid administered intravenously just before skin incision and 1000 mg of tranexamic acid administered intra-articularly after closure of the capsule and retinaculum. In addition, patients received 1000mg/100mL of tranexamic acid administered intravenously 6 hours after the first intravenous administration of tranexamic acid, and 08:00 and 20:00 one day after surgery. Placebo group: Patients received 1000 mg of tranexamic acid administered intravenously just before skin incision and 1000 mg of tranexamic acid administered intra-articularly after closure of the capsule and retinaculum. Patients received 100 mL of normal saline administered intravenously 6 hours after the first intravenous administration of tranexamic acid, and 08:00 and 20:00 one day after surgery.	Hokusuikai Kinen Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	100	Not selected	Japan
142	NCT02795299	January 2018	23 July 2018	Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFa Antagonist Failed in Rheumatoid Arthritis	Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFa Antagonist	Rheumatoid Arthritis	Drug: Gerilimzumab;Drug: Methotrexate;Drug: Folic Acid;Drug: Placebo	Bird Rock Bio, Inc.	Techtrials Pesquisa e Tecnologia Ltda;Pharmagenix	Not recruiting	18 Years	80 Years	All	0	Phase 2
143	JPRN-jRCTs031180050	26/12/2017	10 September 2019	Hydroxychloroquine for Japanese patients with rheumatoid arthritis	Efficacy and safety of hydroxychloroquine for Japanese patients with rheumatoid arthritis	Rheumatoid arthritis;D001172	Treatment with hydroxychloroquine for 24 weeks	Yuko Kaneko		Recruiting	>= 18age old	Not applicable	Both	120	Phase 2-3	None
144	NCT03798028	December 26, 2017	21 January 2019	The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis	The Effects and Safety of Mesenchymal Stem Cells in the Treatment of Moderate/Severe Rheumatoid Arthritis, a Multicenter Randomized Controlled Clinical Study	Rheumatoid Arthritis	Biological: UC-MSCs	Xijing Hospital	Changhai Hospital;Southwest Hospital, China	Recruiting	18 Years	70 Years	All	250	N/A	China
145	EUCTR2017-001970-41-DK	21/12/2017	24 September 2018	Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial	Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months randomised, open label, parallel-group, multi-centre trial - The BIODOPT trial (BIOlogical Dose OPTimisation)	Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10062719 Term: Seronegative rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10076297 Term: Non-radiographic axial spondyloarthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10041672 Term: Spondylitis ankylosing System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10002557 Term: Ankylosing spondylitis and other inflammatory spondylopathies System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10045966 Term: Unspecified inflammatory spondylopathy System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Orencia Product Name: Abatacept Product Code: L04AA24 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125 - Trade Name: Orencia Product Name: Abatacept Product Code: L04AA24 Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 10 - Trade Name: Humira Product Name: Adalimumab Product Code: L04AB04 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40 - Trade Name: Cimzia Product Name: Certolizumab pegol Product Code: L04AB05 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 200 -400 Trade Name: Enbrel Product Name: Etanercept Product Code: L04AB01 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 25 -50 Trade Name: Benepali Product Name: Etanercept Product Code: L04AB01 Pharmaceutical Form: Concentrate and solvent for suspension for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 25 -50 Trade Name: Simponi Product Name: Golimumab Product Code: L04AB06 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal	MD, PhD Salome Kristensen		Authorised			Female: yes Male: yes	180	Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
146	NCT03457792	December 19, 2017	11 June 2018	A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis	Abatacept in Early-Stage Rheumatoid Arthritis Patients: Longterm Experience and Efficacy in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Recruiting	18 Years	N/A	All	400	N/A	Germany
147	NCT03186417	December 15, 2017	22 July 2019	Mesenchymal Stem Cells in Early Rheumatoid Arthritis	Cell-Based Therapy in Rheumatoid Arthritis: Proof of Concept Phase 1 Trial	Rheumatoid Arthritis	Biological: 2 million hMSC/kg;Biological: 4 million hMSC/kg;Biological: 6 million hMSC/kg;Biological: placebo	MetroHealth Medical Center	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Recruiting	18 Years	80 Years	All	20	Phase 1	United States
148	EUCTR2017-001717-92-AT	11/12/2017	7 January 2019	A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in patients with rheumatoid arthritis who have a high interferon signature (TarIFNiRA)	A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in RA patients with a high IFN signature (TarIFNiRA) - TarIFNiRA	High IFN siganture in patients with rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Anifrolumab (MEDI-546) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ANIFROLUMAB Other descriptive name: ANIFROLUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	Medical University of Vienna		Authorised			Female: yes Male: yes	24	Phase 2	Austria;Italy;Switzerland
149	EUCTR2017-001944-36-PL	23/11/2017	15 October 2018	Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy	Rheumatoid Arthritis MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: AMG 592 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG592 Current Sponsor code: AMG592 Other descriptive name: AMG592 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Authorised			Female: yes Male: yes	137	Phase 1;Phase 2	United States;Czech Republic;Mexico;Spain;Poland;Romania;Australia;Bulgaria;Germany;New Zealand;United Kingdom
150	NCT03334851	November 17, 2017	30 September 2019	Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis	A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: PF-06835375;Drug: Placebo	Pfizer		Recruiting	18 Years	70 Years	All	112	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
151	NCT03911830	November 11, 2017	23 April 2019	Aerobic Exercise Program Followed by Cold Water Immersion: Effects on Arthritis Patients Arterial Stiffness	Effects of an Aerobic Exercise Program on Cycloergometer Followed by Cold Water Immersion Recovery in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Cryotherapy Effect;Physical Activity	Other: Exercise followed cold water immersion	Centre Hospitalier Universitaire de Besancon		Not recruiting	20 Years	80 Years	All	18	N/A	France
152	EUCTR2017-003425-15-DK	10/11/2017	11 December 2017	Patients with rheumatoid arthritis and synovitis treated with ultrasound guided intraarticular or intramuscular glucocorticoid injection - A randomised, double-blind, controlled study (Panguian)	Patients with rheumatoid arthritis and synovitis treated with ultrasound guided intraarticular or intramuscular glucocorticoid injection - A randomised, double-blind, controlled study (Panguian)	Treatment of synovitis among rheumatoid arthritis patients MedDRA version: 20.0 Level: PT Classification code 10042868 Term: Synovitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Diprofos Depot Pharmaceutical Form: Solution for injection INN or Proposed INN: BETAMETHASONE ACIBUTATE CAS Number: 5534-05-4 Current Sponsor code: Glucococorticoid Other descriptive name: Binyrebsrkhormon Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 3.5-14 Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intraarticular use Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intramuscular use	Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet		Authorised			Female: yes Male: yes	100	Phase 4	Denmark
153	NCT03357471	November 3, 2017	10 September 2018	Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondylitis;Moderately to Severely Active Crohn's Disease	Drug: e-Device	UCB Biopharma S.P.R.L.		Not recruiting	18 Years	N/A	All	70	Phase 3	United States
154	EUCTR2017-000384-32-BG	02/11/2017	30 April 2019	Phase IIb in Rheumatoid Arthritis	A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate - N/A	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Evobrutinib Product Code: M2951 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Evobrutinib CAS Number: N/A Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Authorised			Female: yes Male: yes	363	Phase 2	Serbia;United States;Ukraine;Russian Federation;Chile;Colombia;Czech Republic;Mexico;Argentina;Brazil;Poland;Bulgaria;South Africa;Germany;Japan
155	JPRN-UMIN000029797	2017/11/02	23 April 2019	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial - Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial	Osteoarthritis of the hip, Avascular necrosis of the femoral head, Rheumatoid arthritis	The combined tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first hip. After closure of fascia, 1000 mg of tranexamic acid (10 mL of 100 mg/mL tranexamic acid) was administered intra-articularly for each hip. Five hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously. The intravenous tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first hip. After closure of the fascia, 10 mL of normal saline was administered intra-articularly for each hip. Five hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously.	Hokusuikai Kinen Hospital		Not Recruiting	18years-old	Not applicable	Male and Female	40	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
156	NCT03329885	November 2, 2017	20 August 2018	A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Patients and Patients With Average to Very Serious Psoriasis	A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis	Rheumatoid Arthritis;Psoriasis;Ankylosing Spondylitis;Inflammatory Bowel Diseases;Nonalcoholic Steatohepatitis	Other: Placebo;Drug: BMS-986251	Bristol-Myers Squibb		Not recruiting	18 Years	70 Years	All	38	Phase 1/Phase 2	Netherlands
157	NCT03387423	November 2, 2017	11 November 2019	Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis	ESCALATE-RA A NON-INTERVENTIONAL STUDY OF CRITICAL FACTORS FOR ESCALATING DRUG TREATMENT IN PATIENTS TREATED WITH TOFACITINIB FOR MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS	Arthritis, Rheumatoid	Drug: Tofacitinib	Pfizer		Recruiting	18 Years	N/A	All	1500	N/A	Germany
158	JPRN-JapicCTI-173747	01/11/2017	16 July 2019	Specific Use Result Survey of PRALIA 60 mg Subcutaneous Injection Syringe - A Long-term Use Survey in Patients with Rheumatoid Arthritis -	Specific Use Result Survey of PRALIA 60 mg Subcutaneous Injection Syringe - A Long-term Use Survey in Patients with Rheumatoid Arthritis -	Rheumatoid Arthritis	Intervention name : PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) Dosage And administration of the intervention : For adults under normal conditions, 60 mg of denosumab (genetic recombination) is injected subcutaneously every six months. If bone erosion progression occurs when denosumab is injected once every 6 months, denosumab can be injected subcutaneously once every 3 months.	DAIICHISANKYO Co., Ltd.		Recruiting			BOTH	1000	NA
159	JPRN-UMIN000029759	2017/11/01	2 April 2019	Percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty as a component of multimodal pain management: a randomized control trial		Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	Percutaneous periarticular analgesic injection including methylprednisolone 80 mg [2 mL], ropivacaine 150 mg [20 mL], and epinephrine 0.2 mg [0.2 mL] at one day after simultaneous bilateral total knee arthroplasty No percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty	Nekoyama Miyao Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	32	Not selected	Japan
160	NCT03440892	November 1, 2017	18 March 2019	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin	Rheumatoid Arthritis	Drug: methotrexate;Drug: sulfasalazine;Drug: abatacept;Drug: tocilizumab;Drug: tofacitinib/baricitinib	Vastra Gotaland Region		Recruiting	20 Years	N/A	All	2500	N/A	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
161	NCT02647762	October 30, 2017	14 October 2019	CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis	A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CF101 1 mg;Drug: CF101 2 mg;Drug: Placebo;Drug: MTX	Can-Fite BioPharma		Recruiting	18 Years	75 Years	All	525	Phase 3	Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia
162	NCT03324412	October 28, 2017	16 December 2017	Efficacy and Safety of TwHF and MTX in Patients With Rheumatoid Arthritis	A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of TwHF and MTX Treating Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Treatment of MTX;Drug: Treatment of MTX and TwHF	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	45 Years	70 Years	All	216	Phase 2/Phase 3
163	NCT03337815	October 28, 2017	16 December 2017	A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid Arthritis	A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of Tripterygium Wilfordii Treating Rheumatoid Arthritis and Establish A Prediction Model	Rheumatoid Arthritis	Drug: Treatment of MTX and TwHF placebo;Drug: Treatment of TwHF and MTX placebo	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Recruiting	45 Years	70 Years	All	264	Phase 2/Phase 3	China
164	NCT03163966	October 5, 2017	8 January 2018	A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Oral CR6086 Administered at the Doses of 30, 90 or 180 mg Bid for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis, DMARD-naive and Early Disease Patients	Drug: CR6086;Drug: Methotrexate;Drug: Placebo	Rottapharm Biotech		Recruiting	18 Years	N/A	All	240	Phase 2	Czechia
165	JPRN-UMIN000029003	2017/10/01	2 April 2019	Percutaneous periarticular analgesic injection at one day after total knee arthroplasty as a component of multimodal pain management: a randomized control trial		Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	Percutaneous periarticular analgesic injection including methylprednisolone 40 mg [1 mL], ropivacaine 150 mg [20 mL], and epinephrine 0.1 mg [0.1 mL] at one day after total knee arthroplasty No percutaneous periarticular analgesic injection at one day after total knee arthroplasty	Nekoyama Miyao Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	40	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
166	NCT03254589	October 1, 2017	26 August 2019	Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis	Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis	Rheumatoid Arthritis;Stiffness, Aortic;Endothelial Dysfunction;Cardiovascular Risk Factor	Drug: Methotrexate;Drug: Sulfasalazine;Drug: Other DMARDs	Flinders University	University of South Australia;medac GmbH	Recruiting	18 Years	N/A	All	124	Phase 4	Australia
167	NCT03257852	September 29, 2017	11 November 2019	A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis (RA)	Drug: ASP5094;Drug: Placebo;Other: Methotrexate therapy	Astellas Pharma Inc		Not recruiting	20 Years	N/A	All	66	Phase 2	Japan
168	EUCTR2016-004300-65-BE	26/09/2017	20 August 2018	Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFa) blocking Agent by immunoscintigraphy with Technetium-labeled Cimzia®).	Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFa) blocking Agent by immunoscintigraphy with Technetium-labeled Cimzia®). - SCINTRA TRIS	rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: 99mTc-S-HYNIC Certolizumab pegol Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.25-	Ghent University Hospital		Authorised			Female: yes Male: yes	120	Phase 4	Belgium
169	EUCTR2017-000384-32-CZ	26/09/2017	11 June 2018	Phase IIb in Rheumatoid Arthritis	A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate - N/A	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Evobrutinib Product Code: M2951 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Evobrutinib CAS Number: N/A Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Authorised			Female: yes Male: yes	363	Phase 2	Japan;Germany;Bulgaria;South Africa;Poland;Brazil;Argentina;Mexico;Czech Republic;Colombia;Chile;Russian Federation;Ukraine;United States;Serbia
170	NCT03233230	September 18, 2017	15 July 2019	Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis	A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Evobrutinib;Drug: Placebo;Drug: Methotrexate	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	75 Years	All	390	Phase 2	United States;Argentina;Brazil;Bulgaria;Chile;Colombia;Czechia;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;Germany;Hungary;Romania;Slovakia;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
171	EUCTR2017-000838-64-SE	11/09/2017	16 October 2017	An early phase study in patients with active Rheumatoid Arthritis to compare the safety and efficacy of AZD9567 and prednisolone	A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Product Name: AZD9567 Product Code: AZD9567 monohydrate Pharmaceutical Form: Oral suspension INN or Proposed INN: N/A CAS Number: 1893415-64-9 Current Sponsor code: ADZ9567 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 0.5-10 Pharmaceutical form of the placebo: Oral suspension Route of administration of the placebo: Oral use Trade Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolone CAS Number: - Current Sponsor code: - Other descriptive name: - Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	AstraZeneca AB		Authorised			Female: yes Male: yes	40	Phase 2	Denmark;Netherlands;Sweden
172	NCT03262740	September 11, 2017	12 March 2018	The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients	The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)	Bristol-Myers Squibb		Not recruiting	18 Years	40 Years	Female	58	Phase 1	United States
173	EUCTR2016-004834-11-BG	04/09/2017	28 February 2019	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Methotrexate® 2.5 mg tablets Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate CAS Number: 59-05-2 Other descriptive name: METHOTREXATE 2.5 mg tablets Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5-	Rottapharm Biotech S.r.l.		Not Recruiting			Female: yes Male: yes	240	Phase 2	Moldova, Republic of;United Kingdom;Bulgaria;Denmark;Romania;Poland;Argentina;Czech Republic
174	NCT03241446	September 2017	15 October 2018	Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)	A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Tilmanocept	Navidea Biopharmaceuticals		Not recruiting	30 Years	65 Years	All	0	Phase 1
175	NCT03254966	September 2017	16 December 2017	Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SHR0302;Drug: Placebo	Jiangsu HengRui Medicine Co., Ltd.		Not recruiting	18 Years	70 Years	All	170	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
176	EUCTR2017-000947-41-FR	18/08/2017	16 October 2017	ORENCIA VERSUS ROACTEMRA BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS.	ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY TRIAL. - SUNSTAR	Adults patients suffering from rheumatoid arthritis and in adequate response to a first line of treatment with a TNF alpha inhibitor. MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: ORENCIA 125 mg, solution injectable en seringue préremplie Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe Trade Name: RoActemra 162 mg solution injectable en seringue préremplie Pharmaceutical Form: Solution for injection	Groupement des Hôpitaux de l’Institut Catholique de Lille		Authorised			Female: yes Male: yes		Phase 4	France
177	NCT03160001	August 15, 2017	18 December 2018	Niclosamide With Etanercept in Rheumatoid Arthritis	Adjuvant Use of Niclosamide With Etanercept in Rheumatoid Arthritis: Experimental and Clinical Study	Rheumatoid Arthritis (RA)	Drug: Placebo;Drug: Niclosamide;Drug: Etanercept	Faiq Gorial		Not recruiting	18 Years	N/A	All	110	Phase 1/Phase 2	Iraq
178	NCT03245515	August 15, 2017	18 January 2018	A Study of BMS-986195 in Healthy Male Subjects	Pharmacokinetics and Metabolism of [14C] BMS-986195 in Healthy Male Subjects	Rheumatoid Arthritis	Drug: BMS-986195	Bristol-Myers Squibb		Not recruiting	18 Years	55 Years	Male	24	Phase 1	Netherlands
179	NCT03156023	August 14, 2017	4 November 2019	Multiple Ascending Doses of AMG 570 in Subjects With Rheumatoid Arthritis	A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 570;Drug: Placebo	Amgen		Not recruiting	18 Years	75 Years	All	34	Phase 1	United States;Germany
180	NCT03327454	August 10, 2017	5 November 2018	Benepali® PEN Patient Satisfaction Survey	Non-Interventional Observational Study on Patient Satisfaction With the Benepali® Pre-Filled Pen	Rheumatoid Arthritis;Spondyloarthropathies	Biological: Benepali	Biogen		Not recruiting	18 Years	N/A	All	500	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
181	NCT03188081	August 4, 2017	23 July 2018	A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept	A Prospective, Multicentric, Observational Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life RA Patients Treated With Abatacept SC	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Recruiting	18 Years	N/A	All	300	N/A	Italy
182	NCT03155347	August 2, 2017	4 November 2019	An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy	A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: MTX;Drug: Placebo Matched to MTX;Drug: Placebo Matched to Tocilizumab	Hoffmann-La Roche		Recruiting	18 Years	70 Years	All	300	Phase 3	China
183	NCT03215407	August 1, 2017	16 December 2017	The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone	The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee	Rheumatoid Arthritis of Knee	Drug: Intra-articular Tocilizumab;Drug: Intra-articular Compound Betamethasone	Chinese PLA General Hospital		Not recruiting	18 Years	65 Years	All	60	Phase 4
184	NCT03250767	August 1, 2017	30 September 2019	Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement	A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement	Osteo Arthritis Shoulders;Traumatic Arthritis;Rheumatoid Arthritis	Device: Integra Titan Modular Shoulder System 2.5	Integra LifeSciences Corporation		Recruiting	18 Years	N/A	All	140	Phase 1/Phase 2	United States
185	JPRN-UMIN000028376	2017/07/26	2 April 2019	Study of ultrasound detected residual synovitis treated with combination of anti-rheumatic therapy and denosumab in rheumatoid arthritis		rheumatoid arthritis	Combination of anti-rheumatic therapy and denosumab Anti-rheumatic therapy alone	Hokkaido Medical Center for Rheumatic Diseases		Recruiting	20years-old	75years-old	Male and Female	30	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
186	NCT02541955	July 20, 2017	9 September 2019	Use of Acthar in Rheumatoid Arthritis (RA) Related Flares	Use of Acthar in Rheumatoid Arthritis Related Flares	Rheumatoid Arthritis (RA)	Drug: Acthar	Dr. Veena Ranganath		Recruiting	18 Years	N/A	All	40	Phase 4	United States
187	EUCTR2016-004834-11-DK	06/07/2017	30 April 2019	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Methotrexate® 2.5 mg tablets Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate CAS Number: 59-05-2 Other descriptive name: METHOTREXATE 2.5 mg tablets Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5-	Rottapharm Biotech S.r.l.		Not Recruiting			Female: yes Male: yes	240	Phase 2	Czech Republic;Argentina;Poland;Romania;Denmark;Bulgaria;Moldova, Republic of;United Kingdom
188	NCT03120949	July 4, 2017	18 December 2018	Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.	A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Olokizumab 64 mg SC q4w;Drug: Olokizumab 64 mg SC q2w;Drug: Methotrexate	R-Pharm	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Recruiting	18 Years	N/A	All	1880	Phase 3	United States;Argentina;Brazil;Bulgaria;Colombia;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom
189	NCT03189017	July 3, 2017	26 August 2019	A Phase I Study of ICP-022 in Healthy Subjects	A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-022 Following Single and Multiple Escalating Dose	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: ICP-022;Drug: Placebos	Innocare Pharma Australia Pty Ltd		Not recruiting	18 Years	55 Years	Male	64	Phase 1	Australia
190	NCT03285191	July 3, 2017	27 August 2018	Subject Insights to Understand Rheumatoid Arthritis (RA)	Patient Interviews to Better Understand Disease Experience and Unmet Treatment Needs in Rheumatoid Arthritis	Arthritis, Rheumatoid	Other: Numerical rating scale;Other: Real-time data capture app	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	30	Phase 1/Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
191	ChiCTR-IPR-17011566	2017-07-01	12 June 2017	The efficacy and safety of sirolimus in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	The efficacy and safety of sirolimus in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	Rheumatoid Arthritis;M05.901	Sirolimus group: Sirolimus; Non-Sirolimus group:Glucocorticoids and Immunosuppressant;	the Second Hospital of Shanxi Medical University		Recruiting	18	65	Both	Sirolimus group:200; Non-Sirolimus group:100;	Post-market	China
192	NCT03394131	July 1, 2017	23 July 2018	?Efficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients	Treatment of Carpal Tunnel in Rheumatoid Arthritis	Treatment Resistant Carpal Tunnel in RA Patients	Drug: Hylase;Drug: Insulin;Other: saline	Assiut University		Recruiting	20 Years	80 Years	All	90	N/A	Egypt
193	ChiCTR-INR-17011772	2017-06-27	3 July 2017	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents	Rheumatoid Arthritis	test group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group;	Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital		Recruiting	18	65	Both	test group:80;Control group:40;	New Treatment Measure Clinical Study	China
194	NCT03278470	June 26, 2017	27 August 2018	A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject	A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximum Tolerable Dose After Single Oral Dose of HL237 in Healthy Male Subject	Rheumatoid Arthritis	Drug: HL237;Drug: Placebo Oral Tablet	Hanlim Pharm. Co., Ltd.		Not recruiting	20 Years	45 Years	Male	57	Phase 1	Korea, Republic of
195	NCT03239080	June 19, 2017	11 February 2019	Effect of Denosumab in Erosion Healing in RA	Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT	Rheumatoid Arthritis	Drug: Denosumab;Other: Placebo	Chinese University of Hong Kong		Not recruiting	18 Years	N/A	All	110	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
196	EUCTR2015-005309-35-GB	16/06/2017	28 February 2019	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis	A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4	Moderately to Severely Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: (CDP6038; L04041) Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	R-Pharm		Authorised			Female: yes Male: yes	1880	Phase 3	United States;Belarus;Taiwan;Estonia;Lithuania;Turkey;Russian Federation;Colombia;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Romania;Bulgaria;Latvia;Germany;Korea, Republic of
197	JPRN-UMIN000027719	2017/06/12	2 April 2019	Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy.		rheumatoid arthritis/remission	add-on iguratimod tapering MTX continuing the treatment	Osaka Medical College		Recruiting	20years-old	100years-old	Male and Female	100	Not selected	Japan
198	EUCTR2016-000569-21-FR	08/06/2017	28 February 2019	Filgotinib in Combination With Conventional Anti-rheumatic Drugs in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD treatment.	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Moderately to severely active rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Gilead Sciences, Inc.		Not Recruiting			Female: yes Male: yes	423	Phase 3	United States;Spain;Israel;Switzerland;United Kingdom;Italy;France;Hungary;Mexico;Argentina;Poland;Belgium;Australia;Netherlands;Germany;Japan;Korea, Republic of
199	NCT03100734	June 1, 2017	15 July 2019	Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel	A Multicentre Observational Study to Evaluate the Real-Life Effectiveness of Benepali® Following Transition From Enbrel® in Patients With Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA) - The BENEFIT Study	Rheumatoid Arthritis;Axial Spondyloarthritis	Biological: Benepali;Biological: Enbrel	Biogen	Samsung Bioepis Co., Ltd.	Not recruiting	18 Years	N/A	All	585	N/A	Germany
200	NCT03139136	May 30, 2017	26 August 2019	Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis	A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: MBS2320;Drug: Placebo	Modern Biosciences plc		Not recruiting	18 Years	75 Years	All	121	Phase 2	Georgia;Moldova, Republic of;Romania
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
201	NCT03193957	May 15, 2017	16 December 2017	An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis	An Open-label, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Device: Autoinjector	Samsung Bioepis Co., Ltd.		Not recruiting	18 Years	55 Years	All	50	Phase 2	Poland
202	NCT03131973	May 13, 2017	8 January 2018	Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin	Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: Pravastatin	Bristol-Myers Squibb		Not recruiting	18 Years	50 Years	All	26	Phase 1	United States
203	EUCTR2016-005017-45-HU	12/05/2017	18 June 2018	A study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis	A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an anti-Toll Like Receptor 4 Monoclonal Antibody in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 19.1 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: NI-0101 Product Code: NI-0101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: NI-0101 Other descriptive name: Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	NovImmune S.A.		Not Recruiting			Female: yes Male: yes	81	Phase 2	Bosnia and Herzegovina;United Kingdom;Moldova, Republic of;Bulgaria;Georgia;Poland;Hungary;Serbia
204	EUCTR2016-005017-45-BG	11/05/2017	28 February 2019	A study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis	A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an anti-Toll Like Receptor 4 Monoclonal Antibody in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: NI-0101 Product Code: NI-0101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: NI-0101 Other descriptive name: Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	NovImmune S.A.		Not Recruiting			Female: yes Male: yes	81	Phase 2	Serbia;Hungary;Poland;Georgia;Bulgaria;Moldova, Republic of;United Kingdom;Bosnia and Herzegovina
205	NCT03241108	May 10, 2017	27 August 2018	Study of an Anti-TLR4 mAb in Rheumatoid Arthritis	Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an Anti-Toll Like Receptor 4 Monoclonal Antibody in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Other: Placebo;Drug: NI-0101	NovImmune SA		Not recruiting	18 Years	N/A	All	90	Phase 2	Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
206	NCT03086343	May 9, 2017	22 October 2019	A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )	A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)	Rheumatoid Arthritis (RA)	Drug: Abatacept;Drug: Upadacitinib;Drug: Abatacept matching placebo;Drug: Upadacitinib matching placebo	AbbVie		Not recruiting	18 Years	N/A	All	657	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Chile;Colombia
207	EUCTR2016-001825-15-BE	08/05/2017	28 February 2019	A PHASE 3B/4 STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG	A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: tofacitinib Product Code: CP 690,550 Pharmaceutical Form: Modified-release tablet INN or Proposed INN: tofacitinib CAS Number: 540737-29-9 Current Sponsor code: CP 690,550 Other descriptive name: TOFACITINIB CITRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 11- Trade Name: Methotrexate 2.5mg Tablets BP Product Name: methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: METHOTREXATE Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Pfizer Inc., 235 East 42nd Street, New York, New York		Not Recruiting			Female: yes Male: yes	680	Phase 3;Phase 4	United States;Philippines;Slovakia;Spain;Russian Federation;Italy;United Kingdom;Czech Republic;Hungary;Mexico;Poland;Belgium;Australia;South Africa;Bulgaria;Germany;Korea, Republic of
208	NCT02808871	April 7, 2017	7 October 2019	Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)	Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)	Rheumatoid Arthritis Interstitial Lung Disease	Drug: Pirfenidone;Drug: Placebo	Ivan O. Rosas		Recruiting	18 Years	85 Years	All	270	Phase 2	United States;Australia;Canada;United Kingdom
209	NCT02908490	April 1, 2017	25 February 2019	Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?	Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?	Arthritis, Rheumatoid;Atherosclerosis	Drug: Sildenafil;Other: Placebo	Kimberly Liang		Recruiting	18 Years	N/A	All	60	Phase 2	United States
210	NCT03275025	April 1, 2017	22 July 2019	A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of YRA-1909 in Patients With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Rheumatoid Arthritis	Drug: YRA-1909 low dose;Drug: YRA-1909 mid dose;Drug: YRA-1909 high dose;Drug: Placebo	Yungjin Pharm. Co., Ltd.		Recruiting	19 Years	80 Years	All	200	Phase 2	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
211	NCT03291457	March 30, 2017	22 October 2019	A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice	A Prospective Non-Interventional Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Glucocorticoid Agent	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	101	Phase 3	Belgium
212	NCT03178955	March 27, 2017	24 June 2019	Circadian RA Study in Rheumatoid Arthritis Subjects	The Effects of Biologic Therapy With Disease Activity and Circadian Rhythm	Rheumatoid Arthritis	Drug: Etanercept	University of California, Davis		Not recruiting	18 Years	80 Years	All	0	Phase 1	United States
213	NCT03348046	March 23, 2017	12 March 2018	Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan	Post-Authorization Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan	Rheumatoid Arthritis	Drug: Biosimilar Infliximab	Hikma Pharmaceuticals LLC	INC Research	Recruiting	18 Years	N/A	All	40	N/A	Jordan
214	NCT03245320	March 20, 2017	4 February 2019	Clinical Evaluation of the TITAN™ Total Shoulder System	A Post-Market Observational Study to Evaluate Performance and Safety of the TITAN™ Total Shoulder System	Arthritis;Arthritis, Degenerative;Rheumatoid Arthritis;Post-traumatic Arthrosis of Other Joints, Shoulder Region;Rotator Cuff Syndrome of Shoulder and Allied Disorders;Fracture;Avascular Necrosis;Joint Instability;Joint Trauma;Dislocation, Shoulder;Pain, Shoulder	Device: Integra TITAN™ Total Shoulder Generation 1.0	Integra LifeSciences Corporation		Not recruiting	18 Years	N/A	All	50	Phase 1	United States
215	NCT03755258	March 16, 2017	10 December 2018	Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis	A Phase Ib Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GCK in Rheumatoid Arthritis Patients	Early Rheumatoid Arthritis	Drug: GCK 100 mg + Placebo 200 mg;Drug: GCK 200 mg + Placebo 100 mg;Drug: GCK 300 mg;Drug: Placebo 300mg	Zhejiang Hisun Pharmaceutical Co. Ltd.		Recruiting	18 Years	65 Years	All	128	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
216	NCT03110094	March 13, 2017	11 June 2018	Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis	Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis, With Analysis of CD4 + Follicular Helper T Subpopulations	Rheumatoid Arthritis	Other: Adalimumab;Other: Healthy volunteers	Rennes University Hospital		Recruiting	18 Years	N/A	All	60	N/A	France
217	EUCTR2015-005307-83-LV	03/03/2017	30 April 2019	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 2	Moderately to Severely Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: (CDP6038; L04041) Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: Adalimumab (Humira®) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: Adalimumab (Humira®) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	R-Pharm		Authorised			Female: yes Male: yes	1575	Phase 3	United States;Taiwan;Estonia;Lithuania;Russian Federation;Colombia;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Romania;Bulgaria;Georgia;Latvia;Germany;Korea, Republic of
218	NCT03082573	March 3, 2017	16 December 2017	Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs	Rheumatoid Arthritis	Drug: H.P. Acthar gel	Iraj Sabahi Research Inc.	Mallinckrodt	Recruiting	21 Years	N/A	All	30	Phase 4	United States
219	EUCTR2016-002126-36-AT	01/03/2017	10 December 2018	A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a Inhibitors	A randomized, double-blind, placebo-controlled, multi-center, three-part phase II study to evaluate the safety and efficacy of RO7123520 as adjunct treatment in patients with moderately to severely active rheumatoid arthritis and an inadequate response to TNF-a inhibitors	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: RO7123520 Product Code: RO7123520/F03-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Not available Current Sponsor code: RO7123520/F03-01 Other descriptive name: RO7123520 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	204	Phase 2	United States;Spain;Guatemala;Austria;Chile;Colombia;United Kingdom;Italy;Czech Republic;Mexico;Argentina;Poland;Brazil;Peru;Germany
220	NCT03025308	February 28, 2017	4 November 2019	Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis	A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis	RheumatoId Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	2731	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
221	NCT03161457	February 27, 2017	23 July 2018	A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis	A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 Versus EU-sourced MabThera® in Anti TNF Inadequate Responder Patients With Moderate to Severe Rheumatoid Arthritis (RA) on Background Methotrexate (MTX) Therapy	Rheumatoid Arthritis;Arthritis, Rheumatoid	Biological: JHL1101;Biological: MabThera	JHL Biotech, Inc.		Recruiting	18 Years	80 Years	All	150	Phase 1	Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;Russian Federation;Taiwan;Ukraine;United Kingdom
222	JPRN-UMIN000026137	2017/02/15	5 November 2019	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total knee arthroplasty: randomized controlled trial	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total knee arthroplasty: randomized controlled trial - Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral TKA: randomized controlled trial	Osteoarthritis of the knee Rheumatoid arthritis	The combined tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first knee. After closure of the capsule and retinaculum, 1000 mg of tranexamic acid (10 mL of 100 mg/mL tranexamic acid) was administered intra-articularly for each knee. Six hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously. The intravenous tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first knee. After closure of the capsule and retinaculum, 10 mL of normal saline was administered intra-articularly for each knee. Six hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously.	Hokusuikai Kinen Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	32	Not selected	Japan
223	NCT03667131	February 13, 2017	26 November 2018	Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.	Effect of Prophylactic Treatment With Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis Patients.	Rheumatoid Arthritis	Drug: Enalapril Maleate;Drug: Placebo	University of Guadalajara		Not recruiting	18 Years	80 Years	Female	59	Phase 2	Mexico
224	ChiCTR-IPR-17010325	2017-01-31	18 April 2017	The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial	The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial	rheumatic disease;M05.901	Metformin Group:Metformin combined Glucocorticoids and DMARDs;Non-Metformin Group:Glucocorticoids and DMARDs;Metformin combined with Coenzyme Q10 Group:Metformin and Coenzyme Q10 combined Glucocorticoids and DMARDs;	the Second Hospital of Shanxi Medical University		Not Recruiting	18	65	Both	Metformin Group:100;Non-Metformin Group:100;Metformin combined with Coenzyme Q10 Group:100;	Post-market	China
225	NCT02997605	January 31, 2017	4 February 2019	Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients	Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients in Low Disease Activity or Remission.	RheumatoId Arthritis	Drug: GlucoCorticoid	University Hospital, Toulouse		Recruiting	18 Years	N/A	All	122	Phase 4	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
226	NCT03052322	January 31, 2017	1 July 2019	MSB11022 in Moderate to Severe Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis	Moderate to Severe Rheumatoid Arthritis	Drug: MSB11022;Drug: EU-Humira	Fresenius Kabi SwissBioSim GmbH		Not recruiting	18 Years	N/A	All	288	Phase 3	Czech Republic;United Kingdom;Poland;Hungary;Germany;Czechia;Bulgaria
227	EUCTR2013-003413-18-NL	30/01/2017	12 March 2018	Arthritis prevention with abatacept	Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. - APIPPRA	The target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPA; rheumatoid factor – RF) and who have joint pains (arthralgia) but no joint swelling. These subjects are deemed to be at highest risk of developing rheumatoid arthritis. MedDRA version: 20.0 Level: PT Classification code 10003239 Term: Arthralgia System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: ORENCIA 125 mg solution for injection Pharmaceutical Form: Solution for infusion in pre-filled syringe Pharmaceutical form of the placebo: Solution for infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Leiden University Medical Center		Authorised			Female: yes Male: yes	206	Phase 2	Netherlands;United Kingdom
228	NCT03028467	January 24, 2017	27 August 2018	Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis	A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination With Methotrexate Therapy, in Japanese Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate	Arthritis, Rheumatoid	Drug: GSK3196165 Dose 1;Drug: GSK3196165 Dose 2;Drug: GSK3196165 Dose 3;Drug: Methotrexate;Drug: Placebo;Drug: Folic acid	GlaxoSmithKline		Not recruiting	20 Years	N/A	All	15	Phase 2	Japan
229	NCT03085940	January 20, 2017	16 December 2017	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Hydroxychloroquine;Drug: Placebo	Indonesia University		Not recruiting	18 Years	N/A	All	37	N/A	Indonesia
230	NCT02984943	January 19, 2017	4 November 2019	The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis	The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis: A Pilot Study	RheumatoId Arthritis	Device: Hyperbaric Oxygen	David Grant U.S. Air Force Medical Center		Not recruiting	18 Years	N/A	All	14	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
231	NCT03112213	January 12, 2017	18 December 2018	Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment	CONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: NSAIDs	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	135	Phase 3	Germany
232	EUCTR2015-003140-39-PL	09/01/2017	10 September 2018	A Study to EValuate the Efficacy and Safety of JTE-051 on Subjects with Active Rheumatoid Arthritis (MOVE-RA)	A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis (MOVE-RA) - MOVE-RA	Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: JTE-051 Product Code: JTE-051 Pharmaceutical Form: Tablet INN or Proposed INN: No proposed INN available CAS Number: 1309784-13-1 Current Sponsor code: JTE-051 Other descriptive name: JTE-051 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Akros Pharma Inc.		Not Recruiting			Female: yes Male: yes	250	Phase 2	United States;Mexico;Argentina;Poland;Ukraine;Romania;Peru;Russian Federation;Bulgaria;Colombia
233	ChiCTR-IPR-17010307	2017-01-01	18 April 2017	The efficacy and safety of rapamycin in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	The efficacy and safety of rapamycin in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	Rheumatoid Arthritis;M05.901	Rapamycin group:Rapamycin;Non-rapamycin group :conventional glucocorticoids and DMARDs;	the Second Hospital of Shanxi Medical University		Recruiting	18	65	Both	Rapamycin group:200;Non-rapamycin group :100;	Post-market	China
234	NCT03855007	January 1, 2017	11 March 2019	The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment	Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Iguratimod;Drug: MTX;Drug: HCQ;Drug: Pred	Qilu Hospital of Shandong University		Recruiting	16 Years	90 Years	All	200	Phase 4	China
235	NCT02865434	January 2017	1 April 2019	Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA	An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls	Arthritis, Rheumatoid	Drug: Tc99m-tilmanocept;Procedure: SPECT Imaging (60 Minutes post-injection);Procedure: SPECT Imaging (180 Minutes post-injection);Procedure: Whole body planar SPECT imaging (15 Minutes post-injection);Procedure: Whole body planar SPECT imaging (60 Minutes post-injection);Procedure: Whole body planar SPECT imaging (180 Minutes post-injection);Procedure: Whole body planar SPECT imaging (18-20 Hours post-injection);Procedure: Blood Collection for PK Testing (15 Mins Before Injection);Procedure: Blood Collection for PK Testing (after injection);Procedure: Blood Collection for PK Testing (15 minutes post injection);Procedure: Blood Collection for PK Testing (60 minutes post injection);Procedure: Blood Collection for PK Testing (180 minutes post injection);Procedure: Blood Collection for PK Testing (18-20 hours post injection);Procedure: Planar Image with both Hands in Field of View	Navidea Biopharmaceuticals		Not recruiting	18 Years	N/A	All	39	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
236	NCT03016884	January 2017	5 February 2018	Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients	Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation	Herpes Zoster	Biological: Zostavax vaccine	HaEmek Medical Center, Israel		Recruiting	50 Years	N/A	All	250	Phase 4	Israel
237	NCT03288584	January 2017	16 July 2018	Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis	The Effect of Inhibition of Interleukin-6 Activity on Vascular, Endothelial and Left Ventricular Function in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Inflammation	Drug: Tocilizumab (Actemra®);Drug: Other biological agent;Drug: Corticosteroid and non-biological agents.	University of Athens		Recruiting	18 Years	80 Years	All	60	Phase 1	Greece
238	NCT02965599	December 27, 2016	8 April 2019	Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis	A Randomised, Multi-center, Double Blind (Sponsor Open), Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Severe, Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Placebo;Drug: GSK3117391	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	3	Phase 1/Phase 2	Mexico;Poland;Romania
239	EUCTR2016-000569-21-GB	23/12/2016	28 February 2019	Filgotinib in Combination With Conventional Anti-rheumatic Drugs in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD treatment.	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Moderately to severely active rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Gilead Sciences, Inc.		Not Recruiting			Female: yes Male: yes	423	Phase 3	United States;Spain;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Mexico;Argentina;Poland;Belgium;Australia;Netherlands;Germany;Japan;Korea, Republic of
240	NCT02969044	December 20, 2016	29 January 2018	Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate	A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: PF-06651600	Pfizer		Not recruiting	18 Years	75 Years	All	74	Phase 2	United States;Bulgaria;Czechia;Georgia;Germany;Hungary;Poland;Serbia;Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
241	EUCTR2014-004704-29-CZ	15/12/2016	1 October 2018	This trial is designed to determine what effects the human body has on the investigational medicine, ABP 710, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, infliximab, in patients with moderate or severe rheumatoid arthritis (RA). This study will assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.	A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis - Not applicable	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ABP 710 Product Code: ABP 710 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ABP 710 Current Sponsor code: ABP 710 Other descriptive name: ABP 710 - Biosimilar to infliximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Remicade Product Name: infliximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Amgen Inc.		Not Recruiting			Female: yes Male: yes	550	Phase 3	United States;Hungary;Czech Republic;Canada;Poland;Spain;Romania;Australia;Bulgaria;Germany
242	NCT02862574	December 15, 2016	16 December 2017	Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis	Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Andecaliximab;Drug: Placebo;Drug: Methotrexate;Drug: TNF Inhibitor	Gilead Sciences		Not recruiting	18 Years	80 Years	All	15	Phase 2	United States;Australia;Hungary;Taiwan
243	EUCTR2016-002852-26-CZ	07/12/2016	17 September 2018	MSB11022 in moderately to severely active rheumatoid arthritis	A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheumatoid arthritis - AURIEL-RA	moderately to severely active rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: adalimumab Product Code: MSB11022 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: MSB11022 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Merck KGaA		Not Recruiting			Female: yes Male: yes	260	Phase 3	Hungary;Czech Republic;Poland;Lithuania;Bulgaria;Germany;United Kingdom
244	EUCTR2015-003140-39-BG	05/12/2016	20 August 2018	A Study to EValuate the Efficacy and Safety of JTE-051 in Subjects with Active Rheumatoid Arthritis (MOVE-RA)	A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis (MOVE-RA) - MOVE-RA	Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: JTE-051 Product Code: JTE-051 Pharmaceutical Form: Tablet INN or Proposed INN: No proposed INN available CAS Number: 1309784-13-1 Current Sponsor code: JTE-051 Other descriptive name: JTE-051 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Akros Pharma Inc.		Not Recruiting			Female: yes Male: yes	250	Phase 2	United States;Mexico;Argentina;Poland;Ukraine;Romania;Peru;Russian Federation;Bulgaria;Colombia
245	NCT02760433	December 2016	18 December 2018	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease	A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy	Rheumatoid Arthritis	Drug: Olokizumab q4w;Drug: Olokizumab q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Recruiting	18 Years	N/A	All	350	Phase 3	United States;Argentina;Brazil;Colombia;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
246	NCT02982083	December 2016	12 December 2016	Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis	Clinical Trial on the Efficacy of Raloxifene on Disease Activity and Glucocorticoid-induced Osteoporosis in Postmenopausal Women With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo Oral Tablet;Drug: Raloxifene hydrochloride	Sara Saeidi Shahri		Not recruiting	50 Years	N/A	Female	40	N/A
247	NCT02990806	December 2016	11 November 2019	A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)	A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Biological: NI-071;Biological: Infliximab	Nichi-Iko Pharmaceutical Co., Ltd.		Not recruiting	18 Years	75 Years	All	683	Phase 3	United States;Czechia;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom
248	NCT03016260	December 2016	16 December 2017	RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFa BIologicals in Rheumatoid Arthritis	Proof-of-Performance Study of RABIOPRED Assay as an In Vitro Diagnostic Test to Identify Patients With Rheumatoid Arthritis Who Are Unlikely to Show Response to 1st Treatment With Anti-TNFa and Methotrexate Combination.	RheumatoId Arthritis	Biological: Infliximab;Biological: Adalimumab;Biological: Etanercept;Biological: Golimumab;Biological: Certolizumab Pegol;Biological: Infliximab biosimilar;Biological: Etanercept biosimilar	TcLand Expression S.A.	European Commission	Recruiting	18 Years	N/A	All	720	N/A	Czechia;France;Israel;Netherlands;Turkey;Czech Republic
249	NCT03337165	December 2016	30 September 2019	Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis	Safety/Efficacy of Intra-articular Administration of Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis	Musculoskeletal Diseases;Joint Disease;Arthritis;Arthritis, Rheumatoid;Rheumatic Diseases;Connective Tissue Diseases;Autoimmune Diseases;Immune System Diseases	Biological: tolerogenic dendritic cells	Russian Academy of Medical Sciences		Not recruiting	18 Years	75 Years	All	10	Phase 1	Russian Federation
250	NCT02983227	November 30, 2016	4 November 2019	A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 (NCT02833350)	A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis	RheumatoId Arthritis	Drug: GDC 0853	Genentech, Inc.		Not recruiting	18 Years	76 Years	All	497	Phase 2	United States;Argentina;Brazil;Bulgaria;Colombia;Mexico;Poland;Russian Federation;Serbia;Ukraine;Chile;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
251	NCT02986139	November 29, 2016	22 July 2019	Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis	A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis	Arthritis, Rheumatoid; Arthritis, Psoriatic	Drug: Commercial Formulation Etanercept;Drug: New Formulation Etanercept	Amgen		Not recruiting	18 Years	N/A	All	111	Phase 3	United States;Puerto Rico
252	NCT02960490	November 26, 2016	28 October 2019	A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics	A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics	Rheumatoid Arthritis	Drug: E6011;Drug: Placebo	Eisai Co., Ltd.		Not recruiting	18 Years	75 Years	All	64	Phase 2	Japan
253	EUCTR2016-000933-37-HU	24/11/2016	22 May 2017	Study to Compare ABT-494 to Abatacept in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-CHOICE)	A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Other descriptive name: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: ORENCIA 250mg powder for concentrate for solution for infusion Product Name: Abatacept Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	313	Phase 3	Portugal;Belarus;United States;Slovakia;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Colombia;Switzerland;Italy;France;Puerto Rico;Australia;Netherlands;Latvia;Korea, Democratic People's Republic of;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Bulgaria;Norway;Germany;New Zealand;Sweden
254	EUCTR2014-005368-13-DE	22/11/2016	23 July 2018	A Study Comparing SAIT101 to MabThera® or Rituxan® in Patients with Rheumatoid Arthritis (RA)	A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 versus MabThera® versus Rituxan® in Patients with Rheumatoid Arthritis (RA).	Severe Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: SAIT101 (proposed rituximab biosimilar) Product Code: SAIT101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: SAIT101 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rituxan® Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Archigen Biotech Limited		Authorised			Female: yes Male: yes	282	Phase 1;Phase 3	United States;Spain;Russian Federation;Italy;India;Czech Republic;Hungary;Mexico;Poland;Bulgaria;Germany;Bosnia and Herzegovina;Korea, Republic of
255	JPRN-UMIN000026819	2016/11/21	23 April 2019	A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients.	A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients. - A RCT of anticoagulant agents for prevention of VTE after THA in elderly or underweight or moderate renal insufficient patients.	osteoarthritis of the hip, osteonecrosis of the femoral head, femoral neck fracture, rheumatoid arthritis, rapidly destructive coxarthropathy, septic arthritis of the hip	Dose: Edoxaban group; Edoxaban 15mg per day Enoxaparin gropu; Enoxaparin 2000 IU per day Intervention period: for 10 days after the surgery	Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences		Recruiting	20years-old	Not applicable	Male and Female	80	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
256	NCT02874092	November 15, 2016	22 July 2019	Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis	Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MTX therapy;Drug: Ticagrelor	NYU Langone Health		Not recruiting	18 Years	N/A	All	9	Phase 4	United States
257	EUCTR2015-005800-27-PL	08/11/2016	5 March 2018	Study of a new drug’s effect in people with severe rheumatoid arthritis who have not responded sufficiently well to treatment with DMARDs	A randomised, multi-center, double blind (sponsor open), placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3117391 in subjects with moderate to severe, active rheumatoid arthritis	Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GSK3117391 Product Code: GSK3117391 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Not applicable CAS Number: 1018673-42-1 Current Sponsor code: GSK3117391 Other descriptive name: GSK3117391 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	40	Phase 2	Poland;Romania;Russian Federation
258	EUCTR2016-002908-15-NL	08/11/2016	18 April 2017	REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritis	REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization - REDO	Rheumatoid arthritis MedDRA version: 19.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7	Sint Maartenskliniek		Authorised			Female: yes Male: yes		Phase 4	Netherlands
259	NCT02919761	November 7, 2016	11 November 2019	Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis	A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease	Arthritis, Rheumatoid	Drug: Acthar;Drug: Placebo	Mallinckrodt		Not recruiting	18 Years	N/A	All	259	Phase 4	United States;Argentina;Mexico;Peru;Puerto Rico;Colombia
260	NCT02960438	November 2, 2016	28 October 2019	A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate	A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate	Rheumatoid Arthritis	Drug: E6011;Drug: Placebo	Eisai Co., Ltd.		Not recruiting	18 Years	75 Years	All	190	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
261	ChiCTR-INR-16009546	2016-11-01	18 April 2017	The Efficacy and Safety of Low Dose IL-2 Conbined IL-6 Antagonist Therapy in Chinese Over-treated Patients with Rheumatoid Arthritis	The Efficacy and Safety of Low Dose IL-2 Conbined IL-6 Antagonist Therapy in Chinese Over-treated Patients with Rheumatoid Arthritis	rheumatoid arthritis;M05.901	IL-2 group:lL-2;IL-2 + IL-6 antagonist group:Tocilizumab;non IL-2 or IL-6 antagonist group:glucocorticoids and DMARDs;	the Second Hospital of Shanxi Medical University		Recruiting	18	65	Both	IL-2 group:15;IL-2 + IL-6 antagonist group:15;non IL-2 or IL-6 antagonist group:15;	New Treatment Measure Clinical Study	China
262	ChiCTR-IPR-16009029	2016-11-01	18 April 2017	Clinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid Arthritis	Clinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid Arthritis	Rheumatoid arthritis	RA:the experimental group:MTX 10-15mg po qw+BiQi Capsule, 1.2g po bid;RA:the control group:MTX 10-15mg po qw+LEF, 10mg, po, bid;OA:The traditional Chinese group:BiQi Capsule, 1.2g po bid+Celecoxib capsules 0.2g po take as needed;OA:The western medicine control group:Calcitriol Soft Capsules 0.25ug, po, bid+Celecoxib capsules 0.2g po take as needed;	Guangdong Provincial Hospital of Chinese Medicine		Not Recruiting	18	65	Both	RA:the experimental group:60;RA:the control group:60;OA:The traditional Chinese group:60;OA:The western medicine control group:60;	Post-market	China
263	NCT02996500	November 2016	12 November 2018	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	A 12 Week Randomized, Double-blind, Double Dummy, Parallel Group, Active And Placebo-controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate	Rheumatoid Arthritis	Drug: PF-06650833;Drug: Placebo;Drug: Tofacitinib	Pfizer		Not recruiting	18 Years	75 Years	All	269	Phase 2	United States;Australia;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine
264	NCT03011281	November 2016	16 December 2017	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tofacitinib	Hanyang University		Recruiting	19 Years	N/A	All	378	N/A	Korea, Republic of
265	NCT03067870	November 2016	18 June 2018	Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis	Transplantation of Autologous Purified Bone Marrow Derived Specific Populations of Stem Cells and Mesenchymal Stem Cells in Patients With Rheumatoid Arthritis	RheumatoId Arthritis;Osteoarthritis, Knee;Osteoarthritis, Hip	Biological: Stem Cell Transplantation	Stem Cells Arabia		Not recruiting	17 Years	75 Years	All	100	Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
266	NCT02819726	October 31, 2016	18 December 2018	PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Biological: SAIT101;Biological: MabThera;Biological: Rituxan;Biological: Rituxan/SAIT101	Archigen Biotech Limited		Not recruiting	18 Years	80 Years	All	294	Phase 1	United States;Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;India;Korea, Republic of;Mexico;Poland;Spain
267	NCT03061838	October 27, 2016	29 July 2019	Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®	Multicenter Double-blind Randomized Clinical Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Biosimilar Drug Ritumax® Compared to Original Drug MabThera® in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MabThera®;Drug: Ritumax®	Biointegrator LLC		Not recruiting	18 Years	N/A	All	8	Phase 1	Russian Federation
268	NCT02858492	October 17, 2016	26 November 2018	Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	A Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GSK2982772 60 mg;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	75 Years	All	52	Phase 1/Phase 2	Germany;Italy;Poland;Russian Federation;Spain;United Kingdom
269	EUCTR2016-000498-19-BG	13/10/2016	10 December 2018	A Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients with Moderate to Severe Rheumatoid Arthritis	A PHASE II OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA29350 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GDC-0853 Product Code: RO7010939 Pharmaceutical Form: Tablet INN or Proposed INN: not available Other descriptive name: GDC-0853 RO7010939 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Genentech, Inc.		Authorised			Female: yes Male: yes	580	Phase 2	Serbia;United States;Mexico;Argentina;Poland;Brazil;Ukraine;Russian Federation;Chile;Bulgaria;Colombia;Korea, Republic of
270	EUCTR2016-002061-54-IT	13/10/2016	7 January 2019	Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases.	Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases. Evaluation of immunogenicity and clinical response - Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®)	Rheumatoid arthritis, seronegative spondylo arthritis, Crohn's Disease, Ulcerative Colitis MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10075634 Term: Acute haemorrhagic ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO Product Name: Remsima Product Code: 42942019 Pharmaceutical Form: Powder for solution for infusion	UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI		Not Recruiting			Female: yes Male: yes	250	Phase 4	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
271	JPRN-jRCTs041180071	13/10/2016	7 October 2019	T-ReX study	Tocilizumab treatment with Reducing and stopping methotreXate in patients with rheumatoid arthritis in stable low disease activity-state - T-ReX study	Rheumatoid arthritis	At week 0, the dosing frequency of MTX was decreased from weekly to biweekly without a change in dose, regardless of the initial dose. At week 12, MTX was discontinued if low disease activity was maintained. TCZ and csDMARDs other than MTX were continued at a stable dose and interval throughout the course of the study. Glucocorticoids were continued at a stable dose up to week 36, and allowed to taper after week 36. The use of oral analgesics (non-steroidal anti-inflammatory drugs, acetaminophen, pregabalin, and tramadol) was not prohibited during the study period. One or more of the following rescue treatments were performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request: changing the dosing frequency back to weekly administration, restarting, or increasing doses of MTX; increasing doses of or adding csDMARDs other than MTX or glucocorticoids; and administering an intraarticular injection of corticosteroids, hyaluronic acid, or lidocaine.	Toshihisa Kojima		Not Recruiting	>= 20age old	Not applicable	Both	51	N/A	none
272	NCT02937701	October 10, 2016	21 January 2019	Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab	A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: ABP 710;Drug: Infliximab	Amgen		Not recruiting	18 Years	80 Years	All	558	Phase 3	United States;Australia;Bulgaria;Canada;Czechia;Germany;Hungary;Poland;Spain;Czech Republic
273	NCT03403140	October 6, 2016	29 January 2018	Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )	Multicenter Extension Study To 104 Weeks To Asses The Efficacy, Safety And Immunogenicity Of Enerceptan® In Combination With Methotrexate For The Treatment Of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept	Gema Biotech S.A.	QUID-Quality in Drugs and Devices Latin American Consulting SRL	Not recruiting	19 Years	99 Years	All	141	Phase 3	Argentina
274	EUCTR2015-004858-17-NL	05/10/2016	10 October 2016	REMission INDuction in very early Rheumatoid Arthritis	REMission INDuction in very early Rheumatoid Arthritis - REMINDRA	Very early Rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Methotrexate Product Name: Methotrexate Product Code: MTX Pharmaceutical Form: INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 7.5-25 Trade Name: Golimumab Product Name: Golimumab Product Code: GOL Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	University Medical Center Utrecht (UMCU)		Authorised			Female: yes Male: yes		Phase 4	Netherlands
275	NCT03364088	October 1, 2016	4 February 2019	Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia	Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia, a Randomized Controlled Trial	Knee Osteoarthritis;Arthropathy of Knee Joint;Knee Pain Chronic;Rheumatoid Arthritis;Anesthesia	Procedure: Spinal anesthesia with tourniquet;Procedure: Spinal anesthesia without tourniquet;Procedure: General anesthesia with tourniquet;Procedure: General anesthesia without tourniquet;Drug: Oxycodone by patient-controlled analgesia (PCA)	Riku Antero Palanne	Helsinki University Central Hospital;Helsinki University;Finland	Not recruiting	18 Years	75 Years	All	402	N/A	Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
276	NCT02805010	October 2016	12 December 2016	Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously	A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects	Rheumatoid Arthritis (RA)	Drug: Abatacept;Other: Placebo	Jiangsu Simcere Pharmaceutical Co., Ltd.	Bristol-Myers Squibb	Not recruiting	18 Years	45 Years	Both	22	Phase 1
277	NCT02881307	October 2016	9 September 2019	Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet	Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet	Rheumatoid Arthritis;Overweight	Dietary Supplement: Whey Protein&Prebiotic Supplement;Behavioral: Dietary Counseling;Behavioral: Dietary recommendations	Dr. Veena Ranganath		Recruiting	18 Years	N/A	All	60	N/A	United States
278	NCT02927522	October 2016	17 October 2016	Donepezil Attenuate Postoperative Cognitive Dysfunction	Donepezil Attenuate Postoperative Cognitive Dysfunction in Aged Patients- A Multi-center, Case Control, Randomized Clinical Trail	Osteoarthritis;Femoral Head Necrosis;Rheumatoid Arthritis	Drug: Donepezil;Drug: Placebo	RenJi Hospital	Shanghai Sixth Hospital;Shanghai Guanghua Hospital;Sanya People's Hospital;Shanghai Sixth Hospital;Shanghai Guanghua Hospital;Sanya People's Hospital	Not recruiting	65 Years	N/A	Both	550	Phase 3
279	NCT02936180	October 2016	27 August 2018	Standard Versus High Dose Inactivated Influenza Vaccine in RA	Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population?	Rheumatoid Arthritis	Biological: HD-TIV;Biological: SD-QIV	McGill University Health Center	The Arthritis Society, Canada	Not recruiting	18 Years	N/A	All	280	Phase 4	Canada
280	NCT02037737	September 30, 2016	19 February 2018	Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting	Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	153	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
281	NCT02648035	September 22, 2016	8 April 2019	EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis	Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study.	Rheumatoid Arthritis	Biological: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	200	Phase 1	Greece
282	EUCTR2014-004904-31-BE	21/09/2016	20 August 2018	A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remsima (infliximab) Pharmaceutical Form: Powder for concentrate for solution for injection/infusion	Mundipharma Pharmaceuticals B.V.		Not Recruiting			Female: yes Male: yes	156	Phase 4	Belgium;Netherlands
283	NCT02885181	September 21, 2016	16 December 2017	Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate	Rheumatoid Arthritis	Drug: GS-9876;Drug: Filgotinib;Drug: GS-9876 placebo;Drug: Filgotinib placebo;Drug: Methotrexate	Gilead Sciences		Not recruiting	18 Years	75 Years	All	83	Phase 2	United States;Bulgaria;Czechia;Georgia;Moldova, Republic of;Poland;Ukraine;Czech Republic;Hungary
284	NCT02919475	September 14, 2016	27 August 2018	Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)	Rheumatoid Arthritis	Drug: Placebo;Drug: JTE-051	Akros Pharma Inc.		Not recruiting	18 Years	75 Years	All	260	Phase 2	United States;Argentina;Bulgaria;Colombia;Mexico;Peru;Poland;Romania;Russian Federation;Ukraine
285	NCT03147248	September 12, 2016	26 August 2019	A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA	A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active RA	Rheumatoid Arthritis	Biological: Infliximab	Celltrion		Not recruiting	18 Years	75 Years	All	412	Phase 3	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
286	NCT02833350	September 9, 2016	30 September 2019	Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)	A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)	Rheumatoid Arthritis	Drug: GDC-0853;Drug: Adalimumab;Drug: Folic Acid;Drug: MTX;Drug: Placebo	Genentech, Inc.		Not recruiting	18 Years	75 Years	All	578	Phase 2	United States;Argentina;Brazil;Bulgaria;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;Chile
287	NCT02831855	September 1, 2016	1 April 2019	Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis	A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION	Rheumatoid Arthritis	Drug: Placebo;Drug: Methotrexate;Drug: CP-690,550	Pfizer		Not recruiting	18 Years	N/A	All	695	Phase 4	United States;Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom
288	NCT02666443	September 2016	12 September 2016	Low Dose Dexamethasone in Supraclavicular Blocks	Low Dose Dexamethasone as an Adjuvant to Supraclavicular Brachial Plexus Blocks: A Prospective Randomized, Double Blinded, Control Study	Rheumatoid Arthritis;Osteoarthritis;Nerve Entrapment;Ligament Injury	Drug: Intravenous Dexamethasone 1 mg;Drug: Peri-neural Dexamethasone 1 mg;Drug: Control intervention (no dexamethasone)	University of Calgary		Recruiting	18 Years	80 Years	Both	306	N/A	Canada
289	NCT02897011	September 2016	7 November 2016	2-week dc of MTX and Influenza Vaccination in RA	Effect of Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial	Rheumatoid Arthritis;Influenza;Methotrexate	Drug: Methotrexate	Seoul National University Hospital		Recruiting	18 Years	65 Years	Both	318	N/A	Korea, Republic of
290	NCT02930343	September 2016	14 October 2019	Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy	Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid;Drug: Sulfasalazine	Jawaharlal Institute of Postgraduate Medical Education & Research		Not recruiting	18 Years	65 Years	All	136	Phase 3	India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
291	NCT03016013	September 2016	10 September 2018	A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.	A Phase III Study of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Poor Efficacy of MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.	Moderate and Severe RheumatoId Arthritis	Biological: Placebo plus MTX;Biological: RC18 160 mg plus MTX	RemeGen		Recruiting	18 Years	65 Years	All	480	Phase 3	China
292	JPRN-UMIN000027242	2016/08/31	2 April 2019	the effect of tofacitinib on bone mineral density in patients with rheumatoid arthritis		to determine the effect of tofacitinib on bone	tofacitinib	Division of rheumatology, hiroshima clinic	Hatta clinic Sky clinic Toyohira hospital	Not Recruiting	18years-old	90years-old	Male and Female	50	Phase 4	Japan
293	EUCTR2016-000912-13-DE	30/08/2016	12 November 2018	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis.	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis.	subjects with moderate to severe rheumatoid arthritis. MedDRA version: 20.0 Level: LLT Classification code 10039076 Term: Rheumatoid arthritis and other inflammatory polyarthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GSK2982772 Product Code: GSK2982772 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not Available CAS Number: Not Availabl Other descriptive name: GSK2982772A, where A denotes the free base Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	36	Phase 2	Poland;Spain;Romania;Germany;Italy;United Kingdom
294	NCT02889796	August 30, 2016	15 July 2019	Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: Adalimumab;Drug: Placebo to match adalimumab;Drug: MTX	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	1759	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic;France
295	EUCTR2016-000335-40-BG	23/08/2016	20 August 2018	A Study examining the treatment effect and Safety of GDC-0853 when compared With Placebo and a biologic therapy (Adalimumab) in Rheumatoid Arthritis Patients who have not responded or intolerance to Previous therapies.	A TWO-COHORT RANDOMIZED PHASE II, DOUBLEBLIND, PARALLEL GROUP STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS EVALUATING THE EFFICACY AND SAFETY OF GDC-0853 COMPARED WITH PLACEBO AND ADALIMUMAB IN PATIENTS WITH AN INADEQUATE RESPONSE TO PREVIOUS METHOTREXATE THERAPY (COHORT 1) AND COMPARED WITH PLACEBO IN PATIENTS WITH AN INADEQUATE RESPONSE OR INTOLERANCE TO PREVIOUS TNF THERAPY (COHORT 2)	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GDC-0853 Product Code: RO7010939 Pharmaceutical Form: Tablet INN or Proposed INN: not available Current Sponsor code: GDC-0853 RO7010939 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection/infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Genentech, Inc.		Not Recruiting			Female: yes Male: yes	600	Phase 2	Serbia;United States;Mexico;Argentina;Poland;Brazil;Ukraine;Russian Federation;Chile;Bulgaria;Colombia;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
296	EUCTR2016-002125-11-LV	23/08/2016	29 August 2016	Evaluating efficacy, pharmacokinetics and safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis	A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis	Active Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CT-P13 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Product Code: CT-P13 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: REMSIMA Product Code: CT-P13 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Celltrion, Inc		Authorised			Female: yes Male: yes	258	Phase 1;Phase 3	Hungary;Estonia;Czech Republic;Poland;Ukraine;Lithuania;Russian Federation;Bulgaria;South Africa;Latvia;Korea, Republic of;Bosnia and Herzegovina
297	NCT02628028	August 22, 2016	6 May 2019	A Study of LY3337641 in Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study	Rheumatoid Arthritis	Drug: LY3337641;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	65 Years	All	286	Phase 2	United States;Argentina;Australia;Austria;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Slovakia;South Africa;Spain;Germany
298	ChiCTR-IIR-16008693	2016-08-20	18 April 2017	Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously	A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects	Rheumatoid Arthritis	Abatacept Group:Single dose of abatacept;Placebo Group:Single dose of placebo;	The First Hospital, Jilin University		Not Recruiting	18	45	Both	Abatacept Group:20;Placebo Group:2;	Phase 1 study	China
299	NCT02705989	August 18, 2016	11 February 2019	Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects	A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects	Rheumatoid Arthritis	Drug: BMS-986195;Other: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	55 Years	All	439	Phase 1	Australia
300	EUCTR2016-000393-37-BG	08/08/2016	26 September 2016	A study to test the effectiveness of bimekizumab as a treatment for rheumatoid arthritis, to look for unwanted side effects and to measure how the drug is distributed, modified and cleared from the body.	A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY/TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE INTRAVENOUS DOSES OF BIMEKIZUMAB (UCB4940) ADMINISTERED TO SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS	RHEUMATOID ARTHRITIS MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Bimekizumab Product Code: UCB4940 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Bimekizumab CAS Number: 1418205-77-2 Current Sponsor code: CDP4940 Other descriptive name: UCB4940 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	UCB Biopharma Sprl		Not Recruiting			Female: yes Male: yes	60	Phase 2	Serbia;Hungary;Macedonia, the former Yugoslav Republic of;Poland;Romania;Russian Federation;Georgia;Bulgaria;Moldova, Republic of;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
301	EUCTR2016-001532-35-HU	08/08/2016	30 October 2017	A Phase II, Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis.	A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis.	Moderate to Severe Rheumatoid Arthritis. MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: LNP1955 Pharmaceutical Form: Capsule, soft Current Sponsor code: LND400111 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use	Lupin Limited		Not Recruiting			Female: yes Male: yes	64	Phase 2	Hungary;Bulgaria
302	NCT02886728	August 8, 2016	3 June 2019	Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy	A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: MTX;Drug: Placebo to match MTX	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	1252	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic
303	NCT03775824	August 1, 2016	30 September 2019	Faecal Analyses in Rheumatoid Arthritis Therapy	Faecal Analyses in Rheumatoid Arthritis Therapy: An Prospective Observational Study of the Intestinal Microbiome in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy	Rheumatoid Arthritis	Drug: MTX start;Drug: TNF start	Region Skane		Not recruiting	18 Years	N/A	All	50	N/A
304	NCT02722694	August 2016	26 September 2016	A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept 125mg Administered Subcutaneously in Chinese Subjects With Active Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis (RA)	Drug: Subcutaneous(SC) Abatacept;Other: Placebo;Drug: Methotrexate	Jiangsu Simcere Pharmaceutical Co., Ltd.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	Both	360	Phase 3	China
305	NCT02892370	August 2016	19 September 2016	Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects	An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on SHR0302 and Mass Balance in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302	Jiangsu HengRui Medicine Co., Ltd.		Recruiting	18 Years	45 Years	Male	14	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
306	NCT02940561	August 2016	31 October 2016	BE Study in Patients - Methotrexate Tablets	A Multicenter, Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single-dose, Two-way, Crossover, Bioequivalence Study of Methotrexate Tablets USP, 2.5 mg Manufactured by Amneal Pharmaceuticals, With Methotrexate Tablets USP 2.5 mg Manufactured for DAVA Pharmaceuticals, Inc., Fort Lee, NJ 07024 USA in Patients With Mild to Severe Psoriasis or Rheumatoid Arthritis, Who Are Already on Established Regimens of 2.5 mg Every 12 Hours Under Fasting Condition.	Psoriasis;Rheumatoid Arthritis	Drug: Methotrexate - Amneal;Drug: Methotrexate - DAVA	Amneal Pharmaceuticals, LLC	Accutest Research Laboratories (I) Pvt. Ltd.	Recruiting	18 Years	65 Years	Both	48	Phase 1	India
307	NCT02784106	July 31, 2016	11 June 2018	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects With Rheumatoid Arthritis on Stable Methotrexate Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: M2951	EMD Serono Research & Development Institute, Inc.	Merck KGaA	Not recruiting	18 Years	75 Years	All	65	Phase 2	United States;Germany
308	JPRN-JapicCTI-163317	28/7/2016	16 July 2019	Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors	Rheumatoid Arthritis	Intervention name : BMS-986142 INN of the intervention : - Dosage And administration of the intervention : BMS-986142 at dose level 1+ Methotrexate as specified. BMS-986142 at dose level 2 + Methotrexate as specified. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo + Methotrexate dose as specified	Bristol-Myers Squibb K.K.		Not Recruiting	18	120	BOTH	408	Phase 2	Japan, Asia except Japan, North America, South America, Europe, Oceania
309	EUCTR2016-000064-42-SK	27/07/2016	31 October 2016	Safety and Efficacy study of M2951 in Subjects with Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy - N/A	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: M2951 Product Code: M2951 Pharmaceutical Form: Capsule INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Merck KGaA		Authorised			Female: yes Male: yes	64	Phase 2	Hungary;Estonia;Czech Republic;Slovakia;Poland;Ukraine;Romania;South Africa;Bulgaria
310	NCT02873936	July 27, 2016	25 March 2019	Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: csDMARDs	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	449	Phase 3	United States;Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Spain;Switzerland;United Kingdom;Italy;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
311	NCT02867306	July 25, 2016	25 March 2019	A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis	A Phase 1 Open-label, Single-sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ASP1707;Drug: methotrexate (MTX)	Astellas Pharma Global Development, Inc.		Not recruiting	18 Years	65 Years	All	10	Phase 1	Moldova, Republic of
312	ChiCTR-IPR-16008793	2016-07-15	18 April 2017	A multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritis	A multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritis	Rheumatoid arthritis	experimental group:ZHENGQING FENGTONGNING sustained release tablets; control group:methotrexate;The combined treatment group:ZHENGQING FENGTONGNING sustained release tablets combine methotrexate;	The First Affiliated Hospital of Third Military Medical University		Recruiting	18	75	Both	experimental group:80; control group:80;The combined treatment group:80;	Post-market	China
313	EUCTR2015-003433-10-GB	05/07/2016	18 April 2017	ADMYRA Trial: Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis	GP17-302 A randomized, double-blind, parallel-group, multicenter study to demonstrate similar efficacy and to compare safety and immunogenicity of GP2017 and Humira® in patients with moderate to severe active rheumatoid arthritis - ADMYRA trial	rheumatoid arthritis MedDRA version: 19.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Adalimumab Product Code: GP2017 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: GP2017 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Product Code: L04AB04 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Hexal, AG		Authorised			Female: yes Male: yes	308	Phase 3	Serbia;United States;Spain;Turkey;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Malaysia;Poland;Romania;Germany;Korea, Republic of
314	NCT02683421	July 2016	9 January 2017	Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging	Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging	Rheumatoid Arthritis	Drug: tilmanocept	Navidea Biopharmaceuticals		Not recruiting	21 Years	N/A	Both	18	Phase 1	United States
315	NCT02585258	June 30, 2016	10 September 2018	The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study	The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis	RheumatoId Arthritis	Drug: Prednisolone;Other: Placebo	VU University Medical Center	European Commission	Recruiting	65 Years	N/A	All	500	Phase 4	Finland;Germany;Hungary;Italy;Netherlands;Portugal;Romania;Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
316	NCT02765074	June 30, 2016	20 May 2019	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizumab in Rheumatoid Arthritis Phase IV Prospective Multicentrique Study	Rheumatoid Arthritis	Drug: subcutaneous tocilizumab	Centre Hospitalier Régional d'Orléans	Rennes University Hospital	Recruiting	18 Years	85 Years	All	60	Phase 4	France
317	NCT03106259	June 29, 2016	19 February 2018	Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj	Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj	Rheumatoid Arthritis	Drug: FURESTEM-RA Inj.	Kang Stem Biotech Co., Ltd.		Not recruiting	19 Years	80 Years	All	9	N/A	Korea, Republic of
318	EUCTR2015-003376-75-ES	23/06/2016	4 July 2016	A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	600	Phase 3	Serbia;United States;Spain;Ukraine;Turkey;Austria;Russian Federation;Chile;Israel;Colombia;European Union;Mexico;Puerto Rico;Argentina;Australia;Japan;New Zealand
319	NCT03333681	June 20, 2016	25 March 2019	Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients	Evaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular and Humoral Immune Responses and Additionally Study on the Effect of Chemokines in Homing of the Immune Cells in Refractory Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Biological: Autologous mesenchymal stem cells	Mashhad University of Medical Sciences		Not recruiting	35 Years	60 Years	Female	15	Phase 1
320	NCT02799472	June 15, 2016	15 July 2019	Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis	A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs	Arthritis, Rheumatoid	Drug: GSK3196165;Drug: Placebo;Drug: MTX;Drug: Folic (or folinic) acid	GlaxoSmithKline	Parexel	Not recruiting	18 Years	N/A	All	39	Phase 2	United States;Germany;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
321	NCT03762824	June 14, 2016	18 December 2018	Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease	Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.	Rheumatoid Arthritis;Systemic Lupus;Sjögren Syndrome;Systemic Vasculitis;Spondyloarthritis	Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: 13-valent pneumococcal conjugate vaccine	Region Skane		Not recruiting	18 Years	N/A	All	300	Phase 4
322	EUCTR2015-005308-27-CZ	07/06/2016	27 August 2018	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3	Moderately to Severely Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: (CDP6038; L04041) Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	R-Pharm		Authorised			Female: yes Male: yes	350	Phase 3	United States;Hungary;Czech Republic;Mexico;Argentina;Poland;Brazil;Germany;Colombia;Korea, Republic of
323	JPRN-UMIN000021929	2016/06/01	7 October 2019	Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis	Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis - OPTIWIT Study	Rheumatoid arthritis	Discontinuation of infliximab	Chiba University		Not Recruiting	18years-old	Not applicable	Male and Female	200	Not selected	Japan
324	NCT02804204	June 2016	25 February 2019	Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF	Analysis of Circulant Rheumatoid Factor, Cyclic Citrullinated Anti-peptide Anti-bodies and Albumin as a Potential Predictor in the Response to the Treatment With Anti-TNF in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Anti-TNF	Hospital Universitari Vall d'Hebron Research Institute	UCB Pharma	Recruiting	18 Years	N/A	All	200	Phase 2	Spain
325	NCT02804581	June 2016	27 June 2016	Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients	Potential Role of Gum Arabic as Immunomodulator In Sudanese Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Dietary Supplement: Gum Arabic	Lamis Kaddam	University of Khartoum;Military hospital	Recruiting	20 Years	50 Years	Both	45	Phase 2	Sudan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
326	EUCTR2016-002035-15-FI	20/05/2016	13 June 2016	Outcome after total knee endoprosthesis under general or regional anesthesia, a randomized study	Outcome after total knee arthroplasty under general or spinal anesthesia, a randomized study - Outcome after total knee arthroplasty under general or spinal anesthesia	Patients undego total knee arthroplasty operation in general or spinal anaesthesia because of osteoarthritis, rheumatoid arthritis or other degenerative condition of the knee MedDRA version: 19.0 Level: LLT Classification code 10031174 Term: Osteoarthrosis System Organ Class: 100000004859 MedDRA version: 19.0 Level: LLT Classification code 10031158 Term: Osteo arthritis knees System Organ Class: 100000004859 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]	Trade Name: Bicain spinal Pharmaceutical Form: Solution for injection INN or Proposed INN: bupivacaine hydrochloride Other descriptive name: BUPIVACAINE HYDROCHLORIDE Trade Name: Propolipid Pharmaceutical Form: Solution for injection INN or Proposed INN: propofol Other descriptive name: PROPOFOL	Helsinki University Central Hospital		Authorised			Female: yes Male: yes		Phase 4	Finland
327	NCT02659150	May 18, 2016	14 January 2019	Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis	A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab	Massachusetts General Hospital	Brigham and Women's Hospital	Recruiting	50 Years	75 Years	Female	21	Phase 4
328	NCT02792699	May 17, 2016	22 October 2018	Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab	A Randomized, Double-blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: ABP 798;Drug: Rituximab	Amgen		Not recruiting	18 Years	80 Years	All	311	Phase 3	United States;Bulgaria;Estonia;Germany;Hungary;Poland;Canada
329	EUCTR2014-004719-36-BG	14/05/2016	9 January 2017	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	A Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 1	Moderately to Severely Active Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: CDP6038 Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Current Sponsor code: CDP6038 Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	R-Pharm		Authorised			Female: yes Male: yes	420	Phase 3	Belarus;Turkey;Russian Federation;Bulgaria
330	NCT02780388	May 12, 2016	10 September 2018	A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis	A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis	Adult Onset Rheumatoid Arthritis	Biological: MEDI4920;Other: Placebo	MedImmune LLC		Not recruiting	18 Years	70 Years	All	57	Phase 1	United States;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
331	JPRN-UMIN000022364	2016/05/10	2 April 2019	Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis	Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis - Effectiveness of minodronate in osteoporotic patients with rheumatoid arthritis	Osteoprotic patients with rheumatoid arthritis	The selection criteria is based on which treatment each patient wants to take Minodronate group: oral intake 50mg per month Minodronate plus active vitamin D group: oral intake 50mg minodronate per month and eldecalcitol 0.75ug per day after breakfast	Department of Orthopaedic Surgery Shinshu University School of Medicine		Not Recruiting	50years-old	100years-old	Male and Female	140	Not applicable	Japan
332	NCT02760316	May 2, 2016	16 December 2017	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.	A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control	Rheumatoid Arthritis	Drug: AZD9567 10 mg;Drug: AZD9567 20 mg;Drug: AZD9567 40 mg;Drug: AZD9567 80 mg;Drug: Prednisolone 20 mg;Drug: AZD9567 125 mg;Drug: AZD9567 155 mg;Drug: Prednisolone 5 mg;Drug: Prednisolone 40 mg	AstraZeneca		Not recruiting	18 Years	55 Years	All	64	Phase 1	Germany;United Kingdom
333	NCT01815411	May 2016	11 June 2018	Effect of Andosan in Patients With Rheumatoid Arthritis	Effect of the Mushroom Extract Andosan on Symptoms and Inflammatory Parameters in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Dietary Supplement: Mushroom extract	Egil Johnson	ImmunoPharma AS	Not recruiting	19 Years	75 Years	All	10	N/A	Norway
334	NCT02538341	May 2016	15 April 2019	Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)	Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)	Rheumatoid Arthritis;Inflammatory Arthritis;Arthritis;Psoriatic Arthritis;Psoriasis;Ankylosing Spondylitis;Enteropathic Arthritis;Crohn's Disease	Biological: Herpes Zoster Vaccine;Drug: Placebo	University of Alabama at Birmingham	Oregon Health and Science University	Not recruiting	50 Years	N/A	All	617	Phase 2	United States
335	NCT02665910	May 2016	2 May 2016	Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients	A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.		Not recruiting	18 Years	70 Years	Both	48	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
336	NCT02760368	May 2016	18 December 2018	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease	A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	Rheumatoid Arthritis	Drug: Olokizumab q4w;Drug: Olokizumab q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Not recruiting	18 Years	N/A	All	428	Phase 3	Bulgaria;Russian Federation;Turkey
337	NCT02760407	May 2016	18 December 2018	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease	A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	Rheumatoid Arthritis	Drug: Olokizumab 64mg q4w;Drug: Olokizumab 64mg q2w;Drug: Adalimumab 40mg q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials	Recruiting	18 Years	N/A	All	1575	Phase 3	United States;Argentina;Brazil;Bulgaria;Colombia;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;China;Czech Republic
338	NCT02762123	May 2016	26 September 2016	A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates	Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy Subjects	Rheumatoid Arthritis	Drug: BMS-986142 200mg;Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin);Drug: BMS-986142 350mg	Bristol-Myers Squibb		Not recruiting	18 Years	50 Years	Both	28	Phase 1	United States
339	NCT02770794	May 2016	23 May 2016	Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis	Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity	Arthritis, Rheumatoid	Drug: Infliximab	Chiba University		Not recruiting	18 Years	N/A	Both	200	Phase 4
340	NCT02603146	April 27, 2016	28 October 2019	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Healthy Participants;Rheumatoid Arthritis (RA) Prevention	Drug: Hydroxychloroquine;Drug: HCQ Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Recruiting	18 Years	N/A	All	200	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
341	NCT02714881	April 2016	23 July 2018	Lipids, Inflammation, and CV Risk in RA	Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis	Rheumatoid Arthritis;Cardiovascular Disease	Radiation: Stress myocardial perfusion PET;Drug: certolizumab	Brigham and Women's Hospital		Recruiting	35 Years	90 Years	All	75	N/A	United States
342	NCT02715908	April 2016	16 July 2018	A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)	A Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With RA Who Have Completed the Treatment Period of LG-ECCL002	Rheumatoid Arthritis	Drug: LBEC0101	LG Life Sciences		Not recruiting	20 Years	75 Years	All	148	Phase 3	Korea, Republic of
343	NCT02722044	April 2016	11 June 2018	Usability of an AI for M923 in Subjects With Moderate to Severe RA	An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Biological: M923;Device: Autoinjector	Momenta Pharmaceuticals, Inc.		Not recruiting	18 Years	N/A	All	33	Phase 3	United States
344	NCT02746380	April 2016	16 December 2017	A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate the Similarity of Efficacy and Safety of LBAL 40mg Subcutaneous Biweekly Injection to Humira® 40mg Subcutaneous Biweekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Arthritis, Rheumatoid	Drug: LBAL;Drug: Humira®	LG Life Sciences	Mochida Pharmaceutical Company, Ltd.	Not recruiting	20 Years	75 Years	All	380	Phase 3	Japan;Korea, Republic of
345	NCT02573012	March 29, 2016	11 November 2019	Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants	Prospective, Multicentre, Placebo-controlled, Double-blind Interventional Study to Compare the Efficacy of Maintenance Treatment With Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Placebo matched to prednisone;Drug: Prednisone;Biological: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	314	Phase 4	France;Germany;Italy;Russian Federation;Serbia;Tunisia;Egypt;Switzerland;Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
346	NCT02679001	March 24, 2016	20 August 2018	A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.	A COMPARATIVE OBSERVATIONAL STUDY FOLLOWING THE USE OF CONCOMITANT CORTICOSTEROID TREATMENT IN RA PATIENTS WHO ARE TREATED WITH A TNF INHIBITOR OR TOCILIZUMAB AS THEIR SECOND BIOLOGICAL TREATMENT	Rheumatoid Arthritis	Drug: TNF inhibitor/TCZ	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	200	Phase 1/Phase 2	Sweden
347	NCT02720523	March 22, 2016	28 October 2019	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Rheumatoid Arthritis	Drug: Placebo;Drug: Upadacitinib	AbbVie		Not recruiting	18 Years	N/A	All	197	Phase 2/Phase 3	Japan
348	NCT02682823	March 21, 2016	12 November 2018	Tocilizumab Real-Life Human Factors (RLHFs) Validation Study	Tocilizumab Real-Life Human Factors Validation Study	Rheumatoid Arthritis	Device: AI-1000 G2;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	91	Phase 4	United States
349	EUCTR2015-002523-26-HU	08/03/2016	11 April 2016	Effects of JAK inhibition on rheumatoid arthritis-related comorbidities: link between bone and vascular effects (investigator-initiated grant proposal)	Effects of JAK inhibition on rheumatoid arthritis-related comorbidities: link between bone and vascular effects (investigator-initiated grant proposal)	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Tofacitinib Product Code: CP-690,55-10 Pharmaceutical Form: Film-coated tablet	Arthritis Alapítvány		Authorised			Female: yes Male: yes			Hungary
350	NCT01961310	March 8, 2016	11 June 2018	Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis	Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Plasma analysis for bacterial translocation;Biological: Stool analysis	Centre Hospitalier Universitaire de Nimes		Not recruiting	18 Years	N/A	All	55	N/A	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
351	NCT02547493	March 3, 2016	11 June 2018	Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients	Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept	Rheumatoid Arthritis	Biological: pneumococcal polysaccharide vaccine;Biological: pneumococcal conjugate vaccine;Drug: Abatacept	University Hospital, Montpellier	Bristol-Myers Squibb	Recruiting	18 Years	85 Years	All	80	N/A	France;Monaco
352	NCT02706951	March 2, 2016	18 March 2019	A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX	Rheumatoid Arthritis	Drug: Methotrexate;Drug: ABT-494;Drug: ABT-494 matching placebo;Drug: Methotrexate matching placebo	AbbVie		Not recruiting	18 Years	99 Years	All	648	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Czechia;Estonia;Greece;Hungary;Israel;Italy;Japan;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;Colombia;Czech Republic;New Zealand
353	JPRN-UMIN000021492	2016/03/01	2 April 2019	To investigate the safety of switch from infliximab biosimilar 1 in rheumatoid arthritis patients.		Rheumatoid arthritis	switch from infliximab to infliximab biosimilar 1 in rheumatoid arthritis patients.	Inoue Hospital		Not Recruiting	18years-old	Not applicable	Male and Female	40	Not selected	Japan
354	NCT02636829	March 2016	26 September 2016	Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis	Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Chronic Inflammatory Arthritis	Multiple Sclerosis;Rheumatoid Arthritis	Other: QALCIMUM questionnaire;Other: Determination of calcium intake by a dietician interview	Centre Hospitalier Universitaire de Nimes		Not recruiting	18 Years	69 Years	Both	100	N/A	France
355	NCT02652299	March 2016	25 March 2019	Fibrocytes in Early and Longstanding Rheumatoid Arthritis	Fibrocytes in Early and Longstanding Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Synovial biopsy	Odense University Hospital		Not recruiting	18 Years	N/A	All	60	N/A	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
356	NCT02714634	March 2016	11 April 2016	Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate	Randomized Controlled Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate	Rheumatoid Arthritis;Insufficient Response to Methotrexate.	Drug: Methotrexate + biologic administration;Drug: methotrexate + salazopyrine + hydroxychloroquine administration	University Hospital, Strasbourg, France		Not recruiting	18 Years	N/A	Both	286	Phase 4
357	NCT02728934	February 25, 2016	11 November 2019	Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis	Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Golimumab Intravenous (IV);Biological: Infliximab;Biological: Biosimilar Infliximab	Janssen Scientific Affairs, LLC		Not recruiting	18 Years	N/A	All	1279	N/A	United States
358	EUCTR2015-002924-17-BE	24/02/2016	23 July 2018	A Study To Evaluate The Efficacy And Safety Of Intravenous Nanocort Compared With A Intramuscular Injection of Methylprednisolone Acetate In Patients With Rheumatoid Arthritis	A Phase III, Randomized, Double-Blind, Double Dummy, Active Controlled, Multi-Center Study To Evaluate The Efficacy And Safety Of Intravenous Pegylated Liposomal Prednisolone Sodium Phosphate (Nanocort) Compared With Intramuscular Injection Of Methylprednisolone Acetate In Subjects With Active Rheumatoid Arthritis	Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Nanocort Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: prednisolone Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Depo Medrol Product Name: Depo Medrol Pharmaceutical Form: Suspension for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use	Sun Pharma Global FZE		Not Recruiting			Female: yes Male: yes	330	Phase 3	Belgium;Netherlands
359	NCT02698657	February 23, 2016	15 July 2019	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate	A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis (RA)	Drug: ASP5094;Drug: Placebo	Astellas Pharma Global Development, Inc.		Not recruiting	18 Years	65 Years	All	30	Phase 1	United States;Poland
360	NCT02706873	February 23, 2016	25 March 2019	A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ABT-494 matching placebo;Drug: Methotrexate;Drug: Methotrexate matching placebo;Drug: ABT-494	AbbVie		Not recruiting	18 Years	99 Years	All	1002	Phase 3	United States;Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Latvia;Lithuania;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;Czech Republic;Finland;Malaysia;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
361	NCT02638948	February 16, 2016	20 August 2018	Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors	Rheumatoid Arthritis	Drug: BMS-986142;Drug: Placebo;Drug: Methotrexate	Bristol-Myers Squibb		Not recruiting	18 Years	120 Years	All	536	Phase 2	United States;Argentina;Austria;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;Belgium
362	NCT02683564	February 2016	23 February 2016	BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study	A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study	Rheumatoid Arthritis	Drug: BOW015;Drug: Remicade	Epirus Biopharmaceuticals (Switzerland) GmbH		Not recruiting	18 Years	80 Years	Both	548	Phase 3
363	NCT03332719	February 2016	16 December 2017	Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis	Multicentric Evaluator-blinded Randomized Non-inferiority Study, to Asses the Compared Efficacy, Safety and Immunogenicity of Enerceptan® With Enbrel® in Combination With Methotrexate for the Treatment of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Etanercept;Drug: Methotrexate	Gema Biotech S.A.	QUID-Quality in Drugs and Devices Latin American Consulting SRL	Not recruiting	19 Years	99 Years	All	168	Phase 3	Argentina
364	NCT03355872	February 2016	9 October 2018	A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs	A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs	Rheumatoid Arthritis	Drug: HLX01	Shanghai Henlius Biotech		Not recruiting	18 Years	65 Years	All	194	Phase 1/Phase 2
365	EUCTR2014-004868-38-GR	26/01/2016	14 March 2016	A study comparing the use of etanercept and methotrexate, used either alone or in combination, for maintaining remission in rheumatoid arthritis.	A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis.	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Methotrexate Product Name: methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: methotrexate CAS Number: 59-05-2 Current Sponsor code: methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Amgen Inc.		Authorised			Female: yes Male: yes	720		United States;Hungary;Czech Republic;Canada;Greece;Argentina;Spain;Bulgaria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
366	NCT02925351	January 25, 2016	11 November 2019	Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases	The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases	Autoimmune Disease;Crohn Disease;Inflammatory Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Takayasu Arteritis	Procedure: Computed Tomography;Radiation: Fluorine F 18 Clofarabine;Procedure: Positron Emission Tomography	Jonsson Comprehensive Cancer Center	National Cancer Institute (NCI)	Not recruiting	18 Years	N/A	All	8	N/A	United States
367	NCT02640612	January 22, 2016	18 December 2018	Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis	Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab	Arthritis, Rheumatoid	Drug: BI 695501	Boehringer Ingelheim		Not recruiting	18 Years	80 Years	All	430	Phase 3	United States;Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine
368	JPRN-UMIN000018931	2016/01/17	2 April 2019	Impact of intravenous acetaminophen on multimodal pain management after total knee arthroplasty: a double-blinded randomized controlled trial		Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	1000 mg of intravenous acetaminophen (100 ml) after total knee arthroplasty at 23:00 of day of surgery, 5:00, 11:00, 17:00, and 23:00 of one day after surgery, 5:00, 11:00, 17:00, and 23:00 of two days after surgery, and 5:00 of three days after surgery. 100ml of intravenous normal saline after total knee arthroplasty at 23:00 of day of surgery, 5:00, 11:00, 17:00, and 23:00 of one day after surgery, 5:00, 11:00, 17:00, and 23:00 of two days after surgery, and 5:00 of three days after surgery.	Nekoyama Miyao Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
369	EUCTR2014-004673-16-DE	12/01/2016	30 April 2018	Randomized, blinded, controlled study to compare the efficacy of treatment with tocilizumab with or without glucocorticoids in rheumatoid arthritis.	Prospective, multicentre, placebo-controlled, double-blind study to compare the efficacy of maintenance treatment with tocilizumab with or without glucocorticoid discontinuation in rheumatoid arthritis patients	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra 162 mg Product Code: RO487-7533/F10-04 Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- Trade Name: Prednisone Tablets USP, 5 mg Product Code: RO001-9265/F04 Pharmaceutical Form: Capsule INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Prednisone Tablets USP, 1 mg Product Code: RO 001-9265/F02-01 Pharmaceutical Form: Capsule INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: RoActemra Product Code: L04AC07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	226	Phase 4	Serbia;France;Egypt;Lebanon;Turkey;Russian Federation;Germany;Italy;Switzerland
370	EUCTR2015-003332-13-SK	12/01/2016	8 February 2016	A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)	A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti- Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	600	Phase 3	Serbia;Belarus;United States;Taiwan;Hong Kong;Slovakia;Ukraine;Russian Federation;Chile;Israel;Colombia;Switzerland;Puerto Rico;Malaysia;Australia;South Africa;Bosnia and Herzegovina;Korea, Republic of;Turkey;Egypt;European Union;Mexico;Canada;Argentina;Brazil;Singapore;Kazakhstan;Japan;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
371	NCT02742597	January 12, 2016	8 January 2018	Patient-Centred Innovations for Persons With Multimorbidity - Ontario	Patient-Centred Innovations for Persons With Multimorbidity - Ontario	Hypertension;Depression;Anxiety;Musculoskeletal Pain;Arthritis;Rheumatoid Arthritis;Osteoporosis;Chronic Obstructive Pulmonary Disease (COPD);Asthma;Chronic Bronchitis;Cardiovascular Disease;Heart Failure;Stroke;Transient Ischemic Attacks;Ulcer;Gastroesophageal Reflux;Irritable Bowel;Crohn's Disease;Ulcerative Colitis;Diverticulosis;Chronic Hepatitis;Diabetes;Thyroid Disorder;Cancer;Kidney Disease;Urinary Tract Problem;Dementia;Alzheimer's Disease;Hyperlipidemia;HIV;Multimorbidity	Behavioral: TIP / IMPACT Plus Care Coordination	Lawson Health Research Institute	Western University, Canada;Université de Sherbrooke;Canadian Institutes of Health Research (CIHR);Sunnybrook Health Sciences Centre;St. Michael's Hospital, Toronto;University Health Network, Toronto;Toronto East General Hospital;Providence HealthCare;Mount Sinai Hospital, Canada;Toronto Central Community Care Access Centre;Women's College Hospital	Not recruiting	18 Years	80 Years	All	1980	N/A	Canada
372	EUCTR2012-002009-23-HU	07/01/2016	3 July 2017	Clinical trial to demonstrate that treatments with GP2015 and Enbrel® are comparable in patients with rheumatoid arthritis	A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and Enbrel® (EU-authorized) in patients with moderate to severe, active rheumatoid arthritis - EQUIRA	Moderate to severe active rheumatoid arthritis MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: GP2015 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Enbrel 50 mg solution for injection in pre-filled syringe Product Name: Enbrel 50 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Hexal AG		Not Recruiting			Female: yes Male: yes	366	Phase 3	Serbia;United States;Estonia;Slovakia;Spain;Lithuania;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Mexico;Poland;Bulgaria;Germany;Latvia
373	EUCTR2015-002634-41-HU	07/01/2016	11 December 2017	Long-term study of BI695501 in patients with active rheumatoid arthritis	Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis (RA): an open-label extension trial for patients who have completed trial 1297.2 and are eligible for long-term treatment with adalimumab	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: BI 695501 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: - CAS Number: - Current Sponsor code: BI 695501 Other descriptive name: BI 695501 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Boehringer Ingelheim International GmbH		Not Recruiting			Female: yes Male: yes	400	Phase 3	Serbia;United States;Estonia;Spain;Thailand;Ukraine;Chile;Russian Federation;Hungary;Malaysia;Poland;Bulgaria;Germany;Korea, Republic of
374	NCT02636907	January 6, 2016	16 December 2017	Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe	Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe	Arthritis, Rheumatoid	Drug: BI 695501 Autoinjector;Drug: BI 695501 Prefilled syringe	Boehringer Ingelheim		Not recruiting	18 Years	80 Years	All	77	Phase 2	United States;Poland;Ukraine
375	NCT02321930	January 2016	16 December 2017	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: tofacitinib 5mg po bid	University of California, Los Angeles		Not recruiting	18 Years	N/A	All	25	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
376	NCT02626026	January 2016	10 October 2016	Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)	A Phase 1, Placebo-Controlled, Randomized Study Evaluating the Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: GS-4059;Drug: Placebo	Gilead Sciences		Not recruiting	18 Years	65 Years	Both	42	Phase 1	United States
377	NCT02643823	January 2016	13 June 2016	Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis	Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: hUC-MSC + DMARDs;Drug: DMARDs	Shenzhen Hornetcorn Bio-technology Company, LTD	Futian People's Hospital	Recruiting	18 Years	80 Years	Both	40	Phase 1	China
378	NCT02762838	January 2016	24 June 2019	Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	International Multi-center Comparative Double-blind Randomized Clinical Trial of Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: BCD-055;Biological: Remicade®;Drug: Methotrexate;Drug: Folic acid	Biocad		Not recruiting	18 Years	75 Years	All	426	Phase 3	Belarus;India;Russian Federation
379	NCT02878161	January 2016	29 August 2016	Predictability Studies on the Efficacy of TNF-a Inhibitors in Chinese RA From Real World	Screening Protein Predictive of Response to Tumor Necrosis Factor-a Inhibitors Treatment in Chinese Rheumatoid Arthritis From Real World and Investigating Its Mechanism Through Signal Pathway	Rheumatoid Arthritis	Drug: methotrexate(necessary);Biological: infliximab;Biological: etanercept;Biological: adalimumab;Drug: leflunomide (permitted, not necessary);Drug: NSAIDs (permitted,not necessary);Drug: Glucocorticoids (permitted,not necessary)	Fen Li		Recruiting	18 Years	75 Years	Both	240	Phase 4
380	NCT02608112	December 31, 2015	5 November 2018	Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year	Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	291	Phase 1	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
381	NCT02644499	December 31, 2015	14 October 2019	Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis	Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid	Jawaharlal Institute of Postgraduate Medical Education & Research		Not recruiting	18 Years	N/A	All	186	Phase 4	India
382	EUCTR2015-003333-95-SK	18/12/2015	6 November 2018	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Humira 40mg/0.8ml solution for injection in pre-filled syringe Product Name: Adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	1500	Phase 3	Ukraine;Ireland;Chile;Israel;Russian Federation;Colombia;Puerto Rico;Malaysia;Denmark;Australia;South Africa;Latvia;Bosnia and Herzegovina;Korea, Republic of;Finland;Lithuania;Turkey;Austria;United Kingdom;Egypt;Czech Republic;Hungary;European Union;Mexico;Canada;Argentina;Belgium;Brazil;Singapore;Croatia;Kazakhstan;Bulgaria;Germany;New Zealand;Portugal;Serbia;Belarus;United States;Taiwan;Hong Kong;Slovakia;Greece;Spain
383	EUCTR2015-004173-32-DK	18/12/2015	30 April 2019	Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring.	Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. A randomized and investigator initiated study.	Rheumatic diseases MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000005156 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Enbrel Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Humira Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Remsima Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 5- Trade Name: Benepali Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 50- Trade Name: Remicade Pharmaceutical Form: Solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 7,5-	Department of Clinical Biochemestry, Aarhus University Hospital		Not Recruiting			Female: yes Male: yes	500	Phase 4	Denmark
384	NCT02675426	December 17, 2015	18 March 2019	A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Rheumatoid Arthritis	Drug: Placebo;Drug: ABT-494	AbbVie		Not recruiting	18 Years	99 Years	All	661	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;Belarus;Brazil;Colombia;Czech Republic;Denmark;Israel;Netherlands;Norway;Serbia;Singapore
385	EUCTR2015-003334-27-SK	11/12/2015	6 November 2018	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who have not Previously taken Methotrexate (SELECT-EARLY)	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	975	Phase 3	Portugal;Serbia;Belarus;United States;Taiwan;Hong Kong;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Chile;Israel;Colombia;Switzerland;Puerto Rico;Malaysia;Australia;South Africa;Latvia;China;Bosnia and Herzegovina;Korea, Republic of;Slovenia;Finland;Lithuania;Turkey;United Kingdom;Egypt;Hungary;Czech Republic;European Union;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Kazakhstan;Bulgaria;New Zealand;Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
386	NCT02680067	December 8, 2015	29 April 2019	NIR Fluorescence Imaging of Lymphatic Transport Using ICG	Near InfraRed Fluorescence Imaging of Lymphatic Transport Using Indocyanine Green	Rheumatoid Arthritis	Drug: Indocyanine Green;Device: MultiSpectral Imaging System	University of Rochester	National Institutes of Health (NIH);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Recruiting	18 Years	89 Years	All	30	Phase 1	United States
387	ChiCTR-IPR-15007368	2015-12-01	18 April 2017	Clinical Research for the Effect of Chinese and Western Medicine on Treating Rheumatoid Arthritis	Comparative Study on the Influences of Gut Microbiota of Chinese and Western Medicine for Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	1:HuaYuTongBiFang;2:HuaYuTongBiFang+MTX;3:ZhengQingFengTongNing Pills+MTX;4:Methotrexate;	Guangdong Provincial Hospital of Chinese Medicine		Not Recruiting	18	65	Male	1:96;2:96;3:96;4:96;	Pilot study	China
388	NCT02629159	December 1, 2015	25 February 2019	A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Rheumatoid Arthritis	Drug: Placebo for Adalimumab;Drug: ABT-494;Drug: Adalimumab;Drug: Placebo for ABT-494	AbbVie		Not recruiting	18 Years	N/A	All	1629	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;Czech Republic;Finland;Netherlands
389	NCT02944799	December 2015	22 October 2018	Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis	Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass	Rheumatoid Arthritis;Osteoporosis	Drug: Placebo;Drug: Alendronate;Drug: Calcium;Drug: Vitamin D	University of Aarhus		Recruiting	18 Years	N/A	All	160	Phase 2	Denmark
390	NCT02758769	November 30, 2015	16 December 2017	Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings	Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings	Rheumatoid Arthritis	Biological: ORENCIA Subcutaneous Injection	Bristol-Myers Squibb	Ono Pharmaceutical Co. Ltd	Recruiting	20 Years	N/A	All	300	N/A	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
391	NCT02557100	November 19, 2015	26 August 2019	Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis	A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Abatacept;Drug: Adalimumab;Drug: Methotrexate	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	120	Phase 4	United States;Algeria;Canada;Mexico
392	NCT02512575	November 18, 2015	9 October 2018	A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.	A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.	Safety;Tolerability;Pharmacokinetics;Pharmacodynamics;Healthy Subjects;Rheumatoid Arthritis	Drug: AZD9567 Monohydrat;Drug: Placebo oral suspension/ Placebo capsule;Drug: Prednisolone	AstraZeneca		Not recruiting	18 Years	55 Years	Male	72	Phase 1	Germany
393	EUCTR2015-002809-12-HU	17/11/2015	2 October 2017	A Study to Compare YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis	A comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: YLB113 Product Code: YLB113 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Current Sponsor code: YLB113 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Enbrel Product Name: Enbrel Product Code: Enbrel Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	YL Biologics Ltd		Not Recruiting			Female: yes Male: yes	500	Phase 3	Czech Republic;Hungary;Spain;Ukraine;Romania;Bulgaria;Latvia;Japan;India
394	EUCTR2013-000337-13-PT	13/11/2015	12 February 2018	Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA)	Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreCePRA) - PreCePRA	Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia Product Name: Cimzia Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Current Sponsor code: UCB SA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution and suspension for suspension for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Universitätsklinikum Erlangen		Authorised			Female: yes Male: yes	156	Phase 3	Serbia;United States;Portugal;Germany
395	JPRN-UMIN000018848	2015/11/01	5 November 2019	Tapering and withdrawal of methotrexate and biologics in patients with rheumatoid arthritis	Tapering and withdrawal of methotrexate and biologics in patients with rheumatoid arthritis - Tapering and withdrawal of methotrexate and biologics in patients with rheumatoid arthritis	Rheumatoid arthritis	control: continue the present treatment intervention: reduce the dosage of methotrexate by half every 3 months and discontinue intervention: extend the interval of biologics to one and a half times every 3 months and discontinue	Keio University Hospital		Not Recruiting	Not applicable	Not applicable	Male and Female	900	Not applicable	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
396	NCT02534896	November 2015	26 November 2018	To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis	To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis	Active Rheumatoid Arthritis	Drug: Sunpharma1505 1;Drug: Sunpharma1505 2;Drug: Reference1505	Sun Pharma Global FZE		Not recruiting	18 Years	90 Years	All	330	Phase 3	Belgium;Netherlands
397	NCT02543931	November 2015	12 December 2016	Curcuma Longa L in Rheumatoid Arthritis	Phase Ib Randomized, Double-Blind, Placebo-Controlled Study of Meriva in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Meriva;Drug: placebo	University of Arizona	Vanderbilt University;National Center for Complementary and Integrative Health (NCCIH);National Institutes of Health (NIH)	Not recruiting	18 Years	N/A	Both	3	Phase 1	United States
398	NCT02723760	November 2015	11 April 2016	99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	Clinical Study of 99mTc-3PRGD2 SPECT/CT in Diagnosis and Efficacy Evaluation of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 99mTc-3PRGD2	First Affiliated Hospital of Fujian Medical University		Recruiting	20 Years	70 Years	Both	40	Phase 0	China
399	NCT02552940	October 31, 2015	11 June 2018	An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice	A PROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE CLINICAL EFFECTIVENESS, THE CONSISTENCY OF EVALUATION SCORES, QUALITY OF LIFE, SAFETY AND TOLERABILITY OF TOCILIZUMAB SUBCUTANEOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	nv Roche sa	Not recruiting	18 Years	N/A	All	140	N/A	Belgium;Luxembourg
400	ChiCTR-OPB-15007284	2015-10-30	18 April 2017	Characterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patients	Characterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patients	Rheumatoid Arthritis	RA group1:Doxycycline;RA group 2:Placebo;	Hong Kong Baptist University		Recruiting	18	80	Both	RA group1:20;RA group 2:20;	Pilot study	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
401	EUCTR2015-001246-28-BE	19/10/2015	16 November 2015	Ultrasound scores as imaging biomarkers of early response to subcutaneous tocilizumab in association with methotrexate in early rheumatoid arthritis (TOVERA study)	Ultrasound scores as imaging biomarkers of early response to subcutaneous tocilizumab in association with methotrexate in early rheumatoid arthritis (TOVERA study) - TOVERA	Rheumatoid Arthritis MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Product Name: RoActemra Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe	Cliniques Universitaires Saint-Luc, Université catholique de Louvain		Authorised			Female: yes Male: yes			Belgium
402	EUCTR2015-000581-58-CZ	14/10/2015	15 October 2018	A Randomized,Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action	A Randomized, Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action - BioBio	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 100- Trade Name: Orencia Product Name: Orencia Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 250- Trade Name: Ro-Actemra Product Name: Ro Actemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumabum CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: up to Concentration number: 20- Trade Name: Mabthera Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: up to Concentration number: 10-	Revmatologicky ustav Praha		Not Recruiting			Female: yes Male: yes	40	Phase 4	Czech Republic
403	NCT02534311	October 13, 2015	12 March 2018	A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)	Prospective Evaluation of Rheumatoid Arthritis Activity Using DAS28 in Patients Treated With Subcutaneously Administered Tocilizumab on Local Level	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	60	N/A	Slovakia
404	NCT02778789	October 2015	7 October 2019	Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers	Non Randomized Parallel-group Clinical Study to Compare the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers.	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: TNF-alpha Inhibitor	University of Erlangen-Nürnberg Medical School		Not recruiting	18 Years	N/A	All	66	N/A	Germany
405	NCT02780323	October 2015	16 December 2017	Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis	A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CELBESTA® placebo;Drug: CELEBREX® placebo;Drug: CELEBREX®;Drug: CELBESTA®	Dong-A ST Co., Ltd.		Recruiting	19 Years	N/A	All	158	Phase 4	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
406	NCT02882087	October 2015	15 April 2019	A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-a Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis	A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Inadequate Response of TNF-a Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis	Moderate and Severe Rheumatoid Arthritis	Drug: RC18 160 mg plus MTX;Drug: Placebo plus MTX	RemeGen		Not recruiting	18 Years	65 Years	All	60	Phase 2	China
407	EUCTR2015-003638-28-DK	30/09/2015	30 April 2019	Treatment of osteoporosis in patients with rheumatoid arthritis.	ALOSTRA Alendronate treatment of osteoporosis in rheumatoid arthritis – indication and duration. A randomized, doubleblind, placebocontrolled multi-centre study to evaluate the effects of discontinuation of alendronate in patients with both rheumatoid arthritis and low bone mass. - ALOSTRA	Rheumatoid arthritis and osteoporosis MedDRA version: 20.0 Level: LLT Classification code 10031289 Term: Osteoporosis, unspecified System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10039076 Term: Rheumatoid arthritis and other inflammatory polyarthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Alendronat Teva Pharmaceutical Form: Tablet INN or Proposed INN: Alendronic Acid Other descriptive name: ALENDRONIC ACID Concentration unit: g gram(s) Concentration type: equal Concentration number: 0.07- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Aarhus University Hospital		Authorised			Female: yes Male: yes	160	Phase 2	Denmark
408	EUCTR2015-002284-42-FI	18/09/2015	28 September 2015	The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit	INTENT: immunogenicity in patients failing response on anti-TNF -Immunogenicity and pharmacokinetics in patients failing to respond to TNF inhibitors (phase 1); -Clinical effectiveness of subsequent TNF inhibitor treatment and predictive value of pharmacokinetics and immunogenicity (phase 2) - INTENT	rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis.;Therapeutic area: Not possible to specify	Trade Name: Enbrel Product Name: etanercept Pharmaceutical Form: Injection Trade Name: Humira Product Name: adalimumab Pharmaceutical Form: Injection Trade Name: Cimzia Product Name: certolizumab pegol Pharmaceutical Form: Injection Trade Name: Simponi Product Name: golimumab Pharmaceutical Form: Injection Trade Name: Remicade Product Name: infliximab Pharmaceutical Form: Infusion	READE		Authorised			Female: yes Male: yes	1650	Phase 1	Finland
409	NCT02605642	September 10, 2015	18 March 2019	Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade	PERSIST: PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS PERSISTENCE OF CT-P13 (INFLIXIMAB) IN PATIENTS WITH RHEUMATOID DISEASES WHO ARE EITHER NAIVE TO BIOLOGICS OR SWITCHED FROM STABLE REMICADE(R) (INFLIXIMAB)	Rheumatoid Diseases;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: CT-P13	Pfizer	Hospira, now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	All	351	Phase 3	Bulgaria;Canada;Czechia;Germany;Greece;Spain;United Kingdom;Czech Republic;France;Italy
410	NCT02535832	September 2015	24 June 2019	Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)	Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis;Insulin Resistance	Drug: Pioglitazone;Drug: Placebo	University of Alabama at Birmingham		Recruiting	35 Years	65 Years	All	36	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
411	NCT02553018	September 2015	16 December 2017	Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe	A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.	Arthritis, Rheumatoid	Drug: Methotrexate	Nordic Pharma SAS		Not recruiting	18 Years	N/A	All	278	Phase 3	France
412	NCT02565810	September 2015	16 December 2017	An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis	An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab PFS and Pen	Samsung Bioepis Co., Ltd.		Not recruiting	18 Years	55 Years	All	49	Phase 2	Poland
413	NCT02717988	September 2015	12 March 2018	Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers	A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SKI-O-703 capsule;Drug: Placebo capsule	Oscotec Inc.	PPD	Not recruiting	18 Years	55 Years	All	48	Phase 1	United States
414	NCT02748785	September 2015	7 November 2016	MTX Discontinuation and Vaccine Response	Effect of Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial	Arthritis, Rheumatoid	Drug: Methotrexate;Biological: Seasonal Influenza vaccine	Seoul National University Hospital		Not recruiting	18 Years	N/A	Both	277	Phase 4	Korea, Republic of
415	NCT02764515	September 2015	16 December 2017	Kunxian for the Treatment of Rheumatoid Arthritis	Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Kunxian Capsule;Drug: Methotrexate	Chinese SLE Treatment And Research Group	CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group;CHINESE RHEUMATISM DATA CENTER	Recruiting	40 Years	70 Years	All	428	Phase 4	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
416	JPRN-UMIN000027241	2015/08/31	2 April 2019	the change of IMT of carotide artery in RA with treatment of tocilizumab		rheumatoid arthritis	tofacitinib	hiroshima clinic		Not Recruiting	18years-old	80years-old	Male and Female	50	Not applicable	Japan
417	NCT02504268	August 31, 2015	22 October 2019	Effects of Abatacept in Patients With Early Rheumatoid Arthritis	A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Other: Abatacept Placebo;Other: Methotrexate Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	1067	Phase 3	United States;Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Singapore;South Africa;Spain;Sweden;Taiwan;United Kingdom;Czech Republic;Puerto Rico;Saudi Arabia;United Arab Emirates
418	NCT02350426	August 12, 2015	16 December 2017	A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques	An Adaptive Design Open Label Pilot Study in Rheumatoid Arthritis Patients to Assess Inflammation Using Molecular Imaging Techniques	Arthritis, Rheumatoid	Other: Gadobutrol;Other: 18F-FDG;Other: 18F-GE-180	GlaxoSmithKline	Cambridge University Hospitals NHS Foundation Trust	Not recruiting	30 Years	85 Years	All	10	Phase 1	United Kingdom
419	JPRN-JapicCTI-153081	01/8/2015	16 July 2019	Effects of Abatacept in Patients With Early Rheumatoid Arthritis	A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive	Rheumatoid Arthritis	Intervention name : Abatacept + Methotrexate Dosage And administration of the intervention : Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week Control intervention name : Methotrexate Dosage And administration of the control intervention : Methotrexate at least 15mg per week tablet or capsule orally Control intervention name : Abatacept Placebo Dosage And administration of the control intervention : Placebo for Abatacept subcutaneous injection once per week Control intervention name : Methotrexate Placebo Dosage And administration of the control intervention : Placebo to match Methotrexate capsule orally once per week	Bristol-Myers Squibb K.K.		Not Recruiting	18		BOTH	1000	Phase 3
420	NCT02451748	August 2015	29 April 2019	IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA	IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA	Rheumatoid Arthritis	Other: Lab Work;Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg);Drug: Certolizumab pegol (CDP870, tradename Cimzia)	University of Illinois at Chicago	UCB Pharma	Not recruiting	18 Years	N/A	All	32	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
421	NCT02797769	August 2015	21 July 2016	A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)	Risk of Cardiovascular Events in Patients Using Tocilizumab as Compared With Other Biologics in Multiple Large Healthcare Databases	Rheumatoid Arthritis	Drug: Other Biologics;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	75000	N/A
422	NCT02481180	July 31, 2015	22 July 2019	Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)	An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance?Pharmacokinetics?Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: T0001;Drug: Enbrel	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.		Not recruiting	18 Years	65 Years	All	36	Phase 1	China
423	EUCTR2015-000665-30-GB	30/07/2015	27 August 2018	Coherus Open-Label Safety Extension Study	An Open-Label Safety Extension Study (OLSES) Evaluating the Long term Safety and Durability of Response of CHS 0214 (CHS 0214-05) - OLSES	Rheumatoid arthritis Chronic Plaque Psoriasis MedDRA version: 18.0 Level: LLT Classification code 10042952 Term: Systemic rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 18.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: CHS-0214 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Etanercept CAS Number: 185243-69-0 Current Sponsor code: CHS-0214 Other descriptive name: BGX-0214 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Coherus BioSciences, Inc.		Not Recruiting			Female: yes Male: yes	447	Phase 3	France;Canada;Spain;Australia;Israel;South Africa;Germany;Japan;Italy;United Kingdom
424	NCT02504671	July 23, 2015	15 April 2019	Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis	A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate	Arthritis, Rheumatoid	Drug: GSK3196165;Drug: MTX;Drug: Folic acid;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	222	Phase 2	Bulgaria;Canada;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic
425	EUCTR2012-003876-38-DE	21/07/2015	28 November 2016	Clinical study to find out if the biologically similar medicine GP2013 is safe in patients with rheumatoid arthritis who have been treated with Rituxan® or MabThera® in the past	A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients with active rheumatoid arthritis, previously treated with Rituxan® or MabThera® - ASSIST-RT	Rheumatoid Arthritis MedDRA version: 19.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GP2013 Product Code: GP2013 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: GP2013 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Trade Name: MabThera® Product Name: MabThera® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	Hexal AG (a Sandoz company)		Not Recruiting			Female: yes Male: yes	100	Phase 3	United States;Hungary;Poland;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
426	NCT02242474	July 2015	20 August 2018	Anti-TNFa Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis	Prospective Randomized Multicentric Trial on Anti-TNFa Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Anti-TNF suspended perioperatively;Drug: Anti-TNFa continued perioperatively	CHU de Quebec-Universite Laval		Recruiting	18 Years	N/A	All	660	Phase 4	Canada
427	NCT02467504	July 2015	23 November 2015	Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-Naive Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: hrIL-2 active;Drug: hrIL-2 placebo;Drug: MTX;Drug: Folic Acid;Drug: Loxoprofen	Peking University People's Hospital	Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd.	Recruiting	18 Years	70 Years	Both	60	Phase 2	China
428	NCT02480946	July 2015	16 December 2017	Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis	A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate	Arthritis, Rheumatoid	Drug: MBS2320;Drug: Placebo;Drug: Methotrexate	Modern Biosciences plc	Covance	Not recruiting	18 Years	70 Years	All	105	Phase 1	United Kingdom
429	NCT02486939	July 2015	16 December 2017	A Long Term Safety Extension Study (CHS-0214-05)	An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)	Rheumatoid Arthritis;Plaque Psoriasis	Drug: CHS-0214	Coherus Biosciences, Inc.	Daiichi Sankyo Co., Ltd.;Shire	Not recruiting	18 Years	N/A	All	359	Phase 3	Japan
430	NCT02514772	July 2015	16 December 2017	GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®	A Randomized, Double- Blind, Controlled, Parallel-group, Multicenter Study to Assess the Safety and Immunogenicity of Transitioning to GP2013 or Re-treatment With Rituxan® or MabThera® in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®	Rheumatoid Arthritis	Biological: GP2013 - A Proposed biosimilar rituximab;Biological: Originator rituximab - Rituxan ® or MabThera ®	Sandoz	Hexal AG	Not recruiting	18 Years	N/A	All	107	Phase 3	United States;Germany;Hungary;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
431	NCT02518620	July 2015	26 August 2019	An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis	A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX-0061	Rheumatoid Arthritis	Biological: ALX-0061	Ablynx		Not recruiting	18 Years	74 Years	All	406	Phase 2	Belgium;Bulgaria;Georgia;Germany;Hungary;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;Macedonia, The Former Yugoslav Republic of
432	NCT02531178	July 2015	11 April 2016	A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABBV-257	Rheumatoid Arthritis	Biological: ABBV-257;Biological: Placebo	AbbVie		Not recruiting	18 Years	75 Years	Both	8	Phase 1	Germany
433	NCT02598466	July 2015	15 February 2016	Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa	Patient-Reported Efficacy of Subcutaneous Abatacept in Rheumatoid Arthritis: An Evaluation Of Patients In a Compassionate Use Programme in South Africa	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	Hexor, South Africa	Not recruiting	18 Years	N/A	Both	69	N/A
434	NCT02480153	June 25, 2015	4 February 2019	A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).	A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE	Rheumatoid Arthritis	Biological: PF-06410293;Biological: Adalimumab	Pfizer		Not recruiting	18 Years	N/A	All	597	Phase 3	United States;Australia;Brazil;Bulgaria;Colombia;Czechia;Estonia;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;Canada;Czech Republic
435	EUCTR2014-003453-34-EE	18/06/2015	29 January 2018	Study of a new drug’s effect in people with rheumatoid arthritis who have not responded sufficiently well to treatment with Methotrexate.	A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate.	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: GSK3196165 Pharmaceutical Form: Solution for injection INN or Proposed INN: INN not available CAS Number: 1638332-55-4 Current Sponsor code: GSK3196165 Other descriptive name: Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	210	Phase 2	Estonia;Spain;Ukraine;Russian Federation;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;South Africa;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
436	NCT02405780	June 10, 2015	5 March 2018	A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients	An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate	Arthritis, Rheumatoid	Drug: FKB327;Drug: Humira®	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not recruiting	18 Years	N/A	All	645	Phase 3	United States;Canada;Chile;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;Bulgaria;Czech Republic
437	EUCTR2015-000538-31-DE	01/06/2015	4 August 2015	Application into the joint of opioids in chronic arthritis of the knee joint	NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint - Neuroimpa - knee joint	chronic arthritis of the knee joint effusion as part of spondyloarthritis (Assessments in SpondyloArthritis international Society, ASAS criteria), Rheumatoid Arthritis, RA (according to American Col-lege of Rheumatology, ACR criteria), undifferentiated mono- or oligoarthritis, Osteoarthritis of the knee, OA. MedDRA version: 18.0 Level: LLT Classification code 10067624 Term: Knee arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Morphine Hexal Pharmaceutical Form: Solution for injection INN or Proposed INN: Morphinsulfat Other descriptive name: MORPHINE SULFATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Triam 40 mg Lichtenstein Pharmaceutical Form: Suspension for injection INN or Proposed INN: TRIAMCINOLONACETONID Other descriptive name: TRIAMCINOLONACETONID EP Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40-	Charité University medicine Berlin		Authorised			Female: yes Male: yes			Germany
438	NCT02402686	May 20, 2015	11 November 2019	Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)	Open-Label, Multi-Center, Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab SC Monotherapy in Daily Clinical Practice (SIMPACT)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	353	N/A	Hungary
439	EUCTR2014-004904-31-NL	19/05/2015	5 September 2016	A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remsima (infliximab) Pharmaceutical Form: Powder for concentrate for solution for injection/infusion	Mundipharma Pharmaceuticals B.V.		Authorised			Female: yes Male: yes		Phase 4	Netherlands
440	JPRN-UMIN000017440	2015/05/18	7 October 2019	In methotrexate resistant rheumatoid arthritis, switching methotrexate to tofacitinib versus adding tofacitinib to methotrexate, open labeled, multicenter randomized non-inferiority study.	In methotrexate resistant rheumatoid arthritis, switching methotrexate to tofacitinib versus adding tofacitinib to methotrexate, open labeled, multicenter randomized non-inferiority study. - RAXEL study	Rheumatoid arthritis	for 3 months Tofacitinib 5mg BID everyday for 3 months Tofacitinib 5mg BID everyday for 3 months Methotrexate6mg-16mg/week	Graduate School of Medicine and School of Medicine, Chiba University the department of allergy and clinical immunology		Not Recruiting	18years-old	90years-old	Male and Female	134	Phase 4	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
441	EUCTR2014-000110-61-CZ	11/05/2015	19 February 2018	Study to assess the long-term efficacy and safety of FKB327 compared with Humira®, when each is administered in combination with Methotrexate in patients with Rheumatoid Arthritis.	An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients with Rheumatoid Arthritis on Concomitant Methotrexate - ARABESC-OLE	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: FKB327 PFS Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: FKB327 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Product Code: FKB327 AI Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: FKB327 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 50-	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not Recruiting			Female: yes Male: yes	680	Phase 3	Bulgaria;Germany;United States;Serbia;Spain;Ukraine;Chile;Russian Federation;Czech Republic;Canada;Poland;Romania;Peru
442	EUCTR2014-003034-42-HU	08/05/2015	10 September 2018	An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Rheumatoid Arthritis	A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed One of the Preceding Phase IIb Studies with ALX-0061	Rheumatoid Arthritis (RA) MedDRA version: 18.1 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ALX-0061 Product Code: ALX-0061 Pharmaceutical Form: Solution for injection INN or Proposed INN: Not available CAS Number: 1628814-88-9 Other descriptive name: ALX-0061 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150-	Ablynx NV		Not Recruiting			Female: yes Male: yes	501	Phase 2	Serbia;Spain;Hungary;Czech Republic;Mexico;Macedonia, the former Yugoslav Republic of;Argentina;Belgium;Poland;Romania;Bulgaria;Georgia;Germany;Moldova, Republic of
443	EUCTR2014-005418-45-SE	04/05/2015	22 May 2017	Are risk factors factors of pertaining to or involving the heart and blood vessels and markers characterized or caused by inflammation in Rheumatoid Arthritis (a chronic, systemic inflammatory disorder that primarily affects joints) and Systemic Lupus Erythematosus (systemic disease in which the body’s immune system mistakenly attacks healthy tissue)improved? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE)	Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - HCQCVDRASLE	Rheumatoid Arthritis and Systemic Lupus Erythematosus;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Plaquenil Pharmaceutical Form: Film-coated tablet INN or Proposed INN: HYDROXYCHLOROQUINE CAS Number: 118-42-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	Christine Bengtsson	Solveig Wållberg-Jonsson	Not Recruiting			Female: yes Male: yes		Phase 2	Sweden
444	NCT02404558	May 2015	11 April 2016	Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis	An Open-label, Randomized, Parallel Group, Single-dose Study to Describe the Safety of IL-6 Receptor Blockade With Sarilumab or Tocilizumab Monotherapy in Japanese Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: tocilizumab	Sanofi	Regeneron Pharmaceuticals	Not recruiting	20 Years	N/A	Both	30	Phase 1	Japan
445	NCT02456844	May 2015	8 February 2016	Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients	Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects	Rheumatoid Arthritis	Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, Leucovorin and BMS-986142	Bristol-Myers Squibb		Not recruiting	18 Years	50 Years	Both	24	Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
446	NCT02460393	May 2015	8 January 2018	A Trial With Humanized TNFa Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects	A Randomized, Double Blind, Placebo Controlled Trial With Humanized TNFa Monoclonal Antibody Injection by Single Dose and Dose Escalation to Explore the Tolerance, Safety and Pharmacokinetic Characteristics in Healthy Subjects	Rheumatoid Arthritis	Drug: Humanized TNFa monoclonal antibody;Other: placebo	Shenyang Sunshine Pharmaceutical Co., LTD.		Not recruiting	18 Years	45 Years	All	72	Phase 1	China
447	NCT02566967	May 2015	15 July 2019	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target	Rheumatoid Arthritis	Drug: tofacitinib	Norman B. Gaylis, MD		Not recruiting	18 Years	N/A	All	20	Phase 3	United States
448	EUCTR2014-003307-30-HU	16/04/2015	22 May 2017	Multiple dose study of UCB4940 as add-on to Certolizumab Pegol in subjects with rheumatoid arthritis	A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Doses of UCB4940 Administered as Add-On to Certolizumab Pegol Therapy in Subjects with Moderate-to-Severe Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BIMEKIZUMAB Product Code: UCB4940 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Bimekizumab CAS Number: 1418205-77-2 Current Sponsor code: UCB4940 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Cimzia Product Name: Cimzia Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200-	UCB Celltech, UK Registered Branch of UCB Pharma SA		Not Recruiting			Female: yes Male: yes	180	Phase 2	Czech Republic;Hungary;Slovakia;Russian Federation;Georgia;United Kingdom;Moldova, Republic of
449	NCT02387762	April 2015	8 April 2019	ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate	A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate	Rheumatoid Arthritis	Drug: acalabrutinib;Drug: Placebo	Acerta Pharma BV		Not recruiting	18 Years	75 Years	All	31	Phase 2	United States
450	NCT02423538	April 2015	1 February 2016	First-in-Human Single Ascending Dose of SHR0302	A Phase I, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.		Not recruiting	18 Years	45 Years	Both	64	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
451	NCT02499315	April 2015	17 May 2016	Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 357;Drug: Placebo	Amgen		Not recruiting	25 Years	70 Years	Female	32	Phase 1	United States
452	NCT02800811	April 2015	8 August 2016	Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104	Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Intravenous Doses of FR104 in Healthy Subjects	Rheumatoid Arthritis;Complication of Transplant	Drug: FR104;Drug: Placebo	OSE Immunotherapeutics		Not recruiting	18 Years	60 Years	Both	64	Phase 1	Belgium
453	ChiCTR-IPR-15006107	2015-03-30	18 April 2017	The clinical trial of tolerance of Ginsenoside compound K	To study the pharmacokinetics and tolerance of Ginsenoside compound K tablet in healthy volunteers after multiple dosing administration	rheumatoid arthritis	three groups:Ginsenoside compound K is administrated after single dose or multiple doses;	Institute of Clinical Pharmacology, Central South University		Not Recruiting	18	45	Male	three groups:12;	Phase 1 study	China
454	JPRN-UMIN000016950	2015/03/27	2 April 2019	Clinical outcome in patients with rheumatoid arthritis switched to tumor nesrosis factor blockers after tocilizumab or abatacept		rheumatoid arthritis	Infliximab or adalimumab or golimumab	Osaka Medical College		Not Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
455	EUCTR2015-000089-72-IT	26/03/2015	19 February 2018	abatacept in obese and overweight RA patiens	FAT GENE EXPRESSION IN OVERWEIGHT AND OBESE PATIENTS WITH PERSISTENTLY ACTIVE RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT AND CLINICAL RESPONSE	MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: ORENCIA Product Name: Orencia abatacept Pharmaceutical Form: Solution for injection	Policlinico Gemelli-CIC- UCSC		Not Recruiting			Female: yes Male: yes	40	Phase 4	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
456	NCT02486302	March 24, 2015	5 February 2018	A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.	A Prospective, Multicenter Non-interventional Study To Evaluate The Efficacy Of Enbrel (Registered) (Etanercept) Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis With Particular Focus On The Clinical Status Improvements Still Observable After 12 Weeks Of Treatment	Rheumatoid Arthritis;Psoriatic Arthritis;Axial Spondyloarthritis;Plaque Psoriasis	Drug: Etanercept	Pfizer		Not recruiting	18 Years	N/A	All	1535	N/A	Germany
457	EUCTR2014-001471-31-HU	23/03/2015	13 June 2016	This is a Phase 2, multicenter, 24-week, open-label extension (OLE) study to assess the safety and tolerability of ABT-122 in rheumatoid arthritis (RA) subjects who have completed Study M12-963.	Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-122 Product Code: ABT-122 Pharmaceutical Form: Lyophilisate for solution for injection INN or Proposed INN: na Other descriptive name: ABT-122 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Product Name: ABT-122 Product Code: ABT-122 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: na Other descriptive name: ABT-122 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	AbbVie Deutschland GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	160	Phase 2	Czech Republic;Hungary;Canada;Poland;Romania;Bulgaria;Germany;New Zealand
458	EUCTR2014-003033-26-BE	23/03/2015	12 September 2016	A clinical trial testing different doses of investigational drug ALX-0061 combined with Methotrexate to treat patients with Moderate to Severe Rheumatoid Arthritis	A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis (RA) MedDRA version: 18.0 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ALX-0061 Product Code: ALX-0061 Pharmaceutical Form: Solution for injection INN or Proposed INN: Not available Other descriptive name: ALX-0061 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Ablynx NV		Not Recruiting			Female: yes Male: yes	330	Phase 2	Serbia;United States;Spain;Czech Republic;Hungary;Mexico;Macedonia, the former Yugoslav Republic of;Argentina;Belgium;Poland;Romania;Bulgaria;Georgia;Germany;Moldova, Republic of
459	EUCTR2014-004419-35-GB	18/03/2015	17 August 2015	Inhibition of Co-Stimulation in Rheumatoid Arthritis	Inhibition of Co-Stimulation in Rheumatoid Arthritis - Inhibition of Co-Stimulation in Rheumatoid Arthritis (ICoSRA)	Rheumatoid Arthritis: patients who are dual ACPA and HLA-DR4 positive MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Abatacept Product Name: Abatacept Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 125-	Greater Glasgow Health Board	University of Glasgow	Authorised			Female: yes Male: yes	25		United Kingdom
460	EUCTR2013-005524-42-NL	10/03/2015	28 November 2016	STAtins to Prevent Rheumatoid Arthritis (STAPRA)	Prevention of rheumatoid arthritis by atorvastatin in seropositive arthralgia patients: a multi-center doubleblind randomized placebo-controlled trial - STAtins to Prevent Rheumatoid Arthritis (STAPRA)	Rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039080 Term: Rheumatoid factor positive System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Atorvastatin Product Name: Atorvastatin Product Code: C10AA05 Pharmaceutical Form: Tablet INN or Proposed INN: ATORVASTATIN CAS Number: 134523-00-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Reade		Authorised			Female: yes Male: yes		Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
461	NCT02304354	March 9, 2015	7 October 2019	Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)	Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)	Rheumatoid Arthritis	Drug: Rituximab	University Hospital, Tours		Not recruiting	18 Years	N/A	All	70	Phase 3	France
462	JPRN-UMIN000015433	2015/03/01	2 April 2019	Safety study of methotrexate low-dose once daily administration in rheumatoid arthritis patients		rheumatoid arthritis	methotrexate	Department of Medical Pharmaceutics , Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama		Recruiting	20years-old	Not applicable	Male and Female	35	Not selected	Japan
463	NCT02287922	March 2015	26 August 2019	A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis	A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate	Rheumatoid Arthritis	Biological: ALX-0061;Biological: Placebo;Biological: Tocilizumab	Ablynx		Not recruiting	18 Years	74 Years	All	251	Phase 2	United States;Belgium;Bulgaria;Czechia;Georgia;Germany;Hungary;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;Czech Republic;Macedonia, The Former Yugoslav Republic of
464	NCT02353780	March 2015	11 June 2019	Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept	Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept	Rheumatoid Arthritis (RA)	Drug: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi);Drug: Abatacept;Drug: Tocilizumab	Dr. Larry W. Moreland	Genentech, Inc.;Bristol-Myers Squibb	Not recruiting	18 Years	64 Years	All	10	Phase 4	United States
465	NCT02414984	March 2015	16 December 2017	Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab	Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia	Rheumatoid Arthritis	Biological: Golimumab	Janssen-Cilag, S.A.		Not recruiting	18 Years	N/A	All	37	N/A	Colombia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
466	NCT02620189	March 2015	14 December 2015	Th17 Responses Evaluated in RA Patients on Inhibitors of TNFa	A Study to Investigate the Role of IL-17 and Th17 Pathway Activation in RA Patients With Inadequate Response to Anti-TNFa Therapies	Rheumatoid Arthritis	Drug: Anti-TNF Biologics Therapy	Queen Mary University of London		Recruiting	18 Years	N/A	Both	50	N/A	United Kingdom
467	NCT02638259	February 21, 2015	1 October 2018	Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: GP2015	Sandoz		Not recruiting	18 Years	N/A	All	376	Phase 3	United States;Bulgaria;Czechia;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;Czech Republic
468	NCT02373813	February 20, 2015	4 November 2019	Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission	A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: etanercept pre-filled syringe sq injection;Drug: Oral methotrexate;Drug: Placebo for etanercept sq injection;Drug: Placebo for methotrexate	Amgen		Not recruiting	18 Years	N/A	All	371	Phase 3	United States;Argentina;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;Czech Republic
469	EUCTR2014-002945-23-GB	18/02/2015	11 April 2016	A 24 week Phase 2 study in subjects with moderate to severe early Rheumatoid Arthritis who’s symptoms are not fully controlled by treatment with methotrexate alone. Subjects will be told if they are in the group receiving either 150 mg namilumab injected under the skin or adalimumab. Responses to the medicine will be measured using MRI.	A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate - A Phase 2 Study of Namilumab vs Anti-Tumor Necrosis Factor in Patients With Rhematoid Arthritis.	Rheumatoid Arthritis (RA) MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Trade Name: Humira 40 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Takeda Development Centre Europe Ltd.		Not Recruiting			Female: yes Male: yes	36	Phase 2	Estonia;Czech Republic;Spain;Russian Federation;United Kingdom
470	EUCTR2013-005418-37-DE	05/02/2015	29 January 2018	A multicenter, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	A multicenter, randomized, double-blind, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 (Dekavil) administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	Patients with active Rheumatoid Arthritis despite methotrexate therapy that had unsuccessful response to at least one anti-TNF treatment. MedDRA version: 17.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Dekavil Product Code: F8IL10 Pharmaceutical Form: Solution for injection INN or Proposed INN: dekavil Current Sponsor code: F8IL10 Other descriptive name: F8IL10 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 3.75-20 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Philogen S.p.A.		Authorised			Female: yes Male: yes	87	Phase 2	Germany;Italy;Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
471	EUCTR2013-004569-16-HU	03/02/2015	8 August 2016	A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis	A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Etanercept Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Pfizer Inc., 235 East 42nd Street, New York, NY 10017		Not Recruiting			Female: yes Male: yes	180	Phase 3	Serbia;Slovakia;Greece;Russian Federation;Colombia;Italy;Hungary;Mexico;Poland;Croatia;South Africa;Bulgaria;Germany
472	JPRN-JapicCTI-152979	01/2/2015	2 April 2019	Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)	A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Intervention name : Namilumab Dosage And administration of the intervention : Namilumab 20 mg, 80 mg or 150 mg subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate (15-25 mg weekly, 6-16 mg weekly in Japan), and folic acid (at least 5 mg/week), orally, throughout the duration of the study. Control intervention name : Placebo Dosage And administration of the control intervention : Namilumab placebo-matching SC injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate (15-25 mg weekly, 6-16 mg weekly in Japan), and folic acid (at least 5 mg/week), orally, throughout the duration of the study.	TAKEDA PHARMACEUTICAL COMPANY LTD.			20		BOTH	108	Phase 2
473	NCT02332590	February 2015	28 October 2019	Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)	A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Adalimumab;Drug: Placebo (for sarilumab);Drug: Placebo (for adalimumab)	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	369	Phase 3	United States;Chile;Czechia;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic;France
474	NCT02357069	February 2015	18 January 2016	A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate Similarity of Efficacy and Safety of LBEC0101 50mg Subcutaneous Weekly Injection to Enbrel® 50mg Subcutaneous Weekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Arthritis, Rheumatoid	Drug: Enbrel;Drug: LBEC0101	LG Life Sciences	Mochida Pharmaceutical Company, Ltd.	Not recruiting	20 Years	75 Years	Both	372	Phase 3	Japan;Korea, Republic of
475	NCT02373202	February 2015	9 January 2017	A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)	A Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin);Drug: sulfasalazine;Drug: leflunomide;Drug: bucillamine;Drug: tacrolimus;Drug: mizoribin	Sanofi	Regeneron Pharmaceuticals	Not recruiting	20 Years	N/A	Both	91	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
476	NCT02390700	February 2015	28 November 2016	Observational Study of Golimumab Intravenous Infusion	Golimumab Intravenous Infusion Registry (GO-IV)	Rheumatoid Arthritis	Biological: Golimumab Intravenous	Janssen Inc.		Not recruiting	18 Years	N/A	Both	78	Phase 4	Canada
477	NCT02466581	February 2015	18 December 2018	Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity	A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity	Rheumatoid Arthritis	Drug: Sulphasalazine + Hydroxychloroquine OR Prednisolone;Biological: Cimzia;Biological: Orencia;Biological: RoActemra	Karolinska Institutet		Recruiting	18 Years	N/A	All	500	Phase 4	Sweden
478	NCT02633332	February 2015	28 December 2015	Use of Well Known Drugs for New Destination - RA Improvement (RANT)	Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used Treatments	Rheumatoid Arthritis;Autoimmune Diseases;Disorder of Synovium;Sjogren's Syndrome;Acute and Chronic Inflammation;Disorder of Pleura and Pleural Cavity;Felty's Syndrome;Rheumatoid Nodules	Drug: Vitamin D3;Drug: Lipitor®;Drug: Acycloguanosine;Drug: Tetracycline;Drug: methotrexate;Drug: etanercept	Università Popolare Homo & Natura		Not recruiting	18 Years	75 Years	Both	15	Phase 1	Italy
479	EUCTR2014-002541-22-CZ	26/01/2015	9 January 2017	Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid Arthritis	A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis - SARIL-RA-MONARCH	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Humira, 40 mg solution for injection in pre-filled syringe Product Name: adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	540	Phase 3	United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Czech Republic;Hungary;Puerto Rico;Poland;Romania;Peru;South Africa;Germany;Korea, Republic of
480	EUCTR2014-000109-11-DE	22/01/2015	16 August 2016	Study to assess the efficacy and safety of FKB327 compared with Humira®, when each is administered in combination with Methotrexate in patients with Rheumatoid Arthritis.	A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety with the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate. - ARABESC	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: FKB327 Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: FKB327 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not Recruiting			Female: yes Male: yes	730	Phase 3	United States;Serbia;Spain;Ukraine;Chile;Russian Federation;Czech Republic;Canada;Poland;Romania;Peru;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
481	EUCTR2014-003255-54-CZ	21/01/2015	11 June 2018	A study evaluating the effects of RGB-03 and MabThera combined with Methotrexate in patients with Rheumatoid Arthritis	A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: RGB-03 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: RGB-03 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Gedeon Richter Plc		Not Recruiting			Female: yes Male: yes	142	Phase 1;Phase 3	Hungary;Estonia;Czech Republic;Poland;Belgium;Spain;Ukraine;Romania;Austria;Russian Federation;Israel;Germany
482	NCT03719469	January 20, 2015	5 November 2018	Circulating microRNAs as Novel Prognosis Biomarkers for Rheumatoid Arthritis	Circulating microRNAs Expression as Predictors of Clinical Response in Rheumatoid Arthritis Patients Treated With Green Tea	Rh Disease	Dietary Supplement: Green tea group	King Saud University		Not recruiting	18 Years	85 Years	All	150	N/A
483	ChiCTR-IPR-15005787	2015-01-15	18 April 2017	The effect of food on the pharmacokinetics of Ginsenoside C-K	To study the effect of food on pharmacokinetics of Ginsenoside C-K tablet in healthy volunteers	rheumatoid arthritis	Two groups:Ginsenoside compound K is administrated after taking food versus fasting;	Institute of Clinical Pharmacology, Central South University		Not Recruiting	18	45	Both	Two groups:24;	Phase 1 study	China
484	NCT02309359	January 2015	26 August 2019	A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis	A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Biological: ALX-0061;Other: Placebo;Drug: Methotrexate	Ablynx		Not recruiting	18 Years	74 Years	All	345	Phase 2	United States;Belgium;Bulgaria;Czechia;Georgia;Germany;Hungary;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;Czech Republic;Macedonia, The Former Yugoslav Republic of
485	NCT02371096	January 2015	2 March 2015	Comparative Pharmacokinetic Trial of RGB-03 and MabThera		Rheumatoid Arthritis	Drug: MabThera (rituximab);Drug: RGB-03	Gedeon Richter Plc.		Not recruiting	18 Years	75 Years	Both		Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
486	NCT02744196	January 2015	5 February 2018	Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC BIOCAD) With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis	Multicenter Comparative Randomised Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC BIOCAD) With Methotrexate in First Line of Biological Therapy of Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Acellbia;Drug: Placebo;Drug: Methotrexate	Biocad		Not recruiting	18 Years	80 Years	All	159	Phase 3
487	NCT02837978	January 2015	25 February 2019	The Clinical Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment	Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Tacrolimus;Drug: MTX	Qiang Shu		Recruiting	18 Years	80 Years	All	100	Phase 4	China
488	NCT02927535	January 2015	17 October 2016	Evaluation of TNFa Blockers Monotherapy in Early Rheumatoid Arthritis in France		Rheumatoid Arthritis	Drug: TNF blockers monotherapy	Centre Hospitalier Universitaire de Nimes	Pfizer;Pfizer	Not recruiting	18 Years	70 Years	Both	813	N/A
489	EUCTR2015-002466-22-Outside-EU/EEA		28 December 2015	A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis	A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: anakinra Pharmaceutical Form: Solution for injection INN or Proposed INN: ANAKINRA CAS Number: 143090-92-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Not Available			Female: yes Male: yes	90		United States;Australia;Canada;Costa Rica;New Zealand
490	JPRN-UMIN000012650	2014/12/31	2 April 2019	In vivo kinematic analysis of total knee arthroplasty with 3-dimensional registration technique.		osteoarthritis or rheumatoid arthritis of the knee joint	Fluoroscopy was performed to continuously capture the knee from the lateral direction in a weight-bearing position and knee bending position.	Dept. of orthopedic surgery, Osaka Medical College		Recruiting	20years-old	90years-old	Male and Female	60	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
491	EUCTR2014-003529-16-GB	16/12/2014	4 December 2018	Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology	Stratification of Biologic Therapies for RA by Pathobiology (STRAP): A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab. - STRAP	Rheumatoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion Trade Name: RoActmera Product Name: RoActmera Pharmaceutical Form: Solution for injection Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled pen	Joint Research & Development Office (QMUL)		Authorised			Female: yes Male: yes	219	Phase 3	United Kingdom
492	JPRN-UMIN000020663	2014/12/16	2 April 2019	A clinical study to evaluate the correlation between the efficacy and the immunological markers in patients with rheumatoid arthritis treated with Tofacitinib.		Rheumatoid arthritis	Period :12 months Patients take Tofacitinib 5mg twice a day.	Kyusyu University Hospital Medicine and biosystemic science		Not Recruiting	20years-old	Not applicable	Male and Female	20	Not applicable	Japan
493	JPRN-UMIN000015794	2014/12/15	2 April 2019	Efficacy of monthly sodium risedronate for the treatment of corticosteroid induced osteoporosis in patients with rheumatoid arthritis (multicenter, double-blind, randomized, placebo-controlled, parallel-group study )		osteoporosis, rheumatoid arthritis	monthly risedronate sodium 75mg for 6 months monthly placebo for 6 months	Division of rheumatology, endcrinology and nephrology, Hokkaido University Graduate School of Medicine		Not Recruiting	20years-old	Not applicable	Male and Female	165	Phase 4	Japan
494	NCT02198651	December 15, 2014	27 August 2018	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)	Rheumatoid Arthritis;Musculoskeletal and Connective Tissue Diseases	Drug: Adalimumab;Other: Placebo	AbbVie		Not recruiting	18 Years	99 Years	All	149	Phase 4	United States;Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom
495	EUCTR2014-000993-20-SE	04/12/2014	5 February 2018	Dosing of glucocorticoid (triamcinolone hexacetonid) when injecting knee joints of rheumatic diseases	Dosing of intraarticular triamcinolone hexacetonid for knee synovitis in chronic polyarthritis	Psoriatic arthritis and rheumatoid arthritis with synovitis of the knee;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Pharmaceutical Form: Injection Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Pharmaceutical Form: Injection	Center for Research and Development Uppsala University/County Council of Gävleborg		Not Recruiting			Female: yes Male: yes	160	Phase 4	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
496	ChiCTR1800014846	2014-12-01	12 February 2018	Effect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplasty	Effect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplasty: A prospective randomized double-blind controlled trial	osteonecrosis of the femoral head, femoral neck fracture, developmental dysplasia of hip, osteoarthritis, rheumatoid arthritis or ankylosing spondylitis	Experiment group:preoperative intravenous parecoxib sodium and postoperative intravenous parecoxib sodium and patient-controlled analgesia;Control Group:preoperative intravenous pure 0.9% saline and postoperative intravenous parecoxib sodium and patient-controlled analgesia;	Peking Union Medical College Hospital		Not Recruiting			Both	Experiment group:50;Control Group:50;	Post-market	China
497	NCT02260791	December 2014	16 December 2017	A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients	A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate	Arthritis, Rheumatoid	Drug: FKB327;Drug: Humira®	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not recruiting	18 Years	N/A	All	728	Phase 3	United States;Bulgaria;Canada;Chile;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;Czech Republic;Serbia
498	NCT02328027	December 2014	11 June 2018	99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)	A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: 99mTc-rhAnnexin V-128	Advanced Accelerator Applications		Not recruiting	18 Years	N/A	All	16	Phase 1/Phase 2	Switzerland
499	NCT02876874	December 2014	29 August 2016	Relationship Between the Activity of Rheumatoid Arthritis and Lymph Node Morphology and Lymphatics Drainage	the Relationship Between the Activity of Rheumatoid Arthritis(RA) and Popliteal/Epitrochlear Lymph Node Morphology and the Drainage of Hand/Foot Superficial Lymphatic Vessels	Rheumatoid Arthritis;Lymph Node Mass;Lymphatic Vessel; Dilatation	Drug: indocyanine green(ICG)	Shanghai University of Traditional Chinese Medicine		Recruiting	18 Years	65 Years	Both	21	N/A	China
500	EUCTR2014-001114-26-GB	25/11/2014	28 February 2019	A study of subjects with rheumatoid arthritis who are in clinical remission to investigate patient and disease characteristics that could help identify which subjects may lose disease control upon reducing their adalimumab dose	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) subjects (PREDICTRA)	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Humira 40 mg/0.8 ml solution for injection Product Name: ADALIMUMAB Product Code: 331731-18-1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: Humira Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	AbbVie Deutschland GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	150	Phase 4	United States;Greece;Spain;Ireland;Austria;United Kingdom;Italy;Hungary;Canada;Australia;Germany;Netherlands;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
501	EUCTR2014-002374-36-SE	19/11/2014	1 December 2014	A study with dose de-escalation of coventional or biologic treatments in early rheeumatoid arthritis in patients with low disease activity.	A multicenter, randomized, open-label, blinded-assessor, follow-up, phase 4 study in patients with rheumatoid arthritis who have completed the initial treatment part (active conventional therapy versus three biologic treatments) in the NORD-STAR study and have reached stable low disease activity - CO-STAR	Rheumatoid arthritis (RA) MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia Pharmaceutical Form: Injection Trade Name: Orencia Pharmaceutical Form: Solution for infusion in pre-filled syringe Trade Name: RoActemra Pharmaceutical Form: Infusion Trade Name: Methotrexate Pharmaceutical Form: Tablet Trade Name: Metoject Pharmaceutical Form: Trade Name: Azathioprine Pharmaceutical Form: Tablet Trade Name: Leflunomide Pharmaceutical Form: Tablet	The Karolinska Institutet, ClinTRID		Authorised			Female: yes Male: yes	500	Phase 4	Sweden
502	NCT02281552	November 18, 2014	16 December 2017	A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate	Rheumatoid Arthritis	Drug: Tofacitinib	Pfizer		Not recruiting	20 Years	N/A	All	209	Phase 3	Japan
503	JPRN-UMIN000015616	2014/11/04	2 April 2019	Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction		rheumatoid arthritis	Adalimumab plus Methotrexate Tocilizumab plus Methotrexate	Biologic Mate Study Group		Not Recruiting	20years-old	75years-old	Male and Female	300	Not selected	Japan
504	NCT02030028	November 2014	18 March 2019	ACTH Gel Therapy in Rheumatoid Arthritis	Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ACTHAR gel	Dr. Larry W. Moreland	Mallinckrodt	Recruiting	18 Years	100 Years	All	20	N/A	United States
505	NCT02287610	November 2014	16 December 2017	A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis	A Non-Interventional Study to Evaluate the Effectiveness of Delayed-Release Prednisone (RAYOS) on Clinical Assessments and Serologic Disease Activity in Patients With Active Rheumatoid Arthritis in the Clinical Practice Setting	Rheumatoid Arthritis	Drug: RAYOS (delayed-release prednisone)	Horizon Pharma Ireland, Ltd., Dublin Ireland		Not recruiting	18 Years	N/A	All	75	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
506	NCT02293902	November 2014	9 January 2017	A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)	A Randomized, Double-blind, Multicenter Study With a Placebo-controlled Period Assessing the Efficacy and Safety of Sarilumab Added to Methotrexate (MTX) in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Other: placebo;Drug: methotrexate;Drug: folic acid	Sanofi	Regeneron Pharmaceuticals	Not recruiting	20 Years	75 Years	Both	243	Phase 3	Japan
507	NCT02296775	November 2014	19 February 2015	Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis		Rheumatoid Arthritis	Biological: DRL_RI;Biological: Rituxan;Biological: MabThera	Dr. Reddy's Laboratories Limited		Recruiting	18 Years	65 Years	Both	276	Phase 1/Phase 2	India;Ukraine
508	NCT02342977	November 2014	5 September 2016	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.	Osteoarthritis;Rheumatoid Arthritis;Avascular Necrosis	Drug: Placebo;Drug: Lacosamide	Indiana University School of Medicine	VA Office of Research and Development	Not recruiting	18 Years	70 Years	Both	0	Phase 2	United States
509	NCT02551575	November 2014	27 June 2016	Efficacy and Safety of Traditional Chinese Medicine (TCM) Comprehensive Therapy in Patients With Rheumatoid Arthritis	Efficacy and Safety of Qingre Huoxue Comprehensive Therapy in the Treatment of Rheumatoid Arthritis (RA): A Randomized, Double-blind, Double-dummy, Multi-center Trial	Rheumatoid Arthritis	Drug: Treatment of MTX and HCQ;Drug: Treatment of TCM;Drug: Integrative Medicine	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	18 Years	65 Years	Both	468	Phase 2/Phase 3	China
510	EUCTR2014-000352-29-CZ	27/10/2014	8 January 2018	A Study of PF-06410293 (Adalimumab-Pfizer) and Adalimumab (Humira) in Combination with Methotrexate in Subjects with Active Rheumatoid Arthritis (REFLECTIONS B538-02).	A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE	RHEUMATOID ARTHRITIS MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Adalimumab-Pfizer Product Code: PF-06410293 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB Current Sponsor code: PF-06410293 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: HUMIRA Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB-EU CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Product Name: Adalimumab-Pfizer Product Code: PR-06410293 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: ADALIMUMAB Current Sponsor code: PF-06410293 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	560	Phase 3	Serbia;Taiwan;Estonia;Spain;Ukraine;Russian Federation;Colombia;France;Australia;Peru;South Africa;Korea, Republic of;Lithuania;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Croatia;Bulgaria;Georgia;Germany;Japan;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
511	EUCTR2014-001299-79-DK	06/10/2014	2 October 2017	Pnemococcal vaccination of rheumatoid arthritis patients in biological treatment	Pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy - Immunovax_RA	Immunoresponse on pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy MedDRA version: 18.0 Level: LLT Classification code 10069594 Term: Pneumococcal immunization System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Trade Name: Prevenar 13 Pharmaceutical Form: Suspension for injection INN or Proposed INN: pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30.8- Trade Name: Pneumovax Pharmaceutical Form: Suspension for injection INN or Proposed INN: pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT) Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 575-	Department of Infectious Diseases, Odense University Hospital		Not Recruiting			Female: yes Male: yes		Phase 3	Denmark
512	JPRN-UMIN000015217	2014/10/01	2 April 2019	Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis	Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis - Orencia Atherosclerosis And Rheumatoid Arthritis Study (ORACLE Arthritis Study)	RA patients aged 20 years or older and have never been treated with biological products or molecular targeted drug therapy.	Abatacept	Yokohama City University Graduate School of Medicine		Recruiting	20years-old	Not applicable	Male and Female	40	Not applicable	Japan
513	JPRN-UMIN000015462	2014/10/01	2 April 2019	Clinical study on drug holiday with regulated rheumatoid arthritis activity after treatment with tofacitinib (Xanadu study)		Rheumatoid arthritis	Continue current treatment Tofacitinib discontinuation MTX discontinuation	School of Medicine, University of Occupational and Environmental Health, Japan		Recruiting	18years-old	Not applicable	Male and Female	400	Not selected	Japan
514	NCT02102594	October 2014	10 December 2018	Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Myasthenia Gravis;Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: Bortezomib	Charite University, Berlin, Germany	Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology);NeuroCure Clinical Research Center, Charite, Berlin	Recruiting	18 Years	75 Years	All	18	Phase 2	Germany
515	NCT02148640	October 2014	16 December 2017	The NOR-SWITCH Study	A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY	Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis;Ulcerative Colitis;Crohn's Disease;Psoriasis Chronic	Drug: Innovator infliximab;Drug: Biosimilar infliximab	Diakonhjemmet Hospital	South-Eastern Norway Regional Health Authority	Not recruiting	18 Years	N/A	All	482	Phase 4	Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
516	NCT02150473	October 2014	16 December 2017	The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients	Delayed Gadolinium-enhanced Magnetic Resonance (MR) Imaging of Cartilage - A Pilot Study to Measure the Effect of Adalimumab Plus MTX Versus Placebo Plus MTX on Cartilage in Early RA Patients	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Placebo	Heinrich-Heine University, Duesseldorf	Abbott	Not recruiting	18 Years	80 Years	All	21	Phase 3	Germany
517	NCT02221258	October 2014	17 October 2016	Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)	Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: FURESTEM-RA Inj.	Kang Stem Biotech Co., Ltd.		Not recruiting	19 Years	80 Years	Both	9	Phase 1	Korea, Republic of
518	NCT02265705	October 2014	25 March 2019	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Baricitinib;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	290	Phase 3	Argentina;Brazil;China
519	NCT02270632	October 2014	5 December 2016	A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.	Rheumatoid Arthritis	Drug: F8IL10;Drug: MTX;Drug: Placebo	Philogen S.p.A.		Recruiting	18 Years	74 Years	Both	87	Phase 2	Germany;Italy;Switzerland
520	NCT02500498	October 2014	3 August 2015	Safety Profile of Nulojix in Home Infusion Settings	Safety Profile of Nulojix in Home Infusion Settings	Rheumatoid Arthritis	Drug: Nulojix	Bristol-Myers Squibb	BiologicTx, LLC	Not recruiting	18 Years	N/A	Both	37	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
521	EUCTR2012-002945-40-DE	22/09/2014	14 November 2016	BI695501 compared to adalimumab in patients with active rheumatoid arthritis	Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial	Rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: BI 695501 Pharmaceutical Form: Solution for injection INN or Proposed INN: - CAS Number: - Current Sponsor code: BI 695501 Other descriptive name: BI 695501 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Boehringer Ingelheim International GmbH		Not Recruiting			Female: yes Male: yes	650	Phase 3	United States;Serbia;Estonia;Thailand;Spain;Ukraine;Chile;Russian Federation;Hungary;Malaysia;Poland;Bulgaria;South Africa;Germany;New Zealand;Korea, Republic of
522	EUCTR2013-005418-37-IT	15/09/2014	23 March 2015	A multicenter, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	A multicenter, randomized, double-blind, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 (Dekavil) administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	Patients with active Rheumatoid Arthritis despite methotrexate therapy that had unsuccessful response to at least one anti-TNF treatment.;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Dekavil Product Code: F8IL10 Pharmaceutical Form: Solution for injection INN or Proposed INN: dekavil Current Sponsor code: F8IL10 Other descriptive name: F8IL10 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 3.75-20 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Philogen S.p.A.		Authorised			Female: yes Male: yes	87	Phase 2	Germany;Italy
523	EUCTR2013-002805-76-CZ	11/09/2014	2 October 2017	A 24-week placebo-controlled clinical study to evaluate the adequate dose, efficacy and safety of 3 doses of namilumab combined with methotrexate in subjects with moderate to severe rheumatoid arthritis.	A 24-week randomized, double-blind, placebo-controlled, phase 2 dose finding study to evaluate the efficacy and safety of 3 doses of namilumab (20 mg, 80 mg and 150 mg) in combination with methotrexate (MTX) in subjects with moderate to severe rheumatoid arthritis (RA) NEXUS.	Rheumatoid Arthritis (RA) MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Takeda Development Centre Europe Ltd.		Not Recruiting			Female: yes Male: yes	108	Phase 2	Czech Republic;Poland;Spain;Russian Federation;Bulgaria;Japan;United Kingdom
524	JPRN-UMIN000014624	2014/09/01	2 April 2019	Effects of postoperative administration of celecoxib on postoperative pain management in patients after total knee arthroplasty. A randomized controlled study.		Osteoarthritis, Rheumatoid arthritis	Administration of celecoxib from 2 hours after TKA surgery Administration of celecoxib from 2 days after TKA surgery	Mito medical center, Mito Kyodo General Hospital, University of Tsukuba		Not Recruiting	20years-old	Not applicable	Male and Female	120	Phase 4	Japan
525	NCT01717859	September 2014	20 May 2019	Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab	Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab	Rheumatoid Arthritis	Drug: Tocilizumab	University of California, Los Angeles	Genentech, Inc.	Not recruiting	18 Years	N/A	All	74	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
526	NCT02154425	September 2014	11 June 2018	A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)	Axial Spondyloarthritis (AxSpA);Non-radiographic Evidence-AxSpA;Ankylosing Spondylitis;Crohn's Disease;Psoriatic Arthritis;Rheumatoid Arthritis	Procedure: Breast milk sampling;Biological: Certolizumab Pegol	UCB BIOSCIENCES, Inc.	PPD;Parexel	Not recruiting	18 Years	N/A	Female	17	Phase 1	United States;Netherlands;Switzerland;France
527	NCT02246257	September 2014	10 December 2018	Early Rheumatoid Arthritis COR Intervention	Multifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis;Cardiovascular Diseases	Other: Simvastatin;Other: Losartan;Other: Metformin;Other: Outpatient rheumatology department;Other: Refered to general practice	MD, PhD, Annemarie Lyng Svensson		Recruiting	18 Years	N/A	All	300	N/A	Denmark
528	EUCTR2013-005543-90-HU	26/08/2014	4 December 2018	This trial is designed to determine the effects the investigational medicine, ABP 798 has on the human body, and what effects the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with moderate or severe rheumatoid arthritis (RA). This study will assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.	A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis - Not applicable	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ABP 798 Product Code: ABP 798 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: rituximab CAS Number: 1446410-99-6 Current Sponsor code: ABP 798 Other descriptive name: ABP 798 - Biosimilar to rituximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rituxan Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Other descriptive name: Rituxan Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Other descriptive name: MabThera Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Amgen Inc		Not Recruiting			Female: yes Male: yes	300	Phase 1;Phase 3	United States;Estonia;Hungary;Canada;Poland;Bulgaria;Germany
529	NCT02222493	August 26, 2014	11 June 2018	A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).	A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate	Rheumatoid Arthritis	Biological: PF-06438179;Biological: Infliximab	Pfizer		Not recruiting	18 Years	N/A	All	650	Phase 3	United States;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czechia;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Jordan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;Colombia;Czech Republic;France
530	NCT02202837	August 12, 2014	16 December 2017	Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice	Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Rheumatoid Arthritis Patients Treated With Etanercept (Enbrel (Registered))	Rheumatoid Arthritis	Drug: etanercept	Pfizer		Not recruiting	18 Years	N/A	All	135	N/A	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
531	NCT02308163	August 8, 2014	15 July 2019	A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs	Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs	Rheumatoid Arthritis	Drug: peficitinib;Drug: Placebo;Biological: Etanercept	Astellas Pharma Inc		Not recruiting	20 Years	N/A	All	509	Phase 3	Japan;Korea, Republic of;Taiwan
532	ChiCTR-RNC-14004887	2014-08-01	18 April 2017	The pharmacogenomics study on Methotrexate in treating rheumatoid arthritis	The pharmacogenomics study on Methotrexate in treating rheumatoid arthritis	rheumatoid arthritis	Case series:Methotrexate;	The people's hospital, Yichun City		Recruiting	18	65		Case series:400;	Post-market	China
533	JPRN-UMIN000014737	2014/08/01	2 April 2019	The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity.		rheumatoid arthritis	Denosumab group: Denosumab 60mg is administered by subcutaneous injections every 6 months (at baseline, at 6 months and at 12 months). All patients are to take vitamin D. BP group: Patients take BP continuously. All patients are to take vitamin D.	Yokohama City University Medical Center		Not Recruiting	50years-old	90years-old	Male and Female	286	Not selected	Japan
534	NCT02176876	August 2014	3 August 2015	Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis	A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: GS-5745;Drug: Placebo to match GS-5745	Gilead Sciences		Not recruiting	18 Years	70 Years	Both	18	Phase 1	Czech Republic;Hungary
535	NCT02187055	August 2014	16 December 2017	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis	Rhematoid Arthritis	Drug: Tofacitinib with methotrexate;Drug: Tofacitinib without methotrexate;Biological: Adalimumab with methotrexate	Pfizer		Not recruiting	18 Years	N/A	All	1132	Phase 4	United States;Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;Croatia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
536	NCT02211469	August 2014	28 September 2015	A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects	A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects	Rheumatoid Arthritis	Drug: BMS-986104;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	49 Years	Male	41	Phase 1	United States
537	NCT02219191	August 2014	16 December 2017	Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases	The Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases	Rheumatoid Arthritis	Drug: puerarin tablet 50 mg;Drug: Atorvastatin tablet 20 mg	Chengdu PLA General Hospital		Not recruiting	18 Years	75 Years	All	150	N/A	China
538	NCT02219347	August 2014	16 December 2017	Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)	Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)	Rheumatoid Arthritis	Drug: DMARD cessation	Newcastle-upon-Tyne Hospitals NHS Trust	Newcastle University;Wellcome Trust	Not recruiting	18 Years	N/A	All	74	N/A	United Kingdom
539	NCT02234960	August 2014	14 November 2016	Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)	TOCILIZUMAB IN FIRST LINE BIOLOGIC TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE IN POLAND - MULTICENTER, NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY (ACT-POL)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	102	N/A	Poland
540	NCT02264301	August 2014	16 December 2017	Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis	The Effect of Qingkailing Injection on Corticosteroids Withdrawal Rate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Puerarin injection 400 mg;Drug: Qingkailing injection 40 ml	Chengdu PLA General Hospital		Recruiting	18 Years	75 Years	All	150	N/A	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
541	NCT02311855	August 2014	16 December 2017	Duration of Immune Response to Influenza Vaccination in Patients With RA	Duration of Immune Response to Influenza Vaccination in Patients With Rheumatoid Arthritis Receiving Treatment With Biologic Agents	Rheumatoid Arthritis	Biological: Influenza vaccine	Bassett Healthcare	New York State Department of Health	Not recruiting	40 Years	75 Years	All	87	Phase 4	United States
542	NCT02305849	July 25, 2014	15 July 2019	A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment	Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Rheumatoid Arthritis	Drug: Peficitinib;Drug: Placebo;Drug: Methotrexate	Astellas Pharma Inc		Not recruiting	20 Years	N/A	All	519	Phase 3	Japan
543	EUCTR2013-005362-19-DE	17/07/2014	17 July 2017	Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB)	Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB) - TAVAB	Myasthenia Gravis Systemic Lupus Erythematosus Rheumatoid Arthritis ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Velcade® Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: BORTEZOMIB CAS Number: 179324-69-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3,5-	Charité - Universitätsmedizin Berlin		Authorised			Female: yes Male: yes		Phase 2	Germany
544	EUCTR2013-004148-49-LT	14/07/2014	3 July 2017	RANDOMIZED STUDY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS	A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Infliximab-Pfizer Product Code: PF-06438179 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: PF-06438179 Other descriptive name: Infliximab-Pfizer Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Other descriptive name: Infliximab-EU Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	614	Phase 3	Poland;Brazil;Bulgaria;Georgia;Germany;Japan;United States;Serbia;Philippines;Morocco;Ukraine;Israel;Russian Federation;Colombia;France;Australia;Peru;South Africa;Tunisia;Bosnia and Herzegovina;Korea, Republic of;Guatemala;Lithuania;United Kingdom;Hungary;Czech Republic;European Union;Mexico;Canada;Argentina
545	JPRN-UMIN000016928	2014/07/03	2 April 2019	Targeted Ultrasound in Rheumatoid Arthritis		Rheumatoid arthritis	If DAS28 increased by >0.6 from baseline, treatment with biweekly Adalimumab 40mg s.c. is commenced and continued until 96 week. If DAS28 increased by >0.6 from baseline or total PD score is 4 or greater, treatment with biweekly Adalimumab 40mg s.c. is commenced and continued until 96 week.	Leeds University		Recruiting	18years-old	Not applicable	Male and Female	400	Not selected	Japan,Europe
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
546	JPRN-UMIN000015175	2014/07/01	2 April 2019	Head-to-head comparison of Subcutaneous Tocilizumab versus Abatacept for Rheumatoid arthritis : prospective, randomized trial.		Rheumatoid Arthritis	Subcutaneous Tocilizumab 162mg every other week. Subcutaneous Abatacept 125mg every week.	St.Marianna University School of Medicine		Recruiting	20years-old	Not applicable	Male and Female	120	Not selected	Japan
547	NCT02011334	July 2014	14 November 2016	A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.	A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	285	Phase 3	Argentina;Brazil;Colombia;Dominican Republic;Mexico;Venezuela;Ecuador;Uruguay
548	NCT02053727	July 2014	25 June 2018	Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background	Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.	Rheumatoid Arthritis;Chronic Hepatitis B	Drug: Abatacept;Drug: Placebo	Suzanne Kafaja		Recruiting	18 Years	N/A	All	20	N/A	United States
549	NCT02141997	July 2014	19 October 2017	A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Biological: adalimumab;Biological: ABT-122	AbbVie		Not recruiting	18 Years	99 Years	All	222	Phase 2	Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States
550	JPRN-UMIN000014311	2014/06/24	2 April 2019	Examination of the clinical remission and functional remission in Infliximab using the increase-in-quantity protocol to TNF-alpha inhibitory drug resistance rheumatoid arthritis		rheumatoid arthritis	The quantity of Infliximab is increased.	Institute of Health Biosciences, The University of Tokushima Graduate School		Not Recruiting	20years-old	75years-old	Male and Female	10	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
551	ChiCTR-TRC-14004824	2014-06-23	18 April 2017	Clinical studies on Ginsenoside C-K	Study on tolerability and pharmacokinetics of Ginsenoside C-K tablet in healthy volunteers after a single dose	rheumatoid arthritis	7 groups:Seven different doses with ginsenoside compound K;	Institute of Clinical Pharmacology, Central South University		Not Recruiting	18	45	Both	7 groups:77;	Phase 1 study	China
552	ChiCTR-BOC-16008925	2014-06-10	18 April 2017	Circulating Tfh subpopulation in very early rheumatoid arthritis	Circulating Bcl-6+ICOS+ Tfh subpopulation correlates with disease activity in very early rheumatoid arthritis	Rheumatoid Arthritis	RA patients:methotrexate;Healthy control (HC) individuals:Nil;	The First Hospital, Jilin University, Changchun		Not Recruiting			Both	RA patients:22;Healthy control (HC) individuals:15;	Other	China
553	JPRN-JapicCTI-142621	09/6/2014	2 April 2019	CHS-0214 Phase III trial	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate	Rheumatoid Arthritis	Intervention name : CHS-0214 Dosage And administration of the intervention : subcutaneous injection Control intervention name : Enbrel INN of the control intervention : Etanercept Dosage And administration of the control intervention : subcutaneous injection	DAIICHISANKYO Co.,Ltd.	Coherus Biosciences, Inc.		20		BOTH	620	Phase 3
554	NCT02196558	June 9, 2014	16 December 2017	A Phase 1/2 Study of E6011 in Japanese Subjects With Rheumatoid Arthritis	A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: E6011	Eisai Co., Ltd.		Not recruiting	20 Years	64 Years	All	37	Phase 1/Phase 2	Japan
555	EUCTR2013-002790-22-HU	02/06/2014	10 July 2015	To evaluate the immunogenicity and safety of sarilumab administered as monotherapy in patients with rheumatoid arthritis (RA)	An open-label, randomized, parallel group study assessing the immunogenicity and safety of sarilumab administered as monotherapy in patients with active rheumatoid arthritis - SARIL-RA-ONE	Rheumatoid Arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 131.6- Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 175-	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	120		United States;Estonia;Czech Republic;Hungary;Argentina;Poland;Russian Federation;Chile
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
556	ChiCTR1900026116	2014-06-01	30 September 2019	The efficacy and safety of low-dose glucocorticoids combined withmethotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a randomized, double-blinded, controlled trial	The efficacy and safety of low-dose glucocorticoids combined withmethotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a randomized, double-blinded, controlled trial	rheumatoid arthritis	Experimental group:Prednisone+methotrexate+Hydrochloroquine;control group:placebo+methotrexate+Hydrochloroquine;	Central Hospital of Jinhua		Not Recruiting	21	73	Both	Experimental group:40;control group:40;	Phase 4	China
557	JPRN-UMIN000013546	2014/06/01	2 April 2019	The effect ofgrepefruit juice on the patients with autoimmune diseases taking tacrolimus		rheumatoid arthritis, lupus nephritis, polymyositis/dermatomyositis with interstitial pneumonia, ulcerative colitis	take a glass of grapefruit juice every day do not take grapefruit juice	Department of Rheumatology and Clinical Immunology, Kyoto University Hospital		Not Recruiting	16years-old	80years-old	Male and Female	20	Not applicable	Japan
558	NCT01984268	June 2014	5 September 2016	ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Adenocorticotrophic Hormone for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: ACTHAR	Dartmouth-Hitchcock Medical Center	Mallinckrodt	Recruiting	18 Years	70 Years	Both	60	Phase 2	United States
559	NCT02147587	June 2014	11 June 2018	A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate	A Randomized, Double-blind, Placebo-controlled, Phase 2 Study To Assess The Immune Response Following Administration Of Zoster Vaccine To Subjects With Rheumatoid Arthritis Receiving Tofacitinib (Cp-690,550) Or Placebo With Background Methotrexate Treatment	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: Placebo	Pfizer		Not recruiting	50 Years	N/A	All	112	Phase 2	United States;United Kingdom
560	NCT02151851	June 2014	20 June 2016	A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis	A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel Group, Randomized 24-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol (CZP) as Additional Medication to Methotrexate in Chinese Subjects With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate	Rheumatoid Arthritis	Biological: Certolizumab Pegol;Drug: Methotrexate;Other: Placebo	UCB Pharma SA, Belgium	Parexel	Not recruiting	18 Years	N/A	Both	431	Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
561	NCT02202395	June 2014	16 December 2017	Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: LTS 0.25mg;Drug: LTS 0.5mg;Drug: LTS 1.0mg;Drug: Placebo	Shanghai Pharmaceuticals Holding Co., Ltd		Not recruiting	35 Years	65 Years	Female	120	Phase 1/Phase 2	China
562	NCT02277574	June 2014	28 November 2016	Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis	A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: AMP-110;Other: Placebo	MedImmune LLC	Daiichi Sankyo Co., Ltd.	Not recruiting	18 Years	75 Years	Both	29	Phase 1	United States
563	EUCTR2013-003984-72-LV	30/05/2014	28 February 2019	A Study Investigating the Efficacy and Safety of ABT-494 given with Methotrexate in Subjects with Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone.	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone.	Rheumatoid Arthritis (RA) MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT 494 3mg Pharmaceutical Form: Capsule INN or Proposed INN: ABT 494 Current Sponsor code: ABT 494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: ABT 494 12mg Pharmaceutical Form: Capsule INN or Proposed INN: ABT 494 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	270	Phase 2	United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Chile;Israel;Russian Federation;Czech Republic;Hungary;European Union;Mexico;Puerto Rico;South Africa;Latvia
564	EUCTR2013-003413-18-GB	13/05/2014	3 July 2017	Arthritis prevention with abatacept	Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. - APIPPRA	The target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPA; rheumatoid factor – RF) and who have joint pains (arthralgia) but no joint swelling. These subjects are deemed to be at highest risk of developing rheumatoid arthritis. MedDRA version: 20.0 Level: PT Classification code 10003239 Term: Arthralgia System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: ORENCIA 125 mg solution for injection Pharmaceutical Form: Solution for infusion in pre-filled syringe Pharmaceutical form of the placebo: Solution for infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use	King’s College London	Guy's and St. Thomas' NHS Foundation Trust	Authorised			Female: yes Male: yes	206	Phase 2	Netherlands;United Kingdom
565	NCT03604406	May 8, 2014	9 September 2019	The Immunogenicity and Safety of Zostavax® in Rheumatoid Arthritis Patients Using Abatacept	The Immunogenicity and Safety of Zostavax® in Rheumatoid Arthritis Patients Using Abatacept	Herpes Zoster;Inflammatory Disease;Rheumatoid Arthritis	Biological: Varicella Zoster Vaccine;Other: Placebo Injection	Kevin Winthrop	University of Alabama at Birmingham;Bristol-Myers Squibb	Recruiting	50 Years	N/A	All	50	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
566	ChiCTR-TRC-14004520	2014-05-01	18 April 2017	To study the signal pathways of Rheumatoid Arthritis Syndrome of Accumulated Dampness and intervention mechanism of Sanhuang Yilong Decoction based the theory that lung, spleen and kidney regulate water	To study the signal pathways of Rheumatoid Arthritis Syndrome of Accumulated Dampness and intervention mechanism of Sanhuang Yilong Decoction based the theory that lung, spleen and kidney regulate water metabolism	rheumatoid arthritis	two:Methotrexate, hydroxychloroquine sulfate pills and NSAIDs in both groups; Sanhuang Yinong decoction will be give in the experimental group;RA patients:NA;	General Hospital of Chengdu Military Region		Recruiting	45	65	Both	two:240;RA patients:40;	Phase 1 study	China
567	NCT01967316	May 2014	18 April 2016	Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users	A Pilot Study of the Safety and Effectiveness of the Live Zoster Vaccine in Anti-TNF Users	Rheumatoid Arthritis	Biological: Herpes Zoster Vaccine;Drug: Placebo	University of Alabama at Birmingham	Oregon Health and Science University	Recruiting	50 Years	N/A	Both	125	Phase 2	United States
568	NCT02105129	May 2014	9 May 2016	A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523	Rheumatoid Arthritis (RA)	Drug: HMPL-523;Drug: Placebo	Hutchison Medipharma Limited		Not recruiting	18 Years	45 Years	Male	118	Phase 1	Australia
569	NCT02115750	May 2014	17 October 2016	Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate	Rheumatoid Arthritis	Drug: Etanercept;Drug: CHS-0214	Coherus Biosciences, Inc.	Daiichi Sankyo Co., Ltd.;Daiichi Sankyo Co., Ltd.	Not recruiting	18 Years	N/A	Both	647	Phase 3	United States;Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom
570	NCT02123264	May 2014	4 March 2019	Zoledronic Acid in Rheumatoid Arthritis	Randomized Clinical Trial on the Prevention of Radiographic Progression With Zoledronic Acid in Patients With Early Rheumatoid Arthritis and Low Disease Activity	Arthritis, Rheumatoid	Drug: Zoledronic acid	Carmen Gómez-Vaquero		Not recruiting	18 Years	N/A	All	28	Phase 3	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
571	NCT02151474	May 2014	19 February 2015	INCB047986 in Rheumatoid Arthritis	A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: INCB047986;Drug: Placebo	Incyte Corporation		Recruiting	18 Years	N/A	Both	60	Phase 2	United States
572	NCT02157012	May 2014	10 December 2018	Evaluation of the Condition of Rheumatoid Arthritis After Treatment	Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: The effectiveness of Xeljanz in rheumatoid arthritis patients	Shinshu University	Showa Inan General Hospital	Recruiting	20 Years	90 Years	All	100	Phase 4	Japan
573	NCT02167139	May 2014	16 December 2017	A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Humira (adalimumab);Drug: SB5 (proposed biosimilar to adalimumab)	Samsung Bioepis Co., Ltd.		Not recruiting	18 Years	75 Years	All	544	Phase 3	Lithuania;Poland
574	NCT02927509	May 2014	17 October 2016	Evaluation of Tumour Necrosis Factor Alpha (TNFa) Blockers in Early Rheumatoid Arthritis in France		Rheumatoid Arthritis	Drug: TNF alpha blockers	Centre Hospitalier Universitaire de Nimes	Pfizer;Pfizer	Not recruiting	18 Years	70 Years	Both	813	N/A
575	EUCTR2013-003177-99-SE	11/04/2014	17 October 2016	A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.	PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: XELJANZ Product Name: Tofacitinib citrate (commercial image) Product Code: CP-690,550-10 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Tofacitinib CAS Number: 540737-29-9 Current Sponsor code: CP-690,550-10 Other descriptive name: TOFACITINIB CITRATE CP-690550 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP-690,550-10 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Tofacitinib CAS Number: 540737-29-9 Current Sponsor code: CP-690,550-10 Other descriptive name: TOFACITINIB CITRATE CP-690550 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Enbrel Product Name: Etanercept Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Pfizer Inc. 235 East 42nd Street, New York, 10017		Authorised			Female: yes Male: yes	4000	Phase 3;Phase 4	Portugal;United States;Taiwan;Slovakia;Spain;Ukraine;Russian Federation;Chile;Israel;Colombia;Italy;France;Malaysia;Peru;Australia;Denmark;South Africa;Netherlands;Korea, Republic of;Slovenia;Finland;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Belgium;Brazil;Romania;Bulgaria;Germany;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
576	EUCTR2013-003493-27-HU	08/04/2014	14 April 2014	Study with the aim to evaluate the safety, tolerability and efficacy of QAL964 in patients with Rheumatoid Arthritis who are treated with anti-rheumatic drug methotrexate but where the treatment does not sufficiently work.	A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable doses of methotrexate and with inadequate response to methotrexate - CQAL964B2201	Rheumatoid Arthritis MedDRA version: 16.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Code: QAL964 Pharmaceutical Form: Capsule Current Sponsor code: QAL964 Other descriptive name: QAL964 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 10-25 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	42		Hungary;Ukraine;Russian Federation
577	EUCTR2013-005013-13-LT	08/04/2014	16 November 2015	A Study Comparing SB5 to Humira® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy	Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB5 is rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), adult Crohn's disease (CD), paediatric CD, ankylosing spondylitis (AS), psoriasis (Ps), psoriatic arthritis (PsA), ulcerative colitis (UC), and psoriasis. MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: SB5 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: SB5 Other descriptive name: SB5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira® Product Name: Humira® Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: not applicable Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Samsung Bioepis Co., Ltd.		Not Recruiting			Female: yes Male: yes	490		Czech Republic;Mexico;Poland;Ukraine;Lithuania;Russian Federation;Bulgaria;United Kingdom;Korea, Republic of;Bosnia and Herzegovina
578	EUCTR2013-004555-21-AT	07/04/2014	29 May 2017	This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis	A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 19.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: CT- P10 Product Code: CT- P10 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Trade Name: MabThera Product Name: MabThera Product Code: L01XC02 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Trade Name: Rituxan Product Name: Rituxan Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	CELLTRION, Inc.		Not Recruiting			Female: yes Male: yes	361	Phase 3	Portugal;Slovakia;Greece;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Colombia;Hungary;Mexico;Poland;Romania;Peru;Bulgaria;Latvia;Germany;Bosnia and Herzegovina;Korea, Republic of
579	NCT02019472	April 4, 2014	16 December 2017	A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: adalimumab 40 mg;Biological: sirukumab 100 mg;Biological: sirukumab 50 mg;Drug: Placebo	Janssen Research & Development, LLC	GlaxoSmithKline	Not recruiting	18 Years	N/A	All	559	Phase 3	United States;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;Argentina;Peru
580	JPRN-UMIN000013440	2014/04/01	2 April 2019	To evaluate the efficacy and safety of subcutaneous and intravenous abatacept.		Rheumatoid arthritis	SC abatacept IV abatacept Extension of SC abatacept	Osaka Medical College		Not Recruiting	20years-old	80years-old	Male and Female	50	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
581	NCT02109289	April 2014	16 December 2017	Etanercept in Rheumatoid Arthritis and Vascular Inflammation	Pilot Open-label Study of the Effect of Etanercept on Vascular Inflammation in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis;Vascular Inflammation	Drug: etanercept	Innovaderm Research Inc.		Not recruiting	18 Years	80 Years	All	5	Phase 4	Canada
582	NCT02101073	March 31, 2014	14 January 2019	ALX-0061 Phase I Bioavailability Study in Healthy Volunteers	A Phase I, Open-Label Study Evaluating the Bioavailability of ALX-0061 After Subcutaneous and Intravenous Administration in Healthy Volunteers.	Rheumatoid Arthritis	Biological: ALX-0061	Ablynx		Not recruiting	18 Years	55 Years	All	70	Phase 1	Netherlands
583	EUCTR2010-020992-21-DE	25/03/2014	28 September 2015	Comparison of efficacy of masitinib versus methotrexate in the treatment of rheumatoid arthritis	A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, Phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1. methotrexate or to 2. any DMARD including at least one biologic drug if patients previously failed methotrexate or to 3. methotrexate in combination with any DMARD including biologic drugs - AB1010 in treatement of patients with active rheumatoide arthritis.	Rheumatoid Arthritis MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: not applicable Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Methotrexate Product Name: Methotrexate Product Code: not applicable Pharmaceutical Form: Capsule, hard INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Current Sponsor code: not applicable Other descriptive name: not applicable Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2,5 mg- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: not applicable Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AB Science		Not Recruiting			Female: yes Male: yes	140	Phase 2b/3	Serbia;United States;Philippines;Taiwan;Morocco;Slovakia;Greece;Spain;Thailand;Ukraine;Russian Federation;Monaco;India;Czech Republic;Mexico;Argentina;Poland;Romania;South Africa;Germany;Tunisia;Bosnia and Herzegovina
584	EUCTR2013-005001-31-ES	25/03/2014	19 September 2016	Study on the ability of zoledronic acid to prevent worsening of radiographs of hands and feet of patients with rheumatoid arthritis diagnosed less than 2 years ago and who have few symptoms in their joints by making treatment with the drugs commonly used for the management of disease.	Randomized clinical trial on the prevention of radiographic progression with zoledronic acid in patients with early rheumatoid arthritis and low disease activity - Prevention of radiographic progression in rheumatoid arthritis with zoledronic acid	Rheumatoid arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Zoledronic acid Product Name: Zoledronic acid Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ZOLEDRONIC ACID CAS Number: 118072-93-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.8-	Dra. Carmen Gómez Vaquero (Servicio de Reumatología del Hospital Universiari de Bellvitge - Idibell)		Not Recruiting			Female: yes Male: yes		Phase 3	Spain
585	EUCTR2013-003780-65-IT	24/03/2014	18 January 2016	Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis	A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have Experienced an Inadequate Response to TNF inhibitors	Rheumatoid Arthritis MedDRA version: 14.1 Level: LLT Classification code 10066578 Term: Progression of rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 14.1 Level: LLT Classification code 10060732 Term: Rheumatoid arthritis flare up System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: CLAZAKIZUMAB Product Code: BMS-945429 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: CLAZAKIZUMAB CAS Number: 1236278-28-6 Current Sponsor code: BMS945429 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Bristol-Myers Squibb International Corporation		Not Recruiting			Female: yes Male: yes	240	Phase 2B	France;United States;Hungary;Czech Republic;Mexico;Canada;Argentina;Australia;South Africa;Japan;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
586	JPRN-UMIN000013362	2014/03/15	2 April 2019	Examination of the remission maintenance effect by low dose etanercept after clinical remission in the rheumatoid arthritis.		Rheumatoid Arthritis	Methotrexate Etanercept	Takarazuka city hospital		Not Recruiting	20years-old	Not applicable	Male and Female	60	Not selected	Japan
587	NCT02092467	March 14, 2014	14 October 2019	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS	Arthritis, Rheumatoid	Drug: tofacitinib;Biological: adalimumab;Biological: etanercept	Pfizer		Not recruiting	50 Years	N/A	All	4414	Phase 4	United States;Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;Austria;Czech Republic;Sweden
588	EUCTR2013-004555-21-LV	03/03/2014	22 May 2017	This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis	A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 16.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: CT- P10 Product Code: CT- P10 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Trade Name: MabThera Product Name: MabThera Product Code: L01XC02 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Trade Name: Rituxan Product Name: Rituxan Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	CELLTRION, Inc.		Not Recruiting			Female: yes Male: yes	361	Phase 3	Portugal;Slovakia;Greece;Spain;Ukraine;Austria;Chile;Israel;Russian Federation;Colombia;Hungary;Mexico;Brazil;Poland;Romania;Peru;Bulgaria;Germany;Latvia;Korea, Republic of;Bosnia and Herzegovina
589	NCT02029599	March 2014	19 October 2015	The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis	A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Fang yi qing feng shi granule;Drug: placebo;Drug: Methotrexate;Drug: Acetaminophen tablets	Maoxiang Group Jilin Pharmaceutical Co., Ltd.		Not recruiting	18 Years	65 Years	Both	240	Phase 2	China
590	NCT02057250	March 2014	16 December 2017	To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy	RA	Drug: Sarilumab;Device: Auto-Injector Device (AID);Device: Pre-filled Syringe (PFS);Drug: Methotrexate;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Hydroxychloroquine	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	217	Phase 3	United States;Chile;Mexico;Poland;Russian Federation;South Africa;France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
591	NCT02066389	March 2014	27 June 2016	A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate (MTX) in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone	Rheumatoid Arthritis	Drug: ABT-494;Drug: Placebo	AbbVie		Not recruiting	18 Years	100 Years	Both	300	Phase 2	United States;Bulgaria;Chile;Czech Republic;Hungary;Israel;Latvia;Mexico;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;Romania;Serbia
592	NCT02097524	March 2014	25 May 2015	Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)		Rheumatoid Arthritis	Drug: Sarilumab;Drug: Tocilizumab	Regeneron Pharmaceuticals	Sanofi	Not recruiting	18 Years	N/A	Both	105	Phase 1	United States
593	EUCTR2013-004051-20-ES	26/02/2014	6 November 2018	NOT CONTROLLED STUDY TO ASSESS THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS WHO ARE CANDIDATES TO BE TREATED WITH A BIOLOGICAL THERAPY AS MONOTHERAPY	NOT CONTROLLED STUDY TO ASSESS THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS WHO ARE CANDIDATES TO BE TREATED WITH A BIOLOGICAL THERAPY AS MONOTHERAPY	RHEUMATOID ARTHRITIS;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra 20 mg/ml concentrado para solución para perfusión Pharmaceutical Form: Solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: ROACTEMRA Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 800-	FUNDACIÓN ESPAÑOLA DE REUMATOLOGIA		Not Recruiting			Female: yes Male: yes	122	Phase 4	Spain
594	NCT02065700	February 25, 2014	22 July 2019	Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients	A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Filgotinib	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	739	Phase 2	United States;Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;Czech Republic
595	EUCTR2013-004654-13-CZ	12/02/2014	28 November 2016	The trial is designed to determine the long-term safety and efficacy of ABP 501 in subjects with moderate to severe rheumatoid arthritis	An Open-Label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis	Moderate to Severe Rheumatoid Arthritis MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ABP 501 Product Code: ABP 501 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: N/A CAS Number: 1446410-95-2 Current Sponsor code: ABP 501 Other descriptive name: ABP 501 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Amgen Inc.		Not Recruiting			Female: yes Male: yes	425	Phase 3	United States;Spain;Russian Federation;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Romania;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
596	EUCTR2013-002007-34-FI	10/02/2014	10 October 2016	Safety and efficacy study of tocilizumab injected under the skin in patients with active rheumatoid arthritis (RA) and inadequate response to disease modifying antirheumatic drugs.	Tocilizumab SC in patients with active rheumatoid arthritis and inadequate response to DMARDs. A single-arm, open-label study to evaluate safety, tolerability and efficacy. In a sub-group of patients inflammation will be measured by ultasound. - TOZULTRA	Rheumatoid Arthritis MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Tocilizumab SC Product Code: Ro 487-7533/F10-04 Pharmaceutical Form: Solution for injection INN or Proposed INN: Tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: Recombinant humanized anti-human monoclonal antibody directed against the IL-6R Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180-	Roche a/s		Not Recruiting			Female: yes Male: yes	137	Phase 3	Finland;Denmark;Sweden
597	JPRN-UMIN000016844	2014/02/07	2 April 2019	The clinical study for seeking strategy how to treat rheumatoid arthritis by TNF Inhibitors		Rheumatoid arthritis	infliximab: standard strategy infliximab: aggressive strategy golimumab: standard strategy golimumab: aggressive strategy	Takarazuka city hospital		Recruiting	20years-old	90years-old	Male and Female	80	Not applicable	Japan
598	JPRN-JapicCTI-142505	01/2/2014	2 April 2019	Phase III study of MRA-SC 162 mg/week	A Randomized, Double-blind, Parallel-group, Phase III Study of MRA-SC in Rheumatoid Arthritis Patients with Inadequate Response to Tocilizumab Subcutaneous Injection 162 mg every 2 weeks	Rheumatoid arthritis	Intervention name : MRA-SC INN of the intervention : tocilizumab Dosage And administration of the intervention : 162 mg QW Control intervention name : MRA-SC INN of the control intervention : tocilizumab Dosage And administration of the control intervention : 162 mg Q2W	Chugai Pharmaceutical Co., Ltd.			20		BOTH	50	Phase 3
599	NCT02001987	February 2014	14 November 2016	A Study Of RoActemra/Actemra (Tocilizumab) in Tocilizumab-Naive Patients With Rheumatoid Arthritis With Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) or Biologic Therapy	A Multicenter Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Tocilizumab in Tocilizumab-Naive Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARD and/or Biologic Therapy	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	139	Phase 3	France
600	NCT02078375	February 2014	23 April 2019	The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis	The PRESS RA Study: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Protein;Dietary Supplement: Carbohydrate (Placebo);Other: Resistance Exercise Program	Johns Hopkins University	National Institute on Aging (NIA);American College of Rheumatology Research and Education Foundation	Not recruiting	60 Years	95 Years	All	23	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
601	NCT02173587	February 2014	19 February 2015	Study Evaluating the Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis	Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Mussel oil capsules;Dietary Supplement: Corn oil capsules	Zhejiang University	Sir Run Run Shaw Hospital	Not recruiting	18 Years	75 Years	Both	56	N/A	China
602	NCT02434757	February 2014	11 May 2015	Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis	Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: H.P. Acthar Gel	Ronald J. Rapoport, MD	Questcor Pharmaceuticals, Inc.	Recruiting	18 Years	N/A	Both	10	N/A	United States
603	NCT02169544	January 31, 2014	16 December 2017	Post-marketing Study Assessing the Long-Term Safety of Abatacept	Post-marketing Study Assessing the Long-Term Safety of Abatacept	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	100000	N/A
604	NCT02049138	January 24, 2014	4 March 2019	An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects	A Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)	Rheumatoid Arthritis	Drug: ABT-494	AbbVie		Not recruiting	18 Years	100 Years	All	494	Phase 2	United States;Belgium;Bulgaria;Chile;Czechia;Hungary;Israel;Latvia;Mexico;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;Australia;Czech Republic
605	EUCTR2012-003655-11-BE	23/01/2014	30 April 2018	Evaluation of long-term safety, tolerability and efficacy of GLPG0634 treatment in subjects with rheumatoid arthritis regarding subject’s disability, fatigue, and quality of life	A multicenter, open-label, long-term follow-up safety and efficacy study of GLPG0634 treatment in subjects with moderately to severely active rheumatoid arthritis	Moderately to severely active rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: filgotinib Product Code: GLPG0634 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: INN - FILGOTINIB Current Sponsor code: GLPG0634 Other descriptive name: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Current Sponsor code: GS-6034 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Gilead Sciences Inc.		Authorised			Female: yes Male: yes	739	Phase 2	United States;Spain;Guatemala;Ukraine;Austria;Russian Federation;Israel;Chile;Colombia;France;Hungary;Czech Republic;Mexico;Argentina;Poland;Belgium;Romania;Peru;Australia;Bulgaria;Latvia;Germany;Moldova, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
606	JPRN-UMIN000012364	2014/01/10	2 April 2019	Drug registry study to evaluate the effectiveness of tramadol / acetaminophen combination tablets as pain management for patient with rheumatoid arthritis.		rheumatoid arthritis	Tramadol / acetaminophen combination tablets will be administrated by 1 tablets / time/ qid and every 4 hours for pain relief. Step by step dose up administration schedule over 4weeks will be applied at beginning of treatment as bellows; Day1-Day7(1 tablet/day, after night meal) Day8-Day14(1 tabletX2 times /day, after morning and night meal) Day15-Day21(1 tabletX3 times /day, after morning, afternoon and night meal Day22-Day30(1 tabletX4 times /day, after morning, night meal and before bedtime) Once dose reached to 1 tabletX4 times /day, then treatment will be continue up to 24 weeks.	Osaka City University Medical School, Department of Orthopedic Surgery		Not Recruiting	25years-old	75years-old	Male and Female	31	Not applicable	Japan
607	NCT01988506	January 6, 2014	27 August 2018	Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases	Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach	Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis	Drug: Interleukin 2	Assistance Publique - Hôpitaux de Paris	Iltoo Pharma	Recruiting	18 Years	N/A	All	132	Phase 2	France
608	JPRN-JapicCTI-142497	01/1/2014	2 April 2019	Phase 2b, Rheumatoid Arthritis Dose Ranging Study for Clazakizumab in Subjects who have Experienced an Inadequate Response to TNF inhibitors.	A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have Experienced an Inadequate Response to TNF inhibitors.	Rheumatoid Arthritis	Intervention name : Clazakizumab Dosage And administration of the intervention : Injection, 1 mg, 5 mg, 25 mg Control intervention name : null	Bristol-Myers K.K.			18		BOTH	140	Phase 2
609	NCT01988012	January 2014	16 December 2017	A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.	An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients.	Rheumatoid Arthritis	Biological: tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	100	Phase 3	Israel
610	NCT02017639	January 2014	18 April 2016	Sarilumab Effect on the Pharmacokinetics of Simvastatin	A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: simvastatin	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	75 Years	Both	19	Phase 1	United States;Korea, Republic of;Moldova, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
611	NCT02019602	January 2014	16 December 2017	A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta	A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia® (Certolizumab Pegol)	Axial Spondyloarthritis (AxSpA);Non-radiographic Evidence-AxSpA;Ankylosing Spondylitis;Crohn's Disease;Psoriatic Arthritis;Rheumatoid Arthritis	Procedure: Blood sampling from mother;Procedure: Blood sampling from infant;Procedure: Blood sampling from umbilical cord;Biological: Certolizumab Pegol	UCB BIOSCIENCES, Inc.	PPD;Parexel	Not recruiting	18 Years	N/A	All	16	Phase 1	United States;France;Netherlands;Switzerland
612	NCT02031471	January 2014	16 December 2017	TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment	TOSCARA: An Open-label, Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Tocilizumab (TCZ) Subcutaneous in TCZ-naïve Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	57	Phase 3	Belgium;Luxembourg
613	EUCTR2014-004558-33-Outside-EU/EEA		6 January 2015	A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis	A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Humira 40 mg/0.8 ml solution for injection Product Name: Adalimumab Product Code: 331731-18-1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: Humira Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Abbott Japan Co., Ltd.		Not Available			Female: yes Male: yes	25		Japan
614	JPRN-UMIN000012690	2013/12/28	2 April 2019	Study of Actemura Remission induction of RA and Sequential Maintenance of Remission by Reasonable cost Treatment		Rheumatoid Arthritis	tocilizumab+tacrolimus+Bucillamine tocilizumab	National hospital organization Chiba east national hospital Clinical Research Center		Not Recruiting	20years-old	99years-old	Male and Female	60	Not applicable	Japan
615	EUCTR2013-004006-26-DK	18/12/2013	26 September 2016	OPAL	Optical images for monitoring treatment changes in rheumatoid arthritis – a longitudinal study with Rheumascan	Detection of synovitis and tenosynovitis in the hands of patients with rheumatoid arthritis; Diagnostic performance of optical imaging in comparison with ultrasound and magnetic resonance imaging. MedDRA version: 16.1 Level: LLT Classification code 10067132 Term: Synovitis wrist System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: ICG-Pulsion Pharmaceutical Form: Powder and solvent for solution for injection/infusion INN or Proposed INN: 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt CAS Number: 3599-32-4 Other descriptive name: INDOCYANINE GREEN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5-	Knowledge Centre for Rheumatology and Back Diseases		Not Recruiting			Female: yes Male: yes		Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
616	EUCTR2013-002150-79-BE	16/12/2013	22 August 2016	A study to evaluate the efficacy and safety of tocilizumab subcutaneous in RA patients	TOSCARA: An open-label, single-arm study to evaluate the efficacy, safety and tolerability of tocilizumab (TCZ) subcutaneous in TCZ-naïve patients with active rheumatoid arthritis - TOSCARA	Rheumatoid Arthritis MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: RoActemra Product Name: tocilizumab SC Product Code: Ro 487-7533/F10-02 Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 180-	N.V. Roche S.A.		Not Recruiting			Female: yes Male: yes	60	Phase 3	Belgium
617	JPRN-UMIN000018816	2013/12/05	2 April 2019	Study on the relationship between arthritis and sleep disturbance	Study on the relationship between arthritis and sleep disturbance - Sleep study in arthritis	Rheumatoid Arthritis	Treatment with melatonin-mimetics, ramelteon. Treatment with biological disease-modifying anti-rheumatic drugs.	Shunichi Shiozawa	Rheumatic Diseases Center, Kohnan Kakogawa Hospital	Not Recruiting	20years-old	Not applicable	Male and Female	200	Not applicable	Japan
618	JPRN-UMIN000012073	2013/12/01	2 April 2019	Effects of Subcutaneous Actemura and MTX Blending in RA		rheumatoid arthritis	Adults with active RA (DAS28 >3.2) despite methotrexate prescription were randomly assigned to continue methotrexate with the addition of tocilizumab (MTX+TCZ) 162mg/body every other week for 52 weeks. Adults with active RA (DAS28 >3.2) despite methotrexate prescription were randomly assigned to switch to tocilizumab (TCZ) 162mg/body every other week for 52 weeks.	Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka City University Medical School		Not Recruiting	20years-old	85years-old	Male and Female	100	Phase 4	Japan
619	NCT01668966	December 2013	14 November 2016	A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	24	Phase 3	Brazil
620	NCT02047604	December 2013	16 December 2017	(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).	Rheumatoid Arthritis	Drug: SAN-300;Drug: Placebo	Valeant Pharmaceuticals International, Inc.		Not recruiting	18 Years	75 Years	All	41	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
621	EUCTR2013-000114-38-DE	29/11/2013	4 August 2015	A 24-week, placebo-controlled, multicenter study to investigate the efficacy and safety of tregalizumab (BT061) in combination with methotrexate in the treatment of subjects with active rheumatoid arthritis who have had an insufficient response to methotrexate alone, followed by a 24-week extension phase: T cell REgulating Arthritis Trial 2b (TREAT 2b)	A 24-week phase IIb, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of tregalizumab (BT061) in combination with methotrexate in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone, followed by a 24-week extension phase: T cell REgulating Arthritis Trial 2b (TREAT 2b) - T cell REgulating Arthritis Trial 2b (TREAT 2b)	Subjects with active rheumatoid arthritis incompletely controlled on stable MTX doses MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Tregalizumab Product Code: BT061 Pharmaceutical Form: Solution for injection INN or Proposed INN: Tregalizumab Current Sponsor code: BT061 Other descriptive name: A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 12.5- INN or Proposed INN: Tregalizumab Current Sponsor code: BT061 Other descriptive name: B Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- INN or Proposed INN: Tregalizumab Current Sponsor code: BT061 Other descriptive name: C Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- INN or Proposed INN: Tregalizumab Current Sponsor code: BT061 Other descriptive name: D Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- INN or Proposed INN: Tregalizumab Current Sponsor code: BT061 Other descriptive name: E Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Biotest AG		Not Recruiting			Female: yes Male: yes	304	Phase 2b	Serbia;United States;Estonia;Slovakia;Ukraine;Lithuania;Russian Federation;Czech Republic;Hungary;Mexico;Canada;Poland;Bulgaria;Germany;Sweden
622	NCT03736044	November 25, 2013	19 November 2018	Reconstitution of CD4+CD25highCD127low/-Tcell	Analysis of T Cell Population to Obtain a Free-drug Remission in Patients Affected by Rheumatoid Athritis in Remission Phase Induced by TNF-blocker Therapy	Rheumatoid Arthritis	Drug: TNF-blockers suspension in patients with rheumatoid arthritis	University Hospital of Ferrara		Not recruiting	18 Years	N/A	All	48	N/A
623	EUCTR2013-002777-22-GB	14/11/2013	16 November 2015	Targeted Ultrasound in Rheumatoid Arthritis (TURA)	Targeted Ultrasound in Rheumatoid Arthritis (TURA) - TURA	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	University of Leeds, Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine		Authorised			Female: yes Male: yes	310		France;Hungary;Spain;Denmark;Germany;Japan;Italy;United Kingdom
624	EUCTR2013-003658-26-NL	13/11/2013	26 November 2013	Individualised treatment strategy based on disease activity for early RA patients in usual clinical practice: The COBRA Cohort Study	Treat-to-target strategy for early RA patients in usual clinical practice: The COBRA Cohort Study - COBRA Cohort Study	Early Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Methotrexate Product Name: Methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 10-25 Trade Name: Prednison Product Name: Prednison Pharmaceutical Form: Tablet INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 10-60 Trade Name: Plaquenil Product Name: hydroxycholoquine Pharmaceutical Form: Tablet INN or Proposed INN: hydroxychloroquine sulfate CAS Number: 747-36-4 Other descriptive name: HYDROXYCHLOROQUINE SULFATE Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 400- Trade Name: Sulfasalazine Product Name: Sulfasalazine Pharmaceutical Form: Tablet INN or Proposed INN: Sulfasalazine Other descriptive name: SULFASALAZINE Concentration unit: g gram(s) Concentration type: up to Concentration number: 2-	VU University Medical Center		Authorised			Female: yes Male: yes			Netherlands
625	JPRN-UMIN000012257	2013/11/12	2 April 2019	Impact of corticosteroid on periarticular injection for pain control following total knee arthroplasty: a double-blind randomized trial		osteoarthritis, rheumatoid arthritis, avascular necrosis of femoral condyle	A periarticular injection including methylprednisolone, ropivacaine, morphine, bosmin, and ketoprofen for pain after total knee arthroplasty A periarticular injection including ropivacaine, morphine, bosmin, and ketoprofen for pain after total knee arthroplasty	Nekoyama Miyao Hospital		Not Recruiting	18years-old	Not applicable	Male and Female	74	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
626	EUCTR2013-003486-34-DK	04/11/2013	14 March 2016	Treatment of Tenosynovitis among rheumatoid arthritis patients	Systemic versus ultrasound-guided local glucocorticoid treatment, among rheumatoid arthritis patients with tenosynovitis - a randomized double blind study - SULTAN	MedDRA version: 16.0 Level: LLT Classification code 10042869 Term: Synovitis and tenosynovitis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Diprofos Depot Pharmaceutical Form: Solution for injection INN or Proposed INN: BETAMETHASONE ACIBUTATE CAS Number: 5534-05-4 Current Sponsor code: Glucocorticoid Other descriptive name: Binyrebarkhormon Concentration unit: mg/l milligram(s)/litre Concentration type: range Concentration number: 3,5-14 Trade Name: Natriumklorid 9mg/ml Pharmaceutical Form: Solution for injection INN or Proposed INN: SODIUM CHLORIDE Current Sponsor code: Natriumklorid Other descriptive name: SODIUM CHLORIDE Concentration unit: mg/l milligram(s)/litre Concentration type: range Concentration number: 4,5-18	Knowledge Centre for Rheumatology and Back Diseases		Not Recruiting			Female: yes Male: yes			Denmark
627	NCT01855789	November 2013	14 November 2016	A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: Placebo;Drug: Tocilizumab;Drug: methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	718	Phase 3	United States
628	NCT01951170	November 2013	19 October 2017	An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis	An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	52	Phase 3	Australia
629	NCT01980836	November 2013	19 February 2015	Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine	The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Cellular Immune Response	Biological: Seasonal influenza vaccine	Tel-Aviv Sourasky Medical Center		Not recruiting	18 Years	N/A	Both	40	Phase 4	Israel
630	NCT01990157	November 2013	16 December 2017	Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis	Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis in Which Methotrexate (MTX) Treatment is Not Effective	Rheumatoid Arthritis	Drug: TAB08	Theramab LLC		Not recruiting	18 Years	65 Years	All	18	Phase 1/Phase 2	Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
631	NCT02005757	November 2013	3 August 2015	Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)	Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug	Rheumatoid Arthritis	Drug: Bredinin tablet 150mg;Drug: Bredinin tablet 50mg	Chong Kun Dang Pharmaceutical		Recruiting	20 Years	80 Years	Both	60	Phase 2	Korea, Republic of
632	NCT02027298	November 2013	16 December 2017	Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study	Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study	Primary Sjogren's Syndrome;Secondary Sjogren's Syndrome;Inflammatory Arthritis;Rheumatoid Arthritis	Drug: Abatacept	The Cleveland Clinic	Bristol-Myers Squibb	Not recruiting	18 Years	N/A	All	0	Phase 2	United States
633	NCT02254655	November 2013	29 January 2018	The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis	The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis, a Controlled and Randomized Trial	Rheumatoid Arthritis	Drug: Puerarin injection 400 mg;Drug: Control	Chengdu PLA General Hospital		Not recruiting	18 Years	75 Years	All	119	Phase 2	China
634	NCT02293590	November 2013	20 August 2018	RICE: Remission by Intra-articular Injection Plus CErtolizumab	An Open Label, Randomised Study to Compare the Efficacy of Certolizumab Pegol (CZP) Plus a Dynamic or Fixed Dose Treatment Strategy in Patients With Rheumatoid Arthritis, a Phase II Study	Rheumatoid Arthritis	Drug: Certolizumab Pegol	Rüdiger B. Müller	UCB Pharma	Not recruiting	18 Years	N/A	All	43	Phase 2	Switzerland
635	EUCTR2012-004074-25-DE	30/10/2013	23 July 2018	Comparison of the effectiveness and safety of two different starting dosages of cortisone, compared to each other and to placebo, in early active rheumatoid arthritis	Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial - CORRA	Early rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: PredniHEXAL® 5mg Tabletten Product Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolon Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: PredniHEXAL® 5mg Tabletten Product Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolon Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7,5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: PredniHEXAL® 10mg Tabletten Product Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolon Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: PredniHEXAL® 5mg Tabletten, PredniHEXAL® 10mg Tabletten Product Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolon Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: PredniHEXAL® 20mg Tabletten Product Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolon Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: PredniHEXAL® 5mg Tabletten, PredniHEXAL® 20mg Tabletten Product Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolon	Ruhr-Universität Bochum		Not Recruiting			Female: yes Male: yes	450	Phase 3	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
636	EUCTR2013-002341-11-GB	25/10/2013	4 August 2015	This is a study in healthy subjects to look at the effect of tocilizumab (RoActemra) on a type of white blood cell	A SINGLE BLIND PHASE IV PHARMACODYNAMIC STUDY TO EVALUATE NEUTROPHIL DISTRIBUTION KINETICS AND FUNCTION FOLLOWING SINGLE-DOSE TOCILIZUMAB TREATMENT IN HEALTHY SUBJECTS	healthy volunteers (intended indication: Rheumatoid Arthritis) MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: no Male: yes		Phase 4	United Kingdom
637	EUCTR2013-000342-19-NL	24/10/2013	5 September 2016	A clinical trial where patients with Rheumatoid Arthritis are treated with the study drug tocilizumab, subcutaneous (injection in the skin), with or without other non-biological anti-rhematic drugs, to study the safety and efficacy of the drug.	MULTI-CENTER, OPEN LABEL, SINGLE ARM PHASE IIIB STUDY ON SAFETY AND EFFICACY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) IN MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO NON-BIOLOGIC DMARDS - OSCAR	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: tocilizumab SC Product Code: Ro 487-7533/F10-04 Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: TOCILIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 162-	Roche Nederland B.V.		Not Recruiting			Female: yes Male: yes		Phase 3	Netherlands
638	JPRN-UMIN000012399	2013/10/16	2 April 2019	Performance of Rheumascan in healthy subjects and patients with active rheumatoid arthritis		Rheumatoid arthritis	Patients with active rheumatoid arthritis (1)Assessment of tender and swollen joints by physical examination (2)Joint ultrasonography (assessment of active synovitis by grading and quantification of vascularity using power Doppler or color Doppler ultrasonography) in 22 joints of bilateral hands (3)Gadolinium-enhanced MRI of the hand with more severe arthritis (4)Examination by Rheumascan, a fluorescence optical imaging device using intravenous indocyanine green (ICG) Healthy subjects (1)Assessment of tender and swollen joints by physical examination (2)Joint ultrasonography (assessment of active synovitis by grading and quantification of vascularity using power Doppler or color Doppler ultrasonography) in 22 joints of bilateral hands (3)Examination by Rheumascan, a fluorescence optical imaging device using intravenous indocyanine green (ICG)	Tokyo Medical and Dental University	Diagnostic Imaging Center, Ochanomizu Surugadai Clinic	Not Recruiting	20years-old	Not applicable	Male and Female	9	Not applicable	Japan
639	EUCTR2013-001999-38-BE	07/10/2013	17 August 2015	A clinical study to test the efficacy of a new product (TNF-Kinoid) in patients with Rheumatoid Arthritis in whom treatment with methotrexate is not working anymore	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy - Phase II study of TNF-K in Rheumatoid Arthritis	Active Rheumatoid Arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: TNF-Kinoid Product Code: TNF-K Pharmaceutical Form: Emulsion for injection INN or Proposed INN: not assigned yet Current Sponsor code: TNF-K Other descriptive name: TNF-Kinoid Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Emulsion for injection Route of administration of the placebo: Intramuscular use	Neovacs SA		Not Recruiting			Female: yes Male: yes	140	Phase 2	Serbia;Hungary;Czech Republic;Macedonia, the former Yugoslav Republic of;Poland;Belgium;Ukraine;Lebanon;Georgia;Russian Federation;Moldova, Republic of
640	EUCTR2013-000054-22-GB	01/10/2013	3 April 2017	OPEN-LABEL, PHASE IIIB STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB (MONOTHERAPY OR COMBINATION THERAPY WITH METHOTREXATE OR OTHER DMARDS) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO CURRENT NON-BIOLOGIC DMARD THERAPY OR THE FIRST ANTI-TNF BIOLOGIC AGENT	OPEN-LABEL, PHASE IIIB STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB (MONOTHERAPY OR COMBINATION THERAPY WITH METHOTREXATE OR OTHER DMARDS) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO CURRENT NON-BIOLOGIC DMARD THERAPY OR THE FIRST ANTI-TNF BIOLOGIC AGENT - ACT-MOVE	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: RoActemra Product Name: tocilizumab SC Product Code: Ro 487-7533/F10-04 Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: Recombinant humanised anti-human monoclonal antibody directed against the IL-6R Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 180-	Roche Products Limited		Not Recruiting			Female: yes Male: yes		Phase 3	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
641	JPRN-JapicCTI-132277	01/10/2013	2 April 2019	AMG 162 Phase III study (DESIRABLE study)	A Confirmatory Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on DMARDs treatment (Phase III)	rheumatoid arthritis	Intervention name : AMG 162 INN of the intervention : Denosumab Dosage And administration of the intervention : Administer 60 mg every 6 months or every 3 months as a subcutaneous injection Control intervention name : Placebo Dosage And administration of the control intervention : Administer placebo as a subcutaneous injection	DAIICHISANKYO Co.,Ltd.			20		BOTH	642	Phase 3
642	JPRN-UMIN000011891	2013/10/01	2 April 2019	Multicenter study of the effect of GoLimumab On the Remission Induction rate and bio-free remission maintenance rate in early rheumatoid Arthritis.		Rheumatoid Arthritis	Golimumab	St.Marianna University School of Medicine		Not Recruiting	20years-old	70years-old	Male and Female	50	Not selected	Japan
643	NCT01773681	October 2013	10 December 2018	Novel Imaging Markers for Rheumatoid Arthritis	Novel Imaging Markers for Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Cimzia;Device: Magnetic Resonance Imaging (MRI);Device: High-resolution peripheral quantitative computed tomography (HR-pQCT)	University of California, San Francisco		Not recruiting	18 Years	N/A	All	30	N/A	United States
644	NCT01947465	October 2013	14 March 2016	Immunogenicity and Safety of Vaccinations in Immunocompromised Persons	A Prospective Cohort Study in 6 Swiss Rheumatology Centres and 4 Travel Clinics on the Immunogenicity and Safety of Tetanus and Hepatitis A Vaccine in Patients With Rheumatoid Arthritis, Axial Spondyloarthritis and Vasculitis and Healthy Controls	Arthritis, Rheumatoid;Spondylarthritis;Vasculitis	Biological: Hepatitis A vaccine and tetanus vaccine	University of Zurich	University of Basel;Swiss Tropical & Public Health Institute;University of Bern;University Hospital, Geneva;Cantonal Hospital of St. Gallen;Cantonal Hospital of Aarau, Switzerland	Not recruiting	18 Years	N/A	Both	645	N/A	Switzerland
645	NCT01960855	October 2013	11 July 2016	A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy	Rheumatoid Arthritis	Drug: ABT-494;Drug: Placebo	AbbVie		Not recruiting	18 Years	100 Years	Both	276	Phase 2	United States;Australia;Belgium;Czech Republic;Hungary;New Zealand;Poland;Puerto Rico;Spain;United Kingdom;Canada;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
646	NCT01962337	October 2013	19 February 2018	Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects	A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis	Healthy;Rheumatoid Arthritis	Drug: FPA008;Drug: Placebo	Five Prime Therapeutics, Inc.		Not recruiting	21 Years	70 Years	All	66	Phase 1	Hungary;Netherlands;Poland
647	NCT01962974	October 2013	16 December 2017	A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)	A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)	Arthritis, Rheumatoid	Biological: Golimumab 2 mg/kg IV	Janssen Biotech, Inc.		Not recruiting	18 Years	76 Years	All	7	Phase 3	United States;Canada;Argentina;Brazil;Colombia;Mexico
648	NCT01966718	October 2013	19 October 2017	Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.	Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action	Rheumatoid Arthritis	Drug: Repository corticotropin injection	Arthritis Treatment Center, Maryland		Not recruiting	18 Years	80 Years	All	8	Phase 4	United States
649	NCT01973569	October 2013	16 December 2017	AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment	A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)	Rheumatoid Arthritis	Drug: denosumab;Drug: placebo	Daiichi Sankyo, Inc.		Not recruiting	20 Years	N/A	All	667	N/A	Japan
650	NCT01975610	October 2013	16 December 2017	Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis	A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CC-292;Drug: Placebo	Celgene		Not recruiting	18 Years	80 Years	Female	47	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
651	NCT01985464	October 2013	15 July 2019	Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis	Feasibility Study of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UC-MSC) in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Umbilical cord mesenchymal stem cells	Translational Biosciences		Not recruiting	18 Years	N/A	All	20	Phase 1/Phase 2	Panama
652	NCT02036931	October 2013	21 January 2019	A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System	A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System	Noninflammatory Degenerative Joint Disease;Rheumatoid Arthritis	Device: Metal on Polyethylene articulation;Drug: Ceramic on Polyethylene articulation;Device: Ceramic on Ceramic articulation	Zimmer Biomet		Not recruiting	18 Years	N/A	All	315	Phase 1	United States;France;Germany;Ireland;Netherlands;Spain
653	NCT02538757	October 2013	21 August 2017	Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)	Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)	Arthritis;Rheumatoid Arthritis;Psoriatic Arthritis;Psoriasis;Ankylosing Spondylitis;Enteropathic Arthritis;Crohn's Disease;Inflammatory Arthritis	Biological: Herpes Zoster Vaccine;Drug: Placebo	University of Alabama at Birmingham	Oregon Health and Science University	Not recruiting	50 Years	N/A	All	125	Phase 2	United States
654	NCT01942174	September 27, 2013	11 February 2019	VACcination In Methotrexate Treated Rheumatoid Arthritis Patients	Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis	Rheumatoid Arthritis	Biological: Prevenar 13;Biological: Pneumo23 / Pneumovax;Drug: Methotrexate - Immediate;Drug: Methotrexate - Delay	University Hospital, Montpellier	APHP (Hospital Cochin);Pfizer	Not recruiting	18 Years	N/A	All	276	Phase 3	France;Monaco
655	EUCTR2013-000359-42-GR	12/09/2013	21 August 2017	Not applicable	Multicenter, open label, phase IIIb study to evaluate the safety and tolerability of subcutaneous tocilizumab as monotherapy and/or in combination with methotrexate or other non-biologic disease modifying antirheumatic drugs in patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Tocilizumab SC Product Code: Ro 487-7533/F10-04 Pharmaceutical Form: Solution for injection	ROCHE HELLAS S.A.		Not Recruiting			Female: yes Male: yes		Phase 3	Greece
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
656	EUCTR2012-005674-61-BE	11/09/2013	21 August 2017	Mesenchymal Precursor Cells (MPCs) for treatment of rheumatoid arthritis	A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-naïve patients with rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 14.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Allogeneic Mesenchymal Precursor Cells Pharmaceutical Form: Suspension for injection Other descriptive name: ALLOGENEIC MESENCHYMAL PRECURSOR CELLS Concentration unit: Munit million units Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use	Mesoblast, Inc		Not Recruiting			Female: yes Male: yes	90	Phase 2	Serbia;Hungary;Estonia;Czech Republic;Poland;Belgium;Croatia;Latvia
657	NCT01907230	September 10, 2013	25 March 2019	Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients	Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial	Rheumatoid Arthritis;Hepatitis B Reactivation;Exposure to Hepatitis B Virus	Drug: Entecavir	Taipei Veterans General Hospital, Taiwan		Not recruiting	20 Years	90 Years	All	115	Phase 4	Taiwan
658	ChiCTR-ONRC-13003578	2013-09-01	18 April 2017	Agkistrodon different formulations inflammatory and analgesic effects on rheumatoid arthritis clinical study	Agkistrodon different formulations inflammatory and analgesic effects on rheumatoid arthritis clinical study	Rheumatoid arthritis	The water decoction group of Agkistrodon:Taking the water decoction of Agkistrodon;Agkistrodon liquor:Taking Agkistrodon liquor agents;Agkistrodon pulvis:Taking the Agkistrodon pulvis;Control group:Taking placebo;	Zhejiang Chinese Medical University		Not Recruiting	18	65	Both	The water decoction group of Agkistrodon:30;Agkistrodon liquor:30;Agkistrodon pulvis:30;Control group:30;	Phase 1 study	China
659	JPRN-JapicCTI-132209	01/9/2013	2 April 2019	Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA (REASSURE-E)	A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the intervention : Subjects will receive 150 mg secukinumab s.c. Control intervention name : null	Novartis Pharma K.K.			18		BOTH	454	Phase 3
660	NCT01787149	September 2013	11 June 2018	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis	Combination With DMARDs	Drug: DMARDs	Mycenax Biotech Inc.		Not recruiting	20 Years	N/A	All	98	Phase 3	Taiwan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
661	NCT01911234	September 2013	1 April 2019	Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs' TNF-Kinoid in Adult Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Biological: TNF-Kinoid;Other: Placebo	Neovacs		Not recruiting	18 Years	75 Years	All	143	Phase 2	Belgium;Georgia;Hungary;Lebanon;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;Czech Republic
662	NCT01948388	September 2013	28 January 2019	The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients	Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging	Rheumatoid Arthritis	Drug: corticotrophin 80 units	Gaylis, Norman B., M.D.		Not recruiting	18 Years	N/A	All	20	Phase 4	United States
663	NCT01955603	September 2013	19 February 2015	A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis	A Randomised, Placebo-controlled, Double-blind Within Cohort, Dose Escalation, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered Subcutaneously to Subjects With Moderate to Severe Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0215-0384;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	Both	24	Phase 1	Germany;Hungary;Poland;Russian Federation
664	NCT02072200	September 2013	19 October 2017	Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)	A New Modified-Release Tablet Formulation of Prednisone in Patients With Rheumatoid Arthritis- Multicenter, Phase IV, Interventional Study to Assess Reduction of Morning Stiffness	Rheumatoid Arthritis	Drug: Lodotra®	Mundipharma Korea Ltd		Not recruiting	20 Years	80 Years	All	147	Phase 4	Korea, Republic of
665	NCT02275299	September 2013	19 February 2015	Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Iguratimod	Jiangsu Simcere Pharmaceutical Co., Ltd.		Recruiting	18 Years	70 Years	Both	240	Phase 4	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
666	NCT02600455	September 2013	16 December 2017	Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL	Outline of Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL	Rheumatoid Arthritis	Drug: Orencia	Bristol-Myers Squibb	Ono Pharmaceutical Co. Ltd	Not recruiting	18 Years	N/A	All	505	N/A	Japan
667	NCT02600468	September 2013	16 December 2017	Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg	Outline of Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg	Rheumatoid Arthritis	Drug: Orencia	Bristol-Myers Squibb	Ono Pharmaceutical Co. Ltd	Not recruiting	18 Years	N/A	All	671	N/A
668	EUCTR2013-000525-31-GB	27/08/2013	10 July 2015	The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe rheumatoid arthritis	A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis	Moderate to Severe Rheumatoid Arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ABP 501 Product Code: ABP 501 Pharmaceutical Form: Solution for injection in pre-filled syringe Current Sponsor code: ABP 501 Other descriptive name: Biosimilar product to adalimumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Other descriptive name: Humira Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Amgen Inc		Not Recruiting			Female: yes Male: yes	500	Phase 3	United States;Spain;Russian Federation;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Romania;Bulgaria;Germany
669	EUCTR2013-002429-52-ES	23/08/2013	17 May 2016	STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) IN SUBJECTS WITH RHEUMATOID ARTHRITIS	A PHASE IIIb STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) GIVEN AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGICS DMARDs IN SUBJECTS WITH RHEUMATOID ARTHRITIS	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Product Name: tocilizumab SC Product Code: Ro 487-7533/F10-04 Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 180-	Roche Farma S.A		Not Recruiting			Female: yes Male: yes	420	Phase 3	Portugal;Spain;Ireland
670	EUCTR2011-005649-10-DE	19/08/2013	10 July 2015	An exploratory clinical study to investigate mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints versus a different antibody whose mechanism works by inhibiting tumor necrosis factor.	A Phase 2 Exploratory Study of Mavrilimumab versus Anti tumor Necrosis Factor in Subjects with Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: mavrilimumab Product Code: CAM-3001 Pharmaceutical Form: Solution for injection INN or Proposed INN: mavrilimumab CAS Number: 1085337-57-0 Current Sponsor code: CAM-3001 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Trade Name: Simponi Product Name: Golimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	MedImmune Ltd		Not Recruiting			Female: yes Male: yes	120	Phase 2	Portugal;Slovakia;Greece;Spain;Russian Federation;Israel;United Kingdom;France;Hungary;Czech Republic;Mexico;Argentina;Brazil;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
671	EUCTR2012-002181-12-SE	19/08/2013	27 October 2014	A Phase IIa POC study to evaluate Safety, Tolerability and Efficacy in Subjects with RA	A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Subjects with Active Rheumatoid Arthritis and an Inadequate Response or Intolerance to Anti-TNF-a Therapy - A Phase IIa POC study to evaluate Safety, Tolerability and Efficacy in Subjects with RA	Active rheumatoid arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: MK-8457 Product Code: MK-8457 Pharmaceutical Form: Capsule INN or Proposed INN: None Other descriptive name: MK-8457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as		Not Recruiting			Female: yes Male: yes	178	Phase 2a	United States;Greece;Spain;Austria;Colombia;Italy;United Kingdom;France;Hungary;Poland;Brazil;Peru;Australia;Denmark;South Africa;New Zealand;Sweden
672	EUCTR2012-005733-37-CZ	16/08/2013	8 August 2016	A Study Comparing SB2 to Remicade® in Subjects with Moderate to Severe Rheumatoid Arthritis	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy	Rheumatoid Arthritis MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: SB2 (infliximab biosimilar) Product Code: SB2 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: SB2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Remicade® Product Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Samsung Bioepis Co., Ltd.		Not Recruiting			Female: yes Male: yes	584	Phase 3	Philippines;Ukraine;Lithuania;United Kingdom;India;Czech Republic;Mexico;Poland;Romania;Bulgaria;Latvia;Bosnia and Herzegovina;Korea, Republic of
673	EUCTR2012-003654-86-HU	15/08/2013	4 August 2015	Evaluation of different oral doses and regimens of GLPG0634 given for 24 weeks in patients with active rheumatoid arthritis and an insufficient response to methotrexate alone	Randomized, double-blind, placebo-controlled, multicenter, phase IIb dose finding study of GLPG0634 administered for 24 weeks as monotherapy to subjects with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate alone	moderately to severely active rheumatoid arthritis MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Proposed INN - FILGOTINIB Current Sponsor code: GLPG0634 Other descriptive name: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Proposed INN - FILGOTINIB Current Sponsor code: GLPG0634 Other descriptive name: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Propsoed INN - FILGOTINIB Current Sponsor code: GLPG0634 Other descriptive name: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Galapagos NV		Not Recruiting			Female: yes Male: yes	280	Phase 2b	United States;Serbia;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Australia;Peru;Latvia;Moldova, Republic of;Guatemala;Lithuania;Austria;Czech Republic;Hungary;Mexico;Argentina;Belgium;Poland;Romania;Bulgaria;Germany;New Zealand
674	EUCTR2012-005026-30-HU	15/08/2013	2 September 2013	A Study Comparing SB4 to Enbrel® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy	A Randomised, Double-Blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy	Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB4 is Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), plaque Psoriasis (PsO) and paediatric plaque PsO. MedDRA version: 14.1 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: SB4 (etanercept biosimilar) Product Code: SB4 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Current Sponsor code: SB4 Other descriptive name: TNFR:Fc Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Enbrel® Product Name: Enbrel® Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Other descriptive name: TNFR:Fc Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Samsung Bioepis Co., Ltd.		Authorised			Female: yes Male: yes	498		Czech Republic;Hungary;Mexico;Poland;Ukraine;Lithuania;Bulgaria;Colombia;United Kingdom;Korea, Republic of;India
675	NCT01856309	August 7, 2013	1 October 2018	Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003	A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)	Arthritis, Rheumatoid	Drug: Sirukumab 100 mg;Drug: Sirukumab 50 mg;Drug: Placebo	Janssen Research & Development, LLC	GlaxoSmithKline	Not recruiting	18 Years	N/A	All	1822	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;France;Germany;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
676	EUCTR2013-000944-25-IT	02/08/2013	22 December 2015	Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with rheumatoid arthritis	A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis - REASSURE-1 Extension	Rheumatoid arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Secukinumab CAS Number: 1229022-83-6 Current Sponsor code: AIN457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Novartis Farma S.p.A.		Not Recruiting			Female: yes Male: yes	454		Panama;United States;Thailand;Guatemala;Colombia;Italy;India;Hungary;Mexico;Canada;Argentina;Belgium;Japan
677	EUCTR2013-001569-17-IT	02/08/2013	10 February 2014	A national, open-label, single-arm, phase IIIB study to evaluate the efficacy of weekly tocilizumab subcutaneous, administered as monotherapy or in combination with other non-biological medicinal products in rheumatoid arthritis (RA) patients.	A national, open-label, single-arm, phase IIIB study to evaluate the efficacy of weekly tocilizumab subcutaneous, administered as monotherapy or in combination with methotrexate and/or other DMARDS in rheumatoid arthritis (RA) patients.	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: tocilizumab SC Product Code: Ro 487-7533/F10-04 Pharmaceutical Form: Solution for injection INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: TOCILIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180-	Roche S.p.A.		Authorised			Female: yes Male: yes		Phase 3B	Italy
678	NCT01394913	August 2013	19 February 2015	Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis	A Prospective, Double-blind, Randomized Study to Compare Efficacy of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Reumatocept (etanercept);Drug: Enbrel (etanercept)	EMS		Not recruiting	18 Years	70 Years	Both	216	Phase 3	Brazil
679	NCT01905735	August 2013	19 February 2015	A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis	A Multicentric,Double-blind,Placebo Controlled,Phase-2 Study to Assess the Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis .	Rheumatoid Arthritis.	Drug: Rhustoxicodendron 30;Drug: placebo	Healthcare Homoeo Charitable Society		Recruiting	25 Years	60 Years	Both	60	Phase 2	India
680	NCT01915537	August 2013	19 February 2015	Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients	A Prospective Cohort Study to Observe the Difference of Efficacy Between Infliximab With Methotrexate and Classic DMARDs in the Severe Rheumatoid Arthritis Patients With Poor Prognosis	Rheumatoid Arthritis(RA)	Drug: Infliximab group;Drug: Classic DMARDs treatment group	Zhang, Xiao, M.D.	Central South University;Tianjin Medical University General Hospital;Xijing Hospital	Not recruiting	18 Years	70 Years	Both	170	N/A	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
681	NCT01925157	August 2013	12 October 2015	A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)	A Single-Dose, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3090106 in Healthy Subjects and Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: LY3090106 - SQ;Biological: LY3090106 - IV;Biological: Placebo - SQ	Eli Lilly and Company		Not recruiting	18 Years	80 Years	Both	43	Phase 1	Bulgaria;Moldova, Republic of;Poland;Romania;Hungary;United States
682	NCT01936181	August 2013	16 December 2017	A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Remicade (infliximab);Drug: SB2 (proposed biosimilar to infliximab)	Samsung Bioepis Co., Ltd.		Not recruiting	18 Years	75 Years	All	584	Phase 3	Bulgaria;Lithuania
683	NCT01932372	July 26, 2013	11 November 2019	Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis	XELJANZ (REGISTERED) TABLETS 5MG SPECIAL INVESTIGATION (ALL-CASES SURVEILLANCE)	Rheumatoid Arthritis	Drug: Tofacitinib (Xeljanz);Drug: Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc	Pfizer		Not recruiting	N/A	N/A	All	10477	N/A	Japan
684	JPRN-JapicCTI-153073	01/7/2013	2 April 2019	Long-term Safety and Efficacy of Sirukumab in Participants with RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003	A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)	Rheumatoid arthritis	Intervention name : Sirukumab Dosage And administration of the intervention : 100 mg Intervention name : Sirukuma Dosage And administration of the intervention : 50mg Control intervention name : null	Janssen Pharmaceutical K.K.			18		BOTH	280	Phase 3
685	NCT01774877	July 2013	19 February 2015	A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome	Efficacy and Safety of Xinfeng Capsule in the Treatment of Rheumatoid Arthritis (RA):A Randomized, Double-blind, Double-dummy, Multi-center Trial	Rheumatoid Arthritis	Drug: Xinfeng capsule;Drug: leflunomide	The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine	Ministry of Science and Technology of the People´s Republic of China	Not recruiting	18 Years	65 Years	Both	304	N/A	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
686	NCT01851070	July 2013	11 June 2018	A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFa Inhibitor	A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFa Inhibitor	Rheumatoid Arthritis	Drug: Allogeneic Mesenchymal Precursor Cells;Drug: Normal Saline	Mesoblast, Ltd.	PPD	Not recruiting	18 Years	80 Years	All	48	Phase 2	United States;Australia
687	NCT01853033	July 2013	16 December 2017	A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis	A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122	Rheumatoid Arthritis	Biological: ABT-122;Biological: Placebo	AbbVie		Not recruiting	18 Years	75 Years	All	19	Phase 1	United States
688	NCT01862224	July 2013	19 February 2015	A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: JNJ-38518168;Drug: Placebo;Drug: Placebo / JNJ-38518168	Janssen Research & Development, LLC		Not recruiting	18 Years	65 Years	Both	21	Phase 2	United States;Moldova, Republic of
689	NCT01890473	July 2013	19 October 2017	Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe	Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	356	Phase 1	United States;Argentina;Mexico;Peru;South Africa
690	NCT01893996	July 2013	16 December 2017	Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease	Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease	Rheumatoid Arthritis;Cardiovascular Disease	Drug: Adalimumab;Drug: Placebo	University of California, San Francisco	American College of Rheumatology Research and Education Foundation;AbbVie	Not recruiting	18 Years	N/A	All	60	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
691	NCT01894516	July 2013	3 August 2015	Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Patients (DARWIN2)	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone	Rheumatoid Arthritis	Drug: GLPG0634;Drug: Placebo	Galapagos NV		Not recruiting	18 Years	N/A	Both	287	Phase 2	United States;Argentina;Australia;Austria;Bulgaria;Chile;Colombia;Germany;Guatemala;Hungary;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine
692	NCT01927263	July 2013	18 April 2016	A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis	A Phase 3 Clinical Study of NI-071 in Patients With Rheumatoid Arthritis ?A Double-blind, Active Drug-controlled Study and Long-term Study?	Rheumatoid Arthritis	Biological: NI-071;Biological: Infliximab	Nichi-Iko Pharmaceutical Co.,Ltd.		Not recruiting	20 Years	75 Years	Both	242	Phase 3	Japan
693	NCT02236481	July 2013	18 December 2018	Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes	No-profit Study to Ensure Normal Clinical Practice, to Evaluate the Efficacy of Anakinra in Reducing the Glycated Haemoglobin in Patients Affected by Rheumatoid Arthritis and Diabetes; Randomized, Open Label, Parallel Group,Controlled Clinical Study	Diabetes Mellitus, Type 2;Arthritis, Rheumatoid	Drug: Anakinra;Drug: TNF alpha inhibitors	Prof. Roberto Giacomelli		Not recruiting	18 Years	N/A	All	41	Phase 4	Italy
694	NCT02519387	July 2013	19 October 2017	Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity	Multicentre Study for Evaluation of the Efficacy and Safety of Buprenorphine Transdermal Patch (SOVENOR®) 5mg and 10mg in Patients With Non-malignant Pain of Moderate Intensity Due to Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain and Joint/Muscle Pain, When an Opioid is Necessary for Obtaining Adequate Analgesia	Osteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle Pain	Drug: Buprenorphine Transdermal Patch	Mundipharma Pharmaceuticals Sdn. Bhd.		Not recruiting	40 Years	N/A	All	78	Phase 4	Malaysia
695	NCT02894047	July 2013	19 September 2016	Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years	Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years	Arthritis, Rheumatoid	Biological: blood	Centre Hospitalier Universitaire, Amiens		Not recruiting	18 Years	N/A	Both	42	N/A	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
696	EUCTR2012-003635-31-BE	26/06/2013	17 August 2015	Evaluation of different oral doses and regimens of GLPG0634 given for 24 weeks in patients with active rheumatoid arthritis and an insufficient response to methotrexate alone	Randomized, double-blind, placebo-controlled, multicenter, phase IIb dose finding study of GLPG0634 administered for 24 weeks in combination with methotrexate to subjects with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate alone.	moderately to severely active rheumatoid arthritis MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Proposed INN - FILGOTINIB Current Sponsor code: GLPG0634 Other descriptive name: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Proposed INN - FILGOTINIB Current Sponsor code: GLPG0634 Other descriptive name: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Propsoed INN - FILGOTINIB Current Sponsor code: GLPG0634 Other descriptive name: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Galapagos NV		Not Recruiting			Female: yes Male: yes	595	Phase 2b	United States;Serbia;Spain;Ukraine;Chile;Israel;Russian Federation;Colombia;France;Australia;Peru;Latvia;Moldova, Republic of;Guatemala;Lithuania;Austria;Hungary;Czech Republic;Mexico;Argentina;Belgium;Poland;Romania;Bulgaria;Germany;New Zealand
697	EUCTR2012-004482-40-ES	18/06/2013	22 July 2013	Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies	Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis (RA) in persistent clinical remission in treatment with biological therapies: open, controlled study and randomized.	Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Infliximab Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 3- Trade Name: HUMIRA Product Name: Adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: ENBREL Product Name: Etanercept Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: CIMZIA Product Name: Certolizumab Pegol Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: SIMPONI Product Name: Golimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: ORENCIA Product Name: Abatacept Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 1000- Trade Name: RoActemra Product Name: Tocilizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 8- Product Name: Infliximab Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram	FRANCISCO J. BLANCO GARCÍA		Authorised			Female: yes Male: yes			Spain
698	NCT01881308	June 17, 2013	30 September 2019	Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis	REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design	Rheumatoid Arthritis	Drug: TNF inhibitors;Drug: Synthetic DMARD(s);Drug: Co-medication: Synthetic DMARDs	Diakonhjemmet Hospital	The Research Council of Norway;South-Eastern Norway Regional Health Authority	Not recruiting	18 Years	80 Years	All	360	Phase 4	Norway
699	EUCTR2012-003686-17-SK	05/06/2013	7 January 2019	A Phase 3 Study in Rheumatoid Arthritis	A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis - RA-BEYOND	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Olumiant Product Name: Olumiant Product Code: LY3009104 Pharmaceutical Form: Tablet INN or Proposed INN: baricitinib Current Sponsor code: LY3009104 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Olumiant Product Name: Olumiant Product Code: LY3009104 Pharmaceutical Form: Tablet INN or Proposed INN: baricitinib Current Sponsor code: LY3009104 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Eli Lilly and Company		Authorised			Female: yes Male: yes	3000	Phase 3	Portugal;United States;Taiwan;Slovakia;Greece;Spain;Russian Federation;Israel;Italy;Switzerland;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;China;Korea, Republic of;Slovenia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan;Sweden
700	NCT01861782	June 2013	19 February 2015	Comparison Between Dead Sea Solar and Water Treatment to Sulfur Pool and Medicinal Mud Treatment in Patients With RA	Comparison Between Dead Sea Solar and Water Treatment to Sulfur Pool and Medicinal Mud Treatment in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Other: Dead Sea Solar and Water Treatment;Other: Sulfur Pool & Medicinal Mud	Soroka University Medical Center		Not recruiting	18 Years	N/A	Both	30	N/A	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
701	NCT01875991	June 2013	19 October 2017	Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept	An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept	Rheumatoid Arthritis;Plaque Psoriasis	Drug: Etanercept via Autoinjector A;Drug: Etanercept via Autoinjector B	Amgen		Not recruiting	18 Years	N/A	All	217	Phase 4	United States;Canada
702	NCT01878318	June 2013	14 November 2016	A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs	Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs	Rheumatoid Arthritis	Drug: methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	0	Phase 4	Venezuela
703	NCT01885819	June 2013	16 December 2017	Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis	Feasibility Study of Non-Expanded Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Autologous stromal vascular fraction cells	Translational Biosciences		Not recruiting	18 Years	N/A	All	0	Phase 1/Phase 2	Panama
704	NCT01895309	June 2013	16 December 2017	A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Enbrel (etanercept);Drug: SB4 (proposed biosimilar to etanercept)	Samsung Bioepis Co., Ltd.		Not recruiting	18 Years	75 Years	All	596	Phase 3	Poland;United Kingdom
705	NCT01901185	June 2013	19 October 2017	Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept	A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept	Rheumatoid Arthritis;Psoriatic Arthritis	Drug: Etanercept / Autoinjector A	Amgen		Not recruiting	18 Years	N/A	All	77	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
706	NCT01961271	June 2013	19 October 2017	Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain	Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia	Osteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle Pain	Drug: Buprenorphine transdermal patch	Mundipharma Pte Ltd.	Mundipharma Korea Ltd;Mundipharma (Hong Kong) Ltd;Mundipharma Distribution GmBH (Philippine Branch)	Not recruiting	18 Years	80 Years	All	114	Phase 4	Hong Kong;Korea, Republic of;Philippines
707	NCT02132234	June 2013	19 February 2015	Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis	Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis	Rheumatoid Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis;Hypertension	Drug: Etanercept;Drug: Adalimumab;Drug: Certolizumab;Drug: Infliximab	Jagiellonian University	Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland	Recruiting	18 Years	N/A	Both	100	Phase 4	Poland
708	NCT01955733	May 31, 2013	16 December 2017	Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis	Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial	Arthritis, Rheumatoid	Drug: BI 695500	Boehringer Ingelheim		Not recruiting	18 Years	82 Years	All	91	Phase 3	United States;Belgium;Bulgaria;Germany;Greece;Netherlands;Poland;Portugal;Spain;Argentina;Brazil;Canada;Chile;Hungary;Ireland;Mexico;United Kingdom
709	EUCTR2012-003686-17-IT	29/05/2013	26 February 2018	A Phase 3 Study in Rheumatoid Arthritis	A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis - RA-BEYOND	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet INN or Proposed INN: baricitinib Current Sponsor code: LY3009104 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet INN or Proposed INN: baricitinib Current Sponsor code: LY3009104 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Eli Lilly and Company		Authorised			Female: yes Male: yes	3000	Phase 3	Portugal;United States;Taiwan;Slovakia;Greece;Spain;Israel;Russian Federation;Switzerland;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;China;Korea, Republic of;Slovenia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan;Sweden
710	JPRN-UMIN000014485	2013/05/24	2 April 2019	Golimumab study for development of tight control and biologics-free condition.		rheumatoid arthritis	Treatment with Golimumab for patients with rheumatoid arthritis	Rheumatology, Internal MedicineJuntendo University School of Medicine, Juntendo Koshigaya Hospital		Recruiting	20years-old	Not applicable	Male and Female	40	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
711	EUCTR2013-000337-13-DE	13/05/2013	11 December 2017	Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA)	Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreCePRA)	Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia Product Name: Cimzia Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Current Sponsor code: UCB SA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution and suspension for suspension for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Universitätsklinikum Erlangen		Authorised			Female: yes Male: yes	156	Phase 3	Serbia;Portugal;Germany
712	NCT01357759	May 2013	23 November 2015	Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects	A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MORAb-022	Morphotek		Not recruiting	18 Years	75 Years	Both	20	Phase 1	United States;Netherlands
713	NCT01846975	May 2013	16 March 2015	Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday	A Phase IV, Open Label Study Introducing a Single IV Treatment With Abatacept in Patients With Rheumatoid Arthritis Currently Receiving Weekly Injections of SC Abatacept to Simulate a Holiday or Patient Vacation	Rheumatoid Arthritis	Drug: IV Abatacept	Rüdiger B. Müller	Bristol-Myers Squibb	Not recruiting	18 Years	N/A	Both	49	Phase 4	Switzerland
714	NCT01873443	May 2013	7 December 2015	Long-Term Efficacy and Safety of CT-P10 in Patients With RA	An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1	Rheumatoid Arthritis	Drug: Rituximab, MTX, folic acid	Celltrion		Not recruiting	18 Years	75 Years	Both	87	Phase 1	Korea, Republic of
715	NCT01927757	May 2013	19 October 2017	Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab	A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent	Moderate to Severe Rheumatoid Arthritis	Biological: Etanercept;Drug: Methotrexate	Amgen		Not recruiting	18 Years	N/A	All	90	Phase 4	United States;Canada;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
716	NCT02035800	May 2013	11 June 2018	Bone Resorption, Osteoclastogenesis and Adalimumab	Bone Resorption, Osteoclastogenesis and Adalimumab	RheumatoId Arthritis	Drug: Adalimumab	Université de Sherbrooke	AbbVie	Recruiting	18 Years	N/A	All	120	Phase 4	Canada
717	NCT02350881	May 2013	19 October 2017	Mid-term Outcomes of First MTP Arthroplasty With Primus™ FGT Implant.	A Post-Market Observational Study to Evaluate Safety and Performance of Primus™ FGT Implant at a Minimum of 5 Years Follow-up	Hallux Limitus of Left Great Toe;Rheumatoid Arthritis;Arthritis of 1st Metatarsophalangeal Joint;Osteoarthritis;Bunion;Hallux Limitus of Right Great Toe	Device: Primus FGTI (Flexible Great toe Implant)	Tornier, Inc.		Not recruiting	18 Years	N/A	All	70	N/A	Italy
718	NCT02468791	May 2013	17 November 2015	MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab	Mabion SA		Recruiting	18 Years	80 Years	Both	863	Phase 3	Bosnia and Herzegovina;Georgia;Poland;Serbia;Ukraine
719	NCT04157010	May 2013	11 November 2019	Tocilizumab REMission in Early RA	Prospective, Single-centre, Open-Label, Randomised, Pilot Study Assessing the Changes in Expression of Janus Kinase/Signal Transducers and Activators of Transcription (JAK-STAT) and Speed & Depth of Remission Induced by Tocilizumab & Methotrexate Combination and Tocilizumab Monotherapy in Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Tocilizumab	University of Leeds	Hoffmann-La Roche	Not recruiting	18 Years	N/A	All	20	Phase 4	United Kingdom
720	EUCTR2012-004090-16-DE	23/04/2013	10 July 2015	Safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects of multiple rising subcutaneous doses of BI655064 in healthy volunteers and in rheumatoid arthritis patients with prior inadequate response to methotrexate therapy.	A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in healthy volunteers and in rheumatoid arthritis patients with prior inadequate response to methotrexate therapy	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: BI 655064 Pharmaceutical Form: Solution for injection Current Sponsor code: BI 655064 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Boehringer Ingelheim Pharma GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	106		Czech Republic;Poland;Spain;Netherlands;Germany;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
721	EUCTR2012-004342-14-LT	11/04/2013	28 August 2014	A Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs	A Phase 2/3 Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: VX-509 Product Code: VX-509 Pharmaceutical Form: Tablet INN or Proposed INN: VX-509 Current Sponsor code: VX-509 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Vertex Pharmaceuticals Incorporated		Not Recruiting			Female: yes Male: yes	40	Phase 2/3	United States;Estonia;Lithuania;Denmark;South Africa;Netherlands
722	NCT01758198	April 11, 2013	16 December 2017	Abatacept Post-marketing Clinical Study in Japan	A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate vs. Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Biological: Abatacept;Drug: Placebo matching with Abatacept;Drug: Methotrexate	Bristol-Myers Squibb	Ono Pharmaceutical Co. Ltd	Not recruiting	20 Years	N/A	All	405	Phase 4	Japan
723	EUCTR2011-004017-17-GB	08/04/2013	15 April 2013	Tocilizumab and Remission in early rheumatoid arthritis	Prospective, Single-centre, Open-Label, Randomised, Pilot Study Assessing the changes in expression of JAK-STAT and Speed & Depth of Remission Induced by Tocilizumab & Methotrexate Combination and Tocilizumab Monotherapy in Patients with Early Rheumatoid Arthritis (TREMERA). - TREMERA	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Product Name: Tocilizumab Product Code: RoActemra Pharmaceutical Form: Concentrate and solvent for solution for infusion	The University of Leeds		Authorised			Female: yes Male: yes	20		United Kingdom
724	EUCTR2012-003057-29-CZ	02/04/2013	12 January 2015	A multi-centre, randomised, double-blind multiple dose study of increasing doses of XmAb5871 in patients with Rheumatoid Arthritis.	A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS - XmAb®5871 Phase IIa, Ascending Multiple Dose Study in Rheumatoid Arthritis Patients	XmAb5871 is a humanized Fc engineered monoclonal antibody that binds to the human B cell restricted cell surface antigen CD19. It has already entered Phase 1 clinical development. The available evidence suggests that XmAb5871 is a potentially useful immunomodulatory antibody for therapy of B cell mediated human disease states such as rheumatoid arthritis. MedDRA version: 16.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: XmAb5871_10.0MG Product Code: XENP5871 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: XmAb®5871 Current Sponsor code: XENP5871 Other descriptive name: Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 9.0-11.0 Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Product Name: XmAb5871_3.0MG Product Code: XENP5871 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: XmAb®5871 Current Sponsor code: XENP5871 Other descriptive name: Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 9.0-11.0 Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Product Name: XmAb5871_1.0MG Product Code: XENP5871 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: XmAb®5871 Current Sponsor code: XENP5871 Other descriptive name: Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 9.0-11.0 Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Product Name: XmAb5871_0.3MG Product Code: XENP5871 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: XmAb®5871 Current Sponsor code: XENP5871 Other descriptive name: Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 9.0-11.0	Xencor Inc.		Not Recruiting			Female: yes Male: yes	58	Phase 2a	Hungary;Czech Republic;Slovakia
725	JPRN-JapicCTI-132121	01/4/2013	2 April 2019	Abatacept Post-marketing Clinical Study in Japan	A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate vs. Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Intervention name : Abatacept Dosage And administration of the intervention : 10 mg/kg IV / month Control intervention name : Placebo Dosage And administration of the control intervention : 0 mg/kg IV / month	Bristol-Myers Squibb K.K.	Ono Pharmaceutical Co.,LTD.		20		BOTH	400	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
726	JPRN-UMIN000009887	2013/04/01	2 April 2019	Associations between the initial concentration of serum TNF alpha and effects due to increasing a dose of Infliximab, and between effects of infliximab and the concentration of serum IL-6		Rheumatoid Arthritis	When 3mg/kg of infliximab brings poor results to RA patients, we will change a dose of infliximab according to the initial concentration of serum TNF alpha. If the initial concentration of serum TNF alpha is less than 1.1 pg/ml, we will raise the dose of infliximab to 6 mg/kg. When 3mg/kg of infliximab brings poor results to RA patients, we will change a dose of infliximab according to the initial concentration of serum TNF alpha. If the initial concentration of serum TNF alpha is more than 1.1 pg/ml, we will raise the dose of infliximab to 10 mg/kg.	Department of Orthopaedic surgery, Tohoku University Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	100	Not applicable	Japan
727	NCT01547091	April 2013	19 February 2015	Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis	Clinical Trial of Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation for Rheumatoid Arthritis-Phase I/II	Rheumatoid Arthritis	Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs);Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs);Biological: UC-MSC+DMARDS	Alliancells Bioscience Corporation Limited		Recruiting	18 Years	70 Years	Both	200	Phase 1/Phase 2	China
728	NCT01764997	April 2013	16 December 2017	An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate	A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Etanercept;Drug: Methotrexate;Drug: Placebo (for sarilumab);Drug: Placebo (for etanercept);Drug: Adalimumab	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	776	Phase 3	United States;Argentina;Australia;Brazil;Chile;Colombia;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic
729	NCT01850680	April 2013	19 February 2015	Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered Sarilumab in Japanese Patients With Rheumatoid Arthritis Receiving Concomitant Methotrexate	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: placebo;Drug: methotrexate;Drug: folic acid	Sanofi	Regeneron Pharmaceuticals	Not recruiting	20 Years	65 Years	Both	61	Phase 1	Japan
730	NCT01851278	April 2013	19 February 2015	Effectiveness Intraarticular Corticosteroid	Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose	Rheumatoid Arthritis	Drug: Triamcinolone hexacetonide	Federal University of São Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Recruiting	18 Years	65 Years	Both	60	N/A	Brazil
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
731	NCT01878123	April 2013	10 October 2016	Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis	A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: AMP-110;Other: Placebo	MedImmune LLC	Daiichi Sankyo Co., Ltd.;Daiichi Sankyo Co., Ltd.	Not recruiting	18 Years	75 Years	Both	26	Phase 1	United States
732	JPRN-UMIN000010286	2013/03/21	2 April 2019	Maintenance Trial by Orencia in Rheumatoid Arthritis		Rheumatoid Arthritis	Patients whose RA status is in low disease activity after 24 weeks of treatment with abatacept receive the reduced dosage of abatacept.	Hokkaido University Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	150	Not selected	Japan
733	EUCTR2012-005275-14-NO	19/03/2013	28 November 2016	Remission in rheumatoid arthritis – assessing withdrawal of disease-modifying antirheumatic drugs	Remission in rheumatoid arthritis – assessing withdrawal of disease-modifying antirheumatic drugs in a non-inferiority design - ARCTIC REWIND	Rheumatoid arthritis (RA) MedDRA version: 15.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Methotrexate Pfizer 2,5 mg tabletter Pharmaceutical Form: Tablet Trade Name: Methotrexate Pfizer 2,5 mg tabletter Pharmaceutical Form: Tablet Trade Name: Metex 50 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte Pharmaceutical Form: Injection Trade Name: Metex 50 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte Pharmaceutical Form: Injection Trade Name: Salazopyrin EN 500 mg enterotabletter Pharmaceutical Form: Tablet Trade Name: Salazopyrin EN 500 mg enterotabletter Pharmaceutical Form: Tablet Trade Name: Plaquenil 200 mg filmdrasjerte tabletter Pharmaceutical Form: Tablet Trade Name: Plaquenil 200 mg filmdrasjerte tabletter Pharmaceutical Form: Tablet Trade Name: Arava 20 mg filmdrasjerte tabletter Pharmaceutical Form: Tablet Trade Name: Arava 20 mg filmdrasjerte tabletter Pharmaceutical Form: Tablet Trade Name: ENBREL 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte. Pharmaceutical Form: Injection Trade Name: Cimzia 200 mg injeksjonsvæske, oppløsning Pharmaceutical Form: Injection Trade Name: Simponi 50 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte. Pharmaceutical Form: Injection Trade Name: Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning. Pharmaceutical Form: Infusion Trade Name: Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte Pharmaceutical Form: Injection	Diakonhjemmet Hospital AS		Authorised			Female: yes Male: yes		Phase 4	Norway
734	EUCTR2012-003644-71-ES	12/03/2013	5 August 2014	Randomized, Double-Blind, Placebo-Controlled Trial of etanercept plus methotrexate in monoclonal antibody (mAb) anti-TNF failure	A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Etanercept in Subjects with Rheumatoid Arthritis Who Have Had and Inadequate Response to Adalimumab or Infliximab Plus Methotrexate.	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	168		France;Hong Kong;Czech Republic;Spain;Australia;Israel;Chile;Russian Federation;Netherlands;Germany;Colombia
735	EUCTR2012-003629-40-CZ	11/03/2013	11 April 2016	An Efficacy And Safety Study of CNTO6785 In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis MedDRA version: 14.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: CNTO6785 Product Code: CNTO6785 Pharmaceutical Form: Lyophilisate for solution for injection INN or Proposed INN: CNTO6785 Current Sponsor code: CNTO6785 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Janssen-Cilag International NV		Not Recruiting			Female: yes Male: yes	250	Phase 2	Philippines;Czech Republic;Argentina;Thailand;Poland;Russian Federation;Colombia;China;India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
736	NCT01558089	March 2013	19 October 2017	Good EULAR Response In Patients With Early Rheumatoid Arthritis	Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece	Rheumatoid Arthritis	Drug: etanercept;Drug: methotrexate	Pfizer		Not recruiting	18 Years	N/A	All	76	N/A	Greece
737	NCT01715896	March 2013	19 October 2017	A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis	A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Golimumab 50 mg;Biological: Mavrilimumab 100 mg	MedImmune LLC		Not recruiting	18 Years	80 Years	All	215	Phase 2	Argentina;Colombia;Czech Republic;France;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;Turkey
738	NCT02843789	March 2013	19 February 2018	Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy	Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy	Arthritis, Rheumatoid	Drug: Tocilizumab	Centre Hospitalier Universitaire de Besancon		Not recruiting	18 Years	80 Years	All	109	Phase 4	France
739	EUCTR2012-002324-32-BE	25/02/2013	16 August 2016	A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease-Modifying Antirheumatic Drugs - RA - BEGIN	Moderately to severely active rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Pharmaceutical Form: Capsule INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Methotrexat HEXAL® 2,5 mg Tabletten Pharmaceutical Form: Capsule INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Methotrexate 2.5mg Tablets Pharmaceutical Form: Capsule INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Methotrexate 2.5 mg tablets Pharmaceutical Form: Capsule INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	550	Phase 3	Portugal;United States;Greece;Austria;Russian Federation;Italy;United Kingdom;India;Mexico;Canada;Argentina;Belgium;Brazil;South Africa;Germany;Japan;Korea, Republic of;Sweden
740	JPRN-UMIN000010126	2013/02/25	23 April 2019	Efficacy and safety of treatment with moderate doses of corticosteroid and immunosuppressants in rheumatoid arthritis patients with interstitial lung disease	Efficacy and safety of treatment with moderate doses of corticosteroid and immunosuppressants in rheumatoid arthritis patients with interstitial lung disease - Efficacy and safety of treatment with moderate doses of corticosteroid and immunosuppressants in RA-ILD	Interstitial lung disease related to rheumatoid arthritis	In cases with UIP/NSIP pattern ILD, treatment is started with prednisolone and tacrolimus. For safety concern, the doses of tacrolimus should not exceed the dose approved in Japan and are adjusted to maintain blood trough levels less than 10 ng/ml. Prednisolone is started at the dose of 0.5 mg/kg/day and continued at the initial dose through 2-4 weeks, then reduced by 5 mg every 2-4 weeks. After the dose of prednisolone reaches 15 mg/day, it is reduced by 2.5 mg. After the dose of prednisolone reaches 10 mg, it is reduced by 1 mg every 4 weeks. The dose of prednisolone should be tapered to achieve 0.2 mg/kg/day at week 24. Prednisolone should be maintained at least 5 mg/day until month 12. Then prednisolone can be either continued, reduced or stopped later on. In cases with OP pattern ILD, prednisolone is started, tapered and maintained as mentioned in cases with UIP/NSIP pattern ILD. Methotrexate is started after the dose of prednisolone reaches 0.3 to 0.4 mg/kg/day. Methotrexate is increased to the maximal tolerable dose, but should not exceed 16 mg/week. Methotrexate should be used following the guideline published by Japan College of Rheumatology. If methotrexate is not feasible by any reason, it can be substituted by tacrolimus and tacrolimus should be used as mentioned in UIP/NSIP pattern ILD cases.	Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University		Not Recruiting	20years-old	Not applicable	Male and Female	34	Not applicable	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
741	EUCTR2012-000609-58-BE	20/02/2013	17 August 2015	A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to anti-TNFa biologics	A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to anti-TNFa biologics	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: 0109-0012A 100 mg/ml Pharmaceutical Form: Solution for injection INN or Proposed INN: N/A Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: 0109-0012A 50 mg/ml Pharmaceutical Form: Solution for injection INN or Proposed INN: N/A Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: 0109-0012A 25 mg/ml Pharmaceutical Form: Solution for injection INN or Proposed INN: N/A Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	268	Phase 2b	United States;Spain;Ukraine;Russian Federation;Italy;United Kingdom;Hungary;Czech Republic;Mexico;European Union;Canada;Argentina;Belgium;Brazil;Germany
742	EUCTR2012-000610-11-BE	20/02/2013	17 August 2015	A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to Methotrexate	A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to Methotrexate	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: 0109-0012A 100 mg/ml Pharmaceutical Form: Solution for injection INN or Proposed INN: N/A Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: 0109-0012A 50 mg/ml Pharmaceutical Form: Solution for injection INN or Proposed INN: N/A Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: 0109-0012A 25 mg/ml Pharmaceutical Form: Solution for injection INN or Proposed INN: N/A Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	268	Phase 2b	United States;Spain;Ukraine;Russian Federation;Italy;Hungary;Czech Republic;Mexico;European Union;Canada;Argentina;Belgium;Brazil;Germany
743	EUCTR2012-003536-23-CZ	20/02/2013	4 August 2015	To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)	A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists - ASCERTAIN	Rheumatoid Arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 131.6- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 175- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: RoActemra 20 mg/ml concentrate for solution for infusion. Product Name: RoActemra Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab Other descriptive name: RoActemra Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	200		United States;Estonia;Finland;Spain;Israel;Russian Federation;Colombia;Italy;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Belgium;Poland;Brazil;Romania;Norway;Netherlands;Sweden
744	EUCTR2012-003724-20-HU	19/02/2013	19 January 2015	A study of IPI-145 or placebo in combination with methotrexate in patients with rheumatoid arthritis who are currently taking methotrexate.	A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone	Rheumatoid Arthritis MedDRA version: 17.0 Level: LLT Classification code 10042952 Term: Systemic rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: IPI 145 Pharmaceutical Form: Capsule CAS Number: 1201438-56-3 Other descriptive name: IPI-145 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Code: IPI 145 Pharmaceutical Form: Capsule CAS Number: 1201438-56-3 Other descriptive name: IPI-145 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Code: IPI 145 Pharmaceutical Form: Capsule CAS Number: 1201438-56-3 Other descriptive name: IPI-145 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Infinity Pharmaceuticals, Inc		Not Recruiting			Female: yes Male: yes	316	Phase 2	Serbia;Hungary;Mexico;Poland;Ukraine;Romania;Russian Federation;Bulgaria;Germany;Colombia;New Zealand
745	EUCTR2012-004090-16-ES	19/02/2013	10 July 2015	Safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects of multiple rising subcutaneous doses of BI655064 in healthy volunteers and in rheumatoid arthritis patients with prior inadequate response to methotrexate therapy.	A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in healthy volunteers and in rheumatoid arthritis patients with prior inadequate response to methotrexate therapy	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: BI 655064 Pharmaceutical Form: Solution for injection INN or Proposed INN: BI 655064 Current Sponsor code: BI 655064 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Boehringer Ingelheim España, S.A.		Not Recruiting			Female: yes Male: yes	130		Czech Republic;Spain;Australia;Netherlands;Germany;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
746	EUCTR2012-005370-62-IT	18/02/2013	7 January 2019	clinical study to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabetes.	“No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabetes; randomized, open label, parallel group, controlled clinical study.	rheumatoid arthritis and type 2 diabetes mellitus as comorbidity. MedDRA version: 14.1 Level: LLT Classification code 10037740 Term: RA System Organ Class: 100000004859 MedDRA version: 14.1 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: *KINERETSC 7SIR 100MG 0,67ML Pharmaceutical Form: Solution for injection INN or Proposed INN: ANAKINRA** CAS Number: 143090-92-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA		Not Recruiting			Female: yes Male: yes	200	Phase 4	Italy
747	JPRN-UMIN000010033	2013/02/14	2 April 2019	To investigate the efficacy of tocilizumab in RA patients with moderate disease activity under biologic therapy		Rheumatoid Arthritis	Tocilizumab (8 mg/kg of body weight) is to be infused every 4 weeks.	Daihei Kida		Not Recruiting	20years-old	75years-old	Male and Female	20	Not selected	Japan
748	EUCTR2011-006344-71-DE	08/02/2013	8 August 2016	Treatment with eggs of pig whipworm for patients with rheumatoid arthritis, who are insufficiently treated with methotrexate	Trichuris suis ova (TSO) as a additional therapy for rheumatoid arthritis patients with insufficient response to methotrexate. A prospective, double-blind, randomized, controlled monocenter study.	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Trichuris suis ova Product Name: Trichuris suis ova Product Code: TSO Pharmaceutical Form: Oral suspension INN or Proposed INN: Trichuris suis ova Current Sponsor code: TSO Other descriptive name: Pig whipworm eggs Concentration unit: thousand organisms thousand organisms Concentration type: equal Concentration number: 2500- Pharmaceutical form of the placebo: Oral suspension Route of administration of the placebo: Oral use	Immanuel Krankenhaus Berlin		Not Recruiting			Female: yes Male: yes	50	Phase 2	Germany
749	NCT01768858	February 5, 2013	11 February 2019	Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice	Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice	Crohn´s Disease;Ulcerative Colitis;Plaque Psoriasis;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: Adalimumab	AbbVie	Raffeiner GmbH	Not recruiting	18 Years	99 Years	All	96	Phase 2	Austria
750	EUCTR2011-003538-16-LT	04/02/2013	10 July 2015	To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)	A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders To Or Intolerant Of TNF-a Antagonists - SARIL-RA-TARGET	Rheumatoid Arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Sarilumab Product Code: SAR153191 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 131.6- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Sarilumab Product Code: SAR153191 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 175- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	522		United States;Portugal;Hong Kong;Taiwan;Slovakia;Ecuador;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Switzerland;Italy;India;Peru;Australia;Korea, Republic of;Guatemala;Turkey;Lithuania;Austria;Hungary;Czech Republic;Mexico;Canada;Argentina;Brazil;Poland;Romania;Germany;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
751	EUCTR2012-003194-25-LT	04/02/2013	27 October 2014	Bioequivalence trial of MabionCD20® (Mabion SA) compared to reference product: MabThera® (rituximab, Roche) in Patients with Rheumatoid Arthritis	Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (rituximab, Roche) in Patients with Rheumatoid Arthritis	Active Rheumatoid Arthritis MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: MabionCD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Current Sponsor code: MabionCD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Mabion S.A.		Not Recruiting			Female: yes Male: yes	863		Serbia;Poland;Ukraine;Croatia;Romania;Lithuania;Russian Federation;Georgia
752	NCT01724931	February 2013	1 June 2015	Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis	A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: LD-aminopterin;Drug: placebo	Syntrix Biosystems, Inc.		Not recruiting	18 Years	N/A	Both	175	Phase 2	Ukraine
753	NCT01742468	February 2013	19 October 2015	Intervention With Long-chain n-3 Polyunsaturated Fatty Acids From Microalgae Oil in Patients With Rheumatoid Arthritis	Intervention With Products Enriched With Long Chain n-3 Polyunsaturated Fatty Acids (n-3 LC-PUFA) From Microalgae Oil in Patients With Rheumatoid Arthritis - Influence on Disease Activity and Inflammation Status	Rheumatoid Arthritis	Dietary Supplement: long-chain n-3 PUFA;Dietary Supplement: sunflower oil	University of Jena	German Federal Ministry of Education and Research	Not recruiting	40 Years	80 Years	Both	38	N/A	Germany
754	NCT01712399	January 28, 2013	16 December 2017	A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis	An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Mavrilimumab 100 mg	MedImmune LLC		Not recruiting	19 Years	79 Years	All	409	Phase 2	Argentina;Bulgaria;Chile;Colombia;Czechia;Estonia;Germany;Greece;Hungary;Israel;Mexico;Poland;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;Czech Republic
755	EUCTR2012-002323-15-PL	25/01/2013	2 February 2015	A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors - RA - BEACON	Moderately to severely active rheumatoid arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	525	Phase 3	United States;Greece;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;India;France;Mexico;Canada;Argentina;Poland;Belgium;Croatia;Australia;Denmark;Netherlands;Germany;Japan;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
756	EUCTR2012-002535-28-GB	21/01/2013	11 December 2017	A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA) - R4-RA	A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA) - R4-RA	Rheumatoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion Trade Name: RoActemra Product Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion	Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)		Authorised			Female: yes Male: yes	160	Phase 4	Portugal;Spain;Belgium;Netherlands;Italy;United Kingdom
757	EUCTR2012-004631-22-BE	15/01/2013	7 October 2014	TapERA: Tapering Etanercept in Reumatoid Artritis.	TapERA: Maintaining remission in RA while tapering Etanercept. - TapERA	reumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Enbrel Product Name: Enbrel Product Code: EMEA/H/C000262 Pharmaceutical Form: Solution for injection in pre-filled syringe	University Hospitals Leuven		Authorised			Female: yes Male: yes			Belgium
758	NCT01715831	January 15, 2013	16 December 2017	A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488	A Multicenter, Open-Label, Single-Arm Extension Study to Describe the Safety of Tocilizumab Treatment In Brazilian Patients With DMARDs Refractory Rheumatoid Arthritis Which Completed Studies ML21530 and MA21488 and Presenting an Indication of Maintaining the Tocilizumab Treatment	Arthritis, Rheumatoid	Drug: DMARDs;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	26	Phase 4	Brazil
759	EUCTR2012-002322-73-HU	14/01/2013	7 December 2015	A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis.	A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy. - RA-BEAM	Moderately to severely active rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40/0.8- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	1280	Phase 3	United States;Portugal;Taiwan;Slovakia;Greece;Spain;Russian Federation;Israel;Switzerland;France;Australia;South Africa;Netherlands;Latvia;China;Korea, Republic of;Slovenia;Lithuania;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Romania;Croatia;Germany;Japan
760	EUCTR2012-002339-27-HU	14/01/2013	19 January 2015	A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis - RA - BUILD	Moderately to severely active rheumatoid arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: baricitinib Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	660	Phase 3	Portugal;Taiwan;Slovakia;Spain;Russian Federation;Italy;United Kingdom;India;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Romania;Croatia;Germany;Japan;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
761	ChiCTR-TRC-13002981	2013-01-07	18 April 2017	Effectiveness and safety of Chinese herbal medicine in low responders in patient population of rheumatoid arthritis under MTX-based conventional therapy	Effectiveness and safety of Chinese herbal medicine in low responders in patient population of rheumatoid arthritis under MTX-based conventional therapy	rheumatoid arthritis;M06.991	A:GTT tablets, 10 mg 3 times a day after meals. Yi Shen Juan Bi (YSJB) ,1 pocket (8 g) 3 times a day after meals;B:Methotrexate (MTX)10 mg/week and Sulfasalazine (SSZ),at an initial dose of 0.5 g three times a day in the first week, from the second week the dose was 1.0g twice a day;	Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences		Not Recruiting	18	70	Both	A:110;B:110;	Post-market
762	NCT02089087	January 7, 2013	15 April 2019	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients	A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Biological: CFZ533;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	75	Phase 1	United States;Taiwan
763	ChiCTR-TRC-13003948	2013-01-01	18 April 2017	The evaluation of clinical curative effect of 'supplying of shen and nourishing sui' law of electroacupuncture combined with ZeLing joint swelling mixture in the treatment of rheumatoid arthritis with yin-deficiency of liver and kidney pattern	The evaluation of clinical curative effect of 'supplying of shen and nourishing sui' law of electroacupuncture combined with ZeLing joint swelling mixture in the treatment of rheumatoid arthritis with yin-deficiency of liver and kidney pattern	rheumatoid arthritis	Control:Methotrexate 10mg qw PO + Leflunomide 10mg qd PO ;EA combined with medicine group:M+L+SEA+ZJSM ;	Institute of Acupuncture-Moxibustion and Meridian, Shanghai University of Traditional Chinese Medicine		Not Recruiting	18	70	Both	Control:60;EA combined with medicine group:60;	Other	China
764	JPRN-UMIN000007404	2013/01/01	2 April 2019	Open-label, multicenter, randomized controlled trials, for comparing remission induction rate of a dose-escalation therapy of methotrexate and an additional combination therapy with bucillamine for naive patients to over 8 mg/weekly of methotrexate.		Rheumatoid arthritis	Dose escalation of methotrexate Concomitant therapy of methotrexate and bucillamine	KONAMON Study Group		Recruiting	Not applicable	Not applicable	Male and Female	90	Not applicable	Japan
765	NCT01965132	January 1, 2013	18 June 2018	Korean College of Rheumatology Biologics Registry	Korean College of Rheumatology Biologics Registry	Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: Biologic DMARD	Seoul National University Hospital		Recruiting	18 Years	N/A	All	3500	Phase 3	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
766	NCT01389388	January 2013	25 May 2015	Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease	Cholesterol Plaques in Carotid and Coronary Arteries and the Effect of Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases	Carotid Artery Plaque;Ankylosing Spondylitis;Rheumatoid Arthritis	Drug: Rosuvastatin	Diakonhjemmet Hospital		Not recruiting	35 Years	80 Years	Both	114	N/A	Norway
767	NCT01721044	January 2013	30 September 2019	A Moderate to Severe Rheumatoid Arthritis Study	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors	Rheumatoid Arthritis	Drug: Placebo;Drug: Baricitinib;Drug: cDMARD	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	527	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;Croatia;India
768	NCT01754935	January 2013	19 February 2015	A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX-509 Using Magnetic Resonance Imaging and Arthroscopic Biopsies in Subjects With Active Rheumatoid Arthritis on Stable Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: VX-509;Drug: VX-509 matching placebo	Vertex Pharmaceuticals Incorporated		Not recruiting	18 Years	65 Years	Both	43	Phase 2	United States;Denmark;Estonia;Lithuania;Netherlands;South Africa
769	NCT01765478	January 2013	25 May 2015	Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers	A Phase1 Study, to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered HM71224 in Healthy, Adult Male Volunteers	Rheumatoid Arthritis	Drug: HM71224 single ascending dose;Drug: HM71224 food effect;Drug: HM71224 Multiple ascending dose	Hanmi Pharmaceutical Company Limited		Not recruiting	18 Years	65 Years	Male	62	Phase 1	Netherlands
770	NCT01767844	January 2013	19 February 2015	Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients?	Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients? A Randomised Controlled Pilot Trial	Rheumatoid Arthritis	Dietary Supplement: Creatine;Dietary Supplement: Placebo	Bangor University		Not recruiting	18 Years	N/A	Both	43	N/A	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
771	NCT01793519	January 2013	11 November 2019	Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis	Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical Trial	Rheumatoid Arthritis	Drug: Etanercept;Drug: Infliximab;Drug: Adalimumab;Drug: Placebo	Georgetown University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);University of Maryland, College Park;Washington D.C. Veterans Affairs Medical Center;Washington Hospital Center;Patient-Centered Outcomes Research Institute;Arthritis and Pain Associates of PG County;Arthritis & Rheumatism Associates, P.C.;Rheumatology Associates of Baltimore, L.L.C.;The Arthritis Clinic of Northern Virginia, P.C.;Arthritis and Rheumatic Disease Associates, P.C.	Recruiting	18 Years	N/A	All	290	Phase 4	United States
772	EUCTR2012-002323-15-IT	18/12/2012	14 September 2015	A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors - RA - BEACON	Moderately to severely active rheumatoid arthritis MedDRA version: 14.1 Level: SOC Classification code 10028395 Term: Musculoskeletal and connective tissue disorders System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: BARICITINIB Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: Baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: BARICITINIB Product Code: LY3009104 Pharmaceutical Form: Tablet Current Sponsor code: LY3009104 Other descriptive name: Baricitinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	ELI LILLY AND COMPANY		Not Recruiting			Female: yes Male: yes	525	Phase 3	United States;Greece;Spain;Turkey;Austria;Israel;United Kingdom;Italy;India;Mexico;Canada;Argentina;Belgium;Poland;Croatia;Australia;Netherlands;Japan;Korea, Republic of
773	JPRN-UMIN000009425	2012/12/06	2 April 2019	A validity inspection study of the treat-to-target strategy with golimumab for the treatment of rheumatoid arthritis patient		Rheumatoid Arthritis	The dose of golimumab should be fixed as 50 mg/month for all period. Treat-to-target strategy might be achieved by MTX or other DMARDs for one year. The goal of treatment is low disease activity. Treat-to-target strategy will be started with 50 mg of golimumab for first 3 months and then 100 mg golimumab can be used for tight control of rheumatoid arthritis to achieve low disease activity (LDA). Also MTX or other DMARDs might be used for tight control. If the LDA is achieved, reduction of dose from 100 to 50 mg/month is allowed. Total period is one year. Treat-to-target strategy will be started with 100 mg of golimumab for first 3 months. If the LDA is achieved, reduction of dose from 100 to 50 mg/month is performed. If not, physicians should control the disease activity using MTX or other DMARDs. Total period is one year.	Osaka City University Medical School		Recruiting	20years-old	Not applicable	Male and Female	150	Phase 4	Japan
774	NCT01491815	December 2012	18 December 2018	Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction	A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment	Rheumatoid Arthritis	Drug: Non-biological DMARD's;Biological: Cimzia;Biological: Orencia;Biological: RoActemra	Karolinska Institutet		Recruiting	18 Years	N/A	All	800	Phase 4	Sweden
775	NCT01717846	December 2012	23 May 2016	Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis	In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis	Apoptotic DNA Damage;Rheumatoid Arthritis;T-cell Lymphocytosis	Drug: Group 1 or Orencia treated group;Other: Group 2 (DMARDS treated group)	University of California, Los Angeles	Bristol-Myers Squibb	Not recruiting	18 Years	85 Years	Both	0	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
776	NCT01721057	December 2012	30 September 2019	A Study in Moderate to Severe Rheumatoid Arthritis Participants	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo;Drug: Baricitinib;Drug: cDMARD	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	684	Phase 3	United States;Argentina;Australia;Belgium;Canada;Croatia;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;Czech Republic
777	NCT01752855	December 2012	19 October 2017	Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab	A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects Who Completed Preceding Study M13-390 With Adalimumab	Rheumatoid Arthritis	Biological: New formulation adalimumab	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	N/A	All	88	Phase 2	United States;Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia
778	NCT01759030	December 2012	16 December 2017	Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis	Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies	Rheumatoid Arthritis	Drug: Rituximab	Biocad		Not recruiting	18 Years	80 Years	All	181	Phase 3	Belarus;India;Russian Federation;Ukraine;Colombia
779	NCT01770106	December 2012	19 February 2015	RA Denosumab on Bone Microstructure Study	Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture in Rheumatoid Arthritis Females With Low Bone Mass: A Randomized Controlled Trial	Rheumatoid Arthritis	Drug: Denosumab;Drug: Alendronate	Chinese University of Hong Kong		Not recruiting	18 Years	80 Years	Female	40	Phase 4	Hong Kong
780	JPRN-UMIN000011181	2012/11/19	2 April 2019	Continuous epidural infusion versus periarticular multimodal drug injection in bilateral simultaneous total knee arthroplasty: a randomized controlled trial		Osteoarthritis of knee, rheumatoid arthritis	A continuous epidural infusion containing ropivacaine and morphine for pain after simultaneous bilateral total knee arthroplasty A periarticular multimodal drug injection including ropivacaine, morphine, bosmin, methylprednisolone, and ketoprofen for pain after simultaneous bilateral total knee arthroplasty	Nekoyama miyao hospital		Not Recruiting	18years-old	Not applicable	Male and Female	60	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
781	EUCTR2012-001618-40-CZ	05/11/2012	6 January 2015	Evaluation of the blood concentration of Tabalumab after the administration of Tabalumab using prefilled syringe or auto-injector in patients with Rheumathoid Arthritis that have not responded correctly to treatment with Methotrexate.	Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate.	Rheumatoid Arthritis MedDRA version: 14.1 Level: LLT Classification code 10042952 Term: Systemic rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: tabalumab Product Code: LY2127399 Pharmaceutical Form: Solution for injection Other descriptive name: TABALUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90-	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	180		United States;Czech Republic;Argentina;Poland;Russian Federation
782	EUCTR2012-001760-30-IT	05/11/2012	7 January 2013	Evaluation effects of treatment with an inhibitor of the receptor of a protein (interleukin-6 IL-6)involved in inflammatory process, on the clinical response and on the changes from baseline in the biomarkers in patients with rheumatoid arthritis (RA)not responding adequately to Disease-modifying antirheumatic drugs (DMARDs) and/or to a first biological agent.	Evaluation effects of treatment with IL-6R inhibitor on clinical response and biomarkers in patients with rheumatoid arthritis (RA) not responding to DMARDs and/or a first biological agent.	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	OSSERVATORIO EPIDEMIOLOGICO GISEA		Authorised			Female: yes Male: yes			Italy
783	EUCTR2012-000609-58-GB	01/11/2012	28 February 2019	A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to anti-TNFa biologics	A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to anti-TNFa biologics	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: 0109-0012A 100 mg/ml Pharmaceutical Form: Solution for injection Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: 0109-0012A 50 mg/ml Pharmaceutical Form: Solution for injection Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: 0109-0012A 25 mg/ml Pharmaceutical Form: Solution for injection Current Sponsor code: NNC0109-0012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	268	Phase 2	United States;Spain;Ukraine;Russian Federation;Italy;United Kingdom;Hungary;Czech Republic;European Union;Mexico;Canada;Argentina;Brazil;Belgium;Germany
784	JPRN-UMIN000009088	2012/11/01	2 April 2019	Bio Logic MateTM clinical performance test for IFX Efficacy prediction		rheumatoid arthritis	IFX plus methotrexate	Bio Logic Mate Study Group		Not Recruiting	20years-old	75years-old	Male and Female	150	Not selected	Japan
785	NCT01689532	November 2012	19 October 2017	A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine	A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously as Monotherapy, in Japanese Subjects With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine	Arthritis, Rheumatoid	Drug: Sirukumab 100 mg;Drug: Sirukumab 50 mg;Drug: Placebo	Janssen Pharmaceutical K.K.	GlaxoSmithKline	Not recruiting	20 Years	N/A	All	122	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
786	NCT01709760	November 2012	11 June 2018	A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: ENIA11;Drug: Placebo	Mycenax Biotech Inc.		Not recruiting	20 Years	N/A	All	91	Phase 3	Taiwan
787	NCT01711359	November 2012	30 September 2019	A Study in Participants With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Baricitinib;Drug: Methotrexate;Drug: Baricitinib Placebo;Drug: MTX Placebo;Drug: Folic Acid	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	588	Phase 3	United States;Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Puerto Rico;Russian Federation;South Africa;Sweden;United Kingdom
788	NCT01725230	November 2012	19 February 2015	Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib	An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily	Rheumatoid Arthritis	Drug: Fostamatinib;Drug: Rosuvastatin;Drug: Simvastatin	AstraZeneca		Not recruiting	18 Years	55 Years	Both	42	Phase 1	United States
789	NCT01741493	November 2012	16 December 2017	A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494	A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494	Rheumatoid Arthritis	Drug: ABT-494;Drug: Placebo;Drug: Tofacitinib	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	75 Years	All	67	Phase 1	United States
790	NCT01749787	November 2012	19 February 2015	Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis	A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: PRTX-100 at 1.5 mcg/kg;Drug: PRTX-100 at 3.0 mcg/kg;Drug: PRTX-100 at 6.0 mcg/kg;Drug: PRTX-100 at 12.0 mcg/kg;Drug: PRTX-100 at 240 mcg;Drug: Placebo;Drug: PRTX-100 at 420 mcg	Protalex, Inc.		Not recruiting	18 Years	N/A	Both	61	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
791	NCT01679951	October 31, 2012	25 March 2019	A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate	A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Dose Range Finding Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: JNJ-38518168 (3 mg);Drug: JNJ-38518168 (10 mg);Drug: JNJ-38518168 (30 mg);Drug: Methotrexate	Janssen Research & Development, LLC		Not recruiting	18 Years	80 Years	All	272	Phase 2	United States;Argentina;Chile;Colombia;Czechia;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;Czech Republic
792	NCT01636843	October 30, 2012	17 September 2018	A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate	A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate	Inflammation;Rheumatoid Arthritis	Drug: NNC0109-0012;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	All	298	Phase 2	United States;Argentina;Belgium;Brazil;Czechia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Spain;Ukraine;Czech Republic
793	NCT01741688	October 26, 2012	16 December 2017	An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis	A Multi-National, Multi-Center Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab	Rheumatoid Arthritis	Biological: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	16	N/A	Peru
794	EUCTR2010-021146-22-GB	23/10/2012	29 October 2012	Alemtuzumab and rheumatoid arthritis - a study to look at the function of the immune system	Alemtuzumab and rheumatoid arthritis - an immunisation study - Alemtuzumab and rheumatoid arthritis - an immunisation study	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; manufacturerd by Cambridge Therapeutic Antibody Centre, Burroughs Wellcome, Glaxo Wellcome) Product Name: Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)	The Newcastle upon Tyne Hospitals NHS Foundation Trust		Authorised			Female: yes Male: yes			United Kingdom
795	NCT01590966	October 18, 2012	2 September 2019	Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFa in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis	Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFa in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis	Axial and Peripheral Spondyloarthritis;Rheumatoid Arthritis	Drug: administration of Cimzia®;Drug: Immunoscintigraphy with radiolabeled Cimzia®.	University Hospital, Ghent	UCB Pharma SA	Not recruiting	18 Years	70 Years	All	41	Phase 3	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
796	NCT01636557	October 11, 2012	16 December 2017	A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis	A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Sirukumab;Drug: Midazolam;Drug: Warfarin;Drug: Vitamin K;Drug: Omeprazole;Drug: Caffeine	Janssen Research & Development, LLC		Not recruiting	18 Years	65 Years	All	12	Phase 1	Germany;Korea, Republic of;Moldova, Republic of;South Africa
797	NCT01736189	October 11, 2012	15 July 2019	Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice	Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice (Combo Study; Adalimumab With High Dose MTX)	Rheumatoid Arthritis	Drug: Adalimumab	AbbVie (prior sponsor, Abbott)		Not recruiting	16 Years	99 Years	All	346	N/A	Japan
798	JPRN-JapicCTI-132091	01/10/2012	2 April 2019	A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFalpha Agents	A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFalpha Agents	Rheumatoid Arthritis	Intervention name : AIN457 INN of the intervention : secukinumab Dosage And administration of the intervention : subcutaneously 75mg, 150mg Control intervention name : null	Novartis Pharma K.K.			18		BOTH	234	Phase 3
799	JPRN-UMIN000008812	2012/10/01	2 April 2019	Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)		Rheumatoid arthritis	tocilizumab monotherapy	Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity		Not Recruiting	16years-old	80years-old	Male and Female	40	Not selected	Japan
800	JPRN-UMIN000010315	2012/10/01	2 April 2019	Prediction of the recurrence after adalimumab discontinuation by using ultrasound assessment		rheumatoid arthritis	In patients with clinical remission by adalimumab (DAS28-CRP <2.6) maintained over 24 weeks, to stop the Adalimumab.	Osaka City University Medical School	Metabolism, Endocrinology, and Molecular Medicine. Osaka City University Graduate School of Medicine. The center for rheumatic diseases. Nara Medical University. Rheumatology. Kitano Hospital.	Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
801	JPRN-UMIN000018101	2012/10/01	2 April 2019	Venous thromboembolism after total knee arthroplasty and high tibial osteotomy with / without edxaban: a prospective study		Osteoarthritis, rheumatoid arthritis, osteonecrosis	To determine whether postoperative VTE is present and to evaluate the efficacy and safety of edoxaban for the prevention of patients undergoing TKA, OWHTO, or CWHTO, angiography of the pulmonary artery and deep veins of the lower limbs is performed in all patients on postoperative day 7. Levels of coagulation and fibrinolysis markers are evaluated on the preoperative day and on postoperative days 1, 3, 7, and 14.	Yokohama City University School of Medicine		Recruiting	Not applicable	Not applicable	Male and Female	100	Not selected	Japan
802	NCT01609205	October 2012	11 June 2018	Doppler Evaluation in RA Patients After Adalimumab.	Doppler Quantitative Evaluation and Follow-up Over 12 Months in RA Patients With Moderate and High Disease Activity Who Are Candidates for Biologic add-on Therapy With Adalimumab	Rheumatoid Arthritis	Biological: Adalimumab	Hamed Rezaei	Abbott	Not recruiting	18 Years	N/A	All	60	Phase 4	Sweden
803	NCT01619176	October 2012	19 February 2015	Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood	Non Inferiority Trial for the Study of Acupuncture on Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: methotrexate;Drug: non-steroidal anti-inflammatory drug (NSAID);Drug: leflunomide;Procedure: Acupuncture	Chinese Academy of Sciences	Shanghai GuangHua Hospital of integrated traditional and western medicine	Not recruiting	18 Years	65 Years	Female	15	N/A	China
804	NCT01709578	October 2012	16 December 2017	To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)	A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-a Antagonists	Rheumatoid Arthritis	Drug: Sarilumab;Drug: placebo;Drug: hydroxychloroquine;Drug: methotrexate;Drug: sulfasalazine;Drug: leflunomide	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	546	Phase 3	United States;Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czechia;Ecuador;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;Czech Republic;Hong Kong
805	NCT01710358	October 2012	30 September 2019	A Study in Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Baricitinib;Drug: Methotrexate;Drug: Adalimumab Placebo;Drug: Baricitinib Placebo	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	1307	Phase 3	United States;Argentina;Belgium;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;Czech Republic;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
806	NCT01730456	October 2012	14 November 2016	A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926	A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	13	Phase 3	Macedonia, The Former Yugoslav Republic of
807	NCT01734993	October 2012	19 October 2017	A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).	A Multicenter, Open-Label Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	11	Phase 3	France
808	NCT01789151	October 2012	7 November 2016	99m-Technetium- Glucosamine in Arthritis	99mTc-labelled D-Glucosamine in the Evaluation of Disease Activity in Patients With Degenerative and Inflammatory Rheumatic Conditions	Rheumatoid Arthritis;Ankylosing Spondylitis	Device: Technetium labelled glucosamine	University of Sydney	AbbVie	Not recruiting	18 Years	90 Years	Both		N/A	Australia
809	NCT01871961	October 2012	23 March 2015	Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient	Evaluation of Rheumatoid Arthritis Patient Performance Using the Metoject® Prefilled Pen (Methotrexate 50 mg/mL, Prefilled Pen) for Subcutaneous Injection and Subsequent Pharmacokinetic Assessment of Drug Delivery	Rheumatoid Arthritis (RA)	Drug: Methotrexate (Metoject® prefilled pen)	medac GmbH	PPD (CRO)	Not recruiting	16 Years	N/A	Both	105	Phase 1	United States
810	NCT02915094	October 2012	16 December 2017	Kineret in the Treatment of Rheumatoid Arthritis	Kineret in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Anakinra	Swedish Orphan Biovitrum		Not recruiting	18 Years	N/A	All	30	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
811	JPRN-jRCTs032180245	28/09/2012	7 October 2019	Wear of 32mm OXINIUM head on XLPE: Multicenter RCT Study	Wear of 32mm Oxidized Zirconium (OXINIUM) head on Cross-linked Polyethylene in Primary Total Hip Arthroplasty: Multicenter Randomized controlled Trial Study - 32mmOX multicenter study	Hip osteoarthritis, Rheumatoid arthritis Hip osteoarthritis, Rheumatoid arthritis	Arm A: Oxidized zirconium alloy (OXINIUM) femoral head Arm B: Standard cobalt chromium alloy head Random allocation is registered automatically at the UMIN Internet Medical Research Data Center (INDICE)	Masanobu Saito		Not Recruiting	>= 20age old	<= 75age old	Both	352	Phase 4	none
812	EUCTR2011-006058-94-CZ	26/09/2012	11 April 2016	Secukinumab efficacy and safety study in patients with active Rheumatoid Arthritis (RA) and an Inadequate response to anti-TNFa agents	A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety, tolerability and usability up to 5 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents - REASSURE 2	Rheumatoid arthritis MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB CAS Number: 1229022-83-6 Current Sponsor code: AIN457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB CAS Number: 1229022-83-6 Current Sponsor code: AIN457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	234	Phase 3	Portugal;Panama;United States;Ecuador;Greece;Guatemala;Colombia;Italy;India;Czech Republic;Argentina;Brazil;Dominican Republic;South Africa;Germany;Japan;Korea, Republic of
813	NCT01711814	September 26, 2012	3 June 2019	A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	A Phase 2 Open-Label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	Arthritis, Rheumatoid	Drug: peficitinib	Astellas Pharma Global Development, Inc.	Janssen Biotech, Inc.	Not recruiting	18 Years	N/A	All	611	Phase 2	United States;Belgium;Bulgaria;Colombia;Czechia;Hungary;Mexico;Poland;Czech Republic
814	JPRN-UMIN000015297	2012/09/19	23 April 2019	The feasibility study of accelated infliximab infusion from initial administration	The feasibility study of accelated infliximab infusion from initial administration - The feasibility study of accelated infliximab infusion from initial administration	patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)	Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable patient continue to receive more five treatment with 60min procedure.	Chiba University Hospital		Recruiting	20years-old	70years-old	Male and Female	54	Phase 2	Japan
815	EUCTR2011-002894-48-GB	14/09/2012	30 April 2019	Efficacy, pharmacokinetics, and safety of BI 695500 in patients with rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial	Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial.	Moderately to severely active Rheumatoid Arthritis that has had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor MedDRA version: 17.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: BI 695500 Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: BI 695500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera 500 mg concentrate for solution for infusion Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rituxan Product Name: Rituxan Pharmaceutical Form: Injection INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Boehringer Ingelheim International GmbH		Not Recruiting			Female: yes Male: yes	300	Phase 1;Phase 3	Bulgaria;Germany;Norway;Belgium;Brazil;Poland;Argentina;Canada;Mexico;Hungary;United Kingdom;Guatemala;Netherlands;South Africa;Peru;France;Italy;Chile;Russian Federation;Ireland;Ukraine;Spain;Greece;Estonia;United States;Portugal;Serbia;New Zealand;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
816	JPRN-JapicCTI-132051	12/9/2012	23 April 2019	Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis	Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis	Rheumatoid Arthritis	Intervention name : iguratimod (Careram) Dosage And administration of the intervention : Oral	Eisai Co., Ltd.					BOTH	2000	NA
817	JPRN-JapicCTI-152782	12/9/2012	23 April 2019	Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis	Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis	Rheumatoid Arthritis	Intervention name : Kolbet INN of the intervention : Iguratimod Dosage And administration of the intervention : Oral	Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)					BOTH	2000	NA
818	NCT01694264	September 1, 2012	16 December 2017	Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFa	A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFa Treatment	Chronic Hepatitis B;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Juvenile Idiopathic Arthritis	Drug: Entecavir;Drug: Placebo	Seoul National University Hospital	Konkuk University Medical Center;Kyungpook National University;Kyunghee University Medical Center;Kyung Hee University Hospital at Gangdong;Gachon University Gil Medical Center;Daegu Catholic University Medical Center;Eulji University Hospital;SMG-SNU Boramae Medical Center;The Catholic University of Korea;Severance Hospital;Ajou University School of Medicine;Ewha Womans University Mokdong Hospital;Inha University Hospital;Chonnam National University Hospital;Chonbuk National University Hospital;Chungnam National University Hospital;Hallym University Medical Center;Hanyang University;Dong-A University;Korea University Guro Hospital	Not recruiting	16 Years	85 Years	All	43	Phase 3	Korea, Republic of
819	NCT01635686	September 2012	19 February 2015	Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers	A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers	Rheumatoid Arthritis	Drug: DWP422 25mg;Drug: ENBREL 25MG PFS INJ.	Daewoong Pharmaceutical Co. LTD.		Not recruiting	20 Years	45 Years	Male	38	Phase 1	Korea, Republic of
820	NCT01640938	September 2012	17 November 2015	Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis	A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Secukinumab (AIN457)	Novartis Pharmaceuticals		Not recruiting	18 Years	N/A	Both	259	Phase 3	United States;Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;Romania
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
821	NCT01676701	September 2012	11 June 2018	Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)	Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Tabalumab Auto-Injector;Drug: Tabalumab Prefilled Syringe	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	8	Phase 3	United States;Argentina;Czechia;Poland;Puerto Rico;Russian Federation;Czech Republic
822	EUCTR2011-006070-73-DE	28/08/2012	27 January 2014	Evaluation of the Effect of Fostamatinib Dosed at 100mg twice a Day on Blood Pressure when Walking, Moving Around and Living Normal Daily Life in Patients with Rheumatoid Arthritis	A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Arthritis - Oskira ABPM	Rheumatoid arthritis MedDRA version: 15.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Fostamatinib 50 mg blue film-coated tablet Product Code: R935788 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib disodium CAS Number: 914295-16-2 Current Sponsor code: R935788 sodium Other descriptive name: R788 sodium hexahydrate, RIG2-01, RIG-G Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	130		United States;Czech Republic;Mexico;Argentina;Brazil;Poland;Ukraine;Peru;Bulgaria;South Africa;Germany
823	EUCTR2012-000535-36-BE	28/08/2012	21 August 2017	A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.	A multicenter, randomized, double-blind, double dummy, parallel design study to assess pharmacokinetic, pharmacodynamic, safety and immunogenicity of a new adalimumab formulation compared to the currently approved adalimumab formulation in subjects with active rheumatoid arthritis.	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Adalimumab Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: Adalimumab Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Abbott GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	100	Phase 2	United States;Czech Republic;Slovakia;Puerto Rico;Poland;Belgium;Romania;Germany
824	NCT01643928	August 16, 2012	16 December 2017	Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)	Extension Study Evaluating Treatment With Pf-05280586 Versus Rituximab In Subjects With Active Rheumatoid Arthritis Who Have Participated In Other Pf-05280586 Clinical Trials	Rheumatoid Arthritis	Biological: Rituximab-Pfizer (PF-05280586) x 3 courses;Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses;Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses	Pfizer		Not recruiting	18 Years	N/A	All	185	N/A	United States;Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;United Kingdom;Switzerland;Ukraine
825	NCT01604343	August 2012	9 January 2017	A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy	Arthritis, Rheumatoid	Drug: Placebo;Drug: Sirukumab	Janssen Research & Development, LLC	GlaxoSmithKline	Not recruiting	18 Years	N/A	Both	1670	Phase 3	United States;Bulgaria;Canada;Chile;Colombia;Croatia;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;Argentina;Brazil;India;Peru
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
826	NCT01606761	August 2012	2 November 2015	A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy	Arthritis, Rheumatoid	Drug: Placebo;Drug: Sirukumab	Janssen Research & Development, LLC	GlaxoSmithKline	Not recruiting	18 Years	N/A	Both	879	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Taiwan;United Kingdom;Brazil;China
827	NCT01636817	August 2012	17 September 2018	A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics	A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics	Inflammation;Rheumatoid Arthritis	Drug: NNC0109-0012;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	All	239	Phase 2	United States;Argentina;Belgium;Brazil;Czechia;France;Germany;Hungary;Italy;Mexico;Poland;Spain;United Kingdom;Czech Republic
828	NCT01652937	August 2012	19 February 2015	BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs	A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BIIB057 in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: BIIB057;Drug: Placebo	Biogen Idec		Not recruiting	18 Years	N/A	Female	0	Phase 2	Canada
829	NCT01662063	August 2012	19 October 2017	A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)	A Multicenter Open-Label, Long-Term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Genentech, Inc.		Not recruiting	18 Years	N/A	All	218	Phase 3	United States;Puerto Rico
830	NCT01706926	August 2012	19 October 2017	A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis	A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Mavrilimumab 30 mg;Biological: Mavrilimumab 100 mg;Biological: Mavrilimumab 150 mg;Other: Placebo	MedImmune LLC	MedImmune Ltd	Not recruiting	18 Years	80 Years	All	420	Phase 2	Argentina;Bulgaria;Chile;Colombia;Czech Republic;Estonia;Germany;Hungary;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;France;Mexico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
831	NCT01746680	August 2012	24 August 2015	Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis	Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tacrolimus with Methotrexate	Chong Kun Dang Pharmaceutical		Not recruiting	20 Years	N/A	Both	111	Phase 4	Korea, Republic of
832	NCT01870908	August 2012	12 October 2015	Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients	Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biological Agents in Daily Clinical Settings	Rheumatoid Arthritis	Drug: tacrolimus;Drug: biological agents	Astellas Pharma Inc		Not recruiting	N/A	N/A	Both	664	N/A	Japan
833	JPRN-UMIN000008572	2012/07/31	2 April 2019	The Kitasato institute Non-inferiorty trial of Etanercept and Tacrolimus ,the combined therapy with Methotrexate in rhumatoid arthritis patients		Rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX)	Tacrolimus group patients receive daily the optimal dosage of tacrolimus within the range between 1.5-3.0 mg/day for 52 weeks. Etanercept group patient receive weekly subcutaneous injection of etanercept 50mg for 52 weeks.	Department of Rheumatology and infectious disease, Kitasato university school of medicine	1)Kitasato institute medical center hospital 2)Kitasato institute hospital 3)Ishikawa internal medicine clinic	Recruiting	20years-old	70years-old	Male and Female	80	Not applicable	Japan
834	NCT01705730	July 31, 2012	10 September 2018	A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy	Mon-ACT: A Multi-center, Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab in Monotherapy	Rheumatoid Arthritis	Drug: tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	71	N/A	Belgium
835	EUCTR2011-005648-93-EE	19/07/2012	11 April 2016	A clinical study to investigate the safety of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.	An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects with Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: mavrilimumab Product Code: CAM-3001 Pharmaceutical Form: Solution for injection INN or Proposed INN: mavrilimumab CAS Number: 1085337-57-0 Current Sponsor code: CAM-3001 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	MedImmune Ltd		Not Recruiting			Female: yes Male: yes	400		Portugal;Serbia;Estonia;Greece;Spain;Ukraine;Chile;Russian Federation;United Kingdom;France;Hungary;Czech Republic;Mexico;Argentina;South Africa;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
836	JPRN-UMIN000010902	2012/07/11	2 April 2019	A randomized controlled trial comparing epidural anesthesia and periarticular multimodal drug injection for total knee arthroplasty		Osteoarthritis of knee, rheumatoid arthritis, avascular necrosis	An epidural anesthesia containing 2mg/ml ropivacaine 100ml and 10mg/ml morphine 0.8ml for pain after total knee arthroplasty A periarticular multimodal drug injection including 7.5mg/ml ropivacaine, 10mg/ml morphine 0.8ml, bosmin 0.3mg, methylprednisolone 40mg, and ketoprofen 50mg for pain after total knee arthroplasty	Nekoyama miyao hospital		Not Recruiting	18years-old	Not applicable	Male and Female	100	Not selected	Japan
837	EUCTR2011-005376-42-LV	06/07/2012	15 July 2013	A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC0114-0006 in subjects with active rheumatoid arthritis	A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC0114-0006 in subjects with active rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: 0114-0006B Pharmaceutical Form: Powder for solution for infusion Current Sponsor code: NNC0114-0006 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	60		Serbia;Hungary;Spain;Poland;Bulgaria;Russian Federation;Latvia
838	NCT01554696	July 6, 2012	11 June 2019	A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate	A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo Controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients Who Have Had an Inadequate Response to Methotrexate	Arthritis, Rheumatoid	Drug: peficitinib;Drug: Placebo;Drug: methotrexate	Astellas Pharma Inc		Not recruiting	18 Years	N/A	All	379	Phase 2	United States;Belgium;Bulgaria;Colombia;Czechia;Hungary;Mexico;Poland;Czech Republic
839	JPRN-UMIN000008404	2012/07/01	2 April 2019	Extension of Tocilizumab Dose Intervals in Patients with Low to Moderate Disease Activity Rheumatoid Arthritis using IL-6 Serum Level as Starting Criteria.		rheumatoid arthritis	Extension of Tocilizumab Dose Intervals	Japan Labour Health and Welfare Organization, Yokohama Rosai Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
840	JPRN-UMIN000033222	2012/07/01	2 April 2019	Clinical Results of Prophylactic Iodine-supported Primary TKA for Compromised Cases		Osteoarthritis, Rheumatoid arthritis of knee joint	prophylactic iodine-suported primaru TKA	Fukui General Hospital		Not Recruiting	50years-old	90years-old	Male and Female	30	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
841	NCT01640054	July 2012	19 October 2017	A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis	(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia	Rheumatoid Arthritis	Drug: Fostamatinib	AstraZeneca		Not recruiting	18 Years	N/A	All	115	Phase 2	Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam
842	NCT01659242	July 2012	19 February 2015	Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study	Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis Patients With Active Disease Despite Methotrexate: an Ultrasound and Magnetic Resonance Imaging Study	Rheumatoid Arthritis	Drug: Methotrexate plus sulfasalazine;Drug: Leflunomide	Singapore General Hospital		Not recruiting	21 Years	65 Years	Both	1	Phase 4	Singapore
843	NCT01665430	July 2012	19 February 2018	A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-Label, Single Arm, Long-Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	38	Phase 3	Poland
844	NCT01793259	July 2012	19 February 2015	Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)	An Open-label, Randomized, Two-period Cross-over Study of Repeated Subcutaneous Injections of Methotrexate 50mg/ml Solution Either by a Pre-filled Syringe (Reference) or by a Disposable Pre-filled Pen (Test) to Assess Patient's Preference and Self-injection Experience and to Compare the Local Tolerability in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: methotrexate prefilled pen;Drug: methotrexate prefilled syringe	medac GmbH		Not recruiting	18 Years	75 Years	Both	120	Phase 3	Germany
845	NCT01893151	July 2012	19 February 2015	Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI	A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI)	Rheumatoid Arthritis	Drug: Iguratimod;Drug: Iguratimod placebo	Jiangsu Simcere Pharmaceutical Co., Ltd.		Recruiting	18 Years	65 Years	Both	200	Phase 4	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
846	EUCTR2011-005260-20-GB	28/06/2012	28 February 2019	RoActemra® (tocilizumab) plus methotrexate (MTX) in stable dosage in comparison with RoActemra® plus reducing (tapering) MTX dosages in patients with severe rheumatoid arthritis (RA) that have inadequate responded to a trial of two disease modifying anti-rheumatic drugs (DMARDs), including MTX and have not been previously treated with a biologic agent, such as a TNF inhibitor.	Randomised, Phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA) who have demonstrated an inadequate response to prior conventional disease-modifying anti-rheumatic drugs (DMARDs) treatment and have initiated RoActemra® (tocilizumab, TCZ) in combination with MTX. - ACT-TAPER	Adult Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: IL-6 receptor inhibitor, recombinant humanized monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Methotrexate 'Lederle' 2.5mg Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Methotrexate Disodium CAS Number: 7413345 Other descriptive name: Methotrexate as methotrexate disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Methotrexate 'Lederle' 2.5mg Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Methotrexate Disodium CAS Number: 7413345 Other descriptive name: Methotrexate as methotrexate disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Methotrexate 2.5mg Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate Disodium CAS Number: 7413345 Other descriptive name: Methotrexate as methotrexate disodium Concentration unit: mg milligram(s) Concentration type: equal	Roche Products Limited		Not Recruiting			Female: yes Male: yes	618	Phase 4	United Kingdom
847	EUCTR2011-005204-15-AT	20/06/2012	30 April 2019	Could ultrasound help to identify the patients with rheumatoid arthritis, in those the treatment with biological DMARDs could be stopped?	Ultrasound as biomarker for withdrawal of biological DMARDs in rheumatoid arthritis (RA-BioStop) - RABioStop	biological DMARDs may be stopped in RA patients treated with a combination of synthetic DMARD plus biological DMARDs which are in persistent clinical remission. Ultrasound may be useful to predict a disease flare in patients stopping biological DMARDs therapy. MedDRA version: 20.0 Level: LLT Classification code 10039076 Term: Rheumatoid arthritis and other inflammatory polyarthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Enbrel Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Humira Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Cimzia Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Trade Name: Simponi Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Roactemra Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB	Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie		Authorised			Female: yes Male: yes	110	Phase 4	Austria
848	NCT01565655	June 19, 2012	11 June 2019	A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis	A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients	Arthritis, Rheumatoid	Drug: peficitinib;Drug: Placebo	Astellas Pharma Global Development, Inc.		Not recruiting	18 Years	N/A	All	289	Phase 2	Hungary;Mexico;Poland;Bulgaria;Czechia;United States;Czech Republic
849	EUCTR2011-001122-18-HU	13/06/2012	10 June 2014	A Study of the Effectiveness and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Under the Skin of Patients with Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy	Rheumatoid Arthritis MedDRA version: 15.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: CNTO 1959 Pharmaceutical Form: Lyophilisate for solution for injection Current Sponsor code: CNTO 1959 Other descriptive name: CNTO 1959 IgG Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: CNTO 1959 Pharmaceutical Form: Lyophilisate for solution for injection Current Sponsor code: CNTO 1959 Other descriptive name: CNTO 1959 IgG Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: Ustekinumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Janssen-Cilag International NV		Not Recruiting			Female: yes Male: yes	250	Phase 2	United States;Korea, Democratic People's Republic of;Turkey;Russian Federation;Chile;Colombia;Hungary;Czech Republic;Mexico;Argentina;Singapore;Peru;Bulgaria
850	NCT01638013	June 13, 2012	22 October 2019	A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K	Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K	Arthritis, Rheumatoid	Drug: peficitinib	Astellas Pharma Inc		Not recruiting	20 Years	N/A	All	843	Phase 3	Japan;Korea, Republic of;Taiwan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
851	EUCTR2009-017998-37-BE	08/06/2012	2 May 2016	Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFa-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy.	Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFa-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy.	Patients with an active spondyloarthropathy and with an active rheumatoid arthritis; who were diagnosed according to the classic ACR-criteria (American College of Rheumatology) for rheumatoid arthritis and according the ASAS-criteria (Assessment of SpondyloArthritis international Society) for spondylarthropathy. Patients with an active rheumatoid arthritis or with an active axial and peripheral spondyloarthropathy. Patients with erosive hand arthrosis. Patients with an active Crohn's disease. MedDRA version: 19.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: HLT Classification code 10052775 Term: Spondyloarthropathies System Organ Class: 100000004859 MedDRA version: 19.0 Level: HLT Classification code 10039078 Term: Rheumatoid arthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia 200 mg solution for injection Product Name: Certolizumab pegol Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Product Name: 99mTc-S-HYNIC Certolizumab pegol Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25-	Ghent University Hospital		Authorised			Female: yes Male: yes			Belgium
852	NCT01611688	June 4, 2012	16 December 2017	First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis	First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0215-0384;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	All	36	Phase 1	Germany
853	JPRN-UMIN000007806	2012/06/01	2 April 2019	The feasibility study of accelated infliximab infusion during maintenance phase		patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)	Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable patient continue to receive more five treatment with 60min procedure.	Chiba University Hospital		Not Recruiting	Not applicable	Not applicable	Male and Female	54	Phase 2	Japan
854	NCT01602302	June 2012	3 September 2018	Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis	Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)	Medical University of Graz		Recruiting	18 Years	90 Years	All	110	Phase 4	Austria
855	NCT01664104	June 2012	16 December 2017	A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting	CRP and BMI Study: Evaluation in Real Life of Clinical Remission Rate and Correlation Between CRP and BMI in Patients Treated With Tocilizumab	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	151	N/A	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
856	NCT02052375	June 2012	19 February 2015	A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis;Pharmacokinetics of ASP2408	Drug: ASP2408;Drug: Placebo	Astellas Pharma Global Development, Inc.		Not recruiting	18 Years	75 Years	Both	24	Phase 1	United States
857	EUCTR2012-000222-21-DE	31/05/2012	13 May 2013	Comparison of the patient's experience with the methotrexate pre-filled syringe and with the methrotexate pre-filled pen and preference of the patient for subcutaneous methotrexate injection.	An open-label, randomized, two-period cross-over study of repeated subcutaneous injections of methotrexate 50mg/ml solution either by a pre-filled syringe (reference) or by a disposable pre-filled pen (test) to assess patient’s preference and self-injection experience and to compare the local tolerability in patients with active rheumatoid arthritis - Preference MTX pre-filled syringe vs pre-filled pen in RA	Rheumatoid Arthritis MedDRA version: 15.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: metex® 50 mg/ml Injektionslösung, Fertigspritze Product Name: metex® 50 mg/ml Injektionslösung, Fertigspritze Product Code: 70930.00.00 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Methotrexate disodium CAS Number: 59-05-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Product Name: methotrexate pre-filled pen Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Methotrexate disodium CAS Number: 59-05-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	medac Gesellschaft für klinische Spezialpräparate mbH		Not Recruiting			Female: yes Male: yes			Germany
858	EUCTR2011-005634-19-HU	30/05/2012	25 February 2013	A Phase 2b to investigate the effectiveness of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.	A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects with Moderate-to-Severe Rheumatoid Arthritis.	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: mavrilimumab Product Code: CAM-3001 Pharmaceutical Form: Solution for injection INN or Proposed INN: mavrilimumab CAS Number: 1085337-57-0 Current Sponsor code: CAM-3001 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	MedImmune Ltd		Authorised			Female: yes Male: yes	280	Phase 2b	Serbia;Estonia;Spain;Ukraine;Chile;Russian Federation;France;Hungary;Czech Republic;Mexico;Argentina;Poland;Bulgaria;South Africa;Germany
859	EUCTR2011-006040-79-DK	25/05/2012	8 January 2018	A clinical trial with the aim to explore the efficacy and safety of adding tocilizumab to standard of care in patients withearly rheumatoid arth	The efficacy and safety of adding tocilizumab to methotrexate and intra-articular glucocorticosteroid treatment in early rheumatoid arthritis. A randomized, double-blinded, placebo-controlled trial. - DanACT Early	Adult Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra® Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	Aarhus University Hospital, Department of Rheumatology U		Not Recruiting			Female: yes Male: yes	180	Phase 4	Denmark
860	EUCTR2011-004419-22-DE	23/05/2012	21 September 2015	Study of VX-509 in Rheumatoid Arthritis Subjects taking Methotrexate	A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy with 104-Week Open Label Extension	Rheumatoid Arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: VX-509 Product Code: VX-509 Pharmaceutical Form: Tablet Current Sponsor code: VX-509 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Vertex Pharmaceuticals Incorporated		Not Recruiting			Female: yes Male: yes	350	Phase 2	Serbia;United States;Estonia;Slovakia;Ukraine;Russian Federation;Hungary;Czech Republic;Mexico;Argentina;Poland;Romania;Peru;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
861	NCT01569152	May 22, 2012	1 April 2019	Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial With a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis (RA)	Drug: MK-8457 100 mg;Drug: Dose-Matched Placebo;Drug: Methotrexate	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	82	Phase 2	Canada;Chile;Denmark;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Moldova, Republic of;Peru;Poland;South Africa;Taiwan;United Kingdom;United States
862	EUCTR2011-005448-87-HU	14/05/2012	10 July 2015	A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITH ETANERCEPT PLUS DMARD(S)	A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITH ETANERCEPT PLUS DMARD(S)	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Enbrel® 50 mg Solution for Injection in Pre-filled Syringe Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Pfizer Inc, 235 East 42nd Street, New York, NY 10017		Not Recruiting			Female: yes Male: yes	320		United Arab Emirates;Philippines;Saudi Arabia;Taiwan;Slovakia;Thailand;Ukraine;Turkey;Russian Federation;Colombia;India;Egypt;Czech Republic;Hungary;Mexico;Argentina;Malaysia;Brazil;Poland;Romania;South Africa;China
863	EUCTR2012-000139-21-AT	14/05/2012	15 October 2018	Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action	A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action - BioBio	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: millilitre(s)/gram Concentration type: up to Concentration number: 100-5 Trade Name: Orencia Product Name: Orencia Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 250- Trade Name: Ro-Actemra Product Name: Ro Actemra Pharmaceutical Form: Concentrate for solution for infusion CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Mabthera Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Orencia Product Name: Orencia Pharmaceutical Form: Solution for injection INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Trade Name: Ro-Actemra Product Name: Ro Actemra Pharmaceutical Form: Solution for injection CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: millilitre(s)/gram Concentration type: equal Concentration number: 162-	Medizinische Universität Wien, Universitätsklinik für Innere Medizin III		Not Recruiting			Female: yes Male: yes		Phase 4	Czech Republic;Slovakia;Austria;Russian Federation;Switzerland
864	EUCTR2012-000439-17-LT	11/05/2012	23 September 2013	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy - Proof-of-Concept of MK-8457 in patients with Rheumatoid Arthritis	active rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: MK-8457 Product Code: MK-8457 Pharmaceutical Form: Tablet INN or Proposed INN: None Other descriptive name: MK-8457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: MK-8457 Product Code: MK-8457 Pharmaceutical Form: Tablet INN or Proposed INN: None Other descriptive name: MK-8457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	MERCK SHARP & DOHME CORP.		Not Recruiting			Female: yes Male: yes	342	Phase 2	United States;Taiwan;Korea, Democratic People's Republic of;Lithuania;Russian Federation;Chile;United Kingdom;India;Hungary;Mexico;Canada;Poland;Brazil;Denmark;Peru;South Africa;Latvia;Germany;Japan;Moldova, Republic of
865	EUCTR2011-005008-14-HU	10/05/2012	12 November 2012	Not applicable	Randomized, Double blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis who have an Inadequate Response to Methotrexate Alone	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard Current Sponsor code: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard Current Sponsor code: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard Current Sponsor code: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: GLPG0634 Pharmaceutical Form: Capsule, hard Current Sponsor code: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Galapagos SASU		Not Recruiting			Female: yes Male: yes	90	Phase 2	Hungary;European Union;Ukraine;Russian Federation;Moldova, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
866	EUCTR2011-005021-48-HU	04/05/2012	9 October 2012	A study to investigate and compare the efficacy, safety, tolerability and pharmacodynamic (biochemical and physiological effects of the drug) of TL011 and MabThera® (rituximab) in patients with severe, active rheumatoid arthritis treated with methotrexate (MTX)	A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability and pharmacodynamic profiles of TL011 infusions compared with MabThera® (rituximab) in subjects with severe, active rheumatoid arthritis treated with methotrexate (MTX) - ALTO	adult patients with severe, active rheumatoid arthritis patients treated with methotrexate (MTX) MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: TL011 Product Code: TL011 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TL011 Current Sponsor code: TL011 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera®, 100 mg concentrate for solution for infusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Teva Pharmaceutical Industries		Not Recruiting			Female: yes Male: yes	544		Hungary;Germany;Netherlands;Bulgaria;Czech Republic;Russian Federation;Serbia;Ukraine;Georgia;Romania;Spain;Macedonia, the former Yugoslav Republic of;Poland
867	EUCTR2011-006125-14-HU	04/05/2012	23 February 2015	A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS - FUNCTION LTE	A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS - FUNCTION LTE	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Product Name: RoActemra Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion	Roche (Magyarország) Kft.		Not Recruiting			Female: yes Male: yes	241		Hungary
868	JPRN-UMIN000007786	2012/05/01	2 April 2019	"Effect examination of infliximab to the effect insufficient example and the example of effect decrease of the 1st TNF inhibitor in rheumatoid arthritis "		Rheumatoid Arthritis	infliximab plus methotrexate	Saitama Medical Center. Saitama Medical University		Not Recruiting	20years-old	75years-old	Male and Female	40	Not applicable	Japan
869	JPRN-UMIN000014484	2012/05/01	2 April 2019	Saitama Actemra study for QOL in patients with Rheumatoid arthritis		rheumatoid arthritis	Treatment with Tocilizumab	Juntendo University, Juntendo Koshigaya Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	40	Not selected	Japan
870	NCT01548001	May 2012	14 March 2016	Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Iguratimod;Drug: Methotrexate	Jiangsu Simcere Pharmaceutical Co., Ltd.		Not recruiting	18 Years	65 Years	Both	910	Phase 4	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
871	NCT01554917	May 2012	14 March 2016	A Study of Iguratimod in Patients With Active Rheumatoid Arthritis	A Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Iguratimod	Jiangsu Simcere Pharmaceutical Co., Ltd.		Not recruiting	18 Years	N/A	Both	1759	Phase 4	China
872	NCT01559103	May 2012	2 March 2015	Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients	A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (Anti-IL-6)	Rheumatoid Arthritis	Biological: MEDI5117;Biological: MEDI5117 Placebo	AstraZeneca		Not recruiting	20 Years	75 Years	Both	39	Phase 1	United States;Germany;United Kingdom
873	NCT01576549	May 2012	11 June 2018	A Study of LY2127399 in Rheumatoid Arthritis	An Exploratory Open-Label Biomarker Study of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Synovial Biopsies	Rheumatoid Arthritis	Drug: LY2127399	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	2	Phase 2	United States
874	NCT01579006	May 2012	19 October 2017	Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis	A Multi National, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (Actemra)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	Clalit Health Services	Not recruiting	18 Years	N/A	All	184	N/A	Israel
875	NCT01613079	May 2012	19 February 2015	Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis	Evaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.	Arthritis, Rheumatoid	Drug: Tripterygium wilfordii Hook F;Drug: Methotrexate	Peking Union Medical College Hospital		Not recruiting	18 Years	65 Years	Both	201	Phase 2/Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
876	NCT01617005	May 2012	19 October 2017	A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)	Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	50	N/A	Montenegro
877	NCT01617590	May 2012	19 February 2015	Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research	A 48-week, Multi-center, Randomized, Open-lable, Controlled Study to Assess the Response (ACR20) Using Different Disease-Modifying Antirheumatic Drugs Cycle Combination Regimen in Adult Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: leflunomide;Drug: methotrexate	Shanxi Medical University		Recruiting	18 Years	75 Years	Both	500	N/A	China
878	NCT01638715	May 2012	12 November 2018	A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action	A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action	Rheumatoid Arthritis	Drug: Remicade;Drug: Orencia;Drug: Ro-Actemra;Drug: Mabthera	Medical University of Vienna		Not recruiting	18 Years	75 Years	All	115	Phase 4	Austria;Czechia;Russian Federation;Switzerland;Czech Republic;Saudi Arabia
879	NCT01664598	May 2012	15 August 2016	An Extension Study of WA19926 of the Long-Term Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	49	Phase 3	Russian Federation
880	NCT01668641	May 2012	19 February 2015	Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone	Rheumatoid Arthritis	Drug: GLPG0634;Drug: Placebo	Galapagos NV		Not recruiting	18 Years	70 Years	Both	91	Phase 2	Hungary;Moldova, Republic of;Russian Federation;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
881	NCT01724268	May 2012	19 February 2015	Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient	Randomized Controlled Clinical Trial of Low Dose Corticosteroids vs Anti TNF Treatment in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient- a Pilot Study	RHEUMATOID ARTHRITIS	Drug: Pred + Meth;Drug: Anti TNF + Meth	Hamad Medical Corporation		Recruiting	18 Years	N/A	Both	80	Phase 3	Qatar
882	JPRN-UMIN000018017	2012/04/23	2 April 2019	Analysis for the reactivation of hepatitis B virus (HBV) in rheumatoid arthritis or psoriasis patients with past HBV infection treated with anti-tumor necrosis factor-alpha therapy		rheumatoid arthritis or psoriasis patients with past hepatitis B virus infection	The effect of preventive lamivudine, adefovir or entecavir on de novo HBV hepatitis.	Department of general internal medicine, Kyushu-University hospital		Not Recruiting	20years-old	Not applicable	Male and Female	70	Not selected	Japan
883	EUCTR2011-004529-28-HU	18/04/2012	29 April 2013	A Study of the Efect of JNJ-40346527 and Placebo in Patients with Active Rheumatoid Arthritis	A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy - not available	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: JNJ-40346527-AAC - capsule - 50 mg Product Code: JNJ-40346527 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Not assigned CAS Number: --- Current Sponsor code: JNJ-40346527-AAC Other descriptive name: Not assigned Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Janssen-Cilag International NV		Not Recruiting			Female: yes Male: yes	90	Phase 2a	Czech Republic;Hungary;Argentina;Poland;Ukraine;Singapore;Chile;Bulgaria;Russian Federation;Korea, Republic of
884	EUCTR2011-001729-25-DE	11/04/2012	16 November 2015	Study designed to demonstrate the efficacy and safety of Certolizumab pegol in combination with Methotrexate in the treatment of subjects suffering from early, progressive active rheumatoid arthritis.	A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical response in the treatment of dmard-naïve adults with early active rheumatoid arthritis. - -	Early active rheumatoid arthritis MedDRA version: 17.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia Product Name: Certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Trexan Product Name: Methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5-	UCB Pharma SA		Not Recruiting			Female: yes Male: yes	800		United States;Spain;Ireland;Austria;Colombia;United Kingdom;Italy;Switzerland;Hungary;Czech Republic;Mexico;Canada;Argentina;Brazil;Australia;Netherlands;Germany;Sweden
885	JPRN-UMIN000011087	2012/04/11	2 April 2019	Efficacy of monthly minodronate for the treatment of osteoporosis associated with rheumatoid arthritis after previous treatment with bisphosphonates		Osteoporosis	Minodronic acid (50mg/month or 1mg/day)	Osaka University Graduate School of Medicine		Not Recruiting	20years-old	Not applicable	Male and Female	100	Not applicable	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
886	JPRN-UMIN000007380	2012/04/01	2 April 2019	Comparison of the effects of single high-dose methotrexate and methotrexate-tocilizumab therapy on rheumatoid arthritis		rheumatoid arthritis	tocilizumab + methotrexate (10mg/week) high-dose methotrexate (stepwisely increased to 16mg/week)	Kinki University Faculty of Medicine, Division of Hematology and Rheumatology		Not Recruiting	20years-old	80years-old	Male and Female	40	Not selected	Japan
887	JPRN-UMIN000007432	2012/04/01	2 April 2019	Prospective research of infliximab treatment in active RA patients refractry to anti-interleukin six receptor monoclonal antibody.		rheumatoid arthritis	Infliximab and Methotrexate. Patient is treated with IFX 3mg/kg for 0, 2, or 6 weeks, and henceforth every 8 weeks till 46weeks. Disease activity is assessed every 4weeks (suitable) or every 8 weeks (indispensable), and if SDAI Score 3.3 or more, it will change into of 3mg/kg 4week or 6mg/kg 4week interval medication, and will administer a drug to patient till 50 weeks. If not remission(SDAI Score 3.3 or more), after change into of 3mg/kg 4week interval medication, it will change into of 6mg/kg 4week interval medication, and will administer a drug to patient till 50 weeks.	Keio University		Not Recruiting	20years-old	75years-old	Male and Female	100	Not selected	Japan
888	NCT01484561	April 2012	19 October 2017	A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis	A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP-690,550 or Placebo;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	148	Phase 1	United States;Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain
889	NCT01557374	April 2012	25 February 2019	TOward the Lowest Effective DOse of Abatacept or Tocilizumab	Tapering Abatacept or Tocilizumab in Rheumatoid Arthritis in Remission. An Evaluation of Disease Activity, Relapse Risk, Structural Progression and the Economic Impact of a Tapering Strategy	Rheumatoid Arthritis	Drug: Tocilizumab, Abatacept;Drug: Decrease Tocilizumab, Abatacept	Assistance Publique - Hôpitaux de Paris	Ministry of Health, France	Not recruiting	18 Years	N/A	All	232	Phase 4	France
890	NCT01569074	April 2012	19 October 2017	Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis	(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Fostamatinib;Drug: Placebo	AstraZeneca		Not recruiting	18 Years	N/A	All	163	Phase 2	Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
891	NCT01579890	April 2012	19 February 2015	Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis	A Non-blinded, Non-placebo Controlled, Compassionate Use, Open Treatment, Open-ended Program of the Safety of Pennsaid Topical Lotion (Diclofenac) in the Treatment of Osteo or Rheumatoid Arthritis	Osteoarthritis of the Hand	Drug: Diclofenac	Mallinckrodt	Nuvo Research Inc.	Not recruiting	N/A	N/A	Both		N/A
892	NCT01583959	April 2012	19 February 2015	Study of Different Doses of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis	Randomized Trial of 10 mg Versus 30 mg Per Week of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Folic Acid;Drug: Placebo	Postgraduate Institute of Medical Education and Research		Not recruiting	18 Years	75 Years	Both	100	Phase 4	India
893	NCT01655381	April 2012	19 October 2017	A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-label, Single Arm, Long-term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	15	Phase 3	France
894	NCT02171143	April 2012	19 February 2015	A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis;Pharmacokinetics of ASP2409	Drug: ASP2409;Drug: Placebo	Astellas Pharma Global Development, Inc.		Not recruiting	18 Years	75 Years	Both	58	Phase 1	United States
895	NCT02818361	April 2012	3 December 2018	Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis	Topical Tripterygium Wilfordii Gel for Treatment in Patients With Moderate Activity Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Topical tripterygium gel;Drug: Placebo gel	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	18 Years	65 Years	All	70	N/A	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
896	EUCTR2011-002392-41-HU	28/03/2012	14 January 2013	A trial to compare Z102 against Prednisone in patients with rheumatoid arthritis.	A PHASE II, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER, RANDOMIZED, LONG TERM SAFETY TRIAL OF Z102 AND PREDNISONE (5 MG OR 7.5 MG) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS	Treatment of patients with moderate to severe rheumatoid arthritis (RA) MedDRA version: 14.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Z102 Product Code: Z102 Pharmaceutical Form: Capsule INN or Proposed INN: Prednisolone CAS Number: 52438-85-4 Current Sponsor code: Prednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.7- INN or Proposed INN: Dipyridamole CAS Number: 58-32-2 Current Sponsor code: Dipyridamole Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 180- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Dacortin ® Product Name: Prednisone Pharmaceutical Form: Capsule INN or Proposed INN: PREDNISONE CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 5.0-7.5 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Zalicus, Inc.		Not Recruiting			Female: yes Male: yes	200	Phase 2	Serbia;United States;Ukraine;Chile;Russian Federation;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Peru;Bulgaria
897	EUCTR2011-006001-10-IT	19/03/2012	25 September 2012	Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthritis, who had been previously treated with rituximab at the standard dose for at least two cycles obtaining a good clinical response	Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthritis, who had been previously treated with rituximab at the standard dose for at least two cycles obtaining a good clinical response -	Rheumatoid arthritis MedDRA version: 14.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: *MABTHERAEV 1FL 50ML 500MG Pharmaceutical Form: Injection INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Trade Name: MABTHERAEV 1FL 50ML 500MG* Pharmaceutical Form: Injection INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	A.O. UNIVERSITARIA INTEGRATA DI VERONA		Authorised			Female: yes Male: yes	48		Italy
898	EUCTR2011-002275-41-CZ	15/03/2012	18 March 2013	A Study of Two Different Adalimumab Formulations in Adults with Rheumatoid Arthritis.	A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects with Rheumatoid Arthritis.	Rheumatoid Arthritis. MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Adalimumab Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: Adalimumab Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Abbott GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	60		Belgium;Czech Republic
899	JPRN-UMIN000017230	2012/03/01	2 April 2019	Correlation between efficacy of the biological therapy (tocilizumab) and levels of oxidative stress markers in Japanese patients with rheumatoid arthritis (inadequate responders to existing therapies)		Rheumatoid arthritis	Biologic treatment (tocilizumab)	Kyushu University		Recruiting	20years-old	Not applicable	Male and Female	60	Not selected	Japan
900	NCT01649999	March 1, 2012	22 July 2019	A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects	Phase 2b Study of ASP015K - A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients	Arthritis, Rheumatoid	Drug: peficitinib;Drug: Placebo	Astellas Pharma Inc		Not recruiting	20 Years	75 Years	All	281	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
901	NCT01526057	March 2012	19 February 2015	A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)	A Randomized, Double-Blind, Study Comparing The Pharmacokinetics And Pharmacodynamics, And Assessing The Safety Of PF-05280586 And Rituximab In Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate Who Have Had An Inadequate Response To One Or More TNF Antagonist Therapies	Rheumatoid Arthritis	Biological: PF-05280586;Biological: MabThera;Biological: Rituxan	Pfizer		Not recruiting	18 Years	N/A	Both	222	Phase 1/Phase 2	United States;Australia;Canada;Colombia;Germany;Israel;Mexico;Russian Federation;South Africa;United Kingdom;Taiwan
902	NCT01565408	March 2012	16 December 2017	Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis	Safety and Tolerability of NNC0114-0006 Following Multiple s.c. Dosing at Escalating Dose Levels in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0114-0006;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	All	32	Phase 1	Germany;Russian Federation
903	NCT01582880	March 2012	4 November 2019	Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis	The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis	Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases	Drug: Riboflavin	Joseph B. Ciolino, MD		Not recruiting	18 Years	N/A	All	1	Phase 1/Phase 2	United States
904	NCT01612377	March 2012	19 February 2015	Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis	A Phase II, Double-blind, Controlled, Multi-center, Randomized, Long Term Safety Trial of z102 and Prednisone (5 mg or 7.5 mg) in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisolone-Dipyridamole;Drug: Prednisone;Drug: prednisone	Zalicus		Not recruiting	18 Years	N/A	Both	18	Phase 2	Serbia
905	NCT01626573	March 2012	25 March 2019	A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis	A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Itacitinib;Drug: Itacitinib Placebo	Incyte Corporation		Not recruiting	18 Years	75 Years	All	106	Phase 2	United States;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
906	NCT01670045	March 2012	19 October 2017	A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	43	N/A	Indonesia;Greece
907	EUCTR2011-004171-36-CZ	15/02/2012	21 August 2012	A study comparing SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthritis (RA)	A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthritis (RA)	Severe Rheumatoid Arthritis (RA) MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: SAIT101 Product Code: SAIT101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: SAIT101 Other descriptive name: Chimeric human/mouse anti-CD-20 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera® Product Name: MabThera® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Samsung Electronics Co. Ltd.		Not Recruiting			Female: yes Male: yes	616		Poland;Spain;Korea, Republic of;Romania;Mexico;Argentina;Taiwan;Canada;United Kingdom;Russian Federation;Czech Republic;Brazil;South Africa;Turkey;Switzerland;Hungary
908	NCT01623752	February 10, 2012	2 July 2018	Prospective Evaluation of the Radiographic Efficacy of Enbrel	A Prospective Evaluation Of The Radiographic Efficacy Of Etanercept In Patients With Rheumatoid Arthritis Or Psoriatic Arthritis.	Rheumatoid Arthritis;Psoriasis Arthritis	Drug: Etanercept	Pfizer		Not recruiting	18 Years	N/A	All	1816	Phase 2
909	JPRN-UMIN000006702	2012/02/01	2 April 2019	A parallel group, randomized clinical trial on the efficacy and safety of intensive treatment strategy with MTX as the anchor-drug in patients with active early rheumatoid Arthritis		rheumatoid arthritis	Intensive treatment group Period: 24 weeks In the intensive treatment group, a patient starts treatment with MTX at 8mg/week. Dosage is increased to 0.25mg/kg/week by week 8 and is further increased to his or her maximum tolerable dosage by week 12. The maximum tolerable dosage is maintained until week 24. If a patient shows inadequate response to MTX and does not achieve SDAI(simplified disease activity index)emission or CDAI (linical disease activity index)remission by week 16, additional treatment with tacrolimus, bucillamine, sarazosulfapyridine, or biologics will be started as scheduled in the protocol. After week 24, both groups receive treatments by attending rheumatologists'discretion and are followed until week 72. Conventional treatment group Period: 24 weeks In the control group, a patient starts treatment with MTX, tacrolimus, bucillamine, sarazosulfapyridine, or biologics by attending rheumatologists' discretion by week 24. Biologics are allowed on and after week 12. After week 24, both groups receive treatments by attending rheumatologists'discretion and are followed until week 72.	Tokyo Medical and Dental University	Department of Pharmacovigilance	Not Recruiting	20years-old	70years-old	Male and Female	290	Not applicable	Japan
910	JPRN-UMIN000007019	2012/02/01	2 April 2019	Efficacy and safety of tocilizumab mono-therapy in patients with adult-onset Still's disease		Rheumatoid arthritis	tocilizumab monotherapy	Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity		Not Recruiting	16years-old	70years-old	Male and Female	40	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
911	JPRN-UMIN000007205	2012/02/01	2 April 2019	The efficacy and safety of adding tacrolimus to methotrexate in elderly patients with rheumatoid arthritis		Rheumatoid arthritis	1) Tacrolimus Oral administration of tacrolimus is started usually at a dose of 1.5 mg/day immediately after informed consent is obtained. The dose can be increased or decreased within the limits of 3 mg/day with taking into account symptoms, adverse reactions and so on. However, the administration of tacrolimus can be started at a dose of 0.5 or 1.0 mg/day in order to reduce adverse effects.	Juntendo University		Not Recruiting	65years-old	Not applicable	Male and Female	30	Not selected	Japan
912	NCT01352858	February 2012	17 September 2018	Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA)	Phase 1 Study of Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TolDC;Drug: Arthroscopy & saline irrigation alone	Newcastle University	Arthritis Research UK;Newcastle-upon-Tyne Hospitals NHS Trust	Recruiting	18 Years	N/A	All	15	Phase 1	United Kingdom
913	NCT01395251	February 2012	25 May 2015	Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis	Phase II/III Study of Oral Prednisolone Test in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisolone	Rheumazentrum Ruhrgebiet		Not recruiting	18 Years	N/A	Both	130	Phase 2/Phase 3	Germany
914	NCT01438892	February 2012	19 February 2015	Impact Of RA Therapy Compliance On Patient-Reported Outcomes	Impact Of RA Therapy Compliance On Patient-Reported Outcomes	Rheumatoid Arthritis	Drug: tDMARDs;Drug: biodmards	Pfizer		Not recruiting	18 Years	N/A	Both	396	N/A	United States
915	NCT01534884	February 2012	1 June 2015	Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis	Phase 1, Randomized, Controlled, Multicenter, 2-Arm, Parallel-Group, Double-Blind Study to Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: rituximab	Celltrion		Not recruiting	18 Years	75 Years	Both	154	Phase 1	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
916	NCT01562327	February 2012	19 October 2017	A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis	A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab Actemra	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	50	N/A	Argentina
917	NCT01567358	February 2012	19 February 2015	Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis	A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade® in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate	Rheumatoid Arthritis	Biological: Infliximab	Nichi-Iko Pharmaceutical Co.,Ltd.		Not recruiting	20 Years	75 Years	Both	14	Phase 1	Japan
918	NCT01613027	February 2012	19 October 2017	An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis	A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)	Rheumatoid Arthritis	Biological: Rituximab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	135	N/A	Greece
919	NCT01646385	February 2012	19 October 2017	Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry	Long-term Safety and Efficacy of Etanercept in a UK Observational Cohort Study - a Retrospective Database Analysis of British Society of Rheumatology Biologics Registry (BSRBR) Data	Rheumatoid Arthritis	Drug: etanercept;Drug: non-biologic anti-rheumatic drugs	Pfizer		Not recruiting	18 Years	N/A	All	6393	N/A
920	NCT01940926	February 2012	16 December 2017	68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	Diagnostic Performance and Evaluation Efficacy of 68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 68Ga-BNOTA-PRGD2	Peking Union Medical College Hospital		Not recruiting	18 Years	N/A	All	50	Early Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
921	NCT02090556	January 31, 2012	26 November 2018	Long-term Experience With Abatacept SC in Routine Clinical Practice	Long-term Experience With Abatacept SC in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	inVentiv Health Clinical;PharmaNet	Not recruiting	18 Years	N/A	All	2896	N/A	Australia;Austria;France;Germany;Greece;Italy;Monaco;Netherlands;Spain;Switzerland;United Kingdom
922	EUCTR2011-002849-36-LV	12/01/2012	28 September 2015	A study of multiple different dosages of JNJ 39758979 and placebo in patients with active Rheumatoid Arthritis	A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy - not available	Rheumatoid Arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: JNJ-39758979-AAC - enteric coated tablet - 10 mg Product Code: JNJ-39758979 Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Not assigned CAS Number: Not assigned Current Sponsor code: JNJ-39758979-AAC Other descriptive name: Not assigned Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Gastro-resistant tablet Route of administration of the placebo: Oral use Product Name: JNJ-39758979-AAC - enteric coated tablet - 30 mg Product Code: JNJ-39758979 Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Not assigned CAS Number: Not assigned Current Sponsor code: JNJ-39758979-AAC Other descriptive name: Not assigned Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Gastro-resistant tablet Route of administration of the placebo: Oral use Product Name: JNJ-39758979-AAC - enteric coated tablet - 100 mg Product Code: JNJ-39758979 Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Not assigned CAS Number: Not assigned Current Sponsor code: JNJ-39758979-AAC Other descriptive name: Not assigned Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Gastro-resistant tablet Route of administration of the placebo: Oral use	Janssen-Cilag International NV		Not Recruiting			Female: yes Male: yes	325	Phase 2b	Japan;Latvia;Romania;Singapore;Malaysia;Poland;Argentina;Mexico;Czech Republic;Colombia;Chile;Russian Federation;Ukraine;United States
923	EUCTR2011-004468-31-GB	06/01/2012	28 August 2012	Evaluating the long-term Safety and Efficacy effects of CT-P13 together with methotrexate in patients with arthritis	An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: CT-P13 Product Code: CT-P13 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Infliximab CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	CELLTRION, Inc		Authorised			Female: yes Male: yes	617		Poland;Philippines;Bosnia and Herzegovina;Spain;Romania;Mexico;Peru;Ukraine;Slovakia;United Kingdom;Lithuania;Austria;Latvia;Italy;Chile;Bulgaria;Colombia;Portugal
924	ChiCTR-TRC-12001859	2012-01-01	18 April 2017	Treatment of coronary heart disease in rheumatoid arthritis with leflunomide combined with ligustrazine in clinical research	Treatment of coronary heart disease in rheumatoid arthritis with leflunomide combined with ligustrazine in clinical research	coronary heart disease in rheumatoid arthritis	1:leflunomide combined with ligustrazine;2:leflunomide combined with placebo;	Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences		Not Recruiting	18	65	Both	1:30;2:30;	Other	China
925	JPRN-UMIN000012613	2012/01/01	2 April 2019	Reduction or withdrawal of etanercept after remission with etanerceptin patients with rheumatoid arthritis patients.		rheumatoid arthritis	etanercept50mg/wk or25mg twice/wk reduction of etanercept to 25mg/wk arfter 3 months from remission	Dept. of orthopedic surgery, Osaka Medical College		Not Recruiting	20years-old	70years-old	Male and Female	30	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
926	NCT01474291	January 2012	19 October 2017	An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice	Evaluation of Factors Influencing Use of RoActemra® as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO	Rheumatoid Arthritis	Biological: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	608	N/A	France;Monaco
927	NCT01502423	January 2012	19 October 2017	A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab	A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Adalimumab	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	N/A	All	61	Phase 2	Australia;Canada;Germany
928	NCT01506661	January 2012	16 December 2017	Zostavax in Rheumatoid Arthritis	Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis;Varicella Zoster	Drug: Zostavax (varicella zoster virus) vaccine	Oklahoma Medical Research Foundation		Not recruiting	50 Years	80 Years	All	20	Phase 1	United States
929	NCT01519791	January 2012	11 June 2018	A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Certolizumab Pegol;Other: Placebo;Biological: Methotrexate	UCB Pharma SA		Not recruiting	18 Years	N/A	All	880	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Colombia;Czechia;France;Germany;Hungary;Ireland;Italy;Mexico;Monaco;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;Czech Republic
930	NCT01521923	January 2012	11 June 2018	A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Certolizumab Pegol + Methotrexate (MTX);Biological: Placebo + Methotrexate (MTX)	UCB Pharma		Not recruiting	18 Years	N/A	All	359	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Colombia;Czechia;France;Germany;Hungary;Ireland;Italy;Mexico;Monaco;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
931	NCT01533714	January 2012	19 February 2015	The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis	Multi-center, Open-label, Follow-up Study to Assess the Long-term Safety and Efficacy of CDP6038 Administered Subcutaneously to Asian Subjects With Active Rheumatoid Arthritis Who Completed Study RA0083	Rheumatoid Arthritis	Biological: Olokizumab	UCB Pharma		Not recruiting	20 Years	N/A	Both	103	Phase 2	Japan;Korea, Republic of;Taiwan
932	EUCTR2010-023782-22-ES	16/12/2011	18 September 2012	A TRIAL TO TEST THE EFFICACY AND SAFETY OF STUDY DRUG PF-04171327(1,5,10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY FOR SUBJECTS WITH RHEUMATOID ARHTRITIS OVER A PERIOD OF 8 WEEKS FOLLOWED BY 4 WEEKS OF TAPERING OF STUDY DRUG	A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMATOID ARTHRITIS OVER AN 8 WEEK PERIOD FOLLOWED BY A 4 WEEK PERIOD OF TAPERING OF STUDY DRUG	Rheumatoid Arthritis MedDRA version: 14.0 Level: LLT Classification code 10066578 Term: Progression of rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: PF-04171327 Pharmaceutical Form: Tablet CAS Number: 1044535-58-1 Current Sponsor code: PF-04171327 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: PF-04171327 Pharmaceutical Form: Tablet CAS Number: 1044535-58-1 Current Sponsor code: PF-04171327 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: PF-04171327 Pharmaceutical Form: Tablet CAS Number: 1044535-58-1 Current Sponsor code: PF-04171327 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Decortin Pharmaceutical Form: Capsule INN or Proposed INN: PREDNISONE CAS Number: 53-03-02 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Pfizer, S.L.U.		Authorised			Female: yes Male: yes	315	Phase 2	Poland;United States;Spain;Romania;Korea, Republic of;Mexico;Canada;Serbia;Ukraine;Czech Republic;Russian Federation;Slovakia;India;South Africa;Bulgaria;Malaysia;Germany;Colombia;Hungary
933	EUCTR2011-000436-28-PL	07/12/2011	18 March 2013	A trial to compare Z102 against placebo in patients with Rheumatoid Arthritis.	A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS	Treatment of patients with moderate to severe rheumatoid arthritis (RA) MedDRA version: 14.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Z102 Product Code: Z102 Pharmaceutical Form: Capsule INN or Proposed INN: Z102 (Prednisolone and Dipyridamole). Current Sponsor code: Z102 (Prednisolone and Dipyridamole). Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 360- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Prednisolone Product Code: Prednisolone Pharmaceutical Form: Capsule INN or Proposed INN: Prednisolone CAS Number: 52438-85-4 Current Sponsor code: Prednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.7- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Dipyridamole Product Code: Dipyridamole Pharmaceutical Form: Capsule INN or Proposed INN: Dipyridamole CAS Number: 58-32-2 Current Sponsor code: Dipyridamole Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 180- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Dacortin ® Pharmaceutical Form: Capsule INN or Proposed INN: PREDNISONE CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Zalicus, Inc.		Not Recruiting			Female: yes Male: yes	250	Phase 2	United States;Serbia;Hungary;Mexico;Argentina;Brazil;Poland;Ukraine;Peru;Chile;Bulgaria;Russian Federation
934	NCT01511003	December 5, 2011	20 August 2018	A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)	An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs	Rheumatoid Arthritis	Drug: Tacrolimus	Astellas Pharma Inc	Astellas Pharma Korea, Inc.	Not recruiting	20 Years	75 Years	All	128	Phase 4	Korea, Republic of
935	NCT01443364	December 2011	16 December 2017	Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis	Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Biological: Certolizumab pegol	UCB Italy s.p.a.		Not recruiting	18 Years	N/A	All	132	Phase 4	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
936	NCT01500278	December 2011	16 December 2017	Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate	A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate	Rheumatoid Arthritis	Biological: Certolizumab Pegol (CZP);Biological: Adalimumab (ADA);Drug: Methotrexate (MTX)	UCB Pharma SA	Parexel	Not recruiting	18 Years	N/A	All	915	Phase 4	Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;Czech Republic;Canada;Bulgaria;Austria;Australia
937	NCT01326962	November 30, 2011	16 December 2017	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF	Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	28	Phase 3	Saudi Arabia
938	EUCTR2011-005036-26-GB	29/11/2011	28 August 2012	A study to investigate what effects FX125L (taken by mouth) has on adults with chronic inflammatory diseases	An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease	Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: FX125L Pharmaceutical Form: Capsule Current Sponsor code: FX125L Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Funxional Therapeutics Ltd		Not Recruiting			Female: yes Male: yes		Phase 2a	United Kingdom
939	ChiCTR-TRC-11001789	2011-11-14	18 April 2017	Effect of TGP combined with MTX and LEF on liver function in RA patients: Clinical study protocol	Effect of TGP combined with MTX and LEF on liver function in RA patients: Clinical study protocol	Rheumatoid Arthritis	Treatment:TGP capsules (TGP) + methotrexate (MTX) + leflunom;Control:methotrexate(MTX) + leflunomide (LEF);	Anhui Provincial Hospital Department of Rheumatism		Not Recruiting	18	65	Both	Treatment:140;Control:140;	Post-market	China
940	NCT01251120	November 2011	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis	A Pragmatic, Randomized, Parallel Group Study of the Effect on Disease Remission, Work Productivity and Tolerability of Tocilizumab in Combination With DMARDs and Individually Designed Best Practice DMARD Therapy in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: DMARD	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	2	Phase 4	Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
941	NCT01408602	November 2011	19 February 2015	A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients	A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MRC375;Drug: Matching Placebo;Drug: MRC375 150mg	Molecular Research Center, Inc.	Camargo Pharmaceutical Services;Clin Data Services;Harrison Clinical Research;BARC Global Central Laboratory;Bilcare Global Clinical Supplies	Not recruiting	18 Years	N/A	Both	300	Phase 2	United States
942	NCT01468077	November 2011	19 October 2017	A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment	Multicenter, Randomized, Parallel Group Study to Compare the Incidence of Tocilizumab Related Infusion Reactions in Patients With Moderate to Severe Active RA, When Infusion is Given Over 31 Minutes Compared to 1 Hour	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	47	Phase 2	Denmark;Iceland
943	NCT01469013	November 2011	30 September 2019	Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of Baricitinib (LY3009104) in Japanese Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy	Arthritis, Rheumatoid	Drug: Placebo;Drug: Baricitinib;Drug: Methotrexate	Eli Lilly and Company		Not recruiting	20 Years	75 Years	All	145	Phase 2	Japan
944	NCT01592292	November 2011	19 October 2017	An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy	A Non-interventional Study for Relative Efficacy Outcome of Rituximab Treatment in RA Patients Who Have Inadequate Response or Have Been Intolerant to a First Anti-TNF Agent	Rheumatoid Arthritis	Drug: Rituximab;Drug: Adalimumab;Drug: Etanercept;Drug: Infliximab	Hoffmann-La Roche		Not recruiting	20 Years	N/A	All	90	N/A	Korea, Republic of
945	NCT02243800	November 2011	8 August 2016	Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency	Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency	Rheumatoid Arthritis;Vitamin D Deficiency	Other: cholecalciferol versus placebo	University Hospital, Clermont-Ferrand	CRINEX Laboratory;BP 337 - 3 rue de Gentilly;92541 MONTROUGE Cedex FRANCE	Recruiting	18 Years	N/A	Both	164	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
946	NCT01451203	October 11, 2011	16 December 2017	Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors	Rheumatoid Arthritis	Drug: Placebo;Drug: CZP;Drug: methotrexate (MTX)	Astellas Pharma Inc	UCB Japan Co. Ltd.	Not recruiting	20 Years	64 Years	All	319	Phase 3	Japan
947	NCT01548768	October 10, 2011	15 July 2019	RHYTHM (Formerly Escape II Myocardium)	RHYTHM (RHeumatoid Arthritis studY of THe Myocardium): How Rheumatoid Arthritis (RA) and Tumor Necrosis Factor (TNF) Inhibitors Affect the Myocardial Structure and Function.	Rheumatoid Arthritis	Drug: TNF inhibitors;Drug: DMARDs	Columbia University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	18 Years	N/A	All	175	Phase 4	United States
948	NCT01292616	October 2011	19 February 2015	Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement		Rheumatoid Arthritis	Drug: therapy with disease-modifying anti rheumatic drugs (DMARD)	University of Zurich		Recruiting	18 Years	N/A	Both	15	N/A	Switzerland
949	NCT01359943	October 2011	19 October 2017	Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate	A Randomized, Double-blind, Placebo-controlled Study of Efficacy, Safety and Tolerability of Secukinumab at 12 Weeks Administered With an Intravenous (i.v.) or Subcutaneous (s.c.) Loading Regimen Compared to Placebo in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate	Rheumatoid Arthritis	Biological: secukinumab (AIN457);Drug: placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	N/A	All	221	Phase 2	United States;Bulgaria;Canada;Hungary;Italy;Poland;Puerto Rico;Slovakia
950	NCT01436370	October 2011	19 October 2017	TIV and High Dose TIV in Subjects With Rheumatoid Arthritis	A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels	Influenza	Biological: Trivalent inactivated influenza vaccine	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	18 Years	64 Years	All	102	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
951	NCT01439204	October 2011	19 October 2017	Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb	A Randomized, Open-label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of Abatacept (BMS-188667) Drug Products Using Active Pharmaceutical Ingredient Manufactured at Devens, MA Site Relative to Active Pharmaceutical Ingredient Manufactured at Lonza, New Hampshire (NH) in Healthy Subjects	Rheumatoid Arthritis	Biological: Abatacept (BMS-188667)	Bristol-Myers Squibb		Not recruiting	18 Years	55 Years	All	223	Phase 1	United States
952	NCT01463059	October 2011	19 February 2015	Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy	A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy	Rheumatoid Arthritis	Biological: Placebo;Biological: Olokizumab 60 mg;Biological: Olokizumab 120 mg;Biological: Olokizumab 240 mg	UCB Japan Co. Ltd.		Not recruiting	20 Years	N/A	Both	119	Phase 2	Japan;Korea, Republic of;Taiwan
953	NCT01557322	October 2011	19 October 2017	Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)	Evaluation of the Clinical Characteristics, Real-world Treatment Pathways, and Outcomes of Patients With Moderate Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: etanercept;Drug: methotrexate (MTX)	Pfizer		Not recruiting	18 Years	N/A	All	1754	N/A
954	NCT01641952	October 2011	19 October 2017	An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent	Non-interventional, Prospective, Multicenter Study to Assess Efficacy and Safety of MabtheRA (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One Anti-TNF Agent - FAST 2 SWITCH Program	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	505	N/A	Romania
955	NCT01954381	October 2011	3 August 2015	Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis	Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Device: transthoracic echocardiographic;Device: Doppler ultrasound.;Biological: blood samples	Assistance Publique Hopitaux De Marseille		Not recruiting	18 Years	N/A	Both	60	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
956	NCT01961505	October 2011	16 December 2017	Topical Compound Tripterygium Wilfordii Hook F for Patients With Active Rheumatoid Arthritis	A Randomized Controlled Study to Determine the Effects and Safety of Topical Compound Tripterygium Wilfordii Hook F in Patients With Active Rheumatoid Arthritis.	Active Rheumatoid Arthritis	Drug: Topical compound tripterygium;Drug: Placebo	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	18 Years	65 Years	All	70	N/A
957	NCT01245439	September 2011	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	65	Phase 3	Turkey
958	NCT01350804	September 2011	19 October 2017	Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor a (Anti-TNFa) Agents (CAIN457F2309 and CAIN457F2309E1)	A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFa Agents (CAIN457F2309) and A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2309E1)	Rheumatoid Arthritis	Biological: AIN457;Biological: Placebo;Biological: Abatacept	Novartis Pharmaceuticals		Not recruiting	18 Years	N/A	All	551	Phase 3	United States;Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain
959	NCT01359150	September 2011	19 October 2017	A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo	A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Background Methotrexate	Rheumatoid Arthritis	Drug: CP-690,550;Drug: placebo	Pfizer		Not recruiting	18 Years	N/A	All	223	Phase 2	United States;Poland
960	NCT01374971	September 2011	19 October 2017	Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)	Open-Label Pre and Post Treatment Arthroscopic Synovial Biopsy Study for the Assessment of Certolizumab Pegol Immunomodulatory Synovial Effects on Select Biomarkers and Gene Expression	Rheumatoid Arthritis	Drug: Certolizumab Pegol (CZP);Procedure: Arthroscopic synovial tissue biopsy	Nathan Wei, MD, FACP, FACR:	University of California, San Diego	Not recruiting	18 Years	N/A	All	12	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
961	NCT01393639	September 2011	18 December 2018	Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis	A Phase 2, Randomized, Double Blind Assessment Of Efficacy And Safety Of Pf 04171327(1, 5, 10, 15 Mg Dose, Daily) Compared To 5 Mg And 10 Mg Prednisone Daily And Placebo Daily In Subjects With Rheumatoid Arthritis Over An 8 Week Period Followed By A 4 Week Period Of Tapering Of Study Drug.	Rheumatoid Arthritis	Drug: PF-04171327;Drug: prednisone;Other: prednisone;Other: placebo	Pfizer		Not recruiting	18 Years	N/A	All	323	Phase 2	United States;Bulgaria;Colombia;Czechia;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;Canada;Czech Republic
962	NCT01399697	September 2011	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With MTX Versus Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 > 3,2)	Rheumatoid Arthritis	Drug: methotrexate;Drug: placebo;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	261	Phase 4	Spain
963	NCT01404585	September 2011	19 February 2015	Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: BMS-817399	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	Both	123	Phase 2	United States;Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain
964	NCT01417052	September 2011	19 February 2015	A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis	A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: 50 mg LX3305 QD;Drug: 100 mg LX3305 QD;Drug: 150 mg LX3305 QD;Drug: 200 mg LX3305 QD;Drug: 250 mg LX3305 QD;Drug: 300 mg LX3305 QD;Drug: 400 mg LX3305 QD;Drug: 250 mg LX3305 BID;Drug: 500 mg LX3305 QD;Drug: Placebo	Lexicon Pharmaceuticals		Not recruiting	18 Years	75 Years	Both	10	Phase 1	United States
965	NCT01446978	September 2011	7 December 2015	Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs	Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate	Vaccine Response Impaired	Biological: hepatitis A vaccine	Sormland County Council, Sweden		Not recruiting	18 Years	N/A	Both	150	Phase 2	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
966	NCT01462162	September 2011	19 October 2017	A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis	A Prospective Observational Study to Evaluate and Correlate the Impact of Treatment With Tocilizumab (RoActemra®) on Fatigue and Different Factors Influencing Fatigue in Participants With Rheumatoid Arthritis in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	122	N/A	Spain
967	NCT01544101	September 2011	19 February 2015	A Nutritional Intervention for Arthritis	A Nutritional Intervention for Arthritis	Rheumatoid Arthritis	Other: Vegan Diet;Dietary Supplement: dietary supplement omega3 fatty acids aand vitamins	Physicians Committee for Responsible Medicine		Not recruiting	18 Years	N/A	Both	32	N/A	United States
968	NCT02076659	September 2011	11 June 2018	Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients	A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: F8IL10;Drug: Methotrexate	Philogen S.p.A.		Not recruiting	18 Years	75 Years	All	36	Phase 1	Italy
969	NCT02164214	September 2011	21 September 2015	Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?	DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)?	Inflammatory Rheumatism;Psoriatic Arthritis;Rheumatoid Arthritis	Drug: etanercept Treatment	Assistance Publique Hopitaux De Marseille		Not recruiting	18 Years	N/A	Both	60	Phase 3	France
970	EUCTR2011-000102-21-CZ	19/08/2011	23 February 2015	Safety and efficacy of secukinumab compared to placebo and abatacept in patients with active rheumatoid arthritis who did not respond to anti-TNFa agents	A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents - NURTURE-1	Rheumatoid arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Powder for solution for injection/infusion INN or Proposed INN: Secukinumab Current Sponsor code: AIN457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: Orencia Product Name: Abatacept Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	548		Germany;Bulgaria;Romania;Brazil;Canada;Mexico;Hungary;Czech Republic;France;Italy;Colombia;Russian Federation;Spain;Slovakia;United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
971	EUCTR2010-023956-99-HU	17/08/2011	4 August 2015	Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in subjects who are not responding to Methotrexate	A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate Pharmacogenetics Blood Sample Amendment 01 - site specific (v1.0, dated 11-Jan-2011) Revised Protocol 04 incorporating Protocol Amendment 12	RHEUMATOID ARTHRITIS,NOS MedDRA version: 17.1 Level: LLT Classification code 10039076 Term: Rheumatoid arthritis and other inflammatory polyarthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: CLAZAKIZUMAB Product Code: BMS-945429 Pharmaceutical Form: Solution for injection INN or Proposed INN: CLAZAKIZUMAB Current Sponsor code: BMS-945429 Other descriptive name: anti-IL-6 mAb Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40/0.8- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Product Name: CLAZAKIZUMAB Product Code: BMS-945429 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: CLAZAKIZUMAB CAS Number: 1236278-28-6 Current Sponsor code: BMS945429 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-	Bristol-Myers Squibb International Corporation		Not Recruiting			Female: yes Male: yes	677	Phase 2B	Korea, Republic of;Japan;Germany;Netherlands;South Africa;Peru;Brazil;Belgium;Argentina;Canada;Mexico;Czech Republic;Hungary;France;Italy;Russian Federation;Spain;Taiwan;United States
972	EUCTR2011-002363-15-IS	17/08/2011	19 January 2015	A clinical trial with the aim to explore infusion reactions from Tocilizumab given either in 31 or 60 minutes to patients with moderate to severe rheumatoid arthritis.	Multicenter, randomized, parallel group study to compare the incidence of Tocilizumab related infusion reactions in patients with moderate to severe active RA, when infusion is given over 31 minutes compared to 1 hour. - ACT FAST	Adult Rheumatoid Arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra® Pharmaceutical Form: Concentrate for solution for infusion	Roche a/s		Not Recruiting			Female: yes Male: yes	56		Denmark;Iceland
973	NCT01331837	August 2, 2011	16 December 2017	A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors	A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	50 Years	N/A	All	3080	Phase 4	United States;Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czechia;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;Brazil;China;Czech Republic
974	NCT01400516	August 2011	16 December 2017	Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial	Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial	Rheumatoid Arthritis	Drug: Teriparatide;Drug: calcium citrate;Drug: Vitamin D;Drug: TNF antagonist	Brigham and Women's Hospital	Eli Lilly and Company	Not recruiting	45 Years	N/A	All	26	Phase 4	United States
975	NCT01414101	August 2011	19 February 2015	Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ISIS CRP Rx or Placebo	Isis Pharmaceuticals		Not recruiting	18 Years	75 Years	Both	51	Phase 2	Canada;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
976	NCT01426789	August 2011	19 October 2017	A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients	A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension	Rheumatoid Arthritis	Drug: Placebo;Drug: Secukinumab	Novartis Pharmaceuticals		Not recruiting	18 Years	N/A	All	100	Phase 2	United States;Belgium;Germany;Russian Federation;United Kingdom
977	NCT01442545	August 2011	19 February 2015	A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants	A Study to Investigate the Effect of Multiple Doses of JNJ 39758979 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients on a Stable Methotrexate Dose	Rheumatoid Arthritis	Drug: JNJ-39758979 / MTX	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		Not recruiting	18 Years	75 Years	Both	21	Phase 1	United States;Germany
978	JPRN-UMIN000013750	2011/07/31	2 April 2019	Study on effects of cytokine targeted therapy on periodontal condition in patients with rheumatoid arthritis		Rheumatoid arthritis, Periodontitis	IL-6 receptor inhibition group: Tocilizumab will be infused in 20 patients, and its effectiveness will be evaluated at 3 and 6 months later. TNF inhibition group: Infliximab, Etanercept, and Adalimumab will be infused in 20 patients, and its effectiveness will be evaluated at 3 and 6 months later.	Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences		Not Recruiting	Not applicable	Not applicable	Male and Female	80	Not selected	Japan
979	EUCTR2011-000275-13-HU	29/07/2011	10 July 2015	Safety and efficacy of secukinumab compared to placebo in patients with active rheumatoid arthritis who did not respond to anti-TNFa drugs	A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Powder for solution for injection/infusion INN or Proposed INN: Secukinumab Current Sponsor code: AIN457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Novartis Pharma AG		Not Recruiting			Female: yes Male: yes	630		Panama;United States;Thailand;Guatemala;Turkey;Colombia;Italy;United Kingdom;India;Hungary;Mexico;Canada;Argentina;Belgium;Peru;Japan
980	EUCTR2011-001863-39-AT	28/07/2011	7 April 2014	A study of saftey and efficacy of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus Tocilizumab Monotherapy in patients with mild to moderate rheumatoid arthritis, who have not adequately responded to their current treatment with MTX.	A multi-center study of the safety and effect on disease activity of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus Tocilizumab monotheraphy in patients with mild to moderate rheumatoid arthritis, with inadequate response to MTX (defined as DAS 28 = 4,5 and > 2,6) - OPTIMISE	Mild to moderate rheumatoid arthritis MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Product Name: Tocilizumab Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: IL-6 receptor inhibitor, recombinant humanized monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Methotrexat Lederle 2.5mg tablets Product Name: Methotrexat Product Code: RO0029893 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Methotrexate Disodium CAS Number: 7413345 Current Sponsor code: RO0029893 Other descriptive name: Methotrexate as methotrexate disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Roche Austria GmbH		Not Recruiting			Female: yes Male: yes			Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
981	NCT01382940	July 26, 2011	16 December 2017	A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis	A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: rituximab;Drug: methotrexate;Drug: methylprednisolone;Drug: acetaminophen;Drug: antihistamine	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	351	Phase 4	United States
982	EUCTR2011-001220-38-GB	12/07/2011	2 October 2012	A study identifying blood serum markers that predict response to a 12 week treatment with secukinumab in patients with Rheumatoid Arthritis	A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension	Rheumatoid Arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Powder for solution for injection or infusion INN or Proposed INN: Secukinumab Current Sponsor code: AIN457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	350		United States;Belgium;United Kingdom;Russian Federation;Germany
983	JPRN-jRCTs032180273	11/07/2011	10 September 2019	Wear of OXINIUM on XLPE: Multicenter RCT Study	Wear of Oxidized Zirconium (OXINIUM) on Cross-linked Polyethylene in Primary Total Hip Arthroplasty: Multicenter Randomized controlled Trial Study - 28mmOX multicenter study	Hip osteoarthritis, Rheumatoid arthritis Hip osteoarthritis, Rheumatoid arthritis	Arm A: Oxidized zirconium alloy (OXINIUM) femoral head Arm B: Standard cobalt chromium alloy head Random allocation is registered automatically at the UMIN Internet Medical Research Data Center (INDICE)	Haruhiko Akiyama		Not Recruiting	>= 20age old	<= 75age old	Both	1308	Phase 4	none
984	JPRN-JapicCTI-111628	01/7/2011	2 April 2019	Phase IIB Rheumatoid Arthritis Dose Ranging Study for Clazakizumab in Subjects Who Are Not Responding to Methotrexate	A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of Clazakizumab Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.	Rheumatoid Arthritis	Intervention name : Clazakizumab Dosage And administration of the intervention : Injection, 25 mg, 100 mg, 200 mg Control intervention name : Methotrexate,Adalimumab Dosage And administration of the control intervention : Methotrexate:Oral,7.5 mg, Adalimumab:Injection,40mg	Bristol-Myers K.K.			18		BOTH	406	Phase 2
985	NCT01390441	July 2011	19 October 2017	A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)	A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera® and US-licensed Rituxan® in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Biological: MK-8808;Biological: MabThera® (rituximab);Drug: Methotrexate;Biological: Rituxan® (rituximab);Drug: Methylprednisolone;Drug: Acetaminophen;Drug: Loratadine	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	65 Years	All	100	Phase 1	Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
986	NCT01410695	July 2011	18 December 2018	Masitinib in Refractory Active Rheumatoid Arthritis	A 24-week With Possible Extension, Prospective, Multicenter, Randomised, Double-blind, Controlled, 3-parallel Groups, Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib at 3 and 6 mg/kg/Day to Methotrexate, With a Randomisation 1:1:1, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including at Least One Biologic Drug if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Biologic Drugs	Rheumatoid Arthritis (RA)	Drug: masitinib 3 mg;Drug: masitinib 6.0 mg;Drug: methotrexate;Drug: Placebo (methotrexate);Drug: Placebo (masitinib)	AB Science		Not recruiting	18 Years	N/A	All	324	Phase 2/Phase 3	Czechia;Czech Republic;France;United States
987	NCT02433184	July 2011	30 September 2019	Very Early Versus Delayed Etanercept in Patients With RA	A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine	University of Leeds		Not recruiting	18 Years	80 Years	All	120	Phase 4	United Kingdom
988	EUCTR2010-019262-86-ES	22/06/2011	2 October 2012	Estudio de extensión multicéntrico no controlado que evalúa la eficacia y seguridad de SAR153191 junto con Fármacos Anti-Reumáticos Modificadores de la Enfermedad (FARMEs) en pacientes con Artritis Reumatoide (AR) activa ______________________________________________ A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA)	Estudio de extensión multicéntrico no controlado que evalúa la eficacia y seguridad de SAR153191 junto con Fármacos Anti-Reumáticos Modificadores de la Enfermedad (FARMEs) en pacientes con Artritis Reumatoide (AR) activa ______________________________________________ A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA)	Artritis Reumatoide _______________________ Rheumatoid Arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: SAR153191 Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75-	sanofi-aventis Recherche & Développement		Authorised			Female: yes Male: yes	1500		Hungary;Finland;Germany;Netherlands;Estonia;Spain;Greece;Lithuania;Austria
989	EUCTR2011-000107-40-GB	16/06/2011	4 February 2013	A 12 weeks study to evaluate effect of revamilst in addition to methotrexate in rheumatiod arthritis patients.	A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumatoid Arthritis who have had an inadequate response to Methotrexate.	Rheumatoid Arthritis MedDRA version: 15.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Revamilast Product Code: GRC 4039 Pharmaceutical Form: Tablet INN or Proposed INN: Revamilast Current Sponsor code: GRC 4039 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Revamilast Product Code: GRC 4039 Pharmaceutical Form: Tablet INN or Proposed INN: Revamilast Current Sponsor code: GRC 4039 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Revamilast Product Code: GRC 4039 Pharmaceutical Form: Tablet INN or Proposed INN: Revamilast Current Sponsor code: GRC 4039 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Glenmark Pharmaceuticals SA		Not Recruiting			Female: yes Male: yes	406	Phase 2b	Philippines;Poland;Sri Lanka;United Kingdom;India
990	EUCTR2008-001523-57-NO	10/06/2011	19 March 2012	Multicenter, Open-Label Study to Assess Early Response to Abatacept with Background Methotrexate Using Power Doppler Ultrasonography in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Multicenter, Open-Label Study to Assess Early Response to Abatacept with Background Methotrexate Using Power Doppler Ultrasonography in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Adult subjects with active rheumatoid arthritis (RA) according to the American Rheumatism Association criteria for the classification of RA and with inadequate response to methotrexate MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Orencia Product Name: Abatacept (IV) Product Code: BMS-188667 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Current Sponsor code: BMS-188667 Other descriptive name: CTLA4Ig Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-	Bristol Myers Squibb International Corporation		Authorised			Female: yes Male: yes	100		Hungary;Germany;United Kingdom;Denmark;France;Norway;Spain;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
991	EUCTR2010-022504-42-GB	07/06/2011	21 August 2012	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients with Active Rheumatoid Arthritis on background Methotrexate Therapy	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients with Active Rheumatoid Arthritis on background Methotrexate Therapy	Rheumatoid Arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: LY3009104 Product Code: LY3009104 Pharmaceutical Form: Capsule* INN or Proposed INN: Not available CAS Number: 1187595-84-1 Current Sponsor code: LY3009104 phosphate Other descriptive name: JAK1 / JAK2 Inhibtor Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: LY3009104 Product Code: LY3009104 Pharmaceutical Form: Capsule* INN or Proposed INN: Not available CAS Number: 1187595-84-1 Current Sponsor code: LY3009104 phosphate Other descriptive name: JAK1 / JAK2 Inhibtor Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Eli Lilly and Company		Authorised			Female: yes Male: yes	270	Phase 2b	Hungary;United Kingdom
992	EUCTR2011-000215-79-FR	07/06/2011	30 April 2019	Tociluzimab effect on Endothelial function in patients with Rheumatoid Arthritis - TEFRA	Tociluzimab effect on Endothelial function in patients with Rheumatoid Arthritis - TEFRA	Polyarthrite rhumatoïde	Trade Name: Roactemra Pharmaceutical Form: Solution for injection CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	CHU de Clermont Ferrand		Not Recruiting			Female: yes Male: yes	30	Phase 3	France
993	JPRN-UMIN000005590	2011/06/01	2 April 2019	Maintenance of remission by tocilizumab mono-therapy after remission obtained by combination with methotrexate in patients with rheumatoid arthritis		Rheumatoid arthritis	Cessation of MTX (tocilizumab monotherapy) Continue MTX with tocilizumab	Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University		Not Recruiting	20years-old	75years-old	Male and Female	40	Not selected	Japan
994	NCT01215942	June 2011	19 February 2015	An Open Label Study for Patients With Rheumatoid Arthritis	A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: LY2127399	Eli Lilly and Company		Not recruiting	18 Years	N/A	Both	1505	Phase 3	United States;Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;France;Germany;Greece;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sri Lanka;Taiwan;Ukraine;Italy;Peru
995	NCT01351480	June 2011	16 December 2017	Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients	Assessment of Structural Benefits of Injectable Abatacept as Measured by MRI in RA Patients Who Have Failed Prior Anti-Tumor Necrosis (TNF) Therapy and Correlated With Clinical Outcomes	Rheumatoid Arthritis	Biological: abatacept	Arthritis & Rheumatic Disease Specialties Research	Bristol-Myers Squibb	Not recruiting	18 Years	N/A	All	34	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
996	NCT01355354	June 2011	19 February 2015	Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects	An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily	Healthy Volunteers;Rheumatoid Arthritis	Drug: Digoxin;Drug: Fostamatinib	AstraZeneca		Not recruiting	18 Years	45 Years	Both	21	Phase 1	United Kingdom
997	NCT01369745	June 2011	19 October 2017	A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis	A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisolone;Drug: dipyridamole;Drug: Prednisone;Drug: Z102;Other: placebo	Zalicus		Not recruiting	18 Years	N/A	All	294	Phase 2	United States
998	NCT01384422	June 2011	19 February 2015	Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients		Rheumatoid Arthritis	Drug: GLPG0634	Galapagos NV		Not recruiting	18 Years	70 Years	Both	36	Phase 2	Moldova, Republic of
999	NCT01405118	June 2011	19 February 2015	Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers	A Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers	Rheumatoid Arthritis	Drug: Metformin/CP-690,550	Pfizer		Not recruiting	18 Years	55 Years	Both	24	Phase 1	Belgium
1000	NCT01450982	June 2011	19 February 2015	A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants	A Study to Investigate the Effects of JNJ-38518168 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Participants on a Stable Methotrexate Dose	Rheumatoid Arthritis	Drug: JNJ-38518168 / MTX	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		Not recruiting	18 Years	75 Years	Both	20	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1001	EUCTR2010-022378-15-DE	25/05/2011	22 October 2012	A clinical study to explore the therapeutic effects of different doses of the new drug veltuzumab, a drug of biologic origin, and placebo, in patients with rheumatoid arthritis.	VELVET (Veltuzumab various doses exploratory trial), a randomized, double blind, placebo controlled, multicentre, multinational phase II dose range finding trial in subjects with moderate to severe rheumatoid arthritis insufficiently controlled with either methotrexate alone or methotrexate plus anti-tumour necrosis factor biological treatment, comparing 3 different subcutaneous dosages of anti-CD20 monoclonal antibody veltuzumab to placebo as an add-on therapy to methotrexate. - VELVET	Rheumatoid arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Veltuzumab solution 75mg/ml Product Code: hA20 (Immu-106) Pharmaceutical Form: Solution for injection INN or Proposed INN: Veltuzumab CAS Number: 728917-18-8 Current Sponsor code: hA20, IMMU-106 Other descriptive name: humanised anti-CD 20 antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 70-80 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Nycomed GmbH		Not Recruiting			Female: yes Male: yes	300	Phase 2	United States;Hungary;Czech Republic;Mexico;Canada;Argentina;Spain;Germany;United Kingdom
1002	EUCTR2011-003016-23-IT	11/05/2011	27 January 2014	Controlled randomized study on maintenance to low activity disease with low doses of SKA citokines compared with standard therapy	Controlled randomized study on maintenance to low activity disease with low doses of SKA citokines compared with standard therapy (DMARDS)of arthritis management - CIDAI STUDY	Rheumatoid Arthritis MedDRA version: 14.1 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Guna-Anti Interleukin 1 Product Code: NA Pharmaceutical Form: Oral drops INN or Proposed INN: NA CAS Number: NA Current Sponsor code: 36172 Other descriptive name: Guna-Antiinterleukin 1 alfa Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: .000000001- INN or Proposed INN: NA CAS Number: NA Current Sponsor code: 36172 Other descriptive name: Guna-Antiinterleukin 1 beta Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: .000000001- Product Name: Interleukin 10 Product Code: NA Pharmaceutical Form: Oral drops INN or Proposed INN: NA CAS Number: NA Current Sponsor code: 36247 Other descriptive name: Guna-Interleukin 10 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: .000000001- Product Name: Interleukin 4 Product Code: NA Pharmaceutical Form: Oral drops INN or Proposed INN: NA CAS Number: NA Current Sponsor code: 36241 Other descriptive name: Guna-Interleukin 4 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: .000000001-	GUNA SPA		Authorised			Female: yes Male: yes			Italy
1003	EUCTR2009-015019-42-DE	10/05/2011	27 October 2014	Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children with Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)	A Multicenter, Double Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Human Anti-TNFa Antibody, in Pediatric Subjects with Active Polyarticular Course Juvenile Idiopathic Arthritis (JIA) Despite Methotrexate Therapy - GO KIDS	Juvenile Idiopathic Arthritis (JIA) MedDRA version: 16.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Current Sponsor code: CNTO148 Other descriptive name: Human anti-TNF-alpha monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Janssen Biologics B.V.		Not Recruiting			Female: yes Male: yes	170		United States;Finland;Lithuania;Austria;Russian Federation;Mexico;Canada;Argentina;Brazil;Poland;Belgium;Peru;Germany;Netherlands
1004	EUCTR2009-016266-90-ES	03/05/2011	11 September 2012	Estudio aleatorizado, doble-ciego, controlado con placebo, multicéntrico, de dos partes, de búsqueda de dosis y confirmatorio, con un diseño operacionalmente adaptativo que evalúa la eficacia y seguridad de SAR153191 junto con metotrexato (MTX), en pacientes con artritis reumatoide activa con respuesta inadecuadada a la terapia con metotrexato __________________________________________________ A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of methotrexate (MTX) in patients with active rheumatoid arthritis who are inadequate responders to MTX therapy - MOBILITY	Estudio aleatorizado, doble-ciego, controlado con placebo, multicéntrico, de dos partes, de búsqueda de dosis y confirmatorio, con un diseño operacionalmente adaptativo que evalúa la eficacia y seguridad de SAR153191 junto con metotrexato (MTX), en pacientes con artritis reumatoide activa con respuesta inadecuadada a la terapia con metotrexato __________________________________________________ A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of methotrexate (MTX) in patients with active rheumatoid arthritis who are inadequate responders to MTX therapy - MOBILITY	Artritis Reumatoide _____________________________________ Rheumatoid Arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis ;Artritis Reumatoide _____________________________________ Rheumatoid Arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: SAR153191 Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: SAR153191 Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: SAR153191 Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: SAR153191 Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: SAR153191 Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Sanofi-aventis Recherche & Développement		Authorised			Female: yes Male: yes	1740		Portugal;Hungary;Finland;Germany;Czech Republic;Netherlands;Estonia;Spain;Greece;Austria;Lithuania
1005	NCT01262118	May 2011	19 October 2017	Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis	An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP-690,550 (tasocitinib)	Pfizer		Not recruiting	18 Years	N/A	All	69	Phase 1	United States;Hungary
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1006	NCT01283971	May 2011	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor	A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: adalimumab;Drug: placebo to tocilizumab;Drug: placebo to adalimumab;Drug: methotrexate;Drug: folate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	96	Phase 4	Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;Denmark;Finland;France;United States;United Kingdom
1007	NCT01328522	May 2011	19 February 2015	Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients		Rheumatoid Arthritis	Drug: SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	75 Years	Both	32	Phase 1	United States
1008	NCT01329991	May 2011	19 February 2015	Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate	A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interaction of PLX5622 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: PLX5622	Plexxikon		Not recruiting	18 Years	N/A	Both	26	Phase 1	United States
1009	NCT01347983	May 2011	19 February 2015	Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Tocilizumab+Methotrexate(MTX)	Chugai Pharma Taiwan		Not recruiting	20 Years	75 Years	Both	72	Phase 3	Taiwan
1010	NCT01370902	May 2011	19 February 2015	Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Single-dose and Multiple-dose, Dose-escalation Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC 0141-0000-0100;Drug: placebo	Innate Pharma		Not recruiting	18 Years	75 Years	Both	92	Phase 1	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1011	NCT01404429	May 2011	19 October 2017	Study of Two Different Starting Doses of Methotrexate When Starting Treatment in Rheumatoid Arthritis	Randomized Controlled Trial of Two Different Starting Doses of Methotrexate in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate	Postgraduate Institute of Medical Education and Research		Not recruiting	18 Years	65 Years	All	100	Phase 4	India
1012	NCT01405326	May 2011	19 February 2015	REstore Working Ability in RheumatoiD Arthritis	The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work	Rheumatoid Arthritis	Biological: adalimumab	The Rheumatological Center of Helsinki	Abbott	Recruiting	25 Years	55 Years	Both	160	Phase 4	Finland
1013	EUCTR2010-022224-77-GB	27/04/2011	27 May 2013	Open-label study to assess the safety and efficacy of CDP6038 in patients who completed RA0056	A PHASE 2 MULTI-CENTER, OPEN-LABEL, FOLLOW-UP STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO COMPLETED STUDY RA0056 - RA0057	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: CDP6038 Product Code: CDP6038 Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab CAS Number: 1007223-17-7 Current Sponsor code: CDP6038 Other descriptive name: Recombinant human Mab of IgG4 subtype Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	UCB Biosciences Inc		Not Recruiting			Female: yes Male: yes	190	Phase 2	United Kingdom;Belgium;United States
1014	EUCTR2010-023692-26-GB	07/04/2011	2 October 2012	Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) (OSKIRA -4)	(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab Monotherapy in Patients with Active Rheumatoid Arthritis - OSKIRA - 4	Rheumatoid arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Fostamatinib disodium Product Code: previously known as R935788 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib disodium CAS Number: 914295-16-2 Other descriptive name: Fostamatinib disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Other descriptive name: Humira Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	AstraZeneca AB		Authorised			Female: yes Male: yes	280	Phase 2B	Hungary;Germany;Netherlands;Bulgaria;South Africa;United Kingdom;Czech Republic;Russian Federation;Slovakia;Canada;Ukraine;United States;Poland
1015	EUCTR2008-007346-63-GB	05/04/2011	15 April 2013	Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients - REUMAP	Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients - REUMAP	Rheumatoid Arthritis	Product Name: bIAP Product Code: EC 3.1.3.1 Pharmaceutical Form: Solution for injection INN or Proposed INN: bovine intesastinal alkaline phosphatase (bIAP) CAS Number: EC 3.1.3.1 Current Sponsor code: bIAP Other descriptive name: bIAP Concentration unit: IU international unit(s) Concentration type: range Concentration number: 800-1500	Alloksys Life Sciences B.V.		Not Recruiting			Female: yes Male: yes		Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1016	JPRN-UMIN000005362	2011/04/01	2 April 2019	Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by non-steroidal anti-inflammatory drugs(NSAIDs).		Patients with rheumatoid arthritis with anemia taking NSAIDs	Treatment with mesalazine	Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine		Not Recruiting	20years-old	70years-old	Male and Female	13	Not selected	Japan
1017	NCT01336218	April 2011	19 February 2015	Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.	An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin	Rheumatoid Arthritis;Healthy Volunteers	Drug: fostamatinib;Drug: rifampicin	AstraZeneca		Not recruiting	18 Years	55 Years	Both	15	Phase 1	United States
1018	EUCTR2010-023910-30-GB	23/03/2011	19 March 2012	A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early versus Delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA) - Very Early versus Delayed Etanercept in patients with RA (VEDERA)	A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early versus Delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA) - Very Early versus Delayed Etanercept in patients with RA (VEDERA)	Rheumatoid Arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Enbrel 50mg pre-filled pen Product Name: Etanercept (Enbrel) Product Code: EU/1/99/126/020 Pharmaceutical Form: Solution for injection INN or Proposed INN: Etanercept CAS Number: 185243-69-0 Current Sponsor code: RR10/9592 Other descriptive name: Enbrel Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Enbrel 50mg pre-filled syringe Product Name: Etanercept (Enbrel) Product Code: EU/1/99/126/017 Pharmaceutical Form: Solution for injection INN or Proposed INN: Etanercept CAS Number: 185243-69-0 Current Sponsor code: RR10/9592 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	University of Leeds		Authorised			Female: yes Male: yes	120		United Kingdom
1019	EUCTR2010-021020-94-DE	10/03/2011	19 March 2012	A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who have failed previous tumor necrosis factor-alpha (TNF-a) antagonists. - Effect of SAR153191with Methotrexate in patients with active rheumatoid arthritis who failed TNF-a	A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who have failed previous tumor necrosis factor-alpha (TNF-a) antagonists. - Effect of SAR153191with Methotrexate in patients with active rheumatoid arthritis who failed TNF-a	active rheumatoid arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Product Code: SAR153191 Pharmaceutical Form: Solution for injection Current Sponsor code: SAR153191 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Simponi Pharmaceutical Form: Solution for injection INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Sanofi-aventis Recherche & Développement		Not Recruiting			Female: yes Male: yes	250		Hungary;Czech Republic;Germany;Spain;Italy
1020	EUCTR2010-023469-22-NL	09/03/2011	19 March 2012	A phase II study of ARA 290 as therapeutic strategy in rheumatoid arthritis - ARA 290 in ARA	A phase II study of ARA 290 as therapeutic strategy in rheumatoid arthritis - ARA 290 in ARA	Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 12.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ARA290 Product Code: ARA290 Pharmaceutical Form: Solution for infusion	LUMC		Authorised			Female: yes Male: yes	12	Phase 2	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1021	EUCTR2010-022865-81-CZ	02/03/2011	29 July 2013	Clinical trial to investigate the safety, efficacy, and absorption, distribution, and elimination of ALX-0061 compared to placebo in patients with rheumatoid arthritis	A phase I/II, multi-center, randomized, double-blind, placebo controlled study, with a single ascending dose part followed by a multiple ascending dose part, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of intravenous ALX-0061 in patients with rheumatoid arthritis - ALX-0061 phase I/II, single ascending dose and multiple ascending dose study in rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ALX-0061 Product Code: ALX-0061 Pharmaceutical Form: Solution for infusion Other descriptive name: ALX-0061 Nanobody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Ablynx NV		Not Recruiting			Female: yes Male: yes	72	Phase 1/2	Czech Republic;Hungary
1022	NCT01313520	March 1, 2011	16 December 2017	A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)	A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)	Arthritis, Rheumatoid	Drug: Infliximab;Drug: Placebo	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	61	Phase 2	Moldova, Republic of;Romania
1023	NCT01232569	March 2011	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab 162 mg;Drug: Placebo	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	656	Phase 3	United States;Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Philippines;Poland;Russian Federation;South Africa;Spain;Switzerland;Thailand;Peru
1024	NCT01276262	March 2011	19 February 2015	Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects	A Single-blind, Placebo-controlled, 2-period, Fixed Sequence Study to Determine the Effects of Coadministration of Fostamatinib 100 mg Twice Daily on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects	Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction;Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction	Drug: fostamatinib;Drug: Microgynon® 30 (Oral contraceptive);Drug: Placebo	AstraZeneca		Not recruiting	18 Years	45 Years	Female	22	Phase 1	United Kingdom
1025	NCT01284569	March 2011	14 January 2019	Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients	A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA	Rheumatoid Arthritis	Biological: ALX-0061;Biological: Placebo	Ablynx		Not recruiting	18 Years	80 Years	All	65	Phase 1/Phase 2	Czechia;Hungary;Poland;Czech Republic;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1026	NCT01294397	March 2011	16 December 2017	Effects of Denosumab on the Pharmacokinetics of Etanercept	The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis	Postmenopausal;Osteopenia;Rheumatoid Arthritis;Osteoporosis	Drug: Etanercept;Drug: Denosumab	Amgen		Not recruiting	45 Years	80 Years	Female	19	Phase 1	United States
1027	NCT01299961	March 2011	19 October 2017	Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis	Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: abatacept	University of California, Los Angeles		Not recruiting	18 Years	N/A	All	25	Phase 3	United States
1028	NCT01301703	March 2011	19 February 2015	Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis	The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)	Tel-Aviv Sourasky Medical Center		Not recruiting	18 Years	64 Years	Both	100	Phase 4	Israel
1029	NCT01309854	March 2011	19 February 2015	Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects	An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily	Rheumatoid Arthritis;Healthy Volunteers;Pharmacokinetics;Pioglitazone;Drug-drug Interaction;Amount of Pioglitazone in Blood	Drug: fostamatinib;Drug: pioglitazone	AstraZeneca		Not recruiting	18 Years	55 Years	Both	15	Phase 1	United States
1030	NCT01311622	March 2011	19 February 2015	Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects	An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Co-Administered With Fostamatinib in Healthy Subjects	Rheumatoid Arthritis;Healthy Subjects	Drug: warfarin;Drug: fostamatinib	AstraZeneca		Not recruiting	18 Years	55 Years	Both	15	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1031	NCT01313208	March 2011	16 December 2017	Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy	Rheumatoid Arthritis	Drug: etanercept;Drug: Placebo;Drug: DMARD Therapy	Amgen		Not recruiting	18 Years	80 Years	All	210	Phase 4	United States;Canada
1032	NCT01317797	March 2011	19 October 2017	A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis	A Phase Ib Double-blind, Placebo-controlled, Randomized, Dose-escalating Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Subcutaneous Injections of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis on Treatment With Methotrexate	Rheumatoid Arthritis	Drug: namilumab (MT203);Drug: Placebo	Takeda		Not recruiting	18 Years	N/A	All	24	Phase 1	Bulgaria;Netherlands
1033	NCT01332994	March 2011	19 October 2017	A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis	Efficacy and Safety Study of a Sequential Therapy of Tocilizumab (TCZ) and, if Initially Inadequately Responded to Tocilizumab (TCZ), Followed by Rituximab (RTX) in DMARD-IR Patients With Rheumatoid Arthritis (MIRAI)	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	519	Phase 3	Germany
1034	NCT01333878	March 2011	19 February 2015	Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage	An Open-Label, Pilot Trial to Assess the Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage Determined by Low Field Extremity MRI (eMRI) and X-ray	Rheumatoid Arthritis	Biological: Subcutaneous Abatacept	Orrin M Troum, M.D. and Medical Associates	Bristol-Myers Squibb	Not recruiting	18 Years	N/A	Both	12	Phase 2/Phase 3	United States
1035	NCT01353859	March 2011	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs	An Open Label, Local, Multicenter , Phase IIIb Interventional Study to Assess the Efficacy of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) in Indonesian Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	39	Phase 3	Indonesia;Greece
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1036	NCT01566201	March 2011	19 February 2015	Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease	The Effect of Inhibition of Interleukin-1 Activity on Vascular and Left Ventricular Function in Patients With Coronary Artery Disease and Coexistent Rheumatoid Arthritis	Rheumatoid Arthritis;Coronary Artery Disease;Inflammation	Drug: anakinra;Drug: placebo	University of Athens		Not recruiting	18 Years	N/A	Both	80	N/A	Greece
1037	EUCTR2010-020839-39-GB	25/02/2011	28 August 2012	Efficacy and safety of CDP6038 in patients with rheumatoid arthritis with an unsuccessful response to anti-TNF therapy	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY WITH AN ACTIVE COMPARATOR TO EVALUATE THE EFFICACY AND SAFETY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY FOR 12 WEEKS TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS HAVING PREVIOUSLY FAILED TNF-BLOCKER THERAPY - RA0056	Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olikizumab Product Code: CDP6038 Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab CAS Number: 1007223-17-7 Current Sponsor code: CDP6038 Other descriptive name: Recombinant human Mab of IgG4 subtype Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: RoActemra 20 mg/ml concentrate for solution for infusion. Product Name: Tocilizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RoActemra® CAS Number: 375823-41-9 Current Sponsor code: EU/1/08/492/001-6 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	UCB Biosciences, Inc		Not Recruiting			Female: yes Male: yes	220		United Kingdom;United States
1038	EUCTR2010-022206-40-HU	23/02/2011	23 September 2013	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy	Rheumatoid Arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: LY2127399 Product Code: LY2127399 Pharmaceutical Form: Solution for injection Current Sponsor code: LY2127399 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: LY2127399 Product Code: LY2127399 Pharmaceutical Form: Solution for injection Current Sponsor code: LY2127399 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	1002	Phase 3	Hungary;Poland;Lithuania;Bulgaria
1039	EUCTR2010-022205-17-HU	18/02/2011	4 March 2013	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: LY2127399 Product Code: LY2127399 Pharmaceutical Form: Solution for injection Current Sponsor code: LY2127399 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: LY2127399 Product Code: LY2127399 Pharmaceutical Form: Solution for injection Current Sponsor code: LY2127399 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	990	Phase 3	Bulgaria;Lithuania;Poland;Hungary
1040	EUCTR2009-012615-18-FR	16/02/2011	25 January 2016	Efficacy and safety of cholecalciferol on rheumatoid arthritis activity in patients with vitamin D deficiency - SCORPION	Efficacy and safety of cholecalciferol on rheumatoid arthritis activity in patients with vitamin D deficiency - SCORPION	Rheumatoid arthritis (RA) MedDRA version: 12.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions	Trade Name: UVEDOSE Pharmaceutical Form: Oral solution INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 100000- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	CHU de Clermont-Ferrand		Not Recruiting			Female: yes Male: yes			France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1041	EUCTR2010-021558-21-HU	08/02/2011	11 September 2012	A Phase IIa, Multi-Centre, Randomised, Double-Blind, Comparator Controlled, Repeated-Dose Study of 2 Dose Levels of AK106 001616 in Patients with Rheumatoid Arthritis	A Phase IIa, Multi-Centre, Randomised, Double-Blind, Comparator Controlled, Repeated-Dose Study of 2 Dose Levels of AK106 001616 in Patients with Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis ;Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: AK106-001616 Product Code: AK106-001616 Pharmaceutical Form: Capsule, hard CAS Number: 590416-75-4 Current Sponsor code: AK106-001616 (form B) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Naprosyn 500 mg Product Name: Naprosyn 500 mg Pharmaceutical Form: Capsule* INN or Proposed INN: naproxen CAS Number: 22204-53-1 Current Sponsor code: naproxen Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: AK106-001616 Product Code: AK106-001616 Pharmaceutical Form: Capsule, hard CAS Number: 590416-75-4 Current Sponsor code: AK106-001616 (form B) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: AK106-001616 Pharmaceutical Form: Capsule, hard CAS Number: 590416-75-4 Current Sponsor code: AK106-001616 (form B) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Naprosyn 500 mg Product Name: Naprosyn 500 mg Pharmaceutical Form: Capsule* INN or Proposed INN: naproxen CAS Number: 22204-53-1 Current Sponsor code: naproxen Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: AK106-001616 Product Code: AK106-001616 Pharmaceutical Form: Capsule, hard CAS Number: 590416-75-4 Current Sponsor code: AK106-001616 (form B) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Asahi Kasei Pharma Corporation		Not Recruiting			Female: yes Male: yes	240	Phase 2a	Hungary;Slovakia;Czech Republic;Germany;United Kingdom
1042	JPRN-UMIN000008164	2011/02/01	2 April 2019	Restart for sustaining remission of rheumatoid arthritis in use of etanercept		Rheumatoid Arthritis	After the administration of etanercept (50mg/week), the dosage of etanercept will be discontinued when the low disease activity (DAS28-ESR<3.2) is achieved. If patients recur from low disease activity, same dose of etanercept will be administered again by the observation of every two months. This strategy will be maintained for two years. We must control the disease activity below the low disease activity using combined medicine except glucocorticoid if patients could not reach low disease activity after the administration of etanercept in three months. It will be considered to be a dropout if patients cannot reach low disease activity within six months.	Osaka City University Medical School		Recruiting	20years-old	Not applicable	Male and Female	50	Phase 4	Japan
1043	NCT01235507	February 2011	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)	Actemra - Local Bosnian Open, Multicentric, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis After Inadequate Response to DMARDs	Rheumatoid Arthritis	Drug: methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	71	Phase 3	Bosnia and Herzegovina
1044	NCT01254331	February 2011	19 October 2017	An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment	Open Label, Multicenter, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	51	Phase 3	Tunisia
1045	NCT01285752	February 2011	8 August 2016	A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)		Rheumatoid Arthritis	Drug: Active comparator;Drug: AK106-001616	Asahi Kasei Pharma Corporation		Not recruiting	18 Years	65 Years	Both	240	Phase 2	Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1046	NCT01292265	February 2011	19 October 2017	A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)	A Phase 3b, Open Label, Multicenter, Exploratory Study to Assess Changes in Joint Inflammation Using Ultrasonography in Subjects With Rheumatoid Arthritis Treated for 12 Weeks With Certolizumab Pegol	Rheumatoid Arthritis	Biological: Certolizumab Pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	3	Phase 3	United States
1047	NCT01339481	February 2011	19 February 2015	A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept	A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept	Rheumatoid Arthritis	Drug: abatacept	Astellas Pharma Inc	Perseid Therapeutics LLC	Not recruiting	18 Years	N/A	Both	26	N/A	United States
1048	NCT01765374	February 2011	19 February 2015	Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis	Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis	Rheumatoid Arthritis	Device: ESAOTE MyLab60;Drug: Rituximab	University Hospital, Rouen		Not recruiting	18 Years	N/A	Both	30	Phase 4	France
1049	NCT02092961	February 2011	19 October 2017	Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study	A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Placebo or Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study	Rheumatoid Arthritis	Drug: Fostamatinib;Drug: Adalimumab;Drug: Placebo of Fostamatinib;Drug: Placebo of Adalimumab	AstraZeneca		Not recruiting	18 Years	N/A	All	198	Phase 2	United States;Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom
1050	EUCTR2010-022049-88-DE	05/01/2011	30 June 2014	Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quately responded to tocilizumab (TCZ), followed by rituximab (RTX) in DMARD-IR patients with rheumatoid arthritis (MIRAI) - MIRAI	Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quately responded to tocilizumab (TCZ), followed by rituximab (RTX) in DMARD-IR patients with rheumatoid arthritis (MIRAI) - MIRAI	Rheumatoid Arthritis (RA) MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: RoActemra 20 mg/ml Concentrate for solution for infusion Product Name: Tocilizumab Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Mabthera 500 mg Concentrate for solution for infusion Product Name: Rituximab Product Code: RO045-2294 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: RO045-2294 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Roche Pharma AG		Not Recruiting			Female: yes Male: yes			Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1051	NCT01202773	January 2011	11 June 2018	A Study in Participants With Rheumatoid Arthritis	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to One or More TNF-a Inhibitors (FLEX V)	Rheumatoid Arthritis	Drug: LY2127399;Drug: Placebo Q4W;Drug: Placebo Q2W	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	456	Phase 3	United States;Argentina;Australia;Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Russian Federation;South Africa;Spain;Taiwan
1052	NCT01207453	January 2011	19 October 2017	Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis	Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Milnacipran;Drug: Placebo	Brigham and Women's Hospital	Forest Laboratories;National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	24 Years	N/A	All	49	Phase 4	United States
1053	NCT01270035	January 2011	19 February 2015	Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate		Rheumatoid Arthritis	Drug: Adalimumab	Keio University	Saitama Medical University	Recruiting	N/A	N/A	Both	40	Phase 4	Japan
1054	NCT01274910	January 2011	19 February 2015	Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial	Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial	Rheumatoid Arthritis	Dietary Supplement: EPAX 6000 EE 1000mg (0.6 gr DHA+EPA);Dietary Supplement: Capsules (Placebo)	Rabin Medical Center		Recruiting	50 Years	80 Years	Both	60	N/A	Israel
1055	NCT01351805	January 2011	22 July 2019	Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain	Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain	Systemic Inflammatory Process;Knee Pain Chronic;Osteoarthritis;Rheumatoid Arthritis;Autoimmune Diseases	Drug: Fish Oil;Dietary Supplement: Vitamin D;Other: placebo pill	Brigham and Women's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	50 Years	N/A	All	25876	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1056	NCT01411215	January 2011	19 October 2017	A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department	A Non-Interventional Study of the Treatment With Etanercept in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) Subjects in Rheumatology Department	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: Enbrel	Pfizer		Not recruiting	18 Years	N/A	All	160	N/A	China
1057	NCT01737944	January 2011	19 October 2017	Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration	Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate (MTX)	Antares Pharma Inc.		Not recruiting	18 Years	N/A	All	38	Phase 1/Phase 2	United States
1058	NCT02586246	January 2011	23 November 2015	Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870	Long-term Treatment Study of CDP870 Self-injection. A Multicenter, Open-label, Long-term Safety Study to Evaluate the Safety and Efficacy of CDP870 Self-injection Administered at a Dose of 200 mg Biweekly for 24 Weeks or Longer in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 Administered Concomitantly With or Without Methotrexate (MTX)	Active Rheumatoid Arthritis	Drug: CDP870	Astellas Pharma Inc	UCB Japan Co. Ltd.	Not recruiting	N/A	N/A	Both	86	Phase 3	Japan
1059	EUCTR2011-001626-15-ES		30 June 2014	A study of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with rheumatoid arthritis with inadequate response to prior treatment with methotrexate and low disease activity with the combination de RoActemra/Actemra y methotrexate.	A multi-centre, randomized, double-blind study of the safety and efficacy of tocilizumab (TCZ) in combination with methotrexate (MTX), versus TCZ (placebo controlled) in patients with active rheumatoid arthritis (RA) with inadequate response to prior MTX treatment and low disease activity (DAS 28 ? 3.2) with the combination TCZ and MTX.	Rheumatoid arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: ROACTEMRA 20 mg/ml, concentrado para solución para perfusión Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: ROACTEMRA 20 mg/ml, concentrado para solución para perfusión Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Methotrexate 'Lederle' 2.5mg Tablets Product Code: Ro 002-9893/F02 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Methotrexate Disodium CAS Number: 7413345 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Roche Farma, S.A.		Not Recruiting			Female: yes Male: yes			Spain
1060	NCT02675803	December 20, 2010	21 January 2019	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients	A Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VAY736 in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Biological: VAY736;Biological: VAY736 placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	65	Phase 1	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1061	EUCTR2010-021283-14-CZ	15/12/2010	12 May 2014	A randomised, double blind, placebo-controlled, multiple dose trial of Anti-IL-20 (109-0012) in subjects with rheumatoid arthritis	A randomised, double blind, placebo-controlled, multiple dose trial of Anti-IL-20 (109-0012) in subjects with rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Anti-IL-20 (109-0012) Product Code: NNC 0109-0000-0012 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: NNC 0109-0000-0012 Other descriptive name: Anti-IL-20 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	66		Portugal;Hungary;Czech Republic;Spain;Italy;United Kingdom
1062	EUCTR2009-015898-12-NL	10/12/2010	19 March 2012	Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination with Methotrexate, Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination with Methotrexate, Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Patients with active rheumatoid arthritis and an inadequate response to Methotrexate MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Product Name: GLPG0259 Product Code: GLPG0259 Pharmaceutical Form: Capsule, hard CAS Number: 1195065-29-2 Current Sponsor code: GLPG0259 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0259 Product Code: GLPG0259 Pharmaceutical Form: Capsule, hard CAS Number: 1195065-29-2 Current Sponsor code: GLPG0259 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0259 Product Code: GLPG0259 Pharmaceutical Form: Capsule, hard CAS Number: 1195065-29-2 Current Sponsor code: GLPG0259 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6.25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GLPG0259 Product Code: GLPG0259 Pharmaceutical Form: Capsule, hard CAS Number: 1195065-29-2 Current Sponsor code: GLPG0259 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Galápagos NV		Not Recruiting			Female: yes Male: yes	200	Phase 2	Netherlands;Belgium
1063	NCT01285310	December 9, 2010	16 December 2017	Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Apremilast 30 mg;Drug: Apremilast 20 mg;Drug: Placebo	Celgene		Not recruiting	18 Years	N/A	All	237	Phase 2	United States;Czechia;Poland;Spain;Czech Republic
1064	EUCTR2010-021435-14-NL	06/12/2010	19 March 2012	Effects of abatacept (Orencia®) on biomarkers in synovial tissue in patients with rheumatoid arthritis	Effects of abatacept (Orencia®) on biomarkers in synovial tissue in patients with rheumatoid arthritis	rheumatoid arthritis	Trade Name: Orencia Product Name: Abatacept Product Code: BMS-188667 Pharmaceutical Form: Powder for solution for injection	Academisch Medisch Centrum Amsterdam		Authorised			Female: yes Male: yes			Netherlands
1065	EUCTR2010-019871-31-GB	01/12/2010	28 February 2019	A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients with Rheumatoid Arthritis	A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: ARCOXIA Product Name: Etoricoxib Product Code: MK-0663 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ETORICOXIB CAS Number: 202409-33-4 Current Sponsor code: MK-0663 Other descriptive name: 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: ARCOXIA Product Name: Etoricoxib Product Code: MK-0663 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ETORICOXIB CAS Number: 202409-33-4 Current Sponsor code: MK-0663 Other descriptive name: 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,		Not Recruiting			Female: yes Male: yes	1800	Phase 3	Czech Republic;Slovakia;Finland;Belgium;Lithuania;Austria;Germany;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1066	NCT01142726	December 2010	19 October 2017	Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis	A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Drug: Abatacept placebo;Drug: Methotrexate placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	511	Phase 3	United States;Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;Norway
1067	NCT01236118	December 2010	19 October 2017	A Study of LY2439821 in Rheumatoid Arthritis	An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate	Rheumatoid Arthritis	Drug: LY2439821	Eli Lilly and Company		Not recruiting	20 Years	N/A	All	28	Phase 1	Japan
1068	NCT01258712	December 2010	19 February 2015	Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Randomized, Placebo-controlled Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Rheumatoid Arthritis (RA)	Drug: Tocilizumab + methotrexate(MTX);Drug: Tocilizumab placebo + methotrexate(MTX)	Chugai Pharma Taiwan		Not recruiting	20 Years	75 Years	Both	86	Phase 3	Taiwan
1069	NCT01261403	December 2010	12 March 2018	Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis	A Phase 2, Randomized, Double- Blind, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: PDA001;Drug: Vehicle Controlled Placebo	Celularity Incorporated	Celgene Corporation	Not recruiting	18 Years	75 Years	All	26	Phase 2	United States
1070	NCT01270997	December 2010	19 February 2015	Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients	A Multicenter Randomized Double-blind Active-controlled Parallel Group Phase ? Trial to Evaluate the Equivalence in Efficacy and Safety of HD203 and Enbrel in Combination With Methotrexate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Etanercept	Hanwha Chemical		Not recruiting	20 Years	N/A	Both	294	Phase 3	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1071	EUCTR2010-021184-32-DE	30/11/2010	24 October 2016	GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy	A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolerant to standard DMARDs and one or up to three anti-TNF therapies	Refractory rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: NA Product Code: GP2013 Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: GP2013 Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 1000- Trade Name: Mabthera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Trade Name: Rituxan (INN: Rituximab), brand name in the United States Product Name: Rituxan Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-	Hexal AG		Not Recruiting			Female: yes Male: yes	164	Phase 2	Germany;Bulgaria;Romania;Brazil;Belgium;Poland;Argentina;Hungary;France;India;Italy;United Kingdom;Austria;Turkey;Spain;Estonia
1072	EUCTR2010-020745-27-BE	23/11/2010	21 August 2017	Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist (OSKIRA - 3)	A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Response to a TNF-alpha antagonist - OSKIRA - 3	Rheumatoid Arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Fostamatinib disodium Product Code: FosD Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib disodium CAS Number: 914295-16-2 Current Sponsor code: FosD Other descriptive name: Fostamatinib disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	450	Phase 3	Portugal;United States;Spain;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Belgium;Brazil;Australia;South Africa;Germany
1073	EUCTR2010-020892-22-BE	23/11/2010	21 August 2017	Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) (OSKIRA-X)	A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA - X	Rheumatoid Arthritis MedDRA version: 16.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Fostamatinib disodium Product Code: FosD Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib disodium CAS Number: 914295-16-2 Current Sponsor code: FosD Other descriptive name: Fostamatinib disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	2000	Phase 3	United States;Serbia;Portugal;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Chile;Italy;India;France;Peru;Australia;South Africa;Netherlands;Latvia;Lithuania;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Bulgaria;Germany
1074	JPRN-UMIN000004412	2010/11/01	2 April 2019	Corticosteroid-sparing effect of Actemra in patients with Rheumatoid Arthritis refractory to anti-TNF agents, methotrexate and corticosteroid		rheumatoid arthritis	tocilizumab	General Internal Medicine, Tenri Hospital		Recruiting	16years-old	80years-old	Male and Female	25	Not applicable	Japan
1075	JPRN-UMIN000008756	2010/11/01	2 April 2019	Abatacept-based approach to cure of RA		Rheumatoid Arthritis	Abatacept treatmentat month 12 MTX treatment at month 12	University of Occupational and Environmental Health, Japan		Recruiting	15years-old	Not applicable	Female	40	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1076	NCT01225393	November 2010	14 November 2016	A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis	A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patient With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MLTA3698A;Drug: adalimumab;Drug: leflunomide;Drug: methotrexate;Drug: placebo	Genentech, Inc.		Not recruiting	18 Years	75 Years	Both	211	Phase 2	Romania;Spain;Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;United States
1077	NCT01225991	November 2010	19 October 2017	Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis	An Open-label Trial of Milnacipran for the Treatment of Pain in Rheumatoid Arthritis (RA) in Older Adults	Rheumatoid Arthritis	Drug: Milnacipran	University of California, Los Angeles	Forest Laboratories	Not recruiting	50 Years	N/A	All	18	Phase 4	United States
1078	NCT01245790	November 2010	19 February 2015	A Study of Fostamatinib in Subjects With Impaired Kidney Function	An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg	Rheumatoid Arthritis;Renal Impairment	Drug: fostamatinib	AstraZeneca		Not recruiting	18 Years	N/A	Both	24	Phase 1	United States
1079	NCT01255761	November 2010	11 June 2018	A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects	Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia	Rheumatoid Arthritis	Biological: Certolizumab Pegol (CZP)	UCB Pharma		Not recruiting	18 Years	N/A	All	736	Phase 4	United States
1080	NCT01287858	November 2010	17 November 2015	Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects	A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects	Rheumatoid Arthritis	Drug: AC430	Daiichi Sankyo Inc.		Not recruiting	18 Years	45 Years	Both	88	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1081	NCT01618019	November 2010	19 October 2017	N-3 PUFA and Rheumatoid Arthritis in Korea	Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Omega-3 fatty acid;Dietary Supplement: Placebo	Hanyang University		Not recruiting	18 Years	80 Years	All	109	N/A	Korea, Republic of
1082	EUCTR2008-006924-68-AT	28/10/2010	17 October 2016	Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy. - this is an extension study to MA21573	Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy. - this is an extension study to MA21573	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Actemra Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	1200	Phase 3	France;Portugal;Hungary;Czech Republic;Spain;Austria;Netherlands;United Kingdom;Italy
1083	EUCTR2010-020743-12-GB	26/10/2010	19 March 2012	A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate - OSKIRA - 1	A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate - OSKIRA - 1	Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Fostamatinib disodium Product Code: FosD Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib disodium CAS Number: 914295-16-2 Current Sponsor code: FosD Other descriptive name: Fostamatinib disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AstraZeneca AB		Authorised			Female: yes Male: yes	900	Phase 3	Hungary;Germany;United Kingdom;Bulgaria;France;Estonia;Poland
1084	EUCTR2010-020744-35-GB	26/10/2010	27 May 2013	Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. (OSKIRA - 2)	A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs - OSKIRA - 2	Rheumatoid Arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Fostamatinib disodium Product Code: FosD Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib disodium CAS Number: 914295-16-2 Current Sponsor code: FosD Other descriptive name: Fostamatinib disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Portugal;Serbia;Spain;Ukraine;Lithuania;Israel;United Kingdom;Italy;India;Czech Republic;Canada;Romania;South Africa;Germany;Latvia
1085	NCT01362062	October 26, 2010	16 December 2017	Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy	A Study to Observe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti TNF Therapy.	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	110	N/A	India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1086	EUCTR2010-018485-24-CZ	20/10/2010	1 December 2014	To investigate the efficacy and safety of SC BT061 in patients with active rheumatoid arthritis	A multi-center, double-blind, randomized, placebo-controlled, dose-finding study in patients with active rheumatoid arthritis incompletely controlled on stable MTX doses to investigate efficacy and safety of SC BT061 - BT061 plus MTX in RA	Patients with active rheumatoid arthritis incompletely controlled on stable MTX doses. MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BT061 Product Code: BT061 Pharmaceutical Form: Solution for injection INN or Proposed INN: Humanised anti-CD4 IgG1 monoclonal Current Sponsor code: BT061 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- INN or Proposed INN: Humanised anti-CD4 IgG1 monoclonal Current Sponsor code: BT061 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Biotest AG		Not Recruiting			Female: yes Male: yes	128		Hungary;Czech Republic;Spain;Latvia;Germany
1087	EUCTR2010-019134-27-CZ	19/10/2010	19 May 2014	A PHASE II, MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, METHOTREXATE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SAFETY, AND TOLERABILITY OF CH-4051 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE SHOWN AN INADEQUATE RESPONSE TO METHOTREXATE MONOTHERAPY	A PHASE II, MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, METHOTREXATE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SAFETY, AND TOLERABILITY OF CH-4051 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE SHOWN AN INADEQUATE RESPONSE TO METHOTREXATE MONOTHERAPY	Rhuematoid Arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Product Name: CH-4051 Product Code: CH-4051 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dipotassium Salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.3- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: CH-4051 Product Code: CH-4051 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dipotassium Salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: CH-4051 Product Code: CH-4051 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dipotassium Salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.0- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Methotrexate Product Name: Methotrextate Pharmaceutical Form: Capsule, hard INN or Proposed INN: Methotrexate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Folic Acid Product Name: Folic Acid Pharmaceutical Form: Capsule, hard INN or Proposed INN: Folic Acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-	Chelsea Therapeutics, Inc		Not Recruiting			Female: yes Male: yes	250	Phase 2	Czech Republic;Bulgaria
1088	EUCTR2010-019871-31-FI	18/10/2010	7 October 2014	Etoricoxib and placebo in patients with rheumatoid arthritis	A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis (RA) MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: ARCOXIA Product Name: Etoricoxib Product Code: MK-0663 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ETORICOXIB CAS Number: 202409-33-4 Current Sponsor code: MK-0663 Other descriptive name: 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: ARCOXIA Product Name: Etoricoxib Product Code: MK-0663 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ETORICOXIB CAS Number: 202409-33-4 Current Sponsor code: MK-0663 Other descriptive name: 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.		Not Recruiting			Female: yes Male: yes	1800	Phase 3	United States;Taiwan;Slovakia;Finland;Lithuania;Austria;Russian Federation;Colombia;United Kingdom;India;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Romania;South Africa;Germany
1089	EUCTR2010-020738-24-GB	12/10/2010	19 March 2012	To see whether for patients with established rheumatoid arthritis that have already achieved a good response to Tumour Necrosis Factor Inhibitor (TNF inhibitor) treatment, whether the treatment be tapered to a minimum dose without affecting the control of disease activity.	Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA) - OPTTIRA	Patients with established Rheumatoid arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Enbrel pre-filled pen Product Name: Etanercept Pharmaceutical Form: Solution for injection INN or Proposed INN: etanercept CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Adalimumab Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Enbrel pre-filled syringe Product Name: Etanercept Pharmaceutical Form: Solution for injection INN or Proposed INN: etanercept CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	King's College London		Authorised			Female: yes Male: yes	0		United Kingdom
1090	EUCTR2010-018646-31-SK	11/10/2010	3 April 2017	A Randomized, Double Blind, Parallel-Group, Phase 3 Study to Demonstrate Equivalence in Efficacy and Safety of CT-P13 Compared With Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis	A Randomized, Double Blind, Parallel-Group, Phase 3 Study to Demonstrate Equivalence in Efficacy and Safety of CT-P13 Compared With Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 12.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CT-P13 Product Code: CT-P13 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Infliximab CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: Remicade Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	CELLTRION, Inc		Not Recruiting			Female: yes Male: yes	584	Phase 3	Portugal;Slovakia;Spain;Lithuania;Austria;Bulgaria;Latvia;Italy;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1091	EUCTR2010-021449-28-FR	04/10/2010	19 March 2012	Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde - AFORA	Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde - AFORA	Polyarthrite rhumatoïde MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: HUMIRA Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	CHRU de TOURS		Authorised			Female: yes Male: yes			France
1092	NCT01034306	October 2010	19 October 2017	Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis	A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors	Rheumatoid Arthritis	Drug: CF101;Drug: Placebo control	Can-Fite BioPharma		Not recruiting	18 Years	75 Years	All	79	Phase 2	Bulgaria;Israel
1093	NCT01098201	October 2010	28 September 2015	Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)	The Effect of Certolizumab on Lower Extremity Lymph Flow in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Certolizumab	University of Rochester		Not recruiting	18 Years	N/A	Both	5	Phase 4	United States
1094	NCT01149057	October 2010	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS	An Open-Label Study to Evaluate the Efficacy and Safety Of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARDs and/or Biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	Clalit Health Services	Not recruiting	18 Years	N/A	All	145	Phase 4	Israel
1095	NCT01164579	October 2010	19 October 2017	Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)	An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tasocitinib plus Methotrexate;Drug: Tofacitinib plus placebo methotrexate;Drug: Placebo tofacitinib plus Methotrexate	Pfizer		Not recruiting	18 Years	N/A	All	109	Phase 2	United States;Argentina;Chile;Croatia;Czech Republic;Hungary;Mexico;Poland;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1096	NCT01185301	October 2010	19 October 2017	Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)	A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)	Early Rheumatoid Arthritis	Biological: adalimumab;Drug: methotrexate	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	N/A	All	395	Phase 3	United States;Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Poland;Puerto Rico;Spain
1097	NCT01185353	October 2010	16 December 2017	A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy	Arthritis, Rheumatoid	Drug: LY3009104;Drug: Placebo;Drug: Methotrexate	Eli Lilly and Company	Incyte Corporation	Not recruiting	18 Years	75 Years	All	301	Phase 2	United States;Croatia;Czechia;Hungary;India;Mexico;Poland;Romania;Ukraine;Argentina;Czech Republic;Peru;United Kingdom
1098	NCT01214733	October 2010	14 December 2015	A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis	An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	30	Phase 3	South Africa
1099	NCT01217086	October 2010	19 February 2015	Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)	Randomized, Double-blind, Parallel-group, Phase 3 Study	Rheumatoid Arthritis	Drug: Infliximab	Celltrion		Not recruiting	18 Years	75 Years	Both	617	Phase 3	Korea, Republic of
1100	NCT01221636	October 2010	14 September 2015	Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept	A Study to Compare the Pharmacokinetics of Abatacept (BMS-188667) Drug Product Using Active Pharmaceutical Ingredient Manufactured With a High Concentration of Metals Relative to the Active Pharmaceutical Ingredient Manufactured With a Low Concentration of Metals	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	55 Years	Both	0	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1101	NCT01264211	October 2010	17 November 2015	Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)	A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study	Rheumatoid Arthritis	Drug: Diacerein;Drug: Placebo	TRB Chemedica		Not recruiting	18 Years	65 Years	Both	40	Phase 2	Thailand
1102	NCT01781702	October 2010	19 February 2015	Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients	A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients	Pelubiprofen;Celebrex;Rheumatoid Arthritis	Drug: Pelubiprofen 30 mg;Drug: Celebrex 200 mg	Daewon Pharmaceutical Co., Ltd.		Not recruiting	18 Years	80 Years	Both	120	Phase 3
1103	NCT02528292	October 2010	31 August 2015	Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis	Phase 4 Study of Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Patients With Rheumatoid Arthritis Undergoing Treatment With Anti-TNF Therapy	Rheumatoid Arthritis	Procedure: Synovial biopsy;Drug: Anti-TNF therapy	Barts & The London NHS Trust		Not recruiting	18 Years	N/A	Both	24	N/A	United Kingdom
1104	ChiCTR1900024107	2010-09-29	1 July 2019	A randomized, controlled, open label, multicenter clinical trial to evaluate the efficacy and safety of recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) with Methotrexate in active rheumatoid arthritis (ReABLE-II)	A randomized, controlled, open label, multicenter clinical trial to evaluate the efficacy and safety of recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) with Methotrexate in active rheumatoid arthritis (ReABLE-II)	Active Rheumatoid Arthritis	A:Treatment of Yisaipu combined with methotrexate for 52 weeks;B:Treatment of Yisaipu combined with methotrexate for the first 24 weeks and followed by methotrexate monotherapy;C:Methotrexate monotherapy for 52 weeks;	Chinese Academy of Medical Sciences & Peking Union Medical College Hospital		Not Recruiting	18	60	Both	A:30;B:30;C:30;	Phase 4	China
1105	EUCTR2010-019694-15-BE	28/09/2010	21 August 2017	Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoid dose reduction once low disease activity is reached - ACT-Alone	Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoid dose reduction once low disease activity is reached - ACT-Alone	Rheumatoid Arthritis in adult MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Medrol 4 mg tablets Pharmaceutical Form: Tablet CAS Number: 83-43-2 Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Trade Name: Medrol A 16 mg tablets Pharmaceutical Form: Tablet CAS Number: 83-43-2 Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 16-	N.V. Roche S.A.		Not Recruiting			Female: yes Male: yes		Phase 4	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1106	JPRN-UMIN000011789	2010/09/21	2 April 2019	Usefulness of intravenous abatacept at an increased dose in rheumatoid arthritis patients with a poor prognosis		Rheumatoid arthritis	Administration of increased dose of abatacept to patients with rheumatoid arthritis previously treated with abatacept.	National Health Organization Nagoya Medical Center		Not Recruiting	Not applicable	Not applicable	Male and Female	20	Not applicable	Japan
1107	EUCTR2010-019935-37-FI	15/09/2010	13 May 2013	A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practice DMARD therapy in patients with early, moderate to severe Rheumatoid Arthritis	A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practice DMARD therapy in patients with early, moderate to severe Rheumatoid Arthritis	Rheumatoid Arthritis (RA) MedDRA version: 12.1 Level: LLT Classification code 10039073 Term:	Trade Name: RoActemra® Product Code: Ro 487-7533/F01 Pharmaceutical Form: Concentrate for solution for infusion CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Roche Oy		Not Recruiting			Female: yes Male: yes	160		Finland
1108	ChiCTR-TRC-10001014	2010-09-01	18 April 2017	Randomized Controlled Study to Evaluate the Clinical Outcomes of Rheumatoid Arthritis Treated with Method of Activating Blood Circulation by Removing Blood Stasis	Randomized Controlled Study to Evaluate the Clinical Outcomes of Rheumatoid Arthritis Treated with Method of Activating Blood Circulation by Removing Blood Stasis	Rheumatoid Arthritis;M06.991	Group A:observation group: Leflunomide Tablets, from the first day to the third day, 50mg, qd, po, then 20mg, qd, po. Ligustrazine Powder-Needle, 0.12g, solubling in 5% GS/NS 100ml, qd, iv, in 30 to 60 minutes. ;Group B:control group: Leflunomide Tablets, from the first day to the third day, 50mg, qd, po, then 20mg, qd, po. ;	Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences		Not Recruiting	18	65	Both	Group A:60;Group B:60;	Phase 1 study	China
1109	NCT01116141	September 2010	19 February 2015	A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)	A Phase II, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy	Rheumatoid Arthritis	Drug: CH-4051;Drug: Methotrexate (MTX);Drug: Folic Acid	Chelsea Therapeutics		Not recruiting	18 Years	80 Years	Both	250	Phase 2
1110	NCT01154647	September 2010	19 February 2015	Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes	Unraveling Impaired Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes: a Series of Experiments Targeting Brain Neurotransmission	Fatigue Syndrome, Chronic;Fibromyalgia;Arthritis, Rheumatoid	Drug: citalopram;Drug: 1 ml 0.9 % NaCl	Vrije Universiteit Brussel	Research Foundation Flanders;Universiteit Antwerpen;University Hospital, Antwerp;Artesis University College, Antwerp	Not recruiting	18 Years	65 Years	Female	70	N/A	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1111	NCT01162421	September 2010	19 October 2017	A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis	Radiographic, Clinical and Patient Outcomes in a Multicenter, Open Label Phase IV Randomized Trial of Earlier Adalimumab Introduction Therapy Versus Later Introduction as Per Standard of Care After Initial Methotrexate Failure in Early Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Biological: adalimumab;Drug: Methotrexate	AbbVie (prior sponsor, Abbott)	Mount Sinai Hospital, Canada	Not recruiting	18 Years	99 Years	All	77	Phase 4	Canada
1112	NCT01163747	September 2010	19 October 2017	A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)	A Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Tocilizumab on Vaccination in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate	Rheumatoid Arthritis	Biological: tocilizumab;Drug: methotrexate;Biological: 23-Valent Pneumococcal Polysaccharide Vaccine;Biological: Tetanus Toxoid Adsorbed Vaccine	Genentech, Inc.		Not recruiting	18 Years	64 Years	All	91	Phase 4	United States
1113	NCT01184001	September 2010	19 February 2015	A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects	A Phase 1, Randomized, 2-Period, 2-Sequence, Open Label, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On Pharmacokinetics Of Tasocitinib (CP-690,550) Tablets In Healthy Subjects	Rheumatoid Arthritis	Drug: Treatment A;Drug: Treatment B	Pfizer		Not recruiting	21 Years	55 Years	Both	16	Phase 1	Singapore
1114	NCT01185288	September 2010	19 October 2017	A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)	A Multicenter, Double-Blind, Randomized, Parallel-Arm Study to Determine the Effect of Methotrexate Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis Treated With Adalimumab (MUSICA)	Rheumatoid Arthritis	Biological: Adalimumab;Drug: Methotrexate	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	N/A	All	309	Phase 4	United States;Puerto Rico
1115	NCT01208506	September 2010	16 December 2017	First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis	First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis;Healthy	Drug: NNC0114-0000-0005;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	All	64	Phase 1	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1116	NCT01213017	September 2010	16 December 2017	The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients	The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: certolizumab pegol	Oklahoma Medical Research Foundation	UCB Pharma	Not recruiting	18 Years	N/A	All	20	Phase 3	United States
1117	NCT01248780	September 2010	19 October 2017	Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Golimumab;Drug: Placebo;Drug: Methotrexate (MTX)	Centocor, Inc.	Schering-Plough	Not recruiting	18 Years	N/A	All	264	Phase 3	China
1118	NCT01282528	September 2010	19 February 2015	Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis	Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Ultrasonography;Infliximab	Biological: infliximab	Peking Union Medical College Hospital	Shanghai Changzheng Hospital;First Hospital of China Medical University;Shenzhen People's Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Wenzhou Medical University;First People's Hospital of Foshan;West China Hospital	Recruiting	18 Years	65 Years	Both	85	Phase 4	China
1119	EUCTR2010-019964-36-BE	26/08/2010	21 August 2017	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy - CARAT-2	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy - CARAT-2	Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CCX354-C Product Code: CCX354-C Pharmaceutical Form: Film-coated tablet Current Sponsor code: CCX354-C Other descriptive name: CCX354 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	ChemoCentryx, Inc.		Not Recruiting			Female: yes Male: yes	150	Phase 2	Czech Republic;Hungary;Belgium;Germany
1120	EUCTR2010-018375-22-ES	03/08/2010	19 March 2012	A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with oderate to severe active rheumatoid arthritis. Estudio randomizado, doble ciego, con grupos de tratamiento paralelos, para evaluar la seguridad y el efecto sobre el resultado clínico de tocilizumab SC frente a tocilizumab IV en combinación con fármacos antirreumáticos modificadores de la enfermedad (FAMEs) tradicionales, en pacientes con artritis reumatoide activa moderada a severa.	A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with oderate to severe active rheumatoid arthritis. Estudio randomizado, doble ciego, con grupos de tratamiento paralelos, para evaluar la seguridad y el efecto sobre el resultado clínico de tocilizumab SC frente a tocilizumab IV en combinación con fármacos antirreumáticos modificadores de la enfermedad (FAMEs) tradicionales, en pacientes con artritis reumatoide activa moderada a severa.	Rheumatoid arthritis Artritis Reumatoide MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: tocilizumab 162mg/0.9ml jeringa SC Product Code: Ro 487-7533/F10 Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 180- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: ROACTEMRA 20 mg/ml, concentrado para solución para perfusión Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TOCILIZUMAB Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd.		Authorised			Female: yes Male: yes	1200		Germany;United Kingdom;Bulgaria;Spain;Italy;Lithuania
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1121	ChiCTR-TRC-10000989	2010-08-01	18 April 2017	A 24 Week Randomized Controlled Study to Evaluate the Clinical Outcomes of Rheumatoid Arthritis Treated with Chinese Medicines –the Second Trial	A 24 Week Randomized Controlled Study to Evaluate the Clinical Outcomes of Rheumatoid Arthritis Treated with Chinese Medicines	rheumatoid arthritis;M06.991	observation group:Methotrexate Tablets, once per week, for first tim;observation group:Leigongtengduogan Pian, 10mg per time, 3 times per day, Yishen Juanbi Wan, 8g per time, 3 times per day, for oral administration, after meals ;Total:;	The Ministry of Science and Technology of the People's Republic of China		Not Recruiting	18	70	Male	observation group:120;observation group:120;Total:240;	Post-market	China
1122	JPRN-JapicCTI-101263	01/8/2010	2 April 2019	DRIVE	A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate (MTX) to Validate Inhibitory Effect on Bone Erosion (Phase II)	Rheumatoid Arthritis	Intervention name : AMG 162 INN of the intervention : Denosumab Dosage And administration of the intervention : AMG 162 60 mg administered subcutaneously - Every 6 months/ Every 3 months/ Every 2 months Control intervention name : Placebo Dosage And administration of the control intervention : Subcutaneously for placebo	DAIICHISANKYO Co.,Ltd.			20	75	BOTH	320	Phase 2
1123	NCT01184092	August 2010	19 February 2015	A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)	Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, Cross-Over, Bioequivalence Study Comparing Phase 2b, Phase 3 And Commercial Image Tablet Formulations Of Tasocitinib (CP-690,550) Under Fasted Conditions	Rheumatoid Arthritis	Drug: Treatment A;Drug: Treatment B;Drug: Treatment C	Pfizer		Not recruiting	21 Years	55 Years	Both	24	Phase 1	Singapore
1124	EUCTR2010-019261-28-DE	26/07/2010	19 March 2012	A randomised, single-dose, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC 0142-0000-0002 in subjects with active rheumatoid arthritis	A randomised, single-dose, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC 0142-0000-0002 in subjects with active rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: NNC 0142-0000-0002 Product Code: NNC 142-0002 Pharmaceutical Form: Powder and solvent for solution for injection Current Sponsor code: NNC 142-0002 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	160		Germany
1125	EUCTR2009-017051-10-NL	13/07/2010	19 March 2012	Metabolic adverse events before and after glucocorticoid pulse therapy in rheumatoid arthritis	Metabolic adverse events before and after glucocorticoid pulse therapy in rheumatoid arthritis	Patients with rheumatoid arthritis, who suffer from a exacerbation of disease can be included in this study. Exacerbation is defined as a Disease Activity Score of 5.1 or higher. Patients will be excluded if they suffer from diabetes (irrespective of medication) or if they have a contra-indication for dexamethason use. MedDRA version: 12.0 Level: LLT Classification code 10060732 Term: Rheumatoid arthritis flare up	Trade Name: Dexamethason Product Name: dexamethason Pharmaceutical Form: Intravenous infusion	UMC Utrecht		Authorised			Female: yes Male: yes			Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1126	EUCTR2009-012041-35-BE	02/07/2010	7 October 2014	A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapy	A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapy - TNF-K-003	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: TNF-Kinoid Product Code: TNF-K Pharmaceutical Form: Emulsion for injection INN or Proposed INN: Not assigned yet Current Sponsor code: TNF-K Other descriptive name: N.A. Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 360- Pharmaceutical form of the placebo: Emulsion for injection Route of administration of the placebo: Intramuscular use	Neovacs SA		Authorised			Female: yes Male: yes	48	Phase 2	France;Argentina;Belgium;Croatia;Romania;Chile;Bulgaria
1127	JPRN-UMIN000003807	2010/07/01	2 April 2019	A study for comparison of triple combination therapy (bucillamine, salazosulphapiridine and methotrexate) with TNF-blocking biologics and methotrexate combination therapy concerning efficacy and tolerability for rheumatoid arthritis		Rheumatoid Arthritis	Combination therapy of three DMARDs (bucillamine, salazosulphapyridine and methotrexate) Combination therapy of TNF-bloking biologics and methotrexate	Japan Association of Rheumatologists in Private Practice		Not Recruiting	Not applicable	Not applicable	Male and Female	160	Not applicable	Japan
1128	JPRN-UMIN000003880	2010/07/01	2 April 2019	Keeping cartilagious quality by adalimumab in patient with rheumatoid arthritis in Kansai area		Rheumatoid arthritis	DAS28>3.2 at 24 weeks Switching to another biologics DAS28>3.2 at 24 weeks Dose up of MTX or addition of other DMARDs DAS28<=3.2 at 24 weeks 40 mg of Adalimumab every two week DAS28<=3.2 at 24 weeks 40 mg of Adalimumab every four week	Osaka City University Medical School	Higashi Sumiyoshi Morimoto Hospital, Yodogawa Christian Hospital, Kitade Hospital, Shirahama Hamayu Hospital	Recruiting	20years-old	Not applicable	Male and Female	100	Not applicable	Japan
1129	NCT01147341	July 2010	19 October 2017	Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia	Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase	Rheumatoid Arthritis	Drug: Cimzia;Drug: Placebo	Michael Schiff, MD	UCB Pharma	Not recruiting	18 Years	75 Years	All	37	Phase 4	United States
1130	NCT01593332	July 2010	19 February 2015	Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis		DMARD Resistant Rheumatoid Arthritis	Drug: Rituximab	Mashhad University of Medical Sciences	Roche Pharma AG	Not recruiting	19 Years	75 Years	Both	44	Phase 4	Iran, Islamic Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1131	EUCTR2009-013758-33-SE	17/06/2010	27 January 2014	MULTICENTER STUDY WITH A 16-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED (DURING THE INITIAL 2 WEEKS) RANDOMIZED PERIOD, FOLLOWED BY A 24-WEEK OPEN LABEL EXTENSION TO ASSESS MAGNETIC RESONANCE IMAGE-VERIFIED EARLY RESPONSE TO CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS	MULTICENTER STUDY WITH A 16-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED (DURING THE INITIAL 2 WEEKS) RANDOMIZED PERIOD, FOLLOWED BY A 24-WEEK OPEN LABEL EXTENSION TO ASSESS MAGNETIC RESONANCE IMAGE-VERIFIED EARLY RESPONSE TO CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia® Product Name: certolizumab pegol (CZP) Product Code: CDP870 Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	UCB Pharma S.A.		Not Recruiting			Female: yes Male: yes	36		Denmark;Netherlands;Sweden
1132	EUCTR2009-012055-19-IE	16/06/2010	19 March 2012	A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritis	A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: GSK315234 Injection 100mg/mL Product Code: GSK315234 Pharmaceutical Form: Injection* Current Sponsor code: GSK315234 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Intravenous use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	45		United Kingdom;Belgium;France;Ireland
1133	EUCTR2010-019873-13-BE	07/06/2010	21 August 2017	Comparative study of the clinical response and cardiorespiratory endurance in early rheumatoid arthritis patients treated with Tociluzimab or Methotrexate Addendum protocol : Global gene expression profiles in synovial biopsies from early rheumatoid arthritis patients treated with Tocilizumab or Methotrexate - TOMERA	Comparative study of the clinical response and cardiorespiratory endurance in early rheumatoid arthritis patients treated with Tociluzimab or Methotrexate Addendum protocol : Global gene expression profiles in synovial biopsies from early rheumatoid arthritis patients treated with Tocilizumab or Methotrexate - TOMERA	early rheumatoid arthritis MedDRA version: 12.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions	Trade Name: RoActemra Product Name: Tocilizumab Pharmaceutical Form: Solution for infusion	UCL Cliniques Universitaires Saint Luc		Not Recruiting			Female: yes Male: yes		Phase 2	Belgium
1134	EUCTR2008-005708-18-GB	04/06/2010	19 March 2012	Prevention of metabolic complications of glucocorticoid excess - Prevention of metabolic complications of glucocorticoid excess	Prevention of metabolic complications of glucocorticoid excess - Prevention of metabolic complications of glucocorticoid excess	Rheumatoid arthritis, SLE, Polymyalgia rheumatica, Disthyroid eye disease, Cushing's syndrome	Trade Name: Glucophage (metformin) Product Name: Metformin Pharmaceutical Form: Tablet	Queen Mary University of London		Authorised			Female: yes Male: yes			United Kingdom
1135	NCT01132118	June 2010	19 October 2017	Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis	Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis	Rheumatoid Arthritis;Insulin Resistance	Drug: Hydroxychloroquine	Brigham and Women's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	18 Years	N/A	All	30	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1136	NCT01143337	June 2010	19 October 2017	Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis	A Multicenter Randomized, Double-blind, Placebo-controlled Study of MP-435 in Combination With MTX in Patients With Rheumatoid Arthritis - Exploratory Study	Rheumatoid Arthritis	Drug: MP-435(dose1) + Methotrexate;Drug: Placebo + Methotrexate	Mitsubishi Tanabe Pharma Corporation		Not recruiting	20 Years	75 Years	All	112	Phase 2	Japan
1137	NCT01146652	June 2010	15 October 2018	Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)	A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	2000	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czechia;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;Czech Republic
1138	EUCTR2009-017163-42-SE	18/05/2010	22 May 2017	Pain modulation in RA – Influence of adalimumab. A randomized, placebo-controlled study using functional magnetic resonance imaging - PARADE	Pain modulation in RA – Influence of adalimumab. A randomized, placebo-controlled study using functional magnetic resonance imaging - PARADE	Rheumatoid arthritis (RA) The overall aim with this project is to investigate central pain mechanisms in RA and healthy controls, and in RA how these are influenced by autonomic neural regulation and TNF-blockade with Humira.	Trade Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Injection Route of administration of the placebo: Subcutaneous use	Karolinska Institute		Not Recruiting			Female: yes Male: yes		Phase 4	Sweden
1139	EUCTR2010-019438-28-SE	17/05/2010	19 March 2012	Vaccination against TBE in patients who use immunosuppressive drugs	Vaccination against TBE in patients who use immunosuppressive drugs	TBE vaccin in patients using immunosuppressive drugs MedDRA version: 12.1 Level: LLT Classification code 10046859 Term: Vaccination MedDRA version: 12.1 Level: LLT Classification code 10037153 Term: Psoriasis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10054980 Term: Immunosuppressant drug therapy	Trade Name: FSME-IMMUN Pharmaceutical Form: Suspension for injection CAS Number: 0 Other descriptive name: TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 2,4-	Mälarsjukhuset Eskilstuna		Authorised			Female: yes Male: yes			Sweden
1140	EUCTR2009-015845-21-GB	13/05/2010	7 August 2012	A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis	A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis	Adult Rheumatoid Arthritis (RA) MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: RoActemra® Product Code: Ro 487-7533/F01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Humira® Product Code: RO 551-6922 Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: RO 551-6922 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	F. Hoffmann-La Roche Ltd.		Authorised			Female: yes Male: yes	300		Portugal;Finland;Czech Republic;Germany;United Kingdom;Belgium;Spain;Greece;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1141	EUCTR2009-015740-42-DE	12/05/2010	23 March 2015	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION RETRO – REduction of Therapy in RA patients in Ongoing remission, Reduzierung der Therapie bei RA-Patienten in Remission - RETRO	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION RETRO – REduction of Therapy in RA patients in Ongoing remission, Reduzierung der Therapie bei RA-Patienten in Remission - RETRO	Rheumatoid arthritis MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Product Name: Prednisolon Product Code: Prednisolon Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISOLONE CAS Number: 50-24-8 Trade Name: Humira Pharmaceutical Form: Injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Product Name: Azathioprin Pharmaceutical Form: Coated tablet CAS Number: 446-86-6 Current Sponsor code: 52424.00.00 Other descriptive name: AZATHIOPRINE Concentration unit: mg/kg milligram(s)/kilogram Trade Name: Immunosporin Product Name: Immunosporin Pharmaceutical Form: Tablet INN or Proposed INN: CICLOSPORIN CAS Number: 59865-13-3 Trade Name: Cimzia Product Name: Cimzia Pharmaceutical Form: Injection INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Current Sponsor code: EU/1/09/544/001-002 Concentration unit: mg milligram(s) Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Injection INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Current Sponsor code: EU/1/99/126/016 Concentration unit: mg milligram(s) Product Name: Quensyl Pharmaceutical Form: Tablet CAS Number: 747-36-4 Other descriptive name: HYDROXYCHLOROQUINE SULFATE Concentration unit: mg/kg milligram(s)/kilogram Trade Name: REMICADE Product Name: Remicade Pharmaceutical Form: INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: EU/1/99/116/001 Concentration unit: mg/kg milligram(s)/kilogram Trade Name: Lantarel Product Name: Lantarel Pharmaceutical Form: Injection INN or Proposed INN: METHOTREXATE SODIUM CAS Number: 15475-56-6 Current Sponsor code: 9709.01.01 Other descriptive name: Lantarel Concentration unit: mg milligram(s) Trade Name: Arava Product Name: Arava Pharmaceutical Form: Tablet INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706-12-6 Current Sponsor code: EU 1/99/118/007 – 008 Other descriptive name: Arava Concentration unit: mg milligram(s) Product Name: Metex 2,5mg Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE SODIUM CAS Number: 15475-56-6 Other descriptive name: Metex 2,5mg	Universitätsklinkum Erlangen		Authorised			Female: yes Male: yes		Phase 3	Germany
1142	EUCTR2009-015950-39-DE	12/05/2010	25 January 2016	Rituximab-Treatment in Addition to Leflunomide in Patients with active rheumatoid arthritis	Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis - AMARA	Active rheumatoid arthritis (RA) Patients who have had an inadequate response to disease modifying anti-rheumatic drugs (not more than 3 DMARDs including leflunomide, not more than one anti-TNF failure) and currently have active disease despite at least 3-month treatment with leflunomide. Active disease is defined as DAS 28 > 3.2 and at least swollen joint count (SJC) = 3 and tender joint count (TJC) = 3 included in the 28 joint count. MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera® Product Name: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	Johann Wolfgang Goethe-Universität Frankfurt/M.		Not Recruiting			Female: yes Male: yes			Germany
1143	EUCTR2010-018331-18-GB	12/05/2010	17 June 2013	A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy	A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy	Adult Rheumatoid Arthritis (RA) MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: RoActemra® Product Code: Ro 487-7533/F01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: R04877533 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	F. Hoffmann-La Roche Ltd.		Not Recruiting			Female: yes Male: yes			United Kingdom
1144	NCT01101555	May 12, 2010	16 December 2017	Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study	A Randomised, Single-blind, Placebo-controlled, Study Toevaluate the Safety, Tolerability, Pharmacodynamics Andpharmacokinetics of Repeat Subcutaneous Administration Ofotelixizumab in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: subcutanious administration;Other: Placebo	GlaxoSmithKline		Not recruiting	18 Years	75 Years	All	28	Phase 1	Russian Federation
1145	JPRN-UMIN000003615	2010/05/01	2 April 2019	Evaluation of the effectiveness of three nonbiologic DMARDs [salazosulfapyridine(SSZ), bucillamine(BUC), methotrexate(MTX)] combination therapy for early RA		RA(Rheumatoid Arthritis)	Using 3 DMARDs(Salazosulfapyridine, Bucillamine, and Methotrexate) for 24 months	St Luke's International Hospital		Recruiting	20years-old	80years-old	Male and Female	20	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1146	NCT01059448	May 2010	13 April 2015	Safety and Efficacy of AMG 827 in Subjects With RA	A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 827	Amgen		Not recruiting	N/A	N/A	Both	211	Phase 2	United States;Bulgaria;Canada;Czech Republic;Latvia;Mexico;Poland;United Kingdom
1147	NCT01090570	May 2010	23 March 2015	Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate		Rheumatoid Arthritis	Drug: PLX3397	Plexxikon		Not recruiting	18 Years	N/A	Both	0	Phase 1	United States
1148	NCT01163617	May 2010	19 October 2017	The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients	A Multicenter, Randomized, Open-Label Study of the Injection Time and Usability of the Physiolis Syringe and Autoinjector in Injection-Experienced Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Device: Adalimumab delivered in current syringe;Device: Adalimumab delivered in Physiolis syringe;Device: Adalimumab delivered in current autoinjector;Device: Adalimumab delivered in Physiolis autoinjector	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	N/A	All	85	Phase 2	United States
1149	NCT01245452	May 2010	19 February 2015	Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate	Comparative Study of the Clinical Response and Cardiorespiratory Endurance in Early Rheumatoid Arthritis Patients Treated With Tocilizumab or Methotrexate Addendum Protocol : Global Gene Expression Profiles in Synovial Biopsies	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Methotrexate	Patrick Durez		Not recruiting	18 Years	70 Years	Both	30	N/A	Belgium
1150	NCT01250548	May 2010	19 February 2015	The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment	Rheumatoid Arthritis	Biological: apremilast;Other: Placebo	Baylor Research Institute		Not recruiting	18 Years	N/A	Both	34	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1151	NCT01253265	May 2010	19 October 2017	A Study in Rheumatoid Arthritis	Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate Treatment	Rheumatoid Arthritis	Drug: LY2439821;Drug: Placebo	Eli Lilly and Company		Not recruiting	20 Years	75 Years	All	32	Phase 1	Japan
1152	NCT01253291	May 2010	19 February 2015	A Study of Japanese Rheumatoid Arthritis Patients	An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate	Rheumatoid Arthritis	Drug: LY2127399	Eli Lilly and Company		Not recruiting	20 Years	75 Years	Both	32	Phase 1	Japan
1153	NCT01077531	April 28, 2010	16 December 2017	Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis	A Randomized, Placebo-controlled, Single-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Otelixizumab in Rheumatoid Arthritis Subjects	Arthritis, Rheumatoid	Drug: Otelixizumab;Drug: Matching placebo	GlaxoSmithKline		Not recruiting	18 Years	75 Years	All	12	Phase 1	Russian Federation;Spain;United Kingdom
1154	EUCTR2009-017379-90-IT	27/04/2010	14 September 2015	Characterization of the secondary failure to TNF-blockers monoclonal antibodies. Receptor as a rescue therapy - ND	Characterization of the secondary failure to TNF-blockers monoclonal antibodies. Receptor as a rescue therapy - ND	RA patients fulfilling the 1987 ACR criteria who discontinued a first antibody TNF-i (Infliximab or Adalimumab) because of secondary inefficacy MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	AZIENDA OSPEDALIERA SENESE		Not Recruiting			Female: yes Male: yes			Italy
1155	EUCTR2009-011791-30-GB	14/04/2010	21 August 2012	A randomised, double-blind, placebo-controlled, multiple dose trial of NNC 0151-0000-0000 in subjects with rheumatoid arthritis	A randomised, double-blind, placebo-controlled, multiple dose trial of NNC 0151-0000-0000 in subjects with rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Product Name: NNC151-0000 Product Code: NNC0151-0000-0000 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: NNC0151-0000-0000 Other descriptive name: Anti-C5aR Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Novo Nordisk A/S		Authorised			Female: yes Male: yes	48		Hungary;Germany;Czech Republic;Russian Federation;United Kingdom;Ukraine;Denmark;Romania;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1156	EUCTR2010-018696-21-FR	14/04/2010	19 March 2012	Etude de l’évolution de la réponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoïde et traités par tocilizumab après échec des autres thérapies - TOCI 17	Etude de l’évolution de la réponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoïde et traités par tocilizumab après échec des autres thérapies - TOCI 17	Polyarthrite rhumatoïde MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: RoACTEMRA Product Name: TOCILIZUMAB Pharmaceutical Form: Solution for injection	CHU DIJON		Authorised			Female: yes Male: yes			France
1157	EUCTR2009-015835-34-IT	09/04/2010	3 April 2017	VITAMIN D EFFECT ON T LYMPHOCYTES AND OSTEOCLASTOGENESIS IN RHEUMAOID ARTHRITIS - ND	VITAMIN D EFFECT ON T LYMPHOCYTES AND OSTEOCLASTOGENESIS IN RHEUMAOID ARTHRITIS - ND	Rheumatoid Arthritis MedDRA version: 12.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid	Trade Name: *DIBASEIM OS 2F 1ML 300000UI/M Pharmaceutical Form: Solution for injection INN or Proposed INN: Colecalciferol** Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 300000- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Oral use	AZIENDA OSPEDALIERA ORDINE MAURIZIANO		Not Recruiting			Female: yes Male: no		Phase 3	Italy
1158	NCT01021735	April 2010	8 June 2015	Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy	Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy	Rheumatoid Arthritis	Drug: etanercept or adalimumab;Drug: Rituximab	University of Glasgow	Arthritis Research Campaign;NHS Lothian;NHS Grampian;NHS Tayside;NHS Borders;NHS Fife	Not recruiting	18 Years	N/A	Both	302	Phase 4	United Kingdom
1159	NCT01060098	April 2010	30 March 2015	T Cells and TNF: The Impact of TNF Blockade	T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents	Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: anti-TNF therapy (etanercept or adalimumab)	Imperial College London		Not recruiting	18 Years	80 Years	Both	52	N/A	United Kingdom
1160	NCT01067430	April 2010	19 February 2015	Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)	Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Etoricoxib;Drug: Diclofenac	Northumbria Healthcare NHS Foundation Trust		Not recruiting	18 Years	N/A	Both	20	Phase 4	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1161	NCT01151644	April 2010	19 February 2015	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases	Rheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixed Connective Tissue Disease;Systemic Vasculitis;Systemic Sclerosis (SSc);Sjögren's Syndrome;Antiphospholipid Syndrome;Juvenile Idiopathic Arthritis;Juvenile SLE;Juvenile DM	Biological: Anti-pandemic H1N1 influenza vaccine	University of Sao Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Not recruiting	N/A	N/A	Both	5000	Phase 4	Brazil
1162	NCT01287533	April 2010	19 February 2015	Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids	Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids	Rheumatoid Arthritis;Osteoporosis;Osteopenia	Drug: Ibandronate;Drug: Placebo	Yeong-Wook Song		Not recruiting	18 Years	75 Years	Female	167	Phase 4	Korea, Republic of
1163	NCT01313858	April 2010	19 October 2017	A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)	Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis	Arthritis, Rheumatoid;Arthritis, Psoriatic;Spondylitis, Ankylosing	Drug: Simponi®;Drug: Methotrexate	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	1613	N/A	Germany
1164	EUCTR2009-015636-15-HU	25/03/2010	19 March 2012	Rheumatoid arthritis	An Open-label Extension Study to Assess the Long-term Safety and Tolerability of ATN-103 in Subjects With Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ATN-103 Product Code: ATN-103 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: ATN-103 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company		Not Recruiting			Female: yes Male: yes	260		Hungary;Russian Federation;Germany;Canada;Switzerland;Belgium;Japan;United States;South Africa
1165	EUCTR2009-015653-20-NL	08/03/2010	19 March 2012	Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naïve for TNF-alpha blocking therapy and patients who do not respond (anymore) to prior treatment with other anti-TNF-alpha medication - Not applicable	Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naïve for TNF-alpha blocking therapy and patients who do not respond (anymore) to prior treatment with other anti-TNF-alpha medication - Not applicable	rheumatoid arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: etanercept Product Name: Etanercept Pharmaceutical Form: Injection* INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Current Sponsor code: ETN-cohortRA2009 Other descriptive name: methotrexate Concentration unit: mg milligram(s) Concentration type: range Concentration number: 5-30			Authorised			Female: yes Male: yes			Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1166	NCT01197066	March 2010	30 September 2019	Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis	A Phase ? Multicenter, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate, in Patients With Active Rheumatoid Arthritis Who Participated in Study 101-KOA-0801i	Rheumatoid Arthritis	Drug: Certolizumab Pegol	Korea Otsuka Pharmaceutical Co., Ltd.		Not recruiting	18 Years	N/A	All	110	Phase 3	Korea, Republic of
1167	NCT01256736	March 2010	19 February 2015	To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: DMARDs	JW Pharmaceutical		Not recruiting	18 Years	N/A	Both	89	Phase 3	Korea, Republic of
1168	NCT01610791	March 2010	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)	A Single Arm, Open Label Study to Assess the Safety, Tolerability and Efficacy of Tocilizumab in Active Rheumatoid Arthritis Patients With Inadequate Response to the DMARDs (REMISSION Study)	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	121	Phase 3	Morocco
1169	NCT02010216	March 2010	19 October 2017	A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)	Non-Randomized Phase IV Trial on Efficacy and Safety of Actemra in the Treatment of Adult Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	23	Phase 4	Kazakhstan
1170	NCT01063062	February 28, 2010	16 December 2017	A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)	A Single-arm, Open-label, Multicenter Study of Tocilizumab Monotherapy or in Combination With Methotrexate to Assess Safety and the Efficacy in Reducing Disease Activity in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs (PICTURE)	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	107	Phase 3	Egypt
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1171	EUCTR2009-016789-10-NL	19/02/2010	19 March 2012	Efficacy of the H1N1 Flu (swine flu) vaccination in patients with Rheumatoid Arthritis treated with rituximab	Efficacy of the H1N1 Flu (swine flu) vaccination in patients with Rheumatoid Arthritis treated with rituximab	To assess the efficacy of A/H1N1 vaccination in patients treated with rituximab therapy	Trade Name: Focetria Trade Name: Pandemrix,	Div KIR AMC		Authorised			Female: yes Male: yes			Netherlands
1172	EUCTR2009-017325-19-FI	11/02/2010	19 March 2012	“The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work”	“The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work”	Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: HUMIRA Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Route of administration of the placebo: Subcutaneous use	Helsingin reumakeskus		Authorised			Female: yes Male: yes			Finland
1173	EUCTR2009-016987-34-SE	09/02/2010	27 May 2013	.	PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP-690,550 COMPARED TO METHOTREXATE IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS	Moderate to severe active Rheumatoid Arthritis MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CP-690,550 Pharmaceutical Form: Film-coated tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Methotrexate Sodium Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE SODIUM CAS Number: 15475-56-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Pfizer Inc., 235 East 42nd Street, New York, NY 10017		Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Philippines;Taiwan;Slovakia;Thailand;Costa Rica;Spain;Ukraine;Chile;Russian Federation;Colombia;India;Malaysia;Australia;Peru;Korea, Republic of;Hungary;Czech Republic;Mexico;Canada;Argentina;Brazil;Poland;Dominican Republic;Bulgaria;Germany;New Zealand;Sweden
1174	EUCTR2009-012566-32-CZ	05/02/2010	19 March 2012	A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Rheumatoid arthritis (RA) MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: AMG 827 Product Code: AMG 827 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG 827 Current Sponsor code: AMG 827 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Not Recruiting			Female: yes Male: yes	240		Hungary;United Kingdom;Czech Republic;Bulgaria;Latvia;Poland
1175	NCT00979771	February 2010	16 December 2017	A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GSK706769;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	0	Phase 2	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1176	NCT01038674	February 2010	16 December 2017	Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis	A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Dose-escalation, Phase 1 Trial of Anti-IL-20 in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: anti-IL-20;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	All	16	Phase 1	Belgium;Poland
1177	NCT01052194	February 2010	19 February 2015	A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis	A 12-week, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo;Drug: VX-509	Vertex Pharmaceuticals Incorporated		Not recruiting	18 Years	75 Years	Both	206	Phase 2	United States;Belgium;Croatia;Germany;Hungary;Poland;Puerto Rico;Romania;Russian Federation;Serbia
1178	NCT01059864	February 2010	19 October 2017	Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550	Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP-690,550;Drug: Atorvastatin;Drug: Atorvastatin Placebo	Pfizer		Not recruiting	18 Years	N/A	All	111	Phase 2	United States;Korea, Republic of
1179	NCT01063803	February 2010	19 February 2015	Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis	An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ATN-103	Ablynx		Not recruiting	18 Years	80 Years	Both	266	Phase 2	United States;Canada;Hungary;Japan;Russian Federation;Serbia;South Africa;Switzerland
1180	NCT01111357	February 2010	19 February 2015	Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis	Study of HLA Polymorphisms in French West-Indian Patients With Rheumatoid Arthritis : A Case Control Study	Rheumatoid Arthritis	Biological: Collect of 10 ml of peripheric blood for DNA extraction	Centre Hospitalier Universitaire de Fort-de-France		Not recruiting	18 Years	N/A	Both	200	N/A	Martinique
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1181	NCT01123070	February 2010	19 February 2015	TL011 in Severe, Active Rheumatoid Arthritis Patients		Rheumatoid Arthritis	Biological: TL011, anti CD20, for the treatment of rheumatoid arthritis;Biological: MabThera infusions	Teva Pharmaceutical Industries		Not recruiting	18 Years	80 Years	Both	48	Phase 1/Phase 2	Czech Republic;Hungary;Italy;Spain;United Kingdom;Germany
1182	NCT01754805	January 22, 2010	24 June 2019	A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis	A Phase 1b, Open-Label, Single Sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: peficitinib;Drug: methotrexate	Astellas Pharma Inc		Not recruiting	18 Years	65 Years	All	15	Phase 1	United States
1183	EUCTR2008-007185-33-DE	12/01/2010	19 March 2012	A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate	A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate	Rheumatoid arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ATN-103 Product Code: ATN-103 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: ATN-103 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use	Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company		Not Recruiting			Female: yes Male: yes	240	Phase 1/2	Hungary;United Kingdom;Germany;Netherlands;Belgium
1184	EUCTR2009-010582-23-DE	04/01/2010	24 February 2014	A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (ENBREL®) or Adalimumab (HUMIRA®)	A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (ENBREL®) or Adalimumab (HUMIRA®)	Rheumatoid arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Golimumab Final Vialed Product (FVP) Product Code: CNTO 148 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Golimumab Current Sponsor code: CNTO 148 Other descriptive name: Human anti TNF-alpha monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 12.5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Golimumab liquid in prefilled pen Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Current Sponsor code: CNTO 148 Other descriptive name: Human anti TNF-alpha monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Janssen Biologics B.V.		Not Recruiting			Female: yes Male: yes	400	Phase 3b	Greece;Belgium;Austria;Germany;United Kingdom;Italy;Sweden
1185	NCT00752154	January 2010	19 February 2015	Curcumin in Rheumatoid Arthritis	Curcumin in Rheumatoid Arthritis - ACross-Over Pilot Study	Rheumatoid Arthritis	Drug: Curcumin (Longvida™)	University of California, Los Angeles		Recruiting	18 Years	N/A	Both	40	Phase 0	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1186	NCT00995449	January 2010	19 October 2017	Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis	A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of the Anti-GM-CSF Monoclonal Antibody KB003 in Subjects With Active Rheumatoid Arthritis and Inadequate Prior Treatment Outcome From Biologic Therapy	Rheumatoid Arthritis	Biological: KB003;Other: Placebo Comparator	KaloBios Pharmaceuticals		Not recruiting	18 Years	N/A	All	9	Phase 2	United States
1187	NCT01039688	January 2010	11 June 2018	Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX	Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP-690,550;Drug: Disease-modifying antirheumatic drug	Pfizer		Not recruiting	18 Years	99 Years	All	956	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;Czech Republic
1188	NCT01071798	January 2010	19 October 2017	An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis	A Prospective, Multi-center, Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months (in Case of Re-therapy the First 12 Months) of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	1653	N/A	Germany;United States
1189	NCT01089023	January 2010	19 October 2017	A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and the Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti- TNF Therapy.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	95	Phase 4	Bahrain;Iran, Islamic Republic of;Kuwait;Qatar;United Arab Emirates
1190	NCT01198509	January 2010	19 October 2017	Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)	Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis;Psoriatic Arthritis;Periodontal Disease	Drug: doxycycline;Drug: vancomycin	New York University School of Medicine	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Memorial Sloan Kettering Cancer Center	Not recruiting	18 Years	70 Years	All	178	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1191	NCT02368093	January 2010	19 October 2017	Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis	A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Dextromethorphan hydrobromide	Taichung Veterans General Hospital	TSH Biopharm Corporation Limited	Not recruiting	18 Years	N/A	All	48	N/A
1192	NCT02731560	January 2010	18 April 2016	Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)	Efficacy and Safety of Rituximab in Pakistani Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Rituximab	Prof. Abid Z. Farooqi	Aga Khan University;Fatima Memorial Hospital;Fauji Foundation Hospital, Rawalpindi	Not recruiting	18 Years	80 Years	Both	74	Phase 4
1193	EUCTR2009-014735-20-LV	29/12/2009	11 February 2013	A Clinical Trial to investigate the effects of Mavrilimumab, a drug used in clinical research, in subjects with rheumatoid arthritis, which is a disease causing pain and swelling in joints.	A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects with Rheumatoid Arthritis - EARTH	Rheumatoid Arthritis MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: mavrilimumab Product Code: CAM-3001 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: mavrilimumab CAS Number: 1085337-57-0 Current Sponsor code: CAM-3001 Other descriptive name: anti-GM-CSF receptor alpha Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	MedImmune Ltd		Not Recruiting			Female: yes Male: yes	264	Phase 2	Hungary;Estonia;Czech Republic;Poland;Ukraine;Romania;Lithuania;Russian Federation;Bulgaria;Latvia;Japan
1194	NCT00950989	December 2009	12 September 2016	AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: AMG 827 70 mg;Drug: AMG 827 140 mg;Drug: AMG 827 210 mg;Drug: Placebo;Drug: Stable weekly dose of methotrexate	Amgen		Not recruiting	18 Years	70 Years	Both	240	Phase 2	Bulgaria;Canada;Czech Republic;Hungary;Latvia;Mexico;Poland;United Kingdom;United States
1195	NCT01000441	December 2009	19 February 2015	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: infliximab, etanercept, adalimumab;Drug: abatacept, rituximab or tocilizumab	University Hospital, Strasbourg, France		Recruiting	18 Years	N/A	Both	300	Phase 4	France;Monaco
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1196	NCT01001832	December 2009	19 October 2017	Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients	A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Intravenous (IV) abatacept;Drug: Subcutaneous (SC) abatacept	Bristol-Myers Squibb		Not recruiting	20 Years	N/A	All	118	Phase 2/Phase 3	Japan
1197	NCT01008852	December 2009	19 February 2015	Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis	Randomized, Parallel, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate	Active Rheumatoid Arthritis	Drug: SBI-087;Drug: Placebo	Pfizer	Emergent Product Development Seattle LLC	Not recruiting	18 Years	N/A	Both	210	Phase 2	United States;Argentina;Canada;Chile;Hungary;Japan;Mexico;Poland;Serbia;Spain;Greece;Turkey
1198	NCT01023256	December 2009	19 October 2017	Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MOR103	MorphoSys AG		Not recruiting	18 Years	N/A	All	96	Phase 1/Phase 2	Bulgaria;Germany;Netherlands;Poland;Ukraine
1199	NCT01027728	December 2009	19 February 2015	Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CCX 354-C	ChemoCentryx		Not recruiting	18 Years	75 Years	Both	24	Phase 1/Phase 2	Belgium;Romania
1200	NCT01029613	December 2009	31 August 2015	Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers	Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers	Rheumatoid Arthritis	Drug: Adalimumab	Glostrup University Hospital, Copenhagen		Not recruiting	18 Years	85 Years	Both	40	N/A	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1201	NCT01044498	December 2009	19 October 2017	A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis	An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Ortho-Novum® 1/35	Hoffmann-La Roche		Not recruiting	18 Years	44 Years	Female	46	Phase 3	United States
1202	EUCTR2009-016055-22-FI	27/11/2009	27 October 2014	Immuunipuutteisten matkailijoiden A-hepatiittisuojaus	Immuunipuutteisten matkailijoiden A-hepatiittisuojaus	Terveet vapaaehtoiset ja vapaaehtoiset potilaat, joilla on diagnosoitu nivelreuma. MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Epaxal Product Name: Epaxal Pharmaceutical Form: Solution for injection	HY, HUS		Not Recruiting			Female: yes Male: yes			Finland;Sweden
1203	EUCTR2009-012424-87-GB	26/11/2009	19 March 2012	T cells and TNF: The impct of TNF blockade on effector T cell populations in rheumatoid arthritis and other conditions treated with anti-TNF-alpha agents. - T cells and TNF	T cells and TNF: The impct of TNF blockade on effector T cell populations in rheumatoid arthritis and other conditions treated with anti-TNF-alpha agents. - T cells and TNF	Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 12.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis MedDRA version: 12.0 Level: LLT Classification code 10002556 Term: Ankylosing spondylitis	Trade Name: Enbrel Pharmaceutical Form: Solution for injection INN or Proposed INN: etanercept CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: adalimumab CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Enbrel Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: etanercept CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Enbrel Pharmaceutical Form: Solution for injection INN or Proposed INN: Etanercept CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-	Imperial College London South Kensington London		Authorised			Female: yes Male: yes			United Kingdom
1204	EUCTR2009-009696-34-DE	23/11/2009	24 April 2012	A Study in Patients with Rheumatoid Arthritis	A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy	Rheumatoid Arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: LY2439821 Product Code: LY2439821 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: N.A. Current Sponsor code: LY2439821 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	648	Phase 2	India;Russian Federation;Germany;Peru;Taiwan;Argentina;Romania;Korea, Republic of;Chile;Poland
1205	EUCTR2009-012185-32-IT	23/11/2009	7 January 2013	Open label, multicentric phase IIIb study to evaluate the effect of tocilizumab in combination with DMARDs in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by dedicated magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis (RA) - ND	Open label, multicentric phase IIIb study to evaluate the effect of tocilizumab in combination with DMARDs in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by dedicated magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis (RA) - ND	Moderate to severe active rheumatoid arthritis (RA), who are inadequate responders to DMARDs. MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Tocilizumab Product Code: Ro487-7533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RoActemra CAS Number: 375823-41-9 Current Sponsor code: Ro487-7533 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	ROCHE		Not Recruiting			Female: yes Male: yes		Phase 3b	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1206	EUCTR2009-012204-42-IE	13/11/2009	19 March 2012	A randomized, double-blind, placebo-controlled, parallel group study to investigate the ability of GSK706769 to maintain clinical efficacy after withdrawal of Enbrel in patients with rheumatoid arthritis	A randomized, double-blind, placebo-controlled, parallel group study to investigate the ability of GSK706769 to maintain clinical efficacy after withdrawal of Enbrel in patients with rheumatoid arthritis	Rheumatoid arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: GSK706769 Product Code: GSK706769 Pharmaceutical Form: Film-coated tablet CAS Number: 880356-67-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	50		Belgium;Ireland
1207	EUCTR2009-014296-40-DE	12/11/2009	10 December 2012	PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE RESPONSE TO TNF INHIBITORS	PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE RESPONSE TO TNF INHIBITORS	Rheumatoid arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: not applicable Product Code: CP-690,550 Pharmaceutical Form: Film-coated tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550-10 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Pfizer Inc., 235 East 42nd Street, New York, NY 10017		Not Recruiting			Female: yes Male: yes	396	Phase 3	France;Belgium;Spain;Ireland;Austria;Germany;United Kingdom;Italy
1208	EUCTR2009-013223-37-CZ	10/11/2009	12 December 2016	A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS	A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS	Rheumatoid Arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: PF-04171327 Product Code: PF-04171327 Pharmaceutical Form: Tablet Current Sponsor code: PF-04171327 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: PF-04171327 Product Code: PF-04171327 Pharmaceutical Form: Tablet Current Sponsor code: PF-04171327 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Pharmaceutical Form: Capsule* INN or Proposed INN: Prednisone CAS Number: 53-03-2 Other descriptive name: Decortin® Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	119	Phase 2	Hungary;Czech Republic;Spain
1209	EUCTR2009-013316-12-NL	10/11/2009	1 December 2014	A multi-center, randomized, double blind, placebo controlled study to evaluate remission in DMARD and biological naïve early reumatoid arthritis (RA) subjects treated with tocilizumab (TCZ) plus tight control methotrexate (MTX) treatment, TCZ monotherapy or tight control MTX monotherapy. - U-Act-Early	A multi-center, randomized, double blind, placebo controlled study to evaluate remission in DMARD and biological naïve early reumatoid arthritis (RA) subjects treated with tocilizumab (TCZ) plus tight control methotrexate (MTX) treatment, TCZ monotherapy or tight control MTX monotherapy. - U-Act-Early	Rheumatoid Arthritis MedDRA version: 15.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Methotrexate 'Lederle' 2,5mg tablets Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Roche Nederland B.V.		Not Recruiting			Female: yes Male: yes			Netherlands
1210	EUCTR2007-006129-29-DE	03/11/2009	27 January 2014	A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to patients with active rheumatoid arthritis	A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to patients with active rheumatoid arthritis - MOR103 Rheumatoid Arthritis PoC Study	Rheumatoid arthritis MedDRA version: 13.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: MOR103 Product Code: MOR103 Pharmaceutical Form: Solution for infusion Current Sponsor code: MOR103 Other descriptive name: Human Recombinant IgG1, lambda Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 8-12 Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	MorphoSys AG		Not Recruiting			Female: yes Male: yes	89		Poland;Ukraine;Bulgaria;Netherlands;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1211	EUCTR2009-014824-40-CZ	03/11/2009	19 March 2012	An open label follow on study to evaluate the long-term safety, tolerability and efficacy of ART621 following fortnightly administration for 48 weeks in patients with rheumatoid arthritis concomitantly taking methotrexate.	An open label follow on study to evaluate the long-term safety, tolerability and efficacy of ART621 following fortnightly administration for 48 weeks in patients with rheumatoid arthritis concomitantly taking methotrexate.	Rheumatoid arthritis	Product Code: ART621 Pharmaceutical Form: Solution for injection Current Sponsor code: ART621 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Arana Therapeutics Ltd		Not Recruiting			Female: yes Male: yes	200		Czech Republic
1212	JPRN-UMIN000002744	2009/11/01	2 April 2019	Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation		rheumatoid arthritis	tocilizumab plus methotrexate tocilizumab	Keio University		Not Recruiting	20years-old	75years-old	Male and Female	300	Not selected	Japan
1213	NCT00844714	November 2009	19 October 2017	Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy	Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy	Endothelial Function;Rheumatoid Arthritis;Inflammation	Drug: Rituxan	University of California, San Francisco	Genentech, Inc.	Not recruiting	18 Years	N/A	All	20	N/A	United States
1214	NCT00976599	November 2009	19 October 2017	A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis	An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP-690,550 + methotrexate;Drug: Placebo + Methotrexate	Pfizer		Not recruiting	18 Years	N/A	All	29	Phase 2	United States
1215	NCT01006681	November 2009	19 February 2015	Vaccination Against Influenza H1N1 in Rheumatic Diseases	Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Immunomodulatory Drugs	Influenza;Rheumatic Diseases	Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)	Tel-Aviv Sourasky Medical Center		Not recruiting	18 Years	65 Years	Both	400	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1216	NCT01007175	November 2009	19 February 2015	Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ATN-103 Administered To Japanese Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate	Rheumatoid Arthritis	Biological: ATN-103 10 mg q4wks;Biological: ATN-103 30 mg q4wks;Biological: ATN-103 80 mg q4wks;Biological: ATN-103 10 mg q8wks;Biological: ATN-103 80 mg q8wks	Ablynx		Not recruiting	20 Years	75 Years	Both	60	Phase 1/Phase 2	Japan
1217	NCT01009879	November 2009	19 February 2015	Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants	Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants	Rheumatoid Arthritis	Drug: Etanercept	University of Pittsburgh	Amgen	Not recruiting	18 Years	N/A	Both	0	Phase 4	United States
1218	NCT01010581	November 2009	19 February 2015	SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SC12267 (4SC-101);Drug: Placebo;Drug: Methotrexate;Drug: Folic Acid	4SC AG		Not recruiting	18 Years	N/A	Both	266	Phase 2	Bulgaria;Czech Republic;Poland;Romania
1219	EUCTR2008-005450-20-BE	29/10/2009	19 March 2012	The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. - Dutch Rheumatoid Arthritis Monitoring (DREAM) Targetted Immune Modulator Evaluation (TIME)	The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. - Dutch Rheumatoid Arthritis Monitoring (DREAM) Targetted Immune Modulator Evaluation (TIME)	Rheumatoid arthritis MedDRA version: 12.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Remicade (infliximab) Pharmaceutical Form: Intravenous infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Other descriptive name: remicade Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 10- Trade Name: Humira (adalimumab) Pharmaceutical Form: Injection* INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Enbrel (etanercept) Pharmaceutical Form: Injection* INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Other descriptive name: Enbrel Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Mabthera (rituximab) Pharmaceutical Form: Intravenous infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Other descriptive name: Mabthera Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Trade Name: Orencia (abatacept) Pharmaceutical Form: Intravenous infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Other descriptive name: Orencia Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-	Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases		Authorised			Female: yes Male: yes	261		Belgium
1220	EUCTR2008-008954-22-NL	27/10/2009	19 March 2012	Non Steroidal Anti-Inflammatory Drugs and the antiplatelet effects of acetylsalicylic acid - NSAIDs and ASA research	Non Steroidal Anti-Inflammatory Drugs and the antiplatelet effects of acetylsalicylic acid - NSAIDs and ASA research	This is a healthy volunteer trial. Indications of the IMP's in the context of this trial are: Elevated risk on cardiovascular event Rheumatoid arthritis	Trade Name: Naproxen Pch Tablet 500mg Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Ibuprofen Pch Tablet 600mg Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Diclofenac Natrium Pch Retard Tablet Mga 75mg Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Meloxicam Cf Tablet 7,5mg Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Acetylsalicylzuur Cardio Pch Disp Tablet 80mg Pharmaceutical Form: Tablet	Medisch Spectrum Twente		Authorised			Female: yes Male: yes			Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1221	EUCTR2009-012118-27-NL	27/10/2009	19 March 2012	A Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of JNJ-38518168 in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy With Synovial Biopsy Substudy	A Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of JNJ-38518168 in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy With Synovial Biopsy Substudy	JNJ-38518168 is being developed for the treatment of Rheumatoid Arthritis. MedDRA version: 9.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions	Product Name: JNJ-38518168 50-mg Over Encapsulated Tablet Product Code: GFI 38518168-AEK-B-007 Pharmaceutical Form: Over encapsulated tablet Current Sponsor code: JNJ-38518168 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Over encapsulated tablet Route of administration of the placebo: Oral use	Janssen-Cilag International NV		Not Recruiting			Female: yes Male: yes	90	Phase 2a	Czech Republic;United Kingdom;Netherlands;Spain
1222	EUCTR2009-012759-12-GB	14/10/2009	19 March 2012	A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and in combination with methotrexate (MTX), versus methotrexate in patients with early, moderate to severe rheumatoid arthritis.	A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and in combination with methotrexate (MTX), versus methotrexate in patients with early, moderate to severe rheumatoid arthritis.	Rheumatoid Arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: RoActemra® Product Code: Ro 487-7533/F01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Methotrexate 'Lederle' 2.5mg Tablets Product Code: Ro 002-9893/F02 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Methotrexate Disodium CAS Number: 7413345 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	F. Hoffmann-La Roche Ltd.		Authorised			Female: yes Male: yes	1128		Hungary;Portugal;Finland;Germany;United Kingdom;Denmark;France;Ireland;Spain;Italy;Greece;Sweden
1223	EUCTR2009-014394-41-DK	12/10/2009	12 December 2016	Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers. Whole-Body MRI in Rheumatoid Arthritis Protocol (WRAP)	Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers. Whole-Body MRI in Rheumatoid Arthritis Protocol (WRAP)	Reumatoid artritis MedDRA version: 12.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid	Trade Name: Humira Product Name: Humira Product Code: Adalimummab Pharmaceutical Form: Injection* INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: Humira Other descriptive name: Adalimumab Concentration unit: 1X 100 milligrams/millilitre Concentration type: equal Concentration number: 40-40	Hvidovre Hospital		Not Recruiting			Female: yes Male: yes		Phase 4	Denmark
1224	EUCTR2009-012218-30-PT	06/10/2009	5 November 2012	A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 weeks after initiation of treatment in patients with moderate to severe rheumatoid arthritis (RA) with inadequate response to non-biological DMARDs - PORTRAIT	A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 weeks after initiation of treatment in patients with moderate to severe rheumatoid arthritis (RA) with inadequate response to non-biological DMARDs - PORTRAIT	Men and women > 18 years of age with RA who are currently experiencing an inadequate clinical response to a stable dose of non-biologic DMARDs (at least 12 weeks) and with MRI documented synovitis of dominant hand.	Trade Name: RoActemra Pharmaceutical Form: Concentrate for solution for infusion	Roche Farmacêutica Química, Lda.		Not Recruiting			Female: yes Male: yes			Portugal
1225	EUCTR2009-011137-26-DE	05/10/2009	27 January 2014	An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-naïve subjects with rheumatoid arthritis (Part 1), followed by a randomized study assessing the value of combined intravenous and subcutaneous GLM administration aimed at inducing and maintaining remission (Part 2). - GO-MORE	An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-naïve subjects with rheumatoid arthritis (Part 1), followed by a randomized study assessing the value of combined intravenous and subcutaneous GLM administration aimed at inducing and maintaining remission (Part 2). - GO-MORE	Active Rheumatoid Arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Simponi Product Name: Golimumab Product Code: SCH 900259 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: Golimumab Product Code: SCH 900259 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Golimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Schering-Plough Research Institute, A Division of Schering Corporation		Not Recruiting			Female: yes Male: yes	3150		Portugal;Greece;Finland;Spain;Ireland;Austria;United Kingdom;Italy;France;Hungary;Czech Republic;Poland;Belgium;Denmark;Germany;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1226	NCT00929864	October 2009	19 October 2017	Abatacept Versus Adalimumab Head-to-Head	A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept;Drug: Adalimumab	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	869	Phase 3	United States;Argentina;Canada;Chile;Peru
1227	NCT00938587	October 2009	18 December 2018	A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis	A Phase 2a, Randomized, Double-Blind, Active And Placebo-Controlled Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: PF-04171327 10 mg;Other: Prednisone Placebo;Drug: PF-04171327 25 mg;Drug: Prednisone 5 mg;Other: Placebo for PF-04171327;Other: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	86	Phase 2	United States;Czechia;Hong Kong;Hungary;Korea, Republic of;Russian Federation;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;Czech Republic
1228	NCT00960440	October 2009	19 October 2017	Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors	Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors	Arthritis, Rheumatoid	Drug: CP-690,550;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	399	Phase 3	United States;Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Puerto Rico;Spain;Taiwan;United Kingdom
1229	NCT00993317	October 2009	19 October 2017	A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis	A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate	Rheumatoid Arthritis	Drug: Placebo of CDP870;Drug: CDP870 200mg;Drug: Methotrexate	Korea Otsuka Pharmaceutical Co., Ltd.		Not recruiting	18 Years	75 Years	All	127	Phase 3	Korea, Republic of
1230	NCT00996203	October 2009	19 October 2017	A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.	Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ)	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: DMARDs (disease-modifying antirheumatic drugs)	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	201	Phase 4	Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1231	NCT01002716	October 2009	19 February 2015	Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis	Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Agrippal S1 (Influenza vaccination)	Tel-Aviv Sourasky Medical Center		Recruiting	18 Years	90 Years	Both	90	Phase 4	Israel
1232	NCT01123655	October 2009	14 December 2015	Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients	Phase 1 Trial of CII APL A12 in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: APL A12	VA Office of Research and Development		Not recruiting	18 Years	85 Years	Both	22	Phase 1	United States
1233	NCT01211834	October 2009	19 February 2015	Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and the Safety During Treatment With Tocilizumab vs Placebo in Combination With Traditional DMARD Therapy in Patients With Moderate to Severe Active RA and an Inadequate Response to Current DMARD Therapy	Rheumatoid Arthritis	Drug: tocilizumab;Drug: DMARDs;Drug: Placebo	JW Pharmaceutical		Not recruiting	18 Years	N/A	Both	90	Phase 3	Korea, Republic of
1234	NCT01873625	October 2009	19 February 2015	Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis	Resurfacing Articular Cartilage With Mesenchymal Stem Cells Transplantation in Patients With Knee Joint Osteoarthritis Affected by Rheumatoid Arthritis: Randomized Triple Blind Clinical Trial Phase II/III (ACRCT)	Rheumatoid Arthritis	Biological: mesenchymal cell transplantation;Biological: placebo	Royan Institute		Not recruiting	10 Years	65 Years	Both	60	Phase 2/Phase 3	Iran, Islamic Republic of
1235	EUCTR2009-011000-34-DE	30/09/2009	19 March 2012	A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extension phase up to a total of 60 weeks in patients with active rheumatoid arthritis despite stable treatment with methotrexate	A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extension phase up to a total of 60 weeks in patients with active rheumatoid arthritis despite stable treatment with methotrexate	Moderate to severe Rheumatoid Arthritis. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: AIN457 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: AIN457 Other descriptive name: rhumAb to Il-17A (IgG1-k-class) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	200		Hungary;Slovakia;Czech Republic;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1236	EUCTR2009-012953-39-CZ	02/09/2009	19 March 2012	A Randomized, Double Blind, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination with Methotrexate compared to Methotrexate Alone in Patients with Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination with Methotrexate compared to Methotrexate Alone in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 12.0 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: SC12267 Product Code: SC12267 Pharmaceutical Form: Film-coated tablet Current Sponsor code: SC12267 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 35- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Metex 2,5mg Tabletten Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Trade Name: Metex 7,5mg Tabletten Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7.5- Trade Name: Metex 10mg Tabletten Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	4SC AG		Not Recruiting			Female: yes Male: yes	244	Phase 2	Czech Republic;Bulgaria;Poland
1237	NCT00913458	September 2009	19 October 2017	Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis	A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate	Active Rheumatoid Arthritis;Arthritis, Rheumatoid;Rheumatoid Arthritis	Drug: etanercept	Pfizer		Not recruiting	18 Years	N/A	All	306	Phase 4	France;Germany;Ireland;Italy;Monaco;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Switzerland;United Kingdom
1238	NCT00959036	September 2009	19 February 2015	Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis	A Seamless, Phase 1/2, Multiple Ascending Dose, Proof Of Concept Study Of ATN-103 Administered To Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate	Active Rheumatoid Arthritis	Drug: ATN-103;Drug: Placebo;Drug: Methotrexate	Ablynx		Not recruiting	18 Years	80 Years	Both	252	Phase 1/Phase 2	United States;Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland
1239	NCT00969527	September 2009	19 February 2015	Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis	Assessment of the Efficacy of Oncoxin+Viusid Administration in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Oncoxin + Viusid;Dietary Supplement: Placebo	Catalysis SL		Not recruiting	18 Years	N/A	Both	86	Phase 3	Cuba
1240	NCT00973479	September 2009	19 October 2017	An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Arthritis, Rheumatoid	Drug: Golimumab;Other: Placebo;Drug: methotrexate (MTX)	Centocor, Inc.	Schering-Plough	Not recruiting	18 Years	N/A	All	592	Phase 3	United States;Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1241	NCT00975130	September 2009	16 December 2017	Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)	An Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Biologic-Naïve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2)	Arthritis, Rheumatoid	Biological: SC golimumab;Biological: IV golimumab	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	3366	Phase 3	Argentina;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Monaco;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom
1242	NCT00984815	September 2009	19 October 2017	Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment	Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment	Osteoarthritis;Rheumatoid Arthritis;Chronic Low Back Pain;Chronic Regional Pain Syndrome;Chronic Soft Tissue Pain	Drug: HZT-501	Horizon Pharma Ireland, Ltd., Dublin Ireland		Not recruiting	40 Years	80 Years	All	86	Phase 3	United States
1243	NCT00993668	September 2009	19 October 2017	Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines	A Phase 4, Randomized, Single-blind, Placebo-controlled, Multicenter Study to Evaluate the Immunogenicity of Pneumococcal and Influenza Vaccines in Adult Subjects With Rheumatoid Arthritis Receiving Certolizumab Pegol or Placebo	Rheumatoid Arthritis	Other: Placebo;Biological: Certolizumab pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	224	Phase 4	United States
1244	NCT01075477	September 2009	14 November 2016	An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)	Naturalistic Prospective Non-interventional Study on Rheumatoid Arthritis (RA) Patients Treated With Rituximab According to Local Treatment Guidelines	Rheumatoid Arthritis	Drug: rituximab [Mabthera/Rituxan]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	151	N/A	Finland;United States
1245	NCT01253226	September 2009	5 November 2018	A Study for Japanese Participants With Rheumatoid Arthritis (RA)	Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate	Rheumatoid Arthritis	Drug: LY2127399 (Tabalumab);Drug: Placebo	Eli Lilly and Company		Not recruiting	20 Years	75 Years	All	32	Phase 1	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1246	EUCTR2009-010813-57-DE	28/08/2009	19 March 2012	A multicenter, randomized, double-blind, placebo-controlled, single dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of intravenous and subcutaneous CDP6038 in male and female subjects with rheumatoid arthritis on a stable dose of methotrexate.	A multicenter, randomized, double-blind, placebo-controlled, single dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of intravenous and subcutaneous CDP6038 in male and female subjects with rheumatoid arthritis on a stable dose of methotrexate.	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CDP6038 Product Code: CDP6038 Pharmaceutical Form: Solution for injection CAS Number: 1007223-17-7 Current Sponsor code: CDP6038 Other descriptive name: recombinant human Mab of IgG4 subtype Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: CDP6038 Product Code: CDP6038 Pharmaceutical Form: Solution for injection CAS Number: 1007223-17-7 Current Sponsor code: CDP6038 Other descriptive name: recombinant human Mab of IgG4 subtype Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	UCB Celltech		Not Recruiting			Female: yes Male: yes	72		Germany
1247	EUCTR2009-011206-42-CZ	18/08/2009	19 March 2012	A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Response to Any Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy including Biologics	A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Response to Any Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy including Biologics	Active Rheumatoid Arthritis MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: INCB028050 phosphate Product Code: INCB028050 Pharmaceutical Form: Capsule* Current Sponsor code: INCB028050 phosphate Other descriptive name: INCB028050 phosphate salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: INCB028050 phosphate Product Code: INCB028050 Pharmaceutical Form: Capsule* Current Sponsor code: INCB028050 phosphate Other descriptive name: INCB028050 phosphate salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: INCB028050 phosphate Product Code: INCB028050 Pharmaceutical Form: Capsule* Current Sponsor code: INCB028050 phosphate Other descriptive name: INCB028050 phosphate salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Incyte Corporation		Not Recruiting			Female: yes Male: yes	100	Phase 2	Czech Republic
1248	EUCTR2009-012705-19-HU	17/08/2009	19 March 2012	A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy - LX3305.201	A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy - LX3305.201	Rheumatoid Arthritis (RA) MedDRA version: 12.0 Level: LLT Classification code 10039073 Term:	Product Name: LX3305 Dihydrate Product Code: LX3305 Pharmaceutical Form: Capsule, hard INN or Proposed INN: None as of yet CAS Number: 1078151-47-9 Current Sponsor code: LX3305 Dihydrate Other descriptive name: LX3305 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: LX3305 Dihydrate Product Code: LX3305 Pharmaceutical Form: Capsule, hard INN or Proposed INN: None as of yet CAS Number: 1078151-47-9 Current Sponsor code: LX3305 Dihydrate Other descriptive name: LX3305 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Lexicon Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	104	Phase 2	Hungary;Czech Republic;Bulgaria
1249	EUCTR2009-010516-15-HU	14/08/2009	10 February 2014	Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Methotrexate	Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Methotrexate	Rheumatoid arthritis (seropositive) MedDRA version: 9.1 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis	Product Name: SBI-087 Product Code: SBI-087 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: n/a CAS Number: n/a Current Sponsor code: SBI-087 Other descriptive name: Anti-CD20 small modular immunopharmaceutical, WYE-400087 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use	Wyeth Research Division of Wyeth Pharmaceuticals Inc.		Not Recruiting			Female: yes Male: yes	200		Hungary;Greece;Poland;Spain
1250	JPRN-UMIN000002340	2009/08/01	2 April 2019	Comparison of effects between higher dosages of infliximab and switching to other biologics for rheumatoid arthritis patients with less responsiveness to infliximab therapy (cHAMLET)		Rheumatoid Arthritis	Treatment with higher dosages of infliximab (3-10 mg/Kg) Every 2 months Follow-up to 54 weeks Treatment with one of other biologics (etanercept, adalimumab, tocilizumab) in standard protocol Follow-up to 54 weeks	Department of Rheumatosurgery, Osaka City University Medical School		Not Recruiting	20years-old	Not applicable	Male and Female	60	Phase 4	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1251	NCT03681639	August 1, 2009	28 October 2019	Metasul Monoblock Component™ Cup in a Hip Resurfacing Application With the Durom® Hip Resurfacing Femoral Component	A Multi-Centre, Prospective Study to Obtain Survival and Clinical Outcome Data on the Zimmer Hip Resurfacing System Utilising the Metasul Monoblock Component™ Cup in a Hip Resurfacing Application With the Durom® Hip Resurfacing Femoral Component	Avascular Necrosis of Hip;Osteoarthritis, Hip;Rheumatoid Arthritis;Inflammatory Arthritis;Post-traumatic; Arthrosis	Diagnostic Test: Serum Metal ion levels determined to monitor changes in chromium and cobalt levels	Zimmer Biomet		Not recruiting	18 Years	65 Years	All	225	N/A	Germany
1252	NCT00929357	August 2009	19 October 2017	Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment	A Retrospective Evaluation of the Radiographic Efficacy of Different Conventional Systemic Therapies and Biologics in Patients With Rheumatoid Arthritis in Routine Practice.	Rheumatoid Arthritis	Drug: DMARDs or Biologics	Pfizer		Not recruiting	18 Years	N/A	All	156	N/A	Denmark
1253	NCT00965653	August 2009	14 November 2016	A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis	Open-label, Multicenter, Randomized, Parallel Study to Investigate pk, pd, Efficacy and Safety of Tocilizumab (TCZ, RO4877533) Following Subcutaneous Administration of TCZ 162 mg Weekly or Every Other Week in Combination With Methotrexate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: folic acid;Drug: methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	75 Years	Both	29	Phase 1	Canada;New Zealand;Spain;United Kingdom
1254	NCT01224041	August 2009	18 January 2016	Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate	Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study	Rheumatoid Arthritis	Drug: Tacrolimus	Astellas Pharma Inc	Astellas Pharma Korea, Inc.	Not recruiting	18 Years	75 Years	Both	78	Phase 4	Korea, Republic of
1255	NCT01870128	August 2009	19 February 2015	Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial	Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial	Rheumatoid Arthritis	Drug: Combination Steroid;Drug: Methotrexate;Drug: Combination	All India Institute of Medical Sciences, New Delhi		Not recruiting	18 Years	60 Years	Both	60	Phase 3	India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1256	EUCTR2008-002623-85-NL	27/07/2009	11 February 2013	A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE	A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE	Moderate to severe early Rheumatoid Arthritis (RA). (Subjects with moderate to severe early Rheumatoid Arthritis (RA), who are currently employed (to constitute a majority of recruited subjects), or if not employed, are able to work and perform a functional role in society, such as caring for home and family, who have had RA symptoms for 1 year or less, and are Methotrexate-naive). MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Enbrel 25mg PFS Product Name: Enbrel (Etanercept) Product Code: 0881 Pharmaceutical Form: Injection* INN or Proposed INN: Etanercept Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use Trade Name: Enbrel 50mg PFS Product Name: Enbrel (Etanercept) Product Code: 0881 Pharmaceutical Form: Injection* INN or Proposed INN: Etanercept Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use Trade Name: Methotrexate 2.5mg Tablets Product Name: Methotrexate 2.5mg Tablets Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59052 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development		Not Recruiting			Female: yes Male: yes	300		France;Spain;Ireland;Germany;Netherlands;United Kingdom;Italy;Sweden
1257	ChiCTR-TRC-09000472	2009-07-20	18 April 2017	Weekly dose of leflunomide for the treatment of early rheumatoid arthritis	Weekly dose of leflunomide for the treatment of early rheumatoid arthritis: a multicentre, open, randomized clincal trial	Rheumatoid arthritis	Group A:leflunomide 10mg,orally taken once daily for 24 weeks;Group B:leflunomide 50mg, orally taken weekly for 24 weeks;	People's Hospital, Peking University		Not Recruiting	18	65	Both	Group A:160;Group B:160;	Post-market	China
1258	ChiCTR-TRC-09000473	2009-07-20	18 April 2017	Efficacy and safety of Alendronate on Structural Benefit and Inflammation in Rheumatoid Arthritis(RA): A randomized, open, placebo-controlled, multicentre clinical trial.	Efficacy and safety of Alendronate on Structural Benefit and Inflammation in Rheumatoid Arthritis(RA): A randomized, open, placebo-controlled, multicentre clinical trial.	Rheumatoid Arthritis	Group B:MTX 7.5-20mg, orally taken once weekly for 48 week;Group A:MTX7.5-20mg, orally taken once weekly combined Alendronate Sodium 70mg,orally taken once weekly for 48 weeks ;	People's Hospital, Peking University		Not Recruiting	18		Both	Group B:160;Group A:160;	Post-market	China
1259	EUCTR2009-010955-29-NL	13/07/2009	19 March 2012	Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.	Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.	Pre-clinical RA patients with a high risk on developing the disease.	Trade Name: MabThera 500 mg (10mg/ml) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use	Division of Clinically Immunology and Rheumatology, AMC		Authorised			Female: yes Male: yes			Netherlands
1260	JPRN-UMIN000002169	2009/07/01	2 April 2019	Safety and efficacy of 3 DMARDs for 2 years of treatment in patients with early rheumatoid arthritis		Rheumatoid Arthritis	Salazosulfapyridine Bucillamine	Higashi-Hiroshima Memorial Hospital		Not Recruiting	20years-old	80years-old	Male and Female	60	Phase 4	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1261	NCT00903383	July 2009	19 October 2017	Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate	A Phase 2, Multi-center, Randomized, Double Blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy	Rheumatoid Arthritis	Drug: LX3305 low dose;Drug: LX3305 mid dose;Drug: LX3305 high dose;Drug: Placebo	Lexicon Pharmaceuticals		Not recruiting	18 Years	75 Years	All	208	Phase 2	United States;Bulgaria;Czech Republic;Hungary;Poland;Serbia
1262	NCT00965757	July 2009	19 October 2017	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: T-614;Drug: Placebo	Eisai Co., Ltd.	Toyama Chemical Co., Ltd.	Not recruiting	20 Years	69 Years	All	253	Phase 3	Japan
1263	EUCTR2009-012141-34-GB	29/06/2009	19 March 2012	Randomised Controlled Trial of the Use of Topical Application of Tranexamic Acid in Primary Total Hip Replacement. - (TRANX-H)	Randomised Controlled Trial of the Use of Topical Application of Tranexamic Acid in Primary Total Hip Replacement. - (TRANX-H)	Blood loss in total hip replacement in patient with ostoearthritis and rheumatoid arthritis.	Trade Name: Cyklokapron® Product Name: Cyklokapron® Product Code: NA Pharmaceutical Form: Injection* Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Local use (Noncurrent)	University Hospital of North Tees and Hartlepool		Not Recruiting			Female: yes Male: yes	150		United Kingdom
1264	EUCTR2008-002381-55-ES	16/06/2009	19 March 2012	Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR. Efficacy of rituximab in patients with Rheumatoid Arthritis, by measurement of disease parameters through magnetic resonance of the hand. RESONAR study.	Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR. Efficacy of rituximab in patients with Rheumatoid Arthritis, by measurement of disease parameters through magnetic resonance of the hand. RESONAR study.	Pacientes con artritis reumatoide (AR) activa refractarios a uno o más fármacos antiTNF (definido por un DAS28>3,2). MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: MABTHERA 500 mg concentrado para solución para perfusión Pharmaceutical Form: Intravenous infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Other descriptive name: RITUXIMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	ROCHE FARMA, S.A.		Not Recruiting			Female: yes Male: yes			Spain
1265	JPRN-JapicCTI-090764	01/6/2009	23 April 2019	Long-Term Treatment Study of Ocrelizumab for Rheumatoid Arthritis	Long-Term Treatment Study of Ocrelizumab for Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : Ocrelizumab Dosage And administration of the intervention : 500 mg will be administered by intravenous infusion on Day 1 and Day 15. Repeat courses of therapy with ocrelizumab may be administered basically every 24 weeks, a minimum interval of 12 weeks, between courses.	Chugai Pharmaceutical Co., Ltd.			20		BOTH	200	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1266	NCT00848354	June 2009	19 October 2017	Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy	A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Biological: Phase 1: Etanercept;Drug: Phase 1: Methotrexate;Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX;Drug: Phase 1: Conventiaonal DMARD	Pfizer	Amgen	Not recruiting	18 Years	69 Years	All	429	Phase 4	Argentina;Chile;Colombia;Mexico;Panama;Brazil;Ecuador;Spain;Venezuela
1267	NCT00883896	June 2009	19 February 2015	Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of ILV-094 Administered Subcutaneously To Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate	Rheumatoid Arthritis	Other: Placebo;Drug: ILV-094	Pfizer		Not recruiting	18 Years	N/A	Both	195	Phase 2	United States;Belgium;Colombia;Croatia;Germany;Hungary;Japan;Mexico;Netherlands;Romania;Russian Federation;Denmark
1268	NCT00927927	June 2009	19 October 2017	First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Dose-escalation, Single and Multiple Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0142-0002 Administered Subcutaneously to Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0142-0002;Drug: placebo	Janssen Research & Development, LLC		Not recruiting	18 Years	75 Years	All	65	Phase 1	Germany
1269	NCT00947492	June 2009	19 February 2015	Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs	Monitoring EBV Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs ; Orencia* (Abatacept) and RoActemra* (Tocilizumab).	Rheumatoid Arthritis	Biological: Venous blood sample	Assistance Publique Hopitaux De Marseille		Not recruiting	18 Years	N/A	Both	60	N/A	France
1270	EUCTR2008-008337-11-SE	27/05/2009	19 November 2012	PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND DMARDS	PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND DMARDS	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: CP-690,550 Pharmaceutical Form: Film-coated tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	750	Phase 3	Greece;Finland;Poland;Spain;Denmark;Germany;United Kingdom;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1271	EUCTR2008-007788-17-CZ	20/05/2009	24 July 2012		PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS -	CP 690,550 is being studied as a DMARD for the treatment of moderate to severe active RA in adults. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CP-690,550 Product Code: CP-690,550 Pharmaceutical Form: Film-coated tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550-10 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	611	Phase 3	Germany;Czech Republic;Bulgaria
1272	EUCTR2008-008338-35-CZ	20/05/2009	10 July 2015	PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE	PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE	CP 690,550 is being studied as a DMARD for the treatment of moderate to severe active RA in adults. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: CP-690,550 Pharmaceutical Form: Film-coated tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	700	Phase 3	Czech Republic;Slovakia;Finland;Spain;Denmark;Bulgaria;Germany;United Kingdom
1273	EUCTR2008-004875-23-BE	18/05/2009	11 August 2014	An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis	An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: LY2127399 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48-	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	236		France;Hungary;Poland;Belgium;Austria;Germany
1274	EUCTR2008-007023-26-CZ	18/05/2009	26 June 2012	PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE	PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE	CP 690,550 is being studied as a disease modifying antirheumatic drug for the treatment of moderate to severe active rheumatoid arthritis in adults. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: CP-690,550 Pharmaceutical Form: Film-coated tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	750	Phase 3	Czech Republic;Bulgaria;Poland
1275	EUCTR2009-011105-17-IT	17/05/2009	19 March 2012	A single-arm, open-label study of early improvement of anemia and fatigue during treatment with tocilizumab (TCZ) in combination with non biologic DMARDs, in adult patients with moderate to severe active rheumatoid arthritis. - Anemia Fatigue	A single-arm, open-label study of early improvement of anemia and fatigue during treatment with tocilizumab (TCZ) in combination with non biologic DMARDs, in adult patients with moderate to severe active rheumatoid arthritis. - Anemia Fatigue	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Tocilizumab Product Code: Ro 487-7533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RoActemra CAS Number: 375823-41-9 Current Sponsor code: Ro 487-7533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	ROCHE		Not Recruiting			Female: yes Male: yes			Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1276	EUCTR2007-006657-63-FI	08/05/2009	3 September 2012	Study comparing the effect on disease activity when reducing or discontinuing Etanercept in subjects with Rheumatoid Arthritis (RA) (DOSERA)	Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA). - DOSERA	Rheumatoid Arthritis (RA) patients who are on Etanercept (ETN) treatment and are in remission or in a Low Disease Activity (LDA) state MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Enbrel 25 mg powder and solvent for solution for injection Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Powder and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Enbrel 50 mg powder and solvent for solution for injection Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Powder and solvent for solution for injection Route of administration of the placebo: Subcutaneous use	Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom		Not Recruiting			Female: yes Male: yes	72		Hungary;Finland;Iceland;Denmark;Norway;Sweden
1277	EUCTR2009-011520-53-SK	04/05/2009	18 April 2016	Evaluation of Adherence and Persistence to Tocilizumab in combination with Methotrexate or Tocilizumab Monotherapy in patients with moderate to severe active rheumatoid arthritis in local environment	Evaluation of Adherence and Persistence to Tocilizumab in combination with Methotrexate or Tocilizumab Monotherapy in patients with moderate to severe active rheumatoid arthritis in local environment	moderate to severe active rheumatoid arthritis	Trade Name: RoActemra® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Other descriptive name: RoActemra Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal	Roche Slovensko s.r.o.		Not Recruiting			Female: yes Male: yes			Slovakia
1278	ChiCTR-TRC-12003871	2009-05-01	18 April 2017	Phase II of Tong Luo Hua Shi Capsules in Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Phase II Study Evaluating the Safety and Efficacy of Tong Luo Hua Shi Capsules in Participants with Rheumatoid Arthritis	Rheumatoid arthritis	A:2 pieces of Tong Luo Hua Shi Capsules. Votalin and Leflunomide Tablets when necessary;B:3 pieces of Tong Luo Hua Shi Capsules. Votalin and Leflunomide Tablets when necessary;C:4 pieces of Tong Luo Hua Shi Capsules. Votalin and Leflunomide Tablets when necessary;D:4 pieces placebo;	The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine		Not Recruiting	18	68	Both	A:60;B:60;C:60;D:60;	Phase 1+Phase 2	China
1279	NCT00279461	May 2009	10 August 2015	Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis	Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells	Arthritis, Rheumatoid;Vitamin D Deficiency	Drug: Placebo in arm A and Vitamin D in arm B;Drug: vitamin D 3 for arm A ,and matching placebo for arm B	Indiana University		Not recruiting	18 Years	N/A	Both	0	Phase 2	United States
1280	NCT00838565	May 2009	19 February 2015	Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis	Phase I, Randomized, Patient and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PF-04236921 in Patients With Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: dose level 1;Drug: dose level 2;Drug: dose level 3;Drug: dose level 4	Pfizer		Not recruiting	18 Years	70 Years	Both	41	Phase 1	United States;Korea, Republic of;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1281	NCT00853385	May 2009	19 October 2017	A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis	Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate	Rheumatoid Arthritis	Drug: CP 690,550;Drug: CP-690,550;Other: Placebo;Biological: Biologic TNFi	Pfizer		Not recruiting	18 Years	N/A	All	717	Phase 3	United States;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom
1282	NCT00856544	May 2009	19 October 2017	A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications	Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS	Arthritis, Rheumatoid	Drug: CP-690,550;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	795	Phase 3	United States;Australia;Chile;China;Colombia;Croatia;Denmark;Finland;Germany;Greece;Malaysia;Mexico;Poland;Russian Federation;Slovakia;Spain;Sweden;Thailand;United Kingdom;Venezuela
1283	NCT00888745	May 2009	19 February 2015	A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: placebo;Drug: PRO283698	Genentech, Inc.		Not recruiting	18 Years	75 Years	Both	65	Phase 1	United States;Hungary;United Kingdom
1284	NCT00891020	May 2009	19 October 2017	A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)	Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Nonbiologic DMARDs of investigator's choice	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	886	Phase 3	United States;Puerto Rico;United Kingdom
1285	NCT00902369	May 2009	8 August 2016	A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)		Rheumatoid Arthritis	Drug: AK106-001616;Drug: Placebo;Drug: Active comparator	Asahi Kasei Pharma Corporation		Not recruiting	18 Years	65 Years	Both	130	Phase 2	Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1286	NCT00902486	May 2009	10 September 2018	INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs	A Randomized, Double-blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients With Active RA With Inadequate Response to Any Disease Modifying Anti-Rheumatic Drugs (DMARD) Therapy Including Biologics	Rheumatoid Arthritis	Drug: INCB028050;Drug: Placebo	Incyte Corporation		Not recruiting	18 Years	N/A	All	127	Phase 2	United States;Czechia;Czech Republic
1287	NCT00920608	May 2009	19 February 2015	A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients	A Phase I, Multi-centre, Open-label, Fixed-sequence Study to Assess the Pharmacokinetics of Methotrexate Alone and When Co-administered With AZD9056 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AZD9056;Drug: Methotrexate	AstraZeneca		Not recruiting	18 Years	70 Years	Both	12	Phase 1
1288	EUCTR2008-006917-25-DE	24/04/2009	19 March 2012	A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA).	A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA).	Patients with active rheumatoid arthritis who are on a stable dose of methotrexate	Trade Name: Ribazen Product Name: Tranilast Pharmaceutical Form: Tablet INN or Proposed INN: Tranilast CAS Number: 53902-12-8 Current Sponsor code: None Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Ribazen Product Name: Tranilast Pharmaceutical Form: Tablet INN or Proposed INN: Tranilast CAS Number: 53902-12-8 Current Sponsor code: None Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Product Name: methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59052	Nuon Therapeutics, Inc.		Not Recruiting			Female: yes Male: yes	250	Phase 2	United Kingdom;Czech Republic;Germany;Bulgaria;Poland
1289	EUCTR2008-008309-23-FR	24/04/2009	19 March 2012	Etude clinique comparative en double aveugle versus placebo sur la rapidité d’action du tocilizumab sur le soulagement des patients atteints de polyarthrite rhumatoïde active avec réponse inadéquate aux DMARDs et/ou aux biothérapies. - TORPEDO	Etude clinique comparative en double aveugle versus placebo sur la rapidité d’action du tocilizumab sur le soulagement des patients atteints de polyarthrite rhumatoïde active avec réponse inadéquate aux DMARDs et/ou aux biothérapies. - TORPEDO	Polyarthrite rhumatoïde active modérée à sévère de moins de 10 ans d'ancienneté, avec réponse inadéquate au méthotrexate (MTX) et/ou à un autre DMARD et/ou à au moins un anti-TNF MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: RoActemra Product Code: RO487-7533/F01-F05 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tolicizumab CAS Number: 357823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use	ROCHE		Authorised			Female: yes Male: yes			France
1290	EUCTR2008-004875-23-PL	22/04/2009	15 May 2012	An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis	An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: LY2127399 Product Code: NA Pharmaceutical Form: Powder for solution for injection Current Sponsor code: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48-	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	236		Hungary;Germany;Belgium;France;Austria;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1291	EUCTR2008-006075-75-DE	22/04/2009	19 March 2012	A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis	A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: AK106-001616 Pharmaceutical Form: Capsule, hard CAS Number: 590416-75-4 Current Sponsor code: AK106-001616 (form B) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Naprosyn 500 mg Product Name: Naprosyn 500 mg Pharmaceutical Form: Capsule* INN or Proposed INN: naproxen CAS Number: 22204-53-1 Current Sponsor code: naproxen Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Asahi Kasei Pharma Corporation		Not Recruiting			Female: yes Male: yes	130	Phase 2a	Hungary;Czech Republic;United Kingdom;Germany
1292	NCT01081717	April 14, 2009	15 July 2019	Golimumab Safety and Surveillance Program Using the Ingenix NHI Database	A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments	Rheumatoid Arthritis;Arthritis, Psoriatic;Ankylosing Spondylitis	Drug: systemic non-biological treatments;Biological: anti-TNF biologics;Biological: golimumab;Biological: non-anti-TNF biologics;Other: general population	Janssen Biotech, Inc.		Not recruiting	N/A	99 Years	All	1064	N/A	United States
1293	EUCTR2009-011044-20-GB	08/04/2009	19 March 2012	A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers	A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers	rheumatoid arthritis MedDRA version: 9.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions	Product Code: AZD5672 Pharmaceutical Form: Tablet Current Sponsor code: AZD5672 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Avelox® Product Name: Avelox- Moxifloxacin Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AstraZeneca AB		Not Recruiting			Female: no Male: yes	64		United Kingdom
1294	JPRN-JapicCTI-090751	01/4/2009	2 April 2019	A study of Adalimumab in Japanese subjects with Rheumatoid Arthritis	A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects with Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : adalimumab INN of the intervention : adalimumab Dosage And administration of the intervention : 40 mg every other week, subcutaneous Control intervention name : Placebo Dosage And administration of the control intervention : every other week, subcutaneous	Abbott Japan Co., Ltd.	Eisai Co., Ltd.		20		BOTH	300	Phase 3
1295	JPRN-UMIN000004271	2009/04/01	2 April 2019	Upper gastrointestinal endoscopic findings in Japanese with rheumatoid arthritis (RA) receiving long-term NSAIDs therapy, and the usefulness of switching to selective COX-2 inhibitor celecoxib		Rheumatoid arthritis (RA) NSAIDs-induced gastrointestinal mucosal injury	Japanese rheumatic patients who have been treated with NSAIDs for twelve or more weeks are switched to CEL (400mg/day). Upper GI endoscopy is conducted before and after administration of CEL. Patients with ulcers at the enrollment are switched to CEL (400mg/day) with famotidine (20mg/day) after healing of their pre-existing ulcers following treatment.	Hoshigaoka Koseinenkin Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	100	Not applicable	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1296	NCT00763139	April 2009	19 October 2017	Inflammation and Insulin Resistance in Rheumatoid Arthritis	Inflammation and Insulin Resistance in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Pioglitazone;Drug: Placebo	Vanderbilt University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	18 Years	N/A	All	34	N/A	United States
1297	NCT00887770	April 2009	19 February 2015	A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart	A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers	Rheumatoid Arthritis	Drug: AZD5672;Drug: Moxifloxacin;Drug: placebo	AstraZeneca	Quintiles Limited	Not recruiting	18 Years	45 Years	Male	64	Phase 1	United Kingdom
1298	NCT00928317	April 2009	19 February 2015	Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate	Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate	Rheumatoid Arthritis	Drug: ART621;Drug: Placebo	Arana Therapeutics Ltd		Not recruiting	18 Years	80 Years	Both	13	Phase 2	United States;Argentina;Australia;Czech Republic;India;Malaysia;New Zealand;Poland
1299	NCT00931086	April 2009	19 February 2015	Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99	An Expanded Access Trial of Belimumab Antibody (Monoclonal Anti-BLyS Antibody) in Patients With Rheumatoid Arthritis (RA) Who Were Previously Treated Under HGS Protocol LBRA99	Rheumatoid Arthritis	Drug: belimumab	Human Genome Sciences Inc., a GSK Company	GlaxoSmithKline	Not recruiting	18 Years	N/A	Both		Phase 4	United States
1300	NCT01075711	April 2009	19 February 2015	Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)	Non-interventional Study for Determining the Improvement in the Activity Status / Life Quality of Patients With Rheumatoid Arthritis Being Treated With the Tempus Tablet	Arthritis, Rheumatoid	Drug: Prednisone	Merck KGaA	Merck Serono GmbH, Germany	Not recruiting	18 Years	N/A	Both	2728	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1301	EUCTR2008-006930-92-CZ	31/03/2009	19 March 2012	A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose administration for 3 months in patients with rheumatoid arthritis concomitantly taking methotrexate	A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose administration for 3 months in patients with rheumatoid arthritis concomitantly taking methotrexate	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: ART621 Pharmaceutical Form: Solution for injection Current Sponsor code: ART621 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Arana Therapeutics Ltd		Not Recruiting			Female: yes Male: yes	200		Czech Republic
1302	EUCTR2008-003011-12-GB	30/03/2009	19 March 2012	Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - TOCRA	Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - TOCRA	Rheumatoid Arthritis	Trade Name: RoActemra®EV Product Code: PRD82321 Product Name: Tocilizumab Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	University of Leeds		Authorised			Female: yes Male: yes	30		United Kingdom
1303	EUCTR2008-006936-37-HU	25/03/2009	19 March 2012	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate	Rheumatoid Arthritis (RA) MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ILV-094 Product Code: ILV-094 Pharmaceutical Form: Powder for injection* Current Sponsor code: ILV-094 Other descriptive name: Recombinant human anti IL-22 monoclonal antibody IgG1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Powder for injection* Route of administration of the placebo: Subcutaneous use	Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development		Not Recruiting			Female: yes Male: yes	180		Hungary;Germany;Netherlands;Belgium
1304	NCT00687193	March 2009	19 October 2017	Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD	Arthritis, Rheumatoid	Drug: Placebo;Drug: CP-690,550	Pfizer		Not recruiting	20 Years	70 Years	All	318	Phase 2	Japan
1305	NCT00808210	March 2009	14 November 2016	A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab	A PHASE II RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE, COMPARED TO INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB	Rheumatoid Arthritis	Drug: infliximab;Drug: methotrexate;Drug: methylprednisolone;Drug: ocrelizumab;Drug: sham	Genentech, Inc.		Not recruiting	18 Years	N/A	Both	28	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1306	NCT00837434	March 2009	18 December 2018	Anti-TNF Agents for the Treatment of Rheumatoid Arthritis	A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Adalimumab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Not recruiting	18 Years	75 Years	All	63	Phase 4	United States
1307	NCT00847613	March 2009	19 October 2017	A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate	Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate	Arthritis, Rheumatoid	Drug: CP-690,550;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	800	Phase 3	United States;Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Greece;India;Japan;Korea, Republic of;Mexico;Poland;Taiwan;Ukraine;Venezuela
1308	NCT00850343	March 2009	19 October 2017	Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients	A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered Without Coadministration of Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-003)	Rheumatoid Arthritis	Drug: Certolizumab pegol	Astellas Pharma Inc	UCB Japan Co. Ltd.	Not recruiting	20 Years	74 Years	All	208	Phase 3	Japan
1309	NCT00851318	March 2009	19 October 2017	Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients	A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered in Combination With Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-001)	Rheumatoid Arthritis	Drug: Certolizumab pegol;Drug: Methotrexate	Astellas Pharma Inc	UCB Japan Co. Ltd.	Not recruiting	20 Years	74 Years	All	285	Phase 3	Japan
1310	NCT00870467	March 2009	19 October 2017	A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis	A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Double-blind adalimumab;Drug: Double-blind Placebo;Biological: Open-label Adalimumab;Biological: Open-labelAdalimumabRescue	Abbott	Eisai Co., Ltd.	Not recruiting	20 Years	N/A	All	334	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1311	NCT00871767	March 2009	19 February 2015	AZD5672 Bioavailability Study in Healthy Male and Female Subjects	An Open-Label, Randomized, 4 Period Crossover, Replicate Study to Assess the Relative Bioavailability of the Phase III and Phase IIb Formulations of AZD5672 in Healthy Male and Female Subjects	Rheumatoid Arthritis	Drug: AZD5672	AstraZeneca		Not recruiting	18 Years	55 Years	Both	24	Phase 1	United Kingdom
1312	NCT00882024	March 2009	19 February 2015	Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)	A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast With Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients With Active Rheumatoid Arthritis (RA)	Active Rheumatoid Arthritis	Drug: Tranilast;Drug: Placebo	Nuon Therapeutics, Inc.		Not recruiting	18 Years	75 Years	Both	250	Phase 2	United States;Argentina;Bulgaria;Czech Republic;Germany;Mexico;Serbia;United Kingdom
1313	NCT02721004	March 2009	21 July 2016	Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis	Documentation of the Efficacy and Safety of RoActemra in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	N/A	N/A	Both	592	N/A	Austria
1314	EUCTR2008-006443-39-ES	23/02/2009	24 April 2012	Estudio piloto de fase II multicéntrico, aleatorizado, en grupos paralelos para comparar la incidencia de las reacciones a la infusión de Tocilizumab en pacientes con AR moderada a grave cuando la infusión se realiza en 1 hora frente a 31 minutos.	Estudio piloto de fase II multicéntrico, aleatorizado, en grupos paralelos para comparar la incidencia de las reacciones a la infusión de Tocilizumab en pacientes con AR moderada a grave cuando la infusión se realiza en 1 hora frente a 31 minutos.	Pacientes adultos con artritis reumatoide (AR) activa moderada o grave que son respondedores inadecuados a los tratamientos con FAMEs no biológicos o con anti-TNFs. MedDRA version: 9 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Tocilizumab Product Code: RO04877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Tocilizumab Current Sponsor code: RO4877533 Other descriptive name: RoActemra Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Roche Farma, S.A.		Not Recruiting			Female: yes Male: yes			Spain
1315	EUCTR2008-004894-16-DE	12/02/2009	19 March 2012	Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy	Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: LY2127399 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 48- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use	Eli Lilly and Company limited		Not Recruiting			Female: yes Male: yes	150	Phase 2	Hungary;Czech Republic;Germany;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1316	NCT00754572	February 2009	19 October 2017	A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	418	Phase 3	Argentina;Brazil;Chile;Colombia;Costa Rica;Ecuador;Mexico;Peru;Uruguay;Venezuela
1317	NCT00777816	February 2009	18 January 2016	Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis	A Blinded, Placebo-controlled, Study of the Safety and Pharmacokinetics of XOMA 052 Administered to Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: XOMA 052;Drug: Placebo	XOMA (US) LLC		Not recruiting	18 Years	75 Years	Both	18	Phase 2	United States
1318	NCT00814307	February 2009	19 October 2017	A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis	Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP-690,550;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	611	Phase 3	United States;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Dominican Republic;Germany;India;Malaysia;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;Ukraine
1319	NCT00837811	February 2009	11 June 2018	An Open Label Extension Study in Participants With Rheumatoid Arthritis	An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Biological: LY2127399	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	182	Phase 2	United States;Australia;Austria;Belgium;Brazil;Canada;Chile;Germany;Hungary;India;Mexico;Poland;Puerto Rico;Romania;Argentina;Czech Republic;France;Slovakia;Ukraine
1320	NCT00847886	February 2009	19 October 2017	Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: LX3305;Drug: LX3305 Placebo;Drug: Methotrexate	Lexicon Pharmaceuticals		Not recruiting	18 Years	N/A	All	15	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1321	NCT00851240	February 2009	19 February 2015	BTT-1023 in Rheumatoid Arthritis	A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Rheumatoid Arthritis - a Double-blind Randomized Placebo-controlled Sequential Group Trial	Rheumatoid Arthritis	Drug: BTT-1023;Drug: Placebo	Biotie Therapies Corp.		Not recruiting	18 Years	75 Years	Both	24	Phase 1	Bulgaria
1322	NCT00854685	February 2009	19 February 2015	Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate	A Factorial-design, Randomised, Double-blind, Placebo-controlled, Dose Optimisation Study to Investigate the Safety, Efficacy, Immunogenicity and Pharmacokinetics of ART621 Following Multiple Dose Administration in Subjects Diagnosed With Rheumatoid Arthritis Concomitantly Taking Methotrexate	Rheumatoid Arthritis	Drug: ART621;Drug: Placebo	Arana Therapeutics Ltd	Trident Clinical Research Pty Ltd	Not recruiting	18 Years	80 Years	Both	27	Phase 2	Sri Lanka
1323	NCT01447264	February 2009	19 February 2015	Effectiveness of Water Exercises on Isokinetic Muscle Strength	Comparison of the Effectiveness Between Land and Water Exercises on Isokinetic Muscle Strength of Lower Limbs in Women With Rheumatoid Arthritis: a Randomized Controlled Trial	Rheumatoid Arthritis	Procedure: Land exercises;Procedure: Water exercises	Federal University of São Paulo	Department of Medicine	Not recruiting	40 Years	65 Years	Female	100	Phase 3	Brazil
1324	EUCTR2008-004754-33-SK	29/01/2009	13 March 2017	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012 when given with Methotrexate to Subjects with Active Rheumatoid Arthritis who have had an Inadequate Response to Coventional Disease-Modifying Anti-rheumatic Drug Therapy	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012 when given with Methotrexate to Subjects with Active Rheumatoid Arthritis who have had an Inadequate Response to Coventional Disease-Modifying Anti-rheumatic Drug Therapy	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: BG00012 Pharmaceutical Form: Capsule, hard CAS Number: 624497 Other descriptive name: Dimeythl Fumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Biogen Idec Limited		Not Recruiting			Female: yes Male: yes	150	Phase 2	Czech Republic;Slovakia;Poland
1325	EUCTR2008-005525-11-ES	29/01/2009	18 April 2012	Estudio randomizado, controlado con placebo, doble ciego y con grupos paralelos para comparar la seguridad y la reducción de la actividad de la enfermedad con la combinación de rituximab (MabThera) y tocilizumab (RoActemra) frente al tratamiento con tocilizumab en pacientes con artritis reumatoide activa con respuesta incompleta a metotrexato. A randomized, placebo controlled, double-blind, parallel group study to compare the safety and efficacy of the combination of rituximab (MabThera) and tocilizumab (Actemra) versus tocilizumab therapy in patients with active rheumatoid arthritis with an incomplete response to methotrexate.	Estudio randomizado, controlado con placebo, doble ciego y con grupos paralelos para comparar la seguridad y la reducción de la actividad de la enfermedad con la combinación de rituximab (MabThera) y tocilizumab (RoActemra) frente al tratamiento con tocilizumab en pacientes con artritis reumatoide activa con respuesta incompleta a metotrexato. A randomized, placebo controlled, double-blind, parallel group study to compare the safety and efficacy of the combination of rituximab (MabThera) and tocilizumab (Actemra) versus tocilizumab therapy in patients with active rheumatoid arthritis with an incomplete response to methotrexate.	Artritis reumatoide Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: MABTHERA 500 mg concentrado para solución para perfusión Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: Ro 45-2294 Other descriptive name: RITUXIMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Product Name: tocilizumab Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab Current Sponsor code: Ro4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	81		United Kingdom;Germany;Netherlands;France;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1326	EUCTR2008-007225-39-BE	06/01/2009	5 June 2018	A 2 year follow up to assess the effectiveness in daily practice of different treatment strategies for early Rheumatoid Arthritis patients.	A 2 year prospective multicentre randomised controlled trial comparing effectiveness in daily practice of different treatment strategies for early RA - CareRA	early active Rheumatoid Arthritis, previously untreated with DMARDS MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Ledertrexate Pharmaceutical Form: Tablet INN or Proposed INN: methotrexate CAS Number: 7413-34-5 Other descriptive name: METHOTREXATE DISODIUM Concentration unit: mg milligram(s) Concentration type: range Concentration number: 7.5-20 Trade Name: Salazopyrine Pharmaceutical Form: Tablet INN or Proposed INN: SULFASALAZINE CAS Number: 599-79-1 Concentration unit: g gram(s) Concentration type: range Concentration number: 1-3 Trade Name: Arava Pharmaceutical Form: Coated tablet INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706-12-6 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 10-20	University Hospitals Leuven		Not Recruiting			Female: yes Male: yes	400	Phase 4	Belgium
1327	NCT00825409	January 2009	19 February 2015	Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head	Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head to Treat Arthritis, Fractures of the Radial Head, Relief of Symptoms After Radial Head Resection, or Revision of a Failed Radial Head Implant.	Degenerative Arthritis;Post-Traumatic Arthritis;Rheumatoid Arthritis	Device: Carbon Modular Radial Head;Device: Metal Radial Head	Ascension Orthopedics, Inc.		Recruiting	18 Years	85 Years	Both	203	N/A	United States
1328	NCT00838058	January 2009	19 February 2015	A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.	An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Controlled And Immediate Release Formulations In Healthy Volunteers	Rheumatoid Arthritis;Healthy Volunteers	Drug: CE-224,535;Drug: CE 224,535	Pfizer		Not recruiting	18 Years	55 Years	Both	11	Phase 1	United States
1329	NCT00858780	January 2009	19 October 2017	Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA	Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA)	Rheumatoid Arthritis	Drug: Etanercept;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	91	Phase 4	Denmark;Finland;Hungary;Iceland;Norway;Sweden
1330	NCT01426347	January 2009	16 December 2017	Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis	Vitamin Therapy in Rheumatoid Arthritis	Rheumatoid Arthritis;Vitamin D Deficiency	Drug: Placebo sugar pill;Drug: Ergocalciferol	Johns Hopkins University		Not recruiting	18 Years	75 Years	All	139	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1331	NCT02405234	January 2009	16 December 2017	Ascension PyroCarbon Radial Head Study	Safety and Effectiveness Study of Ascension PyroCarbon Radial Head Compared to Ascension Metal Radial Head	Degenerative Arthritis;Radial Head Fracture;Rheumatoid Arthritis	Device: Carbon Modular Radial Head replacement;Device: Metal Radial Head replacement	Integra LifeSciences Corporation		Not recruiting	18 Years	85 Years	All	78	N/A	United States
1332	NCT02779114	January 2009	30 May 2016	RETRO (REduction of Therapy in RA Patients in Ongoing Remission)	A Phase 3, Multicenter, Randomized, Open, Prospective, Controlled, Parallel Group Study of Reduction of Therapy in Patients With Rheumatoid Arthritis in Ongoing Remission.	Rheumatoid Arthritis	Drug: Control group;Other: Reduction group 1;Other: Reduction group 2	University of Erlangen-Nürnberg Medical School		Recruiting	18 Years	N/A	Both	318	Phase 3	Germany
1333	NCT02809833	January 2009	19 October 2017	Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine	Tocilizumab for the Treatment of Rheumatoid Arthritis: Findings on The Use of Tocilizumab in Daily Clinical Routine	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	850	N/A	Germany
1334	NCT00848120	December 31, 2008	16 December 2017	A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis	An Open Label Study to Evaluate the Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	29	Phase 3	Philippines
1335	EUCTR2008-002046-27-DE	08/12/2008	24 April 2012	Clinical phase I/IIA study of subcutaneous administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate	Clinical phase I/IIA study of subcutaneous administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Ofatumumab Product Code: GSK1841157 Pharmaceutical Form: Concentrate for solution for injection Current Sponsor code: GSK1841157 Other descriptive name: HuMax-CD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	70	Phase 1/2A	Germany;Belgium;France;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1336	EUCTR2008-004931-39-PL	08/12/2008	19 March 2012	A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80 mg, 160 mg, and 320 mg ALD518 versus Placebo Administered as Multiple Intravenous Infusions to Patients with Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate.	A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80 mg, 160 mg, and 320 mg ALD518 versus Placebo Administered as Multiple Intravenous Infusions to Patients with Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate.	Active Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ALD518 Product Code: ALD518 Pharmaceutical Form: Intravenous infusion Current Sponsor code: ALD518 Other descriptive name: ALD518 monoclonal antibody (anti IL-6 mAb) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use	Alder Biopharmaceuticals, Inc		Not Recruiting			Female: yes Male: yes	120		Poland
1337	ChiCTR-TRC-10001060	2008-12-01	18 April 2017	Efficacy and safety of infliximab in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial	Efficacy and safety of infliximab in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial	rheumatoid arthritis;M05.901	infliximab:intravenous injections of infliximab (3 mg/kg) at weeks 0, 2, 6, 14, with concurrent MTX therapy;placebo:intravenous injections of placebo (3 mg/kg) at weeks 0, 2, 6, 14, with concurrent MTX therapy;	People's Hospital, Beijing University; Shanghai Changzheng Hospital		Not Recruiting	18	65	Both	infliximab:0;placebo:0;	Phase 3 study	China
1338	NCT00767325	December 2008	19 October 2017	A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography	Multi-Center, Open Label Study to Assess Early Response to Abatacept With Background Methotrexate Using Power Doppler Ultrasonography in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	104	Phase 3	Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom
1339	NCT00805116	December 2008	17 May 2016	Marine Oils and Arthritis	Whale Oil Versus Cod Liver Oil in Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Whale blubber oil;Dietary Supplement: Cod liver oil	National Institute of Nutrition and Seafood Research, Norway		Not recruiting	18 Years	N/A	Both	7	N/A	Norway
1340	NCT00810836	December 2008	19 February 2015	Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis	A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of BG00012 When Given With Methotrexate to Subjects With Active RA Who Have Had an Inadequate Response to Conventional Disease-Modifying Anti-rheumatic Drug Therapy	Rheumatoid Arthritis	Drug: BG00012;Drug: placebo	Biogen Idec		Not recruiting	18 Years	75 Years	Both	153	Phase 2	Australia;Canada;Czech Republic;India;Poland;Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1341	NCT00815906	December 2008	19 February 2015	Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis	An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Japanese Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: SBI-087	Pfizer	Emergent Product Development Seattle LLC	Not recruiting	20 Years	70 Years	Both	20	Phase 1	Japan
1342	NCT00818064	December 2008	16 December 2017	Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Single- Dose, Dose-escalation Trial of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis;Healthy	Drug: anti-IL-20;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	75 Years	All	32	Phase 1	Netherlands
1343	NCT01011959	December 2008	19 February 2015	A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate	Rheumatoid Arthritis	Biological: REGN88	Regeneron Pharmaceuticals	Sanofi	Not recruiting	18 Years	N/A	Both	60	Phase 1	United States
1344	NCT01179971	December 2008	19 February 2015	n-3 and n-6 Fatty Acids in Rheumatoid Arthritis	Incorporation of n-3 Long Chain Polyunsaturated Fatty Acids and Gamma Linolenic Acid in Plasma Lipids, Cholesteryl Esters, and Erythrocyte Membranes and Their Influence on Disease Activity in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Fish oil, gamma-linolenic acid	Charite University, Berlin, Germany	University of Jena	Not recruiting	18 Years	80 Years	Both	60	Phase 2
1345	EUCTR2008-006256-22-FR	21/11/2008	19 March 2012	Evaluation by high resolution micro computerized tomography of bone microarchitecture changes in patients with rheumatoid arthritis under anti-TNF therapy.	Evaluation by high resolution micro computerized tomography of bone microarchitecture changes in patients with rheumatoid arthritis under anti-TNF therapy.	rheumatoid arthritis requiring anti-TNF alpha treatment MedDRA version: 9.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions	Trade Name: remicade Pharmaceutical Form: Intravenous infusion INN or Proposed INN: infliximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: humira Pharmaceutical Form: Injection* INN or Proposed INN: adalimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: enbrel Pharmaceutical Form: Injection* INN or Proposed INN: etanercept Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-	CHU Saint-Etienne		Authorised			Female: yes Male: yes			France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1346	NCT00771030	November 2008	14 November 2016	Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 827;Other: Placebo	Amgen		Not recruiting	18 Years	70 Years	Both	40	Phase 1/Phase 2	Canada;Mexico;United States
1347	NCT00783536	November 2008	19 February 2015	A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis	An Randomized, Open Label, Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate With DMARD Therapy in Subjects With Active Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept + Methotrexate;Drug: DMARDS	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	80 Years	Both	402	Phase 4	Mexico
1348	NCT00791921	November 2008	19 October 2017	Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated.	Rheumatoid Arthritis	Drug: CDP870;Drug: Placebo of CDP870	Otsuka Pharmaceutical Co., Ltd.	UCB Japan Co. Ltd.	Not recruiting	20 Years	74 Years	All	230	Phase 3	Japan
1349	NCT00791999	November 2008	19 October 2017	Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX.	Rheumatoid Arthritis	Drug: CDP870 400mg;Drug: CDP870 200mg;Drug: CDP870 100mg;Drug: Placebo of CDP870	Otsuka Pharmaceutical Co., Ltd.	UCB Japan Co. Ltd.	Not recruiting	20 Years	74 Years	All	316	Phase 2/Phase 3	Japan
1350	NCT00796705	November 2008	19 October 2017	Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)	Switching Anti-TNF-alpha Agents in Patients With RA With An Inadequate Response to TNF-alpha Inhibition	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Adalimumab placebo;Drug: Etanercept	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	18 Years	N/A	All	13	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1351	NCT00901550	November 2008	19 February 2015	The Chinese University of Hong Kong Early Arthritis Study	The Chinese University of Hong Kong Early Arthritis Study	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Infliximab	Chinese University of Hong Kong		Not recruiting	18 Years	80 Years	Both	40	N/A	China
1352	NCT00948610	November 2008	16 December 2017	Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy	Sleep & Immune Mechanisms in Rheumatoid Arthritis: Remicade Substudy	Rheumatoid Arthritis	Drug: Remicade	University of California, Los Angeles	National Heart, Lung, and Blood Institute (NHLBI)	Not recruiting	18 Years	85 Years	All	20	N/A	United States
1353	NCT00773461	October 31, 2008	16 December 2017	A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.	A Randomized, Double Blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With DMARD Therapy, in Patients With Active Rheumatoid Arthritis and Inadequate Response to Current DMARD Therapy	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Placebo	Hoffmann-La Roche		Not recruiting	18 Years	70 Years	All	209	Phase 3	China
1354	EUCTR2008-005320-81-AT	21/10/2008	19 March 2012	A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonal antibody in patients with active rheumatoid arthritis - A2201E2	A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonal antibody in patients with active rheumatoid arthritis - A2201E2	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ACZ885 Product Code: ACZ885 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Canakinumab Current Sponsor code: ACZ885 Other descriptive name: Recombinant human monoclonal antibody to inerleukin-1beta of the IgG1-K-class Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	200		Germany;Spain;Austria
1355	EUCTR2008-000742-30-HU	18/10/2008	19 March 2012	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: R935788 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib Disodium CAS Number: 914295-16-2 Current Sponsor code: R935788 sodium hexahydrate Other descriptive name: R788 Sodium, R788 Na, R788 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: R935788 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib Disodium CAS Number: 914295-16-2 Current Sponsor code: R935788 sodium hexahydrate Other descriptive name: R788 Sodium, R788 Na, R788 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Rigel Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	420	Phase 2	Hungary;Bulgaria;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1356	EUCTR2008-001847-20-ES	17/10/2008	28 August 2014	Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad de añadir otros fármacos antirreumáticos modificadores de la enfermedad (FAMEs), en pacientes con artritis reumatoide activa que tienen una respuesta inadecuada al tratamiento previo con MTX.	Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad de añadir otros fármacos antirreumáticos modificadores de la enfermedad (FAMEs), en pacientes con artritis reumatoide activa que tienen una respuesta inadecuada al tratamiento previo con MTX.	Artritis reumatoide MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Tocilizumab Product Code: RO04877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Methotrexate 'Lederle' 2.5mg Tablets Product Name: Methotrexate 'Lederle' 2.5mg Tablets Pharmaceutical Form: Tablet INN or Proposed INN: METOTREXATO SODIO Other descriptive name: METHOTREXATE SODIUM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	F Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	470		France;Estonia;Greece;Spain;Denmark;Germany;Latvia;Netherlands;Italy;United Kingdom;Sweden
1357	EUCTR2007-003288-36-NL	15/10/2008	18 April 2012	A Phase 4, Multicenter, Open-Label, Assessor-blinded, Switch Study o fthe Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) of Adalimumab (HUMIRA) - RESTART	A Phase 4, Multicenter, Open-Label, Assessor-blinded, Switch Study o fthe Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) of Adalimumab (HUMIRA) - RESTART	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Infliximab Other descriptive name: Chimeric Human-Murine IgG1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Centocor BV		Not Recruiting			Female: yes Male: yes	200	Phase 4	Finland;United Kingdom;Germany;Netherlands;France;Spain;Austria
1358	EUCTR2008-005212-40-SE	14/10/2008	19 March 2012	Pain mechanisms and fatigue in rheumatoid arthritis (RA) and healthy volunteers. Can antirheumatic and biological therapy affect pain processing and fatigue in RA? - RA PAIN PROCESSING	Pain mechanisms and fatigue in rheumatoid arthritis (RA) and healthy volunteers. Can antirheumatic and biological therapy affect pain processing and fatigue in RA? - RA PAIN PROCESSING	Rheumatoid arthritis (RA) The overall aim with this project is to investigate central pain mechanisms in RA and healthy controls, and in RA how these are influenced by autonomic neural regulation and TNF-blockade with Remicade. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10060016 Term: Alpha tumor necrosis factor MedDRA version: 9.1 Level: LLT Classification code 10029817 Term: Nuclear magnetic resonance imaging brain MedDRA version: 9.1 Level: LLT Classification code 10053689 Term: Cardiovascular autonomic function test	Trade Name: Remicade Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Infliximab Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Karolinska Institute		Authorised			Female: yes Male: no			Sweden
1359	EUCTR2008-004398-16-SE	08/10/2008	16 September 2013	A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable RA Patients in Clinical remission - ADMIRE	A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable RA Patients in Clinical remission - ADMIRE	Adalimumab has the indication for life-long treatment of RA but can adalimumab be discontinued in patients who are in stable clinical remission (DAS28<2.6) with retained low disease activity or will the RA symptoms relapse? If relapse occurs, how is the response if adalimumab is reinstituted? MedDRA version: 13.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Injection INN or Proposed INN: Adalimumab Current Sponsor code: ABT-Humira Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Abbott Scandinavia AB		Not Recruiting			Female: yes Male: yes	50		Sweden
1360	EUCTR2007-000830-38-FR	07/10/2008	19 March 2012	A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis who participated in the study C87076.	A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis who participated in the study C87076.	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Solution for injection INN or Proposed INN: Certolizumab pegol CAS Number: 428863-50-7 Current Sponsor code: CDP870 Other descriptive name: Anti-TNF humanized antibody Fab fragment - PEG conjugate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200-	UCB Pharma S.A.		Authorised			Female: yes Male: yes	132	Phase 3B	Germany;France;Italy;Poland;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1361	ChiCTR-TRC-10000850	2008-10-01	18 April 2017	Phase III clinical trial of Iguratimodin rheumatoid arthritis	Phase III clinical trial of Iguratimodin rheumatoid arthritis	rheumatoid arthritis	3:Experimental group: Iguratimod tablet, nimesulide dummy tablet; positive control group: taking nimesulide and Iguratimod dummy tablet; placebo group: taking Iguratimod dummy tablet and nimesulide dummy tablet. ;	Anhui Medical University		Not Recruiting	18	65	Both	3:600;	Phase 3 study	China
1362	NCT00768053	October 2008	19 October 2017	Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients	Open-Label Study To Evaluate The EULAR-RAID Score, Rheumatoid Arthritis Impact Of Disease Score, In Rheumatoid Arthritis Patients Eligible To Etanercept And Who Will Receive Etanercept	Rheumatoid Arthritis	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	Lincoln Medical and Mental Health Center;Umanis;SODIA;depolabo	Not recruiting	18 Years	N/A	All	108	Phase 4	France;Monaco
1363	NCT00771329	October 2008	19 February 2015	BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: BIIB023;Other: Placebo (sterile normal saline)	Biogen Idec		Not recruiting	18 Years	65 Years	Both	53	Phase 1	United States;Russian Federation;Ukraine
1364	NCT00771420	October 2008	19 February 2015	A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis	A Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: CAM-3001;Other: Placebo	MedImmune Ltd		Not recruiting	18 Years	70 Years	Both	38	Phase 1	Germany
1365	NCT00779220	October 2008	7 April 2015	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: placebo;Drug: methotrexate;Drug: ocrelizumabu 50mg;Drug: ocrelizumabu 200mg;Drug: ocrelizumab 500mg	Chugai Pharmaceutical		Not recruiting	20 Years	N/A	Both	152	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1366	NCT00785928	October 2008	19 February 2015	A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy	Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy	Rheumatoid Arthritis	Biological: LY2127399;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	75 Years	Both	158	Phase 2	United States;Argentina;Australia;Chile;Germany;Hungary;India;Mexico;Poland;Romania;Slovakia;Ukraine;Brazil;Canada;Czech Republic
1367	NCT00867516	October 2008	16 December 2017	Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis	A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Arthritis, Rheumatoid	Biological: ALD518;Biological: Infusion without ALD518`	Vitaeris INC		Not recruiting	18 Years	80 Years	All	127	Phase 2	Canada;Georgia;India;Poland;Russian Federation;Serbia
1368	EUCTR2008-001282-28-NL	23/09/2008	19 March 2012	Influenza, pneumococcal and hepatitis B vaccination in patients with rheumatic autoimmune diseases treated with immunosuppressive therapy - Vaccinations in rheumatic autoimmune diseases	Influenza, pneumococcal and hepatitis B vaccination in patients with rheumatic autoimmune diseases treated with immunosuppressive therapy - Vaccinations in rheumatic autoimmune diseases	Rheumatic autoimmune diseases including rheumatoid arthritis and poly or dermatomyositis.	Trade Name: Influvac Pharmaceutical Form: INN or Proposed INN: Influvac Concentration unit: ml millilitre(s) Concentration type: equal Concentration number: 0,5- Trade Name: Pneumovax 23 Pharmaceutical Form: INN or Proposed INN: Pneumovax 23 Concentration unit: ml millilitre(s) Concentration type: equal Concentration number: 0,5- Trade Name: HBvaxpro Pharmaceutical Form: INN or Proposed INN: HBVAXPRO Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 10-	Radboud University Nijmegen Medical Centre		Authorised			Female: yes Male: yes			Netherlands
1369	EUCTR2008-001241-26-HU	18/09/2008	19 March 2012	A randomized, placebo-controlled, double-blind, dose escalation study to evaluate the efficacy, safety and tolerability of the study drug BT971 in patients with rheumatoid arthritis receiving concomitant Methotrexate - n.a.	A randomized, placebo-controlled, double-blind, dose escalation study to evaluate the efficacy, safety and tolerability of the study drug BT971 in patients with rheumatoid arthritis receiving concomitant Methotrexate - n.a.	Active rheumatoid arthritis, functional class II-III MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: BT061 (CD4 monoclonal antibody) Product Code: BT971 Pharmaceutical Form: Solution for infusion INN or Proposed INN: BT061 (CD4 monoclonal antibody) Concentration unit: mg milligram(s) Concentration type: equal Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Biotest AG		Not Recruiting			Female: yes Male: yes	110		Hungary;Bulgaria
1370	EUCTR2008-001105-42-BE	16/09/2008	26 November 2013	A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG	A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: LY2127399 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	100	Phase 2	France;Poland;Belgium;Austria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1371	EUCTR2008-004126-16-FI	05/09/2008	19 March 2012	Local Open-Label Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARDs	Local Open-Label Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARDs	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: tocilizumab Product Code: RO4877533 (TCZ) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab Current Sponsor code: RO 4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: -20	Roche Oy		Not Recruiting			Female: yes Male: yes			Finland
1372	NCT00706797	September 2008	19 October 2017	Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects	An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) Added to Methotrexate in Comparison With Usual Treatment in Subjects With Moderate Rheumatoid Arthritis Disease Activity	Rheumatoid Arthritis	Drug: etanercept (EnbrelTM);Drug: methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	All	141	Phase 4	Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;Austria;Croatia;United States
1373	NCT00717808	September 2008	8 June 2015	Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)	A Phase 1, Blinded, Randomised, Crossover Pilot Study to Investigate the Safety, Tolerability and Pharmacokinetics of Tranilast in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis	Drug: Tranilast;Drug: Placebo comparator	Imperial College London	Nuon Therapeutics, Inc.	Not recruiting	18 Years	75 Years	Both	0	Phase 1	United Kingdom
1374	NCT00724672	September 2008	8 June 2015	A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)	Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.	Rheumatoid Arthritis	Drug: etanercept;Drug: infliximab;Drug: adalimumab	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	Both	0	N/A
1375	NCT00746512	September 2008	19 October 2017	A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)	A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Access the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler Ultrasound Signal of Synovium in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisone 15 mg;Drug: Placebo Tablets;Drug: Prednisone 7.5 mg;Drug: Placebo Over-Encapsulated Tablets	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	45	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1376	NCT00753454	September 2008	19 October 2017	Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)	A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.	Rheumatoid Arthritis	Drug: Certolizumab pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	168	Phase 3	United States;Canada
1377	NCT00780793	September 2008	19 February 2015	Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study	Effect of TNF-blocker Injections Spacing on Rheumatoid Arthritis Inflammatory Activity in Patients in Clinical Remission or Low Disease Activity	Rheumatoid Arthritis	Drug: progressive spacing of TNF-blocker injections;Drug: DMARD maintenance	Assistance Publique - Hôpitaux de Paris	French Society of Rheumatology	Not recruiting	18 Years	N/A	Both	250	Phase 4	France
1378	NCT00814866	September 2008	7 November 2016	Bone Resorption, Osteoclastogenesis and Adalimumab	Bone Resorption, Osteoclastogenesis and Adalimumab	Rheumatoid Arthritis	Drug: Adalimumab	Université de Sherbrooke	Abbott	Not recruiting	18 Years	N/A	Both	28	N/A	Canada
1379	NCT01026519	September 2008	19 February 2015	A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis	A Single-dose, Double-Blind, Placebo-Controlled, Parallel Group Safety, Tolerability and Pharmacodynamic Study of Subcutaneous REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate	Rheumatoid Arthritis	Drug: REGN88;Other: Placebo	Regeneron Pharmaceuticals	Sanofi	Not recruiting	18 Years	N/A	Both	32	Phase 1	Russian Federation
1380	EUCTR2008-000105-11-DE	19/08/2008	19 March 2012	Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA - TAMARA - Tocilizumab And DMARDs: Achievements in Rheumatoid Arthritis	Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA - TAMARA - Tocilizumab And DMARDs: Achievements in Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: RoActemra Product Name: Tocilizumab Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Roche Pharma AG		Not Recruiting			Female: yes Male: yes			Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1381	EUCTR2006-000923-32-GB	13/08/2008	19 March 2012	A randomised, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous infusions GSK315234A in patients with active rheumatoid arthritis (RA)	A randomised, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous infusions GSK315234A in patients with active rheumatoid arthritis (RA)	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: GSK315234 Product Code: GSK315234 Pharmaceutical Form: Injection* Current Sponsor code: GSK315234 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Intravenous use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	112		United Kingdom
1382	NCT00718718	August 11, 2008	16 December 2017	A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Arthritis, Rheumatoid	Drug: CNTO 136 100 mg;Drug: CNTO 136 50 mg;Drug: CNTO 136 25 mg;Drug: Placebo;Drug: Methotrexate	Centocor, Inc.		Not recruiting	18 Years	N/A	All	187	Phase 2	United States;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Argentina;Taiwan;Ukraine
1383	NCT00828997	August 2008	18 December 2018	Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar®	Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar®	Rheumatoid Arthritis;Spondylarthropathy	Biological: Prevenar vaccination	Region Skane	Lund University	Not recruiting	18 Years	N/A	All	505	Phase 4	Sweden
1384	EUCTR2007-007888-24-FR	31/07/2008	19 March 2012	Open-label Study to Evaluate the EULAR-RAID Score, Rheumatoid Arthritis Impact of Disease Score, in Rheumatoid Arthritis Patients Eligible to Etanercept and Who Will Receive Etanercept. - RAINBOW	Open-label Study to Evaluate the EULAR-RAID Score, Rheumatoid Arthritis Impact of Disease Score, in Rheumatoid Arthritis Patients Eligible to Etanercept and Who Will Receive Etanercept. - RAINBOW	RHEUMATOID ARTHRITIS	Trade Name: ENBREL Pharmaceutical Form: Injection* INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Wyeth Pharmaceuticals France		Authorised			Female: yes Male: yes	107		France
1385	ChiCTR-TCC-12002824	2008-07-10	18 April 2017	Traditional Chinese and anti-rheumatic drugs for the treatment of rheumatoid arthritis	Integration of Traditional Chinese and Western Medicine treat rheumatoid witharthritis: A prospective, randomized, controlled trial	rheumatoid arthritis with peptic ulcer	Acupuncture treatment:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint. ;ARD treatment:esomeprazole magnesium enteric-coated tablets ,celecoxib capsules and methotrexate tablets ;Combined therapy:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint + oral Shanhuang Wuji decoction ;	Hospital of Chengdu Military Area Command PLA		Not Recruiting	45	65	Both	Acupuncture treatment:20;ARD treatment:20;Combined therapy:20;	Other	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1386	JPRN-UMIN000001240	2008/07/01	2 April 2019	The efficacy of tocilizumab to patients with rheumatoid arthritis refractory to anti-TNF agents: the open trial		rheumatoid arthritis	Tocilizumab (8 mg/kg of body weight) is to be infused every 4 weeks for 3 years	Division of Rheumatology & Clinical Immunology, Jichi Medical University		Not Recruiting	20years-old	Not applicable	Male and Female	20	Not selected	Japan
1387	JPRN-UMIN000001798	2008/07/01	2 April 2019	Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study)		Rheumatoid arthritis	Injection of etanercept by 50 mg/week for one year Injection of etanercept by 25 mg/week for one year	Team RA, Rheumatosurgery, Osaka City University Medical School		Not Recruiting	20years-old	80years-old	Male and Female	100	Not applicable	Japan
1388	JPRN-UMIN000002421	2008/07/01	2 April 2019	Multicenter, open-label parallel-groups study comparing tocilizumab versus conventional treatment in rheumatoid arthritis with the complication of AA amyloidosis		rheumatoid arthritis	tocilizumab Conventional DMARDs and immune suppressive drugs and biologics except for tocilizumab	AA amyloidosis clinical research conference		Recruiting	20years-old	Not applicable	Male and Female	40	Not selected	Japan
1389	NCT00712114	July 2008	19 February 2015	Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis	A Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate	Rheumatoid Arthritis	Drug: HE3286	Harbor Therapeutics		Not recruiting	18 Years	75 Years	Both	14	Phase 1/Phase 2	United States
1390	NCT00713544	July 2008	19 October 2017	A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis	A Randomised, Double Blind, Placebo Controlled, Phase IIb Dose Ranging Study (With Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate.	Rheumatoid Arthritis	Drug: AZD5672;Drug: Etanercept;Drug: Placebo	AstraZeneca		Not recruiting	18 Years	N/A	All	373	Phase 2	Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;Argentina;Netherlands;Peru
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1391	NCT00714493	July 2008	19 October 2017	RESTART C0168Z05 Rheumatoid Arthritis Study	A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).	Rheumatoid Arthritis	Biological: Infliximab	Centocor Ortho Biotech Services, L.L.C.	Schering-Plough	Not recruiting	18 Years	N/A	All	203	Phase 4	United States;Austria;Canada;Finland;France;Germany;Israel;Netherlands;Spain;United Kingdom;Belgium
1392	NCT00717236	July 2008	19 October 2017	Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis	A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Certolizumab pegol (CZP);Other: Placebo	UCB Pharma		Not recruiting	18 Years	N/A	All	1648	Phase 3	United States;Canada;France;Germany;Italy;Netherlands;Spain
1393	NCT00718588	July 2008	19 February 2015	A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MTRX1011A	Genentech, Inc.		Not recruiting	18 Years	80 Years	Both	66	Phase 1	United States
1394	NCT00729209	July 2008	19 February 2015	A Study of ARRY-371797 in Patients With Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: ARRY-371797, p38 inhibitor; oral;Drug: Placebo	Array BioPharma		Not recruiting	18 Years	N/A	Both	28	Phase 1	United States
1395	NCT00782600	July 2008	19 February 2015	Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers	A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers	Rheumatoid Arthritis	Drug: suspension IR;Drug: CR 1;Drug: CR 2;Drug: CR 3	Pfizer		Not recruiting	18 Years	55 Years	Both	16	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1396	NCT01055899	July 2008	19 February 2015	Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate	Rheumatoid Arthritis	Biological: REGN88	Regeneron Pharmaceuticals	Sanofi	Not recruiting	18 Years	N/A	Both	15	Phase 1	United States
1397	EUCTR2007-006150-25-FR	24/06/2008	11 September 2012	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis ;Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: TRU-015 Pharmaceutical Form: Intravenous infusion Current Sponsor code: TRU-015 Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use Trade Name: Decortin 5mg tablets Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISONE CAS Number: 53032 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Solu-Medrone 125mg Pharmaceutical Form: Powder for solution for injection CAS Number: 2375033 Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Pharmaceutical Form: Intravenous infusion Current Sponsor code: TRU-015 Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use Trade Name: Decortin 5mg tablets Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISONE CAS Number: 53032 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Solu-Medrone 125mg Pharmaceutical Form: Powder for solution for injection CAS Number: 2375033 Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Wyeth Research Division of Wyeth Pharmaceuticals Inc.		Authorised			Female: yes Male: yes	216		Hungary;Germany;Netherlands;Belgium;France;Austria
1398	EUCTR2007-006527-13-BG	18/06/2008	19 March 2012	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients with Active Rheumatoid Arthritis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients with Active Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CF101 Pharmaceutical Form: Tablet INN or Proposed INN: methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide Current Sponsor code: CF101 Other descriptive name: IB-MECA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- INN or Proposed INN: methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide Current Sponsor code: CF101 Other descriptive name: IB-MECA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Can-Fite BioPharma Ltd.		Not Recruiting			Female: yes Male: yes	228	Phase 2	Bulgaria
1399	EUCTR2008-000587-17-GB	18/06/2008	19 March 2012	Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy	Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy	Rheumatoid arthritis. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Actemra Product Code: RO4877533 (TCZ) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	1500		Portugal;Hungary;Germany;Netherlands;France;Ireland;Italy;Austria;Sweden;Finland;United Kingdom;Czech Republic;Denmark;Belgium;Spain;Greece
1400	EUCTR2008-000743-34-BE	18/06/2008	26 November 2013	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: R935788 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib Disodium CAS Number: 914295-16-2 Current Sponsor code: R935788 sodium hexahydrate Other descriptive name: R788 Sodium, R788 Na, R788 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Rigel Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	195	Phase 2	France;Belgium;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1401	EUCTR2007-003508-36-HU	17/06/2008	21 August 2012	A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis - CAPRA-2	A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis - CAPRA-2	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Lodotra® Pharmaceutical Form: Tablet INN or Proposed INN: Prednisone CAS Number: 53-03-2 Concentration unit: MBq/mg megabecquerel(s)/milligram Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Nitec Pharma AG		Not Recruiting			Female: yes Male: yes	350		Hungary;Germany;United Kingdom
1402	EUCTR2007-001625-10-HU	16/06/2008	3 July 2012	An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity. - Extra	An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity. - Extra	RHEUMATOID ARTHRITIS MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Etanercept Pharmaceutical Form: Injection* INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Wyeth Pharmaceuticals France		Not Recruiting			Female: yes Male: yes	700		Hungary;Czech Republic;Germany;United Kingdom;Denmark;France;Ireland;Spain;Italy;Greece;Poland;Austria
1403	NCT00686868	June 13, 2008	16 December 2017	Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients	Clinical Phase I/IIA Study of Subcutaneously Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate	Arthritis, Rheumatoid	Other: placebo;Drug: ofatumumab	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	35	Phase 1	United States;Australia;Belgium;France;Italy;New Zealand;Poland;Russian Federation;Spain;Canada;Germany;Hungary;Netherlands
1404	EUCTR2007-001377-28-FR	11/06/2008	19 March 2012	Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL	Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL	Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously, -- AND who developed adverse events (AEs) corresponding to pre-specified newly diagnosed autoimmune disorders OR who developed severe thrombocytopenia. MedDRA version: 9.1 Level: LLT Classification code 10061664 Term: Autoimmune disorder MedDRA version: 9.1 Level: LLT Classification code 10025139 Term: Lupus erythematosus systemic MedDRA version: 9.1 Level: LLT Classification code 10047888 Term: Wegener's granulomatosis MedDRA version: 9.1 Level: LLT Classification code 10002817 Term: Antiphospholipid syndrome MedDRA version: 9.1 Level: LLT Classification code 10040767 Term: Sjogren's syndrome MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10009900 Term: Colitis ulcerative MedDRA version: 9.1 Level: LLT Classification code 10003827 Term: Autoimmune hepatitis MedDRA version: 9.1 Level: LLT Classification code 10049046 Term: Autoimmune thyroiditis MedDRA version: 9.1 Level: LLT Classification code 10003822 Term: Autoimmune haemolytic anaemia NOS MedDRA version: 9.1 Level: LLT Classification code 10034697 Term: Pernicious anemia MedDRA version: 9.1 Level: LLT Classification code 10028417 Term: Myasthenia gravis MedDRA version: 9.1 Level: LLT Classification code 10018620 Term: Goodpasture's syndrome MedDRA version: 9.1 Level: LLT Classification code 10	Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Efalizumab Other descriptive name: EFALIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	Merck Serono International S.A.		Authorised			Female: yes Male: yes	92	Phase 4	Portugal;Germany;Netherlands;France;Austria
1405	EUCTR2007-005464-26-GB	05/06/2008	11 March 2013	Devlopment of Heart and blood vessel problems in patients with conditions which cause long-term, widespread, inflammation in the body.	The role of inflammatory biomarkers in pathophysiology of cardiovascular dysfunction in systemic inflammatory conditions- Part II - Inflammatory Biomarkers and Cardiovascular Function - Part II	Rheumatoid Arthritis MedDRA version: 14.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 3- Trade Name: Enbrel Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 50- Trade Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Cimzia Product Name: Cimzia Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	Kings College London	Guys and St Thomas'NHS Foundation Trust	Authorised			Female: yes Male: yes			United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1406	EUCTR2008-000170-20-FR	03/06/2008	19 March 2012	A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate Response to Methotrexate. Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007); Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)	A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate Response to Methotrexate. Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007); Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)	subjects with rheumatoid arthritis (RA) who are on background therapy with methotrexate (MTX) MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: BMS-582949 Pharmaceutical Form: Tablet Current Sponsor code: BMS-582949 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Bristol Myers Squibb International Corporation		Authorised			Female: yes Male: yes	240		Czech Republic;France;Spain
1407	JPRN-JapicCTI-080587	01/6/2008	2 April 2019	Safety, Efficacy and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis	A Multicenter, Open-label Study of Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis (JRA)	Intervention name : adalimumab INN of the intervention : adalimumab Dosage And administration of the intervention : adalimumab 20 mg for chldren with body weight < 30 kg; adalimumab 40 mg for chldren with body weight >= 30 kg Control intervention name : null	Abbott Japan Co., Ltd.	Eisai Co., Ltd.		4	17	BOTH	25	Phase 3
1408	NCT00147966	June 2008	19 October 2017	Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)	Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies	Rheumatoid Arthritis	Drug: rituximab	University of California, San Diego	Genentech, Inc.	Not recruiting	18 Years	75 Years	All	24	Phase 2	United States
1409	NCT00654368	June 2008	19 October 2017	CAMEO: Canadian Methotrexate and Etanercept Outcome Study	Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)	Rheumatoid Arthritis	Biological: Etanercept;Drug: Methotrexate	Amgen	Wyeth is now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	All	258	Phase 4	Canada
1410	NCT00689728	June 2008	19 February 2015	A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFa Inhibitor Therapy	A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy	Arthritis, Rheumatoid	Biological: LY2127399;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	75 Years	Both	100	Phase 2	United States;Argentina;Austria;Belgium;Brazil;Canada;Germany;Mexico;Poland;Puerto Rico;France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1411	NCT00700986	June 2008	19 February 2015	Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056	A Randomised, Double-Blind, Placebo-Controlled, 2-Period Cross-Over Study in Healthy Male Volunteers, to Investigate Retinal Function Following a Single 800mg Oral Dose of AZD9056	Rheumatoid Arthritis	Drug: AZD9056;Drug: Placebo	AstraZeneca		Not recruiting	18 Years	65 Years	Male	12	Phase 1	United Kingdom
1412	NCT00711074	June 2008	19 February 2015	Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers	An Open-Label, Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of [14C]AZD5672 in Healthy Male Volunteers	Rheumatoid Arthritis	Drug: AZD5672	AstraZeneca		Not recruiting	50 Years	N/A	Male	4	Phase 1	United Kingdom
1413	NCT02151409	June 2008	16 December 2017	Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects	A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.	Inflammation;Systemic Lupus Erythematosus;Rheumatoid Arthritis;Healthy	Drug: NNC 0151-0000-0000;Drug: placebo	Novo Nordisk A/S		Not recruiting	18 Years	55 Years	Male	60	Phase 1	Netherlands
1414	EUCTR2007-001625-10-ES	28/05/2008	3 July 2012	Estudio abierto y aleatorizado para evaluar la eficacia radiológica y la seguridad de Enbrel® (etanercept) añadido a metotrexato en comparación con el tratamiento habitual en pacientes con artritis reumatoide moderada An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity. - Extra	Estudio abierto y aleatorizado para evaluar la eficacia radiológica y la seguridad de Enbrel® (etanercept) añadido a metotrexato en comparación con el tratamiento habitual en pacientes con artritis reumatoide moderada An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity. - Extra	Artritis reumatoide RHEUMATOID ARTHRITIS MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Enbrel Pharmaceutical Form: Injection* INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Wyeth Pharmaceuticals France		Authorised			Female: yes Male: yes	700		Hungary;Czech Republic;Germany;United Kingdom;Denmark;France;Ireland;Spain;Italy;Greece;Poland;Austria
1415	EUCTR2007-007859-14-HU	22/05/2008	19 March 2012	A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS INCOMPLETELY RESPONSIVE TO METHOTREXATE	A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS INCOMPLETELY RESPONSIVE TO METHOTREXATE	Active Rheumatoid Arthritis incompletely responsive to methotrexate MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ARRY-438162 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ARRY-438162 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: ARRY-438162 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ARRY-438162 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Array BioPharma Inc.		Not Recruiting			Female: yes Male: yes	200	Phase 2	Hungary;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1416	EUCTR2008-000327-25-ES	19/05/2008	19 March 2012	ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITIS REUMATOIDE EN PACIENTES CON UN CONTROL INADECUADO CON METROTEXATO A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE	ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITIS REUMATOIDE EN PACIENTES CON UN CONTROL INADECUADO CON METROTEXATO A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE	Artritis Reumatoide MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CE-224,535 Pharmaceutical Form: Tablet CAS Number: 724424-43-5 Current Sponsor code: CE-224,535 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125 mg- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	PFIZER S.A.		Authorised			Female: yes Male: yes	78	Phase 2A	Czech Republic;Spain;Poland
1417	EUCTR2007-007539-14-SK	16/05/2008	13 March 2017	A Randomised, Double-Blind, Placebo-Controlled, Phase IIb Dose-Ranging Study (with Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate - ESCAPE	A Randomised, Double-Blind, Placebo-Controlled, Phase IIb Dose-Ranging Study (with Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate - ESCAPE	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: AZD5672 Product Code: AZD5672 Pharmaceutical Form: Tablet Current Sponsor code: AZD5672 Other descriptive name: AZD5672 Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: AZD5672 Product Code: AZD5672 Pharmaceutical Form: Tablet Current Sponsor code: AZD5672 Other descriptive name: AZD5672 Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection INN or Proposed INN: Etanercept Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	360	Phase 2	Hungary;Czech Republic;Slovakia;Poland;Bulgaria;Latvia;Malta;Italy
1418	EUCTR2007-006288-56-AT	14/05/2008	10 July 2015	Methotrexat-Polyglutamate als Marker fuer das klinische Outcome in der Therapie der rheumatoiden Arthritis	Methotrexat-Polyglutamate als Marker fuer das klinische Outcome in der Therapie der rheumatoiden Arthritis	Rheumatoid Arthritis	Trade Name: Ebetrexat Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59052 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 15-25	Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und Rehabilitation		Not Recruiting			Female: yes Male: yes			Austria
1419	EUCTR2007-005905-23-DE	13/05/2008	19 March 2012	A Multi-center, Randomized, Double-blind, Placebo - controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing	A Multi-center, Randomized, Double-blind, Placebo - controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Humira 40 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Other descriptive name: ABT-Humira Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Humira 40 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Other descriptive name: ABT-Humira Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Abbott GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	424		United Kingdom;Germany
1420	NCT00665626	May 2008	16 December 2017	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic	Rheumatoid Arthritis	Drug: Fostamatinib disodium (R935788);Drug: Placebo	Rigel Pharmaceuticals		Not recruiting	18 Years	N/A	All	219	Phase 2	United States;Belgium;Colombia;France;Germany;Italy;Peru;Brazil
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1421	NCT00665925	May 2008	19 October 2017	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate	Rheumatoid Arthritis	Drug: Fostamatinib disodium (R935788);Drug: Placebo	Rigel Pharmaceuticals		Not recruiting	18 Years	N/A	All	457	Phase 2	United States;Bulgaria;Colombia;Mexico;Poland;Romania;Israel
1422	NCT00667758	May 2008	19 February 2015	Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis	Antagonist to Gonadotropin-Releasing Hormone in Rheumatoid Arthritis (AGRA): A Double-blind, Randomized, Placebo Controlled Trial	Rheumatoid Arthritis	Drug: Cetrorelix;Drug: Placebo	Betanien Hospital	Norwegian Foundation for Health and Rehabilitation;University of Oslo	Not recruiting	18 Years	N/A	Both	104	Phase 2	Norway
1423	NCT00690573	May 2008	19 October 2017	Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis	A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Biological: Adalimumab	Abbott	Eisai Co., Ltd.	Not recruiting	4 Years	17 Years	All	25	Phase 3	Japan
1424	NCT00727987	May 2008	19 February 2015	A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Study of Golimumab (CNTO 148) Administered in Combination With Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CNTO 148;Drug: Placebo;Drug: Methotrexate (MTX)	Janssen Pharmaceutical K.K.	Mitsubishi Tanabe Pharma Corporation	Not recruiting	20 Years	74 Years	Both	269	Phase 3	Japan
1425	NCT00771251	May 2008	17 November 2015	A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)	A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CNTO 148;Drug: Placebo	Janssen Pharmaceutical K.K.	Mitsubishi Tanabe Pharma Corporation;Mitsubishi Tanabe Pharma Corporation	Not recruiting	20 Years	74 Years	Both	311	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1426	NCT01224418	May 2008	19 February 2015	A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate	Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study	Rheumatoid Arthritis	Drug: Tacrolimus	Astellas Pharma Inc	Astellas Pharma Korea, Inc.	Not recruiting	18 Years	75 Years	Both	50	Phase 4	Korea, Republic of
1427	EUCTR2007-004399-38-EE	18/04/2008	26 June 2012	A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, 1-YEAR EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFECTIVENESS OF CRx-102 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS	A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, 1-YEAR EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFECTIVENESS OF CRx-102 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS	RHEUMATOID ARTHRITIS (RA) MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: CRx-102 Pharmaceutical Form: Capsule* INN or Proposed INN: Prednisolone CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.9 and 1.8- INN or Proposed INN: Dipyridamole CAS Number: 58-32-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- Product Code: CRx-102 Pharmaceutical Form: Capsule* INN or Proposed INN: Prednisolone CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.9 and 1.8- INN or Proposed INN: Dipyridamole CAS Number: 58-32-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90 -	CombinatoRx, Incorporated		Not Recruiting			Female: yes Male: yes	616		United Kingdom;Estonia;Lithuania
1428	NCT00658047	April 2008	19 February 2015	A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis	A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CH-1504;Drug: Methotrexate (MTX)	Chelsea Therapeutics		Not recruiting	18 Years	80 Years	Both	201	Phase 2	Canada
1429	NCT00661661	April 2008	19 October 2017	Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan	A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP-690,550	Pfizer		Not recruiting	20 Years	N/A	All	487	Phase 3	Japan
1430	NCT00673920	April 2008	16 December 2017	A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy	A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: methotrexate;Drug: ocrelizumab;Drug: placebo	Genentech, Inc.	Roche Pharma AG	Not recruiting	18 Years	N/A	All	314	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1431	NCT00674635	April 2008	12 December 2016	Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Bayesian Adaptive Dose Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Intravenous Infusions GSK315234A in Patients With Active Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: GSK3152314A;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	75 Years	Both	135	Phase 2	Australia;New Zealand;Russian Federation;Serbia;Ukraine;Former Serbia and Montenegro;United Kingdom
1432	NCT02622503	April 2008	9 January 2017	A Study on Rheumatoid Arthritis Patients Treated With Rituximab	Retrospective Data Collection on Rheumatoid Arthritis (RA) Patients Treated With Rituximab in Finland.	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche		Not recruiting	N/A	N/A	Both	81	N/A	Finland
1433	EUCTR2007-000593-24-GB	28/03/2008	19 March 2012	An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.	An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.	Rheumatoid Arthritis. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Enbrel Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Etanercept CAS Number: 185243-69-0 Other descriptive name: Enbrel Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: adalimumab CAS Number: 331731-18-1 Other descriptive name: Humira Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	52		United Kingdom;Sweden
1434	EUCTR2007-002066-35-HU	28/03/2008	19 March 2012	A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS - not applicable	A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS - not applicable	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CP-690,550 Pharmaceutical Form: Tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550 Other descriptive name: CP-690,550-10 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: CP-690,550 Pharmaceutical Form: Tablet CAS Number: 540737-29-9 Current Sponsor code: CP-690,550 Other descriptive name: CP-690,550-10 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Humira® 40 mg solution for injection in pre-filled syringe Product Name: Adalimumab Pharmaceutical Form: Injection* INN or Proposed INN: Humira® Current Sponsor code: Adalimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use	Pfizer Inc, 235 East 42nd Street, New York, NY 10017		Not Recruiting			Female: yes Male: yes	350	Phase 2B	Hungary;Germany;Czech Republic;Bulgaria;Italy;Greece
1435	EUCTR2007-000896-41-HU	27/03/2008	18 April 2012	A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Administration of Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Moderately Active Rheumatoid Arthritis Who Have Achieved an Adequate Response With Etanercept 50 mg Once Weekly and ethotrexate	A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Administration of Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Moderately Active Rheumatoid Arthritis Who Have Achieved an Adequate Response With Etanercept 50 mg Once Weekly and ethotrexate	Rheumatoid arthritis	Trade Name: Enbrel Product Name: Etanercept Product Code: 0881 Pharmaceutical Form: Injection* Trade Name: Enbrel Product Name: Etanercept Product Code: 0881 Pharmaceutical Form: Injection* Trade Name: Methotrexate Product Name: Methotrexate Pharmaceutical Form: Tablet	Wyeth Pharmaceuticals France		Not Recruiting			Female: yes Male: yes	900		Hungary;United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Italy;Austria;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1436	EUCTR2007-005759-41-FR	19/03/2008	19 March 2012	A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an inadequate Response to Methotrexate Therapy	A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an inadequate Response to Methotrexate Therapy	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ocrelizumab Product Code: RO 496-4913/F03 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO 496-4913/F03 Other descriptive name: RhuMAb 2H7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	300		United Kingdom;Germany;France;Spain;Italy
1437	NCT01000610	March 17, 2008	16 December 2017	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate;Drug: methylprednisolone	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	18	Phase 4	Tunisia
1438	EUCTR2007-006539-29-SE	14/03/2008	19 March 2012	Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar	Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar	Patients with rheumatic diseases (rheumatoid arthritis and spondyloarthripaties) who are going to be vaccinated with Prevenar vaccine in order to study the serological responses to two pneumococcal serotypes and to study the impact of different treatment modalities on serological responses.	Trade Name: Prevenar vaccine Product Name: Prevenar vaccine Pharmaceutical Form: Injection* INN or Proposed INN: 7-valent Pneumococcal Conjugate vaccine	Dept of Rheumatology, Lund University Hospital, Lund, Sweden		Authorised			Female: yes Male: yes	500		Sweden
1439	EUCTR2007-003623-20-ES	12/03/2008	19 March 2012	Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR). Study of the B-cell-targeted therapy (rituximab) effects on the synovial tissue inmunopathology and peripheral blood B cells in rheumatoid arthritis (TESICE-AR study).	Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR). Study of the B-cell-targeted therapy (rituximab) effects on the synovial tissue inmunopathology and peripheral blood B cells in rheumatoid arthritis (TESICE-AR study).	Se estudiaran los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Mabthera Product Name: Rituximab Pharmaceutical Form: Intravenous infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7	Dr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona		Authorised			Female: yes Male: yes			Spain
1440	EUCTR2007-002536-29-FR	03/03/2008	18 September 2012	A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate - Atacicept in anti-TNF alfa-naïve subjects with RA	A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate - Atacicept in anti-TNF alfa-naïve subjects with RA	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Atacicept Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Humira Product Name: Adalimumab Pharmaceutical Form: Solution for injection	Merck Serono International		Authorised			Female: yes Male: yes	264	Phase 2	Portugal;Finland;Germany;Czech Republic;Bulgaria;France;Spain;Italy;Greece;Poland;Austria;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1441	NCT00565409	March 2008	19 October 2017	Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Etanercept;Drug: Methotrexate;Drug: Placebo	Pfizer		Not recruiting	18 Years	70 Years	All	834	Phase 4	Australia;Austria;Belgium;Chile;Colombia;Czech Republic;Former Serbia and Montenegro;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;Brazil;Korea, Democratic People's Republic of;Serbia
1442	NCT00605735	March 2008	19 February 2015	PoC in Rheumatoid Arthritis With Methotrexate	A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate	Rheumatoid Arthritis, NOS	Drug: BMS-582949;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	Both	121	Phase 2	United States;Argentina;Czech Republic;France;Korea, Republic of;Mexico;Spain;Taiwan;Brazil
1443	NCT00620685	March 2008	19 November 2018	A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate	A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate	Arthritis, Rheumatoid	Drug: Placebo;Drug: PH-797804	Pfizer		Not recruiting	18 Years	N/A	All	27	Phase 2	United States
1444	NCT00628095	March 2008	19 February 2015	Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CE-224,535, An Antagonist Of The P2x7 Receptor, In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate	Arthritis, Rheumatoid	Drug: CE-224,535;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	Both	100	Phase 2/Phase 3	United States;Chile;Czech Republic;Korea, Republic of;Mexico;Poland;Spain
1445	NCT00634933	March 2008	19 October 2017	Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate	Arthritis, Rheumatoid	Drug: TRU-015;Drug: Methylprednisolone;Drug: Prednisone	Pfizer	Trubion Pharmaceuticals/Emergent BioSolutions Inc.	Not recruiting	18 Years	N/A	All	222	Phase 2	United States;Belgium;Canada;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1446	NCT00641225	March 2008	19 February 2015	Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis	An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SBI-087	Pfizer	Emergent Product Development Seattle LLC	Not recruiting	18 Years	70 Years	Both	62	Phase 1	United States;Canada
1447	NCT00650767	March 2008	19 October 2017	A Study of ARRY-438162 in Patients With Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: ARRY-438162, MEK inhibitor; oral;Drug: Placebo	Array BioPharma		Not recruiting	18 Years	N/A	All	201	Phase 2	United States;Argentina;Brazil;Hungary;Peru;Poland;Romania
1448	NCT00664521	March 2008	19 October 2017	Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)	A Randomized, Double-blind, Placebo Controlled, Multi-centre, Exploratory, Pilot, Phase II Trial of 150mg Atacicept Given Subcutaneously in Combination With Rituximab in Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Biological: Rituximab;Drug: Atacicept;Drug: Placebo matched to atacicept	Merck KGaA		Not recruiting	18 Years	N/A	All	27	Phase 2	France;Netherlands;Sweden;United Kingdom;Finland
1449	NCT00664820	March 2008	16 December 2017	Effects of Probiotics on Rheumatoid Arthritis Patients	Effects of Probiotics on Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Dietary Supplement: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14	Lawson Health Research Institute	University of Western Ontario, Canada;St. Joseph's Health Care London	Not recruiting	18 Years	80 Years	All	50	N/A	Canada
1450	NCT02109666	March 2008	16 December 2017	Long Term Experience With Abatacept in Routine Clinical Practice	Long Term Experience With Abatacept in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	2364	N/A	Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Spain;Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1451	EUCTR2007-000828-40-FR	26/02/2008	19 March 2012	A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFa Fab'fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis. - C87076	A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFa Fab'fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis. - C87076	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Solution for injection INN or Proposed INN: Certolizumab pegol Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 200-+/- 15 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	UCB Pharma S.A.		Authorised			Female: yes Male: yes	170	Phase 3B	Germany;France;Italy;Poland;Austria
1452	EUCTR2006-006562-42-GB	21/02/2008	19 March 2012	An Observational and Exploratory Study to determine the effect of anti TNF Biologic Treatment in Rheumatoid Cachexia	An Observational and Exploratory Study to determine the effect of anti TNF Biologic Treatment in Rheumatoid Cachexia	Cachexia in patients with Rheumatoid arthritis. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Enbrel Product Name: Etanercept 50mg Pharmaceutical Form: Powder and solvent for solution for injection	Derby Hospitals NHS Foundation Trust		Authorised			Female: yes Male: yes	32		United Kingdom
1453	EUCTR2004-002132-26-GB	19/02/2008	2 October 2012	A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate but with unsatisfactory clinical response. - N/A	A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate but with unsatisfactory clinical response. - N/A	Rheumatoid Arthritis	Product Name: Ocrelizumab / rhuMAb 2H7 Product Code: Ro 496-4913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: N/A Current Sponsor code: Ro 496-4913 Other descriptive name: rhuMAb 2H7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Limited		Authorised			Female: yes Male: yes	160	Phase 1/2	United Kingdom;Spain
1454	EUCTR2007-003647-75-NL	07/02/2008	12 June 2012	A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arthritis. - Atacicept in combination with rituximab in subjects with rheumatoid arthritis	A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arthritis. - Atacicept in combination with rituximab in subjects with rheumatoid arthritis	Rheumatoid arthritis. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Atacicept Product Code: TACI-Fc5 Pharmaceutical Form: Solution for injection INN or Proposed INN: Atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 25-150 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Mabthera Product Name: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: rituximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Merck Serono International		Authorised			Female: yes Male: yes	90	Phase 2	Sweden;France;Finland;United Kingdom;Netherlands
1455	NCT00556894	February 2008	19 October 2017	Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CF101	Can-Fite BioPharma		Not recruiting	18 Years	75 Years	All	230	Phase 2	Bulgaria;Czech Republic;Israel;Poland;Serbia;Ukraine;Former Serbia and Montenegro
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1456	NCT00639834	February 2008	19 February 2015	Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis	A Phase 1, Multicenter, Single-dose, Dose-escalation, Safety and Tolerability Study of MDX-1342 (Anti-CD19 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: MDX-1342	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	Both	26	Phase 1	United States;Germany;Hungary;Ukraine;United Kingdom;Poland
1457	NCT01017367	February 2008	19 February 2015	Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)	Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: MDX-1100;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	Both	70	Phase 2	Romania;Ukraine
1458	NCT01072058	February 2008	19 February 2015	Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker	Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker	Arthritis, Rheumatoid;Spondylitis, Ankylosing	Drug: TNF blockers (infliximab, adalimumab, etanercept)	University of Sao Paulo		Not recruiting	18 Years	70 Years	Both	100	Phase 4	Brazil
1459	EUCTR2007-006729-28-GB	25/01/2008	19 March 2012	Is a single dose intramuscular (IM) triamcinolone acetonide injection more effective in treating symptomatic flare in established rheumatoid arthritis than equivalent dose of oral prednisolone? - Treatment comparison for symptomatic flare in RA	Is a single dose intramuscular (IM) triamcinolone acetonide injection more effective in treating symptomatic flare in established rheumatoid arthritis than equivalent dose of oral prednisolone? - Treatment comparison for symptomatic flare in RA	The objective of this study is to compare the efficacy of equivalent doses of IM triamcinolone acetonide and oral prednisolone in controlling a symptomatic flare in patients with established RA. MedDRA version: 9.1 Level: LLT Classification code 10060732 Term: Rheumatoid arthritis flare up	Trade Name: Kenalog Product Name: Triamcinolone acetonide Pharmaceutical Form: Injection* INN or Proposed INN: TRIAMCINOLONE ACETONIDE CAS Number: 76255 Concentration unit: IU/mg international unit(s)/milligram Concentration type: equal Concentration number: 80- Trade Name: Prednisolone Product Name: Prednisolone Pharmaceutical Form: Coated tablet INN or Proposed INN: PREDNISOLONE CAS Number: 50248 Concentration unit: IU/mg international unit(s)/milligram Concentration type: equal Concentration number: 5-	Trafford NHS Trust		Not Recruiting			Female: yes Male: yes	58		United Kingdom
1460	EUCTR2007-000012-90-GB	23/01/2008	9 January 2017	The Standard care versus Celecoxib Outcome Trial (SCOT): A Large Streamlined Safety Study - SCOT Trial	The Standard care versus Celecoxib Outcome Trial (SCOT): A Large Streamlined Safety Study - SCOT Trial	The Standard Care versus Celecoxib Outcome Trial (SCOT) is a large streamlined safety study designed to compare the cardiovascular safety of celecoxib versus traditional non-selective Non Steroidal Anti-Inflammatory Drug (NSAID) therapy when used to treat pain and inflammation in osteoarthritis or rheumatoid arthritis patients who are free from ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, and moderate or severe heart failure. MedDRA version: 13.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 13.1 Level: PT Classification code 10041591 Term: Spinal osteoarthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Celebrex Pharmaceutical Form: Tablet Trade Name: Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses Pharmaceutical Form: Tablet	University of Dundee		Not Recruiting			Female: yes Male: yes		Phase 4	Denmark;Netherlands;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1461	ChiCTR-CCC-10001054	2008-01-01	18 April 2017	Circulating Dickkopf-1 (DKK-1) is Correlated with Bone Erosion and Inflammation in Rheumatoid Arthritis	Circulating Dickkopf-1 (DKK-1) is Correlated with Bone Erosion and Inflammation in Rheumatoid Arthritis	ra	1:none;2:Infliximab ;	National Sciences Foundation of China		Not Recruiting	28	58	Both	1:39;2:39;	Pilot study	China
1462	ChiCTR-TRC-09000383	2008-01-01	18 April 2017	Efficacy and safety of recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial	Efficacy and safety of recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial	rheumatoid arthritis;M05.901	placebo:daily subcutaneous injections of placebo, with concurrent MTX therapy ;anakinra:daily subcutaneous injections of anakinra (80 mg), with concurrent MTX therapy;	Xi-jing Hospital, the 4th Military Medical University, Shanghai Changzheng Hospital		Not Recruiting	18	65	Both	placebo:10;anakinra:30;	Phase 3 study	China
1463	NCT00611455	January 1, 2008	16 December 2017	Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy	A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Arthritis, Rheumatoid	Drug: ofatumumab;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	265	Phase 3	Argentina;Australia;Belgium;Chile;Czechia;Hungary;Peru;Poland;Romania;Russian Federation;South Africa;Spain;United Kingdom;Czech Republic
1464	NCT00655824	January 1, 2008	16 December 2017	Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403	An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo	Arthritis, Rheumatoid	Drug: ofatumumab	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	124	Phase 2	United States;Denmark;Hungary;Poland;United Kingdom
1465	NCT00559585	January 2008	19 October 2017	Methotrexate-Inadequate Response Study	A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis (RA)	Drug: Subcutaneous (SC) Abatacept;Drug: Intravenous (IV) Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	2492	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;Austria;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1466	NCT00603512	January 2008	19 October 2017	Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan	A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone	Arthritis, Rheumatoid	Drug: Placebo;Drug: CP-690,550	Pfizer		Not recruiting	20 Years	70 Years	All	140	Phase 2	Japan
1467	NCT00603525	January 2008	19 October 2017	Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-a Antagonist Therapy	A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Patients With Active Rheumatoid Arthritis Who Have Previously Had an Inadequate Response to One or More TNF Antagonist Therapies	Arthritis, Rheumatoid	Drug: Ofatumumab;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	169	Phase 3	Argentina;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Norway;Peru;Spain;Sweden;United Kingdom
1468	NCT00741104	January 2008	16 December 2017	A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)	A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients	Rheumatoid Arthritis	Drug: Infliximab	Merck Sharp & Dohme Corp.		Not recruiting	N/A	N/A	All	363	Phase 4
1469	EUCTR2008-000744-13-DE		27 January 2014	An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients with Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study	An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients with Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: R935788 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib Disodium CAS Number: 914295-16-2 Current Sponsor code: R935788 sodium hexahydrate Other descriptive name: R788 Sodium, R788 Na, R788 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: R935788 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Fostamatinib Disodium CAS Number: 914295-16-2 Current Sponsor code: R935788 sodium hexahydrate Other descriptive name: R788 Sodium, R788 Na, R788 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	800		France;Belgium;Bulgaria;Germany;Italy
1470	NCT01362153	December 26, 2007	16 December 2017	A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)	An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Golimumab	Centocor, Inc.		Not recruiting	18 Years	99 Years	All	49	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1471	EUCTR2007-002951-18-NL	10/12/2007	19 March 2012	A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to TNF-a antagonist therapy - Investigating efficacy of ofatumumab in RA patients with inadequate response to TNF-a antagonist	A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to TNF-a antagonist therapy - Investigating efficacy of ofatumumab in RA patients with inadequate response to TNF-a antagonist	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Ofatumumab Product Code: HuMax-CD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ofatumumab CAS Number: 679 818-59-8 Current Sponsor code: HuMax-CD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration number: 20- Route of administration of the placebo: Intravenous use	Genmab A/S		Not Recruiting			Female: yes Male: yes	236	Phase 3	Germany;United Kingdom;Netherlands;Denmark;France;Spain;Italy;Sweden
1472	EUCTR2007-004878-31-DK	10/12/2007	2 June 2014	An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibody, in adult patients with active rheumatoid arthritis who previously received ofatumumab or placebo in Trial Hx-CD20-403 - Long-term efficacy and safety of repeated ofatumumab courses in RA patients who were in Hx-CD20-403	An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibody, in adult patients with active rheumatoid arthritis who previously received ofatumumab or placebo in Trial Hx-CD20-403 - Long-term efficacy and safety of repeated ofatumumab courses in RA patients who were in Hx-CD20-403	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Ofatumumab Product Code: HuMax-CD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ofatumumab CAS Number: 679 818-59-8 Current Sponsor code: HuMax-CD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration number: 20-	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	264	Phase 2	Hungary;Denmark;United Kingdom
1473	NCT00547521	December 2007	19 October 2017	Phase IIIB Subcutaneous Abatacept Monotherapy Study	A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate	Rheumatoid Arthritis (RA)	Drug: abatacept;Drug: Methotrexate (MTX)	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	119	Phase 3	United States;Australia;Mexico;South Africa;Brazil;Canada;Peru
1474	NCT00576433	December 2007	14 November 2016	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.	An Open Label Study to Evaluate the Safety and Effect on Treatment Response of MabThera in Patients With Rheumatoid Arthritis Following Inadequate Response to One Prior Anti-TNF Inhibitor	Rheumatoid Arthritis	Drug: Methotrexate;Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche		Not recruiting	18 Years	80 Years	Both	60	Phase 4	Russian Federation
1475	NCT00576706	December 2007	19 February 2015	PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity	A Phase III, Randomized, Double-dummy, Double Blind, Misoprostol-comparative Clinical Trial to Evaluate the Efficacy and Safety of Mucosta® Tablet in the Prevention of NSAID-induced Gastrointestinal Complications	Rheumatoid Arthritis;Osteoarthritis;Ankylosing Spondylitis	Drug: Rebamipide;Drug: Misoprostol	Korea Otsuka Pharmaceutical Co.,Ltd.		Not recruiting	19 Years	N/A	Both	396	Phase 3	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1476	NCT00580229	December 2007	20 August 2018	A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.	A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: prednisone	University of South Florida		Not recruiting	18 Years	80 Years	All	50	Phase 2/Phase 3	United States
1477	NCT00580840	December 2007	19 October 2017	Dosing Flexibility Study in Patients With Rheumatoid Arthritis	A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Certolizumab pegol;Other: Placebo	UCB Pharma		Not recruiting	18 Years	N/A	All	333	Phase 4	United States;Canada;France;Austria
1478	NCT00647270	December 2007	19 October 2017	Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing	A Multi-center, Randomized, Double-blind,Placebo-controlled Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing	Rheumatoid Arthritis	Drug: adalimumab;Drug: Placebo	Abbott		Not recruiting	18 Years	N/A	All	420	Phase 3	United States;Australia;Canada;Germany;Puerto Rico;United Kingdom
1479	NCT00963703	December 2007	19 February 2015	Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis	Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis Using Rituximab: A Pilot Study Evaluating Synovial Outcomes	Rheumatoid Arthritis	Drug: Rituximab	University of Manitoba	Hoffmann-La Roche	Not recruiting	18 Years	N/A	Both	15	N/A	Canada
1480	NCT01231321	December 2007	19 October 2017	A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis	An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira®) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: adalimumab	Abbott		Not recruiting	18 Years	N/A	All	100	Phase 3	Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1481	EUCTR2007-001585-33-LT	13/11/2007	7 October 2014	A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera®/Rituxan®) in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate - the R.A. SCORE study. - R.A. SCORE	A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera®/Rituxan®) in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate - the R.A. SCORE study. - R.A. SCORE	Rheumatoid arthritis (RA) MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: MabThera 500mg Product Name: MabThera 500mg Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Route of administration of the placebo: Intravenous use	F. Hoffman-La Roche Ltd.		Not Recruiting			Female: yes Male: yes	180		France;Estonia;Greece;Spain;Lithuania;Denmark;Germany;Netherlands;Latvia
1482	NCT00533897	November 2007	19 October 2017	Phase IIIB Subcutaneous Missed Dose Study	A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	270	Phase 3	United States;Argentina;Canada;Mexico;South Africa;Brazil
1483	NCT00554853	November 2007	19 October 2017	PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease	Peroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease	Rheumatoid Arthritis	Drug: pioglitazone;Drug: Sublingual nitroglycerine	University of Michigan	National Heart, Lung, and Blood Institute (NHLBI)	Not recruiting	21 Years	100 Years	All	143	Phase 3	United States
1484	NCT00578305	November 2007	19 October 2017	A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Randomized, Placebo Controlled, Multicenter Clinical Study Investigating Efficacy of Rituximab in the Inhibition of Joint Structural Damage Assessed by Magnetic Resonance Imaging in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Biological: Rituximab;Drug: Placebo;Drug: Methylprednisolone;Drug: Methotrexate;Drug: Folic acid or folate	Hoffmann-La Roche		Not recruiting	18 Years	80 Years	All	185	Phase 3	Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Former Serbia and Montenegro;United Kingdom
1485	NCT00664573	November 2007	19 February 2015	Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Patients	Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.	Rheumatoid Arthritis	Biological: Baminercept alfa (BG9924)	Biogen Idec		Not recruiting	18 Years	75 Years	Both	339	Phase 2	Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1486	NCT01245361	November 2007	19 February 2015	A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit	A Comparative Study Of A 6-Month Infliximab (Remicade®) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis (RA) : Clinical, Radiological (MRI) And Synovial Benefit P1200/001.	Undifferentiated Arthritis	Drug: Infliximab;Drug: sodium chloride	Patrick Durez		Not recruiting	N/A	N/A	Both	30	N/A	Belgium
1487	EUCTR2007-003069-42-EE	31/10/2007	19 March 2012	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)	RHEUMATOID ARTHRITIS (RA) MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: CRx-102 Pharmaceutical Form: Capsule* INN or Proposed INN: Prednisolone CAS Number: 52438-85-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.9 and 1.8- INN or Proposed INN: Dipyridamole CAS Number: 58-32-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Prednisolone Pharmaceutical Form: Capsule* INN or Proposed INN: Prednisolone CAS Number: 52438-85-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.9 and 1.8- Product Name: Dipyridamole Pharmaceutical Form: Capsule* INN or Proposed INN: Dipyridamole CAS Number: 58-32-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- Product Code: CRx-102 Pharmaceutical Form: Capsule* INN or Proposed INN: Prednisolone CAS Number: 52438-85-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.9 and 1.8- INN or Proposed INN: Dipyridamole CAS Number: 58-32-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90 - Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	CombinatoRx, Incorporated		Not Recruiting			Female: yes Male: yes	616		Hungary;United Kingdom;Estonia;Lithuania
1488	NCT00535782	October 31, 2007	16 December 2017	A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis	A Mechanism of Action Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) on Lipids, Arterial Stiffness, and Markers of Atherogenic Risk in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA).	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Placebo;Drug: Methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	75 Years	All	132	Phase 3	United States;Canada;Puerto Rico;United Kingdom
1489	EUCTR2007-001035-58-ES	30/10/2007	19 March 2012	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF MARAVIROC (UK-427,857) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS RECEIVING METHOTREXATE ESTUDIO EN FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y EN GRUPOS PARALELOS PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE MARAVIROC (UK 427,857) EN EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE EN PACIENTES QUE RECIBEN METOTREXATO - N/A	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF MARAVIROC (UK-427,857) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS RECEIVING METHOTREXATE ESTUDIO EN FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y EN GRUPOS PARALELOS PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE MARAVIROC (UK 427,857) EN EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE EN PACIENTES QUE RECIBEN METOTREXATO - N/A	ARTRITIS REUMATOIDE RHEUMATOID ARTHRITIS MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Maraviroc Product Code: UK-427,857 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Maraviroc CAS Number: 376348-65-1 Current Sponsor code: UK-427,857 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Pfizer, S. A.		Authorised			Female: yes Male: yes	114	Phase 2	Portugal;Spain;Italy
1490	EUCTR2006-006591-37-BE	25/10/2007	7 October 2014	A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector and the Etanercept Prefilled Syringe) in Patients with Rheumatoid Arthritis	A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector and the Etanercept Prefilled Syringe) in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis	Trade Name: Enbrel Product Name: Pre-filled syringe Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: Enbrel Auto Injector Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Wyeth Pharmaceuticals France		Not Recruiting			Female: yes Male: yes	264		Greece;Belgium;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1491	NCT00502853	October 25, 2007	16 December 2017	A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.	Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	75 Years	All	10	Phase 4	Italy
1492	EUCTR2007-002945-18-CZ	15/10/2007	19 March 2012	A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthritis receiving non-biologic background disease-modifying antirheumatic drugs - Clinical efficacy and safety of ofatumumab in RA patients receiving background nonbiologic DMARDs	A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthritis receiving non-biologic background disease-modifying antirheumatic drugs - Clinical efficacy and safety of ofatumumab in RA patients receiving background nonbiologic DMARDs	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Ofatumumab Product Code: HuMax-CD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ofatumumab CAS Number: 679 818-59-8 Current Sponsor code: HuMax-CD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration number: 20- Route of administration of the placebo: Intravenous use	Genmab A/S		Not Recruiting			Female: yes Male: yes	1000	Phase 3	Czech Republic
1493	EUCTR2007-000733-19-GB	02/10/2007	19 March 2012	A Phase 2B, Blinded Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA202	A Phase 2B, Blinded Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA202	Rheumatoid arthritis (RA) MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: BG9924 Pharmaceutical Form: Powder for solution for injection Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Biogen Idec Ltd		Not Recruiting			Female: yes Male: yes	380	Phase 2B	Hungary;United Kingdom
1494	EUCTR2007-000734-38-GB	02/10/2007	19 March 2012	An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA203	An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA203	Rheumatoid arthritis (RA) MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: BG9924 Pharmaceutical Form: Powder for solution for injection Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Biogen Idec Ltd		Not Recruiting			Female: yes Male: yes	120		United Kingdom
1495	ChiCTR-TRC-11001755	2007-10-01	18 April 2017	Phase II of Tu Fu Ling Tablets in Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Double-dummy, Phase II Study Evaluating the Safety and Efficacy of Tu Fu Ling Tablets in Participants with Rheumatoid Arthritis	Rheumatoid Arthritis	A:Tu Fu Ling Tablets, 200mg Bid. Other: Placebo;B:Tu Fu Ling Tablets, 100mg Tid. Other: Placebo. ;C:Leflunomide Tablets, 20mg Qd. Other: Placebo;	The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine		Not Recruiting	18	65	Both	A:80;B:80;C:80;	Phase 2 study	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1496	JPRN-UMIN000000837	2007/10/01	2 April 2019	Combination effect of bucillamine and salazosulphapyridine on rheumatoid arthritis; Prospective randomized controlled study		Rheumatoid arthritis	Bucillamine mono-therapy(It's possible to choose the combination therapy with salazosulphapyridine at 6 months after the start of the treatment) Salazosulphapyridine mono-therapy(It's possible to choose the combination therapy with bucillamineat 6 months after the start of the treatment) Combination therapy of bucillamine and salazosulphapyridine (over the study period)	BASIC study group		Recruiting	20years-old	75years-old	Male and Female	180	Not applicable	Japan
1497	NCT00531817	October 2007	19 October 2017	A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Placebo;Drug: Permitted DMARDs	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	619	Phase 3	United States;Puerto Rico
1498	NCT00550043	October 2007	19 October 2017	A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis	A Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: INCB018424;Drug: Placebo	Incyte Corporation		Not recruiting	18 Years	70 Years	All	50	Phase 2	United States;Poland
1499	NCT00551707	October 2007	19 October 2017	Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: CRx-102 (2.7/180);Drug: prednisolone;Drug: dipyridamole;Drug: placebo;Drug: CRx-102 (2.7/360)	Zalicus		Not recruiting	18 Years	N/A	All	51	Phase 2	United States;Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa
1500	NCT00554606	October 2007	16 December 2017	Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis	A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ACZ885	Novartis		Not recruiting	18 Years	75 Years	All	115	Phase 2	United States;Belgium;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1501	NCT00595517	October 2007	19 October 2017	Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Gastric Ulcer;Duodenal Ulcer;Rheumatoid Arthritis;Osteoarthritis;Lumbago	Drug: Esomeprazole 20 mg	AstraZeneca		Not recruiting	20 Years	N/A	All	395	Phase 3	Japan
1502	NCT00626275	October 2007	19 October 2017	Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis	A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ADL5859;Drug: Naproxen;Drug: Placebo	Cubist Pharmaceuticals LLC		Not recruiting	18 Years	75 Years	All	46	Phase 2	United States
1503	NCT00934648	October 2007	19 October 2017	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	15	Phase 4	Morocco
1504	NCT02699892	October 2007	19 October 2017	Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis	Post Marketing Non Interventional Clinical Research of Administration of Rituximab in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche		Not recruiting	18 Years	80 Years	All	130	N/A	Serbia
1505	EUCTR2007-004694-26-BE	17/09/2007	7 October 2014	A Comparative Study Of A 6-Month Infliximab (Remicade) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis : Clinical, Radiological (MRI) And Synovial Benefit P1200/001. - INFLIXIMAB (REMICADE) in UA	A Comparative Study Of A 6-Month Infliximab (Remicade) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis : Clinical, Radiological (MRI) And Synovial Benefit P1200/001. - INFLIXIMAB (REMICADE) in UA	Patient with undifferentiated arthritis and the presence of anti-CCP antibodies are at high risk to develop RA MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Remicade Product Name: REMICADE® (Infliximab) Product Code: - Pharmaceutical Form: Powder for infusion* Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Saint-Luc Universitary Hospital		Authorised			Female: yes Male: yes	30		Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1506	EUCTR2006-006127-40-GB	16/09/2007	19 March 2012	Cerebral Blood Flow following TNF-alpha Antagonism in Rheumatoid Arthritis - a Pilot Study - TNF/CBF in RA	Cerebral Blood Flow following TNF-alpha Antagonism in Rheumatoid Arthritis - a Pilot Study - TNF/CBF in RA	Rheumatoid arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Humira Product Name: Humira 40mg solution for injection in pre-filled syringe (adalimumab) Pharmaceutical Form: Solution for injection INN or Proposed INN: recombinant human monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40mg in 0.8ml-	Newcastle-upon-Tyne Hospitals NHS Foundation Trust		Authorised			Female: yes Male: yes			United Kingdom
1507	EUCTR2007-001665-15-ES	14/09/2007	2 February 2015	Estudio de extensión abierto, multicéntrico, de fase II, de 54 semanas de duración, para evaluar la eficacia, seguridad y tolerabilidad de ACZ885 (anticuerpo monoclonal anti-interleuquina-1ß) en pacientes con artritis reumatoide.	Estudio de extensión abierto, multicéntrico, de fase II, de 54 semanas de duración, para evaluar la eficacia, seguridad y tolerabilidad de ACZ885 (anticuerpo monoclonal anti-interleuquina-1ß) en pacientes con artritis reumatoide.	Artritis Reumatoide MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: ACZ885 Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Canakinumab (proposed) Current Sponsor code: ACZ885 Other descriptive name: ACZ885 Drug Substance Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Novartis Farmaceutica S.A.		Not Recruiting			Female: yes Male: yes	179		Belgium;Spain;Netherlands;Germany;Italy
1508	EUCTR2007-002752-42-FR	13/09/2007	19 March 2012	FAKIR : Variabilité pharmacocinétique et de la relation pharmacocinétique-phamacodynamique de l'infliximab (Remicade®) dans la polyarthrite rhumatoide - FAKIR	FAKIR : Variabilité pharmacocinétique et de la relation pharmacocinétique-phamacodynamique de l'infliximab (Remicade®) dans la polyarthrite rhumatoide - FAKIR	Polyarthrite rhumatoïde MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Remicade® Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277313 Concentration unit: mg/kg/h milligram(s)/kilogram/hour Concentration type: range Concentration number: 1,5-3	CHRU de Tours		Authorised			Female: yes Male: yes			France
1509	EUCTR2007-002950-42-LT	13/09/2007	19 March 2012	A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy - Investigating clinical efficacy of ofatumumab in RA patients who had an inadequate response to MTX	A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy - Investigating clinical efficacy of ofatumumab in RA patients who had an inadequate response to MTX	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Ofatumumab Product Code: HuMax-CD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ofatumumab CAS Number: 679 818-59-8 Current Sponsor code: HuMax-CD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Route of administration of the placebo: Intravenous use	Genmab A/S		Not Recruiting			Female: yes Male: yes	248	Phase 3	Hungary;United Kingdom;Czech Republic;Spain;Poland;Lithuania
1510	EUCTR2007-002976-32-NL	06/09/2007	19 March 2012	COBRA-light study, an open randomised trial comparing a modified COBRA therapy with the COBRA therapy according to BeSt in early rheumatoid arthritis.	COBRA-light study, an open randomised trial comparing a modified COBRA therapy with the COBRA therapy according to BeSt in early rheumatoid arthritis.	Patients with early rheumatoid arthritis wil be treated with a combination therapy: COBRA according to BEST or a modified COBRA schedule (COBRA-light).	Trade Name: Prednisone Pharmaceutical Form: Tablet Trade Name: Methotrexate Pharmaceutical Form: Tablet Trade Name: Sulphasalazine Pharmaceutical Form: Tablet	TIPharma		Authorised			Female: yes Male: yes			Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1511	NCT00539760	September 5, 2007	16 December 2017	A Phase I Rheumatoid Arthritis Study in Healthy Volunteers	A Phase I, Randomized, Observer- and Subject-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1827771 in Healthy Volunteers	Arthritis, Rheumatoid	Drug: GSK1827771;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	45	Phase 1	United States
1512	EUCTR2006-005640-81-GB	04/09/2007	19 March 2012	A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: - EXXTRA	A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: - EXXTRA	Rheumatoid arthritis	Trade Name: Mabthera Product Name: Mabthera Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Methylprednisolone Product Name: Methylprednisolone Pharmaceutical Form: Powder for infusion* Other descriptive name: Methylprednisolone Concentration unit: mg milligram(s) Concentration type: range Concentration number: 200-300	University of Leeds		Authorised			Female: yes Male: yes	60		United Kingdom
1513	NCT00411424	September 2007	19 February 2015	Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis	Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Initial Efficacy of ASK8007 in Comparison With Placebo in Patients With Active Rheumatoid Arthritis - a Randomized, Double Blind, Placebo-controlled, Combined Single Dose Escalation and Multiple Dose Study	Rheumatoid Arthritis	Drug: ASK8007;Drug: Placebo	Astellas Pharma Inc		Not recruiting	18 Years	N/A	Both	54	Phase 1/Phase 2	Belgium;Hungary;Ireland;Netherlands;Spain;United Kingdom;France
1514	NCT00550446	September 2007	19 October 2017	A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis	A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Adalimumab;Drug: CP-690-550;Drug: CP-690,550;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	386	Phase 2	United States;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine
1515	NCT00613106	September 2007	19 October 2017	Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)	Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)	Osteoarthritis;Rheumatoid Arthritis;Chronic Low Back Pain;Chronic Regional Pain Syndrome;Chronic Soft Tissue Pain	Drug: HZT-501;Drug: Ibuprofen	Horizon Pharma Ireland, Ltd., Dublin Ireland		Not recruiting	40 Years	81 Years	All	179	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1516	NCT00660647	September 2007	7 December 2015	Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)	Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Adalimumab;Drug: Placebo	University of Aarhus	Abbott;Meda Pharmaceuticals;Aarhus University Hospital	Not recruiting	18 Years	N/A	Both	180	Phase 3	Denmark
1517	EUCTR2006-003054-26-CZ	31/08/2007	19 March 2012	A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms of in Subjects with Rheumatoid Arthritis - NA	A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms of in Subjects with Rheumatoid Arthritis - NA	Rheumatoid arthritis (RA) MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: TAK-783 Pharmaceutical Form: Tablet Current Sponsor code: TAK-783 Concentration unit: % percent Concentration type: range Concentration number: 90-110 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Takeda Global R&D (Europe) Ltd		Not Recruiting			Female: yes Male: yes	230		Hungary;Czech Republic;Latvia
1518	EUCTR2007-001420-12-BE	23/08/2007	7 October 2014	A Randomised, Double-Blind (with Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Receiving Background Methotrexate or Sulphasalazine	A Randomised, Double-Blind (with Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Receiving Background Methotrexate or Sulphasalazine	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: AZD9056 hydrochloride Product Code: AZD9056 Pharmaceutical Form: Tablet Current Sponsor code: AZD9056 Other descriptive name: None Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: AZD9056 hydrochloride Product Code: AZD9056 Pharmaceutical Form: Tablet Current Sponsor code: AZD9056 Other descriptive name: None Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection INN or Proposed INN: Etanercept Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	360	Phase 2b	France;Czech Republic;Poland;Belgium;Sweden
1519	EUCTR2007-000734-38-BE	17/08/2007	11 November 2013	An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA203	An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA203	Rheumatoid arthritis (RA) MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: BG9924 Pharmaceutical Form: Solution for injection Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Biogen Idec Ltd		Not Recruiting			Female: yes Male: yes	120		Belgium;United Kingdom
1520	EUCTR2007-001754-11-IT	03/08/2007	19 March 2012	Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis. - ND	Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis. - ND	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	ROCHE		Not Recruiting			Female: yes Male: yes			Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1521	NCT00505089	August 2007	19 February 2015	Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis	An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ACZ885	Novartis		Not recruiting	18 Years	75 Years	Both	11	Phase 1/Phase 2	Belgium;Germany;Netherlands;Poland
1522	NCT00511329	August 2007	11 June 2018	Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease	Growth and the Effect of Genotropin in Chronically Ill Children With Juvenile Rheumatoid Arthritis and With Crohn's Disease	Arthritis, Juvenile Rheumatoid;Crohn Disease	Drug: somatropin [rDNA origin] for injection	Nationwide Children's Hospital	Pfizer	Not recruiting	5 Years	17 Years	All	10	Phase 2/Phase 3	United States
1523	NCT00517543	August 2007	19 February 2015	A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability	A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553	Chronic Obstructive Pulmonary Disease (COPD);Rheumatoid Arthritis;Atherosclerosis	Drug: GW856553	GlaxoSmithKline		Not recruiting	18 Years	60 Years	Both	36	Phase 1	United States
1524	NCT00520572	August 2007	19 October 2017	A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)	A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine	Rheumatoid Arthritis	Drug: AZD9056;Drug: Etanercept;Drug: Placebo	AstraZeneca		Not recruiting	18 Years	N/A	All	385	Phase 2	United States;Argentina;Australia;Belgium;Canada;Czech Republic;France;Mexico;Poland;Romania;Russian Federation;Slovakia;Hungary;Sweden
1525	NCT00523328	August 2007	19 February 2015	BG9924 in Combination With Methotrexate Extension of Study 104RA203	An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects With Rheumatoid Arthritis Who Previously Participated in Study 104RA203	Rheumatoid Arthritis	Drug: BG9924	Biogen Idec		Not recruiting	18 Years	75 Years	Both	72	Phase 2	United States;Belgium;Canada;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1526	NCT00538902	August 2007	19 October 2017	Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate	A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate	Rheumatoid Arthritis	Biological: Placebo;Biological: Adalimumab 80 mg;Biological: Adalimumab 40 mg	Abbott		Not recruiting	18 Years	N/A	All	302	Phase 2/Phase 3	China
1527	NCT00542789	August 2007	19 October 2017	Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID	A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Gastric Ulcer;Duodenal Ulcer;Rheumatoid Arthritis;Osteoarthritis;Lumbago	Drug: Esomeprazole;Drug: Placebo	AstraZeneca		Not recruiting	20 Years	N/A	All	343	Phase 3	Japan
1528	NCT00550355	August 2007	19 February 2015	Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Subject and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PD-0360324 in Patients With Rheumatoid Arthritis Receiving Methotrexate	Arthritis, Rheumatoid	Drug: PD 0360324;Drug: Placebo	Pfizer		Not recruiting	21 Years	70 Years	Both	78	Phase 1	United States;Argentina;Bulgaria;Czech Republic;Mexico;Poland;Slovakia;Spain
1529	NCT00597818	August 2007	19 February 2015	Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury	A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients	NSAID-induced Gastroduodenal Injury;Ulcers;Rheumatoid Arthritis;Osteoarthritis	Drug: Cobiprostone;Drug: Placebo	Sucampo Pharmaceuticals, Inc.		Not recruiting	40 Years	70 Years	Both	120	Phase 2	United States
1530	NCT03414502	August 2007	6 May 2019	Treatment of Rheumatoid Arthritis With Methotrexate: Predictors of Response	Treatment of Rheumatoid Arthritis With Methotrexate: Predictors of Response	Rheumatoid Arthritis	Drug: Methotrexate	University of Nebraska		Recruiting	19 Years	N/A	All	300	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1531	EUCTR2006-005147-28-DE	25/07/2007	23 May 2016	MTX-IR Phase III	A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment.	Rheumatoid Arthritis (RA) MedDRA version: 15.0 Level: SOC Classification code 10028395 Term: Musculoskeletal and connective tissue disorders System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ocrelizumab Product Code: RO 496-4913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab Current Sponsor code: RO 496-4913 Other descriptive name: RhuMAb 2H7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	1000	Phase 3	France;Greece;Spain;Belgium;Austria;Germany;United Kingdom
1532	NCT00502840	July 23, 2007	16 December 2017	A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.	An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070).	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche		Not recruiting	18 Years	75 Years	All	193	Phase 3	Germany
1533	EUCTR2006-003698-29-AT	18/07/2007	7 August 2012	A Long-term Assessment of Safety and Physical Function with AMG 108 Subcutaneous Monthly Treatment in Subjects with Rheumatoid Arthritis	A Long-term Assessment of Safety and Physical Function with AMG 108 Subcutaneous Monthly Treatment in Subjects with Rheumatoid Arthritis	Rheumatoid arthritis (RA)	Product Name: AMG 108 Product Code: AMG 108 Pharmaceutical Form: Solution for injection Current Sponsor code: AMG 108 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc.		Not Recruiting			Female: yes Male: yes	784		Hungary;United Kingdom;Czech Republic;Netherlands;Estonia;France;Ireland;Italy;Latvia;Austria;Sweden
1534	EUCTR2006-004666-14-DE	17/07/2007	19 March 2012	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. - not available	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. - not available	Rheumatoid Arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: ACZ885 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Canakinumab (proposed) Current Sponsor code: ACZ885 Other descriptive name: ACZ885 Drug Substance Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	32		Germany
1535	EUCTR2007-000886-40-CZ	17/07/2007	5 December 2016	Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients. - LEADER	Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients. - LEADER	patients with a diagnosis of early active rheumatoid arthritis in the previous 6 months, naïves of previous treatment by a DMARD and who need to be treated by a DMARD MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: ARAVA® Pharmaceutical Form: Coated tablet INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706126 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Trade Name: ARAVA® Pharmaceutical Form: Coated tablet INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706126 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Trade Name: ARAVA® Pharmaceutical Form: Coated tablet INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706126 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	sanofi-aventis groupe		Not Recruiting			Female: yes Male: yes	200	Phase 3	Portugal;Czech Republic;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1536	EUCTR2006-004834-33-LT	05/07/2007	20 February 2017	A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 when Added to Stable Methotrexate in Patients with Moderate or Severe Active Rheumatoid Arthritis - Robust	A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 when Added to Stable Methotrexate in Patients with Moderate or Severe Active Rheumatoid Arthritis - Robust	Rheumatiod Arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Rob 803 Product Code: Rob 803 6.25mg capsule Pharmaceutical Form: Capsule* Current Sponsor code: Rob 803 Other descriptive name: Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6.25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Rob 803 Product Code: Rob 803 12.5mg capsule Pharmaceutical Form: Capsule* Current Sponsor code: Rob 803 Other descriptive name: Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Rob 803 Product Code: Rob 803 15mg capsule Pharmaceutical Form: Capsule* Current Sponsor code: Rob 803 Other descriptive name: Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Rob 803 Product Code: Rob 803 25mg capsule Pharmaceutical Form: Capsule* Current Sponsor code: Rob 803 Other descriptive name: Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	OxyPharma AB		Not Recruiting			Female: yes Male: yes	224	Phase 2	Poland;Belgium;Lithuania;Bulgaria;Latvia;United Kingdom
1537	ChiCTR-TRC-09000377	2007-07-01	18 April 2017	Multicentered Clinical Evaluation Studies on Treating Active Rheumatoid Arthritis by the Method of Clearing Heat and Promoting Blood Flow	Multicentered Clinical Evaluation Studies on Treating Active Rheumatoid Arthritis by the Method of Clearing Heat and Promoting Blood Flow	rheumatoid arthritis	Group of MTX:Methotrexate Tablets: 10mg 1/w ;Group of Both MTX and Herbs:The Formula of Clearing Away Damp-heat and Promoting Blood Flow: 200ml bid; Methotrexate Tablets: 10mg 1/w ;Group of Herbs:The Formula of Clearing Away Damp-heat and Promoting Blood Flow: 200ml bid ;	China Academy of Chinese Medical Science Guang'an Men Hospital		Not Recruiting	18	65	Both	Group of MTX:76;Group of Both MTX and Herbs:77;Group of Herbs:77;	Post-market	China
1538	NCT00405275	July 2007	19 October 2017	Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy	CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Etanercept;Drug: methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine;Drug: Placebo, triple;Drug: Placebo, etanercept	VA Office of Research and Development	Canadian Institutes of Health Research (CIHR);Rheumatoid Arthritis Investigational Network (RAIN);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	18 Years	N/A	All	353	N/A	United States;Canada
1539	NCT00503139	July 2007	16 December 2017	Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan	Enbrel Special Use Result Surveillance	Rheumatoid Arthritis	Drug: Enbrel (etanercept)	Pfizer		Not recruiting	10 Years	N/A	All	684	Phase 4	Japan
1540	NCT00504777	July 2007	19 October 2017	A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.	An Open Label Study to Evaluate the Safety, and Effect on Treatment Response, of MabThera in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One or More Anti-TNF Agents.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	36	Phase 4	Taiwan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1541	NCT00555230	July 2007	19 February 2015	Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis	Effects of HMG-coA Reductase Inhibitor on Progression of Carotid Intima-Media Thickness and Arterial Stiffness in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rosuvastatin;Drug: Placebo	Chinese University of Hong Kong		Not recruiting	18 Years	75 Years	Both	150	Phase 2	China
1542	NCT00664716	July 2007	19 February 2015	Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Patients	Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.	Rheumatoid Arthritis	Biological: Placebo;Biological: baminercept alfa;Biological: Baminercept alfa	Biogen Idec		Not recruiting	18 Years	75 Years	Both	391	Phase 2	Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom
1543	EUCTR2006-006746-33-DE	28/06/2007	19 March 2012	Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070) - Efficacy of re-therapy in anti-TNFalpha IR	Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070) - Efficacy of re-therapy in anti-TNFalpha IR	Rheumatoid arthritis MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: MabThera 500 mg Konzentrat zur Herstellung einer Infusionslösung Product Name: MabThera Product Code: Ro 45-2294 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Roche Pharma AG		Not Recruiting			Female: yes Male: yes	240		Germany
1544	EUCTR2007-000760-24-CZ	21/06/2007	7 November 2016	Activity and safety of oral administration of SSR150106XB for the reduction of inflammation in patients with active rheumatoid arthritis (RA): A 4-week, multi-center, randomized, double-blind, placebo-controlled parallel group study of 90 µg administrered once daily and 90µg once every other day - ACCORD-RA	Activity and safety of oral administration of SSR150106XB for the reduction of inflammation in patients with active rheumatoid arthritis (RA): A 4-week, multi-center, randomized, double-blind, placebo-controlled parallel group study of 90 µg administrered once daily and 90µg once every other day - ACCORD-RA	Patients with active rheumatoid arthritis MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: SSR150106XB Product Code: SSR150106XB Pharmaceutical Form: Oral solution INN or Proposed INN: NA CAS Number: 335267-09-9 Current Sponsor code: SSR150106XB Other descriptive name: NA Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	75	Phase 2	Czech Republic
1545	EUCTR2006-005137-38-FR	19/06/2007	19 March 2012	A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study To Explore And Compare Perceptions And Satisfaction For Two Different Delivery Mechanisms For Etanercept (Etanercept Autoinjector And The Etanercept Prefilled Syringe) In Patients With Rheumatoid Arthritis.	A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study To Explore And Compare Perceptions And Satisfaction For Two Different Delivery Mechanisms For Etanercept (Etanercept Autoinjector And The Etanercept Prefilled Syringe) In Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis MedDRA version: 6.0 Level: LLT Classification code 10039073 Term:	Trade Name: Enbrel Product Name: Enbrel Pre-filled syringe Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: Enbrel Auto Injector Product Code: Auto Injector Pharmaceutical Form: Solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Wyeth Pharmaceuticals France		Authorised			Female: yes Male: yes	724		Finland;Germany;United Kingdom;Denmark;France;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1546	EUCTR2006-005330-20-BE	07/06/2007	25 September 2012	anti TNF-IR phase III	A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-a therapy. -	Rheumatoid arthritis MedDRA version: 14.1 Level: SOC Classification code 10028395 Term: Musculoskeletal and connective tissue disorders System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ocrelizumab Product Code: RO 496-4913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab Current Sponsor code: RO 496-4913 Other descriptive name: RhuMAb 2H7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	800	Phase 3	Hungary;Germany;Netherlands;Slovenia;Belgium;France;Spain;Italy;Sweden
1547	EUCTR2006-004140-23-CZ	06/06/2007	10 July 2015	A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RA	A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RA	Rheumatoid arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Atacicept Product Code: Not Applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany		Not Recruiting			Female: yes Male: yes	240	Phase 2	Portugal;Czech Republic;Greece;Finland;Spain;Belgium;Bulgaria;Germany;Netherlands;United Kingdom;Italy;Sweden
1548	EUCTR2006-004666-14-BE	04/06/2007	11 November 2013	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. - not available	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. - not available	Rheumatoid Arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: ACZ885 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Canakinumab (proposed) Current Sponsor code: ACZ885 Other descriptive name: ACZ885 Drug Substance Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	32		Belgium;Germany
1549	NCT00422227	June 2007	19 October 2017	Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region	A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept , Methotrexate;Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	70 Years	All	300	Phase 4	Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand
1550	NCT00447759	June 2007	13 May 2019	The Standard Care Versus Celecoxib Outcome Trial	Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's	Osteoarthritis;Rheumatoid Arthritis	Drug: Celecoxib;Drug: Diclofenac	University of Dundee	University of Glasgow;University of Nottingham	Not recruiting	60 Years	N/A	All	7297	Phase 4	Denmark;Netherlands;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1551	NCT00462345	June 2007	19 October 2017	A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.	An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Treatment Response in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies	Rheumatoid Arthritis	Drug: rituximab;Drug: Methotrexate;Drug: Corticosteroid or NSAID;Dietary Supplement: Folate	Hoffmann-La Roche		Not recruiting	18 Years	80 Years	All	40	Phase 4	Korea, Republic of
1552	NCT00650156	June 2007	16 December 2017	Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis	A Randomized, Parallel-group, Open-Label, Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis.	Rheumatoid Arthritis	Biological: adalimumab	AbbVie		Not recruiting	18 Years	N/A	All	24	Phase 1	China
1553	NCT00896168	June 2007	19 October 2017	An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis	A Multi-Center, Pre-Marketing Clinical Trial to Evaluate the Efficacy and Safety of Infliximab Treatment on Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Infliximab;Drug: Methotrexate	Xian-Janssen Pharmaceutical Ltd.		Not recruiting	18 Years	65 Years	All	234	Phase 4
1554	EUCTR2007-000082-38-DK	24/05/2007	8 August 2016	The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. - The OPERA Study	The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. - The OPERA Study	In early RA methotrexate and intra-articular glucocorticoid in combination with adalimumab is better than methotrexate and intra-articular glucocorticoid in achieving control of the disease as assessed by DAS28 < 3.2. MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Humira (adalimumab) Product Name: Humira® (adalimumab) Product Code: 2593 Pharmaceutical Form: Injection* INN or Proposed INN: Adalimumab	Aarhus University Hospital, Denmark		Not Recruiting			Female: yes Male: yes	180	Phase 4	Denmark
1555	NCT00476996	May 15, 2007	26 August 2019	A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-a Therapy (SCRIPT)	A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-a Therapy	Rheumatoid Arthritis	Drug: Leflunomide;Drug: Methotrexate;Drug: Ocrelizumab;Drug: Placebo	Genentech, Inc.	Roche Pharma AG	Not recruiting	18 Years	N/A	All	836	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Panama;Peru;Poland;Slovakia;Slovenia;Spain;Sweden;Switzerland;Taiwan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1556	EUCTR2007-001190-28-GB	09/05/2007	4 December 2018	Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT	Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Methotrexate Product Code: Methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59052 Current Sponsor code: Methotrexate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Product Name: Sulfasalazine Product Code: Sulfasalazine Pharmaceutical Form: Tablet INN or Proposed INN: SULFASALAZINE CAS Number: 599791 Current Sponsor code: SULFASALAZINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Product Name: Hydroxychloroquine Product Code: Hydroxychloroquine Pharmaceutical Form: Tablet INN or Proposed INN: Hydroxychloroquine CAS Number: 118423 Current Sponsor code: Hydroxychloroquine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Product Name: Ciclosporin Product Code: Ciclosporin Pharmaceutical Form: Tablet INN or Proposed INN: Ciclosporin CAS Number: 59865133 Current Sponsor code: Ciclosporin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Name: Leflunomide Product Code: Leflunomide Pharmaceutical Form: Tablet INN or Proposed INN: Leflunomide CAS Number: 75706126 Current Sponsor code: Leflunomide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Product Name: Sodium aurothiomalate (intramuscular gold) Product Code: Sodium aurothiomalate (intramuscular gold) Pharmaceutical Form: Injection* INN or Proposed INN: Sodium aurothiomalate CAS Number: 12244574 Current Sponsor code: Sodium aurothiomalate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: methylprednisolone Product Code: methylprednisolone Pharmaceutical Form: Injection* INN or Proposed INN: Methylprednisolone CAS Number: 83432 Current Sponsor code: Methylprednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Product Name: Prednisolone	King's College London		Not Recruiting			Female: yes Male: yes	190	Phase 4	United Kingdom
1557	EUCTR2006-005036-24-SE	04/05/2007	7 August 2012	A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE ALONE. - N/A	A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE ALONE. - N/A	Rheumatoid arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CP-690,550 Pharmaceutical Form: Tablet CAS Number: 540737-29-9 Other descriptive name: (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: CP-690,550 Pharmaceutical Form: Tablet CAS Number: 540737-29-9 Other descriptive name: (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.		Not Recruiting			Female: yes Male: yes	483	Phase 2B	Hungary;Czech Republic;Bulgaria;Sweden
1558	NCT00420199	May 2007	19 October 2017	A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate	Active Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	50	Phase 3	Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;Austria
1559	NCT00443430	May 2007	19 October 2017	Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis	Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA)	Juvenile Chronic Polyarthritis;Juvenile Idiopathic Arthritis;Juvenile Rheumatoid Arthritis	Drug: methotrexate;Drug: methotrexate - etanercept - prednisolone arm	Seattle Children's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Amgen	Not recruiting	2 Years	17 Years	All	85	Phase 4	United States
1560	NCT00455208	May 2007	19 February 2015	A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis	Study Evaluating Cura-100 in Rheumatoid Arthritis and Osteoarthritis	Rheumatoid Arthritis;Osteoarthritis	Drug: Cura-100	Cura Biotech LLC		Not recruiting	20 Years	50 Years	Both	20	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1561	NCT00504595	May 2007	19 October 2017	Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis	A 12-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR20) and to Determine a Biomarker Profile in Adult Patients With Established Rheumatoid Arthritis Responding to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) as Compared to Healthy Subjects Exposed to ACZ885	Rheumatoid Arthritis	Drug: ACZ885 (investigational);Drug: Placebo	Novartis		Not recruiting	18 Years	75 Years	All	80	Phase 2	Russian Federation;Spain;Switzerland;Turkey
1562	NCT00578565	May 2007	19 October 2017	Rituximab in Rheumatoid Arthritis Lung Disease	Rituximab for the Treatment of Rheumatoid Arthritis-Associated Interstitial Pneumonia: A Pilot Study	Rheumatoid Arthritis;Interstitial Pneumonia	Drug: Rituximab	Eric Matteson	Genentech, Inc.;National Center for Research Resources (NCRR)	Not recruiting	18 Years	80 Years	All	10	Phase 3	United States
1563	NCT00760669	May 2007	19 October 2017	An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants	Post Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Patients	Spondylitis, Ankylosing;Arthritis, Rheumatoid;Psoriasis;Arthritis, Psoriatic	Drug: Infliximab; observational study;Drug: Methotrexate	Janssen Korea, Ltd., Korea		Not recruiting	N/A	N/A	All	1061	Phase 4	Korea, Republic of
1564	EUCTR2007-000491-16-ES	30/04/2007	2 February 2015	Estudio de extensión abierto de 76 semanas de duración para evaluar la eficacia, seguridad y tolerabilidad de ACZ885 (anticuerpo monoclonal anti-interleuquina-1ß) en pacientes con artritis reumatoide activa - not available	Estudio de extensión abierto de 76 semanas de duración para evaluar la eficacia, seguridad y tolerabilidad de ACZ885 (anticuerpo monoclonal anti-interleuquina-1ß) en pacientes con artritis reumatoide activa - not available	Artritis Reumatoide MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: ACZ885 Product Code: ACZ885 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Canakinumab (proposed) Current Sponsor code: ACZ885 Other descriptive name: ACZ885 Drug Substance Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Novartis Farmacéutica, S.A.		Not Recruiting			Female: yes Male: yes			Belgium;Spain;Austria;Germany
1565	EUCTR2005-002660-29-HU	20/04/2007	19 March 2012	A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis	A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis	Product Name: Anti IL-1ß antibody Product Code: LY2189102 Pharmaceutical Form: Powder for solution for infusion Current Sponsor code: LY2189102 Other descriptive name: Anti IL-1ß antibody, subclass IgG4 Concentration unit: mg milligram(s) Concentration type: not less then Concentration number: 20- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Eli Lilly and Company Limited		Not Recruiting			Female: yes Male: yes	135	Phase 1b/2	Hungary;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1566	EUCTR2006-005466-39-GB	12/04/2007	19 March 2012	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional DMARD Therapy	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional DMARD Therapy	Rheumatoid arthritis (RA) MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: BG9924 Pharmaceutical Form: Powder for solution for injection Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Biogen Idec Ltd		Authorised			Female: yes Male: yes	380	Phase 2b	Hungary;United Kingdom
1567	EUCTR2006-005467-26-GB	12/04/2007	19 March 2012	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapy	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapy	Rheumatoid Arthritis MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: BG9924 Pharmaceutical Form: Powder for solution for injection Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Biogen Idec Ltd		Authorised			Female: yes Male: yes	120	Phase 2b	United Kingdom
1568	EUCTR2006-004669-32-ES	09/04/2007	2 February 2015	Estudio multicéntrico, de fase II, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración, para evaluar la respuesta al tratamiento (ACR20) y para determinar un perfil de biomarcadores en pacientes adultos con artritis reumatoide establecida respondedores a ACZ885 (anticuerpo monoclonal anti-interleuquina-1ß) comparado con sujetos sanos expuestos a ACZ885 - not available	Estudio multicéntrico, de fase II, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración, para evaluar la respuesta al tratamiento (ACR20) y para determinar un perfil de biomarcadores en pacientes adultos con artritis reumatoide establecida respondedores a ACZ885 (anticuerpo monoclonal anti-interleuquina-1ß) comparado con sujetos sanos expuestos a ACZ885 - not available	Artritis reumatoide establecida MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: ACZ885 Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Canakinumab (proposed) Current Sponsor code: ACZ885 Other descriptive name: ACZ885 Drug Substance Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder and solvent for solution for infusion Route of administration of the placebo: Intravenous use	Novartis Farmacéutica S.A		Not Recruiting			Female: yes Male: yes	80		Spain
1569	EUCTR2006-004139-31-BE	03/04/2007	15 July 2013	A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rheumatoid Arthritis. - OPTIMA	A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rheumatoid Arthritis. - OPTIMA	Rheumatoid Arthritis. MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Humira Pharmaceutical Form: Injection* INN or Proposed INN: Adalimumab Current Sponsor code: ABT-Humira Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use Trade Name: Metex® Pharmaceutical Form: Tablet Current Sponsor code: Methotrexate disodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2,5-	Abbott GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	1000		France;Hungary;Czech Republic;Greece;Spain;Belgium;Austria;Norway;Netherlands;Germany;United Kingdom;Sweden
1570	NCT00409838	April 2007	19 October 2017	A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept Administered Intravenously in Korean Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	113	Phase 3	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1571	NCT00414661	April 2007	19 October 2017	Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550	A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550	Arthritis, Rheumatoid	Drug: CP-690,550	Pfizer		Not recruiting	18 Years	N/A	All	162	N/A	United States;Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Dominican Republic;Finland;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Slovakia;Spain;Ukraine;Australia;Austria;Belgium;Costa Rica;Romania;Sweden
1572	NCT00446784	April 2007	19 February 2015	Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis	A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate	Arthritis, Rheumatoid	Drug: CE-224,535;Drug: Methotrexate	Pfizer		Not recruiting	18 Years	N/A	Both	20	Phase 1	United States
1573	NCT00484237	April 2007	19 February 2015	A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis	A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Safety and Efficacy of Etanercept 10 mg Twice Weekly and 25 mg Once Weekly in Japanese Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: etanercept	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	20 Years	75 Years	Both	80	Phase 3	Japan
1574	NCT00989235	April 2007	19 October 2017	Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis	A Phase 3B, Multi-Center, Randomized, Double-blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate-naïve Early Erosive Rheumatoid Arthritis Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate - Low Dose Sub-Study	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	108	Phase 3
1575	EUCTR2006-006373-25-ES	23/03/2007	25 September 2012		ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO Y EL ESTADO FUNCIONAL DE SUJETOS CON ARTRITIS REUMATOIDE INCLUIDOS PREVIAMENTE EN ESTUDIOS DE CP-690,550 A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/A	CP-690,550 se está desarrollando como fármaco antirreumático modificador de la enfermedad (FARME) para el tratamiento de la artritis reumatoide (AR). CP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: CP-690,550 Pharmaceutical Form: Tablet	Pfizer, S.A.		Not Recruiting			Female: yes Male: yes	300		Finland;United Kingdom;Germany;Czech Republic;Bulgaria;Spain;Greece;Austria;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1576	EUCTR2006-001553-10-BE	20/03/2007	11 November 2013	A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-interleukin-1beta monoclonal antibody) plus MTX as compared to MTX alone in early rheumatoid arthritis patients - 2204	A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-interleukin-1beta monoclonal antibody) plus MTX as compared to MTX alone in early rheumatoid arthritis patients - 2204	Early Rheumatoid Arthritis in adults MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: ACZ885 Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: ACZ885 Drug Substance Current Sponsor code: ACZ885 Other descriptive name: ACZ885 Drug Substance Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder and solvent for solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	92	Phase 2	Belgium;Netherlands;Germany;Italy
1577	NCT04144101	March 1, 2007	4 November 2019	Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis	Comparison of Lower Dosage of Etoricoxib Versus Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis: A Single-center, Parallel-group, Randomized Controlled Pilot Study	Rheumatoid Arthritis	Drug: Etoricoxib;Drug: Aceclofenac	Chung Shan Medical University		Not recruiting	20 Years	80 Years	All	40	Phase 4
1578	NCT00462072	March 2007	19 October 2017	Centocor Microarray Study of Patients	Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases	Rheumatoid Arthritis;Psoriatic Arthritis;Psoriasis;Crohn's Disease	Drug: Infliximab	University of Rochester	Centocor, Inc.	Not recruiting	12 Years	N/A	All	31	Phase 4	United States
1579	NCT00487825	March 2007	19 October 2017	Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis	A 26-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR50) and to Determine a Biomarker Profile in Responders to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) Plus MTX as Compared to MTX Alone in Early Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Canakinumab (investigational);Drug: Placebo;Drug: Methotrexate (MTX)	Novartis		Not recruiting	18 Years	75 Years	All	78	Phase 2	United States;Belgium;Germany;Italy;Netherlands;Spain
1580	NCT00913432	March 2007	18 December 2018	Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis	A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open Label, Uncontrolled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of AB1010 at 3 and 6 mg/kg/Day in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including Anti TNF Alpha if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Anti TNF Alpha	Rheumatoid Arthritis	Drug: masitinib	AB Science		Not recruiting	18 Years	N/A	All	20	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1581	EUCTR2006-006380-22-DE	22/02/2007	19 March 2012	Biological dosimetry in radiation synovectomy of small finger joints with Erbium [169Er] citrate - ER-MM1 biological dosimetry	Biological dosimetry in radiation synovectomy of small finger joints with Erbium [169Er] citrate - ER-MM1 biological dosimetry	Patients with rheumatoid arthritis or seronegative spondylarthropathy with at least one inflamed finger joint (MCP, PIP, DIP) referred for RSO with with Erbium [169Er]citrate MedDRA version: 8.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions	Trade Name: ERMM-1 Pharmaceutical Form: Solution for injection INN or Proposed INN: erbium citrate Concentration unit: MBq/ml megabecquerel(s)/millilitre Concentration type: equal Concentration number: 111-	CIS bio international		Authorised			Female: yes Male: yes			Germany
1582	NCT00413699	February 5, 2007	16 December 2017	Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis	A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP-690,550	Pfizer		Not recruiting	18 Years	N/A	All	4553	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czechia;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;Czech Republic;United States Minor Outlying Islands
1583	NCT00418717	February 2007	19 October 2017	Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA	An Open-label, Multicenter, Dose-regimen Study Evaluating the Efficacy and Safety of Etanercept 50 mg Once-weekly Dose in Japanese Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: etanercept	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	20 Years	75 Years	All	42	Phase 3	Japan
1584	NCT00425932	February 2007	19 February 2015	Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis	Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Rituximab	Gaylis, Norman B., M.D.	Oklahoma Medical Research Foundation;Genentech, Inc.	Not recruiting	18 Years	80 Years	Both	60	Phase 2	United States
1585	NCT00427934	February 2007	19 October 2017	Maraviroc in Rheumatoid Arthritis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate	Arthritis, Rheumatoid	Drug: Maraviroc;Drug: Maraviroc Placebo	Pfizer		Not recruiting	18 Years	N/A	All	128	Phase 2	United States;Australia;Germany;India;Italy;Mexico;Portugal;Spain;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1586	NCT00458146	February 2007	19 February 2015	A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis	A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: MM-093	Merrimack Pharmaceuticals		Not recruiting	18 Years	80 Years	Both	100	Phase 2	United States
1587	NCT00461448	February 2007	19 February 2015	A Pilot Study of Potassium Supplementation for Adult Patients With Rheumatoid Arthritis	Pilot Study of Potassium Supplementation in the Treatment of Rheumatoid Arthritis: a 4-Week, Randomized, Double-Blind, Placebo-Controlled Trial	Rheumatoid Arthritis	Dietary Supplement: Potassium supplement	Shahid Beheshti Medical University		Not recruiting	18 Years	60 Years	Both	36	Phase 1	Iran, Islamic Republic of
1588	EUCTR2006-003983-73-CZ	17/01/2007	1 May 2012	A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: RWJ-445380 Capsules 50 mg Product Code: RWJ-445380-002 Pharmaceutical Form: Capsule* CAS Number: 400797-45-7 Current Sponsor code: RWJ-445380-002 Other descriptive name: JNJ-16240159-AAC Concentration unit: % (W/W) percent weight/weight Concentration type: range Concentration number: 45 mg-55 mg Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: RWJ-445380 capsule 100 mg Product Code: RWJ-445380-002 Pharmaceutical Form: Capsule* CAS Number: 400797-45-7 Current Sponsor code: RWJ-445380-002 Other descriptive name: JNJ-16240159-AAC Concentration unit: % (W/W) percent weight/weight Concentration type: range Concentration number: 90 mg-110 mg Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: RWJ-445380 capsules 150 mg Product Code: RWJ-445380-002 Pharmaceutical Form: Capsule* CAS Number: 400797-45-7 Current Sponsor code: RWJ-445380-002 Other descriptive name: JNJ-16240159-AAC Concentration unit: % (W/W) percent weight/weight Concentration type: range Concentration number: 135 mg-165 mg Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Janssen-Cilag International N.V.		Not Recruiting			Female: yes Male: yes	240	Phase 2a	Germany;Czech Republic
1589	EUCTR2006-006275-21-GB	10/01/2007	19 March 2012	A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis. - Adalimumab versus Etanercept for RA	A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis. - Adalimumab versus Etanercept for RA	Rheumatoid Arthritis MedDRA version: 14.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Humira Pharmaceutical Form: Injection Trade Name: Enbrel Pharmaceutical Form: Injection	University Hospital Birmingham NHS Foundation Trust		Authorised			Female: yes Male: yes			United Kingdom
1590	NCT00413660	January 2007	19 October 2017	Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis	A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone	Arthritis, Rheumatoid	Drug: CP-690,550;Other: placebo	Pfizer		Not recruiting	18 Years	N/A	All	509	Phase 2	United States;Argentina;Brazil;Bulgaria;Chile;Czech Republic;Hungary;Mexico;Poland;Slovakia;Spain;Sweden;Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1591	NCT00424502	January 2007	19 October 2017	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.	An Open-label Study to Evaluate the Effect of MabThera on Treatment Response in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Previous TNF Inhibition.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	20	Phase 4	Hungary
1592	NCT00427804	January 2007	19 October 2017	Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption	Tumor Necrosis Factor-a Induces Vitamin D Resistance in Small Intestinal Calcium Absorption	Rheumatoid Arthritis;Crohn's Disease	Drug: calcitriol	Atlanta VA Medical Center	Emory University	Not recruiting	18 Years	50 Years	Male	9	N/A	United States
1593	NCT00443651	January 2007	16 December 2017	A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis	An Open-Label, Prospective Study of the Safety of Rituximab in Combination With Other Disease-Modifying Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab;Drug: Anti-inflammatory drugs	Genentech, Inc.	Biogen	Not recruiting	18 Years	80 Years	All	578	Phase 3	United States
1594	NCT00716248	January 2007	19 February 2015	Bucillamine Study of Holding Remission After Infliximab Dose-off	The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: bucillamine;Drug: methotrexate	Saitama Medical University	Keio University	Not recruiting	20 Years	N/A	Both	40	Phase 4	Japan
1595	NCT02886689	January 2007	12 September 2016	C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France	C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France	Arthritis, Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic;Arthitis, Juvenile Idiopathic	Drug: TNF-alpha antagonist and other biotherapy	Central Hospital, Nancy, France		Not recruiting	3 Years	75 Years	Both	5400	N/A	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1596	EUCTR2007-003591-19-DE		1 May 2012	AN OPEN, COMPARATIVE, WITHIN PATIENT CONTROLLED MULTICENTRE STUDY OF REPEATED SUBCUTANEOUS INJECTIONS OF METHOTREXATE 50MG/ML AND 10MG/ML TO COMPARE PATIENT SATISFACTION AND LOCAL TOLERABILITY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - MTX 50 versus 10mg/ml	AN OPEN, COMPARATIVE, WITHIN PATIENT CONTROLLED MULTICENTRE STUDY OF REPEATED SUBCUTANEOUS INJECTIONS OF METHOTREXATE 50MG/ML AND 10MG/ML TO COMPARE PATIENT SATISFACTION AND LOCAL TOLERABILITY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - MTX 50 versus 10mg/ml	Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: Methotrexate 50mg/ml solution for injection, pre-filled syringe Pharmaceutical Form: Solution for injection INN or Proposed INN: Methotrexate disodium CAS Number: 7413345 Other descriptive name: Methotrexate disodium Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Metex 10 mg/ml Injektionslösung, Fertigspritze Pharmaceutical Form: Solution for injection INN or Proposed INN: methotrexate disodium CAS Number: 7413345 Other descriptive name: Methotrexate disodium Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	medac Gesellschaft für klinische Spezialpräparate mbH		Not Recruiting			Female: yes Male: yes			Germany
1597	EUCTR2006-005386-19-BE	19/12/2006	7 October 2014	Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab - Anti TNF resistant RA / RTX / mini	Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab - Anti TNF resistant RA / RTX / mini	Rheumatoid arthritis refractory to TNF blockers patients MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: MabThera Pharmaceutical Form: Solution for infusion	Cliniques Universitaires Saint-Luc		Authorised			Female: yes Male: yes			Belgium
1598	EUCTR2005-005664-88-GB	08/12/2006	19 March 2012	Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis	Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis	Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45	Trade Name: Tuberculin PPD RT 23 SSI for mantoux testing Product Name: Tuberculin PPD RT 23 SSI for mantoux testing Product Code: 1 Pharmaceutical Form: Injection*	University of Oxford		Authorised			Female: yes Male: yes	520		United Kingdom
1599	EUCTR2006-003577-27-EE	01/12/2006	19 March 2012	A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS. - na	A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS. - na	Treatment of rheumatoid arthritis (RA) MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: PH-797804 Pharmaceutical Form: Capsule* CAS Number: 586414-48-4 Current Sponsor code: PH-797804 Other descriptive name: S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Code: PH-797804 Pharmaceutical Form: Capsule* CAS Number: 586414-48-4 Current Sponsor code: PH-797804 Other descriptive name: S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Code: PH-797804 Pharmaceutical Form: Capsule* CAS Number: 586414-48-4 Current Sponsor code: PH-797804 Other descriptive name: S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Pfizer Luxembourg SARL Branch Office Estonia		Not Recruiting			Female: yes Male: yes	290	Phase 2A	Czech Republic;Estonia;Spain
1600	NCT00383188	December 2006	19 February 2015	An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis	A 12-Week, Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Safety, Pharmacokinetics, And Efficacy Of PH-797804, Administered Orally Once Daily In Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: placebo;Drug: PH-797804	Pfizer		Not recruiting	18 Years	N/A	Both	305	Phase 2	Australia;Brazil;Chile;Czech Republic;Estonia;India;Korea, Republic of;Peru;Poland;Russian Federation;South Africa;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1601	NCT00392951	December 2006	19 November 2018	Sirolimus for Autoimmune Disease of Blood Cells	Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series	Autoimmune Pancytopenia;Autoimmune Lymphoproliferative Syndrome (ALPS);Evans Syndrome;Idiopathic Thrombocytopenic Purpura;Anemia, Hemolytic, Autoimmune;Autoimmune Neutropenia;Lupus Erythematosus, Systemic;Inflammatory Bowel Disease;Rheumatoid Arthritis	Drug: sirolimus	Children's Hospital of Philadelphia		Not recruiting	1 Year	30 Years	All	30	Phase 1/Phase 2	United States
1602	NCT00406419	December 2006	16 December 2017	A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)	A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment	Rheumatoid Arthritis	Drug: methotrexate;Drug: ocrelizumab;Drug: placebo	Genentech, Inc.	Roche Pharma AG	Not recruiting	18 Years	N/A	All	1015	Phase 3	United States
1603	NCT00413452	December 2006	19 February 2015	Etanercept SFP in RA Patients	Open-Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Etanercept	Amgen	Wyeth is now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	Both	224	Phase 3	United States;Canada
1604	NCT00425321	December 2006	19 February 2015	Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: RWJ-445380 100 mg;Drug: RWJ-445380 200 mg;Drug: RWJ-445380 300 mg;Drug: Placebo	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		Not recruiting	18 Years	N/A	Both	259	Phase 2	United States;Argentina;Brazil;Czech Republic;Germany;Mexico;Poland
1605	NCT00430495	December 2006	19 October 2017	A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)	A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy	Rheumatoid Arthritis	Drug: Atacicept;Drug: Placebo matched to atacicept	EMD Serono	Merck KGaA	Not recruiting	18 Years	N/A	All	256	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1606	NCT00440492	December 2006	19 February 2015	Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis	An Open-Label Study To Evaluate The Potential Pharmacokinetic Interaction Between PLA-695 And Methotrexate When Coadministered Orally To Adult Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: PLA-695	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	75 Years	Both		Phase 1	United States;Canada
1607	NCT00484289	December 2006	19 October 2017	A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis	A Phase III, Multi-center, Open-label, Uncontrolled, Long-term Study to Evaluate the Safety of Abatacept (BMS-188667) in Japanese Subjects With Rheumatoid Arthritis Having Completed Clinical Studies IM101-071, IM101-034, and Also Special DMARD Failures	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	20 Years	N/A	All	217	Phase 3	Japan
1608	EUCTR2006-003142-42-DE	30/11/2006	19 March 2012	A Randomized, Double Blind, Placebo-controlled, Proof of Concept Study to evaluate Efficacy, Safety and Pharmacokinetics of two Different Doses of SC12267 (20mg, 35 mg) in Patients with Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled, Proof of Concept Study to evaluate Efficacy, Safety and Pharmacokinetics of two Different Doses of SC12267 (20mg, 35 mg) in Patients with Rheumatoid Arthritis	Active Rheumatoid Arthritis MedDRA version: 8.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Product Code: SC12267 Pharmaceutical Form: Film-coated tablet Concentration unit: mg milligram(s) Concentration type: equal Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	4SC AG		Not Recruiting			Female: yes Male: yes	120		Germany
1609	EUCTR2006-002216-10-CZ	27/11/2006	19 March 2012	A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexate - RACER	A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexate - RACER	Rheumatoid Arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: PG-760564 Product Code: PG-760564 Pharmaceutical Form: Capsule* Current Sponsor code: PG-760564 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Procter & Gamble Pharmaceuticals		Not Recruiting			Female: yes Male: yes	270		Hungary;United Kingdom;Czech Republic;Netherlands
1610	EUCTR2005-003632-22-ES	22/11/2006	29 May 2012	A study of the pharmacokinetic and pharmacodynamic activity of rituximab in combination with methotrexate (MTX) in synovial tissue and in peripheral blood of patients with rheumatoid arthritis.	An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of rituximab in combination with methotrexate (MTX) in synovial tissue and in peripheral blood of patients with active rheumatoid arthritis	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	F. Hoffmann-La Roche Ltd.		Authorised			Female: yes Male: yes	3		Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1611	NCT00072982	November 2006	19 February 2015	Treatment of Rheumatoid Arthritis With Marine and Botanical Oils	Treatment of Rheumatoid Arthritis With Marine and Botanical Oils	Rheumatoid Arthritis	Drug: fish oil;Drug: borage seed oil;Drug: combination fish oil and borage seed oil	National Center for Complementary and Integrative Health (NCCIH)		Not recruiting	18 Years	85 Years	Both	156	Phase 3	United States
1612	NCT00395577	November 2006	19 February 2015	A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702	A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate	Rheumatoid Arthritis	Drug: VX-702	Vertex Pharmaceuticals Incorporated		Not recruiting	18 Years	75 Years	Both	120	Phase 2	Bulgaria;Croatia;Former Serbia and Montenegro;Poland;Russian Federation;Slovenia
1613	NCT00396812	November 2006	19 October 2017	Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)	An Open Label, Single Arm, Single Center, Phase I/II Trial of Rituximab (a Monoclonal Antibody to CD20) for the Treatment of Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Not recruiting	18 Years	N/A	All	4	Phase 1/Phase 2	United States
1614	NCT00424346	November 2006	19 October 2017	Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis	A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) With Three Different Dose Regimens in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate Including 76-week and 96-week Extensions	Rheumatoid Arthritis	Drug: Canakinumab;Drug: Placebo	Novartis		Not recruiting	18 Years	N/A	All	274	Phase 2	United States;Austria;Belgium;Canada;Germany;Spain;Finland
1615	NCT00589485	November 2006	16 December 2017	Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement	Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement	Osteoarthritis;Rheumatoid Arthritis;Traumatic Arthritis;Knee Arthritis	Device: Simplex® Bone Cement;Device: Cobalt™ Bone Cement	Zimmer Biomet	New Lexington Clinic	Not recruiting	18 Years	N/A	All	0	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1616	NCT00761514	November 2006	19 October 2017	Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira	Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR)	Rheumatoid Arthritis	Drug: Humira (adalimumab)	Abbott		Not recruiting	18 Years	N/A	All	14	Phase 4	Puerto Rico
1617	NCT02079532	November 2006	19 October 2017	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor	An Open-label Study to Evaluate the Safety of MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent	Rheumatoid Arthritis	Drug: rituximab [MabThera]	Hoffmann-La Roche		Not recruiting	18 Years	75 Years	All	302	Phase 3	Germany
1618	EUCTR2006-004715-22-SI	26/10/2006	19 March 2012	A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate	A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate	Rheumatoid Arthritis	Product Code: VX-702 Pharmaceutical Form: Tablet Current Sponsor code: VX-702 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Vertex Pharmaceuticals Incorporated		Not Recruiting			Female: yes Male: yes	120	Phase 2	Slovenia
1619	EUCTR2006-003843-22-IT	24/10/2006	7 January 2013	prospeCtive study on intensive early rheumatoid arthritis treatment with adalimUmab: induction of REmission and maintenance - 'CURE' A Phase IV multicenter, randomized, double-blind study	prospeCtive study on intensive early rheumatoid arthritis treatment with adalimUmab: induction of REmission and maintenance - 'CURE' A Phase IV multicenter, randomized, double-blind study	rheumatoid arthritis MedDRA version: 14.1 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: *HUMIRASC 2SIR+F 40MG 0,8ML+2T Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab Concentration unit: mg milligram(s) Concentration number: 40- Trade Name: METHOTREXATE100CPR 2,5MG* Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate CAS Number: 59-05-2 Concentration unit: mg milligram(s) Concentration number: 2.5- Trade Name: *DELTACORTENE FORTE10CPR 25MG Pharmaceutical Form: Tablet INN or Proposed INN: Prednisone** CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	OSPEDALE POLICLINICO S. MATTEO		Authorised			Female: yes Male: yes		Phase 4	Italy
1620	EUCTR2006-004673-98-HU	16/10/2006	19 March 2012	Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker	Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker	To investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.	Trade Name: MabThera 500 mg concentrate for solution for infusion Pharmaceutical Form: Concentrate for solution for infusion	Roche (Hungary) Ltd.		Not Recruiting			Female: yes Male: yes	20		Hungary
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1621	NCT00346216	October 4, 2006	16 December 2017	Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen	A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen	Arthritis, Rheumatoid	Drug: celecoxib;Drug: Ibuprofen;Drug: Naproxen	Pfizer	The Cleveland Clinic	Not recruiting	18 Years	N/A	All	24081	Phase 4	United States;Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine
1622	EUCTR2006-000363-28-GB	03/10/2006	19 March 2012	DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS - DATA Study	DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS - DATA Study	Rheumatoid arthritis and Psoriatic arthritis	Trade Name: Remicade Product Name: Infliximab Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Infliximab Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 3- Trade Name: Enbrel Product Name: Etanercept Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Etanercept Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-	Greater Glasgow Health Board	Glasgow University	Authorised			Female: yes Male: yes	40		United Kingdom
1623	JPRN-UMIN000000512	2006/10/01	2 April 2019	Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with infliximab and methotrexate		Rheumatoid Arthritis	If the score of DAS28 is under 3.2 in rheumatoid arthritis patients who have received infliximab and methotrexate, doses of methotrexate will reduced to 2mg/w. When the score of DAS28 increses, tacrolimus will be administered instead of methotrexate. Period of observation is 32 weeks. If the score of DAS28 is over 3.2 in rheumatoid arthritis patients who have received infliximab and methotrexate, tacrolimus will be administered. Period of observation is 32 weeks.	Rheumatosurgery, Osaka City University Medical School		Not Recruiting	Not applicable	Not applicable	Male and Female	30	Not applicable	Japan
1624	NCT00393146	October 2006	25 May 2015	A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis	A Randomized, Double Blind, Placebo Controlled Study to Investigate the Safety and Tolerability and Clinical Activity of 28 Days of Oral Repeat Dosing With GW856553 at 7.5mg BID in Subjects With Active Rheumatoid Arthritis on Stable Anti-rheumatic Therapy.	Arthritis, Rheumatoid	Drug: GW856553	GlaxoSmithKline		Not recruiting	18 Years	N/A	Both	57	Phase 2	Romania;Russian Federation;Spain
1625	NCT00399282	October 2006	19 February 2015	Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis	Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omega-3 and Vitamin E supplementation	Shahid Beheshti Medical University		Not recruiting	16 Years	75 Years	Both	75	Phase 1	Iran, Islamic Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1626	NCT00749645	October 2006	4 July 2016	Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients	Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients	Arthritis, Rheumatoid	Drug: FANG(30);Drug: Placebo	Juan C. Bertoglio, MD	Fondo Nacional de Desarrollo Científico y Tecnológico, Chile	Not recruiting	18 Years	70 Years	Both	60	Phase 2	Chile
1627	EUCTR2006-005391-40-IT	25/09/2006	27 January 2014	Study on the effect of intra-articular infiltrations of aulogous platelet gel as inhibitor of erosion in rheumatoid arthritis patients - ND	Study on the effect of intra-articular infiltrations of aulogous platelet gel as inhibitor of erosion in rheumatoid arthritis patients - ND	Patients with Rheumatoid Arthritis Level: PT Classification code 10039073	Product Name: Platelet Rich Plasma Pharmaceutical Form: Solution for injection Current Sponsor code: PRPIN AR2006 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical Form: Solution for injection INN or Proposed INN: Triamcinolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	AZIENDA OSPEDALIERA SENESE		Not Recruiting			Female: yes Male: yes			Italy
1628	EUCTR2006-001000-37-DE	19/09/2006	19 March 2012	Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRST	Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRST	Rheumatoid arthritis MedDRA version: 8.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: MabThera 500 mg Konzentrat zur Herstellung einer Infusionslösung Product Name: MabThera Product Code: Ro 45-2294 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Roche Pharma AG		Not Recruiting			Female: yes Male: yes	300		Germany
1629	EUCTR2006-001428-38-GB	18/09/2006	19 March 2012	Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy - RIVERA	Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy - RIVERA	Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-CCP antibody)	Trade Name: Enbrel Pharmaceutical Form: Solution for injection Trade Name: Methorexate Pharmaceutical Form: Tablet Trade Name: Depo-Medrone Pharmaceutical Form: Solution for injection Trade Name: Salazopyrin En-Tabs Pharmaceutical Form: Tablet Trade Name: Plaquenil Pharmaceutical Form: Tablet	University Hospitals Birmingham NHS Foundation Trust		Authorised			Female: yes Male: yes	20		United Kingdom
1630	NCT00361335	September 2006	19 October 2017	A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Golimumab;Drug: Methotrexate;Drug: Placebo	Centocor, Inc.	Schering-Plough	Not recruiting	18 Years	N/A	All	643	Phase 3	United States;Argentina;Australia;Colombia;Germany;Hungary;Latvia;Lithuania;Malaysia;Malta;Mexico;New Zealand;Peru;Poland;Ukraine;Belgium;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1631	NCT00361634	September 2006	19 October 2017	Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis	DCE-MRI of the Wrist to Measure Short-Term Responses in Rheumatoid Arthritis Subjects Treated With Etanercept	Rheumatoid Arthritis	Drug: Etanercept	Amgen		Not recruiting	18 Years	N/A	All	14	Phase 1	United States;United Kingdom
1632	NCT00367211	September 2006	19 February 2015	Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.	A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.	Osteoarthritis;Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: PN 200 tablets (500 mg naproxen and 20 mg omeprazole);Drug: Naproxen 500 mg tablets (PN 200 minus omeprazole)	POZEN		Not recruiting	18 Years	N/A	Both	400	Phase 3	United States
1633	NCT00369473	September 2006	9 January 2017	Long-Term Assessment of Safety and Physical Function With AMG 108 in RA	A Long-Term Assessment of Safety and Physical Function With AMG 108 Subcutaneous Monthly Treatment in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 108	Amgen		Not recruiting	18 Years	N/A	Both	690	Phase 2	Australia;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;United Kingdom;United States
1634	NCT00488475	September 2006	19 October 2017	Observational Trial With Enbrel	A 1 Year Observational Study of the Use of Etanercept in Routine German Clinical Practice to Treat Rheumatoid Arthritis Patients: a Health Economic, Safety and Effectiveness Evaluation	Rheumatoid Arthritis	Drug: etanercept	Pfizer		Not recruiting	18 Years	N/A	All	4945	N/A	Germany
1635	NCT00588393	September 2006	19 February 2015	FolateScan in Autoimmune Disease	Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases	Rheumatoid Arthritis;Osteoarthritis;Multiple Sclerosis;Crohn's Disease;Systemic Lupus Erythematosus	Drug: FolateScan (Technetium Tc 99mEC20)	Mayo Clinic	Endocyte	Not recruiting	18 Years	N/A	Both	75	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1636	NCT01126541	September 2006	19 October 2017	SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy	A Comparative Study to Assess the Effect of Retreatment With 2 Doses of MabThera on Disease Activity Score in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to antiTNF-alfa Therapy.(SMART)	Rheumatoid Arthritis	Drug: rituximab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	224	Phase 3	France
1637	NCT01308255	September 2006	11 November 2019	Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)	A Multi-centre Randomised Double Blind Placebo Controlled Study Comparing Two Regimens of Combination Therapy in Early DMARD Naive Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Infliximab;Drug: Methylprednisolone;Drug: Methotrexate;Dietary Supplement: Folic acid	University of Leeds		Not recruiting	18 Years	80 Years	All	112	Phase 4	United Kingdom
1638	EUCTR2006-002645-37-HU	25/08/2006	19 March 2012	A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate	A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate	Active rheumatoid arthritis (RA), patients taking stable doses of methotrexate MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: KC706 Product Code: KR002524 Pharmaceutical Form: Capsule* CAS Number: 848144-15-0 Current Sponsor code: KC706 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Kémia, Inc.		Authorised			Female: yes Male: yes	150	Phase 2	Hungary
1639	NCT02006706	August 10, 2006	16 December 2017	A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy	An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate;Drug: methylprednisolone	Hoffmann-La Roche		Not recruiting	18 Years	80 Years	All	15	Phase 3	Serbia
1640	EUCTR2005-006165-14-GB	03/08/2006	19 March 2012	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate - NA	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate - NA	Rheumatoid Arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: MLN3897 Product Code: N/A Pharmaceutical Form: Capsule* INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: MLN3897 Other descriptive name: AVE9897 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10 - Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. Product Name: Methotrexate Product Code: N/A Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: range Concentration number: 7.5-25	Millennium Pharmaceuticals Inc,		Authorised			Female: yes Male: yes	186	Phase 2a	Czech Republic;United Kingdom;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1641	JPRN-C000000452	2006/08/01	2 April 2019	Remission Induction of Very Early Rheumatoid Arthritis with Methotrexate and Etanercept		rheumatoid arthritis	methotrexate 8mg/week methotrexate 8mg/week and etanercept(25mg x1-2/week) for 3 months methotrexate 8mg/week and etanercept(25mgx1-2/week) for 6 months	Johoku Biological Summit		Not Recruiting	Not applicable	Not applicable	Male and Female	50	Phase 4	Japan
1642	NCT00302952	August 2006	16 December 2017	Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis	A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Lovastatin;Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Not recruiting	18 Years	70 Years	All	64	Phase 2	United States
1643	NCT00326339	August 2006	19 February 2015	Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate	Rheumatoid Arthritis	Drug: R788;Drug: Placebo	Rigel Pharmaceuticals		Not recruiting	18 Years	75 Years	Both	189	Phase 2	United States;Mexico
1644	NCT00369928	August 2006	19 October 2017	Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate	A Multicenter, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG-760564 in Adult Patients With RA Receiving Methotrexate	Rheumatoid Arthritis	Drug: PG-760564;Drug: Placebo dose	Procter and Gamble		Not recruiting	18 Years	70 Years	All	254	Phase 2	United States;Czech Republic;Hungary;Netherlands;Poland;United Kingdom
1645	NCT00732875	August 2006	16 December 2017	A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)	A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)	Arthritis, Rheumatoid	Biological: Infliximab + methotrexate (MTX)	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	75 Years	All	92	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1646	EUCTR2006-004062-13-IT	18/07/2006	19 March 2012	Randomised, open label, no profit, clinical, multicenter study of phase II and IIIB to assess efficacy and tolerability of oxycodone/paracetamol compared to anti-inflammatory non-steroidal drugs FANS and corticosteroid, in patients suffering moderate to severe chronic pain due to rheumatoid arthritis. - Do.R.A.	Randomised, open label, no profit, clinical, multicenter study of phase II and IIIB to assess efficacy and tolerability of oxycodone/paracetamol compared to anti-inflammatory non-steroidal drugs FANS and corticosteroid, in patients suffering moderate to severe chronic pain due to rheumatoid arthritis. - Do.R.A.	RHEUMATOID ARTHRITIS MedDRA version: 6.1 Level: PT Classification code 10039073	Trade Name: *DEPALGOS20+325MG 28CPR RP Pharmaceutical Form: Film-coated tablet INN or Proposed INN: OXICODONE DC.IT** CAS Number: 76-42-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- INN or Proposed INN: PARACETAMOLO DC.IT FU CAS Number: 103-90-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	A.U.S.L. RIMINI		Not Recruiting			Female: yes Male: yes	149	Phase 2	Italy
1647	NCT01272908	July 18, 2006	16 December 2017	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)	Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)	Rheumatoid Arthritis	Drug: rituximab	Hoffmann-La Roche		Not recruiting	18 Years	80 Years	All	120	Phase 3	Canada;Sweden
1648	NCT00369187	July 2006	19 February 2015	Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase		Rheumatoid Arthritis	Drug: large protein molecule	Halozyme Therapeutics		Not recruiting	18 Years	N/A	Both	15	Phase 4	United States
1649	NCT00445770	July 2006	19 October 2017	Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Multicenter, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Etanercept;Drug: Methotrexate	Pfizer		Not recruiting	20 Years	75 Years	All	550	Phase 3	Japan
1650	NCT00555542	July 2006	19 February 2015	An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis	B Cell Depletion Therapy in Rheumatoid Arthritis: An Analysis of Peripheral Blood T Cell Subsets	Rheumatoid Arthritis	Drug: rituximab	Chinese University of Hong Kong		Not recruiting	21 Years	70 Years	Both	10	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1651	NCT01685424	June 30, 2006	16 December 2017	Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)	Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis	Osteoarthritis;Rheumatoid Arthritis;Ankylosing Spondylitis;Gout;Arthritis	Drug: Etoricoxib	Merck Sharp & Dohme Corp.		Not recruiting	N/A	N/A	All	79189	N/A	United States
1652	EUCTR2004-001234-17-GB	15/06/2006	1 May 2012	Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subjects with osteoarthritis and rheumatoid arthritis at high-risk of gastrointestinal adverse events - Not Applicable	Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subjects with osteoarthritis and rheumatoid arthritis at high-risk of gastrointestinal adverse events - Not Applicable	Treatment of osteoarthritis (OA) and/or rheumatoid arthritis (RA) in high GI risk patients MedDRA version: 8.0 Level: LLT Classification code 10039073	Trade Name: Celebrex Product Name: Celebrex Product Code: not applicable Pharmaceutical Form: Capsule* INN or Proposed INN: Celecoxib CAS Number: N/A Other descriptive name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Voltrarol SR Product Name: Voltrarol SR Product Code: Not Applicable Pharmaceutical Form: Tablet INN or Proposed INN: Diclofenac sodium CAS Number: N/A Current Sponsor code: Not applicable Other descriptive name: sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Losec Product Name: Losec Product Code: not applicable Pharmaceutical Form: Capsule* INN or Proposed INN: Omeprazole CAS Number: N/A Current Sponsor code: Not applicable Other descriptive name: benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Pfizer Limited		Not Recruiting			Female: yes Male: yes	4402		Portugal;Czech Republic;United Kingdom;Estonia;Ireland;Spain;Greece;Latvia;Lithuania;Sweden
1653	EUCTR2006-001359-36-NL	02/06/2006	19 March 2012	Effects of low-dose aspirin taken at bedtime on pathophysiologic mechanisms underlying hypertension in subjects with grade 1 essential hypertension: the Aspirin In Reduction of Tension (ASPIRETENSION) study - ASPIRETENSION	Effects of low-dose aspirin taken at bedtime on pathophysiologic mechanisms underlying hypertension in subjects with grade 1 essential hypertension: the Aspirin In Reduction of Tension (ASPIRETENSION) study - ASPIRETENSION	Patients should have grade 1 essential hypertension (140/90-159/99 mmHg), but free of history of any cardiovascular events, diabetes mellitus type 1 or 2 or rheumatoid arthritis.	Trade Name: Ascal(r) / carbasalate calcium Pharmaceutical Form: Oral powder Pharmaceutical form of the placebo: Oral powder Route of administration of the placebo: Oral use	Leiden University Medical Center		Authorised			Female: yes Male: yes	15		Netherlands
1654	NCT00280917	June 2006	19 October 2017	Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CF101	Can-Fite BioPharma		Not recruiting	18 Years	75 Years	All	254	Phase 2	United States;Bulgaria;Israel;Poland;Romania;Serbia;Ukraine;Former Serbia and Montenegro
1655	NCT00345748	June 2006	19 February 2015	A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate	A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	20 Years	N/A	Both	194	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1656	NCT00424294	June 2006	19 October 2017	A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CP-195543 And Celecoxib Dual Therapy In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate	Arthritis, Rheumatoid	Drug: CP-195,543;Drug: celecoxib;Drug: Methotrexate	Pfizer		Not recruiting	18 Years	N/A	All	70	Phase 2	United States
1657	NCT00439062	June 2006	19 February 2015	Treatment of Rheumatoid Arthritis With Roxithromycin	Treatment of Rheumatoid Arthritis With Roxithromycin	Rheumatoid Arthritis	Drug: Roxithromycin	Nazilli State Hospital		Not recruiting	18 Years	70 Years	Both	100	Phase 4	Turkey
1658	NCT00443950	June 2006	19 February 2015	Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Etanercept in Chinese Subjects With Active Rheumatoid Arthritis Receiving Methotrexate	Arthritis, Rheumatoid	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	Both	150	Phase 3	China
1659	EUCTR2006-000854-32-AT	29/05/2006	19 March 2012	Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-Blockers	Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-Blockers	Rheumatoid Arthritis	Trade Name: Rituximab - MabThera Product Name: Rituximab MabThera Product Code: no Pharmaceutical Form: Solution for infusion	Vienna Medical University		Not Recruiting			Female: yes Male: yes	20		Austria
1660	EUCTR2005-001742-16-GB	26/05/2006	21 August 2012	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNFalfa Agent(s) - GO-AFTER	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNFalfa Agent(s) - GO-AFTER	Active rheumatoid arthritis (RA)	Product Name: Golimumab Liquid in Vial Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Other descriptive name: Human Anti-TNF IgG1 Monoclonal Antibody; rTNV148B IgG; Human Anti-TNFalfa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50 and-100 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Golimumab Pre-Filled Syringe Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Other descriptive name: Human Anti-TNF IgG1 Monoclonal Antibody; rTNV148B IgG; Human Anti-TNFalfa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50 and-100 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Centocor B.V.		Not Recruiting			Female: yes Male: yes	420		Germany;United Kingdom;Netherlands;Spain;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1661	EUCTR2004-003295-10-GB	17/05/2006	3 September 2012	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve Subjects with Active Rheumatoid Arthritis - NA	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve Subjects with Active Rheumatoid Arthritis - NA	Active Rheumatoid Arthritis (methotrexate [MTX]-naïve)	Product Name: Golimumab Liquid in Vial Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Other descriptive name: Human Anti-TNF IgG1 Monoclonal Antibody; rTNV148B IgG; Human Anti-TNFalfa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50 and-100 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Methotrexate sodium tablets 2.5 mg Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate sodium Other descriptive name: Methylaminopterin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Golimumab Pre-Filled Syringe Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Other descriptive name: Human Anti-TNF IgG1 Monoclonal Antibody; rTNV148B IgG; Human Anti-TNFalfa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50 and-100 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Centocor BV		Not Recruiting			Female: yes Male: yes	600		Hungary;United Kingdom;Spain;Italy
1662	NCT00298272	May 2006	19 October 2017	Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis	A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: IDEC-C2B8 (rituximab);Drug: Placebo;Drug: Methotrexate;Drug: Etanercept;Drug: Adalimumab;Drug: Methylprednisolone;Dietary Supplement: Folate	Biogen	Hoffmann-La Roche;Genentech, Inc.	Not recruiting	18 Years	65 Years	All	54	Phase 2	United States
1663	NCT00380601	May 2006	19 February 2015	Phase?Open-label Study of MRA for Rheumatoid Arthritis(RA)	An Open-label, Phase? Study to Evaluate the Efficacy and Safety of MRA in Patients With RA	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical		Not recruiting	20 Years	N/A	Both	20	Phase 3	Japan
1664	NCT00497614	May 2006	19 February 2015	Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)	18F-FDG Positron Emission Tomography to Study the Response to Adalimumab in Rheumatoid Arthritis. A Monocentric Pilot Study	Rheumatoid Arthritis	Drug: adalimumab	University Hospital, Tours		Not recruiting	18 Years	75 Years	Both	8	N/A	France
1665	NCT01078571	May 2006	19 October 2017	Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis	Safety and Effectiveness of Adalimumab (HUMIRA®) in Patients Diagnosed With Rheumatoid Arthritis (DALI Study)	Rheumatoid Arthritis	Biological: adalimumab (HUMIRA®)	Abbott		Not recruiting	18 Years	N/A	All	705	N/A	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1666	EUCTR2004-001930-18-EE	17/04/2006	21 August 2012	A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-102 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS - CRx-102-RA	A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-102 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS - CRx-102-RA	RHEUMATOID ARTHRITIS	Trade Name: Persantin 100 mg and Product Code: CRx-102 Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone & dipyridamole CAS Number: N/A Current Sponsor code: CRx-102 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1 and 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	CombinatoRx, Inc		Not Recruiting			Female: yes Male: yes	60		Estonia
1667	EUCTR2005-003558-83-CZ	07/04/2006	19 March 2012	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - AMG 108	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - AMG 108	Rheumatoid arthritis (RA)	Product Name: AMG 108 Product Code: AMG 108 Pharmaceutical Form: Solution for injection Current Sponsor code: AMG 108 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc.		Not Recruiting			Female: yes Male: yes	784		United Kingdom;Czech Republic;Netherlands;Estonia;Ireland;Spain;Italy;Latvia;Austria;Sweden
1668	EUCTR2005-005013-37-GB	06/04/2006	19 March 2012	A multi-centre randomised double dummy double blind study comparing two regimens of combination induction therapy in early DMARD naive Rheumatoid Arthritis: The IDEA study (Infliximab as Induction Therapy in Early Rheumatoid Arthritis) - IDEA	A multi-centre randomised double dummy double blind study comparing two regimens of combination induction therapy in early DMARD naive Rheumatoid Arthritis: The IDEA study (Infliximab as Induction Therapy in Early Rheumatoid Arthritis) - IDEA	Early Rheumatoid Arthritis	Trade Name: Remicade Product Name: Remicade Product Code: Infliximab Pharmaceutical Form: Powder for solution for infusion Trade Name: Mextrex Product Name: Methotrexate Product Code: Mextrex Pharmaceutical Form: Tablet INN or Proposed INN: n/a CAS Number: n/a Current Sponsor code: n/a Other descriptive name: Methotrexate Concentration unit: mol/mg mole(s)/milligram Concentration type: equal Concentration number: 10- Trade Name: Ferrograd Folic Tablets Product Name: Folic Acid Product Code: Ferrograd Pharmaceutical Form: Tablet INN or Proposed INN: n/a CAS Number: n/a Current Sponsor code: n/a Other descriptive name: Folic Acid Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 350- Trade Name: Solu-Medrone 2 Gram Product Name: Methylprednisolone Product Code: Solu-Medrone 2 Gram Pharmaceutical Form: Powder for injection* INN or Proposed INN: n/a CAS Number: n/a Current Sponsor code: n/a Other descriptive name: Methylprednisolone Concentration unit: g gram(s) Concentration type: equal Concentration number: 2- Trade Name: Solu-Medrone 2 Gram Product Name: Methylprednisolone Product Code: Solu-Medrone 2 Gram Pharmaceutical Form: Powder for infusion* INN or Proposed INN: n/a CAS Number: n/a Current Sponsor code: n/a Other descriptive name: Methylprednisolone Concentration unit: g gram(s) Concentration type: equal Concentration number: 2-	University of Leeds		Authorised			Female: yes Male: yes	112		United Kingdom
1669	NCT00303563	April 2006	14 November 2016	A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis	A Randomized, Double-blind Study to Compare the Effect of RO4402257 Monotherapy and Methotrexate Monotherapy on Disease Response in Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: P38 Inhibitor (4);Drug: Placebo	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	204	Phase 2	United States;Canada;Croatia;Czech Republic;France;Italy;Mexico;Romania;Serbia;South Africa;Spain;Taiwan;Former Serbia and Montenegro
1670	NCT00319917	April 2006	19 February 2015	A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients	FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients	Rheumatoid Arthritis	Drug: tacrolimus;Drug: placebo	Astellas Pharma Inc		Not recruiting	20 Years	64 Years	Both	123	Phase 4	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1671	EUCTR2004-003296-36-DE	29/03/2006	21 August 2012	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy - NA	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy - NA	Active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy	Product Name: Golimumab Liquid in Vial Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Other descriptive name: Human Anti-TNF IgG1 Monoclonal Antibody; rTNV148B IgG; Human Anti-TNFalfa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50 and-100 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Methotrexate sodium tablets 2.5 mg Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate sodium Other descriptive name: Methylaminopterin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Golimumab Pre-Filled Syringe Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: Golimumab Other descriptive name: Human Anti-TNF IgG1 Monoclonal Antibody; rTNV148B IgG; Human Anti-TNFalfa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50 and-100 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Centocor B.V.		Not Recruiting			Female: yes Male: yes	400		Hungary;Germany
1672	EUCTR2005-004582-41-GB	24/03/2006	19 March 2012	Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RA	Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RA	Active Rheumatoid Arthritis	Trade Name: Mabthera Product Name: Mabthera Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Arava Product Name: Arava Product Code: Leflunomide Pharmaceutical Form: Film-coated tablet Trade Name: Solu-Medrone 2 Gram Product Name: Solu-Medrone 2mg Product Code: Methylprednisolone Pharmaceutical Form: Powder for injection*	University of Leeds		Authorised			Female: yes Male: yes	15		United Kingdom
1673	EUCTR2005-003558-83-GB	21/03/2006	19 March 2012	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis	Rheumatoid arthritis (RA)	Product Code: AMG 108 Pharmaceutical Form: Solution for injection Current Sponsor code: AMG 108 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc.		Authorised			Female: yes Male: yes	784		Czech Republic;United Kingdom;Netherlands;Estonia;Ireland;Spain;Italy;Latvia;Austria;Sweden
1674	EUCTR2004-003771-37-HU	03/03/2006	19 March 2012	A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs. - HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II	A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs. - HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II	Active Rheumatoid Arthritis MedDRA version: 7.0 Level: LLT Classification code 10039073	Product Name: HuMax-CD20 Product Code: HuMax-CD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: N/A CAS Number: 679818-59-8 Current Sponsor code: HuMax-CD20 Other descriptive name: Human monoclonal antibody directed against CD20 on B-cells Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Genmab A/S		Not Recruiting			Female: yes Male: yes	230	Phase 1/2	Hungary
1675	NCT00293826	March 2006	19 February 2015	A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: AMG 108;Drug: Placebo	Amgen		Not recruiting	18 Years	70 Years	Both	813	Phase 2	United States;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Slovakia;Spain;Sweden;United Kingdom;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1676	NCT00308282	March 2006	19 February 2015	A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Patients With Rheumatoid Arthritis	Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate	Arthritis, Rheumatoid	Drug: LY2127399;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	75 Years	Both	126	Phase 2	Romania
1677	NCT00394589	March 2006	16 December 2017	Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)	Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.	Rheumatoid Arthritis	Drug: Infliximab Control;Drug: Infliximab Increased Frequency;Drug: Infliximab Increased Dose	Merck Sharp & Dohme Corp.	Integrated Therapeutics Group	Not recruiting	18 Years	N/A	All	43	Phase 3	Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey
1678	NCT00603993	March 2006	19 October 2017	Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	A Non-Randomized, Open-Label, Roll-Over Study With Self Injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Adalimumab	Abbott	Abbott Japan Co.,Ltd;Eisai Co., Ltd.	Not recruiting	20 Years	N/A	All	88	Phase 3	Japan
1679	EUCTR2004-004995-35-GB	24/02/2006	1 May 2012	A PHASE II MULTI-CENTER, RANDOMIZED, BLINDED STUDY OF 14 WEEKS DURATION COMPARING THE EFFECT OF CRx-139 PLUS DMARD THERAPY TO THAT OF STEROID PLUS DMARD THERAPY USING ACR-20 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS PARTIALLY RESPONSIVE TO THE DMARD. - CRx-139-RA	A PHASE II MULTI-CENTER, RANDOMIZED, BLINDED STUDY OF 14 WEEKS DURATION COMPARING THE EFFECT OF CRx-139 PLUS DMARD THERAPY TO THAT OF STEROID PLUS DMARD THERAPY USING ACR-20 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS PARTIALLY RESPONSIVE TO THE DMARD. - CRx-139-RA	ACTIVE RHEUMATOID ARTHRITIS	Trade Name: Paroxetine hydrochloride 10 & 20 mg and Prednisolone 1 mg BP Product Name: N/A Product Code: CRx-139 Pharmaceutical Form: Tablet INN or Proposed INN: Paroxetine & Prednisolone CAS Number: N/A Current Sponsor code: CRx-139 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10 & 20 and-1 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	CombinatoRx, Inc.		Authorised			Female: yes Male: yes	220	Phase 2	Czech Republic;Germany;United Kingdom;Denmark;Italy
1680	NCT00286689	February 3, 2006	18 December 2018	Effects of Growth Hormone in Chronically Ill Children		Hurler Syndrome;Cerebral Palsy;Juvenile Rheumatoid Arthritis;Crohn Disease;HIV Infections	Drug: Growth Hormone;Procedure: Whole body Protein turnover;Procedure: DEXA scan	University of Texas Southwestern Medical Center		Not recruiting	3 Years	17 Years	All	0	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1681	EUCTR2005-005295-32-GB	01/02/2006	18 April 2012	Trial in rheumatoid arthritis of lisinopril (TRALIS) - TRALIS	Trial in rheumatoid arthritis of lisinopril (TRALIS) - TRALIS	Rheumatoid arthritis	Trade Name: Lisinopril Product Name: Lisinopril Product Code: N/A Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Research and Development Department, Addenbrookes NHS Foundation Trust		Authorised			Female: yes Male: yes	200		United Kingdom
1682	NCT00287794	February 2006	19 February 2015	Quality of Sleep in Patients With Rheumatoid Arthritis	Study on the Quality of Sleep in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: diazepam, melatonin	Kobe University		Recruiting	17 Years	N/A	Both	1000	Phase 1	Japan
1683	NCT00296257	February 2006	19 February 2015	Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114	A Phase 2, Multi-Centre, Randomised, Double Blind, Placebo Controlled Study Evaluating the Efficacy, Safety and Pharmacokinetics of Two Doses of a Candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg Once Daily), Administered in Combination With Ongoing Methotrexate Treatment in Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis (RA)	Drug: SMP-114	Dainippon Sumitomo Pharma Europe LTd.		Not recruiting	18 Years	N/A	Both	312	Phase 2	Czech Republic;Germany;Hungary;Netherlands;Poland;United Kingdom
1684	NCT00299546	February 2006	19 October 2017	A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)	Arthritis, Rheumatoid	Drug: Placebo;Biological: Golimumab 50 mg;Biological: Golimumab 100 mg	Centocor, Inc.	Schering-Plough	Not recruiting	18 Years	N/A	All	461	Phase 3	United States;Australia;Austria;Canada;Finland;Germany;Netherlands;New Zealand;Spain;United Kingdom;France;Switzerland
1685	NCT00422383	February 2006	19 October 2017	A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)	A Randomized, Double-blind Study to Evaluate the Effect of Various Re-treatment Regimens of MabThera in Combination With Methotrexate on Treatment Response in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	378	Phase 3	Australia;Belgium;Brazil;Canada;China;Finland;France;Germany;Hungary;Italy;Netherlands;New Zealand;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;Switzerland;United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1686	NCT00502996	February 2006	19 October 2017	A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.	Multicenter Non-Comparative Expanded Access Program of to Assess Safety of Rituximab (Mab Anti Cd-20) in Patients With Rheumatoid Arthritis (Ser)	Rheumatoid Arthritis	Drug: Methotrexate;Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	246	Phase 3	Argentina;Brazil;Chile;Colombia;Ecuador;El Salvador;Mexico;Peru;Uruguay;Venezuela
1687	EUCTR2005-003694-25-ES	27/01/2006	19 March 2012	Ensayo randomizado, doble ciego, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia y seguridad de RO4402257 como monoterapia en comparación con la monoterapia de metotrexato para pacientes con artritis reumatoide activa (AR) A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoid arthritis (RA).	Ensayo randomizado, doble ciego, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia y seguridad de RO4402257 como monoterapia en comparación con la monoterapia de metotrexato para pacientes con artritis reumatoide activa (AR) A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoid arthritis (RA).	Artritis Reumatoide Rheumatoid Arthritis	Product Name: P38 (4) Map Kinase Inhibitor Product Code: RO4402257 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO4402257 Other descriptive name: P38(4) Map Kinase Inhibitor Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: P38 (4) Map Kinase Inhibitor Product Code: RO4402257 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO4402257 Other descriptive name: P38(4) Map Kinase Inhibitor Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: P38 (4) Map Kinase Inhibitor Product Code: RO4402257 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO4402257 Other descriptive name: P38(4) Map Kinase Inhibitor Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Methotrexate Sodium 2.5mg Tablets Product Name: Methotrexate Sodium 2.5mg Tablets Product Code: PL 00095/5079R Pharmaceutical Form: Tablet Other descriptive name: Methotrexate Sodium 2.5mg Tablets Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	200		Czech Republic;Spain;Italy
1688	NCT00282308	January 23, 2006	16 December 2017	A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate	A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate	Rheumatoid Arthritis	Drug: Rituximab;Drug: Methotrexate;Drug: Methylprednisone;Biological: C. albicans;Biological: Tetanus toxoid adsorbed booster vaccine;Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: Keyhole limpet hemocyanin	Genentech, Inc.		Not recruiting	18 Years	65 Years	All	103	Phase 2	United States
1689	EUCTR2005-002395-15-FI	09/01/2006	28 October 2013	A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis.	A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis.	Rheumatoid arthritis	Trade Name: MabThera 500 mg Product Name: MabThera Product Code: Ro 45-2294 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Product Name: Methotrexate Product Code: Methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: methotrexate	F. Hoffmann-La Roche Ltd.		Not Recruiting			Female: yes Male: yes	853	Phase 3	Czech Republic;Finland;Spain;Denmark;Germany;United Kingdom;Italy;Sweden
1690	EUCTR2005-004385-16-GB	03/01/2006	18 April 2012	CIRCADIAN VARIATIONS IN CYTOKINES AND THE EFFECT OF TIMED RELEASE TABLET PREDNISONE IN RHEUMATOID ARTHRITIS	CIRCADIAN VARIATIONS IN CYTOKINES AND THE EFFECT OF TIMED RELEASE TABLET PREDNISONE IN RHEUMATOID ARTHRITIS	Rheumatoid arthritis	Product Name: Prednisone Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Prednisone CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5 -	United Bristol Healthcare NHS Trust		Authorised			Female: yes Male: yes			United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1691	NCT03496831	January 1, 2006	11 June 2018	Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs	Development of a Prediction Model for the Risk of Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs	Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis	Drug: Biologic Agents	Simon Krabbe	University of Aarhus;Zealand University Hospital;University of Southern Denmark	Not recruiting	18 Years	N/A	All	7500	Phase 2
1692	NCT00234234	January 2006	19 February 2015	Predictors of the Response to Adalimumab in Rheumatoid Arthritis	Predictors of the Response to Adalimumab in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab	University Hospital, Rouen		Not recruiting	18 Years	N/A	Both	200	Phase 4	France
1693	NCT00254293	January 2006	19 October 2017	Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)	A Study to Assess the Steady-State Trough Serum Concentration, Safety, and Immunogenicity of Abatacept (BMS-188667) Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Who Are Receiving Disease Modifying Ant-Rheumatic Drugs (DMARDs)	Rheumatoid Arthritis	Drug: Abatacept or Placebo (both as IV & SC Solution);Drug: Abatacept or Placebo (both as IV & SC solution);Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	87	Phase 1/Phase 2	United States
1694	NCT00264147	January 2006	19 October 2017	Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)	A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: etoricoxib;Drug: Comparator: placebo;Drug: Comparator: diclofenac	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	761	Phase 2	Canada;Colombia;Puerto Rico;Switzerland;United States
1695	NCT00266227	January 2006	19 October 2017	A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate	Rheumatoid Arthritis	Drug: placebo;Drug: rituximab;Drug: methotrexate;Drug: folate	Genentech, Inc.		Not recruiting	18 Years	80 Years	All	559	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1696	NCT00299104	January 2006	16 December 2017	A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis	A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: folate;Drug: methotrexate;Drug: methylprednisolone;Drug: placebo;Drug: rituximab	Genentech, Inc.	Hoffmann-La Roche	Not recruiting	18 Years	80 Years	All	755	Phase 3	United States
1697	NCT00346294	January 2006	19 February 2015	An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-Injector in Subjects With Rheumatoid Arthritis	An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-Injector in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Other: Etanercept	Amgen	Immunex Corporation	Not recruiting	18 Years	N/A	Both	115	Phase 4	United States
1698	NCT00379990	January 2006	19 February 2015	A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.	A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Synovial Thickness and Vascularity of 28 Days Repeat Dosing of GW274150 or 7.5mg Prednisolone in RA Subjects.	Arthritis, Rheumatoid	Drug: GW274150;Drug: Prednisolone;Other: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	Both	48	Phase 2	Serbia;United Kingdom
1699	NCT00422942	January 2006	19 October 2017	A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)	An Open-label, Exploratory Study of the Pharmacokinetic and Pharmacodynamic Activity of MabThera in Combination With Methotrexate in Synovial Tissue and in Peripheral Blood of Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	80 Years	All	3	Phase 2	Netherlands;Spain
1700	NCT00724243	January 2006	19 October 2017	Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)	Remicade Treatment Registry in Rheumatoid Arthritis I	Rheumatoid Arthritis	Drug: Infliximab	Merck Sharp & Dohme Corp.		Not recruiting	N/A	N/A	All	33	N/A	Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1701	NCT02922192	January 2006	17 October 2016	Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis	Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis	Rheumatoid Arthritis;Inflammatory Bowel Disease;Psoriasis;Psoriatic Arthritis;Ankylosing Spondylitis	Drug: TNF-a antagonists, non-TNFs, DMARD non-biologics	Biologics & Biosimilars Collective Intelligence Consortium	HealthCore, Inc.;Aetna, Inc.;University of Alabama; Rheumatologist and Healthcare Research;AbbVie;Amgen;Boehringer Ingelheim;Group Health Cooperative;Harvard Pilgrim Health Care;Merck Sharp & Dohme Corp.;Momenta;Pfizer;UPMC;HealthCore, Inc.;Aetna, Inc.;University of Alabama; Rheumatologist and Healthcare Research;AbbVie;Amgen;Boehringer Ingelheim;Group Health Cooperative;Harvard Pilgrim Health Care;Merck Sharp & Dohme Corp.;Momenta;Pfizer;UPMC	Not recruiting	18 Years	N/A	Both	100000	N/A
1702	EUCTR2005-004530-40-AT	30/12/2005	22 April 2013	Induction of remission in RA patients at low disease activity by additional Infliximab-therapy	Induction of remission in RA patients at low disease activity by additional Infliximab-therapy	Patients with a diagnose of rheumatoid arthritis according to ACR-criteria at least 1 year (max. 10 years) prior to start of therapy with active disease: DAS 28 between 2,8 and 3,5 and a change in DAS 28 score <0.6 during the last 6 weeks before inclusion.	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder and solvent for solution for infusion	AESCA Pharma Ges.m.b.H		Not Recruiting			Female: yes Male: yes	160		Austria
1703	EUCTR2005-002396-33-ES	27/12/2005	28 August 2014	Estudio internacional, randomizado, doble ciego, para evaluar la eficacia y seguridad de diversos regímenes de retratamiento con rituximab en combinación con metotrexato, en pacientes con AR que manifiestan una respuesta inadecuada a metotrexato. A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate response to methotrexate.	Estudio internacional, randomizado, doble ciego, para evaluar la eficacia y seguridad de diversos regímenes de retratamiento con rituximab en combinación con metotrexato, en pacientes con AR que manifiestan una respuesta inadecuada a metotrexato. A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate response to methotrexate.	Artritis Reumatoide (Rheumatoid arthritis)	Trade Name: MabThera 500 mg Product Name: MabThera Product Code: Ro 45-2294 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd.		Not Recruiting			Female: yes Male: yes	375		Hungary;Slovakia;Finland;Spain;Germany;United Kingdom;Italy
1704	EUCTR2005-000902-30-GB	09/12/2005	24 April 2012	A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients	A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients	Rheumatoid arthritis	Trade Name: Prednisolone Tablets USP 5 mg Product Name: Prednisolone Tablets USP 5 mg Pharmaceutical Form: Tablet INN or Proposed INN: Prednisolone CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Limited		Authorised			Female: yes Male: yes	45		United Kingdom
1705	EUCTR2004-002482-20-GB	02/12/2005	15 July 2013	A Pilot Study to Test the Effect of Treating Depression Associated with Rueumatoid Arthritis (RA) using Venlaflaxine - Venlaflaxine & Numact Study	A Pilot Study to Test the Effect of Treating Depression Associated with Rueumatoid Arthritis (RA) using Venlaflaxine - Venlaflaxine & Numact Study	Symptoms of Depression as defined by the Hospital Anxiety and Depression Questionnaire associated with Rheumatoid Arthritis	Trade Name: Efexor XL 75 mg Product Name: Efexor XL 75 mg (venlafaxine) Product Code: NA Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: Venlafaxine Hydrochloride Concentration unit: mg milligram(s) Concentration number: 75-	Newcastle upon Tyne Hospitals NHS Trust		Not Recruiting			Female: yes Male: yes	20		United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1706	NCT00264537	December 2005	19 October 2017	A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive	A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo injections;Drug: Placebo capsules;Drug: Methotrexate capsules;Biological: Golimumab 50 mg injections;Biological: Golimumab 100 mg injections	Centocor, Inc.	Schering-Plough	Not recruiting	18 Years	N/A	All	637	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Brazil;Mexico;Turkey
1707	NCT00281294	December 2005	19 February 2015	A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis	A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Fontolizumab	PDL BioPharma, Inc.		Not recruiting	18 Years	N/A	Both	40	Phase 2	United States
1708	NCT00642629	December 2005	19 February 2015	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes		Active, Moderate to Severe Rheumatoid Arthritis	Drug: STA 5326 mesylate;Drug: Placebo	Synta Pharmaceuticals Corp.		Not recruiting	18 Years	N/A	Both	35	Phase 2	Netherlands
1709	NCT00669942	December 2005	19 October 2017	Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients	A Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients With Pharmacodynamics Assessed in an Expanded Cohort at the Maximum Tolerated Dose	Rheumatoid Arthritis	Biological: AIN457;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	75 Years	All	104	Phase 1/Phase 2	United States;Belgium;Germany;Netherlands;Singapore;Spain
1710	NCT00705289	December 2005	19 October 2017	A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)	Epidemiology, Correlation and Predictive Value of Disease Activity and Biomarkers in RA Patients Initiated on Infliximab in Clinical Practice	Rheumatoid Arthritis	Biological: Infliximab	Merck Sharp & Dohme Corp.		Not recruiting	N/A	N/A	All	728	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1711	EUCTR2005-000784-26-GB	25/11/2005	24 April 2012	A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with Methotrexate Revised Protocol 04, incorporating Protocol Amendments 05, 06, 08, 09 (V1.0 dated 18-Nov-2008) and Administrative Letter 02. Pharmacogenetics Amendment 1 dated 16-May-2005. Protocol Amendments 3 & 4 - Site Specific - dated 28-Dec-2005.	A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with Methotrexate Revised Protocol 04, incorporating Protocol Amendments 05, 06, 08, 09 (V1.0 dated 18-Nov-2008) and Administrative Letter 02. Pharmacogenetics Amendment 1 dated 16-May-2005. Protocol Amendments 3 & 4 - Site Specific - dated 28-Dec-2005.	Rheumatoid Arthritis, Nos	Trade Name: Orencia Product Name: Abatacept Product Code: BMS-188667 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Current Sponsor code: BMS-188667 Other descriptive name: CTLA4Ig Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Bristol Myers Squibb International Corporation		Authorised			Female: yes Male: yes	750	Phase 3B	Czech Republic;Germany;United Kingdom;Belgium;Spain;Ireland;Italy;Austria
1712	EUCTR2005-001889-13-SE	24/11/2005	19 March 2012	Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - Re3	Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - Re3	Adult subjects with a diagnosis of Rheumatoid Arthritis presenting with a disease flare after an initial response to infliximab MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: infliximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Schering-Plough Research Institute, a division of Schering Corporation		Not Recruiting			Female: yes Male: yes	315		Portugal;Germany;Netherlands;Denmark;Belgium;France;Greece;Sweden
1713	EUCTR2005-002392-32-IE	23/11/2005	26 June 2012	A randomised, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (MabThera/Rituxan) in combination with methotrexate, compared to methotrexate monotherapy, in patients with active rheumatoid arthritis.	A randomised, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (MabThera/Rituxan) in combination with methotrexate, compared to methotrexate monotherapy, in patients with active rheumatoid arthritis.	Active rheumatoid arthritis	Trade Name: MabThera 500 mg Product Name: MabThera Product Code: Ro 45-2294 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd.		Authorised			Female: yes Male: yes	500		Germany;United Kingdom;Slovenia;Ireland;Sweden
1714	EUCTR2005-003495-38-IE	17/11/2005	18 April 2012	A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (MTX) therapy.	A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (MTX) therapy.	Rheumatoid Arthritis	Product Name: P38 (4) Map Kinase Inhibitor Product Code: RO4402257 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO4402257 Other descriptive name: P38(4) Map Kinase Inhibitor Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: P38 (4) Map Kinase Inhibitor Product Code: RO4402257 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO4402257 Other descriptive name: P38(4) Map Kinase Inhibitor Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: P38 (4) Map Kinase Inhibitor Product Code: RO4402257 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO4402257 Other descriptive name: P38(4) Map Kinase Inhibitor Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	330		United Kingdom;Germany;Estonia;Spain;Ireland;Greece
1715	EUCTR2004-001825-69-IT	04/11/2005	19 March 2012	A Multi Center, Open label, Extension study of RA 1 using Extracoproreal photoimmune therapy with Uvadex	A Multi Center, Open label, Extension study of RA 1 using Extracoproreal photoimmune therapy with Uvadex	Rheumatoid arthritis MedDRA version: 6.1 Level: PT Classification code 10039073	Trade Name: UVADEX Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Methoxsalen Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200-	THERAKOS		Authorised			Female: yes Male: yes	68		Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1716	NCT00160641	November 2005	19 October 2017	A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis	A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050	Rheumatoid Arthritis	Biological: Certolizumab Pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	567	Phase 3	United States;Bulgaria;Croatia;Czech Republic;Estonia;Israel;Latvia;Lithuania;Poland;Russian Federation;Serbia;Slovakia;Ukraine;Former Serbia and Montenegro
1717	NCT00162292	November 2005	19 February 2015	Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background	Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background	Rheumatoid Arthritis	Drug: BMS-582949 and Methotrexate	Bristol-Myers Squibb		Not recruiting	18 Years	70 Years	Both	33	Phase 1	United States;Mexico
1718	NCT00256919	November 2005	19 February 2015	Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)	A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship	Arthritis, Rheumatoid	Drug: GW856553	GlaxoSmithKline		Not recruiting	18 Years	N/A	Both	51	Phase 2	Bulgaria;Germany;Spain;Sweden;Ukraine
1719	NCT00292422	November 2005	19 February 2015	Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis	A Randomized, Blinded, Placebo-Controlled, Multicenter, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD Therapy	Rheumatoid Arthritis	Drug: BG9924	Biogen Idec		Not recruiting	18 Years	75 Years	Both	50	Phase 2	United States;Poland
1720	NCT00316771	November 2005	14 November 2016	A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy	A Randomized, Double-blind, Placebo-controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.	Rheumatoid Arthritis	Drug: P38 Inhibitor (4) 150mg;Drug: P38 Inhibitor (4) 25mg;Drug: P38 Inhibitor (4) 300mg;Drug: P38 Inhibitor (4) 50mg;Drug: P38 Inhibitor (4) 75mg;Drug: Placebo	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	374	Phase 2	South Africa;Spain;United Kingdom;United States;Australia;Brazil;Canada;Estonia;Germany;Greece;Ireland;Mexico;New Zealand;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1721	NCT00320450	November 2005	19 February 2015	SB-681323 In Subjects With Rheumatoid Arthritis	A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: SB-681323	GlaxoSmithKline		Not recruiting	18 Years	N/A	Both	78	Phase 2	Denmark;Germany;Hong Kong;Italy;Norway;Poland;Spain;Sweden;United Kingdom;Hungary
1722	NCT00380744	November 2005	19 February 2015	A Safety and Pharmacokinetics Study in Patients With Rheumatoid Arthritis	A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: LY2189102;Drug: placebo	Eli Lilly and Company		Not recruiting	18 Years	75 Years	Both	104	Phase 1/Phase 2	United States;Poland;Argentina;Hungary;Spain
1723	EUCTR2005-003436-21-GB	26/10/2005	18 April 2012	A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg once daily), administered in combination with ongoing methotrexate treatment in patients with active rheumatoid arthritis. - ASPECTS- Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment with SMP-114	A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg once daily), administered in combination with ongoing methotrexate treatment in patients with active rheumatoid arthritis. - ASPECTS- Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment with SMP-114	Rheumatoid Arthritis MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: SMP-114 Product Code: SMP-114 Pharmaceutical Form: Tablet INN or Proposed INN: rimacalib CAS Number: 215174-50-8 Current Sponsor code: SMP-114 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Dainippon Sumitomo Pharma Europe Ltd		Not Recruiting			Female: yes Male: yes	300	Phase 2	Hungary;Czech Republic;Germany;United Kingdom
1724	EUCTR2005-002969-37-SE	14/10/2005	1 May 2012	A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. - GM2005/00244/02	A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. - GM2005/00244/02	Rheumatoid Arthritis	Product Code: GW856553 Pharmaceutical Form: Tablet Current Sponsor code: GW856553 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GW856553 Pharmaceutical Form: Tablet Current Sponsor code: GW856553 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GW856553 Pharmaceutical Form: Tablet Current Sponsor code: GW856553 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	48		Germany;Spain;Sweden
1725	NCT00141102	October 2005	19 October 2017	Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis	Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events	Osteoarthritis;Arthritis, Rheumatoid	Drug: Celecoxib;Drug: Diclofenac + Omeprazole	Pfizer		Not recruiting	18 Years	N/A	All	4484	Phase 4	Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Ecuador;Estonia;France;Germany;Greece;Guatemala;Hong Kong;India;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;Former Serbia and Montenegro;Ireland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1726	NCT00241982	October 2005	19 February 2015	Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis	Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: long-circulating liposomal prednisolone	Radboud University	Utrecht University	Not recruiting	18 Years	N/A	Both	22	Phase 2	Netherlands
1727	NCT00249041	October 2005	19 February 2015	Enbrel Liquid Immunogenicity Protocol	Open-label Study to Assess the Antibody Response to Etanercept Liquid in Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: 50 mg Etanercept;Drug: Enbrel liquid	Amgen	Immunex Corporation	Not recruiting	18 Years	N/A	Both	447	Phase 3	United States;Canada
1728	NCT00299130	October 2005	16 December 2017	A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis	A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Folate;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Placebo;Drug: Rituximab	Genentech, Inc.	Hoffmann-La Roche	Not recruiting	18 Years	80 Years	All	511	Phase 3	United States
1729	EUCTR2005-002326-63-LT	21/09/2005	19 March 2012	A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients with Active Rheumatoid Arthritis who have an Incomplete Response to Methotrexate.	A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients with Active Rheumatoid Arthritis who have an Incomplete Response to Methotrexate.	Rheumatoid Arthritis Classification code 10039073	Product Name: Certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Solution for injection INN or Proposed INN: Certolizumab pegol Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	UCB Celltech		Not Recruiting			Female: yes Male: yes	590	Phase 3	Czech Republic;Estonia;Latvia;Lithuania
1730	EUCTR2005-002909-23-ES	21/09/2005	26 June 2012	Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. Estudio de extensión, a largo plazo, de la seguridad durante el tratamiento con tocilizumab (MRA) en pacientes con artritis reumatoide que hayan terminado el tratamiento en estudios trocales con MRA	Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. Estudio de extensión, a largo plazo, de la seguridad durante el tratamiento con tocilizumab (MRA) en pacientes con artritis reumatoide que hayan terminado el tratamiento en estudios trocales con MRA	Rheumatoid arthritis	Product Name: MRA Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: RO4877533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	F Hoffmann La-Roche AG		Not Recruiting			Female: yes Male: yes	2420		Portugal;Finland;United Kingdom;Czech Republic;Germany;Iceland;Slovenia;Denmark;Spain;Italy;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1731	EUCTR2005-002421-31-GB	16/09/2005	24 April 2012	A phase II randomized, double-blind, multicentre, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate	A phase II randomized, double-blind, multicentre, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate	Rheumatoid arthritis Level: PT Classification code 10039073	Product Name: AD 452 4.5 mg Tablet Pharmaceutical Form: Tablet CAS Number: 51742-86-0 Current Sponsor code: AD 452 Other descriptive name: (+) erythromefloquine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: AD 452 9 mg tablet Pharmaceutical Form: Tablet CAS Number: 51742-86-0 Current Sponsor code: AD 452 Other descriptive name: (+)erythromefloquine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: AD 452 18 mg tablet Pharmaceutical Form: Tablet CAS Number: 51742-86-0 Current Sponsor code: AD 452 Other descriptive name: (+)erythromefloquine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Arakis Ltd		Authorised			Female: yes Male: yes	292	Phase 2	Germany;United Kingdom
1732	EUCTR2005-001977-82-GB	09/09/2005	24 April 2012	A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects	A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects	Rheumatoid arthritis	Product Name: GW274150 Tablets Product Code: GW274150 Pharmaceutical Form: Tablet Current Sponsor code: GW274150 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Deltacortril Enteric Product Name: Prednisolone Pharmaceutical Form: Tablet INN or Proposed INN: Prednisolone Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Limited		Authorised			Female: yes Male: yes	45		United Kingdom
1733	EUCTR2005-002219-26-SE	08/09/2005	19 March 2012	A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA)	A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA)	Rheumatoid arthritis (RA)	Product Name: SB-681323 Tablets Product Code: SB-681323 Pharmaceutical Form: Tablet Current Sponsor code: SB-681323 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2,5 and 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	GlaxoSmithKline R&D Ltd		Not Recruiting			Female: yes Male: yes	82		Hungary;United Kingdom;Germany;Norway;Spain;Italy;Sweden
1734	EUCTR2005-002423-13-DE	06/09/2005	7 August 2012	Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA17822	Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA17822	Rheumatoid arthritis	Trade Name: RoActemra Product Name: MRA Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: R04877533 Other descriptive name: MRA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	630		Hungary;Slovakia;Germany;Bulgaria;Italy
1735	EUCTR2005-000551-15-GB	05/09/2005	3 April 2017	Effect of folic acid supplementation and allopurinol on endothelial function in patients with rheumatoid arthritis treated with methotrexate - Endothelial function in rheumatoid arthritis patients on methotrexate	Effect of folic acid supplementation and allopurinol on endothelial function in patients with rheumatoid arthritis treated with methotrexate - Endothelial function in rheumatoid arthritis patients on methotrexate	Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory polyarthritis associated with excess cardiovascular (CV) mortality. Hyperhomocysteinaemia is recognized as an independent CV risk factor and homocysteine levels are frequently elevated in RA patients. Endothelial dysfunction is considered a marker of early atherosclerotic disease and seems to correlate well with future increase CV risk. RA patients are known to have endothelial dysfunction.	Product Name: Allopurinol Product Code: Allopurinol Pharmaceutical Form: Capsule* INN or Proposed INN: Allopurinol CAS Number: 315-30-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Folic acid Product Code: Folic acid Pharmaceutical Form: Capsule* INN or Proposed INN: Folic acid CAS Number: 59-30-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	University of Dundee		Not Recruiting			Female: yes Male: yes		Phase 4	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1736	EUCTR2004-005102-68-GB	01/09/2005	1 May 2012	A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have An Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options. Revised Protocol 3 incorporating amendments 2, 3 and 8. Protocol Amendments 1 & 5.	A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have An Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options. Revised Protocol 3 incorporating amendments 2, 3 and 8. Protocol Amendments 1 & 5.	RHEUMATOID ARTHRITIS,NOS	Product Name: Abatacept Product Code: BMS-188667 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Current Sponsor code: BMS-188667 Other descriptive name: CTLA4Ig Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-	Bristol-Myers Squibb International Corporation		Authorised			Female: yes Male: yes	750	Phase 3	Czech Republic;Germany;United Kingdom;Belgium;Spain;Ireland;Italy
1737	NCT00466037	September 2005	19 February 2015	The Effect of Rituximab on the Humoral Response to Influenza Vaccine	Vaccination Against Influenza in Rheumatoid Arthritis Patients: The Effect of Rituximab on the Humoral Response	Rheumatoid Arthritis	Biological: Influenza vaccine	Tel-Aviv Sourasky Medical Center		Not recruiting	18 Years	85 Years	Both	64	N/A
1738	NCT00691028	September 2005	19 October 2017	Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis	Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TA-650 3 mg/kg;Drug: TA-650 6 mg/kg;Drug: TA-650 10 mg/kg	Mitsubishi Tanabe Pharma Corporation		Not recruiting	20 Years	75 Years	All	327	Phase 3
1739	EUCTR2005-001633-14-DK	17/08/2005	19 March 2012	Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira?) 40 mg s.c. eow versus infliximab (Remicade?) 3 mg/kg i.v. every 6. week in RA patients with unsustainable clinical response to infliximab 3 mg/kg every 8. week - The SWITCH Study	Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira?) 40 mg s.c. eow versus infliximab (Remicade?) 3 mg/kg i.v. every 6. week in RA patients with unsustainable clinical response to infliximab 3 mg/kg every 8. week - The SWITCH Study	Rheumatoid arthritis	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Injection* Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Injection*	Hvidovre Hospital, Dept. Rheumatology		Authorised			Female: yes Male: yes	112		Denmark;Sweden
1740	NCT00111410	August 2005	22 August 2016	Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)	A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Anakinra (r-metHuIL-1ra)	Amgen		Not recruiting	18 Years	74 Years	Both		Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1741	NCT00141830	August 2005	19 February 2015	Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	Rheumatoid Arthritis	Drug: Methotrexate plus ERB-041 for 12 weeks;Drug: Placebo for 12 weeks	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	80 Years	Both	159	Phase 2	United States;Canada;Hungary;Italy;Mexico;Spain
1742	NCT00141934	August 2005	19 February 2015	A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.	Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.	Rheumatoid Arthritis	Drug: AD 452	Sosei		Not recruiting	18 Years	75 Years	Both	232	Phase 2	United States
1743	NCT00243412	August 2005	19 October 2017	A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate	A Double-Blind, Randomized, Multicenter, Phase II Study of the Safety and Efficacy of Two Rituximab Regimens in Subjects With Moderate to Severe Active Rheumatoid Arthritis Receiving Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: folate;Drug: methotrexate;Drug: methylprednisolone;Drug: Placebo;Drug: Rituximab	Genentech, Inc.		Not recruiting	18 Years	65 Years	All	42	Phase 2	United States
1744	NCT00370435	August 2005	16 December 2017	Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)	An Open-label, Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of 90mg of GW274150 in Adult and Elderly RA Subjects.	Arthritis, Rheumatoid	Drug: GW274150	GlaxoSmithKline		Not recruiting	50 Years	N/A	All	6	Phase 2	United Kingdom
1745	NCT00508768	August 2005	19 February 2015	A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid Arthritis	A Randomized, Double-Blind, Parallel-Group, Pharmacokinetic Study of Oral SCIO-469 (90 mg qd and 30 mg Tid) in Female Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Oral SCIO-469 capsule	Scios, Inc.		Not recruiting	18 Years	N/A	Female	16	Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1746	EUCTR2005-001319-23-HU	22/07/2005	19 March 2012	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	Rheumatoid arthritis	Product Name: ERB-041 Product Code: ERB-041 Pharmaceutical Form: Capsule* INN or Proposed INN: Not available CAS Number: 524684-52-4 Current Sponsor code: ERB-041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: ERB-041 Product Code: ERB-041 Pharmaceutical Form: Capsule* INN or Proposed INN: Not available CAS Number: 524684-52-4 Current Sponsor code: ERB-041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: ERB-041 Product Code: ERB-041 Pharmaceutical Form: Capsule* INN or Proposed INN: Not available CAS Number: 524684-52-4 Current Sponsor code: ERB-041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development		Not Recruiting			Female: yes Male: yes	260		Hungary;Spain;Italy
1747	EUCTR2004-002215-80-HU	20/07/2005	19 March 2012	A Double-Blind, Parallel, Randomized Extension Trial to Evaluate Safety and Efficacy of TMI-005 (Apratastat) in Subjects with Rheumatoid Arthritis on Methotrexate Who Have Completed Protocol 3140A1-200-WW	A Double-Blind, Parallel, Randomized Extension Trial to Evaluate Safety and Efficacy of TMI-005 (Apratastat) in Subjects with Rheumatoid Arthritis on Methotrexate Who Have Completed Protocol 3140A1-200-WW	Rheumatoid Arthritis	Product Name: TMI-005 (WAY-177005) Product Code: TMI-005 (WAY-177005) Pharmaceutical Form: Capsule* INN or Proposed INN: Not yet established CAS Number: 287405-51-0 Current Sponsor code: TMI-005 Other descriptive name: WAY-177005 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: TMI-005 (WAY-177005) Product Code: TMI-005 (WAY-177005) Pharmaceutical Form: Capsule* INN or Proposed INN: Not yet established CAS Number: 287405-51-0 Current Sponsor code: TMI-005 Other descriptive name: WAY-177005 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: TMI-005 (WAY-177005) Product Code: TMI-005 (WAY-177005) Pharmaceutical Form: Capsule* INN or Proposed INN: Not yet established CAS Number: 287405-51-0 Current Sponsor code: TMI-005 Other descriptive name: WAY-177005 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development		Authorised			Female: yes Male: yes	360		Hungary
1748	EUCTR2005-000158-61-GB	18/07/2005	9 October 2012		A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in Adults with Rheumatoid Arthritis -	Rheumatoid Arthritis MedDRA version: 7.1 Level: LLT Classification code 10039073	Product Name: GW406381 Product Code: GW406381X Pharmaceutical Form: Capsule, hard CAS Number: 221148-46-5 Current Sponsor code: GW406381 Other descriptive name: GW406381X Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GW406381 Product Code: GW406381X Pharmaceutical Form: Capsule, hard CAS Number: 221148-46-5 Current Sponsor code: GW406381 Other descriptive name: GW406381X Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GW406381 Product Code: GW406381X Pharmaceutical Form: Capsule, hard CAS Number: 221148-46-5 Current Sponsor code: GW406381 Other descriptive name: GW406381X Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: GW406381 Product Code: GW406381X Pharmaceutical Form: Capsule, hard CAS Number: 221148-46-5 Current Sponsor code: GW406381 Other descriptive name: GW406381X Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Celebrex 200 mg capsule, hard Product Name: Celecoxib Pharmaceutical Form: Capsule, hard INN or Proposed INN: Celecoxib CAS Number: 169590-42-5 Current Sponsor code: Celecoxib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	2210	Phase 3	Hungary;Germany;Czech Republic;United Kingdom;Denmark;Estonia;Ireland;Spain;Italy;Latvia;Lithuania
1749	EUCTR2005-001138-33-LT	14/07/2005	11 February 2013	A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate (MTX) monotherapy, in patients with active rheumatoid arthritis.	A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate (MTX) monotherapy, in patients with active rheumatoid arthritis.	Rheumatoid Arthritis MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis	Product Name: MRA Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: R04877533 Other descriptive name: MRA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Product Name: Methotrexate sodium Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate sodium CAS Number: 15475-56-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	F. Hoffmann La-Roche AG		Not Recruiting			Female: yes Male: yes	650		Portugal;Slovenia;Spain;Lithuania;Denmark;Norway;Italy
1750	NCT00109408	July 2005	14 November 2016	A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis	A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Monotherapy Versus Methotrexate Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	673	Phase 3	United States;Argentina;Australia;Canada;China;Denmark;France;Israel;Italy;Lithuania;Mexico;Norway;Peru;Portugal;Serbia;Slovenia;South Africa;Spain;Croatia;Former Serbia and Montenegro
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1751	NCT00122382	July 2005	19 October 2017	Remission and Joint Damage Progression in Early Rheumatoid Arthritis	A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: placebo;Drug: methotrexate	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	1052	Phase 3	United States;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;Austria;Ireland
1752	NCT00503425	June 30, 2005	16 December 2017	A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.	An Open Label Study to Assess the Safety and Effect on Disease Activity of MabThera in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With DMARDs and/or One Anti-TNF Alpha Agent	Rheumatoid Arthritis	Drug: Rituximab [MabThera/Rituxan]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	215	Phase 3	Israel
1753	EUCTR2004-005115-29-GB	24/06/2005	19 March 2012	A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship	A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship	Rheumatoid arthritis	Product Name: SB-681323 Tablets Product Code: SB-681323 Pharmaceutical Form: Tablet Current Sponsor code: SB-681323 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: SB-681323 Tablets Product Code: SB-681323 Pharmaceutical Form: Tablet Current Sponsor code: SB-681323 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Prednisolone Tablets BP Product Name: Overencapsulated Prednisolone Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolone CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10 (2x5)- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Authorised			Female: yes Male: yes	77		Germany;United Kingdom
1754	NCT00134693	June 21, 2005	16 December 2017	A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis	A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship	Arthritis, Rheumatoid	Drug: Prednisolone;Drug: SB-681323	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	77	Phase 2	Australia;France;Germany;Russian Federation;United Kingdom
1755	EUCTR2005-000549-13-CZ	15/06/2005	19 March 2012	A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - VeRA	A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - VeRA	rheumatoid arthritis	Product Code: VX-702 Pharmaceutical Form: Tablet Current Sponsor code: VX-702 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Current Sponsor code: VX-702 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Vertex Pharmaceuticals Incorporated		Not Recruiting			Female: yes Male: yes	300		Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1756	EUCTR2004-002846-36-DE	14/06/2005	19 March 2012	A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS - N/A	A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS - N/A	Rheumatoid Arthritis MedDRA version: 7.1 Level: LLT Classification code 10039073	Product Name: CP690,550 Product Code: CP690,550 Pharmaceutical Form: Tablet INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: CP690,550 Other descriptive name: (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: CP690,550 Product Code: CP690,550 Pharmaceutical Form: Tablet INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: CP690,550 Other descriptive name: (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Pfizer Pharma GmbH		Not Recruiting			Female: yes Male: yes	312	Phase 2A	Germany;Spain;Italy
1757	EUCTR2005-000884-25-DE	14/06/2005	24 April 2012	A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis and an inadequate response to previous anti-TNF therapy.	A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis and an inadequate response to previous anti-TNF therapy.	Rheumatoid Arthritis	Product Name: MRA Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: R04877533 Other descriptive name: MRA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche AG		Not Recruiting			Female: yes Male: yes	450		United Kingdom;Germany;Iceland;Italy;Sweden
1758	NCT00202852	June 1, 2005	16 December 2017	A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)	A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate	Arthritis, Rheumatoid	Other: Placebo;Drug: MTX;Biological: Infliximab	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	75 Years	All	143	Phase 3	Korea, Republic of
1759	NCT00113308	June 2005	16 December 2017	COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis	A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GW406381	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	2208	Phase 3	United States;Argentina;Austria;Belgium;Bulgaria;Canada;Chile;Costa Rica;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic;Estonia;Lithuania;Pakistan;Slovakia;Taiwan
1760	NCT00205478	June 2005	19 February 2015	Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702	A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: VX-702	Vertex Pharmaceuticals Incorporated		Not recruiting	18 Years	75 Years	Both	300	Phase 2	Bulgaria;Croatia;Czech Republic;Former Serbia and Montenegro;Poland;Russian Federation;Slovakia;Slovenia;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1761	NCT00233558	June 2005	19 February 2015	Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis	Multicentre, Randomised, Open Label Study Comparing a “Scheduled Steroid Reduction Strategy” Versus a Free Steroid Reduction Strategy (Physician’s Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months	Rheumatoid Arthritis	Drug: adalimumab (up to 9 months exposure);Drug: methotrexate	Abbott		Not recruiting	18 Years	N/A	Both	160	Phase 4	United States
1762	NCT00688103	June 2005	19 October 2017	Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan	Efficacy and Safety of Etanercept in Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan	Rheumatoid Arthritis	Drug: ETN Alone;Drug: ETN+MTX	Japan Biological Agent Study Integrated Consortium		Not recruiting	18 Years	N/A	All	151	Phase 4	Japan
1763	EUCTR2005-001350-24-SK	31/05/2005	27 February 2017	A Phase III multi-centre, open-label, follow-on study to CDP870-027, to assess the efficacy and safety of lyophilised CDP870 an engineered human anti-TNF PEG conjugate, dosed subcutaneously at 400 mg every two weeks as additional medication to methotrexate, in the treatment of signs and symptoms and preventing structural damage in patients with active rheumatoid arthritis - Follow-on study for CDP870-027	A Phase III multi-centre, open-label, follow-on study to CDP870-027, to assess the efficacy and safety of lyophilised CDP870 an engineered human anti-TNF PEG conjugate, dosed subcutaneously at 400 mg every two weeks as additional medication to methotrexate, in the treatment of signs and symptoms and preventing structural damage in patients with active rheumatoid arthritis - Follow-on study for CDP870-027	Rheumatoid arthritis Classification code 10039073	Product Name: CDP870 Product Code: CDP870 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Certolizumab pegol CAS Number: 428863-50-7 Current Sponsor code: CDP870 Other descriptive name: CDP870 Fab'-PEG Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 150 + or --15	UCB Celltech		Not Recruiting			Female: yes Male: yes	800	Phase 3	Estonia;Hungary;Czech Republic;Slovakia;Finland;Lithuania;Latvia
1764	EUCTR2004-002620-18-DE	13/05/2005	1 May 2012	A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory Arthritis at High Risk for the Development of Rheumatoid Arthritis. Revised protocol 2, dated 02-Feb-06, incorporating Amendments 02 and 03; and Pharmacogenetics Blood Sample Amendment Number 01	A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory Arthritis at High Risk for the Development of Rheumatoid Arthritis. Revised protocol 2, dated 02-Feb-06, incorporating Amendments 02 and 03; and Pharmacogenetics Blood Sample Amendment Number 01	Rheumatoid Arthritis, NOS	Product Name: Abatacept Product Code: BMS-188667 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Current Sponsor code: BMS-188667 Other descriptive name: CTLA4Ig Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Bristol-Myers Squibb International Corporation		Not Recruiting			Female: yes Male: yes	250		United Kingdom;Germany;Belgium;Spain;Italy
1765	EUCTR2005-000549-13-SK	03/05/2005	27 February 2017	A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - VeRA	A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - VeRA	rheumatoid arthritis	Product Code: VX-702 Pharmaceutical Form: Tablet Current Sponsor code: VX-702 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Current Sponsor code: VX-702 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Vertex Pharmaceuticals Incorporated		Not Recruiting			Female: yes Male: yes	300	Phase 2	Czech Republic;Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1766	NCT00106522	May 2005	14 November 2016	A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy	A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Placebo;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	499	Phase 3	United States;Australia;Belgium;Canada;France;Germany;Iceland;Italy;Mexico;Netherlands;Puerto Rico;Sweden;Switzerland;United Kingdom
1767	NCT00115219	May 2005	19 February 2015	Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)	A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)	Rheumatoid Arthritis	Drug: Etanercept	Amgen		Not recruiting	18 Years	N/A	Both	200	Phase 4	United States
1768	NCT00419809	May 2005	19 February 2015	SB-681323-Methotrexate Interaction Study	A Placebo Controlled Study to Evaluate the Safety and Tolerability of Repeat Doses of SB-681323 in Patients Receiving Methotrexate for Rheumatoid Arthritis.	Arthritis, Rheumatoid	Drug: SB-681323 oral tablets	GlaxoSmithKline		Not recruiting	18 Years	75 Years	Both	18	Phase 1	Australia
1769	NCT00432484	May 2005	19 February 2015	Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis	Lingzhi (Ganoderma Lucidum) and Sen Miao San Supplementation in Rheumatoid Arthritis(RA): An Animal Model and A Phase I Study	Rheumatoid Arthritis	Drug: Lingzhi and Sen Miao San	Chinese University of Hong Kong		Not recruiting	18 Years	N/A	Both	70	Phase 2	China
1770	EUCTR2004-005210-37-SE	26/04/2005	19 March 2012	A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.	A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.	Rheumatoid Arthritis	Product Name: MRA Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Current Sponsor code: R04877533 Other descriptive name: MRA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann La-Roche AG		Not Recruiting			Female: yes Male: yes	1200		Finland;Czech Republic;Germany;Spain;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1771	EUCTR2005-000674-43-GB	06/04/2005	3 April 2012	AN OPEN LABEL STUDY OF THE EFFECT OF TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: Clinical, radiological, synovial and immunological outcomes - Rituximab in Rheumatoid Arthritis	AN OPEN LABEL STUDY OF THE EFFECT OF TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: Clinical, radiological, synovial and immunological outcomes - Rituximab in Rheumatoid Arthritis	Rheumatoid Arthritis	Trade Name: Mabthera Product Name: Mabthera Product Code: N/A Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: n/a CAS Number: n/a Current Sponsor code: n/a Other descriptive name: none Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	University of Leeds		Authorised			Female: yes Male: yes	15		United Kingdom
1772	NCT00106574	April 2005	14 November 2016	A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	1220	Phase 3	United States;Argentina;Australia;Brazil;Canada;China;Costa Rica;Czech Republic;Finland;France;Germany;Hong Kong;Mexico;Panama;Russian Federation;South Africa;Spain;Sweden;Thailand
1773	NCT00124982	April 2005	19 October 2017	Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy	A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options	Rheumatoid Arthritis	Drug: Abatacept;Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD);Drug: Anti-Tumor Necrosing Factor (TNF) Therapy	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	1286	Phase 3	United States;Belgium;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;Canada
1774	NCT01745055	April 2005	19 October 2017	Co-Administration Of Methotrexate And CP-690,550	A Phase 1, Open Label Study Of The Pharmacokinetics Of Multiple Doses Of Oral CP-690,550 And Single Doses Of Oral Methotrexate In Rheumatoid Arthritis Subjects	Rheumatoid Arthritis	Drug: CP-690,550 (tofacitinib);Drug: Methotrexate (MTX)	Pfizer		Not recruiting	18 Years	70 Years	All	12	Phase 1	United States
1775	EUCTR2004-004022-27-ES	24/03/2005	19 March 2012	Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.	Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.	Rhematoid Arthritis Classification code 10039073	Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	F.Hoffmann - La Roche Ltd		Authorised			Female: yes Male: yes	160	Phase 2a	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1776	EUCTR2004-003733-14-FI	23/03/2005	1 May 2012	A study investigating whether tocilizumab (study drug) prevents joint damage, and how safe it is, in patients with moderate to severe rheumatoid arthritis randomly divided to groups receiving treatment with tocilizumab and methotrexate or methotrexate and placebo.	A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis. - LITHE	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Product Name: Tocilizumab Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Tocilizumab CAS Number: 375823-41-9 Current Sponsor code: R04877533 Other descriptive name: IL-6 receptor inhibitor, recombinant humanized monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann La-Roche Ltd.		Authorised			Female: yes Male: yes	1170		France;Norway;Italy;Australia;Brazil;South Africa;Finland;Denmark;Mexico;China;Spain;United States;Greece;Poland
1777	EUCTR2005-000129-47-SE	21/03/2005	19 March 2012	The effect of Adalimumab (Humira) on vascular abnormalities in rheumatoid arthritis. A pilot study.	The effect of Adalimumab (Humira) on vascular abnormalities in rheumatoid arthritis. A pilot study.	Rheumatoid Arthritis.	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Dept. of Rhematology UMAS		Not Recruiting			Female: yes Male: yes	15		Sweden
1778	NCT00144586	March 2005	19 February 2015	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA220JP or MRA221JP	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical		Not recruiting	20 Years	75 Years	Both	42	Phase 3
1779	NCT00503503	March 2005	19 February 2015	Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan	Safety and Efficacy From Large Scale All Cases Surveillance for Etanercept in Japan	Rheumatoid Arthritis	Drug: Enbrel (etanercept)	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	11 Years	90 Years	Both		Phase 4
1780	EUCTR2004-002993-49-HU	11/02/2005	9 October 2012		A Phase III multicentre, double blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilised CDP870 given subcutaneously as additional medication to methotrexate in the treatment of signs and symptoms and preventing structural damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate. - CDP870 signs and symptoms and structural damage study	Rheumatoid Arthritis Classification code 10039073	Product Name: CDP870 Product Code: CDP870 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: certolizumab pegol CAS Number: 428863-50-7 Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 150-+ or - 15 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Celltech R&D Ltd		Not Recruiting			Female: yes Male: yes	950	Phase 3	Finland;Hungary;Czech Republic;Germany;Estonia;Latvia;Sweden;Lithuania
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1781	EUCTR2004-004893-96-GB	04/02/2005	1 May 2012	Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis	Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis	Patients with medical diagnosis of Rheumatoid Arthritis	Trade Name: Dalacin C phosphate Product Name: Clindamycin Pharmaceutical Form: Intravenous infusion Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use Trade Name: Tetraccycline Product Name: Tetraccycline-hydrochloride Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Hammersmith Hospitals NHS trust		Authorised			Female: yes Male: yes			United Kingdom
1782	EUCTR2004-001909-10-GB	02/02/2005	15 July 2013	Effect of Rosuvastatin on surrogate markers for cardiovascular events and joint disease progression in patients with rheumatoid arthritis - RORA trial	Effect of Rosuvastatin on surrogate markers for cardiovascular events and joint disease progression in patients with rheumatoid arthritis - RORA trial	Rheumatoid Arthritis	Trade Name: rosuvastatin Product Name: rosuvastatin Product Code: ZD 4522 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	University of Dundee		Not Recruiting			Female: yes Male: yes			United Kingdom
1783	NCT00095147	February 2005	19 October 2017	Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis	A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB);Drug: Infliximab (INF) + MTX, DB;Drug: Placebo (PLA) + MTX, DB;Drug: PLA + MTX switched to ABA+ MTX, DB;Drug: ABA, open-label (OL)	Bristol-Myers Squibb		Not recruiting	18 Years	75 Years	All	431	Phase 3	United States;Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland
1784	NCT00105976	February 2005	19 February 2015	Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)	A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: MM-093	Merrimack Pharmaceuticals		Not recruiting	18 Years	80 Years	Both	260	Phase 2	United States
1785	NCT00124449	February 2005	19 October 2017	Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients	A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA	Arthritis, Rheumatoid	Drug: Abatacept;Drug: placebo	Bristol-Myers Squibb		Not recruiting	18 Years	75 Years	All	56	Phase 2	United States;Australia;Belgium;France;Germany;Italy;Mexico;Puerto Rico;Spain;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1786	NCT00144560	February 2005	19 February 2015	Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)	An Open-Label, Clinical Pharmacology Study to Investigate Drug-Drug Interaction in Patients With RA	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical		Not recruiting	20 Years	75 Years	Both	31	N/A
1787	NCT00291928	February 2005	19 February 2015	HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II	A Double-blind, Randomized, Placebo Controlled, Dose Escalation, Multi-centerphase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20antibody, in Patients With Active Rheumatoid Arthritis Who Have Previously Failedone or More Disease Modifying Anti-rheumatic Drugs	Arthritis, Rheumatoid	Drug: Part A;Drug: Part B	GlaxoSmithKline		Not recruiting	18 Years	N/A	Both	201	Phase 2	United States;Denmark;Finland;France;Hungary;Poland;United Kingdom
1788	NCT00423358	February 2005	19 October 2017	Treatment of Hypovitaminosis D in Rheumatoid Arthritis	Treatment of Hypovitaminosis D in Rheumatoid Arthritis	Rheumatoid Arthritis;Hypovitaminosis D	Dietary Supplement: Vitamin D;Dietary Supplement: placebo	University of Wisconsin, Madison	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	18 Years	90 Years	All	22	N/A	United States
1789	NCT00522184	February 2005	19 February 2015	Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study	Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis	Rheumatoid Arthritis	Procedure: intra-articular injection of etanercept;Procedure: intra-articular injection of steroid	Centre Hospitalier Universitaire de Nice	Wyeth is now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	Both	34	Phase 3	France
1790	EUCTR2004-004302-24-FI	18/01/2005	19 March 2012	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000883191 in Rheumatoid Arthritis - Efficacy, Tolerability, and Satety Study in Rheumatoid Arthritis	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000883191 in Rheumatoid Arthritis - Efficacy, Tolerability, and Satety Study in Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 7.0 Level: LLT Classification code 10039073	Product Name: L-000883191 Product Code: L-000883191 Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: NA Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Paracetamol Product Name: Paracetamol Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: 103-90-2 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 325-	Suomen MSD Oy		Not Recruiting			Female: yes Male: yes	136		Finland;Czech Republic;Germany;Spain;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1791	NCT00106548	January 2005	19 February 2015	A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Placebo;Drug: Methotrexate	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	623	Phase 3	Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;France;Germany;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Switzerland;Thailand;Spain
1792	NCT00123149	January 2005	3 October 2016	Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis	An Open-Label (OL) Extension Study to Assess Safety of PROCRIT (Epoetin Alfa) in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis (RA)	Anemia;Rheumatoid Arthritis	Drug: Epoetin alfa	Ortho Biotech Products, L.P.		Not recruiting	18 Years	99 Years	Both	0	Phase 2
1793	NCT00132769	January 2005	19 October 2017	A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)	A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK-0873 in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MK-0873;Drug: Comparator: Placebo	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	65 Years	All	106	Phase 2	Belgium;Canada;Czech Republic;Finland;Germany;Italy;Norway;Spain;Switzerland
1794	NCT00144573	January 2005	19 February 2015	Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment	An Open-Label, Clinical Pharmacology Study to Evaluate the Safety and PK of MRA in Patients With RA With Renal Impairment	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical		Not recruiting	20 Years	75 Years	Both	14	N/A
1795	NCT00147498	January 2005	19 October 2017	Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP-690,550;Other: Placebo	Pfizer		Not recruiting	18 Years	70 Years	All	264	Phase 2	United States;Belgium;Brazil;Canada;Germany;Italy;Mexico;Slovakia;Spain;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1796	NCT00246168	January 2005	19 February 2015	ULTRACET (Tramadol Hydrochloride and Acetaminophen) for the Treatment of Rheumatoid Arthritis Pain.	ULTRACET (Tramadol Hydrochloride and Acetaminophen) add-on Therapy for the Treatment of the Pain of Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Study	Arthritis, Rheumatoid	Drug: tramadol hydrochloride + acetaminophen	Janssen Korea, Ltd., Korea		Not recruiting	18 Years	79 Years	Both	277	Phase 4
1797	NCT00365001	January 2005	19 February 2015	A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.	A Randomized, Open-label Study to Assess the Pharmacokinetics of Simvastatin and Methotrexate in Combination With Tocilizumab in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Methotrexate;Drug: Simvastatin	Hoffmann-La Roche		Not recruiting	18 Years	75 Years	Both	23	Phase 1	United States;New Zealand
1798	NCT00583557	January 2005	19 October 2017	A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01	A Multi-Center, Open-Label, Continuation Trial of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) Who Completed the Phase 2 Protocol LBRA01	Rheumatoid Arthritis	Drug: belimumab	Human Genome Sciences Inc.		Not recruiting	18 Years	N/A	All	155	Phase 2	United States;Poland
1799	EUCTR2005-000492-18-IT	16/12/2004	19 March 2012	Insulin resistance and endothelial dysfunction TNF-Alpha dependent in patients with rheumatoid arthritis or metabolic syndrome	Insulin resistance and endothelial dysfunction TNF-Alpha dependent in patients with rheumatoid arthritis or metabolic syndrome	Metabolic Syndrome and Rheumatoid Arthritis MedDRA version: 6.1 Level: SOC Classification code 10021428	Trade Name: *REMICADEEV F 100MG+F 2ML Pharmaceutical Form: Solution for injection INN or Proposed INN: Infliximab** CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI		Not Recruiting			Female: yes Male: yes			Italy
1800	EUCTR2004-000922-59-SE	01/12/2004	19 March 2012	A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination with Methotrexate in Controlling Disease Activity in Subjects with Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate. Revised Protocol 1 , incorporating Amendment 02 (v5.0). Pharmacogenomic Amendment 01. Protocol Amendment 03 - Long-Term Extension. Protocol Amendment 05 - Long Term Extension Site Specific (V2.0, Date 23-Dec-2006).	A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination with Methotrexate in Controlling Disease Activity in Subjects with Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate. Revised Protocol 1 , incorporating Amendment 02 (v5.0). Pharmacogenomic Amendment 01. Protocol Amendment 03 - Long-Term Extension. Protocol Amendment 05 - Long Term Extension Site Specific (V2.0, Date 23-Dec-2006).	Rheumatoid Arthrithis, Nos	Product Name: Abatacept Product Code: BMS-188667 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Current Sponsor code: BMS-188667 Other descriptive name: CTLA4Ig Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Infliximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Bristol Myers Squibb International Corporation		Not Recruiting			Female: yes Male: yes	660	Phase 3	Czech Republic;Denmark;Spain;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1801	EUCTR2004-002157-30-FI	01/12/2004	19 March 2012	A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis	Rheumatoid Arthritis	Product Code: TAK-715 Pharmaceutical Form: Tablet Current Sponsor code: TAK-715 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: TAK-715 Pharmaceutical Form: Tablet Current Sponsor code: TAK-715 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Takeda Europe R&D Centre Ltd. (TEuR&D)		Not Recruiting			Female: yes Male: yes	400		Finland;Denmark
1802	EUCTR2004-003741-40-AT	26/11/2004	22 April 2013	A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis.	A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis.	Rheumatoid Arthritis	Product Name: MRA Product Code: RO4877533 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Tocilizumab CAS Number: 375823-41-9 Current Sponsor code: R04877533 Other descriptive name: MRA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann La-Roche AG		Not Recruiting			Female: yes Male: yes	630		Hungary;Austria;Germany;Italy
1803	EUCTR2004-002006-30-GB	17/11/2004	15 July 2013	Triple therapy in early active rheumatoid arthritis - TEAR	Triple therapy in early active rheumatoid arthritis - TEAR	Rheumatoid arthritis	Product Name: Methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 25- Trade Name: Salazopyrin En-Tabs Product Name: sulfasalazine Pharmaceutical Form: Tablet INN or Proposed INN: Sulfasalazine Concentration unit: g gram(s) Concentration type: up to Concentration number: 4- Trade Name: Plaquenil Product Name: Hydroxychloroquine Pharmaceutical Form: Tablet INN or Proposed INN: Hydroxychloroquine Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 400-	North Glasgow NHS Trust		Not Recruiting			Female: yes Male: yes	96		United Kingdom
1804	EUCTR2004-000563-96-HU	12/11/2004	29 May 2012	A 24-MONTH, RANDOMIZED, DOUBLE-BLIND, TWO PERIOD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ETANERCEPT AND METHOTREXATE AND METHOTREXATE ALONE IN SUBJECTS WITH ACTIVE EARLY RHEUMATOID ARTHRITIS: COMBINATION OF METHOTREXATE AND ETANERCEPT IN ACTIVE EARLY RHEUMATOID ARTHRITIS (COMET) - COMET	A 24-MONTH, RANDOMIZED, DOUBLE-BLIND, TWO PERIOD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ETANERCEPT AND METHOTREXATE AND METHOTREXATE ALONE IN SUBJECTS WITH ACTIVE EARLY RHEUMATOID ARTHRITIS: COMBINATION OF METHOTREXATE AND ETANERCEPT IN ACTIVE EARLY RHEUMATOID ARTHRITIS (COMET) - COMET	Rheumatoid Arthritis	Trade Name: Enbrel (etanercept) Product Code: 0881 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: etanercept CAS Number: N/Applicable Current Sponsor code: 0881 Other descriptive name: TNR-001; TNFR:Fc; rhuTNFR:Fc Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Powder and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Methotrexate-Lachema Product Name: methotrexate sodium tablets 2.5 mg Pharmaceutical Form: Capsule* INN or Proposed INN: methotrexate CAS Number: 7413-34-5 Other descriptive name: methotrexate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Methotrexate-Lachema Product Name: methotrexate sodium tablets 2.5 mg Pharmaceutical Form: Capsule* INN or Proposed INN: methotrexate CAS Number: 7413-34-5 Other descriptive name: methotrexate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Wyeth Pharmaceuticals		Not Recruiting			Female: yes Male: yes	580		Finland;Hungary;Denmark;Norway;Ireland;Spain;Italy;Sweden
1805	NCT00170872	November 2004	19 February 2015	6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis	A 6 Week, Multicenter, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Lumiracoxib 200mg o.d. in Patients With Primary Knee Osteoarthritis or Rheumatoid Arthritis	Osteoarthritis;Rheumatoid Arthritis	Drug: Lumiracoxib	Novartis		Not recruiting	18 Years	N/A	Both	135	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1806	NCT00195494	November 2004	19 October 2017	Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis	A 24-Month,Randomized,Double-Blind,Two-Period Study to Evaluate the Efficacy and Safety of the Combination of Etanercept and Methotrexate and Methotrexate Alone in Subjects With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Methotrexate;Drug: Placebo	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	All	542	Phase 4	United States
1807	NCT00236028	November 2004	19 February 2015	A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis	A Randomized, Double-blind, Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared With Methotrexate Alone for the Treatment of Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Infliximab	Centocor, Inc.		Not recruiting	18 Years	75 Years	Both	607	Phase 3
1808	NCT00379600	November 2004	7 November 2016	The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: rosiglitazone XR	GlaxoSmithKline		Not recruiting	18 Years	N/A	Both	96	Phase 2	Lithuania;United Kingdom
1809	NCT00747214	November 2004	19 October 2017	A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA	A Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to That of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects With RA	Rheumatoid Arthritis	Drug: CRx-102;Drug: Placebo;Drug: DMARD Therapy	Zalicus		Not recruiting	18 Years	N/A	All	59	Phase 2
1810	NCT00854321	November 2004	19 February 2015	Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital	One Centre Follow-up Study on Safety and Efficacy	Rheumatoid Arthritis	Drug: rituximab;Drug: rituximab, observational study amon patients with active RA	Kuopio University Hospital		Not recruiting	18 Years	N/A	Both	49	N/A	Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1811	NCT01600521	November 2004	20 April 2015	A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications	A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications	Rheumatoid Arthritis	Drug: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs	University of Minnesota - Clinical and Translational Science Institute		Not recruiting	18 Years	N/A	Both	1748	N/A	China
1812	EUCTR2004-000012-13-CZ	26/10/2004	9 October 2012		A Double-Blind, Placebo-Controlled, Parallel, Randomized Study To Evaluate The Efficacy And Safety Of 3 Oral Dose Levels Of TMI-005 In Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate -	Rheumatoid Arthritis	Product Name: TMI-005 (WAY-177005) Product Code: TMI-005 (WAY-177005) Pharmaceutical Form: Capsule* INN or Proposed INN: Not yet established CAS Number: 287405-51-0 Current Sponsor code: TMI-005 Other descriptive name: WAY-177005 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: TMI-005 (WAY-177005) Product Code: TMI-005 (WAY-177005) Pharmaceutical Form: Capsule* INN or Proposed INN: Not yet established CAS Number: 287405-51-0 Current Sponsor code: TMI-005 Other descriptive name: WAY-177005 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: TMI-005 (WAY-177005) Product Code: TMI-005 (WAY-177005) Pharmaceutical Form: Capsule* INN or Proposed INN: Not yet established CAS Number: 287405-51-0 Current Sponsor code: TMI-005 Other descriptive name: WAY-177005 Concentration unit: mg milligram(s) Concentration number: 150- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development		Authorised			Female: yes Male: yes	360		Czech Republic;Estonia;Italy
1813	EUCTR2004-000482-35-GB	11/10/2004	19 March 2012	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis. - HM2004/00255/00	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis. - HM2004/00255/00	Rheumatoid Arthritis	Product Name: Rosiglitazone Extended Release Tablets Product Code: BRL-049653 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Rosiglitazone CAS Number: 0155141-29-0 Other descriptive name: Rosiglitazone maleate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd.		Authorised			Female: yes Male: yes	96		United Kingdom;Lithuania
1814	NCT00094341	October 2004	19 February 2015	Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes	An Open-Label, Randomized, Crossover Study to Assess Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes	Rheumatoid Arthritis	Drug: Etanercept	Amgen		Not recruiting	18 Years	N/A	Both	215	Phase 4	United States
1815	NCT00242853	October 2004	19 February 2015	A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis	An Enabling Study to Investigate the Correlation of Biomarkers of the Activity of Inducible Nitric Oxide Synthase (iNOS) With Disease Activity and Treatment Response in Patients With Rheumatoid Arthritis(RA)	Rheumatoid Arthritis;Osteoarthritis	Procedure: Power doppler ultrasonography;Procedure: High frequency ultrasonography;Procedure: Exhaled nitric oxide assessment	GlaxoSmithKline		Not recruiting	18 Years	75 Years	Both	48	N/A	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1816	NCT00650390	October 2004	19 February 2015	Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab	Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab	Rheumatoid Arthritis	Biological: adalimumab	Abbott		Not recruiting	18 Years	N/A	Both		N/A
1817	EUCTR2004-001490-26-GB	15/09/2004	15 July 2013	A SINGLE-CENTER, RANDOMIZED, SINGLE-BLIND STUDY COMPARING THE EFFECT OF CRx-150 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS. - CRx-150-RA	A SINGLE-CENTER, RANDOMIZED, SINGLE-BLIND STUDY COMPARING THE EFFECT OF CRx-150 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS. - CRx-150-RA	RHEUMATOID ARTHRITIS	Trade Name: Asendis 50 mg Product Code: CRx-150 Pharmaceutical Form: Tablet INN or Proposed INN: Amoxapine & dipyridamole Current Sponsor code: CRx-150 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50 or 100 and-100 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	CombinatoRx, Inc		Not Recruiting			Female: yes Male: yes			Estonia;United Kingdom
1818	EUCTR2004-000612-54-SE	11/09/2004	19 March 2012	A Multicenter, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoarthritis or Rheumatoid Arthritis After 12 Weeks of Treatment With L-001069957 21 mg Plus Low-Dose Aspirin, L- 01069957 42 mg Plus Low-Dose Aspirin, Celecoxib 400 mg Plus Low-Dose Aspirin, or Low-Dose Aspirin Alone - 12-Week NO-Rofecoxib Plus Aspirin Endoscopy Study	A Multicenter, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoarthritis or Rheumatoid Arthritis After 12 Weeks of Treatment With L-001069957 21 mg Plus Low-Dose Aspirin, L- 01069957 42 mg Plus Low-Dose Aspirin, Celecoxib 400 mg Plus Low-Dose Aspirin, or Low-Dose Aspirin Alone - 12-Week NO-Rofecoxib Plus Aspirin Endoscopy Study	Osteoarthritis (OA) ICD: M19.9 MedDRA: 10031161 Rheumatoid Arthritis (RA) ICD: M06.9 MedDRA: 10039037	Product Name: L-001069957 Product Code: L-001069957 Pharmaceutical Form: Tablet INN or Proposed INN: 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 21- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: L-001069957 Product Code: L-001069957 Pharmaceutical Form: Tablet INN or Proposed INN: 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 42- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Aspirin Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Acetylsalicylic acid CAS Number: 530-75-6 Other descriptive name: Acetylsalicylic Acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Celebrex Product Name: Celecoxib Pharmaceutical Form: Capsule* INN or Proposed INN: Celecoxib CAS Number: 169590-42-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Merck Sharp & Dohme (Sweden) AB		Not Recruiting			Female: yes Male: yes	1360		Sweden
1819	EUCTR2004-000106-41-SE	07/09/2004	19 March 2012	A study to investigate the effect of GW406381 on methotrexate pharmacokinetics in patients treated with methotrexate for rheumatoid arthritis - GW406381 and methotrexate	A study to investigate the effect of GW406381 on methotrexate pharmacokinetics in patients treated with methotrexate for rheumatoid arthritis - GW406381 and methotrexate	The patients entering the trial have rheumatoid arthritis although treatment of the disease itself is not under investigation in this study.	Product Name: GW406381 Product Code: GW406381 Pharmaceutical Form: Capsule*	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes			Sweden
1820	NCT00117091	September 2004	19 February 2015	Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)	An Open-Label Multicentre Study of Anakinra (Kineret®) in Combination With DMARDS in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Anakinra (Kineret®)	Amgen		Not recruiting	18 Years	N/A	Both		Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1821	NCT00412256	September 2004	19 February 2015	Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)	Clinical Trial to Evaluate the Effect of Parenteral Supplementation With Omega-3-Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omegaven (10% fish-oil emulsion; Fresenius-Kabi)	Humanis Klinikum Niederosterreich		Not recruiting	18 Years	N/A	Both	60	Phase 3	Austria
1822	NCT00638950	September 2004	19 February 2015	A Long-term Moderate Intervention With n-3 LC-PUFA-supplemented Dairy Products in Patients With Rheumatoid Arthritis	Long-term Moderate Intervention With n-3 LC-PUFA-supplemented Dairy Products: Effects on Pathophysiological Biomarkers in Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: n-3 LC-PUFA;Dietary Supplement: Placebo	University of Jena		Not recruiting	35 Years	74 Years	Both	45	N/A	Germany
1823	NCT00831649	September 2004	27 June 2016	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201	Rheumatoid Arthritis	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	75 Years	Both		Phase 2
1824	NCT00831922	September 2004	18 December 2018	Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis	A Multicenter, Open Label, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis With Inadequate Response to at Least One Disease Modifying Anti Rheumatic Drugs (DMARD)	Rheumatoid Arthritis	Drug: masitinib (AB1010)	AB Science		Not recruiting	18 Years	N/A	All	43	Phase 2
1825	NCT00095498	August 2004	16 December 2017	Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: placebo;Drug: denosumab	Amgen		Not recruiting	18 Years	N/A	All	227	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1826	NCT00146640	August 2004	19 February 2015	Prednisone Timed-Release Tablet (TRT) Study: TRT Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis	A New Timed-release Tablet Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis- A Randomized, Multi-centre, Double-blind, Active Controlled Study With Open Extension on the New Drug Only	Rheumatoid Arthritis	Drug: Prednisone	Merck KGaA		Not recruiting	18 Years	80 Years	Both	288	Phase 3	Germany;Poland
1827	NCT00234897	August 2004	19 February 2015	Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis	Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)	Rheumatoid Arthritis	Drug: adalimumab	Abbott		Not recruiting	18 Years	N/A	Both	1938	Phase 4	United States
1828	NCT00235872	August 2004	19 October 2017	Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: adalimumab	Abbott	Abbott Japan Co.,Ltd;Eisai Co., Ltd.	Not recruiting	20 Years	N/A	All	309	Phase 3	Japan
1829	NCT00279734	August 2004	19 February 2015	Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers	An Exploratory Study to Evaluate the Effect of Abatacept (BMS-188667) on the Antibody Response Following Tetanus Toxoid and 23-Valent Pneumococcal Vaccinations in Healthy Subjects	Rheumatoid Arthritis	Drug: Tetanus + pnemococcal vaccines alone;Drug: Abatacept + vaccines;Drug: Abatacept + Vaccines	Bristol-Myers Squibb		Not recruiting	18 Years	65 Years	Both	80	Phase 1	United States
1830	NCT00696059	August 2004	19 February 2015	Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?	Can Bone Erosions Heal in Adalimumab (Humira) Treated Rheumatoid Arthritis Patients. An Imaging Study Using Computed Tomography and Magnetic Resonance Imaging.	Rheumatoid Arthritis;Arthritis;Joint Diseases	Drug: Adalimumab (Humira)	Hvidovre University Hospital	Abbott	Not recruiting	18 Years	90 Years	Both	52	Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1831	EUCTR2004-000362-12-CZ	23/07/2004	19 March 2012	A Double-Blind, Randomised, Dose-Ranging Study to Compare K-832 with Placebo in the treatment of Patients with Active Rheumatoid Arthritis - N/A	A Double-Blind, Randomised, Dose-Ranging Study to Compare K-832 with Placebo in the treatment of Patients with Active Rheumatoid Arthritis - N/A	Rheumatoid Arthritis MedDRA version: 6.0 Level: LLT Classification code 10028395	Product Name: K-832 Product Code: K-832 Pharmaceutical Form: Tablet INN or Proposed INN: To be confirmed CAS Number: 225666-85-3 Current Sponsor code: K-832 Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: K-832 Product Code: K-832 Pharmaceutical Form: Tablet INN or Proposed INN: To be confirmed CAS Number: 225666-85-3 Current Sponsor code: K-832 Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Kowa Research Europe Ltd		Not Recruiting			Female: yes Male: yes	260		Czech Republic
1832	EUCTR2004-000074-31-SE	06/07/2004	19 March 2012	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000124467 in Rheumatoid Arthritis Patients - Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000124467 in Rheumatoid Arthritis Patients - Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis	rheumatoid arthritis MedDRA version: 7.0 Level: LLT Classification code 10039073	Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c Product Code: L-000124467 (freebase); L-000124467-009J (succinat Pharmaceutical Form: Tablet INN or Proposed INN: not available Other descriptive name: L-000124467 Concentration unit: mg milligram(s) Concentration number: 0.2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c Product Code: L-000124467 (freebase); L-000124467-009J (succinat Pharmaceutical Form: Tablet INN or Proposed INN: not available Other descriptive name: L-000124467 Concentration unit: mg milligram(s) Concentration number: 1.0- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c Product Code: L-000124467 (freebase); L-000124467-009J (succinat Pharmaceutical Form: Tablet INN or Proposed INN: not available Other descriptive name: L-000124467 Concentration unit: mg milligram(s) Concentration number: 5.0- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: paracetamol (acetaminophen) Product Name: paracetamol (acetaminophen) Pharmaceutical Form: Tablet CAS Number: 103-90-2 Concentration unit: mg milligram(s) Concentration number: 325-	Merck Sharp & Dohme (Sweden) AB		Not Recruiting			Female: yes Male: yes	150		Sweden
1833	NCT00239382	July 1, 2004	20 August 2018	A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis	A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.	Arthritis, Rheumatoid	Drug: Meloxicam ampoule;Drug: Meloxicam tablet	Boehringer Ingelheim		Not recruiting	18 Years	N/A	All	150	Phase 3	China
1834	NCT00089921	July 2004	19 February 2015	SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine	Arthritis, Rheumatoid	Drug: SCIO-469;Drug: Placebo	Scios, Inc.		Not recruiting	18 Years	N/A	Both	302	Phase 2	United States
1835	NCT00154336	July 2004	16 December 2017	A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.	3-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety & Tolerability of Imatinib 400 mg Daily in Combination With Methotrexate (MTX)Compared to MTX Alone in the Treatment of Rheumatoid Arthritis (RA).	Rheumatoid Arthritis	Drug: Imatinib;Drug: Methotrexate;Drug: Imatinib Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	75 Years	All	50	Phase 2	Austria;Canada;Finland;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1836	NCT00236678	July 2004	19 February 2015	Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT	A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT? (Epoetin Alfa)	Anemia;Rheumatoid Arthritis	Drug: Epoetin alfa	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Ortho Biotech Products, L.P.	Not recruiting	18 Years	N/A	Both	29	Phase 2
1837	NCT00506896	July 2004	19 February 2015	Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients	Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study	Rheumatoid Arthritis	Drug: intraarticular injection	Federal University of São Paulo		Not recruiting	18 Years	65 Years	Both	60	Phase 2	Brazil
1838	NCT00094562	June 2004	28 January 2019	A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss	AAFA™ Fish Oil Nutritional Supplementation to Maintain Body Weight in Patients With Disease-Related Weight Loss	Cancer;Cancer Cachexia;Chronic Obstructive Pulmonary Disease;Chronic Heart Failure;Rheumatoid Arthritis	Drug: Fish oil supplement	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	National Center for Complementary and Integrative Health (NCCIH)	Not recruiting	18 Years	90 Years	All	25	Phase 2	United States
1839	NCT00144534	June 2004	19 February 2015	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP	Rheumatoid Arthritis	Drug: MRA (Tocilizumab)	Chugai Pharmaceutical		Not recruiting	20 Years	75 Years	Both	115	Phase 3
1840	NCT00244153	June 2004	19 February 2015	Intraarticular Opioids Vs Glucocorticosteroids in Gonarthritis	Intraarticular Application of Opioids Versus Glucocorticosteroids Versus Placebo in Rheumatoid Arthritis	Rheumatic Disease	Drug: intraarticular morphine;Drug: intraarticular dexamethasone	Charite University, Berlin, Germany		Recruiting	19 Years	N/A	Both	120	Phase 1/Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1841	NCT00252668	June 2004	19 February 2015	Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects	An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects	Rheumatoid Arthritis	Drug: Etanercept;Drug: Methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	Both	300	Phase 4
1842	NCT00273533	June 2004	19 February 2015	Ramipril in Rheumatoid Arthritis	Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Ramipril	University of Zurich	Sanofi	Not recruiting	18 Years	60 Years	Both	13	Phase 2/Phase 3	Switzerland
1843	NCT00542022	June 2004	2 November 2015	Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0812 in Rheumatoid Arthritis Patients	Arthritis, Rheumatoid	Drug: MK0812 / Duration of Treatment: 12 Weeks;Drug: Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	65 Years	Both	149	Phase 2
1844	NCT02097745	June 2004	19 October 2017	A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies	An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies	Rheumatoid Arthritis	Drug: methotrexate;Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche	Biogen	Not recruiting	18 Years	80 Years	All	341	Phase 3	United States;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom
1845	NCT00083759	May 2004	19 October 2017	Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate	A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)	Rheumatoid Arthritis	Drug: natalizumab;Drug: placebo	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	75 Years	All	299	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1846	NCT00099554	May 2004	19 February 2015	Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)	A Phase 4, Open-Label, Single Arm, Observational Study Evaluating the Effectiveness and Safety of Enbrel® (Etanercept) 50 mg Once Weekly in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)	Rheumatoid Arthritis	Drug: Etanercept	Amgen		Not recruiting	18 Years	N/A	Both	200	Phase 4	United States;Canada
1847	NCT00110903	May 2004	19 February 2015	Treatment for Subjects With Active Rheumatoid Arthritis (RA)	Open-Label Study to Assess the Safety of Etanercept Liquid Administered Once Weekly in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept Liquid	Amgen		Not recruiting	18 Years	N/A	Both		Phase 3
1848	NCT00195338	May 2004	19 October 2017	Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg	A Post-Marketing Surveillance Looking At Safety And Adherence To Treatment Of Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg	Rheumatoid Arthritis	Drug: etanercept	Pfizer	Innovex, Inc	Not recruiting	17 Years	N/A	All	25	N/A	Luxembourg
1849	NCT00195403	May 2004	19 October 2017	A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA	A Drug Use Investigation of Enbrel for Post-Marketing Surveillance	Rheumatoid Arthritis	Drug: Etanercept	Pfizer		Not recruiting	4 Years	N/A	All	1014	N/A	Korea, Republic of
1850	NCT00259610	May 2004	19 October 2017	Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)	Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)	Rheumatoid Arthritis	Drug: methotrexate;Drug: sulfasalazine;Drug: hydroxychloroquine;Drug: etanercept	University of Alabama at Birmingham	Amgen;Barr Laboratories;Pfizer	Not recruiting	18 Years	N/A	All	755	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1851	NCT00291915	May 2004	19 February 2015	Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis	Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis	Rheumatoid Arthritis;Arthritis	Drug: Adalimumab;Drug: Methotrexate	Goupe d'Etudes et de Recherche Clinique En Rhumatologie		Recruiting	18 Years	N/A	Both	80	Phase 4	France
1852	NCT00144547	April 2004	19 February 2015	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical		Not recruiting	20 Years	N/A	Both	241	Phase 3
1853	NCT00280644	April 2004	19 February 2015	Leflunomide in Rheumatoid Arthritis	Efficacy of Leflunomide on Joint Inflammation and Destruction of Joint Integrity in Active Rheumatoid Arthritis (RA) Patients	Arthritis, Rheumatoid	Drug: Leflunomide	Sanofi		Not recruiting	18 Years	75 Years	Both	60	Phase 4	Turkey
1854	NCT00468377	March 2004	19 February 2015	Safety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNFa Therapies	An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies	Arthritis, Rheumatoid	Drug: Rituximab	Hoffmann-La Roche	Genentech, Inc.	Not recruiting	18 Years	80 Years	Both	341	Phase 3	United States
1855	NCT00484809	March 2004	19 February 2015	Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children	A Post-Marketing Surveillance Looking at Safety of Enbrel (Etanercept) in Adults With Active Rheumatoid Arthritis (RA) and Children With Juvenile Rheumatoid Arthritis (JRA).	Rheumatoid Arthritis	Drug: Enbrel (Etanercept)	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	4 Years	N/A	Both	100	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1856	NCT00725621	March 2004	19 October 2017	Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)	Real Life Dosing Regimen of Remicade in Austria, Monitored Over 9 Consecutive Infusions in Rheumatoid Arthritis Therapy	Rheumatoid Arthritis	Biological: Infliximab	Merck Sharp & Dohme Corp.	Centocor, Inc.	Not recruiting	N/A	N/A	All	516	N/A	Austria
1857	NCT00077870	February 2004	19 February 2015	A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis	A Randomized, Placebo-Controlled, Multicenter, Blinded Phase I/II Study of the Safety of Escalating Doses of Ocrelizumab (PRO70769) in Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate	Rheumatoid Arthritis	Drug: ocrelizumab	Genentech, Inc.		Not recruiting	18 Years	80 Years	Both	237	Phase 1/Phase 2	United States
1858	NCT00144521	February 2004	19 February 2015	Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)	A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA	Rheumatoid Arthritis	Drug: MRA(Tocilizumab);Drug: MRA placebo;Drug: MTX;Drug: MTX placebo	Chugai Pharmaceutical		Not recruiting	20 Years	75 Years	Both	127	Phase 3
1859	NCT00224562	February 2004	19 February 2015	The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists	The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists	Rheumatoid Arthritis;Crohn's Disease;Ankylosing Spondylitis;Psoriasis	Drug: TNF-alpha antagonists	Assistance Publique - Hôpitaux de Paris		Recruiting	N/A	N/A	Both		N/A	France
1860	NCT00367965	February 2004	19 February 2015	Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis	The Effect of Eszopiclone 3 mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis	Insomnia;Arthritis, Rheumatoid	Drug: Eszopiclone;Drug: placebo	Sunovion		Not recruiting	25 Years	64 Years	Both	153	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1861	NCT00647491	February 2004	19 February 2015	A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis		Rheumatoid Arthritis	Biological: adalimumab;Biological: placebo	Abbott	Eisai Limited	Not recruiting	20 Years	N/A	Both	352	Phase 2/Phase 3	Japan
1862	NCT00679510	February 2004	11 November 2019	Rosuvastatin in Rheumatoid Arthritis (RORA)	Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: rosuvastatin;Drug: placebo	University of Dundee		Not recruiting	40 Years	N/A	All	50	Phase 2/Phase 3	United Kingdom
1863	NCT00157872	January 7, 2004	16 December 2017	A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)	A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 mg Once Daily Versus Naproxen Table 500 mg Twice Daily in the Treatment of Chinese Patient With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MK0966; rofecoxib;Drug: Comparator: naproxen tablet 500 mg	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	150	Phase 4	China
1864	NCT00378261	January 2004	19 February 2015	APART Advanced Profiling of Anti-Rheumatic Therapies	A Multicenter, Randomized, Open Study to Evaluate the Impact of an Electronic Data Capture System on the Care of Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Procedure: Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.	Centocor Ortho Biotech Services, L.L.C.		Not recruiting	18 Years	N/A	Both	1079	Phase 4
1865	NCT00071812	December 2003	19 October 2017	A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)	A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: Placebo;Drug: Belimumab 1 mg/kg;Drug: Belimumab 4 mg/kg;Drug: Belimumab 10 mg/kg	Human Genome Sciences Inc.		Not recruiting	18 Years	65 Years	All	283	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1866	NCT00076206	December 2003	21 December 2015	Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy	A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy	Rheumatoid Arthritis	Drug: CCI-779;Drug: Placebo	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	75 Years	Both		Phase 2	United States
1867	NCT00095173	December 2003	19 October 2017	BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis	A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)	Juvenile Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	6 Years	17 Years	All	214	Phase 3	United States;Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland
1868	NCT00234936	December 2003	19 February 2015	Quality of Life Study With Adalimumab in Rheumatoid Arthritis	Quality of Life Study With Adalimumab in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Methotrexate	Abbott		Not recruiting	18 Years	N/A	Both	200	Phase 3
1869	NCT00619905	December 2003	19 February 2015	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Cohort Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 (Anti-Interleukin-1Beta Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis (RA) Despite Ongoing Treatment With Methotrexate (MTX) 15 mg or More Weekly for at Least 3 Months.	Rheumatoid Arthritis	Drug: ACZ885	Novartis		Not recruiting	18 Years	75 Years	Both	53	Phase 1/Phase 2	Germany;Netherlands;Switzerland
1870	NCT00207714	November 2003	19 October 2017	An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis	A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate	Rheumatoid Arthritis	Drug: Golimumab;Drug: MTX;Drug: Placebo;Drug: Infliximab	Centocor, Inc.	Centocor BV	Not recruiting	18 Years	N/A	All	172	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1871	NCT00162201	October 2003	16 December 2017	An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy	An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	16	Phase 1	United Kingdom
1872	NCT00649922	October 2003	19 February 2015	Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis	Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: adalimumab;Biological: placebo	Abbott		Not recruiting	20 Years	N/A	Both	226	Phase 4
1873	NCT00069017	September 2003	19 February 2015	Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate	A Phase II, Randomized, Double-Blind Study to Evaluate the Effects of MEDI-522, a Humanized MAb to Integrin Alpha V Beta 3, On Disease Activity and Progression of Joint Damage in Pts With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate	Rheumatoid Arthritis	Biological: MEDI-522;Other: Placebo	MedImmune LLC		Not recruiting	18 Years	N/A	Both	300	Phase 2	United States;Canada
1874	NCT00234884	September 2003	19 October 2017	Post-marketing Observational Study in Subjects With Rheumatoid Arthritis	A Five-year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis Formerly Treated in Study M02-497 (ReAct) and Subsequently Prescribed Humira	Rheumatoid Arthritis	Biological: adalimumab	Abbott		Not recruiting	18 Years	N/A	All	3435	Phase 4	Australia;Austria;Belgium;France;Germany;Greece;Italy;Netherlands;Portugal;Spain;United Kingdom
1875	NCT00221000	August 2003	31 October 2016	Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis	A Phase II, Multicenter, Randomized, Double-blind, Sham Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological Agents	Rheumatoid Arthritis	Drug: Methoxsalen;Procedure: Extracorporeal Photopheresis	Mallinckrodt		Not recruiting	18 Years	N/A	Both	86	Phase 2	United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1876	NCT00794898	July 1, 2003	16 December 2017	Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)	Onset of Efficacy of Anti-TNF Chimeric Monoclonal Antibody (Remicade) in the Treatment of Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment	Arthritis, Rheumatoid	Biological: Infliximab (Remicade)	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	75 Years	All	19	Phase 4
1877	NCT00195364	July 2003	19 February 2015	Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain	Long-Term Safety Study of Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain	Rheumatoid Arthritis;Inflammation	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	Both	93	Phase 4	Spain
1878	NCT00235859	July 2003	19 February 2015	Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate	Rheumatoid Arthritis	Drug: adalimumab;Drug: methotrexate	Abbott	Eisai Limited	Not recruiting	18 Years	N/A	Both	128	Phase 3
1879	NCT00647920	July 2003	19 February 2015	Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate	Study of the Human Anti-TNF-Antibody Adalimumab	Rheumatoid Arthritis	Biological: adalimumab;Biological: placebo	Abbott		Not recruiting	18 Years	N/A	Both	47	Phase 3	Taiwan
1880	NCT00649545	July 2003	19 February 2015	Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis	A Multi-Center Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: adalimumab	Abbott		Not recruiting	18 Years	N/A	Both		N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1881	NCT02184052	July 2003	19 February 2015	Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions	Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study	Arthritis, Rheumatoid	Drug: Meloxicam	Boehringer Ingelheim		Not recruiting	N/A	N/A	Both	121	N/A
1882	NCT00062465	June 2003	19 February 2015	Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine	A 24-Week, Double Blind, Randomized Study to Determine the Effects of 24 Weeks of Dosing With Tripterygium Wilfordii Hook F (TwHF) or Sulfasalazine, in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TwHF	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		Not recruiting	N/A	N/A	Both	157	Phase 2	United States
1883	NCT00074438	June 2003	19 February 2015	Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis	Randomized, Multifactorial, Double-blind, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Rituximab (MabThera®/Rituxan®) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: methotrexate;Drug: rituximab;Drug: corticosteroids;Drug: placebo	Genentech, Inc.	Roche Pharma AG	Not recruiting	18 Years	80 Years	Both	465	Phase 2	United States
1884	NCT00213538	June 2003	16 December 2017	Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis	Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Response to anakinra associated with methotrexate	University Hospital, Rouen		Not recruiting	18 Years	N/A	All	341	N/A	France
1885	NCT00235833	June 2003	19 October 2017	Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	Long-term Continuously Repeated Dose Study of Adalimumab (D2E7) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: adalimumab	Abbott	Abbott Japan Co.,Ltd;Eisai Co., Ltd.	Not recruiting	20 Years	N/A	All	25	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1886	NCT00245934	June 2003	19 February 2015	Study Evaluating Enbrel in Patients With Rheumatoid Arthritis	Observational Study With Enbrel in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Enbrel	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	Both	1500	N/A
1887	NCT00317538	June 2003	19 February 2015	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept	Rheumatoid Arthritis	Drug: infliximab, etanercept	Centocor Ortho Biotech Services, L.L.C.		Not recruiting	18 Years	N/A	Both	28	Phase 3
1888	NCT00396747	June 2003	19 February 2015	A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study	Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone	Rheumatoid Arthritis	Drug: Infliximab, methylprednisolone, methotrexate;Drug: Methotrexate;Drug: Methotrexate + Methylprednisolone;Drug: Methotrexate + Infliximab	Université Catholique de Louvain		Not recruiting	18 Years	N/A	Both	45	Phase 4	Belgium
1889	NCT00548834	June 2003	19 February 2015	Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis	Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD	Rheumatoid Arthritis	Drug: CDP870	UCB Pharma		Not recruiting	18 Years	75 Years	Both	220	Phase 3
1890	NCT00095342	May 2003	19 February 2015	Study Evaluating TMI-005 in Active Rheumatoid Arthritis	A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate	Rheumatoid Arthritis	Drug: TMI-005	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	75 Years	Both	390	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1891	NCT00468546	May 2003	19 October 2017	A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy	A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies	Rheumatoid Arthritis	Drug: MabThera/Rituxan;Drug: Methotrexate;Other: Placebo	Hoffmann-La Roche	Biogen	Not recruiting	18 Years	80 Years	All	520	Phase 3	United States;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom
1892	NCT00563849	May 2003	19 February 2015	Leflunomide + Methotrexate in Rheumatoid Arthritis	An Open-Label, Multi-Center Study to Evaluation of Leflunomide Plus Methotexate for the Treatment of Rheumatoid Arthritis in DMARDs:(Disease-Modifying Antirheumatic Drug) na¿ve or Restart (Skip DMARDs More Than 4 Weeks) Subjects.	Rheumatoid Arthritis	Drug: Leflunomide	Sanofi		Not recruiting	18 Years	75 Years	Both	74	Phase 4	Korea, Republic of
1893	NCT02214888	May 2003	19 February 2015	Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis	A 12 Week Double-blind, Randomized, Placebo-controlled Trial to Investigate Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets at Doses of 50 and 70 mg Administered Twice a Day in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD	Arthritis, Rheumatoid	Drug: BIRB 796 BS, low dose;Drug: BIRB 796 BS, high dose;Drug: Placebo	Boehringer Ingelheim		Not recruiting	18 Years	75 Years	Both	170	Phase 2
1894	NCT00195377	April 2003	19 February 2015	Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain	Evaluating Safety and QoL in Patients Treated With Etanercept: an Open Multicenter Study	Arthritis, Psoriatic;Arthritis, Rheumatoid	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	4 Years	N/A	Both	1000	Phase 4	Spain
1895	NCT00213564	April 2003	19 February 2015	Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis	Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: response to infliximab associated with methotrexate	University Hospital, Rouen		Not recruiting	18 Years	N/A	Both	40	Phase 4	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1896	NCT00144508	March 2003	19 February 2015	Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)	An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA	Rheumatoid Arthritis	Drug: MRA (Tocilizumab);Other: current treatment	Chugai Pharmaceutical		Not recruiting	20 Years	N/A	Both	306	Phase 3
1897	NCT00160693	March 2003	11 June 2018	Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis	A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Certolizumab Pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	402	Phase 3	United States;Austria;Belgium;Czechia;Germany;Ireland;United Kingdom;Czech Republic
1898	NCT00234845	March 2003	19 February 2015	Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis	A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: adalimumab;Drug: methotrexate	Abbott		Not recruiting	18 Years	N/A	Both	148	Phase 3	United States
1899	NCT00244556	March 2003	19 February 2015	Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy	A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy	Rheumatoid Arthritis	Drug: Methotrexate plus ENBREL or ENBREL alone	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	Both	300	Phase 4
1900	NCT00356473	March 2003	19 February 2015	Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis	Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Atorvastatin	University of California, Los Angeles		Not recruiting	18 Years	N/A	Both	20	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1901	NCT00908089	March 2003	13 April 2015	TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis	Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo	Helsinki University	Seinajoki Central Hospital;Oulu University Hospital;Jyväskylä Central Hospital;Kuopio University Hospital;Satakunta Central Hospital;University of Turku;Rheumatism Foundation Hospital;Orton Invalid Foundation;South Karelia central hospital;Lappi Central Hospital;Central Hospital of Kanta-Hame	Not recruiting	18 Years	60 Years	Both	100	Phase 4	Finland
1902	NCT00092742	February 2003	3 August 2015	Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)	A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MK0663, etoricoxib;Drug: Comparator: Diclofenac sodium	Merck Sharp & Dohme Corp.		Not recruiting	50 Years	N/A	Both	4086	Phase 3	United States
1903	NCT00650455	February 2003	19 February 2015	Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients	Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population	Arthritis, Rheumatoid	Drug: valdecoxib;Drug: naproxen;Drug: placebo	Pfizer		Not recruiting	18 Years	N/A	Both	489	Phase 4	United States;Canada
1904	NCT00250445	January 2003	10 August 2015	A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)	A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis	Rheumatoid Arthritis,Osteoarthritis	Drug: MK0663, etoricoxib;Drug: Comparator: Diclofenac sodium	Merck Sharp & Dohme Corp.		Not recruiting	50 Years	N/A	Both	23498	Phase 3
1905	NCT00546533	January 2003	19 February 2015	Study Evaluating the Efficacy and Safety of Etanercept	Open-Label Evaluation Of The Efficacy And Safety Of Etanercept In Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	N/A	N/A	Both	40	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1906	NCT00048568	December 2002	19 October 2017	A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	1250	Phase 3	United States
1907	NCT00048581	December 2002	19 October 2017	Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.	A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy	Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	738	Phase 3	United States
1908	NCT00048932	December 2002	19 October 2017	A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: Double-blind Abatacept;Drug: Double-blind Placebo;Drug: Open-label Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	1795	Phase 3	United States
1909	NCT00433875	December 2002	19 February 2015	Phase 2 AMG 714 in Rheumatoid Arthritis	A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs	Rheumatoid Arthritis	Drug: AMG 714	Amgen		Not recruiting	18 Years	N/A	Both	180	Phase 2
1910	NCT00482417	December 2002	7 December 2015	Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)		Rheumatoid Arthritis	Drug: MK0359	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	65 Years	Both	11	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1911	NCT00764725	December 2002	19 February 2015	Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)	A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX	Rheumatoid Arthritis	Drug: conventional DMARD combination;Biological: MTX plus anti-TNF	Karolinska Institutet		Not recruiting	18 Years	N/A	Both	487	Phase 4
1912	NCT00116727	October 2002	19 February 2015	Rheumatoid Arthritis DMARD Intervention and UtilizationStudy	Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2)	Rheumatoid Arthritis	Drug: ENBREL®	Amgen	Immunex Corporation;Wyeth is now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	Both	5103	N/A	United States
1913	NCT00121043	October 2002	19 February 2015	Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire	An Open Label, Randomized, Crossover Study to Assess Acceptability and Functionality of SimpleJectTM Vs Pre-Filled Syringe(s) Using Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using A Self-Reported Questionnaire	Rheumatoid Arthritis	Device: SimpleJectTM;Drug: Kineret® (Anakinra)	Amgen		Not recruiting	18 Years	N/A	Both		Phase 4
1914	NCT00544154	October 2002	19 February 2015	Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis	Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate	Arthritis, Rheumatoid	Drug: CDP870	UCB Pharma		Not recruiting	18 Years	75 Years	Both	247	Phase 3
1915	NCT00042406	September 2002	19 February 2015	Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-alpha Blocker	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active RA Failing Treatment With Methotrexate and TNF-alpha Blocking Agents	Rheumatoid Arthritis	Drug: HuMax-CD4	Emergent Product Development Seattle LLC		Not recruiting	18 Years	N/A	Both	75	Phase 2/Phase 3	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1916	NCT00049751	September 2002	19 February 2015	Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis	A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab	Abbott		Not recruiting	18 Years	N/A	Both	3000	Phase 3	United States
1917	NCT00055133	September 2002	19 February 2015	A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis	A Phase 2 Open-Label Clinical Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Micellar Paclitaxel for Injection	Angiotech Pharmaceuticals		Not recruiting	21 Years	70 Years	Both	50	Phase 2	United States
1918	NCT00121056	September 2002	19 February 2015	REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations	Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations (REKinDLE)	Rheumatoid Arthritis	Drug: Enbrel®;Drug: Kineret®	Amgen		Not recruiting	18 Years	N/A	Both		N/A
1919	NCT00282412	September 2002	8 August 2016	Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism	Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism	Rheumatoid Arthritis	Biological: Hematopoietic Stem Cell Transplantation	Northwestern University		Not recruiting	18 Years	60 Years	Both	4	Phase 1	United States
1920	NCT00448383	September 2002	19 February 2015	A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis	An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-a Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: adalimumab	Abbott		Not recruiting	18 Years	N/A	Both	6610	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1921	NCT00946686	September 2002	16 December 2017	To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions	A Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions	Rheumatoid Arthritis;Psoriatic Arthritis	Drug: Leflunomide 20 mg Tablets (Geneva Pharmaceutical);Drug: Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)	Sandoz		Not recruiting	18 Years	N/A	All	52	Phase 1
1922	NCT00111423	August 2002	19 February 2015	Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Pegsunercept (PEG sTNF-RI)	Amgen		Not recruiting	18 Years	N/A	Both	216	Phase 2
1923	NCT02093026	August 2002	16 December 2017	Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)	An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Folic Acid	Hoffmann-La Roche	Genentech, Inc.	Not recruiting	21 Years	N/A	All	465	Phase 2	United States;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Germany;Israel;Italy;Mexico;New Zealand;Poland;Spain;Sweden;United Kingdom
1924	NCT00043732	July 2002	19 February 2015	Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients in Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: SCIO-469	Scios, Inc.		Not recruiting	18 Years	N/A	Both	120	Phase 2	United States
1925	NCT00650026	July 2002	19 February 2015	Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis	Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: adalimumab	Abbott		Not recruiting	18 Years	N/A	Both		N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1926	NCT00042068	June 2002	19 February 2015	A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis	A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Meloxicam	Boehringer Ingelheim		Not recruiting	18 Years	80 Years	Both	1000	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Korea, Republic of;Russian Federation;Taiwan;Ukraine
1927	NCT00034060	April 2002	19 February 2015	The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept	Suppression of the Growth Hormone/ Insulin-Like Growth Factor-1 (GH/IGF-1) Axis in Women With Rheumatoid Arthritis	Rheumatoid Arthritis;Healthy	Drug: Etanercept	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		Not recruiting	N/A	N/A	Female	36	Phase 2	United States
1928	NCT00034203	April 2002	19 February 2015	Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.		Rheumatoid Arthritis	Drug: efalizumab	XOMA (US) LLC		Not recruiting	18 Years	80 Years	Both		Phase 2	United States
1929	NCT00038298	April 2002	19 February 2015	A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Safety and Tolerability of AMG 719 in Subjects With Rheumatoid Arthritis Receiving Methothrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: AMG 719;Drug: AGM 719;Drug: placebo to AMG 719	Amgen		Not recruiting	18 Years	N/A	Both	53	Phase 2	United States
1930	NCT00036153	March 2002	19 February 2015	Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis	A Randomized, Double-Blind Study to Assess the Efficacy of Tacrolimus (Prograf®)+ Methotrexate Vs. Placebo + Methotrexate in the Treatment of Rheumatoid Arthritis in Patients With Partial Response to Methotrexate	Rheumatoid Arthritis	Drug: Tacrolimus (Prograf®);Drug: Methotrexate	Astellas Pharma Inc	Astellas Pharma US, Inc.	Not recruiting	18 Years	N/A	Both	210	Phase 3	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1931	NCT00451971	March 2002	19 February 2015	Objective Study in Rheumatoid Arthritis	Objective Study in Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: LEFLUNOMIDE	Sanofi		Not recruiting	18 Years	75 Years	Both	249	Phase 4	Australia
1932	NCT00959439	March 2002	16 December 2017	Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)	A Comparative Bioavailability Study of Naproxen Delayed-Release Tablets, 375mg.	Rheumatoid Arthritis;Osteoarthritis	Drug: Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.);Drug: Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)	Sandoz		Not recruiting	21 Years	50 Years	All	34	Phase 1
1933	NCT00029042	January 2002	19 February 2015	Infliximab to Treat Children With Juvenile Rheumatoid Arthritis	A Randomized Double Blind Controlled Intra-Patient Dose Escalation Phase II Trial of Infliximab in Pediatric Patients With Refractory Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Infliximab	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		Not recruiting	N/A	N/A	Both	48	Phase 2	United States
1934	NCT00048321	January 2002	19 February 2015	ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis	ISIS 104838-CS7, A Double-Blind, Placebo-Controlled, Randomized Trial of the Safety, Efficacy and Pharmacokinetic Profile of ISIS 104838 (TNF-Alpha Antisense Oligonucleotide) Subcutaneous Injections in Active Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: ISIS 104838	Isis Pharmaceuticals		Not recruiting	18 Years	N/A	Both	160	Phase 2	United States;Canada
1935	NCT00246064	December 2001	19 February 2015	The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol	The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol. Tapering Methotrexate in Patients With Rheumatoid Arthritis Beginning Therapy With Infliximab	Arthritis, Rheumatoid	Drug: infliximab	Centocor Ortho Biotech Services, L.L.C.		Not recruiting	18 Years	80 Years	Both	210	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1936	NCT00035334	October 2001	19 February 2015	Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis	A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis	Secondary (AA) Amyloidosis;Rheumatoid Arthritis;Nephrotic Syndrome;Familial Mediterranean Syndrome;Kidney Diseases;Gastrointestinal Diseases	Drug: NC-503 (Anti-amyloidotic (AA) Agent)	Bellus Health Inc	FDA Office of Orphan Products Development	Not recruiting	18 Years	N/A	Both	150	Phase 2/Phase 3	United States;Finland;France;Israel;Italy;Lithuania;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom
1937	NCT00036374	October 2001	19 February 2015	A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis	A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis	Rheumatoid Arthritis, Juvenile	Drug: Infliximab	Centocor, Inc.		Not recruiting	4 Years	18 Years	Both	123	Phase 3	United States
1938	NCT00036387	October 2001	19 February 2015	A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.	A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug Background Therapy.	Arthritis, Rheumatoid	Drug: Infliximab	Centocor, Inc.		Not recruiting	18 Years	N/A	Both	347	Phase 3	United States
1939	NCT00116714	October 2001	19 February 2015	Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy	Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 1)	Rheumatoid Arthritis	Drug: DMARD	Amgen	Immunex Corporation;Wyeth is now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	Both	4968	N/A	United States
1940	NCT02180516	October 2001	19 February 2015	Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome	Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome	Arthritis, Rheumatoid	Drug: Meloxicam;Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac	Boehringer Ingelheim		Not recruiting	N/A	N/A	Both	9984	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1941	NCT00144651	August 2001	19 February 2015	Study of MRA in Patients With Rheumatoid Arthritis (RA)	An Open-label, Extension, Phase II Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Were Participated in Study MRA009JP	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical		Not recruiting	20 Years	N/A	Both	135	Phase 2
1942	NCT00537667	August 2001	19 February 2015	The SPECTRA Study	A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: anakinra;Drug: anakinra and PEG sTNF-R1	Amgen		Not recruiting	18 Years	N/A	Both	22	Phase 2
1943	NCT00524160	July 2001	19 February 2015	A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis	Open-Label Study To Assess The Effect On Pain Control Of Durogesic (Fentanyl Transdermic Therapeutic System) Treatment In Subjects With Rheumatoid Arthritis Or Osteoarthritis Of The Knee Or Hip.	Arthritis;Osteoarthritis;Rheumatoid Arthritis	Drug: Fentanyl transdermal patch	Janssen Pharmaceutica N.V., Belgium		Not recruiting	18 Years	N/A	Both	264	Phase 4
1944	NCT00078806	June 2001	19 February 2015	Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis	Phase 3 Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Enbrel;Drug: Placebo	Amgen	Immunex Corporation	Not recruiting	2 Years	18 Years	Both	75	Phase 3	United States;Canada
1945	NCT00037700	May 2001	19 February 2015	Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: anakinra;Drug: pegsunercept	Amgen		Not recruiting	18 Years	N/A	Both		Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1946	NCT02209779	May 2001	19 February 2015	Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis	A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD	Arthritis, Rheumatoid	Drug: BIBR 796 BS;Drug: Placebo	Boehringer Ingelheim		Not recruiting	18 Years	75 Years	Both	167	Phase 2
1947	NCT02251210	May 2001	19 February 2015	Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis	Three Month, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multiple Dose-range Study of the Efficacy and Safety of BIIL 284 BS (5, 25 and 75 mg p.o. Once Daily) in Adult Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: BIIL 284 BS low dose;Drug: BIIL 284 BS medium dose;Drug: BIIL 284 BS high dose;Drug: Placebo	Boehringer Ingelheim		Not recruiting	18 Years	70 Years	Both	404	Phase 2
1948	NCT00014794	April 2001	19 February 2015	Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients	H215O Positron Emission Tomography (PET) in the Assessment of Synovial Blood Flow in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: 15-O labeled water	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		Not recruiting	N/A	N/A	Both	10	Phase 1	United States
1949	NCT02693210	February 2001	7 November 2016	A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis	A Randomised, Double Dummy Controlled, Parallel Group Study of the Efficacy and Safety of MabThera (Rituximab) Alone or in Combination With Either Cyclophosphamide or Methotrexate, in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab;Other: Placebo Rituximab;Other: Placebo Methotrexate;Other: Placebo Cyclophosphamide;Drug: Methotrexate;Drug: Cyclophosphamide	Hoffmann-La Roche		Not recruiting	21 Years	N/A	Both	161	Phase 2	Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
1950	NCT00579644	January 2001	22 January 2018	Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone	Treatment of Early Rheumatoid Arthritis: Minocycline in Combination With Methotrexate Versus Methotrexate Alone	Rheumatoid Arthritis	Drug: Combination of Minocycline and MTX or MTX alone;Drug: methotrexate	University of Nebraska		Not recruiting	19 Years	75 Years	All	91	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1951	NCT00034853	December 2000	19 February 2015	Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)	A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis	Arthritis, Juvenile Rheumatoid	Drug: meloxicam oral suspension;Drug: naproxen oral suspension	Boehringer Ingelheim		Not recruiting	2 Years	17 Years	Both	180	Phase 3	United States;Brazil;Mexico;Ukraine;Argentina
1952	NCT00195663	December 2000	19 October 2017	Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis	A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFa Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis (PREMIER).	Early Rheumatoid Arthritis	Biological: Adalimumab;Drug: Methotrexate;Biological: Adalimumab placebo;Drug: Methotrexate placebo	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	N/A	All	799	Phase 3	United States;Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;Switzerland;United Kingdom
1953	NCT00162266	October 2000	19 October 2017	Abatacept With Methotrexate- Phase IIB	A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate	Rheumatoid Arthritis	Drug: Abatacept (BMS-188667);Drug: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	524	Phase 2	United States;Argentina;Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;South Africa;United Kingdom
1954	NCT00162279	October 2000	19 February 2015	The Study of Abatacept in Combination With Etanercept	A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	Both	141	Phase 2	United States
1955	NCT00393471	October 2000	19 February 2015	Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.	A Double-Blind Study Evaluating the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Comparison to Etanercept Alone or Methotrexate Alone in Rheumatoid Arthritis Patients.	Active Rheumatoid Arthritis	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	Male	615	Phase 3	Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Portugal;Romania;Spain;Sweden;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1956	NCT00006292	September 2000	19 February 2015	Infliximab for the Treatment of Early Rheumatoid Arthritis	Randomized Double Blind Active Treatment Controlled Trial of the Anti-TNF-Alpha Antibody Infliximab in Patients With Erosive Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Infliximab	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		Not recruiting	N/A	N/A	Both	60	Phase 2	United States
1957	NCT00279747	September 2000	19 February 2015	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.	Arthritis, Juvenile Rheumatoid	Drug: meloxicam 0.25 mg/kg;Drug: meloxicam 0.125 mg/kg;Drug: naproxen 10 mg/kg	Boehringer Ingelheim		Not recruiting	2 Years	16 Years	Both	226	Phase 3	Austria;Belgium;France;Germany;Italy;Russian Federation;United Kingdom
1958	NCT00037648	July 2000	19 February 2015	Juvenile Rheumatoid Arthritis	A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuIL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis	Juvenile Chronic Arthritis	Drug: Anakinra;Drug: Placebo	Amgen		Not recruiting	2 Years	17 Years	Both	86	Phase 2	United States
1959	NCT00195650	July 2000	19 October 2017	Long Term Open Label Continuation Study	A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Adalimumab	Abbott		Not recruiting	18 Years	N/A	All	846	Phase 3	United States;Canada
1960	NCT00078793	June 2000	19 February 2015	Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis	Phase IV Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Enbrel®	Amgen	Immunex Corporation	Not recruiting	2 Years	18 Years	Both	600	N/A	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1961	NCT00233571	June 2000	19 February 2015	A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis	A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab)	Rheumatoid Arthritis	Biological: Adalimumab 40 mg subcutaneous (SC) every other week (EOW)	Abbott		Not recruiting	18 Years	N/A	Both	796	Phase 3
1962	NCT00138983	May 2000	19 February 2015	Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.	Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.	Rheumatoid Arthritis;Polymyalgia Rheumatica;Giant Cell Arteritis;Polymyositis;Wegener’s Granulomatosis	Drug: Alendronate versus alfacalcidol (1-alpha OH vitamin D)	UMC Utrecht	Dutch Health Care Insurance Board	Not recruiting	18 Years	90 Years	Both	200	Phase 3	Netherlands
1963	NCT00132418	April 2000	19 February 2015	Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders	Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders	Rheumatoid Arthritis	Drug: Enbrel;Drug: Placebo	Amgen	Immunex Corporation	Not recruiting	18 Years	N/A	Both	564	Phase 4	United States
1964	NCT00006055	March 2000	19 February 2015	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center		Not recruiting	1 Year	55 Years	Both	10	N/A	United States
1965	NCT00195702	February 2000	19 October 2017	Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate	Rheumatoid Arthritis	Biological: Adalimumab;Drug: Placebo	Abbott		Not recruiting	18 Years	N/A	All	619	Phase 3	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1966	NCT00279760	January 2000	26 September 2016	Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis	A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Belatacept;Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	65 Years	Both	210	Phase 1/Phase 2	United States;Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom
1967	NCT02247375	January 2000	19 February 2015	Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)	A Double-blind, Randomized, Three Parallel Group Placebo-controlled Study to Investigate Pharmacokinetics, Effect on Expression of CD11b/CD18 (Mac-1), as Well as Safety and Efficacy of Two Oral Doses of BIIL 284 BS (Dosage: 25 mg Daily, 150 mg Daily) in Patients With Rheumatoid Arthritis Over Two Weeks	Arthritis, Rheumatoid	Drug: Low dose of BIIL 284 BS tablets;Drug: High dose of BIIL 284 BS tablets;Drug: Placebo	Boehringer Ingelheim		Not recruiting	18 Years	65 Years	Both	26	Phase 1
1968	NCT00579878	December 1999	19 February 2015	Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis	Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Leflunomide;Drug: Methotrexate-Sulfasalazine-Hydroxychloroquine;Drug: Leflunomide-Sulfasalazine-Hydroxychloroquine	University of Nebraska		Not recruiting	19 Years	80 Years	Both	70	Phase 3	United States
1969	NCT00012506	October 1999	19 February 2015	The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis		Uveitis;Arthritis, Juvenile Rheumatoid	Drug: TNFR:Fc	National Eye Institute (NEI)		Recruiting	2 Years	18 Years	Both		Phase 3	United States
1970	NCT02932644	October 1999	24 October 2016	Vitamin D and Cardiovascular Events in Rheumatoid Arthritis	Association Between Baseline Vitamin D Metabolite Levels and Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. A Cohort Study With Patient-record Evaluated Outcomes.	Rheumatoid Arthritis;Cardiovascular Disease	Other: Baseline serum vitamin D level at or above 50 nmol/l;Other: Baseline serum vitamin D level below 50 nmol/l	Odense University Hospital	The Danish Rheumatism Association;University of Southern Denmark;Region of Southern Denmark;Pfizer;Odense Patient Explorative data Network (OPEN);The Danish Rheumatism Association;University of Southern Denmark;Region of Southern Denmark;Pfizer;Odense Patient Explorative data Network (OPEN)	Not recruiting	18 Years	75 Years	Both	160	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1971	NCT00000435	September 1999	19 February 2015	dnaJ Peptide for Relieving Rheumatoid Arthritis	A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: dnaJ peptide;Drug: None-placebo	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		Not recruiting	18 Years	85 Years	Both	160	Phase 2	United States
1972	NCT00000401	July 1999	19 February 2015	Oral Collagen for Rheumatoid Arthritis	Open Label Multicenter Induction of CII Tolerance in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Oral bovine type II collagen	University of Tennessee	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	18 Years	80 Years	Both	110	Phase 2	United States
1973	NCT00001862	February 1999	19 February 2015	TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis	The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis;Uveitis	Drug: Enbrel	National Eye Institute (NEI)		Not recruiting	N/A	N/A	Both	15	Phase 2	United States
1974	NCT00356590	December 1998	19 October 2017	Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012	Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012	Rheumatoid Arthritis	Biological: Etanercept	Amgen	Immunex Corporation	Not recruiting	18 Years	N/A	All	468	Phase 3	Canada;United States
1975	NCT00209859	October 1998	19 February 2015	Methotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis	Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Intraarticular betamethasone;Drug: Cyclosporine/placebo-cyclosporine	Hvidovre University Hospital		Not recruiting	18 Years	75 Years	Both	160	Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1976	NCT00001677	June 1998	19 February 2015	Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy	Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy	Arthritis, Rheumatoid;Synovitis	Drug: Methotrexate;Drug: Fludarabine	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)		Not recruiting	N/A	N/A	Both	40	Phase 2	United States
1977	NCT00001614	July 1997	19 February 2015	The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis	The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis	Arthritis, Juvenile Rheumatoid;Uveitis	Drug: Chicken type II collagen	National Eye Institute (NEI)		Not recruiting	N/A	N/A	Both	13	Phase 1	United States
1978	NCT00278551	June 1997	19 February 2015	Stem Cell Support in Patients With Rheumatoid Arthritis	Immune Ablation and Hematopoietic Stem Cell Support in Patients With Rheumatoid Arthritis and High Risk Factors	RHEUMATOID ARTHRITIS	Biological: Immune ablation and hematopoietic stem cell transplant	Richard Burt, MD		Not recruiting	18 Years	60 Years	Both	10	Phase 1	United States
1979	NCT00357903	April 1997	16 December 2017	Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials	Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials	Rheumatoid Arthritis	Biological: Etanercept	Amgen	Immunex Corporation	Not recruiting	4 Years	N/A	All	639	Phase 3	Canada;United States
1980	NCT00269867	March 1997	19 February 2015	Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis	A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment	Rheumatoid Arthritis	Drug: Placebo;Drug: Infliximab 3 mg/kg;Drug: Infliximab 10 mg/kg	Centocor, Inc.		Not recruiting	18 Years	75 Years	Both	428	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1981	NCT00000395	September 1996	9 January 2017	Antifolate Effectiveness in Arthritis	Mechanisms of Antifolate Efficacy in Arthritis	Rheumatoid Arthritis;Adjuvant Arthritis	Drug: Methotrexate;Dietary Supplement: Folinic acid;Dietary Supplement: Folic acid	University of Alabama at Birmingham	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Office of Dietary Supplements (ODS)	Not recruiting	18 Years	85 Years	Both	40	Phase 2	United States
1982	NCT00000429	June 1996	19 February 2015	Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis	Calcium Supplementation for Bone Mineralization in Juvenile Rheumatoid Arthritis (JRA)	Juvenile Rheumatoid Arthritis	Drug: Calcium carbonate	Children's Hospital Medical Center, Cincinnati	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not recruiting	6 Years	18 Years	Both	192	Phase 2	United States
1983	NCT00570934	March 1995	17 October 2016	Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA	Effect of Supplementation With 2000 International Units (IU) Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Dietary Supplement: Cholecalciferol;Dietary Supplement: Calcium;Dietary Supplement: Calcium and cholecalciferol;Drug: Placebo	University of Missouri-Columbia		Not recruiting	3 Years	15 Years	Both	24	Phase 3	United States
1984	NCT00004420	September 1994	7 April 2015	Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis		Juvenile Rheumatoid Arthritis	Drug: gamma-Linolenic acid	FDA Office of Orphan Products Development	University of Massachusetts, Worcester	Not recruiting	1 Year	15 Years	Both	50	N/A
1985	JPRN-JapicCTI-050016		23 April 2019	A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA)	A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA)	RA	Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion	Chugai Pharmaceutical Co., Ltd.			20				Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1986	JPRN-JapicCTI-050018		23 April 2019	Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)	Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)	RA	Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion	Chugai Pharmaceutical Co., Ltd.			20	74			Phase 3
1987	JPRN-JapicCTI-050146		23 April 2019	Clinical Study to assess the efficacy and safety of increased dose of TA-650 in patients with Rheumatoid Arthritis	Clinical Study to assess the efficacy and safety of increased dose of TA-650 in patients with Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : TA-650 (Infliximab) Dosage And administration of the intervention : Intravenous drip infusion	Mitsubishi Tanabe Pharma Corporation			20	75	BOTH		Phase 3
1988	JPRN-JapicCTI-070479		23 April 2019	A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.	A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.	Rheumatoid arthritis	Intervention name : Ocrelizumab Dosage And administration of the intervention : Patients will be randomized to receive placebo, ocrelizumab 200mg i.v. or ocrelizumab 500mg i.v. on days 1 and 15. A repeat course of i.v. treatment will be administered at weeks 24 and 26.	Chugai Pharmaceutical Co., Ltd.			20		BOTH		Phase 3
1989	JPRN-JapicCTI-080531		23 April 2019	A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis, Lumbago	Intervention name : esomeprazole Dosage And administration of the intervention : Oral	AstraZeneca			20		BOTH		Phase 3
1990	JPRN-JapicCTI-080565		23 April 2019	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis, Lumbago	Intervention name : esomeprazole Dosage And administration of the intervention : Oral	AstraZeneca			20		BOTH		Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1991	JPRN-JapicCTI-080650		23 April 2019	Dose-Response Study of Ocrelizumab for Rheumatoid Arthritis.	Dose-Response Study of Ocrelizumab for Rheumatoid Arthritis.	Rheumatoid Arthritis	Intervention name : Ocrelizumab Dosage And administration of the intervention : 50mg,200mg,500mg twice as an IV infusion on Days1 and 15 Control intervention name : Placebo Dosage And administration of the control intervention : administered twice as an IV infusion on Days1 and 15	Chugai Pharmaceutical Co., Ltd.			20		BOTH		Phase 2
1992	JPRN-JapicCTI-111601		23 April 2019	A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agents	A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agents	Rheumatoid Arthritis	Intervention name : Secukinumab INN of the intervention : Secukinumab Dosage And administration of the intervention : s.c. i.v.	Novartis Pharma K.K.			18		BOTH		Phase 3
1993	JPRN-JapicCTI-121843		23 April 2019	OSKIRA-Asia-1	A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy	Rheumatoid Arthritis	Intervention name : Fostamatinib Dosage And administration of the intervention : 100mg twice daily for 12 weeks Intervention name : Fostamatinib Dosage And administration of the intervention : 75mg twice daily for 12 weeks Intervention name : Fostamatinib Dosage And administration of the intervention : 50mg twice daily for 12 weeks Intervention name : Fostamatinib Dosage And administration of the intervention : 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12 Control intervention name : Placebo Dosage And administration of the control intervention : twice daily for 12 weeks	AstraZeneca			18		BOTH		Phase 2
1994	JPRN-JapicCTI-121990		23 April 2019	OSKIRA-Asia-1X	A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia	Rheumatoid Arthritis	Intervention name : Fostamatinib Dosage And administration of the intervention : 100mg once daily	AstraZeneca			18		BOTH		Phase 2
1995	JPRN-JapicCTI-132125		23 April 2019	A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Intervention name : Baricitinib Dosage And administration of the intervention : Baricitinib administered orally once daily through Week 52 Control intervention name : Placebo Dosage And administration of the control intervention : Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous injection every 2 weeks through Week 50 Control intervention name : Adalimumab Dosage And administration of the control intervention : Adalimumab administered by SC injection every 2 weeks through Week 50	Eli Lilly Japan K.K.			18		BOTH		Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1996	JPRN-JapicCTI-132134		16 July 2019	A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease-Modifying Antirheumatic Drugs	A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Intervention name : Baricitinib Dosage And administration of the intervention : Baricitinib administered orally once daily through Week 52. Control intervention name : Placebo Dosage And administration of the control intervention : Baricitinib placebo administered orally once daily through Week 52 and MTX placebo administered orally once weekly through Week 52. Control intervention name : Methotrexate Dosage And administration of the control intervention : Methotrexate (MTX) administered orally once weekly with dose ranging from 7.5 to 12.5 mg per week through Week 52.	Eli Lilly Japan K.K.		Not Recruiting	18		BOTH		Phase 3
1997	JPRN-JapicCTI-132138		23 April 2019	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : Baricitinib Dosage And administration of the intervention : Baricitinib administered orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study. Control intervention name : Placebo Dosage And administration of the control intervention : Placebo administered orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study.	Eli Lilly Japan K.K.			18		BOTH		Phase 3
1998	JPRN-JapicCTI-132156		16 July 2019	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors	Rheumatoid Arthritis	Intervention name : Baricitinib Dosage And administration of the intervention : Baricitinib administered orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study. Control intervention name : Placebo Dosage And administration of the control intervention : Placebo administered orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study.	Eli Lilly Japan K.K.		Recruiting	18		BOTH		Phase 3
1999	JPRN-JapicCTI-142405		16 July 2019	A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis	A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : Baricitinib Dosage And administration of the intervention : Baricitinib administered orally once daily Intervention name : placebo Dosage And administration of the intervention : Placebo administered orally once daily	Eli Lilly Japan K.K.		Not Recruiting	18		BOTH		Phase 3

先頭へ